,,,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,Text,,,,,,Integer,Integer,Integer,Integer,Integer,Date,Date,Date,Date,Date,Date ,Date ,Date ,Date ,Date ,Date ,Date ,Date ,Date ,Date ,Date ,Date ,Date ,Date ,Date ,Date ,Date ,Date ,Percentage Number,Percentage Number,Percentage Number,Percentage Number,Percentage Number,Date ,Date ,Date ,Date ,Percentage Number,Percentage Number,Percentage Number,Percentage Number,Percentage Number,Percentage Number,Link,Link,Link,Link,Link,Link,Link
,,,,,,,,,,,,,,Finance,,,,,,,,,,,,Drug,,,,,,,,,,,,,,,,,,,Study Contacts,,,,,,,,,,,,,,,,,,,Countries,,,Sites Activation,,Subj Enrollment,,,,,,,,Timelines,,,,,,,,,,,,,,,,,,,Completion Tracking,,,,,,,,,,,,,,,,,,,Document Links,,,,,,
Sponsor Name,Study Sponsor,Study Number,Sponsor Number,Study Title,Study Description,Study Short Name,Indication,Disease Area,Therapeutic Area,Oncology Tumor Type,Oncology Group,Business rationale,Scientific Rationale,Study Finance Code,Funded Bys,Registry Status,Study Phase,Study Type,Blinding Status,Study Designs,Subject Type,Compassionate,Methodology,Pharmacogenetic,Comparative,Sponsor Drug,Compound Name,Compound Number,Compound Type,compund Subtype,Compound MOA,Product,Generic Name,Trade Name,EU approved,Covered fin Disclosure,Extension Study,Protocol Closed,Study Is Critical,Project Code,Project Name,Study Proj Desc,Business Category Unit,Business Subunit,Project manager,Project Planner,Clinical Program Manager,Lead Study Manager,Clinician,Translational Oncology Lead,Biomarker Assay Lead,Regulatory Lead,Site Monitoring Lead,Finance Manager,Study Budget Lead,Global Study Manager,Outsourcing Lead,Data Manager,Clinical Data Scientist,Asset Lead,Global Clinical Lead,Global Medicine Lead,Statistician,Planned Country Codes,Planned Countries, ,Planned Sites,Actual Sites Activated ,Gender,Age,Planned Subjects,Subjects Screened,Subjects enrolled,Subjects Active,Subjects Discontinued,Subjects Completed, FAP, CRF Approved, SAP Finish, DBR Ready, First Drug Ship, First Site Active, First Sub Randomized, FSFV, FSFD, FSLV, LSFD, LSLD, Primary Completion, DBR, Final Tables, FINAL CSR Min, FINAL CSR Max,Final CSR  , TLR,Date 25% Sites Active,Date 50% Sites Active,Date 75% Sites Active,Date 100% Sites Active,% Cmpl FAP,% Cmpl SAP,% Cmpl Work Order,% Cmpl DBR Ready,% Cmpl First Drug Ship,Date 25% Sub enrolled,Date 50% Sub enrolled,Date 75% Sub enrolled,Date 100% Sub enrolled,% Cmpl Primarary Completion,% Cmpl DBR Release,% Cmpl Final Tables,% Cmpl Final CSR Min,% Cmpl Final CSR Max,% Cmpl TLR,Study ID,FAP,CRF,ICF,Study Protocol,Study Statistical Plan,Study Documents -Outside Links
AbbVie,AbbVie,ST00020,SP00001,Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response,,CHOICE,Hepatitis C Virus (HCV),,Virology,,,,,,Industry,Recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Geralyn K,Gertrudis T,Tiffiny K,James y,Louann C,John G,Selizabeth F,Tiffiny K,Kandace p,Jeanene Y,Jeanene Y,Suk T,Dalton E,Kandace p,Jeanene Y,Garnet T,Harry A,Stephan T,John G,,,"Irkutsk Regional Center for the Prevention and Control of AIDS and Infections /ID# 229509, Irkutsk, Russian Federation|Specialized Clinical Infectious Diseases Hospital /ID# 229814, Krasnodar, Russian Federation|Infectious Clinical Hosp #1 /ID# 225063, Moscow, Russian Federation|S. P. Botkin City Hospital /ID# 229510, Oryol, Russian Federation|Samara Region Clinical HIV/AIDS Prevention and Control Center /ID# 226591, Samara, Russian Federation",81.95252951,73.75727656,All,"18 Years and older ¬† (Adult, Older Adult)",70,69,67,65,6,4,10/24/2027,5/11/2028,3/21/2028,4/25/2028,3/16/2028,4/9/2028,4/19/2028,3/19/2019,4/15/2019,2/16/2021,5/5/2021,8/12/2021,12/14/2021,1/16/2022,2/17/2022,3/26/2022,5/21/2022,6/24/2022,8/9/2022,10/6/2028,4/4/2029,10/1/2029,3/30/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04577482,,,,,,
AbbVie,AbbVie,ST00022,SP00001,A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study,,MAGELLAN-3,Hepatitis C Virus Infection,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Donovan H,Gertrudis T,Selizabeth F,John G,Kandace p,Lyman W,Otis Thode †,Selizabeth F,Selizabeth F,Suzie K,Xochitl D,Selizabeth F,Lavina S,Otis Thode †,Kandace p,James y,Jaquelyn H,Selizabeth F,John G,,,"Digestive Health Specialists of the Southeast /ID# 155719, Dothan, Alabama, United States|Ruane Clinical Research Group /ID# 155714, Los Angeles, California, United States|Digestive Disease Associates - Baltimore /ID# 155713, Baltimore, Maryland, United States|Henry Ford Health System /ID# 155720, Detroit, Michigan, United States|University of Buffalo /ID# 155721, Buffalo, New York, United States|Carolinas Center For Liver Dis /ID# 155731, Statesville, North Carolina, United States|Gastro One /ID# 155729, Germantown, Tennessee, United States|TX Liver Inst, Americ Res Corp /ID# 157881, San Antonio, Texas, United States|Royal Brisbane and Women's Hospital /ID# 200944, Herston, Queensland, Australia|The Royal Melbourne Hospital /ID# 155727, Parkville, Victoria, Australia|University of Calgary - Cumming School of Medicine - Adult Cystic Fibrosis Clini /ID# 155726, Calgary, Alberta, Canada|Beijing Di Tan Hospital, Capital Medical University /ID# 218496, Beijing, China|West China Hospital, Sichuan University /ID# 217613, Chengdu, China|The First Hospital Affiliated to AMU (Southwest Hospital) /ID# 218494, Chongqing, China|Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 218495, Fuzhou, China|Medizinisches Versorgungszentrum Mauss, Schmutz, Hegener, Athmann, Nguyen /ID# 155592, D√ºsseldorf, Nordrhein-Westfalen, Germany|Asklepios Klinik St. Georg /ID# 155733, Hamburg, Germany|Samsung Medical Center /ID# 214844, Seoul, Korea, Republic of|Auckland City Hospital /ID# 200945, Grafton, Auckland, New Zealand|Dunedin Hospital /ID# 155591, Dunedin, Otago, New Zealand|Waikato Hospital /ID# 155728, Hamilton, Waikato, New Zealand|Medical Company Hepatolog /ID# 214314, Samara, Samarskaya Oblast, Russian Federation|Hospital Universitario Puerta de Hierro, Majadahonda /ID# 155734, Majadahonda, Madrid, Spain|Duplicate_Karolinska Univ Sjukhuset /ID# 155735, Solna, Sweden|Inselspital, Universit√§tsspital Bern /ID# 155716, Bern, Switzerland|Duplicate_Imperial College Healthcare NHS Trust /ID# 155718, London, United Kingdom",56.67137521,51.00423769,All,5 Years to 12 Years ¬† (Child),72,69,68,29,34,5,12/5/2027,6/19/2028,4/10/2028,5/10/2028,4/12/2028,4/28/2028,5/8/2028,4/4/2019,4/12/2019,6/5/2020,5/22/2020,9/30/2020,1/14/2021,2/25/2021,4/15/2021,5/30/2021,7/20/2021,8/30/2021,10/10/2021,10/25/2028,4/23/2029,10/20/2029,4/18/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02939989,,,,,,
AbbVie,AbbVie,ST00059,SP00001,"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ¬± Dasabuvir, ¬± Ribavirin in Patients With Chronic Hepatitis C in Colombia",,outCome,Chronic Hepatitis C,,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Donovan H,John G,Xochitl D,Frank T,Kala R,Liberty A,Corrine U,Mara A,Naren G,Selizabeth F,Dinah R,Suzie K,Anthony P,Aleta H,John G,Naren G,Stephan T,Selizabeth F,Perter K,,,"Fundacion Cardioinfantil, Bogot√°, Colombia|Cic Cali, Cali, Colombia|Centro Medico lmbanaco de Cali I, Cali, Colombia|Pharos Centro de Estudios Clin, Cartagena, Colombia|IPS Medicos Internistas Del Ca I, Manizales, Colombia|Fundacion Hospitalaria San Vin, Medell√≠n, Colombia",40.30082932,36.27074639,All,14 Years to 17 Years ¬† (Child),73,72,69,62,3,4,8/19/2028,2/16/2029,12/6/2028,1/16/2029,12/23/2028,12/27/2028,1/6/2029,11/6/2013,11/13/2013,9/6/2017,11/4/2017,6/24/2018,8/30/2018,10/22/2018,12/5/2018,1/8/2019,3/1/2019,4/11/2019,5/27/2019,6/25/2029,12/22/2029,6/20/2030,12/17/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02851069,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02851069/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02851069/SAP_001.pdf"
AbbVie,AbbVie,ST00060,SP00001,A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530,,,Hepatitis C,,Virology,,,,,,Industry,Completed,Phase 2|Phase 3,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Otis Thode †,Lilla Stilson †,Garnet T,Stephan T,Livia Pacheo †,Beulah N,Perter K,Jerold Goo †,Geralyn K,Tamesha T,Harry A,Suzie K,John G,Christian G,Kala R,Suzie K,Donovan H,Stephan T,Otis Thode †,,,"Digestive Health Specialists of the Southeast /ID# 136725, Dothan, Alabama, United States|Felizarta /ID# 141033, Bakersfield, California, United States|Southern California Res. Ctr. /ID# 141799, Coronado, California, United States|Research & Education, Inc. /ID# 169591, San Diego, California, United States|eStudySite San Diego /ID# 141040, San Diego, California, United States|eStudySite San Diego /ID# 141047, San Diego, California, United States|eStudySite San Diego /ID# 141048, San Diego, California, United States|Midway Immunology and Research /ID# 169477, Fort Pierce, Florida, United States|Delta Research Partners /ID# 141028, Bastrop, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 141024, Shreveport, Louisiana, United States|Henry Ford Health System /ID# 141039, Detroit, Michigan, United States|Binghamton Gastroenterology /ID# 141026, Binghamton, New York, United States|Carolinas Center for Liver Dis /ID# 155390, Statesville, North Carolina, United States|Northwest Gastroenterology Cli /ID# 141036, Portland, Oregon, United States|Gastro One /ID# 169478, Germantown, Tennessee, United States|Quality Medical Research, PLLC /ID# 141042, Nashville, Tennessee, United States|TX Clinical Research Institute /ID# 141037, Arlington, Texas, United States|Inquest Clinical Research /ID# 141045, Baytown, Texas, United States|TX Liver Inst, Americ Res Corp /ID# 136727, San Antonio, Texas, United States|Bon Secours St. Mary's Hospita /ID# 165106, Richmond, Virginia, United States|St. Vincent's Hospital, Darlinghurst /ID# 155395, Darlinghurst, New South Wales, Australia|St. Vincents Hospital /ID# 155394, East Lismore, New South Wales, Australia|Westmead Hospital /ID# 155392, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital /ID# 155396, Herston, Queensland, Australia|Royal Adelaide Hospital /ID# 155391, Adelaide, South Australia, Australia|Royal Melbourne Hospital /ID# 155393, Parkville, Victoria, Australia|Cliniques Universitaires Saint Luc /ID# 155397, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|CHU St. Pierre /ID# 155399, Brussels, Belgium|UZ Leuven /ID# 155398, Leuven, Belgium|University of Calgary /ID# 155400, Calgary, Alberta, Canada|Toronto Liver Centre /ID# 155401, Toronto, Ontario, Canada|Universit√§tsklinikum Frankfurt /ID# 169817, Frankfurt am Main, Hessen, Germany|Mauss, Schmutz, Hegener, Athma /ID# 155402, Dusseldorf, Germany|Gastroenterologisch-Hepatologi /ID# 169820, Kiel, Germany|Auckland City Hospital /ID# 155403, Auckland, New Zealand|Gastro-Hepato & Geriatric Ctr /ID# 141060, Ponce, Puerto Rico|Klinical Investigations Group /ID# 141059, San Juan, Puerto Rico|Innovative Care P.S.C. /ID# 141061, San Juan, Puerto Rico|The Royal London Hospital /ID# 155405, London, London, City Of, United Kingdom|King's College Hospital NHS /ID# 155406, London, United Kingdom|St. Mary's Hospital /ID# 155404, London, United Kingdom|Derriford Hospital /ID# 155407, Plymouth, United Kingdom",70.28529054,63.25676149,All,18 Years to 35 Years ¬† (Adult),76,74,70,45,18,7,7/4/2028,1/29/2029,12/10/2028,1/12/2029,12/8/2028,12/28/2028,1/7/2029,4/1/2016,4/6/2016,1/22/2019,1/14/2019,8/18/2019,10/15/2019,11/20/2019,12/21/2019,2/11/2020,4/8/2020,5/26/2020,6/29/2020,6/26/2029,12/23/2029,6/21/2030,12/18/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02441283,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02441283/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02441283/SAP_001.pdf"
AbbVie,AbbVie,ST00071,SP00001,"Effectiveness of Paritaprevir/r - Ombitasvir, ¬± Dasabuvir, ¬± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study",,,Chronic Hepatitis C,,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Lilla Stilson †,Naren G,Frank T,Otis Thode †,Dalton E,Mara A,Tamesha T,Anthony P,Mara A,Quentin N,Selizabeth F,Mara A,Frank T,Louann C,Anthony P,Stephan T,Jerold Goo †,Donovan H,Ross S,,,,56.13935023,50.52541521,All,"18 Years to 65 Years ¬† (Adult, Older Adult)",79,76,71,54,10,7,9/23/2028,3/27/2029,1/5/2029,1/31/2029,1/16/2029,1/26/2029,2/5/2029,5/26/2015,6/21/2015,11/15/2016,11/9/2016,1/29/2017,6/12/2017,8/4/2017,9/11/2017,10/11/2017,12/7/2017,1/28/2018,3/26/2018,7/25/2029,1/21/2030,7/20/2030,1/16/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02798315,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02798315/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02798315/SAP_001.pdf"
AbbVie,AbbVie,ST00072,SP00001,"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ¬± Dasabuvir, ¬± Ribavirin in Participants With Chronic Hepatitis C",,,Chronic Hepatitis C,,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Only|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,In Bellini †,Clarice N,Liberty A,Clarice N,Lyman W,Perter K,Naren G,Tammara F,Mac L,Perter K,Naren G,Mee M,Kala R,Selizabeth F,Kala R,Xochitl D,Dinah R,Perter K,Frank T,,,,4.515738863,4.064164977,All,"18 Years and older ¬† (Adult, Older Adult)",78,77,72,27,41,4,10/25/2028,3/27/2029,12/28/2028,2/14/2029,1/14/2029,1/27/2029,2/6/2029,8/9/2013,8/16/2013,8/24/2017,1/19/2017,6/10/2017,10/31/2017,12/17/2017,1/28/2018,3/2/2018,4/18/2018,5/23/2018,7/3/2018,7/26/2029,1/22/2030,7/21/2030,1/17/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02725866,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02725866/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02725866/SAP_001.pdf"
AbbVie,AbbVie,ST00073,SP00001,"The Effectiveness of ABT-450/r - Ombitasvir, ¬± Dasabuvir, ¬± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland",,REACH,Chronic Hepatitis C,,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Only|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Marceline R,Mary H,Federico L,Mara A,Tamesha T,Stephan T,Jene M,Remedios Z,Doreen T,Marcelina X,Corrine U,Terisa Sikora †,Anthony P,Lilla Stilson †,Harry A,Tammara F,Anthony P,Tiffiny K,Tamesha T,,,,8.140671913,7.326604722,All,"18 Years and older ¬† (Adult, Older Adult)",79,76,73,43,24,6,10/14/2028,3/8/2029,1/11/2029,2/11/2029,1/10/2029,1/31/2029,2/10/2029,9/21/2014,9/30/2014,6/21/2017,4/25/2017,9/17/2017,11/29/2017,1/10/2018,2/12/2018,3/18/2018,4/25/2018,6/24/2018,8/15/2018,7/30/2029,1/26/2030,7/25/2030,1/21/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02582671,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02582671/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02582671/SAP_001.pdf"
AbbVie,AbbVie,ST00074,SP00001,"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ¬± Dasabuvir, ¬± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C",,3DUTCH,Chronic Hepatitis C,,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Lucie P,Beulah N,Marcelina X,Quentin N,Donovan H,Livia Pacheo †,Terisa Sikora †,Tiffiny K,James y,Livia Pacheo †,John G,John G,Stephan T,Corrine U,Corrine U,Doreen T,Xochitl D,Lilla Stilson †,Jeanene Y,,,"Albert Schweitzer Ziekenhuis /ID# 152597, Dordrecht, Zuid-Holland, Netherlands|Noordwest Ziekenhuisgroep /ID# 152604, Alkmaar, Netherlands|Duplicate_Onze Lieve Vrouwe Gasthuis /ID# 152600, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen /ID# 152596, Groningen, Netherlands|Leids Universitair Medisch Centrum /ID# 154637, Leiden, Netherlands|Radbound University Medical Ce /ID# 152598, Nijmegen, Netherlands|Erasmus Medisch Centrum /ID# 154635, Rotterdam, Netherlands|Maasstad Ziekenhuis /ID# 152592, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht /ID# 152595, Utrecht, Netherlands",71.17831464,64.06048318,All,"18 Years to 95 Years ¬† (Adult, Older Adult)",79,78,74,58,10,6,10/3/2028,3/30/2029,1/13/2029,2/14/2029,1/26/2029,2/1/2029,2/11/2029,2/12/2015,3/14/2015,5/13/2017,5/17/2017,11/22/2017,3/7/2018,5/3/2018,6/3/2018,7/5/2018,8/13/2018,9/22/2018,11/11/2018,7/31/2029,1/27/2030,7/26/2030,1/22/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02817594,,,,,,"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02817594/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02817594/Prot_001.pdf"
AbbVie,AbbVie,ST00075,SP00001,"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ¬± Dasabuvir, ¬± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C",,CITRINE,Chronic Hepatitis C,,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Only|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Ross S,John G,Gertrudis T,Kandace p,Beulah N,Mary H,Kandace p,Suzie K,Harry A,Stephan T,Federico L,Corrine U,Louann C,Tammara F,Selizabeth F,Lyman W,John G,Jerold Goo †,Terrell p,,,"Soroka Medical Center /ID# 169357, Be'er Sheva, HaDarom, Israel|Rabin Medical Center /ID# 153696, Petakh Tikva, Tel-Aviv, Israel|Rabin Medical Center /ID# 158648, Petakh Tikva, Tel-Aviv, Israel|Tel Aviv Sourasky Medical Ctr /ID# 153693, Tel Aviv-Yafo, Tel-Aviv, Israel|Ha'Emek Medical Center /ID# 153695, Afula, Israel|Soroka Medical Ctr /ID# 153697, Be'er Sheva, Israel|Assaf Harofeh Medical Center /ID# 153708, Be'er Ya'akov, Israel|Maccabi Health Services /ID# 158647, Gush Dan, Israel|Hillel Yaffe Medical Center /ID# 153702, Hadera, Israel|Rambam Health Care Campus /ID# 153694, Haifa, Israel|Bnai Zion Medical Center /ID# 153700, Haifa, Israel|The Lady Davis Carmel MC /ID# 153692, Haifa, Israel|The Edith Wolfson Medical Cent /ID# 153706, Holon, Israel|Shaare Zedek Medical Center /ID# 153699, Jerusalem, Israel|Hadassah /ID# 153701, Jerusalem, Israel|Meir Medical Center /ID# 153698, Kfar Saba, Israel|Western Galilee Medical Center /ID# 153705, Nahariya, Israel|Sheba Medical Center /ID# 153707, Ramat Gan, Israel",20.74737872,18.67264085,All,"18 Years to 75 Years ¬† (Adult, Older Adult)",77,76,75,43,26,6,10/24/2028,3/31/2029,1/6/2029,2/16/2029,1/13/2029,2/2/2029,2/12/2029,6/15/2014,7/4/2014,9/15/2018,2/22/2018,6/8/2018,10/21/2018,12/18/2018,2/14/2019,4/9/2019,6/4/2019,8/1/2019,9/2/2019,8/1/2029,1/28/2030,7/27/2030,1/23/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02803138,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02803138/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02803138/SAP_001.pdf"
AbbVie,AbbVie,ST00077,SP00001,Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6,,,Hepatitis C,,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Donovan H,Mac L,Tien C,John G,Rima Y ,Lilla Stilson †,Aleta H,Jeanene Y,Jaquelyn H,Christian G,Livia Pacheo †,Remedios Z,Tiffiny K,Quentin N,Lyman W,Suk T,Patria R,Ngan D,Otis Thode †,,,"Klinikum Klagenfurt am Woerthersee, Apotheke /ID# 169931, Klagenfurt Am Woerthersee, Kaernten, Austria|University Hospital St. Polten /ID# 169918, St. P√∂lten, Niederoesterreich, Austria|KH der Elisabethinen Linz GmbH /ID# 169915, Linz, Oberoesterreich, Austria|Medizinische Universit√§t Graz /ID# 169932, Graz, Steiermark, Austria|Landeskrankenhaus Hall /ID# 169930, Hall in Tirol, Tirol, Austria|Landeskrankenhaus /ID# 169922, Innsbruck, Austria|Klinikum Wels - Grieskirchen /ID# 169916, Wels, Austria|Wilhelminenspital der Stadt Wien /ID# 169914, Wien, Austria|Uza /Id# 170960, Edegem, Antwerpen, Belgium|UCL Saint-Luc /ID# 170964, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Algemeen Stedelijk Ziekenhuis /ID# 170876, Aalst, Oost-Vlaanderen, Belgium|UZ Gent /ID# 170922, Gent, Oost-Vlaanderen, Belgium|Universitair Ziekenhuis Leuven /ID# 170921, Leuven, Vlaams-Brabant, Belgium|Centre Hospitalier de Wallonie Picarde /ID# 200822, Tournai, Wallonne, Region, Belgium|Zna /Id# 170927, Antwerpen, Belgium|CHU Saint-Pierre /ID# 170920, Brussels, Belgium|Hopital Erasme /ID# 170918, Brussels, Belgium|CHU Brugmann /ID# 170956, Bruxelles, Belgium|Z.O.L - Campus St. Jan /ID# 171058, Genk, Belgium|AZ Middelares Gent /ID# 170874, Gent, Belgium|Jessa Ziekenhuis /ID# 170958, Hasselt, Belgium|AZ Groeninge /ID# 170931, Kortrijk, Belgium|Centre Hospitalier Universitaire du Sart Tilman CHU de Liege /ID# 170930, Liege, Belgium|CHC Liege /ID# 170926, Liege, Belgium|CHU Ambroise Pare /ID# 171107, Mons, Belgium|Clinique Edith Cavell /ID# 170932, Uccle, Belgium|CHU Dinant Godinne /ID# 170929, Yvoir, Belgium|CHR Orleans - Hopital de la Source /ID# 202360, Orleans CEDEX 2, Centre-Val De Loire, France|CH Georges Renon /ID# 202737, Niort CEDEX, Deux-Sevres, France|CHU de Besancon - Jean Minjoz /ID# 208502, Besancon, Doubs, France|CHU Dupuytren /ID# 202514, Limoges CEDEX 1, Franche-Comte, France|Hopital Haut-L√©v√™que /ID# 202501, Pessac CEDEX, Gironde, France|Hopital Purpan /ID# 202357, TOULOUSE Cedex 9, Haute-Garonne, France|Hopital Purpan /ID# 204201, TOULOUSE Cedex 9, Haute-Garonne, France|CH Annecy Genevois Site Annecy /ID# 202804, Epagny Metz Tessy, Haute-Savoie, France|CH Sp√©cialis√© Esquirol /ID# 204522, Limoges, Haute-Vienne, France|Centre Hospitalier de B√©ziers /ID# 202948, Beziers CEDEX, Herault, France|Hopital Saint Eloi /ID# 202512, Montpellier CEDEX 5, Herault, France|Hopital Beaujon /ID# 202675, Clichy, Ile-de-France, France|Hopital Broussais /ID# 202677, St Malo CEDEX, Ille-et-Vilaine, France|CHU NANCY - Hopital Brabois Adultes /ID# 202570, Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, France|Hopital de la Timone /ID# 202792, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|Charles Nicolle CHU Rouen /ID# 203518, Rouen CEDEX, Seine-Maritime, France|Centre Hosp Intercommunal de Creteil /ID# 202566, Creteil, Val-de-Marne, France|Cabinet medical /ID# 202794, Aix En Provence, France|CHU d'Angers /ID# 202500, Angers, France|Clinique du Tondu /ID# 207508, Bordeaux, France|Centre Endo Nord Isere /ID# 204181, Bourgoin Jallieu, France|Hopital de la Cavale Blanche /ID# 202640, Brest, France|Hopital Antoine Beclere /ID# 202676, Clamart, France|CHU Estaing /ID# 202949, Clermont Ferrand, France|Hopital Henri Mondor /ID# 202806, Creteil, France|Centre Hospitalier Universitaire de Grenoble - Hopital Michallon /ID# 202957, Grenoble, France|CH d'Hyeres /ID# 202515, Hyeres, France|Dr. Cuissard, Le Port, FR /ID# 203487, Le Port, France|C.H. de Bretagne Sud /ID# 202362, Lorient, France|Hopital de la Croix Rousse /ID# 203071, Lyon, France|Hopital Edouard Herriot /ID# 203149, Lyon, France|Hopital Europeen /ID# 205073, Marseille, France|Hopital Saint Joseph /ID# 202519, Marseille, France|Cabinet Medical, Boyer Darrigr /ID# 202050, Nanterre, France|Hopital l'Archet 2 /ID# 205295, Nice, France|CHU Nimes /ID# 208200, Nimes Cedex 9, France|Hopital Saint Antoine /ID# 202565, Paris Cedex 12, France|Hopital Bichat-Claude Bernard /ID# 202513, Paris, France|Hopital Pitie Salpetriere /ID# 202364, Paris, France|Centre Hospitalier PERPIGNAN /ID# 205762, Perpignan, France|Hopital Robert Debre /ID# 202953, Reims, France|Institut Arnault Tzanck /ID# 202363, Saint Laurent Du Var, France|Gastrodoc /Id# 206290, St Jean de Vedas, France|Cabinet Medical, Dr. Constant, /ID# 202361, Toulon, France|Clinique Amroise Pare /ID# 205064, Toulouse, France|Hopital Joseph Ducuing /ID# 205666, Toulouse, France|Ctre Hospitalier de Tourcoing /ID# 202358, Tourcoing, France|Ctre Hospitalier de Tourcoing /ID# 202805, Tourcoing, France|Hopital Paul Brousse /ID# 202623, Villejuif, France|General Hospital of Athens Laiko /ID# 206421, Athens, Attiki, Greece|General Oncological Hospital of Kifisia Oi Agioi Anargyroi /ID# 206419, Kifissia, Attiki, Greece|Tzaneio general hospital of Piraeus /ID# 208828, Piraeus, Attiki, Greece|Papageorgiou General Hospital Thessaloniki /ID# 207980, Nea Efkarpia, Thessaloniki, Greece|Gen Univ Hosp Alexandroupolis /ID# 206416, Alexandroupolis, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 206414, Athens, Greece|General Hospital Nikaias-Piraeus St. Panteleimon /ID# 206420, Pireaus, Greece|Bioclinic Thessaloniki /ID# 207981, Thessaloniki, Greece|University Gen Hosp AHEPA /ID# 209961, Thessaloniki, Greece|Interbalkan Medical Center /ID# 206417, Thessaloniki, Greece|Soroka Medical Center /ID# 169321, Be'er Sheva, HaDarom, Israel|HaEmek Medical Center /ID# 169318, Afula, Israel|Assaf Harofeh Medical Center /ID# 169370, Be'er Ya'akov, Israel|Maccabi Health Services /ID# 169372, Gush Dan, Israel|Hillel Yaffe Medical Center /ID# 169368, Hadera, Israel|Rambam Medical Center /ID# 169316, Haifa, Israel|Bnai Zion Medical Center /ID# 169358, Haifa, Israel|Carmel Medical Center /ID# 169309, Haifa, Israel|Shaare Zedek Medical Center /ID# 169329, Jerusalem, Israel|Gastroenterology Institute, Division of Medicine /ID# 169360, Jerusalem, Israel|Meir Medical Center /ID# 169327, Kfar Saba, Israel|Galilee Medical Center /ID# 169325, Nahariya, Israel|Rabin Medical Center /ID# 169320, Petakh Tikva, Israel|Sheba Medical Center /ID# 169365, Ramat Gan, Israel|Tel Aviv Medical Center /ID# 169313, Tel Aviv, Israel|AOU Federico II /ID# 168131, Naples, Campania, Italy|Ospedale Sant Orsola Malpighi /ID# 168127, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 168711, Modena, Emilia-Romagna, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 168138, Milano, Lombardia, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 168712, Milano, Lombardia, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 168137, Milan, Lombardia, Italy|IBD Center - IRCCS Istituto Clinico Humanitas /ID# 169353, Rozzano, Milano, Italy|AOU Citta della Salute Scienza /ID# 168142, Turin, Piemonte, Italy|Fondazione PTV Policlinico Tor Vergata /ID# 168709, Rome, Roma, Italy|Universit√† Cattolica Sacro Cuore /ID# 168781, Rome, Roma, Italy|Policlinico Paolo Giaccone /Id# 168134, Palermo, Sicilia, Italy|Azienda Universitaria Ospedali /ID# 168129, Bari, Italy|AOU di Cagliari - Presidio di /ID# 168132, Cagliari, Italy|A.O.U Sant'Anna di Ferrara /ID# 168714, Ferrara, Italy|AOU Riuniti di Foggia /ID# 168143, Foggia, Italy|Ospedale SM Goretti /ID# 169257, Latina, Italy|A.O.U. Policlinico G. Martino /ID# 168139, Messina, Italy|Ospedale S. Carlo Borromeo /ID# 168144, Milan, Italy|Azienda Ospedaliera Luigi Sacc /ID# 168136, Milan, Italy|Azienda Ospedaliera Luigi Sacc /ID# 168140, Milan, Italy|Azienda Ospedaliera di Rilievo /ID# 168141, Naples, Italy|AO Domenico Cutugno /ID# 168133, Napoli, Italy|Universita degli Studi della /ID# 168135, Napoli, Italy|Azienda Ospedaliera Maggiore d /ID# 168710, Novara, Italy|Azienda Ospedaliera di Padova /ID# 168125, Padua, Italy|Azienda Ospedaliera di Padova /ID# 168126, Padua, Italy|Azienda Ospedaliero - Universi /ID# 168130, Pisa, Italy|IRCCS Lazzaro Spallanzani /ID# 169234, Rome, Italy|AOU OO. RR. San Giovanni di Di /ID# 168715, Salerno, Italy|Specjalistyczny Szpital im. dra Alfreda Sokolowskiego /ID# 208862, Walbrzych, Dolnoslaskie, Poland|NZOZ - Lubuska Specjalistyczna Poradnia Chor√≥b WƒÖtroby Sp. z o.o. /ID# 208449, Zielona Gora, Dolnoslaskie, Poland|NZOZ Przychodnia Specjalistycz /ID# 208334, Zychlin, Lodzkie, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawla II /ID# 208451, Krakow, Malopolskie, Poland|Szpital Wojewodzki w Opolu /ID# 208444, Opole, Opolskie, Poland|Uniwersytecki Szpital Kliniczny w Bialymstoku /ID# 208604, Bialystok, Podlaskie, Poland|Szpital Specjalistyczny W Chorzowie /Id# 209129, Chorzow, Slaskie, Poland|NZOZ All-Medicus /ID# 208452, Katowice, Slaskie, Poland|ID Clinic /ID# 208332, Myslowice, Slaskie, Poland|Wojewodzki Szpital Obserwacyjn /ID# 209345, Bydgoszcz, Poland|Wojew√≥dzki Szpital Zespolony w Kielcach /ID# 210569, Kielce, Poland|Wojewodzki Szpit Bieganskiego /ID# 208445, Lodz, Poland|Wojewodzki Szpit Bieganskiego /ID# 209608, Lodz, Poland|MED-FIX Centrum Medyczne Sp. z /ID# 208453, Warsaw, Poland|Centro Hospitalar Barreiro Montijo, EPE /ID# 211267, Barreiro, Lisboa, Portugal|Centro Hospitalar Vila Nova Gaia/Espinho, EPE /ID# 208195, Vila Nova De Gaia, Porto, Portugal|Hospital Garcia de Orta, E.P.E /ID# 207717, Almada, Setubal, Portugal|Centro Hospitalar Universit√°rio Lisboa Central, EPE - Hospital Curry Cabral /ID# 208463, Lisboa, Portugal|Centro Hospitalar Universit√°rio de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 207910, Lisboa, Portugal|Centro Hospitalar do Porto EPE /ID# 207733, Porto, Portugal|Hopitaux Universitaires de Geneve /ID# 203435, Gen√®ve, Geneve, Switzerland|Kantonsspital St. Gallen /ID# 201025, St. Gallen, Sankt Gallen, Switzerland|Inselspital, Universitaetsklinik /ID# 201022, Bern, Switzerland|Fondazione Epatocentro Ticino /ID# 201024, Lugano, Switzerland|Hopital Neuchatelois /ID# 201026, Neuchatel, Switzerland|Universitaetsspital Zuerich /ID# 201023, Zurich, Switzerland",13.33618754,12.00256878,All,"18 Years and older ¬† (Adult, Older Adult)",85,81,76,57,8,11,9/10/2028,3/31/2029,1/29/2029,3/1/2029,1/25/2029,2/14/2029,2/24/2029,1/27/2015,2/13/2015,7/28/2019,5/3/2019,12/2/2019,1/24/2020,3/15/2020,5/9/2020,7/6/2020,9/3/2020,10/19/2020,11/29/2020,8/13/2029,2/9/2030,8/8/2030,2/4/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03303599,,,,,,
AbbVie,AbbVie,ST00087,SP00001,Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6,,,Hepatitis C Virus (HCV),,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Lucie P,Aleta H,Livia Pacheo †,Doreen T,Livia Pacheo †,Mary H,Naren G,Suk T,Marceline R,Naren G,Doreen T,Louann C,Suk T,Doreen T,Frank T,Mary H,Terisa Sikora †,Patria R,Beulah N,,,"Abbvie Japan /ID# 161985, Tokyo, Japan",55.50472503,49.95425253,All,"18 Years and older ¬† (Adult, Older Adult)",82,80,77,50,20,7,10/24/2028,4/22/2029,2/8/2029,3/12/2029,2/10/2029,2/27/2029,3/9/2029,10/10/2017,11/1/2017,7/5/2020,2/27/2020,6/7/2020,9/15/2020,10/31/2020,12/23/2020,2/4/2021,3/12/2021,5/5/2021,6/14/2021,8/26/2029,2/22/2030,8/21/2030,2/17/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03341871,,,,,,
AbbVie,AbbVie,ST00092,SP00001,"Quality of Life Measurement in Treatment Na√Øve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax¬Æ/Exviera¬Æ)",,HEMATITE,Chronic Hepatitis C Virus (HCV),,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Jeanene Y,Terisa Sikora †,Perter K,Suzie K,Tiffiny K,Mac L,Suzie K,Corrine U,Suk T,Geralyn K,Liberty A,Terisa Sikora †,Ngan D,Donovan H,Clarice N,Suzie K,Jerold Goo †,Suk T,Liberty A,,,"Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland|Inselspital, Universitaetsklin, Bern, Switzerland|Fondazione Epatocentro Ticino, Lugano, Switzerland|Hopital Neuchatelois, Neuchatel, Switzerland|Universitaetsspital Zuerich, Zurich, Switzerland",95.70662733,86.1359646,All,"20 Years to 86 Years ¬† (Adult, Older Adult)",86,83,78,68,3,7,10/3/2028,4/19/2029,2/14/2029,3/12/2029,2/10/2029,3/5/2029,3/15/2029,12/12/2016,1/3/2017,5/24/2017,9/27/2017,11/29/2017,4/25/2018,6/10/2018,7/12/2018,9/3/2018,10/27/2018,11/30/2018,1/21/2019,9/1/2029,2/28/2030,8/27/2030,2/23/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03002818,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03002818/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03002818/SAP_001.pdf"
AbbVie,AbbVie,ST00095,SP00001,Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Na√Øve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ‚â§1,,,Hepatitis C Virus (HCV),,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Gertrudis T,In Bellini †,Ngan D,Kala R,Mary H,Frank T,Lyman W,Christian G,In Bellini †,John G,Frank T,Anthony P,Naren G,Terrell p,Mary H,Beulah N,Christian G,Patria R,Dalton E,,,"Parkway Medical Center /ID# 161261, Birmingham, Alabama, United States|Arkansas Gastroenterology /ID# 161266, North Little Rock, Arkansas, United States|UC Davis Medical Center /ID# 161138, Sacramento, California, United States|Yale University /ID# 161258, New Haven, Connecticut, United States|Univ Maryland School Medicine /ID# 161157, Baltimore, Maryland, United States|Digestive Disease Associates - Baltimore /ID# 161260, Baltimore, Maryland, United States|University of Michigan Hospitals /ID# 161265, Ann Arbor, Michigan, United States|Northwest Gastroenterology Cli /ID# 161257, Portland, Oregon, United States|Liver Associates of Texas, P.A /ID# 161262, Houston, Texas, United States|University of Vermont Medical Center /ID# 161263, Burlington, Vermont, United States|Digestive and Liver Disease Sp /ID# 161259, Norfolk, Virginia, United States|DCC Aleksandrovska /ID# 161340, –°–æ—Ñ–∏—è, Sofia, Bulgaria|DCC Mladost M /ID# 161339, Varna, Bulgaria|South Health Campus /ID# 161385, Calgary, Alberta, Canada|The Moncton Hospital /ID# 161384, Moncton, New Brunswick, Canada|Brampton Civic Hospital /ID# 161380, Brampton, Ontario, Canada|Toronto Liver Centre /ID# 161381, Toronto, Ontario, Canada|Hopital Saint Joseph /ID# 161571, Marseille CEDEX 08, Bouches-du-Rhone, France|CHU de Rennes - PONTCHAILLOU /ID# 161492, Rennes, Bretagne, France|CHU de Besancon - Jean Minjoz /ID# 161485, Besancon, Doubs, France|Hopitaux de Brabois Adultes /ID# 161482, Vandoeuvre les Nancy, Lorraine, France|Universit√§tsklinikum Frankfurt /ID# 161397, Frankfurt am Main, Hessen, Germany|Universitaetsmedizin der Johannes-Gutenberg Universit√§t Mainz /ID# 161396, Mainz, Rheinland-Pfalz, Germany|Charit√© Universit√§tsmedizin Campus Mitte /ID# 161395, Berlin, Germany|ICH Study Center GmbH & Co KG /ID# 161394, Hamburg, Germany|Centrum Badan Klinicznych /Id# 162218, Wroc≈Çaw, Dolnoslaskie, Poland|HepID - Diagnostyka I Terapia /ID# 162219, Lublin, Lubelskie, Poland|Uniwersytecki Szpital Kliniczn /ID# 162216, Bialystok, Poland|ID Clinic /ID# 162217, Myslowice, Poland|Innovative Care P.S.C. /ID# 162787, San Juan, Puerto Rico|A. F. Agafonov Republican Clin /ID# 163164, Kazan, Tatarstan, Respublika, Russian Federation|South Ural State Medical univ /ID# 163163, Chelyabinsk, Russian Federation|A.I. Evdokimov Moscow State Un /ID# 163162, Moscow, Russian Federation|Hospital Fundacion Alcorcon /ID# 161436, Alcorcon, Spain|Hospital Clinic de Barcelona /ID# 161437, Barcelona, Spain|Hospital Vall d'Hebron /ID# 162022, Barcelona, Spain|Hosp Uni Virgen de la Victoria /ID# 164383, Malaga, Spain|Complexo Hospitalario universi /ID# 165603, Pontevedra, Spain|Bradford Teaching Hospitals /ID# 161424, Bradford, United Kingdom|Glasgow Royal Infirmary /ID# 161458, Glasgow, United Kingdom|Gloucester Royal Hospital /ID# 161423, Gloucester, United Kingdom|Freeman Hospital /ID# 161459, Newcastle Upon Tyne, United Kingdom",24.37155331,21.93439798,All,"18 Years to 65 Years ¬† (Adult, Older Adult)",87,83,79,71,2,6,11/27/2028,4/8/2029,2/28/2029,3/21/2029,2/28/2029,3/8/2029,3/18/2029,3/22/2014,4/3/2014,8/16/2017,12/6/2017,6/15/2018,8/13/2018,9/16/2018,10/31/2018,12/9/2018,1/11/2019,2/14/2019,4/1/2019,9/4/2029,3/3/2030,8/30/2030,2/26/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03212521,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03212521/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03212521/SAP_001.pdf"
AbbVie,AbbVie,ST00096,SP00001,A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection,,ENDURANCE-5 6,Hepatitis C Virus (HCV),,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Mara A,Mara A,Jeanene Y,Dinah R,Anthony P,Suk T,Tamesha T,Frank T,Liberty A,Selizabeth F,Clarice N,Terrell p,Lavina S,Donovan H,Dinah R,Liberty A,Mary H,Lavina S,Tien C,,,"Research & Education, Inc. /ID# 157042, San Diego, California, United States|Kaiser Permanente /ID# 157044, San Diego, California, United States|Zuckerberg San Francisco Gener /ID# 157040, San Francisco, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 157045, West Hollywood, California, United States|Einstein Medical Center /ID# 157436, Philadelphia, Pennsylvania, United States|University of Washington /ID# 157041, Seattle, Washington, United States|Nepean Hospital Kingswood /ID# 157027, Kingswood, New South Wales, Australia|Royal Brisbane and Women's Hospital /ID# 157025, Herston, Queensland, Australia|Royal Melbourne Hospital /ID# 157024, Parkville, Victoria, Australia|AZ Groeninge /ID# 157029, Kortrijk, Belgium|UZ Leuven /ID# 157030, Leuven, Belgium|University of Calgary /ID# 157031, Calgary, Alberta, Canada|Toronto General Hospital /ID# 157032, Toronto, Ontario, Canada|Hopital Haut-L√©v√™que /ID# 157035, Pessac CEDEX, Gironde, France|Hopital Beaujon /ID# 157028, Clichy, Ile-de-France, France|CHU Estaing /ID# 157034, Clermont Ferrand, France|Hopital Saint Antoine /ID# 157036, Paris, France|Auckland Clinical Studies Ltd /ID# 157033, Auckland, New Zealand|National University Hospital /ID# 156855, Singapore, Singapore|Singapore General Hospital /ID# 157037, Singapore, Singapore|Wits Clinical Research Site /ID# 157038, Johannesburg, Gauteng, South Africa|University of Cape Town /ID# 157039, Cape Town, Western Cape, South Africa|National Hospital of Tropical Diseases /ID# 162282, Hanoi, Vietnam|Hoa Hao Medic Co. Ltd. /ID# 162283, Ho Chi Minh, Vietnam|Tropical Diseases Hospital /ID# 162281, Ho Chi Minh, Vietnam",88.46342724,79.61708452,All,"18 Years and older ¬† (Adult, Older Adult)",90,87,80,71,0,9,11/2/2028,5/1/2029,2/9/2029,3/20/2029,2/28/2029,3/9/2029,3/19/2029,5/11/2015,5/19/2015,10/15/2017,11/7/2017,2/26/2018,6/6/2018,7/20/2018,8/24/2018,10/19/2018,12/17/2018,1/23/2019,3/24/2019,9/5/2029,3/4/2030,8/31/2030,2/27/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02966795,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02966795/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02966795/SAP_001.pdf"
AbbVie,AbbVie,ST00097,SP00001,A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease,,AIM-CD,Crohn's Disease,,I&I,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug A,,,,,,,,,,,,,,,,,,,John G,Mara A,Harry A,Doreen T,Livia Pacheo †,Tien C,Marceline R,Lucie P,Stephan T,Ross S,Beulah N,Jeanene Y,Dinah R,Mary H,Anthony P,Jaquelyn H,Perter K,Federico L,Dalton E,,,"Hoag Memorial Hosp Presbyterian /ID# 233555, Irvine, California, United States|Medical Research Center of CT /ID# 233542, Hamden, Connecticut, United States|Nature Coast Clinical Research - Inverness /ID# 233514, Inverness, Florida, United States|Atlantic Medical Research Group /ID# 233506, Margate, Florida, United States|Gastroenterology Group Naples /ID# 233829, Naples, Florida, United States|IMIC Inc. Medical Research /ID# 233821, Palmetto Bay, Florida, United States|University of Chicago /ID# 233824, Chicago, Illinois, United States|Southwest Gastroenterology /ID# 234278, Oak Lawn, Illinois, United States|Tri-State Gastroenterology /ID# 233805, Crestview Hills, Kentucky, United States|University of Louisville /ID# 233766, Louisville, Kentucky, United States|MGG Group Co, Inc.Chevy Chase Clinical Research /ID# 233553, Chevy Chase, Maryland, United States|University of Michigan Health Systems /ID# 233765, Ann Arbor, Michigan, United States|Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinic /ID# 233763, Wyoming, Michigan, United States|Mayo Clinic - Rochester /ID# 238516, Rochester, Minnesota, United States|Las Vegas Medical Research /ID# 233826, Las Vegas, Nevada, United States|The Mount Sinai Hospital /ID# 233823, New York, New York, United States|Lenox Hill Hospital /ID# 239312, New York, New York, United States|University of Cincinnati /ID# 234237, Cincinnati, Ohio, United States|Digestive Disease Specialists /ID# 233825, Oklahoma City, Oklahoma, United States|Vanderbilt University Medical Center /ID# 233920, Nashville, Tennessee, United States|Texas Digestive Disease Consultants /ID# 233764, Cedar Park, Texas, United States|Texas Digestive Disease Consultants - Southlake /ID# 233744, Southlake, Texas, United States|Tyler Research Institute, LLC /ID# 233730, Tyler, Texas, United States|Texas Digestive Disease Consultants - Webster /ID# 233924, Webster, Texas, United States|Hunter Holmes McGuire VA Medical Center /ID# 233759, Richmond, Virginia, United States|Royal Adelaide Hospital /ID# 233705, Adelaide, South Australia, Australia|Medizinische Universitaet Wien /ID# 234218, Vienna, Wien, Austria|Medizinische Universitat Innsbruck,Universitatsklinik fur Innere Medizin 1 /ID# 234217, Innsbruck, Austria|Landeskrankenhaus Salzburg-Universit√§tsklinikum der PMU (LKH) /ID# 234069, Salzburg, Austria|UCL Saint-Luc /ID# 232435, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|CHU de Liege /ID# 232436, Liege, Belgium|AZ-Delta /ID# 232437, Roeselare, Belgium|University Multiprofile Hospit /ID# 232468, Plovdiv, Bulgaria|UMHAT Tsaritsa Joanna - ISUL /ID# 234135, Sofia, Bulgaria|Acibadem City Clinic University Hospital EOOD /ID# 240003, Sofia, Bulgaria|Heritage Medical Research Clinic (University of Calgary) /ID# 233838, Calgary, Alberta, Canada|Allen Whey Khye Lim Professional Corporation /ID# 233831, Edmonton, Alberta, Canada|Covenant Health /ID# 234277, Edmonton, Alberta, Canada|QE II Health Sciences Centre /ID# 233839, Halifax, Nova Scotia, Canada|Scott Shulman Medicine Professional Corporation /ID# 239567, North Bay, Ontario, Canada|Toronto Digestive Disease Asso /ID# 234143, Vaughan, Ontario, Canada|Chu de Nice-Hopital L'Archet Ii /Id# 234226, Nice, Alpes-Maritimes, France|CHU de SAINT ETIENNE - Hopital Nord /ID# 234225, St. Priest En Jarez, Loire, France|CHRU Nancy - H√¥pitaux de Brabois /ID# 234224, Vand≈ìuvre-l√®s-Nancy, Meurthe-et-Moselle, France|AP-HP - Hopital Saint-Louis /ID# 234227, Paris, France|Universitaetsklinikum Freiburg /ID# 233719, Freiburg, Baden-Wuerttemberg, Germany|Universitatsklinikum Mannheim /ID# 233716, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Ulm /ID# 233531, Ulm, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 233529, Erlangen, Bayern, Germany|Universitatsklinik Regensburg /ID# 238702, Ratisbon, Bayern, Germany|Praxiszentrum fuer Gastroenterologie /ID# 233722, Grevenbroich, Nordrhein-Westfalen, Germany|Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 233527, Kiel, Schleswig-Holstein, Germany|DRK Kliniken Berlin Westend /ID# 233718, Berlin, Germany|Medizinische Hochschule Hannover /ID# 238804, Hannover, Germany|EUGASTRO GmbH /ID# 233717, Leipzig, Germany|Klinikum Lueneburg /ID# 233720, Lueneburg, Germany|General Hospital of Athens Ippokratio /ID# 231655, Athens, Attiki, Greece|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 231660, Athens, Attiki, Greece|University General Hospital of Heraklion PA.G.N.I /ID# 231657, Heraklion, Kriti, Greece|General Hospital of Nikaia-Piraeus ""Agios Panteleimon""- general hospital dytikis /ID# 231659, Pireaus, Greece|Soroka University Medical Center /ID# 233458, Beer Sheva, HaDarom, Israel|Sheba Medical Center /ID# 233457, Ramat Gan, Tel-Aviv, Israel|Tel Aviv Sourasky Medical Center /ID# 238525, Tel Aviv-Yafo, Tel-Aviv, Israel|Shaare Zedek Medical Center /ID# 233460, Jerusalem, Israel|Hadassah Medical Center-Hebrew University /ID# 233518, Jerusalem, Israel|Policlinico Agostino Gemelli /ID# 233380, Rome, Lazio, Italy|ASST Rhodense/Presidio Ospedaliero di Rho /ID# 233386, Rho, Milano, Italy|Azienda Ospedaliera Universitaria Consorziale Policlinico /ID# 233387, Bari, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 233382, Milan, Italy|Azienda Ospedaliera di Padova /ID# 233389, Padova, Italy|Okayama University Hospital /ID# 239757, Okayama-shi, Okayama, Japan|The Catholic University of Korea, Daejeon St.Mary's Hospital /ID# 233700, Daejeon, Korea, Republic of|Asan Medical Center /ID# 233701, Seoul, Korea, Republic of|Samsung Medical Center /ID# 233698, Seoul, Korea, Republic of|Academisch Medisch Centrum /ID# 232123, Amsterdam, Netherlands|Wellington Regional Hospital /ID# 238326, Newtown, Wellington, New Zealand|Hutt Hospital /ID# 238327, Lower Hutt, New Zealand|Dunedin Hospital /ID# 238325, Otago, New Zealand|Planetmed Sp. z o.o. /ID# 238447, Wroclaw, Dolnoslaskie, Poland|WIP Warsaw IBD Point Profesor Kierkus /ID# 233533, Warsaw, Mazowieckie, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 238653, Warszawa, Mazowieckie, Poland|Immanuel Kant Baltic Federal University /ID# 234165, Kaliningrad, Kaliningradskaya Oblast, Russian Federation|Uninova Medical Center /ID# 238775, Saint Petersburg, Leningradskaya Oblast, Russian Federation|LLC Medical Center /ID# 238774, Novosibirsk, Novosibirskaya Oblast, Russian Federation|Perm Clinical Center of the Federal Medical and Biological Agency /ID# 234166, Perm, Permskiy Kray, Russian Federation|First Moscow State Medical University n.a I.M. Sechenov /ID# 238773, Moscow, Russian Federation|Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 232373, Banska Bystrica, Slovakia|GASTRO I., s.r.o. /ID# 232372, Presov, Slovakia|Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 232299, Ferrol, A Coruna, Spain|Hospital Santa Creu i Sant Pau /ID# 232301, Barcelona, Spain|Hospital Universitario La Paz /ID# 232300, Madrid, Spain|Hospital Clinico Universitario de Valencia /ID# 234103, Valencia, Spain|China Medical University Hospital /ID# 234132, Taichung City, Taiwan|Taichung Veterans General Hospital /ID# 234131, Taichung, Taiwan|National Taiwan University Hospital /ID# 234134, Taipei City, Taiwan|Barts Health NHS Trust /ID# 234188, London, London, City Of, United Kingdom|Guy's and St Thomas' NHS Foundation Trust /ID# 234191, London, London, City Of, United Kingdom|NHS Greater Glasgow and Clyde /ID# 234186, Glasgow, Scotland, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 234187, Newcastle Upon Tyne, United Kingdom",81.09567984,72.98611186,All,20 Years to 60 Years ¬† (Adult),85,83,81,33,42,6,11/4/2018,5/7/2019,2/25/2019,3/15/2019,2/13/2019,3/8/2019,3/17/2019,3/18/2019,4/7/2019,1/7/2023,5/31/2023,11/10/2023,12/29/2023,2/1/2024,3/13/2024,4/28/2024,6/4/2024,7/30/2024,9/2/2024,9/4/2019,3/2/2020,8/29/2020,2/25/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05068284,,,,,,
AbbVie,AbbVie,ST00135,SP00001,A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis,,,Psoriasis,,I&I,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Chetan K,John G,Jeanene Y,Suzie K,Hee Y,Mary H,Jaquelyn H,Kandace p,Chetan K,Terisa Sikora †,Jene M,John G,Garnet T,Stephan T,Perter K,Terisa Sikora †,John G,Corrine U,Tien C,,,"UAB Department of Dermatology /ID# 238563, Birmingham, Alabama, United States|Providence Clinical Research /ID# 239536, North Hollywood, California, United States|Medderm Associates /ID# 238834, San Diego, California, United States|Lakes Research, LLC /ID# 238831, Miami, Florida, United States|Lenus Research & Medical Group /ID# 238695, Sweetwater, Florida, United States|Clinical Research Trials of Florida, Inc. /ID# 238709, Tampa, Florida, United States|ForCare Clinical Research /ID# 238856, Tampa, Florida, United States|Marietta Dermatology Clinical Research /ID# 238679, Marietta, Georgia, United States|Arlington Dermatology /ID# 238701, Rolling Meadows, Illinois, United States|Dawes Fretzin, LLC /ID# 238704, Indianapolis, Indiana, United States|Mayo Clinic - Rochester /ID# 239250, Rochester, Minnesota, United States|Skin Specialists, PC /ID# 238514, Omaha, Nebraska, United States|Forest Hills Dermatology Group /ID# 238708, Kew Gardens, New York, United States|Icahn School of Medicine at Mount Sinai /ID# 238942, New York, New York, United States|Buffalo Medical Group /ID# 239068, Williamsville, New York, United States|Darst Dermatology /ID# 238677, Charlotte, North Carolina, United States|Dermatology Consulting Service /ID# 238678, High Point, North Carolina, United States|Dermatologists of Southwest Ohio, Inc /ID# 238939, Mason, Ohio, United States|Oregon Dermatology and Research Center /ID# 238823, Portland, Oregon, United States|Clinical Research Center of the Carolinas /ID# 238827, Charleston, South Carolina, United States|Health Concepts /ID# 238510, Rapid City, South Dakota, United States|Tennessee Clinical Research Center /ID# 238682, Nashville, Tennessee, United States|Orion Clinical Research /ID# 238619, Austin, Texas, United States|Progressive Clinical Research /ID# 238565, San Antonio, Texas, United States|Dermatology Specialists of Spokane /ID# 238809, Spokane, Washington, United States|Premier Clinical Research /ID# 238507, Spokane, Washington, United States|West Virginia Research /ID# 238517, Morgantown, West Virginia, United States",26.86431891,24.17788702,All,"18 Years to 65 Years ¬† (Adult, Older Adult)",86,85,82,47,30,5,3/14/2018,8/30/2018,6/17/2018,7/28/2018,7/1/2018,7/14/2018,7/27/2018,7/29/2018,8/9/2018,6/20/2022,6/5/2022,1/12/2023,2/16/2023,4/4/2023,5/7/2023,6/25/2023,7/26/2023,9/10/2023,10/20/2023,1/10/2019,7/9/2019,1/5/2020,7/3/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05044234,,,,,,
AbbVie,AbbVie,ST00151,SP00001,A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD),,,Atopic Dermatitis,,I&I,,,,,,Industry,Not yet recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Harry A,Chetan K,Jaquelyn H,Gertrudis T,Doreen T,Anthony P,Suk T,John G,Jene M,Mac L,Ross S,Beulah N,Dinah R,Anthony P,Dalton E,Suzie K,Tammara F,Mary H,Jene M,,,,62.07769359,55.86992423,All,"Child, Adult, Older Adult",88,86,83,77,8,2,8/24/2024,3/6/2025,1/8/2025,2/8/2025,1/9/2025,1/22/2025,1/30/2025,2/1/2025,2/17/2025,8/8/2025,8/9/2025,11/15/2025,2/28/2026,4/13/2026,5/24/2026,7/9/2026,8/11/2026,10/2/2026,11/29/2026,7/21/2025,1/17/2026,7/16/2026,1/12/2027,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05029895,,,,,,
AbbVie,AbbVie,ST00152,SP00001,Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer Receiving Intravenous (IV) ABBV-400,,,Non-Small Cell Lung Cancer,,Oncology,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Perter K,Aleta H,Geralyn K,Selizabeth F,Lyman W,Perter K,Jene M,Gertrudis T,Garnet T,Marceline R,Lyman W,Donovan H,Selizabeth F,Stephan T,Federico L,Frank T,Tamesha T,Otis Thode †,Kala R,,,"Univ of Colorado Cancer Center /ID# 231574, Aurora, Colorado, United States|Carolina BioOncology Institute /ID# 231541, Huntersville, North Carolina, United States|Virginia Cancer Specialists - Fairfax /ID# 231575, Fairfax, Virginia, United States|National Cancer Center Hospital East /ID# 232008, Kashiwa-shi, Chiba, Japan|National Cancer Center Hospital /ID# 232007, Chuo-ku, Tokyo, Japan|Pan American Center for Oncology Trials, LLC /ID# 231580, Rio Piedras, Puerto Rico",21.95054873,19.75549386,All,"18 Years and older ¬† (Adult, Older Adult)",92,89,84,65,11,8,5/29/2023,11/22/2023,10/18/2023,10/30/2023,10/8/2023,10/23/2023,11/7/2023,11/8/2023,11/26/2023,7/14/2024,10/25/2024,4/18/2025,6/28/2025,8/9/2025,9/8/2025,10/20/2025,11/19/2025,1/6/2026,2/17/2026,4/20/2024,10/17/2024,4/15/2025,10/12/2025,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05029882,,,,,,
AbbVie,AbbVie,ST00157,SP00001,Observational Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules,,REACH,Heavy Menstrual Bleeding|Uterine Fibroids,,,,,,,,Industry,Not yet recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,James y,Terrell p,Mac L,Donovan H,Mara A,Chetan K,Harry A,Mary H,Quentin N,Lavina S,Marceline R,Anthony P,Naren G,Chetan K,Suzie K,Perter K,Frank T,Dalton E,Mara A,,,,33.62592516,30.26333265,Female,"18 Years and older ¬† (Adult, Older Adult)",89,88,85,41,38,6,11/16/2017,5/31/2018,3/18/2018,4/25/2018,4/6/2018,4/13/2018,4/28/2018,5/1/2018,5/19/2018,6/4/2022,1/1/2022,5/7/2022,8/31/2022,10/13/2022,12/4/2022,1/18/2023,3/9/2023,5/4/2023,7/2/2023,10/10/2018,4/8/2019,10/5/2019,4/2/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05026502,,,,,,
AbbVie,AbbVie,ST00181,SP00001,"Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab",,,Non-Small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma,,Oncology,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Marcelina X,Dalton E,Chetan K,John G,Kandace p,Suzie K,Federico L,Naren G,Harry A,Chetan K,Stephan T,Mac L,Perter K,In Bellini †,Donovan H,Naren G,Tamesha T,Naren G,Mary H,,,"Carolina BioOncology Institute /ID# 232597, Huntersville, North Carolina, United States|Sheba Medical Center /ID# 238332, Ramat Gan, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 238333, Haifa, Israel|National Cancer Center Hospital /ID# 238372, Chuo-ku, Tokyo, Japan",84.62864088,76.16577679,All,"20 Years to 65 Years ¬† (Adult, Older Adult)",91,90,86,55,24,7,6/25/2023,12/26/2023,11/17/2023,12/2/2023,11/4/2023,11/26/2023,11/29/2023,11/30/2023,12/8/2023,1/15/2026,7/26/2025,1/22/2026,5/2/2026,6/19/2026,8/7/2026,9/21/2026,11/13/2026,12/28/2026,2/13/2027,5/24/2024,11/20/2024,5/19/2025,11/15/2025,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05005403,,,,,,
AbbVie,AbbVie,ST00228,SP00001,"A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154",,AIM-PMR,Polymyalgia Rheumatica,,,,,,,,Industry,Recruiting,Phase 1,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Donovan H,Mara A,Suzie K,Louann C,Suzie K,Terisa Sikora †,Mary H,Jaquelyn H,Naren G,Jaquelyn H,Quentin N,Tien C,Chetan K,Jerold Goo †,Federico L,Patria R,Terrell p,Perter K,Tammara F,,,"Arthritis and Rheumatism Associates /ID# 232089, Jonesboro, Arkansas, United States|Providence Medical Foundation /ID# 228681, Fullerton, California, United States|Care Access Research, Huntington Beach /ID# 228677, Huntington Beach, California, United States|Arthritis & Osteo Medical Ctr /ID# 228680, La Palma, California, United States|Hans Richard Barthel, M.D., Inc /ID# 231902, Santa Barbara, California, United States|Medvin Clinical Research /ID# 228675, Tujunga, California, United States|Inland Rheum & Osteo Med Grp /ID# 228679, Upland, California, United States|Delaware Arthritis /ID# 230110, Lewes, Delaware, United States|Rheumatology Associates of South Florida (RASF) - Clinical Research /ID# 232238, Boca Raton, Florida, United States|International Medical Research - Daytona /ID# 228765, Daytona Beach, Florida, United States|Lakes Research, LLC /ID# 228757, Miami, Florida, United States|HMD Research LLC /ID# 228767, Orlando, Florida, United States|Springfield Clinic /ID# 228840, Springfield, Illinois, United States|Four Rivers Clinical Research /ID# 228858, Paducah, Kentucky, United States|Rheumatology Consultants - Clinical Research /ID# 232137, Tupelo, Mississippi, United States|Dartmouth-Hitchcock Medical Center /ID# 229557, Lebanon, New Hampshire, United States|Ocean Rheumatology, PA /ID# 232539, Toms River, New Jersey, United States|Hospital for Special Surgery /ID# 228577, New York, New York, United States|St. Lawrence Health System /ID# 229702, Potsdam, New York, United States|Paramount Medical Research Con /ID# 228839, Middleburg Heights, Ohio, United States|Clinical Research Source, Inc. /ID# 231903, Perrysburg, Ohio, United States|Altoona Ctr Clinical Res /ID# 232493, Duncansville, Pennsylvania, United States|Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 228860, Summerville, South Carolina, United States|West Tennessee Research Institute /ID# 228854, Jackson, Tennessee, United States|Rheumatology Care Center PLLC /ID# 232306, Bellaire, Texas, United States|Emeritus Research Sydney /ID# 229166, Botany, New South Wales, Australia|Tasman Oncology Research /ID# 230829, Southport, Queensland, Australia|The Queen Elizabeth Hospital /ID# 229049, Woodville South, South Australia, Australia|Emeritus Research /ID# 229270, Camberwell, Victoria, Australia|Austin Health /ID# 229164, Heidelberg, Victoria, Australia|Fiona Stanley Hospital /ID# 229050, Murdoch, Western Australia, Australia|Rheuma-Zentrum Wien-Oberlaa GmbH /ID# 229436, Vienna, Wien, Austria|Klinik Hietzing /ID# 229437, Vienna, Wien, Austria|Rheumatology Research Associates /ID# 230363, Edmonton, Alberta, Canada|The Waterside Clinic /ID# 230364, Barrie, Ontario, Canada|CISSSBSL -Hopital regional de Rimouski /ID# 228394, Rimouski, Quebec, Canada|Centre de Recherche Musculo-Squelettique /ID# 228392, Trois-rivi√®res, Quebec, Canada|CHU Montpellier - H√¥pital Lapeyronie /ID# 228347, Montpellier, Herault, France|Centre Hospitalier du Mans /ID# 229044, Le Mans CEDEX 9, Sarthe, France|Hopital de la Cavale Blanche /ID# 228348, Brest, France|CHRU Tours - Hopital Trousseau /ID# 228349, Chambray Les Tours, France|AP-HP - Hopital Cochin /ID# 231800, Paris, France|Medius Klinik Kirchheim /ID# 228660, Kirchheim unter Teck, Baden-Wuerttemberg, Germany|Immanuel Krankenhaus Berlin /ID# 228659, Berlin-buch, Germany|Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 228661, Berlin, Germany|MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH /ID# 228658, Hamburg, Germany|Obudai Egeszsegugyi Centrum Kft. /ID# 231121, Budapest, Pest, Hungary|Clinexpert Kft /ID# 229677, Budapest, Hungary|Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz /ID# 229758, Gyula, Hungary|Pest Megyei Flor Ferenc Korhaz /ID# 229676, Kistarcsa, Hungary|CMED Rehabilitacios es Diagnosztikai Kozpont /ID# 230065, Szekesfehervar, Hungary|Csongrad-Csanad Megyei Dr. Bugyi Istvan Korhaz /ID# 229793, Szentes, Hungary|Vital Medical Center Orvosi es Fogaszati Kozpont (Vital Medicina Kft.) /ID# 229674, Veszpr√©m, Hungary|Obudai Egeszsegugyi Centrum Kft. Zalaegerszeg /ID# 229759, Zalaegerszeg, Hungary|ASL 3 Genovese - Ospedale la Colletta /ID# 229282, Arenzano, Genova, Italy|Azienda Ospedaliero-Universitaria di Modena /ID# 228825, Modena, Italy|A.O.U. Citta della Salute e della Scienza di Torino /ID# 229080, Turin, Italy|Azienda Ospedaliera Universitaria Friuli Centrale/Presidio Ospedaliero Universit /ID# 228815, Udine, Italy|Daido Clinic /ID# 230204, Nagoya-shi, Aichi, Japan|NHO Nagoya Medical Center /ID# 232420, Nagoya-shi, Aichi, Japan|National Hospital Organization Shimoshizu National Hospital /ID# 230500, Yotsukaido-shi, Chiba, Japan|Matsuyama Red Cross Hospital /ID# 230458, Matsuyama-shi, Ehime, Japan|Sanuki Municipal Hospital /ID# 230202, Sanuki-shi, Kagawa, Japan|Kuwana City Medical Center /ID# 231936, Kuwana-shi, Mie, Japan|Kyushu University Beppu Hospital /ID# 232250, Beppu-shi, Oita, Japan|Japanese Red Cross Okayama Hospital /ID# 230857, Okayama-shi, Okayama, Japan|Tokyo Medical And Dental University, Medical Hospital /ID# 232206, Bunkyo-ku, Tokyo, Japan|Toyama Prefectural Central Hospital /ID# 230616, Toyama-shi, Toyama, Japan|Hanyang University Seoul Hospital /ID# 228719, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Kyungpook National Univ Hosp /ID# 228716, Daegu, Korea, Republic of|ZiekenhuisGroep Twente /ID# 229071, Almelo, Netherlands|Universitair Medisch Centrum Groningen /ID# 227727, Groningen, Netherlands|Maastricht Universitair Medisch Centrum /ID# 227779, Maastricht, Netherlands|Maasstad Ziekenhuis /ID# 228064, Rotterdam, Netherlands|Viecuri Medisch Centrum /ID# 228250, Venlo, Netherlands|Optimal Clinical Trials Ltd /ID# 229048, Grafotn, Auckland, New Zealand|Middlemore Clinical Trials /ID# 229099, Papatoetoe, Auckland, New Zealand|Timaru Medical Specialists Ltd /ID# 229098, Timaru, Canterbury, New Zealand|Waikato Hospital /ID# 229047, Hamilton, Waikato, New Zealand|Wellington Regional Hospital /ID# 229490, Newtown, Wellington, New Zealand|NZOZ Biogenes Sp. z o.o. /ID# 228357, Wroclaw, Dolnoslaskie, Poland|Szpital Uniwersytecki nr 2 im. dr. Jana Biziela /ID# 228353, Bydgoszcz, Kujawsko-pomorskie, Poland|ReumaClinic Gabinet Reumatologiczny Izabela Domyslawska /ID# 228466, Bialystok, Podlaskie, Poland|AI Centrum Medyczne Sp. z o.o. sp.k. /ID# 228951, Poznan, Wielkopolskie, Poland|Ortopedyczno-Rehabilitacyjny Szpital Kliniczny im. Wiktora Degi /ID# 228314, Poznan, Wielkopolskie, Poland|Hospital Unversitario Marques de Valdecilla /ID# 229297, Santander, Cantabria, Spain|Hospital Universitario Canarias /ID# 229451, San Crist√≥bal de La Laguna, Santa Cruz De Tenerife, Spain|Hospital General Universitario Gregorio Maranon /ID# 229302, Madrid, Spain|Hospital Clinico Universitario San Carlos /ID# 229296, Madrid, Spain|North West Anglia NHS Foundation Trust /ID# 230866, Bretton, Cambridgeshire, United Kingdom|Leicester Royal Infirmary /ID# 231967, Leicester, England, United Kingdom|The Royal Free London NHS Foundation Trust /ID# 231707, London, London, City Of, United Kingdom|Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 231966, Norwich, Norfolk, United Kingdom|UH Coventry & Warwickshire /ID# 228588, Coventry, United Kingdom|Manchester University NHS Foundation Trust /ID# 230886, Manchester, United Kingdom|The Royal Wolverhampton NHS Trust /ID# 230302, Wolverhampton, United Kingdom",69.68411225,62.71570102,All,"18 Years and older ¬† (Adult, Older Adult)",96,92,87,67,8,12,10/20/2017,3/10/2018,12/25/2017,2/8/2018,1/4/2018,1/23/2018,1/30/2018,2/4/2018,2/11/2018,7/13/2022,4/26/2022,10/13/2022,12/13/2022,2/4/2023,3/29/2023,5/3/2023,6/13/2023,7/29/2023,9/17/2023,7/22/2018,1/18/2019,7/17/2019,1/13/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04972968,,,,,,
AbbVie,AbbVie,ST00267,SP00001,Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms,,CisCP,Chronic Pancreatitis,,,,,,,,Industry,Recruiting,Phase 3,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Naren G,John G,Tien C,Lavina S,Kandace p,Jene M,Jeanene Y,Suk T,John G,Terisa Sikora †,Terrell p,Christian G,Garnet T,Jerold Goo †,Stephan T,Chetan K,Chetan K,Lavina S,Hee Y,,,"Stanford University School of Med /ID# 229530, Stanford, California, United States|University of Florida - Archer /ID# 227057, Gainesville, Florida, United States|John Hopkins University /ID# 227061, Baltimore, Maryland, United States|University of Minnesota - Minneapolis /ID# 227364, Minneapolis, Minnesota, United States|NYU Langone Health /ID# 230818, New York, New York, United States|Duke University Hospital /ID# 227065, Durham, North Carolina, United States|The Ohio State University Wexner Medical Center /ID# 227844, Columbus, Ohio, United States|Baylor College of Medicine - Baylor Medical Center /ID# 227067, Houston, Texas, United States",56.63429788,50.97086809,All,"Child, Adult, Older Adult",90,89,88,57,20,11,12/21/2019,5/29/2020,3/27/2020,4/27/2020,3/20/2020,4/11/2020,4/19/2020,4/22/2020,5/10/2020,7/18/2021,11/26/2021,2/8/2022,7/1/2022,8/5/2022,9/24/2022,10/27/2022,12/16/2022,2/5/2023,4/5/2023,10/8/2020,4/6/2021,10/3/2021,4/1/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04949828,,,,,,
AbbVie,AbbVie,ST00300,SP00001,A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC),,,,,Oncology,,,,,,Industry,Terminated,Phase 1,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Donovan H,Tamesha T,Quentin N,Naren G,James y,Donovan H,James y,Mee M,Perter K,Jene M,Ngan D,Jaquelyn H,Tammara F,In Bellini †,Lyman W,John G,Mary H,Selizabeth F,Louann C,,,"University of Chicago /ID# 169231, Chicago, Illinois, United States|Washington University School /ID# 169177, Saint Louis, Missouri, United States|Memorial Sloan Kettering /ID# 201016, New York, New York, United States|Gabrail Cancer Center Research /ID# 168756, Canton, Ohio, United States|Oklahoma University /ID# 200937, Oklahoma City, Oklahoma, United States|Tennessee Oncology-Sarah Cannon Research Institute /ID# 169233, Nashville, Tennessee, United States|Baylor University /ID# 169860, Houston, Texas, United States|MD Anderson Cancer Center /ID# 169232, Houston, Texas, United States",66.85011305,60.16510174,All,"18 Years and older ¬† (Adult, Older Adult)",97,95,89,38,44,7,3/18/2016,8/8/2016,6/21/2016,7/27/2016,6/29/2016,7/7/2016,7/21/2016,7/22/2016,7/29/2016,7/31/2018,3/17/2018,7/6/2018,10/5/2018,11/19/2018,1/16/2019,2/20/2019,4/1/2019,5/14/2019,6/29/2019,1/3/2017,7/2/2017,12/29/2017,6/27/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03316794,,,,,,
AbbVie,AbbVie,ST00333,SP00001,A Study of SC-007 in Subjects With Advanced Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 1,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Jerold Goo †,Kala R,Chetan K,Chetan K,Aleta H,Federico L,Clarice N,Suzie K,Jaquelyn H,John G,Marcelina X,Aleta H,Jerold Goo †,Xochitl D,Lavina S,Garnet T,Tamesha T,Anthony P,Mee M,,,"University of California, Los Angeles, Los Angeles, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University-School of Medicine, Saint Louis, Missouri, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Tennessee Oncology-Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States",48.98682535,44.08814281,All,"18 Years and older ¬† (Adult, Older Adult)",100,99,90,41,42,7,6/26/2013,11/15/2013,9/29/2013,10/17/2013,9/21/2013,10/5/2013,10/12/2013,10/17/2013,10/28/2013,1/21/2018,8/1/2017,1/25/2018,3/20/2018,5/15/2018,6/19/2018,8/14/2018,10/5/2018,11/18/2018,1/14/2019,4/3/2014,9/30/2014,3/29/2015,9/25/2015,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03253185,,,,,,
AbbVie,AbbVie,ST00336,SP00001,"SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers",,,,,Oncology,,,,,,Industry,Terminated,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Lucie P,Livia Pacheo †,Marcelina X,Donovan H,Clarice N,Suzie K,Terrell p,Dinah R,Frank T,Ross S,Perter K,Remedios Z,Kala R,Mee M,Marcelina X,Suzie K,Dinah R,Ngan D,Christian G,,,"University of Alabama /ID# 202249, Birmingham, Alabama, United States|Highlands Oncology Group /ID# 209165, Fayetteville, Arkansas, United States|City of Hope /ID# 202493, Duarte, California, United States|University of Chicago /ID# 200735, Chicago, Illinois, United States|Henry Ford Health System /ID# 202480, Detroit, Michigan, United States|Mayo Clinic - Rochester /ID# 200732, Rochester, Minnesota, United States|Washington University School /ID# 164091, Saint Louis, Missouri, United States|The Ohio State University - Columbus /ID# 164089, Columbus, Ohio, United States|Univ Oklahoma HSC /ID# 164090, Oklahoma City, Oklahoma, United States|Tennessee Oncology-Nashville Centennial /ID# 164088, Nashville, Tennessee, United States|MD Anderson Cancer Center /ID# 200048, Houston, Texas, United States|Huntsman Cancer Institute /ID# 209164, Salt Lake City, Utah, United States",13.28676259,11.95808633,Female,"18 Years and older ¬† (Adult, Older Adult)",99,98,91,72,10,9,10/29/2016,3/17/2017,1/19/2017,3/3/2017,1/21/2017,2/11/2017,2/26/2017,3/2/2017,3/17/2017,12/20/2018,8/6/2018,2/4/2019,5/2/2019,6/10/2019,8/6/2019,10/2/2019,11/25/2019,1/15/2020,3/5/2020,8/10/2017,2/6/2018,8/5/2018,2/1/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03138408,,,,,,
AbbVie,AbbVie,ST00368,SP00001,"A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab",,,,,Oncology,,,,,,Industry,Terminated,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Jaquelyn H,Stephan T,Lilla Stilson †,Federico L,Jene M,Suk T,Xochitl D,Liberty A,Mary H,Aleta H,Perter K,Harry A,Suzie K,Jaquelyn H,Dinah R,Gertrudis T,Frank T,John G,John G,,,"Ironwood Cancer & Res Ctr /ID# 200044, Chandler, Arizona, United States|Highlands Oncology Group /ID# 169289, Fayetteville, Arkansas, United States|City of Hope /ID# 200501, Duarte, California, United States|St. Joseph Heritage Healthcare /ID# 200100, Fullerton, California, United States|USC Norris Cancer Center /ID# 200410, Los Angeles, California, United States|Hoag Memorial Hosp Presbyterian /ID# 202661, Newport Beach, California, United States|Torrance Health Association (DBA)Torrance Memorial Physician Network/Cancer Care /ID# 202488, Redondo Beach, California, United States|UC Davis Comprehensive Cancer Center - Main /ID# 207227, Sacramento, California, United States|Pacific Central Coast Health Centers-SLO Oncology and Hematology Health Center /ID# 201215, San Luis Obispo, California, United States|Central Coast Medical Oncology /ID# 200227, Santa Maria, California, United States|University of California, Los /ID# 169294, Santa Monica, California, United States|Kaiser Permanente, Waterpark III Institute for Health Research /ID# 200801, Aurora, Colorado, United States|Georgetown University Hospital /ID# 202903, Washington, District of Columbia, United States|Florida Cancer Specialist - South /ID# 203796, Fort Myers, Florida, United States|Florida Cancer Specialists-Panhandle /ID# 203787, Tallahassee, Florida, United States|IACT Health /ID# 169292, Columbus, Georgia, United States|Ingalls Memorial Hosp /ID# 169892, Harvey, Illinois, United States|Illinois Cancer Care, PC /ID# 202189, Peoria, Illinois, United States|Fort Wayne Medical Oncology /ID# 201616, Fort Wayne, Indiana, United States|Cancer Center of Kansas /ID# 200627, Wichita, Kansas, United States|Norton Cancer Institute /ID# 200674, Louisville, Kentucky, United States|Ochsner Clinic Foundation-New Orleans /ID# 169291, New Orleans, Louisiana, United States|Whiteside Institute for Clinic /ID# 200802, Duluth, Minnesota, United States|Mmcorc /Id# 202099, Saint Louis Park, Minnesota, United States|Washington University School /ID# 200621, Saint Louis, Missouri, United States|University of Nebraska /ID# 203195, Omaha, Nebraska, United States|The Valley Hospital /ID# 169999, Paramus, New Jersey, United States|Duke University Medical Center /ID# 169657, Durham, North Carolina, United States|Fairview Hospital - Moll Pavilion /ID# 205910, Cleveland, Ohio, United States|Cleveland Clinic Main Campus /ID# 200325, Cleveland, Ohio, United States|Hillcrest Hospital /ID# 205911, Mayfield Heights, Ohio, United States|INTEGRIS Cancer Institute of OK/INTEGRIS Southwest Medical Center /ID# 200831, Oklahoma City, Oklahoma, United States|INTEGRIS Cancer Institute /ID# 200832, Oklahoma City, Oklahoma, United States|Oregon Health and Science University /ID# 170807, Portland, Oregon, United States|Thomas Jefferson University /ID# 200833, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Ctr /ID# 200672, Pittsburgh, Pennsylvania, United States|Greenville Hospital System /ID# 203021, Greenville, South Carolina, United States|Tennessee Oncology-Nashville Centennial /ID# 203424, Nashville, Tennessee, United States|Tennessee Oncology, PLLC /ID# 203581, Nashville, Tennessee, United States|Ut Southwestern Medical Center /Parkland Health and Hospital System /Id# 210112, Dallas, Texas, United States|UTSW-Dallas /ID# 204031, Dallas, Texas, United States|Millennium Oncology /ID# 204925, Houston, Texas, United States|Virginia Cancer Specialists /ID# 169293, Fairfax, Virginia, United States|Kadlec Clinic Hematology and O /ID# 170811, Kennewick, Washington, United States|Medical Oncology Associates /ID# 169290, Spokane, Washington, United States|Univ of Wisconsin Hosp/Clinics /ID# 200424, Madison, Wisconsin, United States|UZ Gent /ID# 200691, Gent, Oost-Vlaanderen, Belgium|Imelda Ziekenhuis /ID# 200693, Bonheiden, Belgium|Cliniques universitaires Saint /ID# 203101, Brussels, Belgium|UZ Antwerp /ID# 200694, Edegem, Belgium|UZ Leuven /ID# 200001, Leuven, Belgium|Hospital Maisonneuve-Rosemont /ID# 171590, Montreal, Quebec, Canada|Jewish General Hospital /ID# 171584, Montreal, Quebec, Canada|National Cancer Center /ID# 170879, Goyang, Gyeonggido, Korea, Republic of|Samsung Medical Center /ID# 170875, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 170878, Seoul, Korea, Republic of|Asan Medical Center /ID# 170877, Seoul, Korea, Republic of|Hospital Universitario Vall d'Hebron /ID# 200186, Barcelona, Spain|Hospital General Universitario Gregorio Maranon /ID# 200189, Madrid, Spain|Hospital Clinico Universitario San Carlos /ID# 201721, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz /ID# 200187, Madrid, Spain|Hospital Universitario HM Sanchinarro /ID# 200190, Madrid, Spain|National Taiwan Univ Hosp /ID# 170677, Taipei City, Taipei, Taiwan|Taichung Veterans General Hosp /ID# 170123, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 170675, Taipei City, Taiwan",88.07183649,79.26465284,All,"18 Years and older ¬† (Adult, Older Adult)",105,101,92,54,30,8,8/22/2016,3/16/2017,2/7/2017,2/22/2017,1/24/2017,2/12/2017,2/24/2017,3/1/2017,3/28/2017,2/26/2019,2/26/2019,11/4/2019,12/18/2019,1/30/2020,3/21/2020,4/23/2020,5/31/2020,7/18/2020,9/10/2020,8/11/2017,2/7/2018,8/6/2018,2/2/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03368859,,,,,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03368859/Prot_SAP_000.pdf"
AbbVie,AbbVie,ST00390,SP00001,A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer,,,,,Oncology,,,,,,Industry,Recruiting,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Christian G,Mac L,Christian G,Dinah R,Rima Y ,Suzie K,Ngan D,Selizabeth F,Suzie K,In Bellini †,Remedios Z,Patria R,Frank T,Perter K,James y,Stephan T,Otis Thode †,Tammara F,Hee Y,,,"University of Alabama at Birmingham - Main /ID# 207295, Birmingham, Alabama, United States|Highlands Oncology Group /ID# 207176, Springdale, Arkansas, United States|University of California, Davis Comprehensive Cancer Center /ID# 207548, Sacramento, California, United States|Yale School of Medicine /ID# 207559, New Haven, Connecticut, United States|University of Iowa Hospitals and Clinics /ID# 207560, Iowa City, Iowa, United States|University of Kentucky Chandler Medical Center /ID# 208217, Lexington, Kentucky, United States|Massachusetts General Hospital /ID# 207549, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 213032, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center /ID# 207177, Ann Arbor, Michigan, United States|Henry Ford Hospital /ID# 233539, Detroit, Michigan, United States|Mayo Clinic - Rochester /ID# 207555, Rochester, Minnesota, United States|Washington University-School of Medicine /ID# 207168, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center-Koch Center /ID# 208216, New York, New York, United States|Duke Cancer Center /ID# 207547, Durham, North Carolina, United States|UH Cleveland Medical Center /ID# 207561, Cleveland, Ohio, United States|The Ohio State University /ID# 207552, Columbus, Ohio, United States|Tennessee Oncology, PLLC /ID# 207175, Nashville, Tennessee, United States|Vanderbilt Ingram Cancer Center /ID# 207551, Nashville, Tennessee, United States|NEXT Oncology /ID# 207167, San Antonio, Texas, United States|University of Utah /ID# 207553, Salt Lake City, Utah, United States|University of Washington /ID# 207557, Seattle, Washington, United States|Univ of Wisconsin Hosp/Clinics /ID# 207556, Madison, Wisconsin, United States|National Cancer Center Hospital East /ID# 230943, Kashiwa-shi, Chiba, Japan|National Hospital Organization Shikoku Cancer Center /ID# 229737, Matsuyama-shi, Ehime, Japan|Hokkaido Cancer Center /ID# 229101, Sapporo-shi, Hokkaido, Japan|Shizuoka Cancer Center /ID# 230911, Sunto-gun, Shizuoka, Japan|Wakayama Medical University Hospital /ID# 229111, Wakayama-shi, Wakayama, Japan",91.58419536,82.42577583,All,"18 Years and older ¬† (Adult, Older Adult)",100,96,93,77,1,15,11/4/2020,4/29/2021,2/23/2021,4/10/2021,3/7/2021,3/24/2021,4/7/2021,4/8/2021,4/13/2021,6/24/2024,9/26/2024,4/9/2025,5/13/2025,7/7/2025,8/12/2025,9/15/2025,10/28/2025,12/21/2025,1/25/2026,9/20/2021,3/19/2022,9/15/2022,3/14/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03639194,,,,,,
AbbVie,AbbVie,ST00396,SP00001,A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug G,,,,,,,,,,,,,,,,,,,James y,Jerold Goo †,Xochitl D,John G,Perter K,Lilla Stilson †,Terrell p,Lyman W,Remedios Z,Chetan K,Anthony P,Gertrudis T,Terisa Sikora †,John G,Marcelina X,Xochitl D,Geralyn K,Anthony P,Rima Y ,,,"Highlands Oncology Group /ID# 201182, Fayetteville, Arkansas, United States|University of California, Los Angeles /ID# 160882, Los Angeles, California, United States|University of Michigan Hospitals /ID# 167101, Ann Arbor, Michigan, United States|Mayo Clinic - Rochester /ID# 160884, Rochester, Minnesota, United States|Washington University-School of Medicine /ID# 160883, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center /ID# 160881, New York, New York, United States|Carolina BioOncology Institute /ID# 202712, Huntersville, North Carolina, United States|Oklahoma University /ID# 202713, Oklahoma City, Oklahoma, United States|Tennessee Oncology-Nashville Centennial /ID# 160880, Nashville, Tennessee, United States",27.85372983,25.06835685,All,"Child, Adult, Older Adult",98,97,94,34,54,6,10/30/2014,4/20/2015,2/21/2015,3/21/2015,2/25/2015,3/1/2015,3/14/2015,3/16/2015,3/28/2015,1/13/2019,8/23/2018,12/16/2018,3/28/2019,5/20/2019,6/28/2019,8/22/2019,10/15/2019,11/14/2019,12/29/2019,8/28/2015,2/24/2016,8/22/2016,2/18/2017,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03035279,,,,,,
AbbVie,AbbVie,ST00435,SP00001,"A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy",,,,,Oncology,,,,,,Industry,Terminated,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Jerold Goo †,Suzie K,Lavina S,Terrell p,Rima Y ,Lucie P,Chetan K,Suk T,Jaquelyn H,Tammara F,Aleta H,Selizabeth F,Naren G,Rima Y ,John G,Beulah N,Hee Y,Mee M,Perter K,,,"Joliet Oncology-Hematology Associates, LTD /ID# 215051, Joliet, Illinois, United States|Massachusetts General Hospital /ID# 214833, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 214832, Boston, Massachusetts, United States|Masonic Cancer Center /ID# 216101, Minneapolis, Minnesota, United States|Memorial Sloan Kettering Cancer Center /ID# 214886, New York, New York, United States|University of Pennsylvania /ID# 216357, Philadelphia, Pennsylvania, United States|Greenville Health System Cance /ID# 216059, Greenville, South Carolina, United States|Vanderbilt University Med Ctr /ID# 213852, Nashville, Tennessee, United States|MD Anderson Cancer Center /ID# 214867, Houston, Texas, United States|Utah Cancer Specialists /ID# 215375, Salt Lake City, Utah, United States|Swedish Cancer Institute /ID# 216120, Seattle, Washington, United States|Universitaetsklinik Heidelberg /ID# 214679, Heidelberg, Baden-Wuerttemberg, Germany|Universitaetsklinikum Ulm /ID# 214678, Ulm, Thueringen, Germany|Charite Universitaetsmedizin Berlin /ID# 215287, Berlin, Germany|Universitatsklinikum Tubingen /ID# 217021, Tuebingen, Germany|Aichi Cancer Center Hospital /ID# 224527, Nagoya-shi, Aichi, Japan|Pan American Center for Oncology Trials, LLC /ID# 216862, Rio Piedras, Puerto Rico|GCM Medical Group PSC - Hato Rey /ID# 216904, San Juan, Puerto Rico",18.72668822,16.85401939,All,"18 Years to 80 Years ¬† (Adult, Older Adult)",102,99,95,52,36,7,5/15/2017,12/8/2017,10/2/2017,11/1/2017,10/21/2017,10/25/2017,10/28/2017,11/2/2017,11/14/2017,7/25/2020,2/4/2020,8/24/2020,10/8/2020,11/30/2020,1/18/2021,3/7/2021,5/2/2021,6/26/2021,7/29/2021,4/23/2018,10/20/2018,4/18/2019,10/15/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04274933,,,,,,
AbbVie,AbbVie,ST00455,SP00001,"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug A,,,,,,,,,,,,,,,,,,,Clarice N,Liberty A,Tamesha T,Patria R,Jeanene Y,Beulah N,Lavina S,Quentin N,Kala R,Mara A,Mary H,Marcelina X,Anthony P,Chetan K,Quentin N,Naren G,Remedios Z,Lyman W,Naren G,,,"Banner MD Anderson Cancer Ctr /ID# 125011, Gilbert, Arizona, United States|University of Arkansas for Medical Sciences /ID# 124992, Little Rock, Arkansas, United States|City of Hope /ID# 127117, Duarte, California, United States|California Cancer Associates for Research & Excellence (cCARE) /ID# 136078, Fresno, California, United States|Moore UC San Diego Cancer Center /ID# 124991, La Jolla, California, United States|Hematology and Oncology Assoc /ID# 130058, Newport Beach, California, United States|Cancer Research Collaboration /ID# 128860, Santa Ana, California, United States|Icri /Id# 128520, Whittier, California, United States|Univ of Colorado Cancer Center /ID# 124983, Aurora, Colorado, United States|Saint Joseph Hospital /ID# 131768, Denver, Colorado, United States|Norwalk Hospital /ID# 133509, Norwalk, Connecticut, United States|Lynn Cancer Institute, Boca /ID# 125013, Boca Raton, Florida, United States|Holy Cross Hospital /ID# 125012, Fort Lauderdale, Florida, United States|Sacred Heart Hospital /ID# 128279, Pensacola, Florida, United States|Moffitt Cancer Center /ID# 124990, Tampa, Florida, United States|Florida Cancer Specialists - East /ID# 125007, West Palm Beach, Florida, United States|Winship Cancer Institute of Emory University /ID# 133192, Atlanta, Georgia, United States|The Cancer Ctr at DeKalb Med C /ID# 125024, Decatur, Georgia, United States|University of Illinois - Chicago /ID# 127576, Chicago, Illinois, United States|NorthShore University HealthSystem /ID# 124996, Evanston, Illinois, United States|Midwestern Regional CTC /ID# 124986, Zion, Illinois, United States|McFarland Clinic, PC /ID# 129904, Ames, Iowa, United States|Johns Hopkins University /ID# 125015, Baltimore, Maryland, United States|Baystate Medical Center /ID# 139461, Springfield, Massachusetts, United States|UMass Memorial Medical Center /ID# 129067, Worcester, Massachusetts, United States|Henry Ford Health System /ID# 134497, Detroit, Michigan, United States|Spectrum Health Medical Group /ID# 133568, Grand Rapids, Michigan, United States|Spectrum Health Medical Group /ID# 148471, Grand Rapids, Michigan, United States|William Beaumont Hospital /ID# 125019, Royal Oak, Michigan, United States|Univ of Mississippi Med Ctr,US /ID# 131352, Jackson, Mississippi, United States|St. Lukes Cancer Institute /ID# 125023, Kansas City, Missouri, United States|Washington University-School of Medicine /ID# 127575, Saint Louis, Missouri, United States|Nebraska Hematology Oncology /ID# 132711, Lincoln, Nebraska, United States|Rutgers Cancer Institute of New Jersey /ID# 125017, New Brunswick, New Jersey, United States|University of New Mexico /ID# 125349, Albuquerque, New Mexico, United States|Beth Israel Medical Center /ID# 125001, New York, New York, United States|Mount Sinai St. Luke's /ID# 125003, New York, New York, United States|Mission Cancer Center /ID# 134248, Asheville, North Carolina, United States|Duke Cancer Center /ID# 124999, Durham, North Carolina, United States|The Ohio State University /ID# 125022, Columbus, Ohio, United States|University of Toledo /ID# 134849, Toledo, Ohio, United States|Oregon Health and Science University /ID# 134229, Portland, Oregon, United States|Lehigh Valley Health Network /ID# 130059, Allentown, Pennsylvania, United States|Lehigh Valley Hosp/Muhlenberg /ID# 130277, Bethlehem, Pennsylvania, United States|Penn State University and Milton S. Hershey Medical Center /ID# 124997, Hershey, Pennsylvania, United States|Allegheny General Hospital /ID# 135094, Pittsburgh, Pennsylvania, United States|University of Pittsburgh MC /ID# 125005, Pittsburgh, Pennsylvania, United States|Texas Health Physicians Group /ID# 137740, Arlington, Texas, United States|University of Texas Southwestern Medical Center /ID# 124989, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center /ID# 125353, Houston, Texas, United States|University of Vermont Medical Center /ID# 125350, Burlington, Vermont, United States|Swedish Cancer Institute /ID# 131534, Seattle, Washington, United States|Swedish Cancer Institute /ID# 131548, Seattle, Washington, United States|Swedish Cancer Institute /ID# 131549, Seattle, Washington, United States|Swedish Medical Center /ID# 125021, Seattle, Washington, United States|Northwest Medical Specialties - Tacoma /ID# 125344, Tacoma, Washington, United States|COIBA Centro de Oncologia e Investigacion de Buenos Aires /ID# 124839, Berazategui, Buenos Aires, Argentina|Clinica Pergamino /ID# 127158, Pergamino, Buenos Aires, Argentina|Instituto de Oncoloia de Rosario /ID# 127157, Rosario, Santa Fe, Argentina|Centro Oncologico Riojano Integral /ID# 127938, La Rioja, Argentina|St George Hospital /ID# 129416, Kogarah, New South Wales, Australia|Duplicate_The Prince of Wales Hospital /ID# 124845, Randwick, New South Wales, Australia|Southern Medical Day Care Centre /ID# 124844, Wollongong, New South Wales, Australia|Townsville University Hospital /ID# 126731, Douglas, Queensland, Australia|Duplicate_Flinders Centre for Innovation /ID# 127535, Bedford Park, South Australia, Australia|Royal Hobart Hospital /ID# 124849, Hobart, Tasmania, Australia|The Royal Melbourne Hospital /ID# 124846, Parkville, Victoria, Australia|Hollywood Private Hospital /ID# 124843, Nedlands, Western Australia, Australia|Ordensklinikum Linz GmbH Elisabethinen /ID# 126185, Linz, Oberoesterreich, Austria|Medizinische Universitaet Graz /ID# 126450, Graz, Steiermark, Austria|Medizinische Universitaet Wien /ID# 126184, Vienna, Wien, Austria|Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 126449, Salzburg, Austria|Bobruysk Interdistrict Onco. /ID# 137729, Bobruisk, Belarus|State Institution Republican Scientific Practical Center of Oncology and Medical /ID# 125223, Minsk, Belarus|Duplicate_Mogilev Reg Clin Oncology Dis /ID# 137728, Mogilev, Belarus|Vitebsk Regional Clinical Oncology Dispensary /ID# 125219, Vitebsk, Belarus|Universitair Ziekenhuis Antwerpen /ID# 124977, Edegem, Antwerpen, Belgium|UCL Saint-Luc /ID# 124976, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Grand H√¥pital de Charleroi /ID# 124981, Charleroi, Hainaut, Belgium|Universitair Ziekenhuis Leuven /ID# 124980, Leuven, Vlaams-Brabant, Belgium|Duplicate_AZ St-Jan Brugge-Oostende AV /ID# 124975, Brugge, West-Vlaanderen, Belgium|ZNA Middelheim /ID# 124978, Antwerp, Belgium|CHU UCL Namur - Sainte Elisabeth /ID# 124979, Namur, Belgium|Duplicate_Sunnybrook Health Sciences Ctr /ID# 124882, Toronto, Ontario, Canada|Duplicate_Jewish General Hospital /ID# 124880, Montreal, Quebec, Canada|CHUM - Notre-Dame Hospital /ID# 124879, Montr√©al, Quebec, Canada|Duplicate_CHUQ-Hospital St. Sacrement /ID# 124881, Quebec City, Quebec, Canada|Hospital Clinico Vina del Mar /ID# 130100, Vina Del Mar, Valpara√≠so, Chile|Hospital Clinico Vina del Mar /ID# 148502, Vina Del Mar, Valpara√≠so, Chile|Instituto Nacional del Cancer /ID# 129343, Santiago, Chile|ICOS - Inst Clinic Oncology /ID# 125236, Temuco, Chile|Hospital Pablo Tobon Uribe /ID# 126657, Medell√≠n, Antioquia, Colombia|Instituto Medico de Alta Tecnologia Oncom√©dica S.A /ID# 129211, Monteria, Cordoba, Colombia|Administradora del Country_S.A-Clinica Del Country /ID# 125255, Bogota, Cundinamarca, Colombia|Hospital Univ San Ignacio /ID# 126655, Bogota, Cundinamarca, Colombia|Centro Medico Imbanaco de Cali /ID# 126656, Cali, Colombia|Fakultni Nemocnice Brno /ID# 128176, Brno, Czechia|Masarykuv onkologicky ustav /ID# 124886, Brno, Czechia|Duplicate_FN Hradec Kralove /ID# 127080, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc /ID# 124885, Olomouc, Czechia|Vseobecna fakultni nemocnice v Praze /ID# 124887, Praha, Czechia|Rigshospitalet /ID# 124891, Copenhagen √ò, Hovedstaden, Denmark|Sygehus Lilleb√¶lt, Vejle /ID# 124892, Vejle, Syddanmark, Denmark|East Tallinn Central Hospital /ID# 126475, Tallinn, Harjumaa, Estonia|Docrates Cancer Center /ID# 124896, Helsinki, Finland|Duplicate_Helsinki Univ Central Hospital /ID# 124897, Helsinki, Finland|Duplicate_Tampere University Hospital /ID# 124898, Tampere, Finland|Vaasa Central Hospital /ID# 132548, Vaasa, Finland|Institut Paoli-Calmettes /ID# 124903, Marseille, Bouches-du-Rhone, France|Institut Curie /ID# 124902, Paris CEDEX 05, Ile-de-France, France|Institut de Canc√©rologie de l'Ouest Ren√© Gauducheau /ID# 137726, St Herblain CEDEX, Loire-Atlantique, France|Institut Curie - site CLCC Ren√© Huguenin /ID# 124904, Saint-cloud, France|Universitaetsklinik Heidelberg /ID# 126664, Heidelberg, Baden-Wuerttemberg, Germany|Universitaetsklinikum Tuebingen /ID# 129968, Tubingen, Baden-Wuerttemberg, Germany|Universitaetsklinikum Ulm /ID# 135230, Ulm, Baden-Wuerttemberg, Germany|Universitaetsklinikum Koeln /ID# 126905, K√∂ln, Nordrhein-Westfalen, Germany|Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 127180, Dresden, Germany|Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 125256, Munich, Germany|Sana Klinikum Offenbach /ID# 126733, Offenbach am Main, Germany|Semmelweis Egyetem /ID# 132485, Budapest, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 125259, Pecs, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz /ID# 124911, Szolnok, Hungary|Duplicate_Zala Megyei Korhaz /ID# 131341, Zalaegerszeg, Hungary|Sheba Medical Center /ID# 124918, Ramat Gan, Tel-Aviv, Israel|Tel Aviv Sourasky Medical Center /ID# 130276, Tel Aviv-Yafo, Tel-Aviv, Israel|Duplicate_Soroka University Medical Center /ID# 124917, Be'er Sheva, Israel|Assaf Harofeh Medical Center /ID# 124915, Be'Er Ya'Akov, Israel|Rambam Health Care Campus /ID# 124916, Haifa, Israel|Shaare Zedek Medical Center /ID# 130275, Jerusalem, Israel|Gastroenterology Institute, Division of Medicine /ID# 124919, Jerusalem, Israel|Kaplan Medical Center /ID# 124914, Rehovot, Israel|Ospedale San Raffaele IRCCS /ID# 125261, Milan, Lombardia, Italy|IEO -Istituto Europeo di Oncologia /ID# 125260, Milan, Milano, Italy|IRCCS Ospedale Sacro Cuore Don Calabria /ID# 125262, Negrar, Verona, Italy|Centro di Riferimento Oncologico /ID# 126738, Aviano, Italy|Grande Ospedale Metropolitano Bianchi Melacrino Morelli /ID# 125263, Reggio Calabria, Italy|National Cancer Center /ID# 125602, Goyang, Gyeonggido, Korea, Republic of|Severance Hospital /ID# 125599, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Korea University Anam Hospital /ID# 128968, Seoul, Korea, Republic of|Seoul National University Hospital /ID# 125600, Seoul, Korea, Republic of|Asan Medical Center /ID# 125601, Seoul, Korea, Republic of|Samsung Medical Center /ID# 125598, Seoul, Korea, Republic of|Pauls Stradins Clinical University Hospital /ID# 125264, Riga, Latvia|Riga East Clinical University Hospital /ID# 125265, Riga, Latvia|Hospital of Lithuanian University of Health Sciences Kaunas Clinics /ID# 125266, Kaunas, Lithuania|National Cancer Institute /ID# 125267, Vilnius, Lithuania|Centro de Estudios Cl√≠nicos Especializados /ID# 128680, M√©rida, Yucatan, Mexico|Centro Oncologico de Chihuahua /ID# 128679, Chihuahua, Mexico|Instituto Nacional de Cancerolog√≠a INCAN /ID# 128676, Ciudad de Mexico, Mexico|Erasmus Medisch Centrum /ID# 124935, Rotterdam, Zuid-Holland, Netherlands|Universitair Medisch Centrum Groningen /ID# 129069, Groningen, Netherlands|Maastricht Universitair Medisch Centrum /ID# 129068, Maastricht, Netherlands|Haukeland University Hospital /ID# 150177, Bergen, Hordaland, Norway|Wojewodzki Szpital Specjalistyczny /ID# 127258, Wroclaw, Dolnoslaskie, Poland|Centrum Onkologii Lukaszczyka /ID# 124938, Bydgoszcz, Kujawsko-pomorskie, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopern /ID# 126999, Lodz, Lodzkie, Poland|Mrukmed. Lekarz Beata Madej Mruk i Partner /ID# 124939, Rzeszow, Podkarpackie, Poland|Wojewodzki Szpital Zespolony /ID# 126998, Elblag, Warminsko-mazurskie, Poland|Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE /ID# 126510, Vila Nova De Gaia, Porto, Portugal|Centro Hospitalar Universit√°rio do Algarve, EPE - Hospital Faro /ID# 125298, Faro, Portugal|Centro Hospitalar Universit√°rio de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 125299, Lisboa, Portugal|Unidade Local de Sa√∫de de Matosinhos, EPE /ID# 126511, Matosinhos, Portugal|IPO Porto FG, EPE /ID# 125297, Porto, Portugal|Centro Hospitalar Universitario de Sao Joao, EPE /ID# 126508, Porto, Portugal|Ad-Vance Medical Research, LLC /ID# 126043, Ponce, Puerto Rico|San Juan Municipal Hospital /ID# 124695, San Juan, Puerto Rico|S.C. Centrul de Oncologie Sf. Nectarie S.R.L. /ID# 124948, Craiova, Dolj, Romania|Duplicate_lnstitutul Oncologic Prof Dr Alexandru Trestioreanu /ID# 124943, Bucharest, Romania|Spitalul Clinic Judetean de Urgenta Cluj -Napoca /ID# 124945, Cluj-Napoca, Romania|Oncomed SRL /ID# 127598, Timisoara, Romania|Sverdlovsk Regional Oncology Dispensary /ID# 130950, Yekaterinburg, Sverdlovskaya Oblast, Russian Federation|Regional Oncology Dispensary /ID# 125936, Kursk, Tatarstan, Respublika, Russian Federation|Duplicate_archangel Clinical Oncology /ID# 126031, Arkhangelsk, Russian Federation|Altay Regional Oncological Dispesary /ID# 127160, Barnaul, Russian Federation|Belgorod Oncology Dispensary /ID# 129315, Belgorod, Russian Federation|Duplicate_Saratov State Medical University n.s. Chernyshevskiy /ID# 139395, Saratov, Russian Federation|LLC BioEq Ltd. /ID# 134529, St. Petersburg, Russian Federation|Siberian State Medical University /ID# 127161, Tomsk, Russian Federation|Volgograd Regional Clinical Oncology Dispensary /ID# 124952, Volzhsky, Russian Federation|National University Hospital /ID# 125315, Singapore, Singapore|Johns Hopkins Singapore IMC /ID# 125316, Singapore, Singapore|GVI Oncology /ID# 125321, Gqeberha, Eastern Cape, South Africa|University of Free State, Universitas Annex (National Hospital Grounds) /ID# 128499, Bloemfontein, Free State, South Africa|Wits Clinical Research Site /ID# 125317, Johannesburg, Gauteng, South Africa|Medical Oncology Ctr Rosebank /ID# 125322, Johannesburg, Gauteng, South Africa|Sandton Oncology Centre /ID# 125323, Johannesburg, Gauteng, South Africa|Mary Potter Oncology Centre /ID# 133269, Pretoria, Gauteng, South Africa|The Oncology Centre /ID# 126104, Durban, Kwazulu-Natal, South Africa|Netcare Oncology Intervent Ctr /ID# 125320, Cape Town, Western Cape, South Africa|Cancercare Outeniqua Oncology Centre /ID# 125319, George, Western Cape, South Africa|Hospital Santa Creu i Sant Pau /ID# 124963, Barcelona, Spain|Hospital General Universitario Gregorio Maranon /ID# 124962, Madrid, Spain|Hospital Universitario HM Sanchinarro /ID# 124960, Madrid, Spain|Hospital Universitario Virgen de la Victoria /ID# 124961, Malaga, Spain|Hospital Clinico Universitario de Valencia /ID# 124959, Valencia, Spain|Skane University hospital /ID# 124966, Malmo, Skane Lan, Sweden|Norrlands University hospital /ID# 124967, Umea, Vasterbottens Lan, Sweden|Sahlgrenska University Hospital /ID# 124965, Gothenburg, Vastra Gotalands Lan, Sweden|Linkoping University Hospital /ID# 126795, Linkoping, Sweden|Duplicate_Karolinska Univ Sjukhuset /ID# 124964, Solna, Sweden|Uppsala University Hospital /ID# 126512, Uppsala, Sweden|Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 125575, Kaohsiung, Taiwan|National Taiwan University Hospital /ID# 125324, Taipei City, Taiwan|Hacettepe University Faculty of Medicine /ID# 125336, Ankara, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi /ID# 125337, Ankara, Turkey|Duplicate_Akdeniz University Medical Fac /ID# 125339, Antalya, Turkey|Bezmi Alem Univ Med Fac Hosp /ID# 127901, Istanbul, Turkey|Istanbul University Istanbul Medical Faculty /ID# 145144, Istanbul, Turkey|Municipal Non-Profit Enterprise City Clinical Hospital No.4 of Dnipro City Counc /ID# 124968, Dnipro, Ukraine|Donetsk Regional Antitumor Ctr /ID# 124970, Donetsk, Ukraine|Communal non-profit enterprise Regional Center of Oncology /ID# 124972, Kharkiv, Ukraine|Lviv Oncological Regional Therapeutical and Diagnostic Centre /ID# 124974, Lviv, Ukraine|Poltava Regional Clinical Oncology Centre of Poltava Regional Council /ID# 124969, Poltava, Ukraine|Zaporizhzhia Med. Academy MOH /ID# 129800, Zaporizhia, Ukraine|ME Kryviy Rih Oncology Dispensary /ID# 129806, –ö—Ä–∏–≤–∏–π –†—ñ–≥, Ukraine|University Hospitals Bristol /ID# 128343, Bristol, Bristol, City Of, United Kingdom|Nottingham University Hospitals NHS Trust /ID# 125340, Nottingham, Nottinghamshire, United Kingdom|University Hospitals Birmingham NHS Foundation Trust /ID# 125342, Birmingham, United Kingdom|Hull University Teaching Hospitals NHS Trust /ID# 133030, Hull, United Kingdom",20.29895298,18.26905768,All,"18 Years and older ¬† (Adult, Older Adult)",101,99,96,71,13,12,1/1/2015,6/30/2015,4/17/2015,5/27/2015,5/3/2015,5/11/2015,5/13/2015,5/16/2015,6/3/2015,5/24/2018,8/7/2018,2/13/2019,4/5/2019,5/15/2019,6/28/2019,7/29/2019,9/5/2019,10/25/2019,12/2/2019,11/7/2015,5/5/2016,11/1/2016,4/30/2017,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02163694,,,,,,
AbbVie,AbbVie,ST00462,SP00001,"A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer",,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Harry A,Lavina S,Tamesha T,Stephan T,John G,James y,Geralyn K,Tamesha T,James y,Suzie K,Mac L,Anthony P,Kala R,Terrell p,Suk T,Suzie K,Clarice N,Ngan D,Christian G,,,"National Cancer Ctr Hosp East /ID# 161432, Kashiwa-shi, Chiba, Japan|Kyushu University Hospital /ID# 161430, Fukuoka-shi, Fukuoka, Japan|Kinki University -Osakasayama Campus /ID# 161431, Osakasayama-shi, Osaka, Japan|National Cancer Center Hospital /ID# 161429, Chuo-ku, Tokyo, Japan|Wakayama Medical University /ID# 161428, Wakayama, Japan",24.21454334,21.793089,All,"18 Years to 75 Years ¬† (Adult, Older Adult)",101,99,97,85,5,7,12/15/2012,7/28/2013,6/1/2013,6/13/2013,5/15/2013,6/8/2013,6/19/2013,6/23/2013,7/18/2013,7/26/2017,7/3/2017,11/17/2017,1/30/2018,3/12/2018,4/28/2018,6/12/2018,8/6/2018,9/18/2018,11/6/2018,12/5/2013,6/3/2014,11/30/2014,5/29/2015,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03086239,,,,,,
AbbVie,AbbVie,ST00488,SP00001,A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer,,,,,Oncology,,,,,,Industry,Not yet recruiting,Phase 1,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Naren G,Frank T,Clarice N,Perter K,Suzie K,Frank T,Perter K,Clarice N,Doreen T,Tamesha T,Rima Y ,Suzie K,Kandace p,Frank T,Remedios Z,Suzie K,Mara A,Mee M,Ngan D,,,"Lifespan Cancer Institute /ID# 200130, Providence, Rhode Island, United States|Herlev Hospital /ID# 201073, Herlev, Hovedstaden, Denmark",67.94821676,61.15339508,Female,"Child, Adult, Older Adult",110,106,98,38,56,4,3/18/2020,10/24/2020,8/27/2020,9/26/2020,8/13/2020,9/6/2020,9/8/2020,9/10/2020,9/16/2020,7/14/2024,3/5/2024,9/9/2024,11/29/2024,1/9/2025,2/25/2025,4/13/2025,5/21/2025,7/13/2025,8/19/2025,3/5/2021,9/1/2021,2/28/2022,8/27/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03400306,,,,,,
AbbVie,AbbVie,ST00520,SP00001,The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug A,,,,,,,,,,,,,,,,,,,Frank T,Donovan H,Beulah N,Corrine U,Naren G,Anthony P,Stephan T,Suzie K,Mary H,Lucie P,Anthony P,Mara A,Perter K,Frank T,Ngan D,Jene M,Lilla Stilson †,Suzie K,Naren G,,,"University of Alabama at Birmingham - Main /ID# 62994, Birmingham, Alabama, United States|Banner MD Anderson Cancer Ctr /ID# 118695, Gilbert, Arizona, United States|University of Arkansas for Medical Sciences /ID# 60750, Little Rock, Arkansas, United States|Moore UC San Diego Cancer Center /ID# 60754, La Jolla, California, United States|The Angeles Clinic and Researc /ID# 60743, Los Angeles, California, United States|Stanford University School of Med /ID# 65488, Stanford, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 60760, West Hollywood, California, United States|Univ of Colorado Cancer Center /ID# 60751, Aurora, Colorado, United States|Lynn Cancer Institute, Boca /ID# 60749, Boca Raton, Florida, United States|Holy Cross Hospital /ID# 62995, Fort Lauderdale, Florida, United States|Moffitt Cancer Center /ID# 60746, Tampa, Florida, United States|Florida Cancer Specialists - East /ID# 60762, West Palm Beach, Florida, United States|University of Illinois - Chicago /ID# 106175, Chicago, Illinois, United States|Northwestern University Feinberg School of Medicine /ID# 60755, Chicago, Illinois, United States|Rush University Medical Center /ID# 65489, Chicago, Illinois, United States|Midwestern Regional CTC /ID# 60744, Zion, Illinois, United States|Johns Hopkins University /ID# 60759, Baltimore, Maryland, United States|Massachusetts General Hospital /ID# 64582, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 93833, Boston, Massachusetts, United States|William Beaumont Hospital /ID# 95417, Royal Oak, Michigan, United States|Washington University-School of Medicine /ID# 62724, Saint Louis, Missouri, United States|Beth Israel Medical Center /ID# 87993, New York, New York, United States|Memorial Sloan Kettering Cancer Center /ID# 63222, New York, New York, United States|Duke University Medical Center /ID# 60747, Durham, North Carolina, United States|Penn State University and Milton S. Hershey Medical Center /ID# 62723, Hershey, Pennsylvania, United States|University of Pennsylvania /ID# 60753, Philadelphia, Pennsylvania, United States|University of Pittsburgh MC /ID# 60758, Pittsburgh, Pennsylvania, United States|University of Pittsburgh MC /ID# 65486, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina /ID# 60752, Charleston, South Carolina, United States|The West Clinic /ID# 65487, Memphis, Tennessee, United States|The West Clinic /ID# 94599, Memphis, Tennessee, United States|The West Clinic /ID# 94600, Memphis, Tennessee, United States|UT Southwestern Medical Center /ID# 60745, Dallas, Texas, United States|Houston Methodist Hospital - Scurlock Tower /ID# 60742, Houston, Texas, United States|Coiba /Id# 65219, Berazategui, Buenos Aires, Argentina|ISIS Centro Especializado /ID# 65226, Santa Fe, Argentina|The Prince of Wales Hospital /ID# 63271, Randwick, New South Wales, Australia|Southern Medical Day Care Ctr /ID# 63274, Wollongong, New South Wales, Australia|Mater Misericordiae Limited /ID# 63276, South Brisbane, Queensland, Australia|Royal Adelaide Hospital /ID# 63280, Adelaide, South Australia, Australia|Royal Hobart Hospital /ID# 63279, Hobart, Tasmania, Australia|Peter MacCallum Cancer Ctr /ID# 63272, Melbourne, Victoria, Australia|Royal Melbourne Hospital /ID# 63278, Parkville, Victoria, Australia|Mount Hospital /ID# 65262, Perth, Western Australia, Australia|Cliniques Universitaires Saint Luc /ID# 96135, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Grand H√¥pital de Charleroi /ID# 96136, Charleroi, Hainaut, Belgium|AZ St-Jan Brugge-Oostende AV /ID# 107315, Brugge, West-Vlaanderen, Belgium|UZ Antwerp /ID# 96945, Edegem, Belgium|UZ Leuven /ID# 96138, Leuven, Belgium|CHU UCL Namur /ID# 110595, Namur, Belgium|Hospital Bruno Born / Sociedade Beneficencia e Caridade de Lajeado /ID# 65247, Lajeado, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de /ID# 65244, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clinicas de Porto Alegre /ID# 65242, Porto Alegre, Rio Grande Do Sul, Brazil|Sunnybrook Health Sciences Ctr /ID# 77373, Toronto, Ontario, Canada|Jewish General Hospital /ID# 69893, Montreal, Quebec, Canada|CHUM - Notre-Dame Hospital /ID# 67862, Montr√©al, Quebec, Canada|CHUQ-Hospital St. Sacrement /ID# 68902, Quebec City, Quebec, Canada|Masarykuv onkologikcy ustav /ID# 65170, Brno, Czechia|Palacky University /ID# 63923, Olomouc, Czechia|Vseobecna Fakultni Nemocnice /ID# 65172, Prague, Czechia|Vejle Sygehus /ID# 65173, Vejle, Syddanmark, Denmark|Rigshospitalet, Finsen Centre /ID# 67822, Copenhagen, Denmark|Docrates Cancer Center /ID# 63924, Helsinki, Finland|Tampere University Hospital /ID# 102417, Tampere, Finland|Hopital Universitaire Purpan /ID# 98815, Toulouse, Haute-Garonne, France|Institut Curie /ID# 63926, Paris CEDEX 05, Ile-de-France, France|Institut de Cancer de l'Ouest /ID# 63927, St Herblain CEDEX, Loire-Atlantique, France|Centre Leon Berard /ID# 106675, Lyon CEDEX 08, Rhone, France|Pays-Basque Ctr Oncology/Radio /ID# 65176, Bayonne, France|Duplicate_Institut Paoli-Calmettes /ID# 65175, Marseille, France|Hopital Rene Huguenin /ID# 65177, Saint-cloud, France|Centre Paul Strauss /ID# 100275, Strasbourg, France|Bajcsy-Zsilinszky Korhaz /ID# 65179, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont /ID# 65178, Debrecen, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz /ID# 63928, Szolnok, Hungary|Rabin Medical Center /ID# 63929, Petakh Tikva, Tel-Aviv, Israel|Soroka University Medical Center /ID# 65180, Be'er Sheva, Israel|Assaf Harofeh Medical Center /ID# 65181, Be'er Ya'akov, Israel|Rambam Health Care Campus /ID# 63930, Haifa, Israel|Shaare Zedek Medical Center /ID# 116575, Jerusalem, Israel|Gastroenterology Institute, Division of Medicine /ID# 63931, Jerusalem, Israel|Sheba Medical Center /ID# 63932, Ramat Gan, Israel|Kaplan Medical Center /ID# 63933, Rehovot, Israel|Erasmus Medisch Centrum /ID# 96275, Rotterdam, Netherlands|Haukeland University Hospital /ID# 67982, Bergen, Hordaland, Norway|Mrukmed. Lekarz Beata Madej Mruk i Partner /ID# 94975, Rzesz√≥w, Podkarpackie, Poland|Centrum Onkologii Lukaszczyka /ID# 73393, Bydgoszcz, Poland|Olsztynski Osrodek Onkologi /ID# 71060, Olsztyn, Poland|NZOZ Centrum Medyczne HCP /ID# 68102, Poznan, Poland|Wielkopolskie Centrum Onkologi /ID# 71061, Poznan, Poland|S.C. lanuli Med Consult SRL /ID# 106955, Bucharest, Romania|lnstitutul Oncologic Trestiore /ID# 96742, Bucharest, Romania|Spitalul Clinic Judetean de Urgenta /ID# 96741, Cluj, Romania|Inst Oncology Prof. Chiricuta /ID# 96740, Cluj, Romania|Sc Oncolab Srl /Id# 96745, Craiova, Romania|Federal State Budgetary Scientific Institution N.N. Blokhin Russian Cancer Resea /ID# 65263, Moscow, Moskva, Russian Federation|Chelyabinsk Reg Clin Oncology /ID# 63938, Chelyabinsk, Russian Federation|State Regional Budgetary Healthcare Institution "" Murmansk Regional Oncology Dis /ID# 102415, Murmansk, Russian Federation|City Clinical Hospital 1 /ID# 102416, Novosibirsk, Russian Federation|Pyatigorsk Oncology Dispensary /ID# 65264, Pyatigorsk, Russian Federation|Birch A Healthcare /ID# 65265, St. Petersburg, Russian Federation|N.N. Petrov Research Inst Onc /ID# 65269, St. Petersburg, Russian Federation|N.N. Petrov Research Inst Onc /ID# 78973, St. Petersburg, Russian Federation|Volgograd Reg Onc Disp #3 /ID# 98035, Volzhsky, Russian Federation|Hospital Universitario Vall d'Hebron /ID# 97415, Barcelona, Spain|Hospital Santa Creu i Sant Pau /ID# 97418, Barcelona, Spain|Hospital General Universitario Gregorio Maranon /ID# 97417, Madrid, Spain|Hospital Universitario HM Sanchinarro /ID# 97416, Madrid, Spain|Hospital Universitario Virgen de la Victoria /ID# 97976, Malaga, Spain|Hospital Clinico Universitario de Valencia /ID# 97975, Valencia, Spain|Skanes Universitetssjukhus /ID# 96475, Malm√∂, Skane Lan, Sweden|Sahlgrenska University Hosp /ID# 97715, Goteborg, Sweden|Karolinska Univ Sjukhuset /ID# 98037, Solna, Sweden|Communal non-profit enterprise Regional Center of Oncology /ID# 97696, Kharkiv, Kharkivska Oblast, Ukraine|Cherkassy Regional Onc Ctr /ID# 97698, Cherkasy, Ukraine|Municipal Non-Profit Enterprise City Clinical Hospital No.4 of Dnipro City Counc /ID# 63940, Dnipro, Ukraine|Lviv Oncological Regional Therapeutical and Diagnostic Centre /ID# 63941, Lviv, Ukraine|Odessa National Medical Univ /ID# 65278, Odesa, Ukraine|Poltava Regional Clinical Oncology Centre of Poltava Regional Council /ID# 97697, Poltava, Ukraine|Municipal Non-Profit Enterprise of Sumy Regional Council Sumy Regional Clinical /ID# 65280, Sumy, Ukraine",40.48208211,36.4338739,All,"18 Years and older ¬† (Adult, Older Adult)",107,104,99,42,50,7,2/11/2017,8/1/2017,5/28/2017,7/2/2017,6/9/2017,6/21/2017,7/1/2017,7/5/2017,7/14/2017,8/1/2018,4/2/2018,10/20/2018,12/13/2018,2/3/2019,3/18/2019,4/24/2019,6/18/2019,7/20/2019,9/17/2019,12/18/2017,6/16/2018,12/13/2018,6/11/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01506609,,,,,,
Amgen,Amgen,ST00113,SP00002,Study of AMG 757 in Participants With Small Cell Lung Cancer (SCLC),,,Relapsed/Refractory Small Cell Lung Cancer,,Oncology,,,,,,Industry,Not yet recruiting,Phase 4,Interventional,,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Corrine U,Rima Y ,Tien C,Doreen T,Lyman W,Ross S,Gertrudis T,Naren G,John G,Louann C,Clarice N,Harry A,Lyman W,Remedios Z,Anthony P,Beulah N,Selizabeth F,Donovan H,Louann C,,,,9.530240914,8.577216823,All,18 Years to 55 Years ¬† (Adult),106,104,100,38,56,6,8/17/2021,3/24/2022,1/15/2022,2/21/2022,1/27/2022,2/6/2022,2/10/2022,2/14/2022,3/4/2022,7/29/2023,1/25/2023,7/29/2023,9/26/2023,11/16/2023,12/30/2023,2/11/2024,4/3/2024,5/24/2024,7/5/2024,8/5/2022,2/1/2023,7/31/2023,1/27/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05060016,,,,,,
Amgen,Amgen,ST00121,SP00002,Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants,,,Healthy Participants,,,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Dinah R,Tammara F,Clarice N,Mee M,Geralyn K,Terrell p,John G,Dalton E,Mac L,In Bellini †,Doreen T,Christian G,Patria R,Perter K,Hee Y,Tamesha T,Quentin N,Frank T,Geralyn K,,,,67.68461012,60.9161491,All,"18 Years and older ¬† (Adult, Older Adult)",109,106,101,37,59,5,11/2/2019,6/19/2020,4/16/2020,5/2/2020,4/15/2020,4/27/2020,5/9/2020,5/11/2020,5/21/2020,11/6/2021,5/3/2021,1/3/2022,2/15/2022,4/11/2022,6/2/2022,7/21/2022,9/2/2022,10/11/2022,12/3/2022,10/24/2020,4/22/2021,10/19/2021,4/17/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05056246,,,,,,
Amgen,Amgen,ST00122,SP00002,Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression,,FORTITUDE-101,Gastric Cancer|Gastroesophageal Junction Adenocarcinoma,,Oncology,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Chetan K,Donovan H,Tamesha T,Mara A,Kandace p,Jeanene Y,Chetan K,Corrine U,Tamesha T,Ngan D,Jaquelyn H,Aleta H,Quentin N,Naren G,Selizabeth F,Xochitl D,Marcelina X,Doreen T,Christian G,,,,54.05785735,48.65207162,All,"18 Years and older ¬† (Adult, Older Adult)",114,110,102,68,24,10,11/22/2019,4/15/2020,2/15/2020,4/1/2020,2/22/2020,3/12/2020,3/14/2020,3/19/2020,3/25/2020,10/12/2024,6/17/2024,10/20/2024,1/6/2025,2/22/2025,4/5/2025,5/11/2025,6/28/2025,8/18/2025,10/3/2025,9/8/2020,3/7/2021,9/3/2021,3/2/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05052801,,,,,,
Amgen,Amgen,ST00127,SP00002,A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy Participants,,,Healthy Participants,,,,,,,,Industry,Recruiting,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Suzie K,Terisa Sikora †,Quentin N,John G,Gertrudis T,Naren G,Anthony P,Rima Y ,Xochitl D,Frank T,Suzie K,Selizabeth F,Rima Y ,Gertrudis T,Selizabeth F,Aleta H,Mary H,Clarice N,Naren G,,,"Covance Clinical Research Unit, Daytona Beach, Florida, United States|Covance Clinical Research Unit, Dallas, Texas, United States",6.482559474,5.834303527,All,"18 Years and older ¬† (Adult, Older Adult)",111,107,103,94,2,7,7/18/2016,12/28/2016,11/3/2016,12/3/2016,11/2/2016,11/21/2016,12/1/2016,12/3/2016,12/27/2016,11/9/2020,3/4/2021,7/28/2021,11/7/2021,1/1/2022,2/13/2022,3/15/2022,4/24/2022,6/2/2022,7/25/2022,5/20/2017,11/16/2017,5/15/2018,11/11/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05048784,,,,,,
Amgen,Amgen,ST00131,SP00002,Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants,,,Healthy Participants,,,,,,,,Industry,Recruiting,Not Applicable,Interventional,,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Marceline R,In Bellini †,Dalton E,Lucie P,Perter K,Harry A,Mary H,Kala R,Rima Y ,Perter K,Liberty A,Livia Pacheo †,Patria R,Lyman W,Mee M,Frank T,Mary H,Otis Thode †,Terrell p,,,"Covance Clinical Research Unit - Daytona Beach, Daytona Beach, Florida, United States",95.57312872,86.01581585,All,"18 Years and older ¬† (Adult, Older Adult)",112,109,104,69,24,11,12/2/2019,4/27/2020,2/20/2020,3/22/2020,3/1/2020,3/15/2020,3/23/2020,3/24/2020,4/4/2020,3/13/2021,3/19/2021,6/4/2021,10/18/2021,12/13/2021,2/7/2022,3/28/2022,5/6/2022,7/1/2022,8/5/2022,9/11/2020,3/10/2021,9/6/2021,3/5/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05045638,,,,,,
Amgen,Amgen,ST00188,SP00002,A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM),,ProxiMMity-1,Relapsed/Refractory Multiple Myeloma,,Oncology,,,,,,Industry,Not yet recruiting,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Jerold Goo †,Garnet T,Stephan T,Jeanene Y,Corrine U,Stephan T,Ross S,Gertrudis T,Mary H,Lyman W,Aleta H,Otis Thode †,Rima Y ,Jerold Goo †,Perter K,Marcelina X,Kandace p,Clarice N,Mara A,,,,19.93113002,17.93801702,All,11 Years to 17 Years ¬† (Child),112,108,105,103,9,7,3/14/2019,10/4/2019,7/29/2019,8/29/2019,8/1/2019,8/10/2019,8/24/2019,8/29/2019,9/27/2019,7/27/2023,9/25/2023,1/1/2024,4/24/2024,6/20/2024,7/23/2024,9/17/2024,11/2/2024,12/14/2024,2/11/2025,2/6/2020,8/4/2020,1/31/2021,7/30/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04998747,,,,,,
Amgen,Amgen,ST00193,SP00002,Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia,,,Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL),,,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Kandace p,Anthony P,Remedios Z,Frank T,Federico L,Frank T,Marcelina X,Doreen T,Perter K,Jene M,Liberty A,Marceline R,Tammara F,Quentin N,Remedios Z,John G,Chetan K,Jeanene Y,Naren G,,,,26.54079937,23.88671943,All,"18 Years and older ¬† (Adult, Older Adult)",121,116,106,94,2,10,3/23/2020,10/12/2020,8/16/2020,9/10/2020,8/4/2020,8/22/2020,8/28/2020,8/30/2020,9/11/2020,12/25/2024,10/24/2024,4/13/2025,7/13/2025,9/8/2025,10/8/2025,11/25/2025,1/17/2026,2/28/2026,4/4/2026,2/18/2021,8/17/2021,2/13/2022,8/12/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04994717,,,,,,
Amgen,Amgen,ST00204,SP00002,"Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants",,,Inflammatory Diseases,,,,,,,,Industry,Recruiting,Not Applicable,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Mara A,Lucie P,Tammara F,Clarice N,Terisa Sikora †,Hee Y,Beulah N,Lucie P,In Bellini †,Remedios Z,Quentin N,Aleta H,Perter K,Kandace p,Rima Y ,Terisa Sikora †,Naren G,Chetan K,Perter K,,,"Covance Clinical Research Unit - Leeds, Leeds, LDS, United Kingdom",85.28244848,76.75420363,All,"18 Years and older ¬† (Adult, Older Adult)",112,110,107,74,21,12,4/26/2020,12/13/2020,9/22/2020,11/4/2020,10/10/2020,10/15/2020,10/29/2020,11/1/2020,11/9/2020,1/28/2021,2/13/2021,8/20/2021,11/22/2021,1/19/2022,3/1/2022,4/6/2022,5/15/2022,6/22/2022,8/14/2022,4/13/2021,10/10/2021,4/8/2022,10/5/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04987333,,,,,,
Amgen,Amgen,ST00205,SP00002,"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)",,,Elevated Serum Lipoprotein(a),,,,,,,,Industry,"Active, not recruiting",Phase 1,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug D,,,,,,,,,,,,,,,,,,,John G,Livia Pacheo †,Donovan H,John G,Jaquelyn H,Perter K,Garnet T,Jaquelyn H,Chetan K,Kala R,Suzie K,Perter K,Gertrudis T,Beulah N,Harry A,Louann C,Stephan T,Suzie K,Anthony P,,,"Queen Mary Hospital, Hong Kong, HK, Hong Kong",26.42582564,23.78324308,All,"19 Years and older ¬† (Adult, Older Adult)",116,113,108,104,14,10,12/8/2019,5/5/2020,3/18/2020,4/10/2020,3/20/2020,4/5/2020,4/9/2020,4/12/2020,5/10/2020,6/27/2021,6/28/2021,1/20/2022,3/23/2022,5/6/2022,6/24/2022,7/31/2022,8/31/2022,10/20/2022,12/14/2022,10/2/2020,3/31/2021,9/27/2021,3/26/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04987320,,,,,,
Amgen,Amgen,ST00206,SP00002,Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis,,,Ulcerative Colitis,,I&I,,,,,,Industry,Not yet recruiting,Phase 1,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Doreen T,Mee M,Clarice N,Tamesha T,Terrell p,Frank T,Geralyn K,Quentin N,Lavina S,Mary H,Aleta H,Patria R,Clarice N,Terrell p,Livia Pacheo †,Perter K,Chetan K,Stephan T,James y,,,,11.8422635,10.65803715,All,"18 Years and older ¬† (Adult, Older Adult)",116,111,109,89,8,12,10/29/2019,5/20/2020,3/19/2020,4/7/2020,3/28/2020,4/2/2020,4/16/2020,4/18/2020,4/29/2020,11/18/2022,1/10/2023,8/10/2023,9/27/2023,11/21/2023,1/5/2024,2/14/2024,4/8/2024,5/26/2024,7/5/2024,9/29/2020,3/28/2021,9/24/2021,3/23/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04987307,,,,,,
Amgen,Amgen,ST00345,SP00002,A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer,,,,,Oncology,,,,,,Industry,Recruiting,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Federico L,Anthony P,Mara A,Mee M,Lucie P,Naren G,Dinah R,Federico L,Suzie K,Suzie K,James y,Corrine U,In Bellini †,James y,Stephan T,Stephan T,Jeanene Y,Lavina S,Jene M,,,"Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Landeskrankenhaus Salzburg, Salzburg, Austria|Universitair Ziekenhuis Gent, Gent, Belgium",47.35687182,42.62118464,Male,"Child, Adult, Older Adult",116,113,110,67,30,13,2/3/2019,8/30/2019,6/14/2019,7/18/2019,6/20/2019,7/1/2019,7/4/2019,7/5/2019,7/22/2019,4/19/2022,8/11/2022,12/18/2022,3/17/2023,5/15/2023,6/19/2023,8/10/2023,9/28/2023,11/14/2023,1/10/2024,12/28/2019,6/25/2020,12/22/2020,6/20/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04702737,,,,,,
Amgen,Amgen,ST00346,SP00002,AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug I,,,,,,,,,,,,,,,,,,,Tiffiny K,Clarice N,Chetan K,Christian G,Lilla Stilson †,Donovan H,Marcelina X,Doreen T,Anthony P,Dalton E,Suk T,Aleta H,Ngan D,Otis Thode †,Liberty A,Tiffiny K,Frank T,Remedios Z,Suzie K,,,,45.24368301,40.71931471,Male,"18 Years and older ¬† (Adult, Older Adult)",125,121,111,34,71,6,3/17/2004,9/15/2004,7/25/2004,8/22/2004,7/29/2004,8/8/2004,8/10/2004,8/11/2004,8/28/2004,9/28/2007,9/5/2007,3/5/2008,5/16/2008,6/15/2008,8/6/2008,9/15/2008,10/28/2008,12/5/2008,1/27/2009,2/4/2005,8/3/2005,1/30/2006,7/29/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00089674,,,,,,
Amgen,Amgen,ST00360,SP00002,Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer,,,,,Oncology,,,,,,Industry,Recruiting,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Selizabeth F,Aleta H,Frank T,Remedios Z,Garnet T,Lyman W,Donovan H,Lavina S,Harry A,Federico L,Stephan T,Garnet T,Mac L,Suk T,Mary H,Tien C,Jeanene Y,Tien C,Selizabeth F,,,"City of Hope National Medical Center, Duarte, California, United States|University of California San Francisco, San Francisco, California, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care Incorporated, Cincinnati, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical CenterCancer Pavillion, Pittsburgh, Pennsylvania, United States|Prisma Health Upstate, Greenville, South Carolina, United States|Sanford Health, Sioux Falls, South Dakota, United States|Chris OBrien Lifehouse, Camperdown, New South Wales, Australia|Monash Medical Centre, Clayton, Australia|National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, Taiwan",85.65760054,77.09184049,Male,"28 Years to 72 Years ¬† (Adult, Older Adult)",123,120,112,75,22,15,8/21/2023,2/14/2024,12/9/2023,12/29/2023,11/24/2023,12/16/2023,12/23/2023,12/28/2023,1/22/2024,1/17/2025,12/27/2024,8/22/2025,10/22/2025,12/19/2025,1/28/2026,3/6/2026,4/14/2026,5/24/2026,7/11/2026,6/13/2024,12/10/2024,6/8/2025,12/5/2025,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04221542,,,,,,
Amgen,Amgen,ST00400,SP00002,ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Selizabeth F,Tiffiny K,In Bellini †,Jeanene Y,Corrine U,Selizabeth F,Tammara F,Corrine U,Aleta H,Suzie K,Lucie P,Terrell p,Perter K,Otis Thode †,Jerold Goo †,Aleta H,Suk T,Donovan H,Lyman W,,,,59.82726834,53.84454151,Female,"18 Years and older ¬† (Adult, Older Adult)",121,116,113,98,3,12,3/3/2004,8/27/2004,6/30/2004,8/1/2004,7/12/2004,7/16/2004,7/28/2004,7/29/2004,8/27/2004,1/4/2007,11/3/2006,1/31/2007,6/1/2007,7/16/2007,9/9/2007,10/13/2007,12/10/2007,2/4/2008,3/29/2008,1/12/2005,7/11/2005,1/7/2006,7/6/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00261313,,,,,,
Amgen,Amgen,ST00452,SP00002,Treatment for Elderly Patients With High Risk Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Christian G,Perter K,Perter K,Gertrudis T,Suzie K,Tammara F,Lavina S,Jerold Goo †,Jaquelyn H,Terrell p,Chetan K,Selizabeth F,Doreen T,Aleta H,Frank T,Selizabeth F,Xochitl D,Jeanene Y,Marceline R,,,,17.00964659,15.30868193,Female,"18 Years to 80 Years ¬† (Adult, Older Adult)",127,125,114,74,26,14,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/3/1900,3/15/1900,5/14/1900,7/9/1900,8/30/1900,10/14/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00117910,,,,,,
Amgen,Amgen,ST00496,SP00002,Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC),,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Quentin N,Aleta H,Tamesha T,Dalton E,Selizabeth F,Otis Thode †,Doreen T,Ngan D,Lavina S,Tien C,Ross S,Selizabeth F,Tiffiny K,Otis Thode †,Mary H,Quentin N,Patria R,Geralyn K,Geralyn K,,,,1.401132479,1.261019231,All,"18 Years and older ¬† (Adult, Older Adult)",127,123,115,81,24,10,3/31/2001,10/8/2001,8/5/2001,9/8/2001,8/24/2001,8/28/2001,9/4/2001,9/8/2001,10/2/2001,4/26/2005,2/11/2005,8/2/2005,12/1/2005,1/8/2006,2/25/2006,4/5/2006,5/16/2006,7/15/2006,8/28/2006,2/24/2002,8/23/2002,2/19/2003,8/18/2003,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00094822,,,,,,
Amgen,Amgen,ST00503,SP00002,AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC),,,,,Oncology,,,,,,Industry,Not yet recruiting,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Dalton E,Terrell p,Terisa Sikora †,Naren G,Dalton E,Mac L,Quentin N,Ross S,Jene M,Jene M,Quentin N,Lilla Stilson †,Lyman W,Rima Y ,Suzie K,Perter K,Jeanene Y,Corrine U,In Bellini †,,,,58.90001951,53.01001756,All,"18 Years to 75 Years ¬† (Adult, Older Adult)",125,121,116,38,72,6,11/10/2019,6/1/2020,4/5/2020,5/8/2020,4/12/2020,4/24/2020,4/26/2020,4/29/2020,5/25/2020,3/23/2024,7/23/2024,10/30/2024,3/7/2025,4/22/2025,6/2/2025,7/8/2025,8/21/2025,9/24/2025,11/17/2025,10/21/2020,4/19/2021,10/16/2021,4/14/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04885998,,,,,,
Amgen,Amgen,ST00530,SP00002,Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug H,,,,,,,,,,,,,,,,,,,Mary H,Gertrudis T,Marceline R,Naren G,Kala R,Otis Thode †,Perter K,Jene M,Stephan T,Jeanene Y,Xochitl D,Frank T,Frank T,Jaquelyn H,Kandace p,Liberty A,Doreen T,Mary H,John G,,,,98.92857181,89.03571463,Female,"18 Years and older ¬† (Adult, Older Adult)",130,128,117,37,75,5,11/3/2006,5/27/2007,3/20/2007,4/23/2007,4/12/2007,4/15/2007,4/17/2007,4/19/2007,5/6/2007,11/28/2008,12/27/2008,4/11/2009,8/11/2009,9/10/2009,10/20/2009,11/27/2009,1/24/2010,3/18/2010,5/10/2010,10/12/2007,4/9/2008,10/6/2008,4/4/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00479817,,,,,,
Amgen,Amgen,ST00549,SP00002,Study of AMG 757 in Participants With Small Cell Lung Cancer (SCLC),,,,,Oncology,,,,,,Industry,Not yet recruiting,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Jaquelyn H,Stephan T,Terisa Sikora †,Marceline R,Suzie K,Kandace p,Naren G,Tamesha T,Clarice N,Tamesha T,Anthony P,Mac L,Jaquelyn H,Aleta H,Kandace p,Suk T,Perter K,In Bellini †,Jeanene Y,,,,93.55449025,84.19904123,All,,131,125,118,93,12,13,12/28/2020,6/23/2021,4/28/2021,6/5/2021,5/1/2021,5/20/2021,5/26/2021,5/27/2021,6/3/2021,1/21/2023,12/22/2022,5/28/2023,9/26/2023,11/4/2023,12/30/2023,1/30/2024,3/7/2024,4/27/2024,6/26/2024,11/16/2021,5/15/2022,11/11/2022,5/10/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05060016,,,,,,
Amgen,Amgen,ST00552,SP00002,Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Tiffiny K,John G,Naren G,Kala R,Federico L,Selizabeth F,Jaquelyn H,Lucie P,Mary H,Naren G,Marcelina X,Beulah N,Suzie K,Lucie P,Lyman W,Marcelina X,Mary H,Federico L,Naren G,,,,76.68476699,69.01629029,All,,129,126,119,53,57,9,9/7/2013,2/9/2014,11/29/2013,12/28/2013,11/30/2013,12/21/2013,12/23/2013,12/28/2013,1/15/2014,8/23/2016,2/8/2016,8/12/2016,11/30/2016,1/21/2017,3/14/2017,5/11/2017,6/19/2017,8/8/2017,9/29/2017,6/19/2014,12/16/2014,6/14/2015,12/11/2015,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01732783,,,,,,
Amgen,Amgen,ST00567,SP00002,Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC),,,,,Oncology,,,,,,Industry,Recruiting,Phase 1|Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Tiffiny K,Aleta H,Mara A,Mara A,Tiffiny K,Patria R,Lilla Stilson †,Liberty A,Marcelina X,Perter K,Tammara F,Anthony P,Patria R,Rima Y ,Dalton E,James y,Donovan H,Garnet T,Gertrudis T,,,"University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California San Francisco Mission Bay Campus, San Francisco, California, United States|Norton Cancer Institute, Louisville, Kentucky, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|St Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia|Rigshospitalet, Kobenhavn O, Denmark|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Skanes universitetssjukhus, Lund, Sweden|Karolinska Universitetssjukhuset Solna, Stockholm, Sweden|Akademiska sjukhuset, Uppsala, Sweden|Royal Marsden Hospital, Sutton, United Kingdom",15.18002183,13.66201965,Male,,128,124,120,84,27,9,5/15/2021,11/3/2021,9/15/2021,10/20/2021,9/8/2021,10/1/2021,10/10/2021,10/11/2021,10/31/2021,8/6/2022,5/14/2022,7/28/2022,11/30/2022,1/27/2023,3/11/2023,5/7/2023,6/16/2023,8/15/2023,10/2/2023,3/30/2022,9/26/2022,3/25/2023,9/21/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04631601,,,,,,
AstraZeneca,AstraZeneca,ST00112,SP00003,A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition,,MONETTE,Melanoma,,Oncology,,,,,,Industry,Not yet recruiting,Phase 1|Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Patria R,Ngan D,Lilla Stilson †,Chetan K,Mac L,Christian G,Mary H,Tien C,Clarice N,Jaquelyn H,Lavina S,Harry A,Anthony P,Garnet T,Aleta H,Patria R,Mac L,Jerold Goo †,,,,70.73592569,63.66233312,All,"18 Years and older ¬† (Adult, Older Adult)",128,126,121,96,10,15,8/20/2018,3/14/2019,1/1/2019,1/19/2019,1/2/2019,1/14/2019,1/26/2019,1/27/2019,2/21/2019,3/27/2023,4/25/2023,8/13/2023,12/18/2023,2/12/2024,3/26/2024,5/3/2024,6/7/2024,7/10/2024,8/18/2024,7/13/2019,1/9/2020,7/7/2020,1/3/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05061134,,,,,,
AstraZeneca,AstraZeneca,ST00117,SP00003,"A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults",,VICTORIA,"COVID-19, SARS-CoV-2",,Virology,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Dinah R,Lyman W,Aleta H,Selizabeth F,Terisa Sikora †,Ngan D,Selizabeth F,Selizabeth F,Otis Thode †,Christian G,Tammara F,Suzie K,Livia Pacheo †,Perter K,Mary H,Xochitl D,Chetan K,Perter K,Mac L,,,"Cl√≠nica de la Costa Ltda., Barranquilla, Colombia|Fundaci√≥n Cardiovascular de Colombia - Instituto del Coraz√≥n Floridablanca, Floridablanca, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Colombia|Sir Ganga Ram Hospital, New Delhi, Delhi, India|ESIC Medical College and Hospital, Faridabad, Haryana, India|Shetty Hospital, Bengaluru, Karnataka, India|Mavens Hospital, Ajmer, Rajasthan, India|Apollo Gleneagles Hospitals Ltd., Kolkata, West Bengal, India|Siriraj Hospital, Bangkok-noi, Bangkok, Thailand|King Chulalongkorn Memorial Hospital, Pathumwan, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Muang, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen, Thailand|CNE Ivano-Frankivsk Reg Clin Infectious Hospital of Ivano-Frankivsk Regional Council, Ivano-Frankivsk, Ukraine|Pratia Clinic Ukraine LLC, Kharkiv, Ukraine|SI ""Shalimov's National Institute of Surgery and Transplantation"" of NAMSU, Kyiv, Ukraine|Lviv Communal 4th City Clinical Hospital, Lviv, Ukraine",96.03810221,86.43429199,All,"22 Years and older ¬† (Adult, Older Adult)",137,134,122,69,43,10,4/29/2020,11/17/2020,9/13/2020,10/11/2020,9/19/2020,9/21/2020,9/26/2020,9/27/2020,10/19/2020,3/18/2022,1/17/2022,7/9/2022,9/29/2022,11/22/2022,1/21/2023,3/18/2023,5/1/2023,6/10/2023,7/26/2023,3/20/2021,9/16/2021,3/15/2022,9/11/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05057897,,,,,,
AstraZeneca,AstraZeneca,ST00118,SP00003,A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,,MAJIC,Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,,,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Dalton E,Livia Pacheo †,Suzie K,Frank T,Naren G,Lavina S,Anthony P,Stephan T,Livia Pacheo †,Marcelina X,Clarice N,Terrell p,Clarice N,Anthony P,Mary H,Tien C,Beulah N,Anthony P,Clarice N,,,,20.99875929,18.89888336,All,18 Years to 55 Years ¬† (Adult),138,133,123,68,46,9,7/31/2023,1/7/2024,10/23/2023,11/30/2023,10/29/2023,11/14/2023,11/21/2023,11/24/2023,12/12/2023,8/28/2028,12/18/2027,6/9/2028,9/29/2028,11/28/2028,1/11/2029,2/21/2029,4/12/2029,5/22/2029,6/26/2029,5/12/2024,11/8/2024,5/7/2025,11/3/2025,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05057494,,,,,,
AstraZeneca,AstraZeneca,ST00119,SP00003,A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia,,STABILIZE-CKD,"Renal Insufficiency, Chronic|Hyperkalemia",,,,,,,,Industry,Not yet recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Suk T,Terrell p,Harry A,Mac L,Suzie K,Mara A,Donovan H,John G,Anthony P,James y,Rima Y ,Mary H,Clarice N,Tammara F,Terisa Sikora †,Perter K,Frank T,Lucie P,James y,,,"Research Site, Canyon Country, California, United States|Research Site, Granada Hills, California, United States|Research Site, Northridge, California, United States|Research Site, San Dimas, California, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocoee, Florida, United States|Research Site, Flint, Michigan, United States|Research Site, Kansas City, Missouri, United States|Research Site, New Bern, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Arlington, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Newport News, Virginia, United States|Research Site, Zhengzhou City, China|Research Site, Bari, Italy|Research Site, Brescia, Italy|Research Site, Messina, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Ponce, Puerto Rico|Research Site, Saint Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Marbella, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Tenerife, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Keelung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kahramanmaras, Turkey|Research Site, Kocaeli, Turkey",65.94202238,59.34782015,All,"up to 80 Years ¬† (Child, Adult, Older Adult)",140,135,124,101,3,20,10/10/2022,3/12/2023,1/5/2023,2/8/2023,1/4/2023,1/22/2023,1/28/2023,2/1/2023,2/6/2023,8/16/2024,4/24/2024,11/2/2024,1/15/2025,3/1/2025,4/5/2025,5/22/2025,7/15/2025,9/6/2025,10/20/2025,7/21/2023,1/17/2024,7/15/2024,1/11/2025,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05056727,,,,,,
AstraZeneca,AstraZeneca,ST00123,SP00003,Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam,,,Healthy Volunteers,,,,,,,,Industry,Not yet recruiting,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Anthony P,Doreen T,Harry A,Ross S,Clarice N,Lyman W,Tammara F,Jaquelyn H,Jerold Goo †,Doreen T,Chetan K,Livia Pacheo †,Lucie P,Ngan D,Jaquelyn H,John G,Livia Pacheo †,Rima Y ,,,"Research Site, Harrow, United Kingdom",12.46473985,11.21826587,All,"18 Years and older ¬† (Adult, Older Adult)",131,128,125,54,62,9,10/4/2019,2/7/2020,12/27/2019,1/19/2020,12/12/2019,1/3/2020,1/8/2020,1/11/2020,1/25/2020,10/3/2021,3/28/2021,9/22/2021,11/26/2021,12/27/2021,2/5/2022,3/13/2022,4/19/2022,6/1/2022,7/7/2022,7/1/2020,12/28/2020,6/26/2021,12/23/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05052710,,,,,,
AstraZeneca,AstraZeneca,ST00137,SP00003,"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC",,SAMETA,Papillary Renal Cell Carcinoma,,Oncology,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,John G,Livia Pacheo †,Lavina S,Suzie K,Xochitl D,Rima Y ,Louann C,James y,Marceline R,Ross S,Dinah R,Suzie K,Beulah N,Selizabeth F,Tammara F,Frank T,Frank T,Mary H,Patria R,,,"Research Site, San Miguel de Tucuman, Argentina|Research Site, Westmead, Australia|Research Site, Porto Alegre, Brazil|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 8, Czechia|Research Site, Praha, Czechia|Research Site, Nice, France|Research Site, Villejuif, France|Research Site, Firenze, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Monterrey, Mexico|Research Site, M√©xico, Mexico|Research Site, Queretaro, Mexico|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Otwock, Poland|Research Site, Barcelona, Spain|Research Site, Tainan, Taiwan|Research Site, Ankara, Turkey|Research Site, London, United Kingdom",95.52991984,85.97692786,All,4 Years to 14 Years ¬† (Child),142,138,126,104,6,16,12/24/2020,7/25/2021,6/4/2021,7/3/2021,6/2/2021,6/17/2021,6/21/2021,6/23/2021,7/19/2021,12/24/2023,7/6/2023,12/1/2023,3/8/2024,4/28/2024,6/20/2024,8/8/2024,10/7/2024,11/26/2024,1/8/2025,12/14/2021,6/12/2022,12/9/2022,6/7/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05043090,,,,,,
AstraZeneca,AstraZeneca,ST00145,SP00003,"Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants",,,Healthy Participants,,,,,,,,Industry,Not yet recruiting,Phase 1,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Garnet T,Frank T,Garnet T,Mara A,Suzie K,Stephan T,Tammara F,Lyman W,Terisa Sikora †,Rima Y ,Selizabeth F,Harry A,Jaquelyn H,Perter K,Kala R,Suzie K,Aleta H,Selizabeth F,Frank T,,,"Research Site, Glendale, California, United States",17.49489929,15.74540936,All,18 Years to 60 Years ¬† (Adult),136,133,127,48,74,5,1/25/2021,7/27/2021,5/24/2021,6/16/2021,5/21/2021,5/29/2021,6/12/2021,6/13/2021,7/5/2021,5/1/2022,11/26/2021,5/12/2022,7/12/2022,8/13/2022,10/9/2022,11/23/2022,1/21/2023,2/27/2023,4/8/2023,11/25/2021,5/24/2022,11/20/2022,5/19/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05033431,,,,,,
AstraZeneca,AstraZeneca,ST00179,SP00003,Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis,,MAHALE,Non-cystic Fibrosis Bronchiectasis,,,,,,,,Industry,Recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Lilla Stilson †,Christian G,Mac L,Mary H,Tammara F,Selizabeth F,Marcelina X,Mara A,Kandace p,Selizabeth F,Mac L,Otis Thode †,Rima Y ,Remedios Z,Mary H,Ngan D,Lucie P,Rima Y ,Tiffiny K,,,"Research Site, Birmingham, Alabama, United States|Research Site, Newport Beach, California, United States|Research Site, Northridge, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Hinesville, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Rincon, Georgia, United States|Research Site, Kansas City, Kansas, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Rochester, Minnesota, United States|Research Site, Statesville, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, El Paso, Texas, United States|Research Site, Caba, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Florida, Argentina|Research Site, San Fernando, Argentina|Research Site, Tucum√°n, Argentina|Research Site, Melbourne, Australia|Research Site, South Brisbane, Australia|Research Site, Calgary, Alberta, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Quebec, Canada|Research Site, Beijing, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Haikou, China|Research Site, Nanchang, China|Research Site, Shanghai, China|Research Site, Wuhan, China|Research Site, Xuzhou, China|Research Site, Aalborg, Denmark|Research Site, Hellerup, Denmark|Research Site, Hvidovre, Denmark|Research Site, K√∏ge, Denmark|Research Site, Vejle, Denmark|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Borstel, Germany|Research Site, Donaustauf, Germany|Research Site, D√ºsseldorf, Germany|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Gauting, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Hessen, Germany|Research Site, M√ºnchen, Germany|Research Site, Coimbatore, India|Research Site, Hyderabad, India|Research Site, Jaipur, India|Research Site, New Delhi, India|Research Site, Noida, India|Research Site, Bari, Italy|Research Site, Catania, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Palermo, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Jeonju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Davao City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Bia≈Çystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Pozna≈Ñ, Poland|Research Site, Sosnowiec, Poland|Research Site, Wejherowo, Poland|Research Site, Wroc≈Çaw, Poland|Research Site, Chelyabinsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Ulyanovsk, Russian Federation|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Valencia, Spain|Research Site, Cambridge, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam",86.00983975,77.40885578,All,"11 Years and older ¬† (Child, Adult, Older Adult)",141,138,128,79,34,15,9/8/2019,2/8/2020,12/24/2019,1/12/2020,12/20/2019,1/5/2020,1/20/2020,1/21/2020,2/4/2020,11/3/2023,9/17/2023,2/16/2024,6/10/2024,7/21/2024,9/1/2024,10/2/2024,11/24/2024,1/18/2025,3/18/2025,7/3/2020,12/30/2020,6/28/2021,12/25/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05006573,,,,,,
AstraZeneca,AstraZeneca,ST00185,SP00003,Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE),,,Systemic Lupus Erythematosus,,,,,,,,Industry,Recruiting,Not Applicable,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Tammara F,Mac L,Harry A,Federico L,Ngan D,Mara A,Stephan T,Doreen T,Marceline R,John G,Perter K,Aleta H,Suk T,Stephan T,Mary H,Frank T,Tien C,Lucie P,,,"Research Site, Beijing, China|Research Site, Nantong, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Suzhou, China",27.27559386,24.54803448,All,18 Years to 35 Years ¬† (Adult),137,135,129,44,78,7,7/29/2018,2/1/2019,12/8/2018,12/30/2018,12/11/2018,12/21/2018,12/25/2018,12/26/2018,1/10/2019,9/2/2021,11/15/2021,4/4/2022,8/24/2022,10/14/2022,11/16/2022,12/18/2022,1/21/2023,3/14/2023,4/27/2023,6/19/2019,12/16/2019,6/13/2020,12/10/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05001698,,,,,,
AstraZeneca,AstraZeneca,ST00187,SP00003,"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours",,,Locally Advanced or Metastatic Solid Tumours,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Xochitl D,In Bellini †,Mary H,Aleta H,Ngan D,Tiffiny K,John G,Christian G,Frank T,Ngan D,Lavina S,Mary H,Otis Thode †,James y,Suk T,Clarice N,Lucie P,Perter K,Tamesha T,,,,6.718222864,6.046400578,All,"18 Years and older ¬† (Adult, Older Adult)",146,142,130,122,9,1,2/29/2020,8/17/2020,6/27/2020,7/20/2020,6/26/2020,7/8/2020,7/12/2020,7/15/2020,8/6/2020,5/16/2023,2/18/2023,10/4/2023,11/28/2023,1/7/2024,2/17/2024,4/9/2024,6/2/2024,7/7/2024,8/9/2024,1/4/2021,7/3/2021,12/30/2021,6/28/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04999969,,,,,,
AstraZeneca,AstraZeneca,ST00190,SP00003,Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia,,GRAZE,Hyperkalaemia,,,,,,,,Industry,Recruiting,,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Perter K,Patria R,Mara A,Terisa Sikora †,Terrell p,Anthony P,Lyman W,Liberty A,John G,Tammara F,Perter K,Doreen T,Mara A,Suk T,Naren G,Perter K,Mac L,Terrell p,Jeanene Y,,,"Research Site, Torrance, California, United States|Research Site, Victorville, California, United States|Research Site, Hartford, Connecticut, United States|Research Site, Middlebury, Connecticut, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bronx, New York, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Conroe, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Bradford, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, York, United Kingdom",8.836478959,7.952831063,All,"Child, Adult, Older Adult",145,139,131,124,10,3,7/15/2019,2/6/2020,12/11/2019,1/10/2020,12/12/2019,12/24/2019,12/29/2019,1/2/2020,1/20/2020,5/21/2022,12/11/2021,6/10/2022,7/31/2022,9/6/2022,11/4/2022,12/23/2022,1/25/2023,3/10/2023,4/27/2023,6/21/2020,12/18/2020,6/16/2021,12/13/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04997161,,,,,,
AstraZeneca,AstraZeneca,ST00191,SP00003,A Study to Assess the Safety and Efficacy of AZD2936 in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC),,ARTEMIDE-01,Non-Small-Cell Lung Carcinoma,,Oncology,,,,,,Industry,Not yet recruiting,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Clarice N,Suzie K,Chetan K,Suzie K,Mara A,Kala R,Lavina S,Jerold Goo †,Lucie P,Suzie K,Liberty A,Suzie K,Gertrudis T,Stephan T,Gertrudis T,Anthony P,Rima Y ,John G,Livia Pacheo †,,,"Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Copenhagen, Denmark|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands",45.40328606,40.86295745,All,"18 Years and older ¬† (Adult, Older Adult)",151,145,132,87,32,13,4/8/2019,8/24/2019,6/27/2019,8/3/2019,6/28/2019,7/20/2019,8/2/2019,8/7/2019,8/12/2019,12/12/2022,3/17/2023,7/15/2023,11/14/2023,12/22/2023,2/13/2024,4/7/2024,6/4/2024,7/29/2024,9/25/2024,1/16/2020,7/14/2020,1/10/2021,7/9/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04995523,,,,,,
AstraZeneca,AstraZeneca,ST00196,SP00003,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers",,,Healthy Participants,,,,,,,,Industry,Recruiting,Phase 1,Interventional,,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Jeanene Y,Selizabeth F,Garnet T,Garnet T,Harry A,Gertrudis T,Lavina S,Mary H,Mara A,Terisa Sikora †,Stephan T,Jene M,Perter K,Terrell p,Lyman W,Louann C,Ngan D,Marceline R,Christian G,,,"Research Site, Glendale, California, United States",53.37012609,48.03311348,All,"18 Years and older ¬† (Adult, Older Adult)",146,141,133,95,26,12,10/14/2019,4/19/2020,2/18/2020,3/11/2020,2/7/2020,2/25/2020,2/28/2020,3/2/2020,3/24/2020,11/25/2021,7/12/2021,10/22/2021,3/14/2022,5/8/2022,7/7/2022,8/21/2022,10/17/2022,12/12/2022,2/7/2023,8/23/2020,2/19/2021,8/18/2021,2/14/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04994106,,,,,,
AstraZeneca,AstraZeneca,ST00199,SP00003,"Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, a Post Authorization Safety Study",,,Asthma|Neoplasms,,Oncology,,,,,,Industry,Recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Terrell p,Jeanene Y,Marceline R,Naren G,Corrine U,Mara A,Selizabeth F,Perter K,Lucie P,Dalton E,Naren G,Frank T,Christian G,Stephan T,Patria R,Ross S,Jene M,Beulah N,Gertrudis T,,,"Research Site, Stockholm, Sweden|Research Site, Norwich, Norfolk, United Kingdom",91.03454902,81.93109412,All,"18 Years and older ¬† (Adult, Older Adult)",150,146,134,110,13,11,11/10/2019,7/2/2020,4/9/2020,5/13/2020,4/18/2020,5/4/2020,5/14/2020,5/16/2020,6/4/2020,5/30/2023,3/12/2023,9/27/2023,12/31/2023,2/17/2024,3/24/2024,5/7/2024,6/10/2024,7/13/2024,8/21/2024,10/31/2020,4/29/2021,10/26/2021,4/24/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04991805,,,,,,
AstraZeneca,AstraZeneca,ST00200,SP00003,Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants,,,Chronic Kidney Disease,,Metabolic,,,,,,Industry,Recruiting,Not Applicable,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Tien C,Stephan T,Mary H,Remedios Z,Harry A,Perter K,Quentin N,Harry A,Dinah R,Kandace p,In Bellini †,Hee Y,Naren G,Stephan T,Jene M,Lyman W,Aleta H,Kandace p,Kandace p,,,"Research Site, Brooklyn, Maryland, United States",45.32103195,40.78892876,All,"18 Years and older ¬† (Adult, Older Adult)",150,144,135,116,3,16,4/9/2017,10/21/2017,9/2/2017,10/4/2017,9/9/2017,9/17/2017,9/28/2017,9/30/2017,10/14/2017,6/24/2021,3/14/2021,7/29/2021,10/6/2021,11/20/2021,1/4/2022,3/3/2022,4/28/2022,6/15/2022,8/5/2022,3/16/2018,9/12/2018,3/11/2019,9/7/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04991571,,,,,,
AstraZeneca,AstraZeneca,ST00201,SP00003,"Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer",,HALO,Fallopian Tube Cancer,,Oncology,,,,,,Industry,Recruiting,Not Applicable,Observational,,Observational Model: Other|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Lyman W,Aleta H,Jerold Goo †,Ross S,Suzie K,John G,Mary H,Tamesha T,Terrell p,James y,Liberty A,Chetan K,Patria R,Lyman W,Suzie K,Lucie P,Patria R,Perter K,Mary H,,,"Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, Chelyabinsk, Russian Federation|Oncological Dispensary of Rostov-on-Don Region, Rostov-on-Don, Russian Federation|Multidisciplinary clinical medical center ""Medical City"", Tyumen, Russian Federation|Bashkortostan Republican Clinical Oncological Dispensary, Ufa, Russian Federation",2.198682759,1.978814484,Female,"up to 100 Years ¬† (Child, Adult, Older Adult)",144,142,136,82,39,15,1/15/2017,6/1/2017,4/12/2017,5/10/2017,4/17/2017,4/27/2017,4/30/2017,5/5/2017,5/16/2017,9/15/2021,9/11/2021,1/28/2022,3/31/2022,5/30/2022,7/6/2022,8/5/2022,9/6/2022,10/7/2022,11/19/2022,10/24/2017,4/22/2018,10/19/2018,4/17/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04991051,,,,,,
AstraZeneca,AstraZeneca,ST00207,SP00003,Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%,,ENDEAVOR,Heart Failure With Preserved Ejection Fraction,,Cardiovascular,,,,,,Industry,Recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Mara A,Gertrudis T,Terrell p,Jene M,Beulah N,Clarice N,John G,Chetan K,Patria R,Donovan H,Garnet T,Dinah R,Suzie K,Remedios Z,John G,Naren G,Perter K,Rima Y ,Tammara F,,,"Research Site, Alexander City, Alabama, United States|Research Site, Fort Payne, Alabama, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Jackson, Mississippi, United States|Research Site, Omaha, Nebraska, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Falls Church, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Aracaju, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Brasilia, Brazil|Research Site, Brasillia, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Campinas, Brazil|Research Site, Curitiba, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeir√£o Preto, Brazil|Research Site, Ribeir√£o Preto, Brazil|Research Site, Santo Andre, Brazil|Research Site, Santo Andr√©, Brazil|Research Site, S√£o Lu√≠s, Brazil|Research Site, Vit√≥ria, Brazil|Research Site, Haskovo, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Vancouver, British Columbia, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Guelph, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Stoney Creek, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, York, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Benesov, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Ceske Budejovice, Czechia|Research Site, Jaromer, Czechia|Research Site, Kolin, Czechia|Research Site, Louny, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, Pribram, Czechia|Research Site, Roznov pod Radhostem, Czechia|Research Site, Copenhagen O, Denmark|Research Site, Herlev, Denmark|Research Site, Hvidovre, Denmark|Research Site, K√∏benhavn NV, Denmark|Research Site, K√∏benhavn, Denmark|Research Site, Odense C, Denmark|Research Site, Viborg, Denmark|Research Site, √Örhus N, Denmark|Research Site, Bayonne, France|Research Site, Bobigny, France|Research Site, Bron, France|Research Site, Corbeil-Essonnes, France|Research Site, Dijon Cedex, France|Research Site, La Tronche, France|Research Site, Le Coudray Cedex, France|Research Site, Marseille Cedex 20, France|Research Site, Montpellier Cedex, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pierre Benite, France|Research Site, Rennes Cedex 9, France|Research Site, Saint Brieuc, France|Research Site, Toulon, France|Research Site, Toulouse Cedex 9, France|Research Site, TOURCOING cedex, France|Research Site, Vandoeuvre les Nancy Cedex, France|Research Site, Moscow, Israel|Research Site, Higashiohmi-shi, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Minami-ku, Japan|Research Site, Nagano, Japan|Research Site, Oita-shi, Japan|Research Site, Omihachiman-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Otaru-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sayama-shi,, Japan|Research Site, Sendai-shi, Japan|Research Site, Toshima-ku, Japan|Research Site, Ueda-shi, Japan|Research Site, Uwajima-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Bydgoszcz, Poland|Research Site, Krak√≥w, Poland|Research Site, Legnica, Poland|Research Site, Lublin, Poland|Research Site, Pu≈Çawy, Poland|Research Site, Rzeszow, Poland|Research Site, Skierniewice, Poland|Research Site, Tczew, Poland|Research Site, Tychy, Poland|Research Site, Warszawa, Poland|Research Site, ≈Å√≥d≈∫, Poland|Research Site, Aramil, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Brezno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Martin, Slovakia|Research Site, Presov, Slovakia|Research Site, Presov, Slovakia|Research Site, Svidnik, Slovakia|Research Site, G√∂teborg, Sweden|Research Site, J√∂nk√∂ping, Sweden|Research Site, Link√∂ping, Sweden|Research Site, Lund, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Ume√•, Sweden|Research Site, Uppsala, Sweden|Research Site, √ñrebro, Sweden|Research Site, Hsinchu, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Keelung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei 112, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Yilan, Taiwan",83.77840674,75.40056606,All,18 Years to 30 Years ¬† (Adult),154,148,137,109,14,14,8/12/2019,1/11/2020,10/21/2019,11/30/2019,11/15/2019,11/19/2019,11/28/2019,11/29/2019,12/29/2019,5/26/2024,1/31/2024,8/30/2024,9/30/2024,11/21/2024,1/18/2025,3/18/2025,5/15/2025,7/11/2025,9/2/2025,5/17/2020,11/13/2020,5/12/2021,11/8/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04986202,,,,,,
AstraZeneca,AstraZeneca,ST00226,SP00003,"Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults",,AZD2816,COVID-19|SARS-CoV-2,,Virology,,,,,,Industry,Recruiting,Phase 4,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Aleta H,John G,Jerold Goo †,Jeanene Y,Federico L,Terisa Sikora †,Mary H,Jaquelyn H,Suk T,Clarice N,Mee M,Suzie K,Perter K,Naren G,Jene M,Beulah N,Marceline R,Quentin N,Tien C,,,"Research Site, Brasilia, Brazil|Research Site, Curitiba, Brazil|Research Site, Natal, Brazil|Research Site, Natal, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Salvador, Brazil|Research Site, S√£o Paulo, Brazil|Research Site, Krak√≥w, Poland|Research Site, Lublin, Poland|Research Site, O≈õwiƒôcim, Poland|Research Site, Pu≈Çawy, Poland|Research Site, Sk√≥rzewo, Poland|Research Site, Trzebnica, Poland|Research Site, Zamosc, Poland|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Somerset West, South Africa|Research Site, Birmingham, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Harrow, United Kingdom|Research Site, Hull, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle-upon-Tyne, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Portsmouth, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Truro, United Kingdom",76.17728457,68.55955611,All,"18 Years to 70 Years ¬† (Adult, Older Adult)",147,145,138,62,67,9,7/5/2017,12/10/2017,10/10/2017,10/29/2017,10/2/2017,10/24/2017,11/7/2017,11/11/2017,11/25/2017,12/15/2020,1/16/2021,6/17/2021,10/8/2021,11/18/2021,12/23/2021,2/12/2022,4/7/2022,5/17/2022,7/1/2022,4/22/2018,10/19/2018,4/17/2019,10/14/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04973449,,,,,,
AstraZeneca,AstraZeneca,ST00237,SP00003,Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6),,SERENA-6,ER-Positive HER2-Negative Breast Cancer,,Oncology,,,,,,Industry,Recruiting,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,,,,Drug A,,,,,,,,,,,,,,,,,,,Tiffiny K,Dalton E,Remedios Z,Mary H,Rima Y ,Suk T,Dalton E,Perter K,Beulah N,Xochitl D,John G,Kala R,Rima Y ,Tien C,Jene M,Marcelina X,Rima Y ,Gertrudis T,Rima Y ,,,"Research Site, Phoenix, Arizona, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Denver, Colorado, United States|Research Site, Jacksonville, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Blue Ash, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, West Columbia, South Carolina, United States|Research Site, Bedford, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Subiaco, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Panagyurishte, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British COL, Canada|Research Site, Ottawa, Canada|Research Site, Quebec, Canada|Research Site, Lyon Cedex 08, France|Research Site, Paris Cedex 5, France|Research Site, Saint-cloud, France|Research Site, Ansbach, Germany|Research Site, Aschaffenburg, Germany|Research Site, Augsburg, Germany|Research Site, Bonn, Germany|Research Site, Chemnitz, Germany|Research Site, Dresden, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Leipzig, Germany|Research Site, Mannheim, Germany|Research Site, M√ºnchen, Germany|Research Site, Paderborn, Germany|Research Site, Ravensburg, Germany|Research Site, Ulm, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Miskolc, Hungary|Research Site, Szeksz√°rd, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Chuo-ku, Japan|Research Site, Hidaka-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Ota-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Takasaki-shi, Japan|Research Site, Tsukuba, Japan|Research Site, Yokohama-shi, Japan|Research Site, Cheonan-si, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Gdynia, Poland|Research Site, Konin, Poland|Research Site, Koszalin, Poland|Research Site, Olsztyn, Poland|Research Site, Pozna≈Ñ, Poland|Research Site, Tomasz√≥w Mazowiecki, Poland|Research Site, Warszawa, Poland|Research Site, ≈Å√≥d≈∫, Poland|Research Site, Guimar√£es, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Loures, Portugal|Research Site, Porto, Portugal|Research Site, Vila Nova de Gaia, Portugal|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Podolsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Sankt-Peterburg, Russian Federation|Research Site, Barcelona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, La Coruna, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Murcia, Spain|Research Site, Sevilla, Spain|Research Site, Bern, Switzerland|Research Site, Chur, Switzerland|Research Site, Winterthur, Switzerland|Research Site, Kaohsiung city, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, ƒ∞stanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Kayseri, Turkey|Research Site, Blackpool, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Portsmouth, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Taunton, United Kingdom",60.86702885,54.78032597,All,"18 Years to 130 Years ¬† (Adult, Older Adult)",155,148,139,114,9,16,5/24/2019,11/2/2019,8/26/2019,10/15/2019,9/2/2019,9/25/2019,10/5/2019,10/8/2019,10/20/2019,7/4/2023,1/25/2023,6/13/2023,9/28/2023,11/25/2023,1/5/2024,3/1/2024,4/25/2024,6/10/2024,7/15/2024,3/23/2020,9/19/2020,3/18/2021,9/14/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04964934,,,,,,
AstraZeneca,AstraZeneca,ST00238,SP00003,"Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia",,CREEK,Chronic Lymphocytic Leukemia,,,,,,,,Industry,Not yet recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Anthony P,Mara A,Selizabeth F,Jerold Goo †,Mac L,Selizabeth F,Suzie K,Stephan T,James y,Quentin N,Mary H,Tammara F,Jaquelyn H,Rima Y ,Mara A,Beulah N,Beulah N,John G,Harry A,,,,66.65630728,59.99067656,All,"20 Years to 85 Years ¬† (Adult, Older Adult)",154,151,140,129,13,2,2/16/2017,8/26/2017,6/25/2017,7/25/2017,6/23/2017,7/8/2017,7/23/2017,7/26/2017,8/22/2017,6/13/2021,5/11/2021,11/30/2021,1/31/2022,3/14/2022,4/25/2022,6/2/2022,7/25/2022,9/23/2022,11/11/2022,1/4/2018,7/3/2018,12/30/2018,6/28/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04964908,,,,,,
AstraZeneca,AstraZeneca,ST00239,SP00003,"A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia",,SOLANO,Hyperlipidaemia,,Metabolic,,,,,,Industry,Recruiting,Not Applicable,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Perter K,Beulah N,Lilla Stilson †,Frank T,Lyman W,Jeanene Y,Gertrudis T,Marcelina X,Mee M,Selizabeth F,Corrine U,Patria R,Marcelina X,Marcelina X,Gertrudis T,Doreen T,Mee M,John G,Chetan K,,,"Research Site, Huntsville, Alabama, United States|Research Site, Canoga Park, California, United States|Research Site, Lincoln, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Inverness, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Columbus, Georgia, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Indianapolis, Indiana, United States|Research Site, New Windsor, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Stow, Ohio, United States|Research Site, Medford, Oregon, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Roanoke, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Benesov, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Brno, Czechia|Research Site, Jaromer, Czechia|Research Site, Liberec 2, Czechia|Research Site, Louny, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Pribram, Czechia|Research Site, Teplice, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Aarhus N, Denmark|Research Site, Herlev, Denmark|Research Site, Herning, Denmark|Research Site, Hvidovre, Denmark|Research Site, K√∏benhavn NV, Denmark|Research Site, Roskilde, Denmark|Research Site, Svendborg, Denmark|Research Site, Viborg, Denmark|Research Site, Balatonf√ºred, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, B√©k√©scsaba, Hungary|Research Site, Debrecen, Hungary|Research Site, Orosh√°za, Hungary|Research Site, Szeged, Hungary|Research Site, Amsterdam, Netherlands|Research Site, Doetinchem, Netherlands|Research Site, Ede, Netherlands|Research Site, Gouda, Netherlands|Research Site, Harderwijk, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Bydgoszcz, Poland|Research Site, Chrzan√≥w, Poland|Research Site, Katowice, Poland|Research Site, Krak√≥w, Poland|Research Site, Pu≈Çawy, Poland|Research Site, Ruda ≈ölƒÖska, Poland|Research Site, Tarn√≥w, Poland|Research Site, Tychy, Poland|Research Site, Wierzchos≈Çawice, Poland|Research Site, ≈Å√≥d≈∫, Poland|Research Site, Bratislava, Slovakia|Research Site, Brezno, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Presov, Slovakia|Research Site, Roznava, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trebi≈°ov, Slovakia|Research Site, Ferrol, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, La Coru√±a, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Zaragoza, Spain",18.53976176,16.68578558,All,"18 Years and older ¬† (Adult, Older Adult)",153,148,141,72,60,9,12/29/2018,7/21/2019,5/23/2019,7/4/2019,5/24/2019,6/16/2019,6/24/2019,6/28/2019,7/16/2019,8/25/2021,9/30/2021,3/7/2022,7/8/2022,8/27/2022,10/24/2022,12/15/2022,2/6/2023,3/12/2023,4/24/2023,12/13/2019,6/10/2020,12/7/2020,6/5/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04964557,,,,,,
AstraZeneca,AstraZeneca,ST00245,SP00003,HRR Prevalence in LatAm PROSPECT Study,,PROSPECT,Castration-resistant Prostate Cancer,,Oncology,,,,,,Industry,Recruiting,Phase 2,Observational,,Observational Model: Other|Time Perspective: Retrospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Lyman W,Naren G,Mac L,Hee Y,Patria R,Christian G,Perter K,Lyman W,Suzie K,Gertrudis T,Selizabeth F,Suk T,Dinah R,Frank T,Quentin N,Jaquelyn H,Dalton E,Naren G,Federico L,,,"Research Site, Ciudad Aut√≥noma de Buenos Aires, Argentina|Research Site, Rosario, Argentina|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, S√£o Paulo, Brazil|Research Site, Bogot√°, Colombia|Research Site, San Jos√©, Costa Rica|Research Site, Ciudad de M√©xico, Mexico DF, Mexico|Research Site, Ciudad de M√©xico, Mexico|Research Site, Panam√°, Panama|Research Site, Lima, Peru",5.470699694,4.923629725,Male,18 Years to 40 Years ¬† (Adult),158,151,142,101,22,19,6/22/2019,12/11/2019,10/27/2019,11/10/2019,10/11/2019,11/1/2019,11/6/2019,11/9/2019,11/21/2019,2/27/2021,7/12/2021,11/19/2021,1/31/2022,3/18/2022,5/11/2022,6/17/2022,8/15/2022,9/19/2022,10/25/2022,4/29/2020,10/26/2020,4/24/2021,10/21/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04962880,,,,,,
AstraZeneca,AstraZeneca,ST00251,SP00003,"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin",,VOLGA,Muscle Invasive Bladder Cancer,,Oncology,,,,,,Industry,Recruiting,Not Applicable,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Chetan K,Clarice N,Terrell p,Lilla Stilson †,Suk T,Anthony P,Quentin N,Patria R,Naren G,Beulah N,Naren G,Hee Y,Tiffiny K,Aleta H,Naren G,Selizabeth F,Selizabeth F,Selizabeth F,Naren G,,,"Research Site, Orange, California, United States|Research Site, Santa Monica, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Detroit, Michigan, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Fort Worth, Texas, United States|Research Site, Irving, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Berazategui, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Aut√≥noma Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Pergamino, Argentina|Research Site, Pilar, Argentina|Research Site, Rosario, Argentina|Research Site, Graz, Austria|Research Site, Krems, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wiener Neustadt, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Barretos, Brazil|Research Site, Curitiba, Brazil|Research Site, Fortaleza, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santa Maria, Brazil|Research Site, Santo Andr√©, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, SƒÉo Paulo, Brazil|Research Site, Uberl√¢ndia, Brazil|Research Site, Hamilton, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Barranquilla, Colombia|Research Site, Medellin, Colombia|Research Site, Amiens, France|Research Site, Bordeaux Cedex, France|Research Site, Clermont Ferrand, France|Research Site, Lille, France|Research Site, Lyon, France|Research Site, Marseille CEDEX, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nice, France|Research Site, Quint-Fonsegrives, France|Research Site, Rennes, France|Research Site, Strasbourg, France|Research Site, Suresnes, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Bielefeld, Germany|Research Site, Bochum, Germany|Research Site, D√ºsseldorf, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Giessen, Germany|Research Site, Hannover, Germany|Research Site, Hannover, Germany|Research Site, K√∂ln, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, Mannheim, Germany|Research Site, Muenchen, Germany|Research Site, M√ºnster, Germany|Research Site, Regensburg, Germany|Research Site, Reutlingen, Germany|Research Site, Ulm, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Sheffield, Greece|Research Site, Hadera, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Tel Aviv, Israel|Research Site, Aviano, Italy|Research Site, Bari, Italy|Research Site, Firenze, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Milan, Italy|Research Site, Napoli, Italy|Research Site, Pozzuoli, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Terni, Italy|Research Site, Tricase (Lecce), Italy|Research Site, Verona, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Ichikawa-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kita-gun, Japan|Research Site, Kobe-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Miyazaki-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Toyama-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seodaemun-gu, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Colima, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Tlalpan, Mexico|Research Site, Arnhem, Netherlands|Research Site, Breda, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hilversum, Netherlands|Research Site, Hoofddorp, Netherlands|Research Site, Leiden, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Sk√≥rzewo, Poland|Research Site, Warszawa, Poland|Research Site, Braga, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisbon, Portugal|Research Site, Porto, Portugal|Research Site, Vila Nova de Gaia, Portugal|Research Site, Ekaterinburg, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Belgrad, Serbia|Research Site, Nis, Serbia|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Las Palmas de Gran Canaria, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, Santander, Spain|Research Site, Sevilla, Spain|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Dusit, Thailand|Research Site, Songkhla, Thailand|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Karsiyaka, Turkey|Research Site, Malatya, Turkey|Research Site, Dnipropetrovsk, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kiev, Ukraine|Research Site, Blackburn, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Gillingham, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Wirral, United Kingdom|Research Site, Ha Noi, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Ho Chi Minh city, Vietnam",60.98159523,54.8834357,All,"18 Years and older ¬† (Adult, Older Adult)",152,149,143,47,89,7,12/26/2023,7/17/2024,5/22/2024,6/17/2024,5/5/2024,5/30/2024,6/8/2024,6/11/2024,6/30/2024,11/27/2024,9/26/2024,3/6/2025,7/10/2025,8/24/2025,10/10/2025,12/1/2025,1/26/2026,3/11/2026,4/13/2026,11/26/2024,5/25/2025,11/21/2025,5/20/2026,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04960709,,,,,,
AstraZeneca,AstraZeneca,ST00256,SP00003,A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours,,,Solid Tumour,,,,,,,,Industry,Recruiting,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Chetan K,Naren G,Chetan K,Mee M,Anthony P,Jene M,Suk T,Gertrudis T,Tamesha T,Gertrudis T,Garnet T,Christian G,Garnet T,Lyman W,Livia Pacheo †,Naren G,Beulah N,Xochitl D,Doreen T,,,"Research Site, West Hollywood, California, United States|Research Site, Baltimore, Maryland, United States|Research Site, Jackson, Mississippi, United States|Research Site, Jackson, Mississippi, United States|Research Site, Durham, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dallas, Texas, United States",63.75401832,57.37861649,All,"18 Years to 75 Years ¬† (Adult, Older Adult)",153,151,144,80,55,9,2/25/2019,9/22/2019,8/13/2019,8/28/2019,8/10/2019,8/19/2019,8/31/2019,9/3/2019,9/22/2019,6/7/2022,4/12/2022,8/29/2022,1/19/2023,3/18/2023,5/8/2023,6/27/2023,8/3/2023,10/1/2023,11/2/2023,2/15/2020,8/13/2020,2/9/2021,8/8/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04958226,,,,,,
AstraZeneca,AstraZeneca,ST00285,SP00003,"Patterns of Care in Hormone-receptor Positive, Advanced Breast Cancer",,,,,Oncology,,,,,,Industry,Terminated,,Observational,,Observational Model: Case-Only|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,John G,James y,Livia Pacheo †,Mary H,Anthony P,Frank T,James y,Terisa Sikora †,Chetan K,Remedios Z,Xochitl D,Suzie K,Selizabeth F,Tamesha T,Mara A,Otis Thode †,Selizabeth F,Otis Thode †,Mary H,,,"Research Site, Rio de Janeiro, RJ, Brazil|Research Site, Porto Alegre, RS, Brazil|Research Site, Sao Paulo, SP, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Mogi das Cruzes, Brazil|Research Site, Ribeirao Preto, Brazil",7.665976421,6.899378779,Female,"18 Years and older ¬† (Adult, Older Adult)",152,147,145,98,30,17,2/10/2008,9/18/2008,7/5/2008,8/6/2008,7/9/2008,7/20/2008,7/25/2008,7/27/2008,8/19/2008,3/10/2012,5/5/2012,8/1/2012,12/1/2012,1/11/2013,2/11/2013,4/7/2013,5/7/2013,6/27/2013,8/3/2013,1/16/2009,7/15/2009,1/11/2010,7/10/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01277926,,,,,,
AstraZeneca,AstraZeneca,ST00286,SP00003,"A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer",,,,,Oncology,,,,,,Industry,Terminated,Phase 1,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Mary H,Naren G,Clarice N,Terrell p,Selizabeth F,Stephan T,Christian G,Mara A,Mac L,Selizabeth F,Corrine U,Dalton E,Xochitl D,Selizabeth F,John G,Suzie K,Doreen T,Mara A,Louann C,,,"Research Site, New York, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain",6.097464708,5.487718237,All,"18 Years to 90 Years ¬† (Adult, Older Adult)",154,150,146,77,54,15,1/21/2014,8/19/2014,6/19/2014,7/15/2014,6/29/2014,7/5/2014,7/8/2014,7/12/2014,8/5/2014,8/19/2016,1/6/2016,8/21/2016,9/30/2016,10/30/2016,12/11/2016,1/14/2017,3/8/2017,4/22/2017,6/9/2017,1/1/2015,6/30/2015,12/27/2015,6/24/2016,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02561832,,,,,,
AstraZeneca,AstraZeneca,ST00288,SP00003,Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Suk T,Perter K,Stephan T,Tiffiny K,Mary H,Xochitl D,Mary H,Mee M,Dalton E,Federico L,Dalton E,John G,Tamesha T,Remedios Z,Frank T,Mara A,Anthony P,Kandace p,Dalton E,,,"Research Site, Beijing, China|Research Site, Chongqing, China|Research Site, Dalian, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Jiangsu, China|Research Site, Kunming, China|Research Site, Nanning, China|Research Site, Shandong, China|Research Site, Shanghai, China|Research Site, Shijiazhuang, China|Research Site, Taiyuan, China|Research Site, Tianjin, China",57.22670948,51.50403853,Female,"18 Years to 90 Years ¬† (Adult, Older Adult)",153,150,147,145,20,18,4/13/2012,10/23/2012,8/18/2012,9/15/2012,8/26/2012,9/5/2012,9/13/2012,9/17/2012,10/8/2012,3/2/2013,6/7/2013,10/19/2013,3/1/2014,4/4/2014,6/1/2014,7/1/2014,8/15/2014,10/7/2014,11/26/2014,3/4/2013,8/31/2013,2/27/2014,8/26/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01300351,,,,,,
AstraZeneca,AstraZeneca,ST00290,SP00003,"Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India",,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Cross-Sectional,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Doreen T,Donovan H,Aleta H,Suzie K,Otis Thode †,John G,Lavina S,Lucie P,Terrell p,Terrell p,Garnet T,Quentin N,Tien C,Doreen T,Ngan D,In Bellini †,Kala R,Jerold Goo †,Donovan H,,,"Research Site, Bangalore, Karnataka, India|Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Delhi, New Delhi, India|Research Site, Delhi, New Delhi, India|Research Site, Delhi, New Delhi, India|Research Site, Hyderabad, Telangana, India|Research Site, Kolkata, West Bengal, India",38.64604617,34.78144155,Female,"18 Years and older ¬† (Adult, Older Adult)",157,153,148,71,64,13,11/22/2016,5/11/2017,3/17/2017,4/17/2017,3/27/2017,3/30/2017,4/13/2017,4/17/2017,4/28/2017,4/24/2018,4/9/2018,11/16/2018,12/21/2018,1/31/2019,3/27/2019,5/14/2019,6/29/2019,8/16/2019,9/25/2019,9/26/2017,3/25/2018,9/21/2018,3/20/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03471572,,,,,,
AstraZeneca,AstraZeneca,ST00292,SP00003,Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Recruiting,Phase 4,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Jerold Goo †,James y,Perter K,Lucie P,Perter K,Remedios Z,Jeanene Y,Doreen T,Naren G,Geralyn K,John G,Rima Y ,Clarice N,Jaquelyn H,Geralyn K,Kala R,Suzie K,John G,Beulah N,,,"Research Site, Guwahati, Assam, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Ernamkulam, Kerala, India|Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Bhubaneshwar, Orissa, India|Research Site, Chandigarh, Punjab, India|Research Site, Vellore, Tamil Nadu, India|Research Site, Kolkata, West Bengal, India|Research Site, Kolkata, West Bengal, India",81.79084416,73.61175974,Female,"18 Years and older ¬† (Adult, Older Adult)",158,154,149,119,14,16,8/23/2020,1/24/2021,11/21/2020,12/25/2020,12/11/2020,12/15/2020,12/28/2020,12/30/2020,1/23/2021,11/13/2021,11/10/2021,3/3/2022,7/31/2022,9/27/2022,11/13/2022,12/24/2022,2/2/2023,3/29/2023,5/19/2023,6/13/2021,12/10/2021,6/8/2022,12/5/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04330040,,,,,,
AstraZeneca,AstraZeneca,ST00293,SP00003,Reasons for Changing HOrmonal Therapy of Advanced Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Only|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Tien C,Mee M,Jeanene Y,Lilla Stilson †,Selizabeth F,Patria R,Donovan H,Suzie K,Garnet T,Mary H,Hee Y,In Bellini †,Naren G,Clarice N,Ngan D,Patria R,Gertrudis T,Tiffiny K,John G,,,"Research Site, Benesov u Prahy, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Ceske Budejovice, Czech Republic|Research Site, Cesky Krumlov, Czech Republic|Research Site, Cheb, Czech Republic|Research Site, Chomutov, Czech Republic|Research Site, Havlickuv Brod, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Jablonec nad Nisou, Czech Republic|Research Site, Jicin, Czech Republic|Research Site, Jihlava, Czech Republic|Research Site, Karvina, Czech Republic|Research Site, Kladno, Czech Republic|Research Site, Kolin, Czech Republic|Research Site, Liberec, Czech Republic|Research Site, Most, Czech Republic|Research Site, Nachod, Czech Republic|Research Site, Novy Jicin, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Opava, Czech Republic|Research Site, Ostrava - Fifejdy, Czech Republic|Research Site, Ostrava - Vitkovice, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Pisek, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Prerov, Czech Republic|Research Site, Prostejov, Czech Republic|Research Site, Rakovnik, Czech Republic|Research Site, Sokolov, Czech Republic|Research Site, Strakonice, Czech Republic|Research Site, Sumperk, Czech Republic|Research Site, Tabor, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Zlin, Czech Republic|Research Site, Znojmo, Czech Republic",84.11235244,75.70111719,Female,"18 Years and older ¬† (Adult, Older Adult)",169,161,150,68,73,9,12/31/2007,5/23/2008,3/24/2008,4/16/2008,3/24/2008,4/9/2008,4/21/2008,4/26/2008,5/26/2008,2/9/2011,4/7/2011,6/21/2011,11/1/2011,12/6/2011,1/21/2012,3/17/2012,5/2/2012,6/3/2012,7/13/2012,10/6/2008,4/4/2009,10/1/2009,3/30/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01265654,,,,,,
AstraZeneca,AstraZeneca,ST00295,SP00003,Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Dalton E,In Bellini †,Perter K,Suk T,James y,Lucie P,Naren G,John G,Selizabeth F,Terrell p,Perter K,Livia Pacheo †,Perter K,Jerold Goo †,Perter K,Louann C,Aleta H,Hee Y,Jaquelyn H,,,"Research Site, Coru√±a, Spain|Research Site, Granada, Spain|Research Site, Huelva, Spain|Research Site, Ibiza, Spain|Research Site, Jerez, Spain|Research Site, La Rioja, Spain|Research Site, Lugo, Spain|Research Site, Malaga, Spain|Research Site, Mallorca, Spain|Research Site, Pontevedra, Spain|Research Site, Santander, Spain|Research Site, Sevilla, Spain",58.01259771,52.21133794,Female,"18 Years to 75 Years ¬† (Adult, Older Adult)",162,160,151,47,95,9,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/9/1900,3/19/1900,4/26/1900,6/14/1900,7/28/1900,9/25/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00623519,,,,,,
AstraZeneca,AstraZeneca,ST00297,SP00003,National Survey on Infiltrative Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Chetan K,Aleta H,Chetan K,Stephan T,Xochitl D,Corrine U,Mara A,Suk T,Livia Pacheo †,Lucie P,Tien C,Rima Y ,Marcelina X,Stephan T,Tiffiny K,Selizabeth F,Perter K,Jene M,Rima Y ,,,"Research Site, Aix En Provence Cedex 1, France|Research Site, Aix En Provence, France|Research Site, Ales Cedex, France|Research Site, Amilly, France|Research Site, Angers Cedex 01, France|Research Site, Annecy Cedex, France|Research Site, Annecy, France|Research Site, Arpajon Cedex, France|Research Site, Arras, France|Research Site, Aubervilliers Cedex, France|Research Site, Aulnay Sous Bois Cedex, France|Research Site, Auxerre Cedex, France|Research Site, Avignon Cedex 2, France|Research Site, Avignon, France|Research Site, Beaune Cedex, France|Research Site, Besancon, France|Research Site, Beziers, France|Research Site, Bleriot, France|Research Site, Bordeaux Cedex, France|Research Site, Bordeaux, France|Research Site, Bourg En Bresse Cedex, France|Research Site, Brest Cedex 2, France|Research Site, Bruay La Buissiere Cedex, France|Research Site, Bruges Cedex, France|Research Site, Caen Cedex 4, France|Research Site, Caen Cedex 5, France|Research Site, Carcassonne, France|Research Site, Castelnau Le Lez Cedex, France|Research Site, Chalon Sur Saone, France|Research Site, Chambery Cedex, France|Research Site, Chambery, France|Research Site, Chartre, France|Research Site, Cherbourg Octeville Cedex, France|Research Site, Clermont Ferrand Cedex 1, France|Research Site, Colmar Cedex, France|Research Site, Colmar, France|Research Site, Colombes Cedex, France|Research Site, Coudekerque Branche Cedex, France|Research Site, Creteil Cedex, France|Research Site, Croix, France|Research Site, Cucq, France|Research Site, Dax Cedex, France|Research Site, Dijon Cedex, France|Research Site, Evreux, France|Research Site, Grasse Cedex, France|Research Site, Grenoble Cedex 2, France|Research Site, Guilherand Granges, France|Research Site, Hyeres, France|Research Site, La Chaussee St Victor, France|Research Site, La Garenne Colombes, France|Research Site, La Seyne Sur Mer, France|Research Site, La Tronche, France|Research Site, Lagny Sur Marne Cedex, France|Research Site, Le Chesnay Cedex, France|Research Site, Le Mans Cedex 2, France|Research Site, Lens Cedex, France|Research Site, Levallois Perret Cedex, France|Research Site, Libourne Cedex, France|Research Site, Lille Cedex, France|Research Site, Lille, France|Research Site, Limoges Cedex 1, France|Research Site, Limoges, France|Research Site, Loos, France|Research Site, Lorient Cedex, France|Research Site, Lormont, France|Research Site, Lyon Cedex 03, France|Research Site, Lyon Cedex 04, France|Research Site, Lyon Cedex 08, France|Research Site, Lyon Cedex 09, France|Research Site, Lyon, France|Research Site, Mantes La Jolie Cedex, France|Research Site, Mareuil Les Meaux, France|Research Site, Marseille Cedex 06, France|Research Site, Marseille Cedex 09, France|Research Site, Marseille Cedex 12, France|Research Site, Marseille, France|Research Site, Meudon La Foret, France|Research Site, Mont de Marsan Cedex, France|Research Site, Montmorency, France|Research Site, Montpellier Cedex 5, France|Research Site, Montpellier, France|Research Site, Mulhouse Cedex 1, France|Research Site, Nancy, France|Research Site, Nantes, France|Research Site, Neuilly Sur Seine, France|Research Site, Nice Cedex 2, France|Research Site, Nice, France|Research Site, Nimes, France|Research Site, Orleans Cedex 1, France|Research Site, Paris Cedex 04, France|Research Site, Paris Cedex 05, France|Research Site, Paris Cedex 10, France|Research Site, Paris Cedex 15, France|Research Site, Paris Cedex 20, France|Research Site, Paris, France|Research Site, Pessac, France|Research Site, Pierre Benite Cedex, France|Research Site, Ploemeur, France|Research Site, Poissy Cedex, France|Research Site, Quimper Cedex, France|Research Site, Reims Cedex, France|Research Site, Reims, France|Research Site, Rennes Cedex, France|Research Site, Roanne Cedex, France|Research Site, Rodez Cedex 9, France|Research Site, Rouen Cedex, France|Research Site, Rouen, France|Research Site, Saint Mandee, France|Research Site, Saintes Cedex, France|Research Site, Sarcelles, France|Research Site, Sarcelle, France|Research Site, St Benoit La Foret, France|Research Site, St Brieuc Cedex 1, France|Research Site, St Cloud, France|Research Site, St Herblain Cedex, France|Research Site, St Herblain, France|Research Site, St Jean, France|Research Site, St Martin Des Champs, France|Research Site, St Maur Des Fosses, France|Research Site, St Michel, France|Research Site, St Nazaire, France|Research Site, St Priest En Jarez Cedex, France|Research Site, Strasbourg, France|Research Site, Thionville Cedex, France|Research Site, Toulon Cedex, France|Research Site, Toulon, France|Research Site, Toulouse Cedex 3, France|Research Site, Toulouse, France|Research Site, TOURS cedex 2, France|Research Site, Tours Cedex 9, France|Research Site, Troyes Cedex, France|Research Site, Valence, France|Research Site, Valenciennes Cedex, France|Research Site, Vandoeuvre Les Nancy Cedex, France|Research Site, Vichy Cedex, France|Research Site, Villejuif Cedex, France",23.15977765,20.84379988,Female,"18 Years to 75 Years ¬† (Adult, Older Adult)",170,167,152,62,82,8,7/24/2006,1/9/2007,10/29/2006,12/4/2006,11/5/2006,11/17/2006,11/21/2006,11/25/2006,12/24/2006,5/11/2008,10/3/2007,3/17/2008,7/1/2008,8/8/2008,9/14/2008,10/27/2008,12/19/2008,2/16/2009,3/24/2009,5/16/2007,11/12/2007,5/10/2008,11/6/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00696527,,,,,,
AstraZeneca,AstraZeneca,ST00307,SP00003,ZD1839 (Iressa‚Ñ¢) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Stephan T,Suzie K,Jerold Goo †,Suk T,Doreen T,Dinah R,Selizabeth F,Federico L,Perter K,Mac L,Chetan K,Mary H,Lavina S,Doreen T,Marceline R,Terisa Sikora †,Tiffiny K,Remedios Z,James y,,,"Research Site, Dijon, France|Research Site, Paris, France|Research Site, Saint Cloud, France|Research Site, Saint Germain en Laye, France|Research Site, Villejuif Cedex, France",13.26007373,11.93406636,Female,"18 Years to 75 Years ¬† (Adult, Older Adult)",171,165,153,123,11,19,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/8/1900,3/9/1900,4/22/1900,6/20/1900,8/18/1900,10/7/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00247481,,,,,,
AstraZeneca,AstraZeneca,ST00308,SP00003,Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Cross-Sectional,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Anthony P,Frank T,Jaquelyn H,Xochitl D,Mary H,Suzie K,Jerold Goo †,Anthony P,Tamesha T,Remedios Z,Suzie K,Terrell p,Kala R,John G,Suzie K,Quentin N,Selizabeth F,Lilla Stilson †,Louann C,,,"Research Site, Aichi, Japan|Research Site, Akita, Japan|Research Site, Aomori, Japan|Research Site, Chiba, Japan|Research Site, Fukuoka, Japan|Research Site, Fukushima, Japan|Research Site, Gifu, Japan|Research Site, Hyogo, Japan|Research Site, Ibaraki, Japan|Research Site, Izumo, Japan|Research Site, Kanagawa, Japan|Research Site, Kumamoto, Japan|Research Site, Kyoto, Japan|Research Site, Maebashi, Japan|Research Site, Matsuyama, Japan|Research Site, Mie, Japan|Research Site, Miyagi, Japan|Research Site, Morioka, Japan|Research Site, Nagano, Japan|Research Site, Nagasaki, Japan|Research Site, Nara, Japan|Research Site, Niigata, Japan|Research Site, Okayama, Japan|Research Site, Okinawa, Japan|Research Site, Osaka, Japan|Research Site, Saga, Japan|Research Site, Saitama, Japan|Research Site, Sapporo, Japan|Research Site, Sendai, Japan|Research Site, Tochigi, Japan|Research Site, Tokushima, Japan|Research Site, Tokyo, Japan|Research Site, Toon, Japan|Research Site, Tottori, Japan|Research Site, Yamagata, Japan",74.68158928,67.21343036,Female,"18 Years and older ¬† (Adult, Older Adult)",166,159,154,106,32,16,6/12/2014,11/1/2014,9/13/2014,10/3/2014,9/13/2014,9/26/2014,10/8/2014,10/10/2014,10/30/2014,11/24/2017,9/16/2017,5/12/2018,7/6/2018,8/25/2018,10/21/2018,12/10/2018,1/14/2019,3/2/2019,4/5/2019,3/25/2015,9/21/2015,3/19/2016,9/15/2016,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03229122,,,,,,
AstraZeneca,AstraZeneca,ST00312,SP00003,Second Line Breast Cancer Trial,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Dinah R,Mary H,Kala R,Marceline R,Christian G,Federico L,Frank T,Tamesha T,Quentin N,Mary H,Garnet T,Kala R,Chetan K,Tammara F,Garnet T,Mara A,In Bellini †,Naren G,Donovan H,,,,3.674552671,3.307097404,Female,"18 Years to 75 Years ¬† (Adult, Older Adult)",165,163,155,107,35,13,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/4/1900,3/10/1900,4/23/1900,6/15/1900,7/25/1900,8/25/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00635713,,,,,,
AstraZeneca,AstraZeneca,ST00313,SP00003,"Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer",,,,,Oncology,,,,,,Industry,Recruiting,,Observational,,Observational Model: Other|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Kala R,Tiffiny K,Naren G,Anthony P,Kala R,Aleta H,Remedios Z,Mary H,Mara A,Dalton E,Suzie K,Lilla Stilson †,Louann C,Xochitl D,Frank T,Ngan D,Donovan H,Rima Y ,Aleta H,,,"Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, Chelyabinsk, Russian Federation|Oncological Dispensary of Rostov-on-Don Region, Rostov-on-Don, Russian Federation|Multidisciplinary clinical medical center ""Medical City"", Tyumen, Russian Federation|Bashkortostan Republican Clinical Oncological Dispensary, Ufa, Russian Federation",54.36259655,48.92633689,Female,"18 Years to 85 Years ¬† (Adult, Older Adult)",172,168,156,67,80,9,6/4/2019,11/18/2019,9/19/2019,10/16/2019,9/18/2019,10/2/2019,10/6/2019,10/10/2019,10/27/2019,7/15/2021,8/11/2021,12/4/2021,3/31/2022,5/27/2022,7/15/2022,9/11/2022,10/22/2022,11/26/2022,12/31/2022,3/30/2020,9/26/2020,3/25/2021,9/21/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04991051,,,,,,
AstraZeneca,AstraZeneca,ST00314,SP00003,Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Patria R,Lucie P,Quentin N,Kandace p,Ross S,Marceline R,Kandace p,Frank T,Kandace p,Terrell p,Naren G,Patria R,Clarice N,Xochitl D,James y,Perter K,Kandace p,Mary H,Naren G,,,,75.67596034,68.1083643,Female,"18 Years and older ¬† (Adult, Older Adult)",171,168,157,50,98,9,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/21/1900,4/9/1900,5/10/1900,6/20/1900,8/10/1900,10/3/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00562458,,,,,,
AstraZeneca,AstraZeneca,ST00315,SP00003,Comparison of Fulvestrant (FASLODEX‚Ñ¢) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.,,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Tien C,Quentin N,Mary H,Tamesha T,Frank T,Kala R,John G,Anthony P,Terisa Sikora †,Anthony P,Suk T,Ross S,Kala R,In Bellini †,Xochitl D,Clarice N,Doreen T,Tamesha T,Anthony P,,,"Research Site, Casa Grande, Arizona, United States|Research Site, Fountain Valley, California, United States|Research Site, New Britain, Connecticut, United States|Research Site, Crystal River, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Urbana, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Greenville, North Carolina, United States|Research Site, Pasadena, Texas, United States|Research Site, West Bend, Wisconsin, United States|Research Site, Brasschaat, Belgium|Research Site, Brussels, Belgium|Research Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Li√®ge, Belgium|Research Site, Turnhout, Belgium|Research Site, Barretos, Brazil|Research Site, Londrina, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Recife, Brazil|Research Site, Salvador, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Antofagasta, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Bogota, Colombia|Research Site, Cali, Colombia|Research Site, Brno, Czechia|Research Site, Ceske Budejovice, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 8, Czechia|Research Site, Tabor, Czechia|Research Site, V Uvalu 84, Czechia|Research Site, Ny√≠regyh√°za, Hungary|Research Site, Szombathely, Hungary|Research Site, Sz√©kesfeh√©rv√°r, Hungary|Research Site, Ansari Nagar, India|Research Site, Bhopal, India|Research Site, Hyderabad, India|Research Site, Jaipur, India|Research Site, Kolkata, India|Research Site, Manipal, India|Research Site, Marg Jaipur, India|Research Site, Mumbai, India|Research Site, Pune, India|Research Site, Trivandrum, India|Research Site, Vellore, India|Research Site, Aviano, Italy|Research Site, Bergamo, Italy|Research Site, Carpi, Italy|Research Site, Genova, Italy|Research Site, Prato, Italy|Research Site, Reggio Emilia, Italy|Research Site, Varese, Italy|Research Site, Floriana, Malta|Research Site, Mexico Distrito Federal, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Bia≈Çystok, Poland|Research Site, Pozna≈Ñ, Poland|Research Site, ≈Å√≥d≈∫, Poland|Research Site, Ivanovo, Russian Federation|Research Site, Kazan, Tatarstan, Russian Federation|Research Site, Kazan, Tatarstan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Lipetsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, St-Petersburg, Russian Federation|Research Site, St.-Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Nitra, Slovakia|Research Site, Trnava, Slovakia|Research Site, A Coru√±a, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Oviedo, Spain|Research Site, Salamanca, Spain|Research Site, Sevilla, Spain|Research Site, Cherkasy, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Sumy, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Caracas, Venezuela",41.53642486,37.38278237,Female,"18 Years and older ¬† (Adult, Older Adult)",177,173,158,93,51,14,6/3/2005,12/8/2005,9/30/2005,10/27/2005,9/29/2005,10/17/2005,11/1/2005,11/3/2005,11/18/2005,11/17/2008,6/1/2008,10/13/2008,2/27/2009,4/4/2009,5/11/2009,6/25/2009,8/16/2009,10/12/2009,12/9/2009,4/15/2006,10/12/2006,4/10/2007,10/7/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00099437,,,,,,
AstraZeneca,AstraZeneca,ST00316,SP00003,National Lung Cancer Registry in Men and Women Based on Diagnosis in Algeria,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Mary H,Mee M,Aleta H,Dalton E,Marcelina X,Anthony P,Chetan K,Jerold Goo †,Clarice N,Liberty A,Dalton E,John G,Selizabeth F,Jeanene Y,Jaquelyn H,Terisa Sikora †,Federico L,Mac L,Remedios Z,,,"Research Site, Algiers, Algeria|Research Site, Constantine, Algeria|Research Site, Oran, Algeria",96.7525923,87.07733307,All,"18 Years to 120 Years ¬† (Adult, Older Adult)",168,162,159,90,54,15,12/15/2018,5/21/2019,3/27/2019,4/13/2019,3/8/2019,4/1/2019,4/15/2019,4/19/2019,5/5/2019,7/9/2020,7/14/2020,11/10/2020,2/28/2021,4/24/2021,5/29/2021,7/14/2021,9/5/2021,10/11/2021,11/27/2021,9/28/2019,3/26/2020,9/22/2020,3/21/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02725892,,,,,,
AstraZeneca,AstraZeneca,ST00317,SP00003,Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292).,,,,,Oncology,,,,,,Industry,Recruiting,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug F,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Hee Y,Hee Y,Tien C,Aleta H,Perter K,Clarice N,Dalton E,Liberty A,Patria R,Suzie K,Chetan K,Naren G,In Bellini †,Federico L,James y,Louann C,Xochitl D,John G,,,"Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Nashville, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Darlinghurst, Australia|Research Site, Nedlands, Australia|Research Site, Leuven, Belgium|Research Site, Chicoutimi, Canada|Research Site, Montreal, Canada|Research Site, Odense C, Denmark|Research Site, St Herblain, France|Research Site, Villejuif, France|Research Site, Bydgoszcz, Poland|Research Site, Gda≈Ñsk, Poland|Research Site, Krak√≥w, Poland|Research Site, Warszawa, Poland|Research Site, Solna, Sweden",28.7573062,25.88157558,All,"18 Years to 75 Years ¬† (Adult, Older Adult)",175,167,160,152,8,0,11/23/2020,7/12/2021,5/12/2021,5/29/2021,5/3/2021,5/20/2021,5/25/2021,5/27/2021,6/8/2021,7/27/2024,1/8/2024,5/30/2024,10/21/2024,11/23/2024,1/11/2025,2/11/2025,4/8/2025,5/9/2025,6/12/2025,11/16/2021,5/15/2022,11/11/2022,5/10/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04862663,,,,,,
AstraZeneca,AstraZeneca,ST00319,SP00003,Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Kandace p,Doreen T,Corrine U,Jerold Goo †,Mary H,Jaquelyn H,Suzie K,Garnet T,John G,Xochitl D,In Bellini †,Chetan K,Chetan K,Mac L,Suzie K,John G,Garnet T,John G,Lucie P,,,"Research Site, Helsinki, Finland",14.34032119,12.90628907,Male,"35 Years to 120 Years ¬† (Adult, Older Adult)",172,167,161,135,7,19,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/26/1900,4/23/1900,6/22/1900,8/7/1900,9/14/1900,11/5/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00241475,,,,,,
AstraZeneca,AstraZeneca,ST00320,SP00003,AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug I,,,,,,,,,,,,,,,,,,,Mac L,Clarice N,Lavina S,Mary H,Marcelina X,Marcelina X,Terrell p,Clarice N,Stephan T,Chetan K,Selizabeth F,Lavina S,Harry A,Terrell p,Aleta H,In Bellini †,In Bellini †,Tien C,Terrell p,,,"Research Site, Burbank, California, United States|Research Site, Los Angeles, California, United States|Research Site, Palm Springs, California, United States|Research Site, Boca Raton, Florida, United States|Research Site, Honolulu, Hawaii, United States|Research Site, New York, New York, United States|Research Site, Fitzroy, Australia|Research Site, Parkville, Australia|Research Site, Perth, Australia|Research Site, Waratah, Australia|Research Site, Belo Horizonte, Brazil|Research Site, Curitiba, Brazil|Research Site, Fortaleza, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Santro Andre, Brazil|Research Site, S√£o Paulo, Brazil",57.02043861,51.31839475,Female,"18 Years and older ¬† (Adult, Older Adult)",178,173,162,49,105,8,1/10/2006,6/20/2006,4/16/2006,5/22/2006,4/16/2006,5/9/2006,5/18/2006,5/23/2006,6/13/2006,10/31/2008,2/19/2008,7/28/2008,12/1/2008,1/15/2009,3/15/2009,5/10/2009,6/15/2009,7/26/2009,9/18/2009,11/5/2006,5/4/2007,10/31/2007,4/28/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00454805,,,,,,
AstraZeneca,AstraZeneca,ST00328,SP00003,Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Mary H,Perter K,Geralyn K,Remedios Z,Ngan D,Lilla Stilson †,Terisa Sikora †,Stephan T,Lavina S,Lavina S,Ross S,Patria R,Suk T,Mary H,Otis Thode †,Beulah N,Anthony P,Frank T,Jerold Goo †,,,"Research Site, La Jolla, California, United States|Research Site, San Diego, California, United States|Research Site, Orlando, Florida, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Rockville, Maryland, United States|Research Site, Columbia, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Lake Success, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Houston, Texas, United States|Research Site, Temple, Texas, United States|Research Site, Cali, Colombia|Research Site, Aguascalientes, Mexico|Research Site, Guadalajara, Mexico|Research Site, Morelia, Mexico|Research Site, Barcelona, Venezuela|Research Site, Barquisimeto, Venezuela|Research Site, Caracas, Venezuela|Research Site, Maracaibo, Venezuela|Research Site, Puerto Ordaz, Venezuela|Research Site, San Cristobal, Venezuela|Research Site, Valencia, Venezuela",22.69816372,20.42834735,Female,"18 Years and older ¬† (Adult, Older Adult)",177,170,163,106,44,13,4/28/2008,9/11/2008,7/3/2008,8/6/2008,7/8/2008,7/31/2008,8/9/2008,8/11/2008,9/3/2008,2/7/2013,8/17/2012,1/15/2013,5/1/2013,6/24/2013,8/6/2013,9/16/2013,10/16/2013,12/8/2013,1/31/2014,1/27/2009,7/26/2009,1/22/2010,7/21/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00077025,,,,,,
AstraZeneca,AstraZeneca,ST00332,SP00003,Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer,,,,,Oncology,,,,,,Industry,Recruiting,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug H,,,,,,,,,,,,,,,,,,,Lilla Stilson †,Dalton E,Naren G,Beulah N,Mary H,Lyman W,Xochitl D,Suzie K,Ngan D,Christian G,Suk T,Jaquelyn H,Tien C,Mara A,Marcelina X,Gertrudis T,Gertrudis T,Chetan K,Chetan K,,,"Research Site, Gilbert, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Orange, California, United States|Research Site, Redlands, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Maria, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Whittier, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Marietta, Georgia, United States|Research Site, Westwood, Kansas, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, Paramus, New Jersey, United States|Research Site, Farmington, New Mexico, United States|Research Site, Lake Success, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Midlothian, Virginia, United States|Research Site, Puyallup, Washington, United States|Research Site, Berazategui, Argentina|Research Site, Ciudad Autonoma De Buenos Aire, Argentina|Research Site, La Rioja, Argentina|Research Site, Rosario, Argentina|Research Site, Viedma, Argentina|Research Site, Adelaide, Australia|Research Site, Ballarat, Australia|Research Site, Birtinya, Australia|Research Site, Box Hill, Australia|Research Site, Concord, Australia|Research Site, East Albury, Australia|Research Site, Kurralta Park, Australia|Research Site, North Sydney, Australia|Research Site, Orange, Australia|Research Site, Ringwood East, Australia|Research Site, South Brisbane, Australia|Research Site, Waratah, Australia|Research Site, Wendouree, Australia|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Namur, Belgium|Research Site, Wilrijk, Belgium|Research Site, Winnipeg, Manitoba, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Baoding, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Foshan, China|Research Site, Gongshu District, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Linyi, China|Research Site, Nanchang, China|Research Site, Neijiang, China|Research Site, Shanghai, China|Research Site, Shantou, China|Research Site, Shenyang, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Xuzhou, China|Research Site, Zhengzhou City, China|Research Site, Zhengzhou, China|Research Site, Besancon, France|Research Site, Brest, France|Research Site, Metz Cedex 03, France|Research Site, Montpellier, France|Research Site, Pierre Benite CEDEX, France|Research Site, Plerin SUR MER, France|Research Site, Pringy, France|Research Site, Rouen, France|Research Site, STRASBOURG Cedex, France|Research Site, Toulouse cedex 9, France|Research Site, Berlin, Germany|Research Site, Cottbus, Germany|Research Site, Dresden, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt, Germany|Research Site, Gelsenkirchen, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Jena, Germany|Research Site, Kiel, Germany|Research Site, Mannheim, Germany|Research Site, Minden, Germany|Research Site, Muenchen, Germany|Research Site, M√ºnchen, Germany|Research Site, M√ºnchen, Germany|Research Site, M√ºnster, Germany|Research Site, Paderborn, Germany|Research Site, Potsdam, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Kecskem√©t, Hungary|Research Site, P√©cs, Hungary|Research Site, Szeksz√°rd, Hungary|Research Site, Szolnok, Hungary|Research Site, Afula, Israel|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar-Saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Bergamo, Italy|Research Site, Candiolo, Italy|Research Site, Catanzaro, Italy|Research Site, Genova, Italy|Research Site, Livorno, Italy|Research Site, Macerata, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Napoli, Italy|Research Site, Prato, Italy|Research Site, Reggio Nell'emilia, Italy|Research Site, Roma, Italy|Research Site, Chiba-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukushima-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Koto-ku, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Ota-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Tsu-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seo-Gu, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Arequipa, Peru|Research Site, Lima, Peru|Research Site, Bydgoszcz, Poland|Research Site, Krakow, Poland|Research Site, Olsztyn, Poland|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, A Coru√±a, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, C√≥rdoba, Spain|Research Site, Hosp de Llobregat(Barcelona), Spain|Research Site, Ja√©n, Spain|Research Site, La Laguna (Tenerife), Spain|Research Site, L√©rida, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Malaga, Spain|Research Site, Pamplona, Spain|Research Site, Reus,Tarragona, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Kaohsiung City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Aberdeen, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Cheltenham, United Kingdom|Research Site, Derby, United Kingdom|Research Site, Huddersfield, United Kingdom|Research Site, Lancaster, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, York, United Kingdom",7.826447377,7.043802639,All,"18 Years and older ¬† (Adult, Older Adult)",177,170,164,158,11,5,10/2/2020,2/26/2021,12/21/2020,2/3/2021,1/4/2021,1/20/2021,1/25/2021,1/29/2021,2/10/2021,7/31/2022,3/18/2022,8/9/2022,12/19/2022,2/2/2023,4/3/2023,5/11/2023,7/4/2023,8/6/2023,9/14/2023,7/19/2021,1/15/2022,7/14/2022,1/10/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04305496,,,,,,
AstraZeneca,AstraZeneca,ST00337,SP00003,"A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer",,,,,Oncology,,,,,,Industry,Recruiting,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Tamesha T,Ross S,Selizabeth F,Liberty A,Christian G,Lucie P,Jerold Goo †,Terrell p,Tammara F,James y,Mara A,Anthony P,Jaquelyn H,Corrine U,In Bellini †,Lavina S,Perter K,Tammara F,Clarice N,,,"Research Site, Batumi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Aguascalientes, Mexico|Research Site, D.F, Mexico|Research Site, Mexico City, Mexico|Research Site, M√©xico, Mexico|Research Site, Tlalpan, Mexico|Research Site, Bournemouth, United Kingdom|Research Site, Derby, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Sutton In Ashfield, United Kingdom",85.23795182,76.71415664,Female,"18 Years and older ¬† (Adult, Older Adult)",173,171,165,90,61,14,12/9/2020,7/9/2021,5/17/2021,6/9/2021,5/9/2021,5/22/2021,5/26/2021,5/28/2021,6/6/2021,2/17/2022,3/31/2022,12/24/2022,1/23/2023,3/20/2023,5/19/2023,7/8/2023,8/20/2023,9/25/2023,10/27/2023,11/18/2021,5/17/2022,11/13/2022,5/12/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04588298,,,,,,
AstraZeneca,AstraZeneca,ST00342,SP00003,Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Stephan T,Quentin N,Geralyn K,Lavina S,Mary H,Suzie K,Dalton E,Beulah N,Beulah N,Mac L,Jerold Goo †,Suk T,Xochitl D,Tien C,Rima Y ,Mara A,John G,Beulah N,Mara A,,,"Research Site, Praha 8, Czech Republic|Research Site, Arkhangelsk, Russian Federation|Research Site, Belgorod, Russian Federation|Research Site, Kaliningarad, Russian Federation|Research Site, Kazan, Tatarstan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, St-petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Odessa, Ukraine|Research Site, Uzhgorod, Ukraine",81.87450581,73.68705523,Female,"18 Years and older ¬† (Adult, Older Adult)",174,170,166,152,2,12,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/25/1900,4/2/1900,5/11/1900,7/1/1900,8/16/1900,10/5/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00322348,,,,,,
AstraZeneca,AstraZeneca,ST00343,SP00003,Arthralgia During Anastrozole Therapy for Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug F,,,,,,,,,,,,,,,,,,,James y,Geralyn K,Lilla Stilson †,Selizabeth F,Anthony P,Perter K,Tien C,Suzie K,Frank T,Tamesha T,Ngan D,Terrell p,Selizabeth F,Louann C,John G,Jeanene Y,Lucie P,Rima Y ,Federico L,,,"Research Site, Bordeaux, France|Research Site, Caen, France|Research Site, Lyon, France|Research Site, Paris, France|Research Site, Poitiers, France",7.874100181,7.086690163,Female,"18 Years and older ¬† (Adult, Older Adult)",185,179,167,142,3,22,3/22/2007,8/21/2007,5/30/2007,7/1/2007,6/6/2007,6/23/2007,7/5/2007,7/10/2007,7/30/2007,9/26/2008,5/11/2008,9/7/2008,1/1/2009,2/12/2009,3/27/2009,5/14/2009,7/11/2009,8/30/2009,10/20/2009,12/20/2007,6/17/2008,12/14/2008,6/12/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00323479,,,,,,
AstraZeneca,AstraZeneca,ST00348,SP00003,A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Kandace p,Lyman W,Hee Y,John G,Liberty A,Anthony P,John G,Aleta H,Tien C,Jerold Goo †,Jaquelyn H,Naren G,Beulah N,Terrell p,Dalton E,Suzie K,Mary H,Garnet T,Naren G,,,"Research Site, Frederick, Maryland, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Teaneck, New Jersey, United States|Research Site, Austin, Texas, United States|Research Site, Duncanville, Texas, United States|Research Site, Barretos, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Goi√¢nia, Brazil|Research Site, Ja√∫, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Shumen, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Jicin, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 4, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Nice, France|Research Site, Poitiers, France|Research Site, Saint-cloud, France|Research Site, Napoli, Italy|Research Site, Sassari, Italy|Research Site, Krak√≥w, Poland|Research Site, Olsztyn, Poland|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, C√≥rdoba, Spain|Research Site, L√©rida, Spain|Research Site, Pontevedra, Spain|Research Site, Derby, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom",13.87489171,12.48740254,Female,"20 Years to 80 Years ¬† (Adult, Older Adult)",180,178,168,114,39,15,8/6/2004,2/13/2005,12/28/2004,1/28/2005,12/19/2004,1/10/2005,1/17/2005,1/22/2005,2/15/2005,8/27/2007,5/16/2007,10/24/2007,1/10/2008,3/7/2008,4/21/2008,6/1/2008,7/31/2008,9/22/2008,11/21/2008,7/9/2005,1/5/2006,7/4/2006,12/31/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00274469,,,,,,
AstraZeneca,AstraZeneca,ST00349,SP00003,Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,,,,Drug I,,,,,,,,,,,,,,,,,,,Tien C,Clarice N,Jerold Goo †,Mary H,Geralyn K,Mac L,Doreen T,Selizabeth F,Anthony P,Marcelina X,John G,Christian G,Tien C,Selizabeth F,Mara A,Dinah R,Suzie K,Jaquelyn H,Louann C,,,"Research Site, Hakata, Fukuoka, Japan|Research Site, Kumamoto, Japan|Research Site, Nagoya, Japan|Research Site, Osaka, Japan",13.62897883,12.26608095,Female,"18 Years and older ¬† (Adult, Older Adult)",187,185,169,135,16,18,11/22/2005,5/20/2006,3/19/2006,4/14/2006,4/6/2006,4/9/2006,4/20/2006,4/21/2006,5/1/2006,1/3/2009,1/8/2009,6/26/2009,11/1/2009,12/6/2009,1/9/2010,2/23/2010,3/30/2010,5/18/2010,7/5/2010,10/6/2006,4/4/2007,10/1/2007,3/29/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00605267,,,,,,
AstraZeneca,AstraZeneca,ST00352,SP00003,To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.,,,,,Oncology,,,,,,Industry,Withdrawn,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Kandace p,Xochitl D,Lilla Stilson †,Lyman W,John G,Lucie P,Lilla Stilson †,Jerold Goo †,Clarice N,Suzie K,Mac L,Mary H,Dalton E,In Bellini †,Ross S,Suk T,Selizabeth F,Federico L,Federico L,,,"Research Site, Beijing, China|Research Site, Chengdu, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shijiazhuang, China|Research Site, Tianjin, China",5.787051796,5.208346617,Female,"18 Years and older ¬† (Adult, Older Adult)",185,180,170,158,16,4,3/3/2017,9/26/2017,7/25/2017,9/4/2017,8/5/2017,8/23/2017,9/4/2017,9/9/2017,9/27/2017,2/19/2021,4/14/2021,8/1/2021,11/4/2021,12/30/2021,2/19/2022,4/10/2022,5/27/2022,6/30/2022,8/1/2022,2/19/2018,8/18/2018,2/14/2019,8/13/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03658213,,,,,,
AstraZeneca,AstraZeneca,ST00353,SP00003,10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI),,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Only|Time Perspective: Cross-Sectional,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Terrell p,Frank T,Stephan T,Mary H,Liberty A,Kandace p,Anthony P,Lilla Stilson †,John G,Garnet T,Tamesha T,Louann C,Tammara F,Kala R,Patria R,Geralyn K,Livia Pacheo †,Mary H,Liberty A,,,"Research Site, Cheonan, Chungcheongnam-do, Korea, Republic of|Research Site, Chuncheon, Gangwon-do, Korea, Republic of|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Pohang, Gyeongsangbuk-do, Korea, Republic of|Research Site, Masan-si, Gyeongsangnam-do, Korea, Republic of|Research Site, Anyang, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Chunan, Korea, Republic of|Research Site, DaeGu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Daejon, Korea, Republic of|Research Site, GuangJu, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Inchon, Korea, Republic of|Research Site, Jeonju, Korea, Republic of|Research Site, Kangnung, Korea, Republic of|Research Site, Koyang, Korea, Republic of|Research Site, Kyunggi, Korea, Republic of|Research Site, Pusan, Korea, Republic of|Research Site, Seoul(Kangbuk), Korea, Republic of|Research Site, Seoul(Kangdong), Korea, Republic of|Research Site, Seoul(Kangnam), Korea, Republic of|Research Site, Seoul(Yeouido), Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Ulsan, Korea, Republic of",2.485427041,2.236884337,Female,"25 Years to 85 Years ¬† (Adult, Older Adult)",191,185,171,96,57,18,9/8/2005,1/19/2006,11/24/2005,12/26/2005,11/18/2005,12/11/2005,12/22/2005,12/23/2005,12/29/2005,10/23/2009,5/5/2009,10/19/2009,3/1/2010,4/8/2010,5/23/2010,6/25/2010,8/20/2010,10/5/2010,11/23/2010,6/9/2006,12/6/2006,6/4/2007,12/1/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00885612,,,,,,
AstraZeneca,AstraZeneca,ST00354,SP00003,Depiction of Prostate Cancer Treatment Alternatives in Greece,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Only|Time Perspective: Retrospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Donovan H,Ross S,Terisa Sikora †,Kandace p,Terrell p,Dalton E,Suzie K,Mara A,Quentin N,Chetan K,Quentin N,John G,Lilla Stilson †,Mary H,Suzie K,Perter K,Terisa Sikora †,Mary H,,,"Research Site, Athens, Greece|Research Site, Karditsa, Greece|Research Site, Serres, Greece|Research Site, Xsanthi, Greece",29.00851262,26.10766135,Male,"18 Years and older ¬† (Adult, Older Adult)",183,179,172,89,72,11,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/6/1900,3/17/1900,4/19/1900,6/4/1900,7/6/1900,8/7/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00733213,,,,,,
AstraZeneca,AstraZeneca,ST00356,SP00003,"Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer",,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Cross-Sectional,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Marceline R,Donovan H,Chetan K,In Bellini †,Remedios Z,Harry A,Ngan D,Selizabeth F,Dinah R,Lucie P,Christian G,Terrell p,Geralyn K,Perter K,Doreen T,Dalton E,Patria R,Quentin N,Stephan T,,,"Research Site, Kyoto-shi, Japan",51.3629644,46.22666796,All,"Child, Adult, Older Adult",183,181,173,130,19,24,2/19/2017,9/23/2017,7/28/2017,8/21/2017,7/28/2017,8/9/2017,8/19/2017,8/24/2017,9/18/2017,9/6/2019,7/27/2019,10/29/2019,3/23/2020,5/4/2020,6/17/2020,8/7/2020,10/4/2020,11/12/2020,12/19/2020,2/5/2018,8/4/2018,1/31/2019,7/30/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04052113,,,,,,
AstraZeneca,AstraZeneca,ST00357,SP00003,A Trial to Evaluate the Combination of Iressa & Faslodex¬Æ in Patients With Advanced or Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Lilla Stilson †,Tien C,Livia Pacheo †,John G,Stephan T,Selizabeth F,Marcelina X,Geralyn K,Federico L,John G,Terrell p,Corrine U,Beulah N,Jene M,Naren G,Mara A,Dalton E,Selizabeth F,Marcelina X,,,"Investigative Site, Alicante, Spain|Investigative Site, Gerona, Spain|Investigative Site, Jaen, Spain|Investigative Site, Madrid, Spain|Investigative Site, Seville, Spain|Investigative Site, Valencia, Spain|Investigative Site, Zaragoza, Spain",32.5354254,29.28188286,Female,"18 Years and older ¬† (Adult, Older Adult)",178,176,174,140,10,24,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,1/30/1900,3/17/1900,4/26/1900,6/23/1900,8/17/1900,9/17/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00234403,,,,,,
AstraZeneca,AstraZeneca,ST00359,SP00003,AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 1,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Geralyn K,Selizabeth F,Chetan K,Hee Y,Jerold Goo †,Marceline R,Selizabeth F,Tiffiny K,Remedios Z,Donovan H,Jeanene Y,Donovan H,Gertrudis T,Frank T,Perter K,Clarice N,John G,Selizabeth F,Livia Pacheo †,,,"Research Site, Sarasota, Florida, United States|Research Site, Detroit, Michigan, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Greenville, South Carolina, United States|Research Site, Nashville, Tennessee, United States",99.48140644,89.5332658,Female,"18 Years and older ¬† (Adult, Older Adult)",181,178,175,126,35,14,1/25/2014,7/11/2014,5/26/2014,6/17/2014,5/27/2014,6/7/2014,6/18/2014,6/19/2014,6/30/2014,2/20/2016,1/12/2016,5/27/2016,8/4/2016,9/22/2016,11/11/2016,12/24/2016,2/17/2017,3/26/2017,5/20/2017,12/4/2014,6/2/2015,11/29/2015,5/27/2016,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01597388,,,,,,
AstraZeneca,AstraZeneca,ST00361,SP00003,"An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer",,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Mary H,Doreen T,Gertrudis T,Dinah R,Christian G,Lavina S,Doreen T,Jene M,Perter K,Lyman W,Corrine U,Selizabeth F,Ngan D,Livia Pacheo †,Tiffiny K,Perter K,John G,Terisa Sikora †,Donovan H,,,"Research Site, Denver, Colorado, United States|Research Site, Fort Myers, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Decatur, Illinois, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States",59.85589322,53.8703039,Male,"18 Years to 120 Years ¬† (Adult, Older Adult)",191,186,176,154,8,14,4/26/2018,11/26/2018,10/2/2018,11/5/2018,10/4/2018,10/20/2018,11/3/2018,11/7/2018,12/3/2018,1/13/2022,8/23/2021,5/17/2022,6/16/2022,8/9/2022,9/12/2022,11/5/2022,12/8/2022,1/11/2023,2/25/2023,4/18/2019,10/15/2019,4/12/2020,10/9/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04089553,,,,,,
AstraZeneca,AstraZeneca,ST00363,SP00003,Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Selizabeth F,Remedios Z,Ross S,Anthony P,Patria R,Louann C,Clarice N,Lucie P,Doreen T,Mary H,Lavina S,Naren G,Mary H,Mary H,Liberty A,Mary H,Lyman W,Selizabeth F,Xochitl D,,,"Research Site, Birmingham, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Los Angeles, California, United States|Research Site, Torrance, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Barretos, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeir√£o Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, S√£o Jos√© do Rio Preto, Brazil|Research Site, S√£o Paulo, Brazil|Research Site, Odense C, Denmark|Research Site, Angers Cedex 01, France|Research Site, Bordeaux Cedex, France|Research Site, Caen Cedex 5, France|Research Site, Lyon, France|Research Site, Toulouse Cedex 9, France|Research Site, Villejuif Cedex, France|Research Site, Augsburg, Germany|Research Site, Essen, Germany|Research Site, Leipzig, Germany|Research Site, Catania, Italy|Research Site, Napoli, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Gliwice, Poland|Research Site, Kielce, Poland|Research Site, Pozna≈Ñ, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Zgierz, Poland|Research Site, G√∂teborg, Sweden|Research Site, Link√∂ping, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden",64.90479559,58.41431603,All,"19 Years and older ¬† (Adult, Older Adult)",199,192,177,97,64,16,1/26/2015,6/14/2015,4/11/2015,5/23/2015,4/15/2015,5/3/2015,5/14/2015,5/16/2015,6/7/2015,7/10/2017,10/25/2017,4/14/2018,5/18/2018,7/17/2018,8/20/2018,10/12/2018,12/1/2018,1/5/2019,2/28/2019,10/30/2015,4/27/2016,10/24/2016,4/22/2017,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01843062,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01843062/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01843062/SAP_001.pdf"
AstraZeneca,AstraZeneca,ST00365,SP00003,A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Clarice N,Liberty A,Marcelina X,Mary H,Perter K,Lucie P,Geralyn K,Chetan K,Dinah R,Lavina S,Donovan H,Jerold Goo †,Mary H,Mac L,In Bellini †,Tiffiny K,James y,Garnet T,Stephan T,,,"Research Site, Buenos Aires, Argentina|Research Site, Rosario, Argentina|Research Site, Santiago de Chile, Chile|Research Site, Cali, Colombia|Research Site, Cordoba, Colombia|Research Site, Medellin, Colombia|Research Site, Santo Domingo, Dominican Republic|Research Site, Anand, India|Research Site, Bangalore, India|Research Site, Calicut, India|Research Site, Chennai, India|Research Site, Mohali, India|Research Site, Mumbai, India|Research Site, Nashik, India|Research Site, New Delhi, India|Research Site, Odissa, India|Research Site, Srinagar, India|Research Site, West Bengal, India|Research Site, Guadalajara, Mexico|Research Site, Mexico City, Mexico|Research Site, Toluca, Mexico|Research Site, Lima, Peru|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, TaoYuan, Taiwan|Research Site, Bangkoknoi, Thailand|Research Site, Dusit, Thailand|Research Site, Pathumwan, Thailand|Research Site, Ratchathewi, Thailand|Research Site, Montevideo, Uruguay",5.963624234,5.36726181,All,"18 Years and older ¬† (Adult, Older Adult)",200,191,178,132,24,22,8/9/2014,1/19/2015,11/3/2014,11/30/2014,11/16/2014,11/25/2014,12/4/2014,12/8/2014,12/22/2014,10/30/2018,3/5/2019,5/17/2019,9/30/2019,11/21/2019,1/4/2020,2/21/2020,4/9/2020,5/16/2020,6/15/2020,5/24/2015,11/20/2015,5/18/2016,11/14/2016,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03725475,,,,,,
AstraZeneca,AstraZeneca,ST00369,SP00003,Epidemiology and Management of Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Suzie K,Harry A,Lucie P,Stephan T,Tammara F,Mary H,Mary H,Naren G,Donovan H,Ross S,Selizabeth F,Chetan K,Frank T,Christian G,Marceline R,Rima Y ,Hee Y,Gertrudis T,Stephan T,,,"Doina Coste Gherasim, Baia Mare, Romania|Daniel Ciurescu, Brasov, Romania|Dana Lucia Stanculeanu, Bucharest, Romania|Dragos Median, Bucharest, Romania|Mircea Dediu, Bucharest, Romania|Rodica Tudor, Bucharest, Romania|Alexandru Eniu, Cluj, Romania|Gabriela Morar Bolba, Cluj, Romania|Bena Sandra, Craiova, Romania|Nelly Cherciu, Craiova, Romania|Diana Petroiu, Iasi, Romania|Simona Angelescu, Targoviste, Romania|Cristina Oprean, Timisoara, Romania|Stefan Curescu, Timisoara, Romania|Cristina Elen Pirau, Vaslui, Romania",9.992345637,8.993111073,Female,"18 Years and older ¬† (Adult, Older Adult)",189,182,179,134,20,25,1/29/2009,8/15/2009,6/5/2009,7/16/2009,6/15/2009,7/2/2009,7/12/2009,7/13/2009,8/1/2009,10/3/2012,8/18/2012,4/14/2013,6/1/2013,7/3/2013,8/27/2013,10/6/2013,11/6/2013,12/13/2013,1/16/2014,12/29/2009,6/27/2010,12/24/2010,6/22/2011,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01711502,,,,,,
AstraZeneca,AstraZeneca,ST00370,SP00003,IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 1|Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Donovan H,In Bellini †,Anthony P,Perter K,Rima Y ,Chetan K,Mary H,Selizabeth F,Mary H,Lilla Stilson †,Jaquelyn H,Donovan H,Kala R,Gertrudis T,John G,Ross S,Suk T,Selizabeth F,Marceline R,,,"Research Site, Barcelona, Spain|Research Site, Valencia, Spain",16.25869846,14.63282861,All,"18 Years to 70 Years ¬† (Adult, Older Adult)",201,195,180,148,17,15,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/21/1900,4/4/1900,5/9/1900,6/14/1900,7/16/1900,8/31/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,3/6/1900,9/2/1900,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00234416,,,,,,
AstraZeneca,AstraZeneca,ST00372,SP00003,"Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer",,,,,Oncology,,,,,,Industry,Withdrawn,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Harry A,John G,Jene M,Quentin N,Rima Y ,Kandace p,Suzie K,Chetan K,John G,Dalton E,Hee Y,Corrine U,Perter K,Mara A,Anthony P,Suk T,John G,Terrell p,Naren G,,,"Research Center, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Catania, Italy|Research Site, Cremona, Italy|Research Site, Cuneo, Italy|Research Site, L'Aquila, Italy|Research Site, La Spezia, Italy|Research Site, Milano, Italy|Research Site, Palermo, Italy|Research Site, Pescara, Italy|Research Site, Rozzano, Italy|Research Site, Torino, Italy|Research Site, Venezia, Italy",50.86533059,45.77879753,All,"18 Years and older ¬† (Adult, Older Adult)",205,198,181,153,10,18,1/18/2004,6/29/2004,4/22/2004,5/8/2004,4/19/2004,5/2/2004,5/4/2004,5/6/2004,5/30/2004,9/16/2005,6/8/2005,11/19/2005,1/1/2006,2/7/2006,4/4/2006,6/1/2006,7/26/2006,8/25/2006,9/28/2006,10/29/2004,4/27/2005,10/24/2005,4/22/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00233623,,,,,,
AstraZeneca,AstraZeneca,ST00373,SP00003,First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX,,,,,Oncology,,,,,,Industry,Completed,Phase 2|Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug H,,,,,,,,,,,,,,,,,,,Gertrudis T,Kala R,Naren G,Geralyn K,Remedios Z,Christian G,John G,Marceline R,Livia Pacheo †,Harry A,Mary H,Tien C,Remedios Z,Livia Pacheo †,Otis Thode †,Ngan D,Xochitl D,Jene M,Terisa Sikora †,,,"Research Site, Anniston, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Casa Grande, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Palm Springs, California, United States|Research Site, San Diego, California, United States|Research Site, Fairfield, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Bay Pines, Florida, United States|Research Site, Fort Meyers, Florida, United States|Research Site, Port St Lucie, Florida, United States|Research Site, Port St. Lucie, Florida, United States|Research Site, Galesburg, Illinois, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Quincy, Illinois, United States|Research Site, Layfayette, Indiana, United States|Research Site, New Albany, Indiana, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Layfayette, Louisiana, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, St Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Summit, New Jersey, United States|Research Site, Fresh Meadows, New York, United States|Research Site, Northport, New York, United States|Research Site, Rochester, New York, United States|Research Site, Fayetteville, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Middletown, Ohio, United States|Research Site, Zanesville, Ohio, United States|Research Site, Coos Bay, Oregon, United States|Research Site, Hilton Head Island, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, White River Junction, Vermont, United States|Research Site, Abingdon, Virginia, United States|Research Site, Alexandria, Virginia, United States|Research Site, Armidale, New South Wales, Australia|Research Site, Coffs Harbour, New South Wales, Australia|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Hornsby, New South Wales, Australia|Research Site, Kogarah, New South Wales, Australia|Research Site, Port Macquarie, New South Wales, Australia|Research Site, Randwick, New South Wales, Australia|Research Site, St. Leonards, New South Wales, Australia|Research Site, Tamworth, New South Wales, Australia|Research Site, Waratah, New South Wales, Australia|Research Site, South Brisbane, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Hobart, Tasmania, Australia|Research Site, Epping, Victoria, Australia|Research Site, Ashford, Australia|Research Site, Bedford Park, Australia|Research Site, Bendigo, Australia|Research Site, Box Hill, Australia|Research Site, Camperdown, Australia|Research Site, Coffs Harbour, Australia|Research Site, Darlinghurst, Australia|Research Site, East-Melbourne, Australia|Research Site, Epping, Australia|Research Site, Herston, Australia|Research Site, Hobart, Australia|Research Site, Hornsby, Australia|Research Site, Kogarah, Australia|Research Site, Lismore, Australia|Research Site, Malvern, Australia|Research Site, Nedlands, Australia|Research Site, Port Macquarie, Australia|Research Site, Randwick, Australia|Research Site, South Brisbane, Australia|Research Site, St. Leonards, Australia|Research Site, Tamworth, Australia|Research Site, Waratah, Australia|Research Site, Wodonga, Australia|Research Site, Woodville South, Australia|Research Site, Kundratstrasse 3, Vienna, Austria|Research Site, Innsbruck, Austria|Research Site, Kundratstrasse 3, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Zams, Austria|Research Site, Bonheiden, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels (woluwe-st-lambert), Belgium|Research Site, Brussels (Woluw√©-St-Lambert), Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Ghent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Roeselare, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, St Catharines, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, York, Ontario, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czech Republic|Research Site, Chomutov, Czech Republic|Research Site, Kutna Hora, Czech Republic|Research Site, Nova Ves pod Plesi, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Tabor, Czech Republic|Research Site, Alexandria, Egypt|Research Site, Cairo, Egypt|Research Site, Helsinki, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Vaasa, Finland|Research Site, Boulogne Cedex, France|Research Site, La Roche S YON, France|Research Site, Marseille Cedex 08, France|Research Site, Nantes,, France|Research Site, Nantes, France|Research Site, Paris Cedex 15, France|Research Site, Paris, France|Research Site, Saint Gregoire, France|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Freiburg, Germany|Research Site, Halle, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Munchen, Germany|Research Site, M√ºnchen, Germany|Research Site, Neu-isenburg, Germany|Research Site, Tubingen, Germany|Research Site, T√ºbingen, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Pecs, Hungary|Research Site, P√©cs, Hungary|Research Site, Szeged, Hungary|Research Site, Tatabanya, Hungary|Research Site, Tatab√°nya, Hungary|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Pune, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Varanasi, Uttar Prad, India|Research Site, Kolkata, W Bengal, India|Research Site, Bangalore, India|Research Site, Bhopal, India|Research Site, Chennai, India|Research Site, Hyderabad, India|Research Site, Jaipur, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Pune, India|Research Site, Sheikhpura, India|Research Site, Holon, Israel|Research Site, Kfar-saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel-Hashomer, Israel|Research Site, Tiberias, Israel|Research Site, Tzrifin, Israel|Research Site, Genova, GE, Italy|Research Site, Rozzano, MI, Italy|Research Site, Ancona, Italy|Research Site, Genova, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Riga, Latvia|Research Site, Floriana, Malta|Research Site, Valletta, Malta|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Molo, Philippines|Research Site, Quezon City, Philippines|Research Site, Bytom, Poland|Research Site, Elblag, Poland|Research Site, Gdynia, Poland|Research Site, Krakow, Poland|Research Site, Krak√≥w, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Pozna≈Ñ, Poland|Research Site, Rybnik, Poland|Research Site, Warszawa, Poland|Research Site, Barnaul, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tumen, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Cape Town, South Africa|Research Site, Lyttelton Manor, South Africa|Research Site, Polokwane, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, Cordoba, Andalucia, Spain|Research Site, Zaragoza, Aragon, Spain|Research Site, Oviedo, Asturias, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Granollers, Cataluna, Spain|Research Site, Hospitalet de Llobregat(barcel, Cataluna, Spain|Research Site, Terrassa(barcelona), Cataluna, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A Coruna, Galicia, Spain|Research Site, A Coru√±a, Spain|Research Site, C√≥rdoba, Spain|Research Site, Granollers, Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Madrid, Spain|Research Site, Manresa, Spain|Research Site, Oviedo, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-yuan, Taiwan|Research Site, Nakhonratchasima, Naimuang, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Rachathewi, Thailand|Research Site, Songkla, Thailand|Research Site, Istanbul, Goztepe, Turkey|Research Site, Ankara, Turkey|Research Site, Izmir, Turkey|Research Site, Cherkassy, Ukraine|Research Site, Chernigiv, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkov, Ukraine|Research Site, Kherson, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lugansk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Simferopol, Ukraine|Research Site, Sumy, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Ternopol, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Southampton, Hampshire, United Kingdom|Research Site, Maidstone, Kent, United Kingdom|Research Site, Northwood, Middlesex, United Kingdom|Research Site, Sutton, Surrey, United Kingdom|Research Site, Bebington, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Ipswich, United Kingdom|Research Site, London, United Kingdom|Research Site, Maidstone, United Kingdom|Research Site, Newcastle Upon Tyne, United Kingdom|Research Site, Newcastle-upon-tyne, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Stockport, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Hanoi city, Vietnam|Research Site, Ho Chi Minh city, Vietnam|Research Site, Ho Chi Minh, Vietnam",19.27129672,17.34416704,All,"18 Years to 85 Years ¬† (Adult, Older Adult)",205,196,182,60,110,12,2/1/2005,8/27/2005,6/16/2005,7/26/2005,6/21/2005,7/15/2005,7/22/2005,7/26/2005,8/1/2005,9/30/2009,2/19/2009,9/4/2009,11/15/2009,1/12/2010,3/3/2010,5/1/2010,6/20/2010,8/13/2010,10/9/2010,1/11/2006,7/10/2006,1/6/2007,7/5/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00384176,,,,,,
AstraZeneca,AstraZeneca,ST00375,SP00003,Open Label Prostate Cancer Study,,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Jeanene Y,Garnet T,John G,Beulah N,Kandace p,James y,Quentin N,Liberty A,Gertrudis T,Selizabeth F,Marcelina X,Suzie K,Mee M,Suzie K,Stephan T,Louann C,Terisa Sikora †,Beulah N,Jerold Goo †,,,"Research Site, Portland, Oregon, United States|Research Site, Amsterdam, Netherlands|Research Site, Glasgow, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Surrey, United Kingdom",56.70335661,51.03302095,Male,"Child, Adult, Older Adult",196,193,183,133,35,15,11/29/2009,5/7/2010,2/27/2010,4/12/2010,3/17/2010,3/24/2010,3/31/2010,4/5/2010,4/21/2010,4/28/2012,8/12/2012,11/13/2012,3/1/2013,4/27/2013,6/4/2013,7/31/2013,9/24/2013,11/11/2013,12/25/2013,9/20/2010,3/19/2011,9/15/2011,3/13/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01162395,,,,,,
AstraZeneca,AstraZeneca,ST00376,SP00003,Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Clarice N,Ross S,Clarice N,Marceline R,Lucie P,Ross S,Geralyn K,Suzie K,Perter K,Liberty A,Quentin N,Frank T,Tien C,Remedios Z,Geralyn K,Remedios Z,Anthony P,Mac L,Lucie P,,,,66.20531078,59.5847797,Female,"18 Years and older ¬† (Adult, Older Adult)",199,197,184,124,40,20,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/14/1900,3/20/1900,5/13/1900,7/1/1900,8/9/1900,10/8/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00681369,,,,,,
AstraZeneca,AstraZeneca,ST00377,SP00003,Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Tien C,Perter K,Lucie P,Stephan T,Clarice N,Mee M,Naren G,Anthony P,Remedios Z,Garnet T,Remedios Z,Aleta H,Garnet T,Tamesha T,Lucie P,Louann C,Mara A,Lavina S,,,,20.34257464,18.30831717,Female,"18 Years to 120 Years ¬† (Adult, Older Adult)",206,200,185,141,21,23,12/17/2004,7/28/2005,5/16/2005,6/24/2005,5/24/2005,6/12/2005,6/23/2005,6/24/2005,7/16/2005,12/2/2007,8/10/2007,1/16/2008,5/1/2008,6/8/2008,7/30/2008,9/23/2008,11/9/2008,12/20/2008,2/13/2009,12/9/2005,6/7/2006,12/4/2006,6/2/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00727883,,,,,,
AstraZeneca,AstraZeneca,ST00379,SP00003,An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Mac L,Rima Y ,Stephan T,Perter K,Lilla Stilson †,Rima Y ,Kala R,Federico L,Lilla Stilson †,Tien C,Jene M,In Bellini †,Geralyn K,Aleta H,Patria R,James y,Aleta H,Kandace p,Christian G,,,"Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Hue, Vietnam",99.2447055,89.32023495,Female,"52 Years to 79 Years ¬† (Adult, Older Adult)",196,193,186,157,3,26,9/5/2006,3/26/2007,2/4/2007,3/10/2007,2/2/2007,2/18/2007,2/24/2007,3/1/2007,3/7/2007,3/10/2010,6/6/2010,10/18/2010,3/1/2011,3/31/2011,5/6/2011,6/17/2011,8/13/2011,10/7/2011,11/7/2011,8/17/2007,2/13/2008,8/11/2008,2/7/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00737009,,,,,,
AstraZeneca,AstraZeneca,ST00380,SP00003,"Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Tamesha T,Tammara F,Frank T,Terisa Sikora †,Geralyn K,Christian G,Ross S,Mara A,Jaquelyn H,Ross S,Christian G,Mary H,Donovan H,Perter K,Terrell p,Terrell p,Federico L,Stephan T,Mary H,,,"Research Site, Tucson, Arizona, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Toronto, Ontario, Canada|Research Site, Amsterdam, Netherlands",67.81525205,61.03372684,Female,"18 Years and older ¬† (Adult, Older Adult)",204,198,187,73,101,13,11/17/2016,4/26/2017,2/15/2017,3/10/2017,2/8/2017,3/3/2017,3/16/2017,3/19/2017,4/4/2017,8/25/2018,5/27/2018,8/6/2018,12/13/2018,1/30/2019,3/27/2019,5/13/2019,7/3/2019,8/31/2019,10/30/2019,8/30/2017,2/26/2018,8/25/2018,2/21/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02272790,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02272790/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02272790/SAP_001.pdf"
AstraZeneca,AstraZeneca,ST00381,SP00003,Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Mara A,Federico L,Perter K,Ross S,Stephan T,Jerold Goo †,In Bellini †,Frank T,Harry A,Mary H,Marceline R,Patria R,Mara A,Chetan K,Harry A,Suk T,Jerold Goo †,Suk T,Mary H,,,"Research Site, Balatonfoldvar, Hungary|Research Site, Bekescsaba, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Dombovar, Hungary|Research Site, Gyongyos, Hungary|Research Site, Gyor, Hungary|Research Site, Gyula, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Mosdos, Hungary|Research Site, Nagyatad, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Orfu, Hungary|Research Site, Papa, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szekszard, Hungary|Research Site, Szentes, Hungary|Research Site, Szombathely, Hungary|Research Site, Veszprem, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Zirc, Hungary",10.02912019,9.026208171,Female,"18 Years and older ¬† (Adult, Older Adult)",208,199,188,123,48,17,1/5/2010,8/12/2010,6/8/2010,7/10/2010,6/28/2010,7/3/2010,7/7/2010,7/10/2010,7/19/2010,6/5/2011,3/15/2011,5/10/2011,10/1/2011,11/16/2011,1/5/2012,2/28/2012,4/18/2012,5/26/2012,6/30/2012,12/30/2010,6/28/2011,12/25/2011,6/22/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01081509,,,,,,
AstraZeneca,AstraZeneca,ST00383,SP00003,Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in Algeria,,,,,Oncology,,,,,,Industry,"Active, not recruiting",,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Rima Y ,Geralyn K,Xochitl D,Beulah N,Marceline R,Selizabeth F,Dalton E,Chetan K,Beulah N,Tiffiny K,Christian G,Marceline R,Ngan D,Frank T,Mary H,Quentin N,Chetan K,Xochitl D,Tamesha T,,,"CPMC, Algiers, Algeria|CHU Constantine, Constantine, Algeria|CHU Oran, Oran, Algeria",54.60486612,49.14437951,Female,"18 Years to 75 Years ¬† (Adult, Older Adult)",201,196,189,98,81,10,3/14/2018,9/4/2018,7/11/2018,7/28/2018,6/22/2018,7/17/2018,7/24/2018,7/27/2018,8/3/2018,5/6/2021,7/23/2021,12/4/2021,2/28/2022,4/1/2022,5/28/2022,6/28/2022,8/26/2022,10/22/2022,11/28/2022,1/13/2019,7/12/2019,1/8/2020,7/6/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02733601,,,,,,
AstraZeneca,AstraZeneca,ST00384,SP00003,IRESSA‚Ñ¢ (Gefitinib) in Breast Cancer Patients,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Selizabeth F,Mary H,Doreen T,Corrine U,Jaquelyn H,Quentin N,James y,Kala R,Jerold Goo †,James y,Mac L,John G,Perter K,Federico L,Hee Y,Mac L,Patria R,Selizabeth F,Garnet T,,,,47.0724508,42.36520572,Female,"18 Years and older ¬† (Adult, Older Adult)",205,200,190,77,104,9,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/4/1900,3/22/1900,5/2/1900,6/20/1900,8/10/1900,9/14/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00632723,,,,,,
AstraZeneca,AstraZeneca,ST00387,SP00003,"AZD6244 vs. Capecitabine (Xeloda¬Æ) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy",,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Clarice N,Lavina S,Geralyn K,Remedios Z,Federico L,John G,Perter K,Marcelina X,Aleta H,Jene M,Otis Thode †,Harry A,Jaquelyn H,Beulah N,Perter K,Lavina S,Garnet T,Perter K,Lavina S,,,"Research Site, Alhambra, California, United States|Research Site, Bakersfield, California, United States|Research Site, Palm Springs, California, United States|Research Site, Santa Maria, California, United States|Research Site, Orlando, Florida, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, New York, New York, United States|Research Site, Nashville, Tennessee, United States|Research Site, Temple, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Heidelburg, Australia|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Budapest, Hungary|Research Site, Cluj-Napoca, Romania",78.55093942,70.69584548,All,"18 Years and older ¬† (Adult, Older Adult)",199,195,191,66,113,12,8/7/2003,2/28/2004,12/10/2003,1/6/2004,12/21/2003,1/1/2004,1/9/2004,1/11/2004,1/17/2004,2/20/2008,7/22/2007,3/1/2008,4/1/2008,5/12/2008,7/11/2008,9/8/2008,10/18/2008,12/7/2008,1/13/2009,6/29/2004,12/26/2004,6/24/2005,12/21/2005,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00372944,,,,,,
AstraZeneca,AstraZeneca,ST00388,SP00003,ZD1839 (IRESSA‚Ñ¢) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Mac L,Selizabeth F,Christian G,Chetan K,Anthony P,Harry A,Ngan D,Louann C,Selizabeth F,Naren G,Lilla Stilson †,Remedios Z,Ngan D,Lyman W,Tien C,Mara A,Suzie K,Jene M,Hee Y,,,"Research Facility, Granada, Spain|Research Facility, Madrid, Spain|Research Facility, Murcia, Spain|Research Site, Sevilla, Spain",99.55091268,89.59582142,All,"19 Years to 80 Years ¬† (Adult, Older Adult)",206,199,192,185,30,23,8/21/2004,2/9/2005,12/21/2004,1/25/2005,12/19/2004,1/10/2005,1/14/2005,1/17/2005,2/5/2005,4/8/2005,7/19/2005,12/11/2005,3/1/2006,4/10/2006,5/16/2006,6/23/2006,8/7/2006,9/26/2006,11/5/2006,7/9/2005,1/5/2006,7/4/2006,12/31/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00242762,,,,,,
AstraZeneca,AstraZeneca,ST00389,SP00003,Phase II Efficacy Study of AZD6244 in Colorectal Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Livia Pacheo †,Federico L,Chetan K,Tammara F,Mee M,Rima Y ,Livia Pacheo †,Tien C,Harry A,Anthony P,Frank T,Tamesha T,Selizabeth F,Tien C,Tamesha T,Xochitl D,Selizabeth F,Ross S,Stephan T,,,"Research Site, Goiania, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil",29.38994178,26.4509476,All,"18 Years and older ¬† (Adult, Older Adult)",216,210,193,175,2,16,11/26/2005,5/25/2006,3/18/2006,4/20/2006,4/6/2006,4/8/2006,4/21/2006,4/26/2006,5/5/2006,11/23/2006,11/13/2006,2/9/2007,6/1/2007,7/15/2007,9/3/2007,11/2/2007,12/6/2007,1/22/2008,3/4/2008,10/5/2006,4/3/2007,9/30/2007,3/28/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00514761,,,,,,
AstraZeneca,AstraZeneca,ST00391,SP00003,Management of Metastatic Breast Cancer in Clinical Practice - Retrospective Study,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Mary H,Gertrudis T,Suk T,Geralyn K,Dinah R,Tiffiny K,Mara A,Garnet T,Aleta H,Harry A,Anthony P,Xochitl D,Quentin N,Lucie P,Marceline R,Ngan D,Ngan D,Anthony P,Aleta H,,,"Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Reaseach Site, Varna, Bulgaria",80.83099084,72.74789176,Female,"20 Years to 80 Years ¬† (Adult, Older Adult)",208,205,194,76,108,10,1/14/2010,7/20/2010,6/7/2010,6/22/2010,6/8/2010,6/15/2010,6/30/2010,7/4/2010,7/31/2010,11/23/2012,9/2/2012,4/22/2013,6/1/2013,7/12/2013,8/26/2013,10/25/2013,12/24/2013,1/24/2014,3/18/2014,12/12/2010,6/10/2011,12/7/2011,6/4/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01715155,,,,,,
AstraZeneca,AstraZeneca,ST00393,SP00003,"A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer",,,,,Oncology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Frank T,Mara A,Perter K,Dalton E,Kala R,Naren G,Tien C,Marcelina X,Garnet T,Mara A,Mee M,Suzie K,Dalton E,Lyman W,Stephan T,Mary H,Jeanene Y,John G,Tamesha T,,,,93.71614069,84.34452662,Female,"18 Years and older ¬† (Adult, Older Adult)",222,214,195,120,56,19,3/15/2004,8/16/2004,6/15/2004,6/30/2004,6/9/2004,6/23/2004,7/8/2004,7/13/2004,7/24/2004,9/23/2007,2/24/2007,7/9/2007,11/1/2007,12/21/2007,2/17/2008,3/31/2008,5/5/2008,6/30/2008,8/10/2008,12/20/2004,6/18/2005,12/15/2005,6/13/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00544986,,,,,,
AstraZeneca,AstraZeneca,ST00394,SP00003,A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer,,,,,Oncology,,,,,,Industry,Recruiting,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,,,,,Drug E,,,,,,,,,,,,,,,,,,,Garnet T,Jene M,Jene M,Harry A,Suzie K,Anthony P,Aleta H,Kandace p,Tiffiny K,John G,Harry A,Dalton E,Mara A,John G,Garnet T,Beulah N,Perter K,Kala R,Rima Y ,,,"Research Site, Phoenix, Arizona, United States|Research Site, Duarte, California, United States|Research Site, Orange, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Boca Raton, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Wichita, Kansas, United States|Research Site, Ashland, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Silver Spring, Maryland, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Morristown, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Port Jefferson Station, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Bend, Oregon, United States|Research Site, Medford, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Austin, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, Fort Belvoir, Virginia, United States|Research Site, Kennewick, Washington, United States|Research Site, Kirkland, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autonoma De Buenos Aire, Argentina|Research Site, Florencio Varela, Argentina|Research Site, La Plata, Argentina|Research Site, Pergamino, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Salvador de Jujuy, Argentina|Research Site, Viedma, Argentina|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Rankweil, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Gent, Belgium|Research Site, Li√®ge, Belgium|Research Site, Mons, Belgium|Research Site, Barretos, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Campinas, Brazil|Research Site, Curitiba, Brazil|Research Site, Florian√≥polis, Brazil|Research Site, Natal, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Santa Maria, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, S√£o Jos√© do Rio Preto, Brazil|Research Site, Teresina, Brazil|Research Site, Vitoria, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Vi√±a del Mar, Chile|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Changzhou, China|Research Site, Chengdu, China|Research Site, Guang Zhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guiyang, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Kunming, China|Research Site, Linhai, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Ningbo, China|Research Site, Ningbo, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenyang, China|Research Site, Shenzhen, China|Research Site, Shenzhen, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Xiamen, China|Research Site, Xian, China|Research Site, Xintai, China|Research Site, Yangzhou, China|Research Site, Zhengzhou, China|Research Site, San Jos√©, Costa Rica|Research Site, San Jos√©, Costa Rica|Research Site, Avignon Cedex, France|Research Site, Bordeaux, France|Research Site, Lyon Cedex 08, France|Research Site, Nice, France|Research Site, Toulon Cedex 9, France|Research Site, Tours, France|Research Site, Vantoux, France|Research Site, Bielefeld, Germany|Research Site, Frankfurt am Main, Germany|Research Site, G√∂ttingen, Germany|Research Site, Immenstadt im Allg√§u, Germany|Research Site, K√∂ln, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gy√∂ngy√∂s - M√°trah√°za, Hungary|Research Site, Gy≈ër, Hungary|Research Site, T√∂r√∂kb√°lint, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Chandigarh, India|Research Site, Coimabatore, India|Research Site, Delhi, India|Research Site, Erode, India|Research Site, Gurgaon, India|Research Site, Gurgaon, India|Research Site, Kolkata, India|Research Site, Madurai, India|Research Site, Maharashtra, India|Research Site, Manipal, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, Mysuru, India|Research Site, Nagpur, India|Research Site, Namakkal, India|Research Site, Nasik, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Surat, India|Research Site, Thane, India|Research Site, Vishakhapatnam, India|Research Site, Ancona, Italy|Research Site, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Monza, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Verona, Italy|Research Site, Habikino-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Kitakyushu-shi, Japan|Research Site, Kurashiki shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Toyoake-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Guadalajara, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, M√©xico, Mexico|Research Site, M√©xico, Mexico|Research Site, Pachuca de Soto, Mexico|Research Site, Arnhem, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Arequipa, Peru|Research Site, Bellavista, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, San Isidro, Peru|Research Site, Davao City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Makati, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Bia≈Çystok, Poland|Research Site, Olsztyn, Poland|Research Site, Otwock, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroc≈Çaw, Poland|Research Site, Hato Rey Central, Puerto Rico|Research Site, Cluj Napoca, Romania|Research Site, Constanta, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Suceava, Romania|Research Site, Kazan, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, M√°laga, Spain|Research Site, Oviedo, Spain|Research Site, Pamplona, Spain|Research Site, San Sebastian, Spain|Research Site, Santiago De Compostela(A Coru, Spain|Research Site, Valencia, Spain|Research Site, Changhua, Taiwan|Research Site, Kaohsiung City, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Chiang Rai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Lampang, Thailand|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam",51.30307492,46.17276743,All,"40 Years and older ¬† (Adult, Older Adult)",212,207,196,127,52,17,2/9/2020,8/30/2020,7/3/2020,7/23/2020,6/21/2020,7/10/2020,7/13/2020,7/16/2020,7/23/2020,8/9/2023,8/4/2023,12/31/2023,4/30/2024,6/13/2024,7/23/2024,8/22/2024,9/22/2024,11/11/2024,1/2/2025,1/6/2021,7/5/2021,1/1/2022,6/30/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03800134,,,,,,
AstraZeneca,AstraZeneca,ST00395,SP00003,Faslodex Advanced Breast Cancer Local Chinese Study,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug F,,,,,,,,,,,,,,,,,,,Hee Y,Stephan T,Lavina S,Dinah R,Xochitl D,Otis Thode †,Anthony P,Lyman W,Rima Y ,Tammara F,Donovan H,Marceline R,Mee M,Tammara F,Suzie K,Naren G,Mary H,Harry A,Clarice N,,,"Research Site, Beijing, China|Research Site, Dalian, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Hankou, China|Research Site, He Fei, China|Research Site, Huangzhou, China|Research Site, Ji Nan, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Wuhan, China|Research Site, Xi AN, China",33.95436242,30.55892617,Female,"18 Years to 110 Years ¬† (Adult, Older Adult)",217,209,197,186,14,3,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/9/1900,3/13/1900,5/11/1900,7/9/1900,8/25/1900,10/14/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00327769,,,,,,
AstraZeneca,AstraZeneca,ST00399,SP00003,Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC),,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Only|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Naren G,Selizabeth F,In Bellini †,Christian G,Otis Thode †,Corrine U,Otis Thode †,Naren G,James y,Mary H,Selizabeth F,Clarice N,Ross S,Dinah R,Garnet T,Perter K,Jaquelyn H,Tien C,Livia Pacheo †,,,"Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Klagenfurt, Austria|Research Site, Leoben, Austria|Research Site, Linz, Austria|Research Site, Oberpullendorf, Austria|Research Site, Rankweil, Austria|Research Site, Rottenmann, Austria|Research Site, Salzburg, Austria|Research Site, St. Veit, Austria|Research Site, Steyr, Austria|Research Site, Vienna, Austria|Research Site, Wr. Neustadt, Austria",59.39608909,53.45648018,Female,"18 Years and older ¬† (Adult, Older Adult)",207,200,198,135,39,24,7/22/2005,1/29/2006,12/14/2005,1/13/2006,12/26/2005,12/30/2005,1/2/2006,1/6/2006,1/12/2006,5/1/2010,12/17/2009,6/5/2010,9/1/2010,10/20/2010,12/9/2010,1/13/2011,2/18/2011,4/18/2011,5/31/2011,6/28/2006,12/25/2006,6/23/2007,12/20/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00880711,,,,,,
AstraZeneca,AstraZeneca,ST00402,SP00003,Open Label Trial to Assess Iressa in Prostate Cancer Patients,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),,,,,,Drug D,,,,,,,,,,,,,,,,,,,Suk T,Liberty A,John G,Mara A,Geralyn K,Mac L,Patria R,In Bellini †,Mary H,Suk T,Xochitl D,Frank T,Patria R,Corrine U,Tammara F,Frank T,Ngan D,Suzie K,Beulah N,,,,37.22241429,33.50017286,All,"18 Years and older ¬† (Adult, Older Adult)",209,205,199,138,34,27,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/12/1900,3/22/1900,4/29/1900,6/17/1900,8/11/1900,9/27/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00635856,,,,,,
AstraZeneca,AstraZeneca,ST00404,SP00003,Lynparza Breast Cancer Clinical Experience Investigation,,,,,Oncology,,,,,,Industry,"Active, not recruiting",,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Lucie P,Kala R,Mac L,Federico L,Perter K,Terrell p,Mary H,John G,Mara A,Selizabeth F,Louann C,Patria R,Anthony P,Garnet T,Xochitl D,Perter K,Terrell p,Mary H,Patria R,,,"Research Site, Aichi, Japan|Research Site, Aomori, Japan|Research Site, Chiba, Japan|Research Site, Ehime, Japan|Research Site, Fukui, Japan|Research Site, Fukuoka, Japan|Research Site, Gunma, Japan|Research Site, Hiroshima, Japan|Research Site, Hokkaido, Japan|Research Site, Hyogo, Japan|Research Site, Ibaraki, Japan|Research Site, Ishikawa, Japan|Research Site, Kagawa, Japan|Research Site, Kagoshima, Japan|Research Site, Kanagawa, Japan|Research Site, Kochi, Japan|Research Site, Kumamoto, Japan|Research Site, Kyoto, Japan|Research Site, Miyagi, Japan|Research Site, Nagano, Japan|Research Site, Nara, Japan|Research Site, Okayama, Japan|Research Site, Okinawa, Japan|Research Site, Osaka, Japan|Research Site, Saitama, Japan|Research Site, Shiga, Japan|Research Site, Shimane, Japan|Research Site, Shizuoka, Japan|Research Site, Tokyo, Japan|Research Site, Toyama, Japan|Research Site, Yamagata, Japan|Research Site, Yamaguchi, Japan",40.68074567,36.6126711,All,"20 Years to 70 Years ¬† (Adult, Older Adult)",226,218,200,79,106,15,7/8/2016,1/24/2017,12/16/2016,1/7/2017,12/15/2016,12/25/2016,12/30/2016,1/3/2017,1/31/2017,10/4/2021,3/14/2021,9/11/2021,12/28/2021,2/23/2022,4/5/2022,5/6/2022,6/25/2022,8/22/2022,10/12/2022,6/23/2017,12/20/2017,6/18/2018,12/15/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03590938,,,,,,
AstraZeneca,AstraZeneca,ST00409,SP00003,Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Only|Time Perspective: Prospective,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Perter K,Quentin N,Marceline R,James y,Mary H,Suk T,James y,Perter K,Xochitl D,Anthony P,Suzie K,Corrine U,John G,John G,Doreen T,Aleta H,Mary H,Anthony P,Lyman W,,,"Research Site, Cakovec, Croatia|Research Site, Dubrovnik, Croatia|Research Site, Karlovac, Croatia|Research Site, Pula, Croatia|Research Site, Rijeka, Croatia|Research Site, Sibenik, Croatia|Research Site, Sisak, Croatia|Research Site, Slavonski brod, Croatia|Research Site, Split, Croatia|Research Site, Vinkovci, Croatia|Research Site, Virovitica, Croatia|Research Site, Vukovar, Croatia|Research Site, Zabok, Croatia|Research Site, Zadar, Croatia|Research Site, Zagreb, Croatia",75.00057897,67.50052107,Male,"18 Years and older ¬† (Adult, Older Adult)",218,212,201,85,101,15,11/17/2004,5/17/2005,3/23/2005,4/28/2005,4/8/2005,4/15/2005,4/22/2005,4/24/2005,5/13/2005,4/11/2009,5/7/2009,10/4/2009,1/1/2010,2/10/2010,4/4/2010,5/25/2010,7/23/2010,9/6/2010,10/25/2010,10/12/2005,4/10/2006,10/7/2006,4/5/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00871585,,,,,,
AstraZeneca,AstraZeneca,ST00410,SP00003,LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Frank T,James y,Suk T,John G,John G,Ngan D,Livia Pacheo †,Suzie K,Jene M,Christian G,Marcelina X,Terisa Sikora †,Dinah R,Stephan T,Remedios Z,Beulah N,Christian G,Stephan T,Lucie P,,,"Research Site, Chita, Russian Federation|Research Site, Irkutsk, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Khanty-Mansiysk, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, S-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Tula, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Vladivostok, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yaroslavl, Russian Federation",43.13870823,38.82483741,Female,"18 Years and older ¬† (Adult, Older Adult)",232,221,202,182,2,18,7/13/2011,11/29/2011,10/16/2011,11/9/2011,10/17/2011,10/27/2011,11/6/2011,11/10/2011,11/23/2011,3/8/2014,3/23/2014,9/6/2014,1/1/2015,2/26/2015,4/12/2015,5/20/2015,7/19/2015,9/1/2015,10/12/2015,4/24/2012,10/21/2012,4/19/2013,10/16/2013,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01561443,,,,,,
AstraZeneca,AstraZeneca,ST00412,SP00003,Study to Compare Zoladex‚Ñ¢ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Federico L,Geralyn K,Perter K,Mary H,Mary H,Mary H,Lyman W,Jene M,Aleta H,Jene M,Livia Pacheo †,Mac L,Perter K,Harry A,Tiffiny K,James y,Naren G,Anthony P,Dalton E,,,"Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Hubli, India|Research Site, Hyderabad, India|Research Site, Jaipur, India|Research Site, Mumbai, India|Research Site, Nagpur, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Pune, India|Research Site, Pune, India|Research Site, Thiruvananthapuram, India|Research Site, Amagasaki-shi, Japan|Research Site, Chiba, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hamamatsu, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kamogawa-shi, Japan|Research Site, Kitaadachi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Mitaka-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka, Japan|Research Site, Sakai-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Cebu City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Pasay City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Maharat Nakorn Ratchasima, Thailand|Research Site, Songkla, Thailand|Research Site, Ubonratchathani, Thailand",81.28297776,73.15467999,Female,"18 Years and older ¬† (Adult, Older Adult)",223,215,203,199,29,25,3/12/2009,8/21/2009,6/27/2009,7/15/2009,7/7/2009,7/10/2009,7/12/2009,7/13/2009,8/5/2009,1/4/2012,2/8/2012,6/18/2012,9/19/2012,11/2/2012,12/30/2012,2/1/2013,3/22/2013,5/7/2013,7/2/2013,1/6/2010,7/5/2010,1/1/2011,6/30/2011,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01073865,,,,,,
AstraZeneca,AstraZeneca,ST00416,SP00003,Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Time Perspective: Prospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Otis Thode †,John G,Mara A,Mary H,Chetan K,Lyman W,Harry A,Anthony P,Marcelina X,Marcelina X,Mee M,Tammara F,Dalton E,Ngan D,Federico L,Marceline R,Terisa Sikora †,Ross S,Clarice N,,,"Research Site, Vojvodina, Sremska Kamenica, Serbia|Research Site, Belgrade, Serbia",4.510790964,4.059711868,Female,"18 Years to 65 Years ¬† (Adult, Older Adult)",224,221,204,73,123,8,1/8/2008,5/24/2008,3/13/2008,4/23/2008,3/29/2008,4/9/2008,4/18/2008,4/20/2008,5/11/2008,7/25/2012,2/29/2012,6/26/2012,11/1/2012,12/30/2012,2/11/2013,3/29/2013,5/25/2013,7/2/2013,8/12/2013,10/6/2008,4/4/2009,10/1/2009,3/30/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01208779,,,,,,
AstraZeneca,AstraZeneca,ST00418,SP00003,C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population,,,,,Oncology,,,,,,Industry,"Active, not recruiting",,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Naren G,Otis Thode †,Kala R,Chetan K,Harry A,Stephan T,Ross S,Livia Pacheo †,Frank T,Chetan K,Selizabeth F,Corrine U,Lavina S,Chetan K,Terisa Sikora †,Xochitl D,Quentin N,Corrine U,Stephan T,,,"Research Site, Amberg, Germany|Research Site, Aschaffenburg, Germany|Research Site, Augsburg, Germany|Research Site, Bad Homburg, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Bottrop, Germany|Research Site, Brandenburg an der Havel, Germany|Research Site, Braunschweig, Germany|Research Site, Bremen, Germany|Research Site, Chemnitz, Germany|Research Site, Coburg, Germany|Research Site, Donauwoerth, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Duesseldorf, Germany|Research Site, Duisburg, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Esslingen am Neckar, Germany|Research Site, Eutin, Germany|Research Site, Frankfurt, Germany|Research Site, Freiburg im Breisgau, Germany|Research Site, Fuerstenwalde, Germany|Research Site, Georgsmarienhuette, Germany|Research Site, Halle (Saale), Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Heidenheim an der Brenz, Germany|Research Site, Hildesheim, Germany|Research Site, Homburg/Saar, Germany|Research Site, Jena, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Kempten, Germany|Research Site, Kiel, Germany|Research Site, Koeln, Germany|Research Site, Krefeld, Germany|Research Site, Kulmbach, Germany|Research Site, Landshut, Germany|Research Site, Luebeck, Germany|Research Site, Mainz, Germany|Research Site, Mannheim, Germany|Research Site, Moenchengladbach, Germany|Research Site, Muenchen, Germany|Research Site, Muenster, Germany|Research Site, Mutlangen, Germany|Research Site, Nuernberg, Germany|Research Site, Oberhausen, Germany|Research Site, Osnabrueck, Germany|Research Site, Paderborn, Germany|Research Site, Plauen, Germany|Research Site, Regensburg, Germany|Research Site, Rosenheim, Germany|Research Site, Rostock, Germany|Research Site, Saarbruecken, Germany|Research Site, Schwerin, Germany|Research Site, Singen, Germany|Research Site, Solingen, Germany|Research Site, Stralsund, Germany|Research Site, Stuttgart, Germany|Research Site, Traunstein, Germany|Research Site, Troisdorf, Germany|Research Site, Tuebingen, Germany|Research Site, Wiesbaden, Germany|Research Site, Wolfsburg, Germany|Research Site, Wuerzburg, Germany",63.48850207,57.13965186,Female,"45 Years to 85 Years ¬† (Adult, Older Adult)",227,221,205,113,71,21,7/16/2020,1/25/2021,12/12/2020,12/29/2020,11/25/2020,12/18/2020,12/28/2020,1/2/2021,1/24/2021,1/5/2022,5/3/2022,11/19/2022,12/31/2022,2/10/2023,4/1/2023,5/17/2023,6/19/2023,8/13/2023,10/2/2023,6/16/2021,12/13/2021,6/11/2022,12/8/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02503436,,,,,,
AstraZeneca,AstraZeneca,ST00419,SP00003,Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA),,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Mary H,Harry A,Lilla Stilson †,Mara A,Marceline R,Chetan K,Stephan T,Perter K,Chetan K,Xochitl D,Christian G,Doreen T,Ngan D,Clarice N,Tamesha T,Harry A,Selizabeth F,Remedios Z,Harry A,,,"Research Site, Phoenix, Arizona, United States|Research Site, La Jolla, California, United States|Research Site, Orange, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Bronx, New York, United States|Research Site, Lake Success, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Spring, Texas, United States|Research Site, Barretos, Brazil|Research Site, Fortaleza, Brazil|Research Site, Londrina, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, S√£o Jos√© do Rio Preto, Brazil|Research Site, S√£o Paulo, Brazil|Research Site, Antofagasta, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Temuco, Chile|Research Site, Vi√±a del Mar, Chile|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Hefei, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenyang, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gy≈ër, Hungary|Research Site, Kaposv√°r, Hungary|Research Site, Szeged, Hungary|Research Site, Ahmedabad, India|Research Site, Coimbatore, India|Research Site, Gurgaon, India|Research Site, Madurai, India|Research Site, Mumbai, India|Research Site, Nagpur, India|Research Site, Nasik, India|Research Site, New Delhi, India|Research Site, Vishakhapatnam, India|Research Site, Fukuoka-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Kyoto-shi, Japan|Research Site, Nakazu-gun, Japan|Research Site, Osaka-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Toon-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Alc. Cuauht√©moc, Mexico|Research Site, Deleg. Tlalpan, Mexico|Research Site, Guadalajara Jalisco, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, M√©rida, Mexico|Research Site, San Luis Potos√≠, Mexico|Research Site, Veracruz, Mexico|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Baguio City, Philippines|Research Site, Cebu, Philippines|Research Site, Iloilo, Philippines|Research Site, Makati, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Bialystok, Poland|Research Site, Gda≈Ñsk, Poland|Research Site, Gliwice, Poland|Research Site, Lublin, Poland|Research Site, ≈Å√≥d≈∫, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Johannesburg, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan",45.02233721,40.52010349,Female,"18 Years and older ¬† (Adult, Older Adult)",219,215,206,147,39,20,9/14/2017,4/26/2018,2/17/2018,3/21/2018,2/20/2018,3/4/2018,3/14/2018,3/18/2018,3/25/2018,11/16/2021,4/9/2022,9/5/2022,10/27/2022,12/11/2022,2/2/2023,3/23/2023,5/2/2023,6/27/2023,7/28/2023,8/31/2018,2/27/2019,8/26/2019,2/22/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03830866,,,,,,
AstraZeneca,AstraZeneca,ST00422,SP00003,Bicalutamide (Casodex‚Ñ¢) Versus Placebo in Patients With Early Prostate Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,,,,Drug G,,,,,,,,,,,,,,,,,,,Frank T,Otis Thode †,Chetan K,Chetan K,Patria R,Remedios Z,Lavina S,Gertrudis T,Mac L,Lyman W,Liberty A,Louann C,Federico L,Terisa Sikora †,Mary H,Chetan K,Rima Y ,Kala R,John G,,,"Research Site, Birmingham, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Berkeley, California, United States|Research Site, Laguna Woods, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Monica, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Torrance, California, United States|Research Site, Van Nuys, California, United States|Research Site, Denver, Colorado, United States|Research Site, Middlebury, Connecticut, United States|Research Site, New Haven, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Aventura, Florida, United States|Research Site, Bay Pines, Florida, United States|Research Site, Boca Raton, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, St. Augustine, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Greenwood, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Greenbelt, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Burlington, Massachusetts, United States|Research Site, Newtown, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, Jackson, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, Manhasset, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Cordova, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Danville, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Cheyenne, Wyoming, United States|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada",29.8867086,26.89803774,Male,"45 Years to 95 Years ¬† (Adult, Older Adult)",222,218,207,179,4,24,8/5/2006,2/13/2007,11/15/2006,12/31/2006,11/22/2006,12/15/2006,12/28/2006,1/2/2007,1/15/2007,7/11/2007,11/25/2007,3/8/2008,7/1/2008,8/6/2008,9/24/2008,10/24/2008,11/23/2008,1/4/2009,2/3/2009,6/13/2007,12/10/2007,6/7/2008,12/4/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00657904,,,,,,
AstraZeneca,AstraZeneca,ST00423,SP00003,Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment,,,,,Oncology,,,,,,Industry,Recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,In Bellini †,Dalton E,Lavina S,Lavina S,Lavina S,Garnet T,Beulah N,Perter K,Quentin N,Remedios Z,Louann C,Hee Y,Selizabeth F,Tien C,Naren G,James y,Tammara F,Marceline R,Mara A,,,"Research Site, Wilmington, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Utrecht, Netherlands|Research Site, London, United Kingdom",72.87763644,65.5898728,All,"50 Years to 70 Years ¬† (Adult, Older Adult)",234,223,208,155,37,16,1/26/2021,7/22/2021,6/15/2021,7/8/2021,6/10/2021,6/20/2021,6/24/2021,6/27/2021,7/21/2021,6/8/2024,2/14/2024,5/19/2024,9/1/2024,10/13/2024,11/30/2024,1/6/2025,3/6/2025,4/22/2025,5/28/2025,12/17/2021,6/15/2022,12/12/2022,6/10/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02695121,,,,,,
AstraZeneca,AstraZeneca,ST00425,SP00003,(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,,,,Drug H,,,,,,,,,,,,,,,,,,,John G,Tien C,Mac L,Remedios Z,Mac L,Doreen T,Federico L,Remedios Z,Anthony P,Tammara F,Christian G,Geralyn K,Tammara F,Clarice N,Lavina S,Mary H,Garnet T,Xochitl D,Patria R,,,"Research Site, Wooloongabba, Queensland, Australia|Research Site, East Melbourne, Victoria, Australia|Research Site, Graz, Austria|Research Site, Linz, Austria|Research Site, Mistelbach, Austria|Research Site, Oberwart, Austria|Research Site, St. Polten, Austria|Research Site, Antwerpen, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Mons, Belgium|Research Site, Oostende, Belgium|Research Site, Seraing, Belgium|Research Site, Brno, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Dresden, Germany|Research Site, Freiburg, Germany|Research Site, Heidelberg, Germany|Research Site, Jena, Germany|Research Site, Lubeck, Germany|Research Site, Ludenscheid, Germany|Research Site, Mannheim, Germany|Research Site, Munchen, Germany|Research Site, Regensburg, Germany|Research Site, Sigmaringen, Germany|Research Site, Budapest, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Dublin 4, Ireland|Research Site, Dublin 7, Ireland|Research Site, Haifa, Israel|Research Site, Petach Tikva, Israel|Research Site, Tel-aviv, Israel|Research Site, Tel-hashomer, Israel|Research Site, Bari, BA, Italy|Research Site, Bergamo, BG, Italy|Research Site, Belluno, BL, Italy|Research Site, Bologna, BO, Italy|Research Site, Brescia, BS, Italy|Research Site, Como, CO, Italy|Research Site, Cesena, FO, Italy|Research Site, Anagni, FR, Italy|Research Site, Carpi, MO, Italy|Research Site, Fidenza, PR, Italy|Research Site, Siena, SI, Italy|Research Site, Torino, TO, Italy|Research Site, Treviso, TV, Italy|Research Site, Udine, UD, Italy|Research Site, Varese, VA, Italy|Research Site, Dolo, VE, Italy|Research Site, Portogruaro, VE, Italy|Research Site, Roma, Italy|Research Site, Mexico, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Breda, Netherlands|Research Site, Capelle A/d Ijssel, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Enschede, Netherlands|Research Site, Gouda, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Roosendaal, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Spijkenisse, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Almada, Portugal|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Vila Nova de Gaia, Portugal|Research Site, Somerset West, Cape Town, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, George, South Africa|Research Site, Johannesburg, South Africa|Research Site, Pietermarizberg, South Africa|Research Site, Pretoria, South Africa|Research Site, Granada, Andalucia, Spain|Research Site, Malaga, Andalucia, Spain|Research Site, Sevilla, Andalucia, Spain|Research Site, Oviedo, Asturias, Spain|Research Site, Guadalajara, Castilla La Mancha, Spain|Research Site, Salamanca, Castilla Leon, Spain|Research Site, Badalona(barcelona), Cataluna, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Hospitalet de Llobregat(barcel, Cataluna, Spain|Research Site, Alcala de Henares, Comunidad de Madrid, Spain|Research Site, Getafe, Comunidad de Madrid, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, San Juan(alicante), Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A Coruna, Galicia, Spain|Research Site, Vigo(pontevedra), Galicia, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Bilbao, Pais Vasco, Spain|Research Site, Reading, Berkshire, United Kingdom|Research Site, Colchester, Essex, United Kingdom|Research Site, Barnet, Hertfordshire, United Kingdom|Research Site, Tooting, London, United Kingdom|Research Site, Belfast, Northern Ireland, United Kingdom|Research Site, Taunton, Somerset, United Kingdom|Research Site, Gwent, South Wales, United Kingdom|Research Site, Eastbourne, Sussex, United Kingdom|Research Site, Birmingham, West Midlands, United Kingdom|Research Site, Bolton, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Cleveland, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Falkirk, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Kent, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Shrewsbury, United Kingdom",9.310682282,8.379614053,Male,"18 Years and older ¬† (Adult, Older Adult)",228,220,209,150,30,29,12/5/2003,7/27/2004,5/1/2004,6/14/2004,5/21/2004,5/29/2004,6/5/2004,6/7/2004,6/16/2004,11/14/2007,10/29/2007,6/5/2008,8/1/2008,9/5/2008,10/6/2008,11/18/2008,12/22/2008,2/14/2009,3/22/2009,11/25/2004,5/24/2005,11/20/2005,5/19/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00673205,,,,,,
AstraZeneca,AstraZeneca,ST00426,SP00003,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,,,,Drug H,,,,,,,,,,,,,,,,,,,Lavina S,Jeanene Y,John G,Tien C,Mara A,Dinah R,John G,Naren G,Donovan H,Mary H,Marcelina X,Jene M,Mac L,Xochitl D,Geralyn K,Suk T,Suzie K,Naren G,Tien C,,,"Research Site, Tucson, Arizona, United States|Research Site, Greenbrae, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Denver, Colorado, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boca Raton, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Port St. Lucie, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Kansas City, Kansas, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Brooklyn, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Mystle Beach, South Carolina, United States|Research Site, Raleigh, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Seattle, Washington, United States|Research Site, Wenatchee, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Santa Fe, Argentina|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Hornsby, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Wollongong, New South Wales, Australia|Research Site, Wodonga, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Sydney, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Wels, Austria|Research Site, (Wilrijk) Antwerpen, Belgium|Research Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Goiania, Goias, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Curitiba, Parana, Brazil|Research Site, Londrina, PR, Brazil|Research Site, Porto Alegre, Rio Grande do Sul, Brazil|Research Site, Rio de Janeiro, RJ, Brazil|Research Site, Santo Andre, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Greenfeild Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Point-Claire, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, La Serena, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Vina del Mar, Chile|Research Site, Nanjing, Jiangsu, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Chongqing, China|Research Site, Guangzhou City, China|Research Site, Hubei, China|Research Site, Jiangsu, China|Research Site, Shanghai, China|Research Site, Shanxi, China|Research Site, Tianjin, China|Research Site, Zejiang, China|Research Site, Bogota, Colombia|Research Site, Medellin, Colombia|Research Site, Brno, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Jablonec nad Nisou, Czech Republic|Research Site, Kromeriz, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Prague 2, Czech Republic|Research Site, Prague 4, Czech Republic|Research Site, Prague 6, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Aalborg, Denmark|Research Site, Frederiksberg, Denmark|Research Site, Herlev, Denmark|Research Site, Holstebro, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Odense, Denmark|Research Site, Roskilde, Denmark|Research Site, Helsinki, Finland|Research Site, Joensuu, Finland|Research Site, Oulu, Finland|Research Site, Seinajoki, Finland|Research Site, Tampere, Finland|Research Site, Caen cedex, France|Research Site, Creteil, France|Research Site, Lille, France|Research Site, Lyon cedex 03, France|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Orleans Cedex, France|Research Site, Paris, France|Research Site, Pierre Benite cedex, France|Research Site, Poitiers Cedex, France|Research Site, Reims cedex, France|Research Site, Reims, France|Research Site, Rennes cedex 9, France|Research Site, Rouen, France|Research Site, Suresnes, France|Research Site, Toulouse, France|Research Site, Vandoeuvre-les-Nancy cedex, France|Research Site, Villejuif, France|Research Site, Augsburg, Germany|Research Site, Bad Ems, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Borken, Germany|Research Site, Chemnitz, Germany|Research Site, Emmendingen, Germany|Research Site, Fuerth, Germany|Research Site, Gelsenkirchen-Buer, Germany|Research Site, Germering, Germany|Research Site, Goettingen, Germany|Research Site, Holzminden, Germany|Research Site, Kirchheim/Teck, Germany|Research Site, Leipzig, Germany|Research Site, Lubeck, Germany|Research Site, Mannheim, Germany|Research Site, Muehlacker, Germany|Research Site, Muehlheim an der Ruhr, Germany|Research Site, Muenchen-Planegg, Germany|Research Site, Muenchen, Germany|Research Site, Muenster, Germany|Research Site, Reutlingen, Germany|Research Site, Rostock, Germany|Research Site, Tuebingen, Germany|Research Site, Waltshut-Tiengen, Germany|Research Site, Wuppertal, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Ahmedabad, Gujarat, India|Research Site, Nadiad, Gujarat, India|Research Site, Kochi, Kerala, India|Research Site, Pune, Maharashtra, India|Research Site, Chennai, Tamil Nadu, India, India|Research Site, Lucknow, Uttar Pradesh, India|Research Site, Kolkota, West Bengal, India|Research Site, New Delhi, India|Research Site, Dublin 7, Ireland|Research Site, Dublin 8, Ireland|Research Site, Dublin, Ireland|Research Site, Be'er Sheva, Israel|Research Site, Be'er-Ya'akov, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jeruslaem, Israel|Research Site, Petah-Tikva, Israel|Research Site, Tel-HaShomer - Ramat Gan, Israel|Research Site, Ancona, Italy|Research Site, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Catania, Italy|Research Site, Como, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Pisa, Italy|Research Site, Rome, Italy|Research Site, Terni, Italy|Research Site, Varese, Italy|Research Site, Hirosaki-City, Aomori, Japan|Research Site, Chiba-City, Chiba, Japan|Research Site, Narashino-city, Chiba, Japan|Research Site, Matsuyama-City, Ehime, Japan|Research Site, Fukuoka-City, Fukuoka, Japan|Research Site, Maebashi-City, Gunma, Japan|Research Site, Otake-City, Hiroshima, Japan|Research Site, Sapporo-City, Hokkaido, Japan|Research Site, Kobe-City, Hyogo, Japan|Research Site, Ibaraki-machi, Ibaraki, Japan|Research Site, Mito-City, Ibaraki, Japan|Research Site, Tsukuba-City, Ibaraki, Japan|Research Site, Kita-gun, Kagawa, Japan|Research Site, Sagamihara-City, Kanagawa, Japan|Research Site, Kamigyo-ku, Kyoto, Japan|Research Site, Kyoto-City, Kyoto, Japan|Research Site, Sendai-City, Miyagi, Japan|Research Site, Ueda-City, Nagano, Japan|Research Site, Kashihara, Nara, Japan|Research Site, Oita-City, Oita, Japan|Research Site, Kurashiki, Okayama, Japan|Research Site, Osaka-City, Osaka, Japan|Research Site, Osaka-Sayama-City, Osaka, Japan|Research Site, Suita-City, Osaka, Japan|Research Site, Wako-City, Saitama, Japan|Research Site, Hamamatsu-city, Shizuoka, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Fuchu_city, Tokyo, Japan|Research Site, Itabashi-Ku, Tokyo, Japan|Research Site, Meguro-ku, Tokyo, Japan|Research Site, Minato-Ku, Tokyo, Japan|Research Site, Mitaka-City, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Kyoto, Japan|Research Site, Nagasaki, Japan|Research Site, Bundang-Gu, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Seo-gu, Pusan, Korea, Republic of|Research Site, Gangnam-gu, Seoul, Korea, Republic of|Research Site, Seodaemun-gu, Seoul, Korea, Republic of|Research Site, Seongbuk-gu, Seoul, Korea, Republic of|Research Site, Songpa-gu, Seoul, Korea, Republic of|Research Site, Liepaja, Latvia|Research Site, Riga, Latvia|Research Site, Distrito Federal, Ciudad de Mexico, Mexico|Research Site, Mexico DF, Distrito Federal, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Hertogenbosch, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Tonsberg, Norway|Research Site, Trondheim, Norway|Research Site, Arequipa, Peru|Research Site, Bellavista, Peru|Research Site, Jesus Maria, Peru|Research Site, Lima, Peru|Research Site, Gdynia, Poland|Research Site, Kielce, Poland|Research Site, Koscierzyna, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Coimbra, Portugal|Research Site, Porto, Portugal|Research Site, Timisoara, Timis, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Omsk, Omsk region, Russian Federation|Research Site, Izhevsk, Russia, Russian Federation|Research Site, Tomsk, Tomsk Region, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Nis, Serbia|Research Site, Novi Sad, Serbia|Research Site, Observatory, Cape Town, South Africa|Research Site, Tygerberg, Cape Town, South Africa|Research Site, Overport, Durban, South Africa|Research Site, Parktown, Johannesburg, South Africa|Research Site, Pietermaritzburg, South Africa|Research Site, Pretoria, South Africa|Research Site, Elche, Alicante, Spain|Research Site, Barakaldo, Bizkaia, Spain|Research Site, Bilbao, Vizcaya, Spain|Research Site, A Corunna, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Gothenburg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Jonkoping, Sweden|Research Site, Orebro, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Aarau, Switzerland|Research Site, CH-4031 Basel, Switzerland|Research Site, Locarno, Switzerland|Research Site, Zuerich, Switzerland|Research Site, Taipei, Taiwan|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Reading, Berkshire, United Kingdom|Research Site, Cottingham, East Yorkshire, United Kingdom|Research Site, Stevenage, Hertfordshire, United Kingdom|Research Site, Maidstone, Kent, United Kingdom|Research Site, Guildford, Surrey, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Huddersfield, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom",47.89696935,43.10727242,Male,"18 Years to 120 Years ¬† (Adult, Older Adult)",228,221,210,182,3,25,9/13/2006,4/2/2007,2/5/2007,2/15/2007,2/7/2007,2/10/2007,2/18/2007,2/19/2007,3/13/2007,8/1/2010,5/22/2010,10/24/2010,1/1/2011,2/21/2011,4/16/2011,6/9/2011,7/17/2011,8/29/2011,10/2/2011,8/9/2007,2/5/2008,8/3/2008,1/30/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00626548,,,,,,
AstraZeneca,AstraZeneca,ST00428,SP00003,Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Lavina S,Suzie K,Lucie P,Tien C,Federico L,Jene M,Liberty A,Suk T,Clarice N,Frank T,Lucie P,Tamesha T,Stephan T,Terisa Sikora †,Donovan H,Gertrudis T,Kala R,Harry A,In Bellini †,,,"Nagoya City University Hospital, Nagoya, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan|Hirosaki University Hospital, Hirosaki, Aomori, Japan|Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan|Ehime University Hospital, Toon, Ehime, Japan|National Hospital Organization Kure Medical Center, Kure, Hiroshima, Japan|Hakodate Goryoukaku Hospital, Hakodate, Hokkaido, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Kobe University Hospital, Kobe, Hyogo, Japan|University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kagawa University Hospital, Miki, Kagawa, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, Japan|Nara Medical University Hospital, Kashihara, Nara, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Saitama Medical Center, Kawagoe, Saitama, Japan|Tottori University Hospital, Yonago, Tottori, Japan|Yamaguchi University Hospital, Ube, Yamaguchi, Japan|Chiba University Hospital, Chiba, Japan|Gifu University Hospital, Gifu, Japan|Kyoto Prefectural University of Medicine, Kyoto, Japan|University of Miyazaki Hospital, Miyazaki, Japan|Okayama University Hospital, Okayama, Japan",70.97065982,63.87359384,Male,"50 Years to 74 Years ¬† (Adult, Older Adult)",232,221,211,155,32,24,10/10/2017,3/10/2018,12/27/2017,2/7/2018,1/7/2018,1/23/2018,1/31/2018,2/2/2018,2/26/2018,5/1/2020,3/23/2020,10/30/2020,12/18/2020,1/26/2021,3/26/2021,5/24/2021,7/10/2021,8/15/2021,9/17/2021,7/22/2018,1/18/2019,7/17/2019,1/13/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04425200,,,,,,
AstraZeneca,AstraZeneca,ST00434,SP00003,Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Mee M,Mee M,Chetan K,Jaquelyn H,Remedios Z,Selizabeth F,Perter K,Chetan K,Christian G,Geralyn K,Selizabeth F,Jene M,Frank T,Perter K,Naren G,Garnet T,Tamesha T,Terisa Sikora †,Perter K,,,"Research Site, Basel, Switzerland|Research Site, Bern, Switzerland",13.35479945,12.0193195,All,"18 Years and older ¬† (Adult, Older Adult)",224,221,212,79,119,14,7/24/2007,1/27/2008,11/16/2007,12/20/2007,11/25/2007,12/15/2007,12/24/2007,12/27/2007,1/10/2008,4/18/2009,1/1/2009,7/20/2009,10/1/2009,11/5/2009,12/14/2009,2/1/2010,3/13/2010,5/6/2010,6/25/2010,6/12/2008,12/9/2008,6/7/2009,12/4/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00681967,,,,,,
AstraZeneca,AstraZeneca,ST00436,SP00003,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,,,,Drug H,,,,,,,,,,,,,,,,,,,Jene M,Doreen T,Marcelina X,Selizabeth F,Kandace p,Geralyn K,Geralyn K,Gertrudis T,Christian G,Donovan H,Stephan T,Gertrudis T,Doreen T,Patria R,Dinah R,Selizabeth F,Otis Thode †,Anthony P,Garnet T,,,"Research Site, Greenbrae, California, United States|Research Site, San Diego, California, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Myers, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, PORTUGALt St. Lucie, Florida, United States|Research Site, Rockville, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Santa Fe, Argentina|Research Site, Darlinghurst, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Wollongong, New South Wales, Australia|Research Site, Redcliffe, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Wodonga, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Subiaco, Western Australia, Australia|Research Site, Fortaleza, Ceara/ LA, Brazil|Research Site, Goiania, Goias/ LA, Brazil|Research Site, Goiania, Goias, Brazil|Research Site, Belo Horizonte, Minas GERMANYais, Brazil|Research Site, Curitiba, Parana/ Brazil, Brazil|Research Site, Londrina, PR, Brazil|Research Site, PORTUGALto Alegre, Rio Grande do Sul/ LA, Brazil|Research Site, Rio de Janeiro, RJ, Brazil|Research Site, Ribeirao Preto, Sao Paulo/ LA, Brazil|Research Site, Santo Andre, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Winnipeg, Manitoba, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Brno, CZECHOSLOVAKIA Republic, Czech Republic|Research Site, Jablonec nad Nisou, Czech Republic|Research Site, Kromeriz, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Prague 2, Czech Republic|Research Site, Prague 6, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Helsinki, Finland|Research Site, Joensuu, Finland|Research Site, Seinajoki, Finland|Research Site, La Roche sur Yon, FRANCEnce, France|Research Site, Marseille, FRANCEnce, France|Research Site, Paris, FRANCEnce, France|Research Site, Reims, FRANCEnce, France|Research Site, Villejuif, FRANCEnce, France|Research Site, Paris, France|Research Site, Saint Herblain, France|Research Site, Hannover, GERMANYmany, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Dresden, Germany|Research Site, Emmendingen, Germany|Research Site, Kirchheim-Teck, Germany|Research Site, Leipzig, Germany|Research Site, Luebeck, Germany|Research Site, Muenster, Germany|Research Site, Tuebingen, Germany|Research Site, Wuppertal, Germany|Research Site, Budapest, HUNGARYary, Hungary|Research Site, Gyor, HUNGARYary, Hungary|Research Site, Miskolc, HUNGARYary, Hungary|Research Site, Ny Regyh Za, HUNGARYary, Hungary|Research Site, Szeged, HUNGARYary, Hungary|Research Site, Bangalore, Karnataka, India|Research Site, Trivandrum, Kerala, India|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Pune, Maharashtra, India|Research Site, Bikaner, Rajasthan, India|Research Site, Jaipur, Rajasthan, India|Research Site, Vellore, Tamil Nadu, India|Research Site, Kolkata, West Bengal, India|Research Site, Kolkota, West Bengal, India|Research Site, Delhi, India|Research Site, New Delhi, India|Research Site, Genoa, Italy|Research Site, Lugo (RA), Italy|Research Site, Rome, Italy|Research Site, Cheongju, Chungbuk, Korea, Republic of|Research Site, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Nowon-gu, Seoul, Korea, Republic of|Research Site, Seodaemun-gu, Seoul, Korea, Republic of|Research Site, Songpa-gu, Seoul, Korea, Republic of|Research Site, Nijmegen, Netherlands|Research Site, Cercado de Arequipa, Arequipa, Peru|Research Site, Cercado, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Lublin, POLANDand, Poland|Research Site, Swidnica, POLANDand, Poland|Research Site, Warszaa, POLANDand, Poland|Research Site, Koscierzyna, Poland|Research Site, Wroclaw, Poland|Research Site, Coimbra, PORTUGALtugal, Portugal|Research Site, PORTUGALto, PORTUGALtugal, Portugal|Research Site, Bucharest, Romania|Research Site, Sibiu, Romania|Research Site, Timisoara, Romania|Research Site, Barnaul, RUSSIAsia, Russian Federation|Research Site, Izhevsk, RUSSIAsia, Russian Federation|Research Site, Kursk, RUSSIAsia, Russian Federation|Research Site, Sochi, RUSSIAsia, Russian Federation|Research Site, Voronezh, RUSSIAsia, Russian Federation|Research Site, Belgrade, SERBIAbia, Serbia|Research Site, Beograd, SERBIAbia, Serbia|Research Site, Nis, SERBIAbia, Serbia|Research Site, Panorama, Cape Town, South Africa|Research Site, TyGERberg, Cape Town, South Africa|Research Site, Overport, Durban, South Africa|Research Site, Bloemfontein, South Africa|Research Site, PORt Elizabeth, South Africa|Research Site, Madrid, Spain|Research Site, Valencia, Spain|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Aarau, Switzerland|Research Site, Locarno, Switzerland|Research Site, Sursee, Switzerland|Research Site, Kaohsiung, TAIWANwan, Taiwan|Research Site, TAIWANpei, TAIWANwan, Taiwan|Research Site, Reading, Berkshire, United Kingdom|Research Site, Westgate Road, Newcastle Upon Tyne, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",75.10796654,67.59716988,Male,"45 Years to 75 Years ¬† (Adult, Older Adult)",232,225,213,142,49,22,8/4/2007,1/9/2008,11/6/2007,11/30/2007,11/17/2007,11/25/2007,12/8/2007,12/12/2007,12/19/2007,10/11/2010,8/16/2010,1/17/2011,5/1/2011,6/2/2011,7/25/2011,9/10/2011,10/31/2011,12/30/2011,2/4/2012,5/23/2008,11/19/2008,5/18/2009,11/14/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00617669,,,,,,
AstraZeneca,AstraZeneca,ST00440,SP00003,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug I,,,,,,,,,,,,,,,,,,,Ross S,Chetan K,In Bellini †,Lyman W,Kala R,Quentin N,Geralyn K,Hee Y,Kala R,Dinah R,Ngan D,Anthony P,Marceline R,Perter K,Federico L,Perter K,Hee Y,Xochitl D,Jerold Goo †,,,"Research Site, Tucson, Arizona, United States|Research Site, Greenbrae, California, United States|Research Site, Los Angeles, California, United States|Research Site, Palm Springs, California, United States|Research Site, San Mateo, California, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Gainsville, Florida, United States|Research Site, Port St.Lucie, Florida, United States|Research Site, Des Moines, Iowa, United States|Research Site, Canton, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Norfolk, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Wheeling, West Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Buenos Aires, Buenos Aires Province, Argentina|Research Site, Santa Fe, Santa Fe Province, Argentina|Research Site, Hornsby, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Redcliffe, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Subiaco, Western Australia, Australia|Research Site, Graz, Austria|Research Site, Wels, Austria|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Fortaleza, Ceara, Brazil|Research Site, Goiania, Goias, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Curitiba, Parana, Brazil|Research Site, Porto Alegre, Rio Grande do Sul, Brazil|Research Site, Ribeirao Preto, Sao Paulo, Brazil|Research Site, Santo Andre, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Kentville, Nova Scotia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Granby, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Point-Claire, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Haidian District, Beijing, China|Research Site, Xi Cheng District, Beijing, China|Research Site, Xicheng District, Beijing, China|Research Site, Wuhan, Hubei, China|Research Site, Nanjing, Jiangsu, China|Research Site, Pudong New Area, Shanghai, China|Research Site, Shanghai, Shanghai, China|Research Site, Xuhui District, Shanghai, China|Research Site, Xi'an, Shanxi, China|Research Site, Prague 4, Prague, Czech Republic|Research Site, Prague 6, Prague, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Aalborg, Denmark|Research Site, Aarhus, Denmark|Research Site, Herlev, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Joensuu, Finland|Research Site, Kajaanintie, Finland|Research Site, Tampere, Finland|Research Site, Montpellier, France|Research Site, Paris, France|Research Site, Poitiers Cedex, France|Research Site, Suresnes, France|Research Site, Toulouse, France|Research Site, Villejuif, France|Research Site, Planegg, Muenchen, Germany|Research Site, Kirchheim, Teck, Germany|Research Site, Augsburg, Germany|Research Site, Bad Gegeberg, Germany|Research Site, Berlin, Germany|Research Site, Emmendingen, Germany|Research Site, Leipzig, Germany|Research Site, Luebeck, Germany|Research Site, Mannheim, Germany|Research Site, Muenchen, Germany|Research Site, Reutlingen, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Tuen Mun, Hong Kong|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Rohini, Delhi, India|Research Site, Trivandrum, Kerala, India|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Mumbai, Maharashtra, India|Research Site, Chandigarh, Punjab, India|Research Site, Ludhiana, Punjab, India|Research Site, Bikaner, Rajasthan, India|Research Site, Jaipur, Rajasthan, India|Research Site, Kolkota, West Bengal, India|Research Site, Gujarat, India|Research Site, New Delhi, India|Research Site, Milan, Italy|Research Site, Rome, Italy|Research Site, Asahi-City, Chiba, Japan|Research Site, Chiba-City, Chiba, Japan|Research Site, Narashino-city, Chiba, Japan|Research Site, Matsuyama-City, Ehime, Japan|Research Site, Fukuoka-City, Fukuoka, Japan|Research Site, Maebashi-City, Gunma, Japan|Research Site, Otake-City, Hiroshima, Japan|Research Site, Sapporo-City, Hokkaido, Japan|Research Site, Kobe-City, Hyogo, Japan|Research Site, Tsukuba-City, Ibaraki, Japan|Research Site, Kita-gun, Kagawa, Japan|Research Site, Sagamihara-City, Kanagawa, Japan|Research Site, Kyoto-City, Kyoto, Japan|Research Site, Sendai-City, Miyagi, Japan|Research Site, Oita-City, Oita, Japan|Research Site, Osaka-City, Osaka, Japan|Research Site, Osaka-Sayama-City, Osaka, Japan|Research Site, Suita-City, Osaka, Japan|Research Site, Wako-City, Saitama, Japan|Research Site, Hamamatsu-city, Shizuoka, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Fuchu_city, Tokyo, Japan|Research Site, Itabashi-Ku, Tokyo, Japan|Research Site, Meguro-ku, Tokyo, Japan|Research Site, Mitaka-City, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Nagasaki, Japan|Research Site, Heungduk-gu Cheongju, Chungbuk, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Seo-gu, Pusan, Korea, Republic of|Research Site, Gangnam-gu, Seoul, Korea, Republic of|Research Site, Songpa-gu, Seoul, Korea, Republic of|Research Site, Metepec, Estado de Mexico, Mexico|Research Site, Distrito Federal Ciudad, Mexico|Research Site, Mexico City, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Groningen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Bialystok, Poland|Research Site, Koscierzyna, Poland|Research Site, Krakow, Poland|Research Site, Rzeszow, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Stary Oskol, Belgorodskaya region, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, St. Petersgurg, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Nis, Serbia|Research Site, Novi Sad, Serbia|Research Site, Singapore, Singapore|Research Site, Tygerberg, Cape Town, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Pietermaritzburg, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Goteborg, Sweden|Research Site, Gothenburg, Sweden|Research Site, Stockholm, Sweden|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Locarno, Switzerland|Research Site, Sursee, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Reading, Berkshire, United Kingdom|Research Site, Cambridge, Cambridgeshire, United Kingdom|Research Site, Maidstone, Kent, United Kingdom|Research Site, Huddersfield, Yorkshire, United Kingdom|Research Site, London, United Kingdom",45.98965906,41.39069315,Male,"Child, Adult, Older Adult",222,219,214,100,103,11,11/29/2006,5/18/2007,2/26/2007,4/9/2007,3/15/2007,3/26/2007,4/7/2007,4/8/2007,4/29/2007,10/17/2009,12/9/2009,5/2/2010,7/1/2010,8/21/2010,9/24/2010,11/6/2010,1/2/2011,2/6/2011,3/9/2011,9/22/2007,3/20/2008,9/16/2008,3/15/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00554229,,,,,,
AstraZeneca,AstraZeneca,ST00442,SP00003,A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer,,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Liberty A,Chetan K,John G,Terrell p,John G,Suzie K,Tien C,Tiffiny K,Donovan H,Gertrudis T,Kandace p,Suk T,Livia Pacheo †,Chetan K,Selizabeth F,Rima Y ,Naren G,Terisa Sikora †,Donovan H,,,"Research Site, Goodyear, Arizona, United States|Research Site, Santa Rosa, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Port Saint Lucie, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Waterloo, Iowa, United States|Research Site, Topeka, Kansas, United States|Research Site, Bethesda, Maryland, United States|Research Site, Burlington, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Saint Louis Park, Minnesota, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Middleton, Ohio, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Fort Worth, Texas, United States|Research Site, Spokane, Washington, United States|Research Site, Wenatchee, Washington, United States|Research Site, Wien, Austria|Research Site, Brussel, Belgium|Research Site, Gent, Belgium|Research Site, Gilly, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Li√®ge, Belgium|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Brno, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 8, Czechia|Research Site, Praha, Czechia|Research Site, Bordeaux Cedex, France|Research Site, Brest Cedex, France|Research Site, Creteil, France|Research Site, Dijon, France|Research Site, Le Mans Cedex 02, France|Research Site, Marseille, France|Research Site, Pessac, France|Research Site, Rennes Cedex 09, France|Research Site, Saint Herblain Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Borstel, Germany|Research Site, Dortmund, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Freiburg, Germany|Research Site, Gro√ühansdorf, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, K√∂ln, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gy≈ër, Hungary|Research Site, Szolnok, Hungary|Research Site, Tatabanya, Hungary|Research Site, Torokbalint, Hungary|Research Site, Candiolo, Italy|Research Site, Catania, Italy|Research Site, Milano, Italy|Research Site, Monza, Italy|Research Site, Orbassano, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Akashi-shi, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Habikino-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Hirakata-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Kobe-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Kurume-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Natori-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama, Japan|Research Site, Sakai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Ube-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Goyang-si, Korea, Republic of|Research Site, Hwasun-gun, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Cebu City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Gda≈Ñsk, Poland|Research Site, Warszawa, Poland|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Barcelona, Spain|Research Site, Gerona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, M√°laga, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Hat Yai, Thailand|Research Site, Muang, Thailand|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Stoke-on-Trent, United Kingdom",60.37647075,54.33882368,All,"18 Years and older ¬† (Adult, Older Adult)",238,232,215,167,31,17,7/22/2011,12/10/2011,10/6/2011,11/2/2011,10/19/2011,10/27/2011,10/31/2011,11/4/2011,11/18/2011,8/4/2015,9/16/2015,3/20/2016,6/3/2016,7/19/2016,9/14/2016,10/20/2016,11/29/2016,12/29/2016,1/31/2017,4/24/2012,10/21/2012,4/19/2013,10/16/2013,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02087423,,,,,,
AstraZeneca,AstraZeneca,ST00445,SP00003,A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Liberty A,Lavina S,Ngan D,Perter K,Patria R,Hee Y,Suk T,Christian G,Livia Pacheo †,James y,Ross S,Frank T,Mara A,Remedios Z,Jene M,Suzie K,Naren G,Mary H,Corrine U,,,"Research Site, Istanbul, Turkey",85.98628216,77.38765394,All,"18 Years to 75 Years ¬† (Adult, Older Adult)",226,219,216,162,36,18,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/11/1900,4/2/1900,5/30/1900,7/3/1900,8/14/1900,10/7/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00590278,,,,,,
AstraZeneca,AstraZeneca,ST00447,SP00003,Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT),,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Aleta H,Lavina S,Suzie K,Mac L,Kandace p,Tamesha T,Jerold Goo †,Naren G,Mary H,John G,Marcelina X,Naren G,Stephan T,Mac L,Quentin N,Louann C,Tien C,Jerold Goo †,Jerold Goo †,,,"Research Site, El Ejido, Almeria, Spain|Research Site, Huercal Overa, Almeria, Spain|Research Site, Merida, Badajoz, Spain|Research Site, El Hospitalet de Llobregat, Barcelona, Spain|Research Site, Sabadell, Barcelona, Spain|Research Site, Aranda de Duero, Burgos, Spain|Research Site, Miranda de Ebro, Burgos, Spain|Research Site, Ferrol, Coru?a, Spain|Research Site, San Sebastian, Guipuzcoa, Spain|Research Site, Palma de Mallorca, Illes Balears, Spain|Research Site, Logrono, La Rioja, Spain|Research Site, Monforte (casco Urbano), Lugo, Spain|Research Site, Alcala de Henares, Madrid, Spain|Research Site, Coslada, Madrid, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, San Sebastian de Los Reyes, Madrid, Spain|Research Site, Antequera, Malaga, Spain|Research Site, Vigo, Pontevedra, Spain|Research Site, Osuna, Sevilla, Spain|Research Site, Reus, Tarragona, Spain|Research Site, Baracaldo, Vizcaya, Spain|Research Site, Bilbao, Vizcaya, Spain|Research Site, Galdakao, Vizcaya, Spain|Research Site, Calatayud, Zaragoza, Spain|Research Site, Albacete, Spain|Research Site, Barcelona, Spain|Research Site, Cordoba, Spain|Research Site, Granada, Spain|Research Site, Guadalajara, Spain|Research Site, Jaen, Spain|Research Site, Madrid, Spain|Research Site, Toledo, Spain|Research Site, Zaragoza, Spain",70.21735277,63.1956175,Male,"18 Years and older ¬† (Adult, Older Adult)",242,237,217,72,131,14,3/24/2011,8/29/2011,6/15/2011,7/14/2011,6/14/2011,7/6/2011,7/9/2011,7/11/2011,8/6/2011,9/17/2012,4/9/2012,7/12/2012,12/1/2012,12/31/2012,2/10/2013,3/28/2013,4/27/2013,6/3/2013,7/9/2013,1/2/2012,6/30/2012,12/27/2012,6/25/2013,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01284608,,,,,,
AstraZeneca,AstraZeneca,ST00448,SP00003,Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Otis Thode †,Suzie K,Mara A,Mary H,Rima Y ,Federico L,In Bellini †,Gertrudis T,Tiffiny K,Mary H,Terisa Sikora †,Jaquelyn H,Anthony P,Kala R,Beulah N,Donovan H,Dalton E,Lyman W,Liberty A,,,"Research Site, Feldkirch, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Klagenfurt, Austria|Research Site, Leoben, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, St. Veit, Austria|Research Site, Wiener Neustadt, Austria|Research Site, Wien, Austria|Research Site, Bayreuth, Germany|Research Site, Essen, Germany|Research Site, Hamburg-Eppendorf, Germany|Research Site, Heidelberg, Germany|Research Site, Munich, Germany|Research Site, Rostock, Germany|Research Site, Tubingen, Germany|Research Site, Drammen, Norway|Research Site, Fredrikstad, Norway|Research Site, Kristiansand, Norway|Research Site, Oslo, Norway|Research SIte, Porsgrunn, Norway|Research Site, Stavanger, Norway|Research Site, Tonsberg, Norway|Research Site, Trondheim, Norway",96.51323467,86.8619112,Female,"19 Years and older ¬† (Adult, Older Adult)",237,233,218,98,110,10,3/1/2006,9/27/2006,7/19/2006,8/30/2006,8/5/2006,8/14/2006,8/22/2006,8/24/2006,9/17/2006,3/28/2008,2/21/2008,5/25/2008,10/1/2008,11/23/2008,12/27/2008,2/18/2009,3/23/2009,5/11/2009,6/27/2009,2/10/2007,8/9/2007,2/5/2008,8/3/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00357110,,,,,,
AstraZeneca,AstraZeneca,ST00453,SP00003,The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug I,,,,,,,,,,,,,,,,,,,Ross S,Quentin N,Suk T,Frank T,Christian G,John G,Tiffiny K,Patria R,Terisa Sikora †,Kandace p,Rima Y ,Jene M,Mary H,Federico L,Livia Pacheo †,Dalton E,Tamesha T,Lavina S,Perter K,,,"Research Site, Birmingham, Alabama, United States|Research Site, Arcadia, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Laverne, California, United States|Research Site, Long Beach, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Torrington, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boca Raton, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Harvey, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Iowa City, Iowa, United States|Research Site, Overland Park, Kansas, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Frederick, Maryland, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Royal Oak, Michigan, United States|Research Site, St Joseph, Michigan, United States|Research Site, Hooksett, New Hampshire, United States|Research Site, Livingston, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Columbia, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Spartenburg, South Carolina, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Richmond, Virginia, United States|Research Site, Ciudad de Buenos Aires, Buenos Aires, Argentina|Research Site, Mar Del Plata, Buenos Aires, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Brussels, Belgium|Research Site, Leuven, Belgium|Research Site, Ottignies, Belgium|Research Site, Wilrijk, Belgium|Research Site, Goiania, GO, Brazil|Research Site, Rio de Janeiro, RJ, Brazil|Research Site, Porto Alegre, RS, Brazil|Research Site, Sao Paulo, SP, Brazil|Research Site, Edmonton, Alberta, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Kingston, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Alborg, Denmark|Research Site, Herning, Denmark|Research Site, Hillerod, Denmark|Research Site, Kobenhavn O, Denmark|Research Site, Roskilde, Denmark|Research Site, Sonderborg, Denmark|Research Site, Bordeaux Cedex, France|Research Site, Lille Cedex, France|Research Site, Montpellier Cedex 5, France|Research Site, Vandoeuvre Les Nancy, France|Research Site, Augsburg, Germany|Research Site, Berlin, Germany|Research Site, Hamburg, Germany|Research Site, Regensburg, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Szeged, Hungary|Research Site, Haifa, Israel|Research Site, Tel-aviv, Israel|Research Site, Obninsk, Kaluga Region, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, St-petersburg, Russian Federation|Research Site, Klerksdorp, North West Province, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Johannesburg, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, Sevilla, Andalucia, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Hospitalet Dellobregat(barcelo, Cataluna, Spain|Research Site, Terrassa(barcelona), Cataluna, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Halmstad, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Nottingham, United Kingdom",56.73912314,51.06521083,Female,"18 Years and older ¬† (Adult, Older Adult)",240,233,219,188,3,28,7/29/2004,2/22/2005,1/8/2005,1/30/2005,1/2/2005,1/21/2005,1/28/2005,2/2/2005,2/24/2005,4/21/2006,8/20/2005,3/28/2006,6/1/2006,7/4/2006,9/1/2006,10/28/2006,11/30/2006,1/25/2007,3/4/2007,7/20/2005,1/16/2006,7/15/2006,1/11/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00065325,,,,,,
AstraZeneca,AstraZeneca,ST00454,SP00003,"Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer",,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Xochitl D,Patria R,Federico L,Tien C,Dalton E,Mac L,Mary H,Quentin N,Frank T,Quentin N,Stephan T,Tamesha T,Gertrudis T,Quentin N,Jeanene Y,Geralyn K,Mara A,Otis Thode †,Gertrudis T,,,"Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Campana, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Moron, Buenos Aires, Argentina|Research Site, Pergamino, Buenos Aires, Argentina|Research Site, San Martin, Buenos Aires, Argentina|Research Site, Tandil, Buenos Aires, Argentina|Research Site, Vicente Lopez, Buenos Aires, Argentina|Research Site, Santa Rosa, La Pampa, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Rio Grande, Tierra del Fuego, Argentina|Research Site, Cordoba, Argentina|Research Site, Mendoza, Argentina|Research Site, Tucuman, Argentina",79.07605516,71.16844964,Female,"18 Years and older ¬† (Adult, Older Adult)",245,236,220,155,42,23,9/23/2007,4/21/2008,2/29/2008,3/27/2008,3/9/2008,3/13/2008,3/16/2008,3/18/2008,4/13/2008,12/15/2009,3/16/2010,8/13/2010,12/1/2010,1/27/2011,3/23/2011,5/21/2011,7/8/2011,8/12/2011,9/25/2011,9/9/2008,3/8/2009,9/4/2009,3/3/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00878930,,,,,,
AstraZeneca,AstraZeneca,ST00458,SP00003,Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Doreen T,Terisa Sikora †,Remedios Z,Jerold Goo †,Frank T,Tiffiny K,Selizabeth F,Tiffiny K,Lyman W,Aleta H,Clarice N,Mara A,Mary H,Frank T,Chetan K,Christian G,Clarice N,Otis Thode †,Tiffiny K,,,"Research Site, Englewood, Colorado, United States|Research Site, Fort Myers, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Peoria, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Nashville, Tennessee, United States",46.71514825,42.04363343,All,"18 Years to 99 Years ¬† (Adult, Older Adult)",239,235,221,134,61,26,10/15/2012,3/3/2013,1/4/2013,2/11/2013,1/11/2013,1/24/2013,2/8/2013,2/11/2013,3/5/2013,3/5/2015,10/4/2014,3/28/2015,6/1/2015,7/24/2015,9/3/2015,10/19/2015,12/15/2015,2/8/2016,3/22/2016,7/23/2013,1/19/2014,7/18/2014,1/14/2015,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02087241,,,,,,
AstraZeneca,AstraZeneca,ST00459,SP00003,"Open Label, Multicenter, Real World Practice of Durvalumab in Lung Cancer (Imfinzi PMS)",,,,,Oncology,,,,,,Industry,Recruiting,,Observational,,Observational Model: Case-Only|Time Perspective: Prospective,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Tien C,Clarice N,Suk T,Anthony P,Mac L,Lilla Stilson †,Patria R,Livia Pacheo †,Rima Y ,John G,Selizabeth F,James y,John G,Liberty A,Mary H,Jaquelyn H,Lavina S,Terisa Sikora †,Mary H,,,"Research Site, Ansan-si, Korea, Republic of|Research Site, Anyang-si, Korea, Republic of|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheonan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Gyeonggi-do, Korea, Republic of|Research Site, Gyeongsangnam-do, Korea, Republic of|Research Site, Gyeongsangnam-do, Korea, Republic of|Research Site, Hwasun-gun, Korea, Republic of|Research Site, Iksan-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jeonju-si, Korea, Republic of|Research Site, Pohang-si, Korea, Republic of|Research Site, Seo-gu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Yongin-si, Korea, Republic of",97.84130975,88.05717877,All,"18 Years to 99 Years ¬† (Adult, Older Adult)",248,237,222,94,112,16,3/28/2019,9/15/2019,6/24/2019,7/31/2019,7/8/2019,7/21/2019,7/26/2019,7/30/2019,8/22/2019,10/1/2023,3/8/2023,8/5/2023,12/31/2023,2/14/2024,3/29/2024,5/7/2024,6/24/2024,7/29/2024,9/9/2024,1/17/2020,7/15/2020,1/11/2021,7/10/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04068168,,,,,,
AstraZeneca,AstraZeneca,ST00465,SP00003,"A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer",,,,,Oncology,,,,,,Industry,Recruiting,Phase 1,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Lilla Stilson †,Lyman W,Rima Y ,Chetan K,Stephan T,Kala R,Tammara F,Suzie K,Quentin N,Selizabeth F,Patria R,Doreen T,Marceline R,Mary H,Clarice N,Aleta H,Anthony P,Stephan T,Perter K,,,"Research Site, Chuo-ku, Japan|Research Site, Kashiwa, Japan|Research Site, Koto-ku, Japan",44.50342787,40.05308509,Female,"18 Years and older ¬† (Adult, Older Adult)",252,243,223,104,108,11,6/5/2021,10/30/2021,9/1/2021,9/22/2021,8/30/2021,9/14/2021,9/18/2021,9/22/2021,10/18/2021,5/4/2022,5/4/2022,8/8/2022,11/30/2022,1/25/2023,3/17/2023,5/16/2023,7/15/2023,8/24/2023,10/5/2023,3/13/2022,9/9/2022,3/8/2023,9/4/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04541433,,,,,,
AstraZeneca,AstraZeneca,ST00468,SP00003,An Open Label Prostate Cancer Study in Japanese Patients,,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Jerold Goo †,Marcelina X,Aleta H,Jene M,Jaquelyn H,Doreen T,Geralyn K,Terisa Sikora †,Tammara F,Marcelina X,Marcelina X,Corrine U,Perter K,Mara A,Clarice N,Clarice N,Jene M,Otis Thode †,Suzie K,,,"Research Site, Sagamihara, Kanagawa, Japan|Research Site, Sunto-gun, Shizuoka, Japan",70.22980453,63.20682408,Male,"50 Years to 75 Years ¬† (Adult, Older Adult)",242,232,224,88,125,11,9/26/2011,4/9/2012,1/16/2012,2/25/2012,2/3/2012,2/11/2012,2/17/2012,2/19/2012,3/3/2012,11/14/2012,7/27/2012,11/18/2012,3/1/2013,4/21/2013,6/2/2013,7/5/2013,8/31/2013,10/7/2013,11/26/2013,8/9/2012,2/5/2013,8/4/2013,1/31/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01351688,,,,,,
AstraZeneca,AstraZeneca,ST00474,SP00003,Casodex/Zoladex Hormonal therApy Study for assessMent of Correlation Between PSA & BAI in prOstate Cancer patieNts,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Liberty A,Frank T,Lucie P,Terrell p,Livia Pacheo †,Rima Y ,Tammara F,Otis Thode †,Terrell p,James y,Donovan H,Lucie P,Perter K,Lavina S,Selizabeth F,Tamesha T,Mary H,Lucie P,Mary H,,,"Research Site, Kyunggi, Anyang-si Dongan-gu, Korea, Republic of|Research Site, Seoul, Jongro-gu, Korea, Republic of|Research Site, Seoul, Songpa-gu, Korea, Republic of",76.075701,68.4681309,Male,"18 Years and older ¬† (Adult, Older Adult)",244,240,225,119,92,14,4/22/2005,11/18/2005,9/30/2005,10/15/2005,10/1/2005,10/9/2005,10/19/2005,10/23/2005,11/11/2005,5/20/2008,3/30/2008,7/20/2008,11/1/2008,12/22/2008,1/27/2009,3/9/2009,4/10/2009,5/30/2009,7/7/2009,4/7/2006,10/4/2006,4/2/2007,9/29/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00523484,,,,,,
AstraZeneca,AstraZeneca,ST00476,SP00003,"Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients",,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 1|Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug I,,,,,,,,,,,,,,,,,,,Mary H,Mara A,Corrine U,Tammara F,Lyman W,Patria R,Harry A,Dinah R,Dinah R,Rima Y ,Jene M,Anthony P,Otis Thode †,In Bellini †,James y,Jerold Goo †,Terrell p,Rima Y ,Mara A,,,"Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Paris Cedex 5, France|Research Site, Pierre Benite CEDEX, France|Research Site, Villejuif, France|Research Site, Chiba-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Mitaka-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Estado de M√©xico, Mexico|Research Site, Juchitan, Mexico|Research Site, Monterrey, Mexico|Research Site, Oaxaca, Mexico|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Miraflores, Peru|Research Site, Singapore, Singapore|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Valencia, Spain|Research Site, Glasgow, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Sutton, United Kingdom",67.62395967,60.8615637,Female,"30 Years to 74 Years ¬† (Adult, Older Adult)",251,242,226,194,6,26,6/27/2012,2/5/2013,11/23/2012,1/7/2013,12/3/2012,12/21/2012,1/3/2013,1/5/2013,2/2/2013,6/10/2016,4/27/2016,10/9/2016,1/28/2017,3/11/2017,4/26/2017,6/23/2017,8/17/2017,10/12/2017,11/20/2017,6/19/2013,12/16/2013,6/14/2014,12/11/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01625286,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT01625286/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT01625286/SAP_001.pdf"
AstraZeneca,AstraZeneca,ST00478,SP00003,Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.,,,,,Oncology,,,,,,Industry,Recruiting,Phase 1,Interventional,,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Suk T,Terisa Sikora †,Frank T,Stephan T,James y,Kala R,Mara A,Lilla Stilson †,Perter K,Marcelina X,Doreen T,John G,Terisa Sikora †,Gertrudis T,Terisa Sikora †,Mara A,Christian G,Mee M,In Bellini †,,,"Research Site, Aurora, Colorado, United States|Research Site, Sarasota, Florida, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Nashville, Tennessee, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Cambridge, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Sutton, United Kingdom",89.58628049,80.62765244,Female,"18 Years and older ¬† (Adult, Older Adult)",255,249,227,212,9,6,3/22/2018,9/7/2018,6/14/2018,7/23/2018,7/11/2018,7/14/2018,7/28/2018,7/30/2018,8/25/2018,5/5/2022,3/13/2022,8/24/2022,10/31/2022,12/24/2022,2/17/2023,4/7/2023,5/31/2023,7/15/2023,9/5/2023,1/10/2019,7/9/2019,1/5/2020,7/3/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03616587,,,,,,
AstraZeneca,AstraZeneca,ST00479,SP00003,Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 1|Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Marceline R,Gertrudis T,Naren G,Mara A,Suzie K,Frank T,James y,Rima Y ,Marceline R,John G,Jene M,Liberty A,Remedios Z,Jaquelyn H,Jene M,Kala R,Terrell p,Mara A,Jene M,,,"Research Centre, Helsinki, Finland",53.01354478,47.71219031,All,"18 Years and older ¬† (Adult, Older Adult)",237,233,228,135,74,19,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/17/1900,4/15/1900,6/11/1900,8/8/1900,9/23/1900,11/14/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,1/27/1900,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00239304,,,,,,
AstraZeneca,AstraZeneca,ST00481,SP00003,AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,,,,Drug A,,,,,,,,,,,,,,,,,,,Geralyn K,John G,Gertrudis T,Geralyn K,Mary H,Aleta H,Otis Thode †,Remedios Z,Frank T,Mara A,Patria R,Mary H,Suk T,Lyman W,Dalton E,Quentin N,In Bellini †,Garnet T,Selizabeth F,,,"Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Alborg, Denmark|Research Site, Herning, Denmark|Research Site, Naestved, Denmark|Research Site, Paris, Cedex 04, France|Research Site, Avignon, France|Research Site, Bordeaux Cedex, France|Research Site, Caen Cedex, France|Research Site, Lyon Cedex 08, France|Research Site, Montpellier Cedex 5, France|Research Site, Nantes, France|Research Site, Pierre Benite Cedex, France|Research Site, Reims Cedex, France|Research Site, Vandoeuvre Les Nancy, France|Research Site, Amsterdam, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Leiden, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Bergen, Norway|Research Site, Oslo, Norway|Research Site, Lima, Peru|Research Site, Coimbra, Portugal|Research Site, Funchal, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Baia Mare, Maramures, Romania|Research Site, Alba Iulia, Romania|Research Site, Bucharest, Romania|Research Site, Cluj Napoca, Romania|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Cordoba, Andalucia, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Hospitalet Dellobregat(barcelo, Cataluna, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Coventry, United Kingdom",15.10368566,13.59331709,Female,"18 Years and older ¬† (Adult, Older Adult)",248,239,229,76,142,11,4/13/2007,11/4/2007,8/25/2007,9/19/2007,9/2/2007,9/8/2007,9/12/2007,9/15/2007,10/15/2007,4/26/2009,11/21/2008,3/17/2009,8/1/2009,9/25/2009,10/29/2009,12/18/2009,2/5/2010,3/11/2010,5/10/2010,3/6/2008,9/2/2008,3/1/2009,8/28/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00610714,,,,,,
AstraZeneca,AstraZeneca,ST00494,SP00003,Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,John G,Anthony P,John G,Beulah N,Geralyn K,Aleta H,Naren G,Kandace p,Louann C,Perter K,Jene M,Dalton E,Clarice N,Selizabeth F,Mara A,Corrine U,Xochitl D,Mara A,Tiffiny K,,,"Research Site, Auchenflower, Australia|Research Site, Parkville, Australia|Research Site, Perth, Australia|Research Site, Wien, Austria|Research Site, Leuven, Belgium|Research Site, Toronto, Ontario, Canada",1.820597322,1.63853759,Female,"18 Years and older ¬† (Adult, Older Adult)",261,251,230,155,49,26,12/12/2004,5/24/2005,2/27/2005,4/9/2005,3/20/2005,3/26/2005,4/1/2005,4/6/2005,5/1/2005,4/22/2009,1/14/2009,7/2/2009,11/9/2009,1/4/2010,2/9/2010,3/29/2010,5/8/2010,7/7/2010,9/5/2010,9/22/2005,3/21/2006,9/17/2006,3/16/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00707707,,,,,,
AstraZeneca,AstraZeneca,ST00509,SP00003,A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,In Bellini †,Lyman W,Harry A,Lucie P,Tien C,Kala R,Beulah N,Hee Y,Marceline R,Lilla Stilson †,In Bellini †,Anthony P,Tiffiny K,Hee Y,Louann C,Perter K,James y,Jeanene Y,Federico L,,,"Research Site, Little Rock, Arkansas, United States|Research Site, Fountain Valley, California, United States|Research Site, La Jolla, California, United States|Research Site, Orange, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Venice, Florida, United States|Research Site, Decatur, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Mason City, Iowa, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Gloucester, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Columbus, Ohio, United States|Research Site, Meadowbrook, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Austin, Texas, United States|Research Site, Galveston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Temple, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Lacey, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Rosario, Argentina|Research Site, Camperdown, Australia|Research Site, Concord, Australia|Research Site, Heidelburg, Australia|Research Site, Melbourne, Australia|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Antwerpen, Belgium|Research Site, Haine-Saint Paul, Belgium|Research Site, Hasselt, Belgium|Research Site, Leuven, Belgium|Research Site, Belo Horizonte, Brazil|Research Site, Goiania, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Edmonton, Alberta, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Weston, Ontario, Canada|Research Site, York, Ontario, Canada|Research Site, Chicoutimi, Canada|Research Site, Montreal, Canada|Research Site, Kotka, Finland|Research Site, Kuopio, Finland|Research Site, Rovaniemi, Finland|Research Site, Clermont Ferrand, France|Research Site, Evreux, France|Research Site, Lyon, France|Research Site, Montpellier, France|Research Site, Pierre-Benite, France|Research Site, Rodez, France|Research Site, Rouen, France|Research Site, Tours, France|Research Site, Frankfurt, Germany|Research Site, Gottingen, Germany|Research Site, Rostock, Germany|Research Site, Budapest, Hungary|Research Site, P√©cs, Hungary|Research Site, Szolnok, Hungary|Research Site, Sz√©kesfeh√©rv√°r, Hungary|Research Site, Dublin, Ireland|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Forli, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Palermo, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Reggio Calabria, Italy|Research Site, Reggio Emilia, Italy|Research Site, Rozzano, Italy|Research Site, Sassari, Italy|Research Site, Trieste, Italy|Research Site, Amagasaki, Japan|Research Site, Fukuoka, Japan|Research Site, Kitakyusyu, Japan|Research Site, Kumamoto, Japan|Research Site, Matsuyama, Japan|Research Site, Nagoya, Japan|Research Site, Niigata, Japan|Research Site, Oita, Japan|Research Site, Osaka, Japan|Research Site, Saitama, Japan|Research Site, Sapporo, Japan|Research Site, Suita, Japan|Research Site, Tokyo, Japan|Research Site, Guadalajara, Mexico|Research Site, Mexico, D.F., Mexico|Research Site, Den Haag, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Palmerston North, New Zealand|Research Site, Bydgoszcz, Poland|Research Site, Krakow, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Coimbra, Portugal|Research Site, Moscow, Russian Federation|Research Site, Cape Town, South Africa|Research Site, Johannesburg, South Africa|Research Site, Lyttelton Manor, South Africa|Research Site, Badalona, Spain|Research Site, Guadalajara, Spain|Research Site, Madrid, Spain|Research Site, M√°laga, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Istanbul, Turkey|Research Site, Belfast, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Chelmsford, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Huddersfield, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Luton, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle Upon Tyne, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Prescot, United Kingdom|Research Site, Telford, United Kingdom|Research Site, Whitehaven, United Kingdom|Research Site, Worthing, United Kingdom|Research Site, York, United Kingdom",50.07388213,45.06649392,Female,"18 Years and older ¬† (Adult, Older Adult)",257,248,231,124,93,14,4/25/2002,11/18/2002,9/29/2002,11/5/2002,10/6/2002,10/19/2002,11/3/2002,11/7/2002,11/19/2002,3/12/2006,6/9/2006,12/11/2006,3/1/2007,4/20/2007,6/7/2007,8/4/2007,9/14/2007,10/20/2007,11/29/2007,4/17/2003,10/14/2003,4/11/2004,10/8/2004,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00241449,,,,,,
AstraZeneca,AstraZeneca,ST00510,SP00003,Fulvestrant (FASLODEX‚Ñ¢) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Lavina S,Tamesha T,Selizabeth F,Liberty A,Frank T,Mee M,Chetan K,Remedios Z,Naren G,Terrell p,Selizabeth F,Mac L,Mary H,Harry A,Mee M,Naren G,Gertrudis T,Frank T,Mac L,,,"Research Site, Little Rock, Arkansas, United States|Research Site, Boston, Massachusetts, United States|Research Site, Winchester, Massachusetts, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Laredo, Texas, United States|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Vienna, Austria|Research Site, Wien, Austria|Research Site, Barretos, Brazil|Research Site, Florianopolis, Brazil|Research Site, Goiamia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo Andre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Berlin, Germany|Research Site, Hannover, Germany|Research Site, Magdeburg, Germany|Research Site, Munchen, Germany|Research Site, Rostock, Germany|Research Site, Bangalore, India|Research Site, Hyderabaad, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Trivandrum, India|Research Site, Birmingham, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom",85.26593129,76.73933816,Female,"18 Years and older ¬† (Adult, Older Adult)",256,244,232,101,120,11,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/9/1900,3/18/1900,5/2/1900,6/3/1900,8/1/1900,9/8/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00093002,,,,,,
AstraZeneca,AstraZeneca,ST00528,SP00003,"Cediranib (AZD2171, RECENTIN‚Ñ¢) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer",,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug I,,,,,,,,,,,,,,,,,,,Suzie K,Selizabeth F,Perter K,Mee M,Mara A,Suk T,Livia Pacheo †,Garnet T,Beulah N,Jeanene Y,Garnet T,Frank T,Ross S,Harry A,Jene M,Ngan D,Jaquelyn H,Suk T,Federico L,,,"Research Site, Buenos Aires City, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, C√≥rdoba, Argentina|Research Site, Resistencia, Argentina|Research Site, Rosario, Argentina|Research Site, Santa Fe, Argentina|Research Site, Ashford, Australia|Research Site, Camperdown, Australia|Research Site, Heidelberg, Australia|Research Site, Hornsby, Australia|Research Site, Liverpool, Australia|Research Site, Waratah, Australia|Research Site, Wodonga, Australia|Research Site, Curitiba, Brazil|Research Site, Goi√¢nia, Brazil|Research Site, Ja√∫, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Salvador, Brazil|Research Site, Santo Andr√©, Brazil|Research Site, Sao Paulo, Brazil|Research Site, S√£o Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Chengdu, China|Research Site, ChongQing, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Shanghai, China|Research Site, Tianjin, China|Research Site, Brno, Czech Republic|Research Site, Ceske Budejovice, Czech Republic|Research Site, Cheb, Czech Republic|Research Site, Jicin, Czech Republic|Research Site, Jihlava, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Pribram - Zdabor, Czech Republic|Research Site, Sumperk, Czech Republic|Research Site, Zlin, Czech Republic|Research Site, Znojmo, Czech Republic|Research Site, Essen, Germany|Research Site, Freiburg, Germany|Research Site, Goslar, Germany|Research Site, Hamburg, Germany|Research Site, Hildesheim, Germany|Research Site, Mannheim, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gy√∂r, Hungary|Research Site, Kecskem√©t, Hungary|Research Site, Ny√≠regyh√°za, Hungary|Research Site, Szombathely, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Hyderabad, India|Research Site, Trivandrum, India|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon, Philippines|Research Site, Bydgoszcz, Poland|Research Site, Gda≈Ñsk, Poland|Research Site, Gliwice, Poland|Research Site, Krak√≥w, Poland|Research Site, Olsztyn, Poland|Research Site, Toru≈Ñ, Poland|Research Site, Wroc≈Çaw, Poland|Research Site, Bellinzona, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Locarno, Switzerland|Research Site, Z√ºrich, Switzerland|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Aberdeen, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Manchester, United Kingdom",59.99183599,53.99265239,All,"21 Years to 80 Years ¬† (Adult, Older Adult)",242,238,233,157,48,28,1/28/2006,8/25/2006,6/23/2006,7/8/2006,6/28/2006,6/30/2006,7/11/2006,7/12/2006,8/10/2006,10/17/2009,6/4/2009,1/13/2010,3/1/2010,4/19/2010,6/16/2010,7/21/2010,9/17/2010,11/1/2010,12/28/2010,12/27/2006,6/25/2007,12/22/2007,6/19/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00399035,,,,,,
AstraZeneca,AstraZeneca,ST00531,SP00003,"Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer",,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Christian G,Aleta H,Remedios Z,Perter K,Tammara F,Dinah R,Frank T,Marceline R,Mac L,John G,Remedios Z,Anthony P,Ross S,Terrell p,Lyman W,John G,Mee M,Lucie P,Kandace p,,,"Research Site, Los Angeles, California, United States|Research Site, Santa Monica, California, United States|Research Site, Camperdown, Australia|Research Site, Heidelberg, Australia|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Taipei, Taiwan",48.70997384,43.83897646,All,"21 Years and older ¬† (Adult, Older Adult)",257,248,234,190,20,24,1/25/2016,7/22/2016,6/3/2016,6/26/2016,5/25/2016,6/12/2016,6/23/2016,6/24/2016,7/8/2016,10/8/2016,11/14/2016,7/19/2017,8/19/2017,10/13/2017,12/4/2017,1/10/2018,2/25/2018,4/2/2018,5/12/2018,12/9/2016,6/7/2017,12/4/2017,6/2/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02228369,,,,,,
AstraZeneca,AstraZeneca,ST00539,SP00003,Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients,,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug G,,,,,,,,,,,,,,,,,,,Tien C,Anthony P,Liberty A,Frank T,Mary H,Selizabeth F,Tiffiny K,Lucie P,Anthony P,Selizabeth F,Mara A,Jaquelyn H,Tammara F,Marcelina X,Frank T,Ross S,John G,Mary H,John G,,,"Research Site, Anyang, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Jeonju, Korea, Republic of|Research Site, Jeonnam, Korea, Republic of|Research Site, Seongnam, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Taegu, Korea, Republic of",64.4655837,58.01902533,All,"18 Years and older ¬† (Adult, Older Adult)",257,247,235,199,8,28,5/31/2010,11/20/2010,9/5/2010,9/27/2010,9/8/2010,9/21/2010,9/28/2010,10/2/2010,10/13/2010,12/9/2011,8/22/2011,2/3/2012,5/11/2012,6/17/2012,8/16/2012,10/8/2012,11/12/2012,1/4/2013,3/4/2013,3/20/2011,9/16/2011,3/14/2012,9/10/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01063517,,,,,,
AstraZeneca,AstraZeneca,ST00543,SP00003,Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Only|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Selizabeth F,Xochitl D,Mary H,Dalton E,Mary H,Corrine U,Jerold Goo †,Mary H,Stephan T,Jaquelyn H,Mary H,John G,Frank T,John G,Remedios Z,Mary H,Tamesha T,Suzie K,Mara A,,,"Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of",54.98571229,49.48714106,Male,"18 Years to 95 Years ¬† (Adult, Older Adult)",262,253,236,213,10,13,9/29/2009,4/25/2010,2/8/2010,3/24/2010,2/11/2010,3/6/2010,3/14/2010,3/16/2010,4/10/2010,6/22/2013,7/12/2013,11/10/2013,2/1/2014,3/26/2014,5/20/2014,7/6/2014,8/13/2014,10/7/2014,11/16/2014,9/2/2010,3/1/2011,8/28/2011,2/24/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01303692,,,,,,
AstraZeneca,AstraZeneca,ST00548,SP00003,Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 4,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Tiffiny K,Aleta H,Christian G,Selizabeth F,Chetan K,Ross S,Otis Thode †,Dalton E,Doreen T,Perter K,James y,Suzie K,Jaquelyn H,Hee Y,Naren G,Lucie P,Dinah R,Clarice N,Mary H,,,"Research Site, Palm Springs, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, New Orleans, Louisiana, United States|Research Site, New York, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, Burnaby, Canada|Research Site, Edmonton, Canada|Research Site, Montreal, Canada|Research Site, Quebec City, Canada|Research Site, Vancouver, Canada|Research Site, Bordeaux, France|Research Site, Caen, France|Research Site, Lyon, France|Research Site, Saint-Cloud, France|Research Site, Saint-Herblain, France|Research Site, Athens, Greece|Research Site, Iraklion, Greece|Research Site, Den Haag, Netherlands|Research Site, Goes, Netherlands|Research Site, Ijssel, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Bloemfontain, South Africa|Research Site, Cape Town, South Africa|Research Site, Tygerberg, South Africa|Research Site, Pamplona, Spain|Research Site, Pontevedra, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Belfast, United Kingdom|Research Site, Bolton, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Luton, United Kingdom",73.7343326,66.36089934,Female,,259,251,237,216,12,9,8/4/2004,2/18/2005,12/4/2004,1/10/2005,12/27/2004,1/2/2005,1/16/2005,1/18/2005,1/28/2005,3/17/2007,12/26/2006,7/25/2007,10/1/2007,11/10/2007,12/30/2007,2/25/2008,4/20/2008,6/6/2008,7/6/2008,7/1/2005,12/28/2005,6/26/2006,12/23/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00082277,,,,,,
AstraZeneca,AstraZeneca,ST00550,SP00003,"Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)",,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug E,,,,,,,,,,,,,,,,,,,Perter K,John G,Jene M,Selizabeth F,Marceline R,Mee M,Louann C,Lavina S,Tammara F,Mac L,Terisa Sikora †,Patria R,Lyman W,Mac L,John G,Beulah N,Xochitl D,Selizabeth F,Anthony P,,,"Research Site, Innsbruck, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Bonheiden, Belgium|Ressearch Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Chomutov, Czech Republic|Research Site, Nova Ves Pod Plesi, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Montpellier, France|Research Site, Saint Herblain, France|Research Site, Berlin, Germany|Research Site, Freiburg, Germany|Research Site, Halle, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, M√ºnchen, Germany|Research Site, Stuttgart, Germany|Research Site, Genova, Italy|Research Site, La Torretta, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Rozzano, Italy|Research Site, A Coru√±a, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Glasgow, United Kingdom|Research Site, Ipswich, United Kingdom|Research Site, Maidstone, United Kingdom|Research Site, Newcastle-upon-tyne, United Kingdom|Research Site, Sutton, United Kingdom",85.83371453,77.25034308,All,,247,244,238,186,18,34,6/26/2003,12/15/2003,9/29/2003,11/3/2003,10/1/2003,10/20/2003,11/3/2003,11/8/2003,12/1/2003,2/15/2007,3/14/2007,9/17/2007,11/1/2007,12/1/2007,1/19/2008,2/27/2008,4/21/2008,5/31/2008,7/2/2008,4/17/2004,10/14/2004,4/12/2005,10/9/2005,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00278889,,,,,,
AstraZeneca,AstraZeneca,ST00572,SP00003,"Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status",,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Tiffiny K,Liberty A,Naren G,Terisa Sikora †,Liberty A,Suk T,Federico L,Liberty A,Hee Y,Marceline R,Jeanene Y,John G,Corrine U,Mara A,Ross S,James y,Lavina S,Selizabeth F,Doreen T,,,"Research Site, Los Angeles, California, United States|Research Site, Palm Springs, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Newark, Delaware, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Seattle, Washington, United States",41.58127007,37.42314307,All,,262,255,239,196,10,33,1/17/2009,7/28/2009,5/14/2009,6/11/2009,5/12/2009,6/2/2009,6/17/2009,6/22/2009,7/8/2009,7/18/2011,7/24/2011,12/12/2011,3/1/2012,4/29/2012,6/22/2012,7/23/2012,9/10/2012,10/31/2012,12/9/2012,11/29/2009,5/28/2010,11/24/2010,5/23/2011,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00912743,,,,,,
Biogen,Biogen,ST00099,SP00004,A Study to Evaluate Higher Dose (HD) Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Previously Treated With Risdiplam,,ASCEND,Spinal Muscular Atrophy,,Neurology,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Christian G,Christian G,Donovan H,Perter K,Selizabeth F,Perter K,Jerold Goo †,Corrine U,Perter K,Chetan K,Frank T,Mara A,Federico L,Stephan T,Mara A,Chetan K,John G,Naren G,Mac L,,,,38.23882024,34.41493822,All,18 Years to 45 Years ¬† (Adult),266,256,240,158,62,20,7/29/2022,1/15/2023,11/22/2022,12/25/2022,11/19/2022,12/8/2022,12/19/2022,12/21/2022,1/13/2023,2/10/2027,10/16/2026,3/16/2027,6/14/2027,8/6/2027,9/6/2027,10/17/2027,11/24/2027,1/4/2028,3/3/2028,6/6/2023,12/3/2023,5/31/2024,11/27/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05067790,,,,,,
Biogen,Biogen,ST00116,SP00004,MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study,,,Multiple Sclerosis (MS),,Neurology,,,,,,Industry,Recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Louann C,Mac L,Christian G,Jerold Goo †,Gertrudis T,Lucie P,Liberty A,Xochitl D,Naren G,Remedios Z,Lyman W,Chetan K,Kandace p,Rima Y ,Suk T,Anthony P,Mee M,Terisa Sikora †,Tamesha T,,,"Research Site, Baltimore, Maryland, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, New York, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States",24.1109746,21.69987714,All,"18 Years to 90 Years ¬† (Adult, Older Adult)",272,265,241,209,2,30,2/8/2017,8/17/2017,6/3/2017,7/10/2017,6/6/2017,7/1/2017,7/10/2017,7/12/2017,8/11/2017,9/22/2021,9/23/2021,2/27/2022,5/13/2022,7/6/2022,8/20/2022,10/6/2022,11/16/2022,1/7/2023,3/4/2023,12/28/2017,6/26/2018,12/23/2018,6/21/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05058729,,,,,,
Biogen,Biogen,ST00138,SP00004,Pediatric SMA China Registry,,,"Muscular Atrophy, Spinal",,,,,,,,Industry,Not yet recruiting,Phase 1|Phase 2,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Tiffiny K,Terisa Sikora †,Kandace p,Dinah R,Christian G,Clarice N,Dalton E,Hee Y,Marceline R,Jaquelyn H,Suzie K,Quentin N,Louann C,Otis Thode †,Garnet T,Ngan D,Quentin N,Livia Pacheo †,Xochitl D,,,,85.74531382,77.17078244,All,"3 Years and older ¬† (Child, Adult, Older Adult)",252,249,242,221,15,6,1/30/2022,7/23/2022,6/1/2022,7/1/2022,6/9/2022,6/14/2022,6/20/2022,6/22/2022,7/20/2022,8/31/2023,11/27/2023,4/11/2024,6/30/2024,8/5/2024,9/8/2024,10/11/2024,12/4/2024,1/11/2025,2/21/2025,12/11/2022,6/9/2023,12/6/2023,6/3/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05042921,,,,,,
Biogen,Biogen,ST00229,SP00004,Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis,,,Superoxide Dismutase 1-Amyotropic Lateral Sclerosis,,Neurology,,,,,,Industry,Available,Not Applicable,Expanded Access:Individual Patients,,,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Suzie K,Chetan K,Lucie P,Mara A,John G,Otis Thode †,Tiffiny K,Kandace p,Corrine U,Anthony P,Lyman W,John G,Corrine U,Doreen T,Mary H,Mara A,Mary H,Tiffiny K,Dinah R,,,,67.96867956,61.1718116,All,"18 Years and older ¬† (Adult, Older Adult)",262,251,243,75,154,14,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,1/31/1900,3/24/1900,5/21/1900,7/6/1900,8/14/1900,10/10/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04972487,,,,,,
Biogen,Biogen,ST00250,SP00004,A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care,,TOPAZ-2,"Lupus Erythematosus, Systemic",,,,,,,,Industry,Recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug A,,,,,,,,,,,,,,,,,,,Lyman W,Kandace p,Kala R,Perter K,Mary H,Rima Y ,Xochitl D,Frank T,Dinah R,Frank T,Mara A,Terisa Sikora †,Mary H,Ngan D,Dinah R,Terisa Sikora †,Beulah N,Hee Y,Doreen T,,,"Research Site, Mesa, Arizona, United States|Research Site, Covina, California, United States|Research Site, Boca Raton, Florida, United States|Research Site, Freehold, New Jersey, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Summerville, South Carolina, United States|Research Site, Austin, Texas, United States|Research Site, Barranquilla, Colombia|Research Site, Bogot√°, Colombia|Research Site, Bucaramanga, Colombia|Research Site, Chia, Colombia|Research Site, Zipaquir√°, Colombia",16.03178497,14.42860647,All,"up to 18 Years ¬† (Child, Adult)",264,259,244,90,139,15,7/4/2020,1/20/2021,11/18/2020,12/24/2020,12/9/2020,12/15/2020,12/28/2020,12/29/2020,1/10/2021,1/31/2025,10/15/2024,4/18/2025,6/13/2025,7/18/2025,8/19/2025,10/2/2025,11/19/2025,12/27/2025,2/1/2026,6/13/2021,12/10/2021,6/8/2022,12/5/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04961567,,,,,,
Biogen,Biogen,ST00269,SP00004,Exploring Diroximel Fumarate Real-world Experience in Canada and Israel,,EXPER-CA/IL,Relapsing Forms of MS,,,,,,,,Industry,Not yet recruiting,Phase 2,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Mac L,Mary H,Chetan K,Suzie K,Tien C,John G,Suzie K,Aleta H,Perter K,Dinah R,Liberty A,Perter K,Perter K,Selizabeth F,Otis Thode †,Suzie K,Stephan T,Suzie K,Anthony P,,,,66.94779326,60.25301394,All,"18 Years and older ¬† (Adult, Older Adult)",259,252,245,166,56,23,12/30/2021,6/10/2022,3/28/2022,5/1/2022,3/19/2022,4/13/2022,4/17/2022,4/19/2022,5/11/2022,9/5/2025,5/13/2025,10/10/2025,2/1/2026,3/4/2026,5/1/2026,6/1/2026,7/13/2026,9/1/2026,10/1/2026,10/10/2022,4/8/2023,10/5/2023,4/2/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04948606,,,,,,
Biogen,Biogen,ST00289,SP00004,Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Mara A,Perter K,Hee Y,Marceline R,Gertrudis T,Kala R,Federico L,Mac L,Harry A,Stephan T,Marceline R,Livia Pacheo †,Jeanene Y,Remedios Z,Tien C,Lyman W,Jene M,Jeanene Y,Mary H,,,"Research Site, Alabaster, Alabama, United States|Research Site, Encinitas, California, United States|Research Site, Encinitas, California, United States|Research Site, Gilroy, California, United States|Research Site, Long Beach, California, United States|Research Site, Davie, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Rochester, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Berkeley Heights, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Fargo, North Dakota, United States|Research Site, Columbus, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Lacey, Washington, United States|Research Site, Waratah, New South Wales, Australia|Research Site, Wollongong, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Redcliffe, Queensland, Australia|Research Site, Hobart, Tasmania, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Brasschaat, Belgium|Research Site, Edegem, Belgium|Research Site, Kortrijk, Belgium|Research Site, Liege, Belgium|Research Site, Mons, Belgium|Research Site, Kuzmolovskiy, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, St. Petersburg, Russian Federation",10.55335371,9.498018335,Female,"18 Years and older ¬† (Adult, Older Adult)",269,266,246,154,76,16,9/16/2006,4/21/2007,2/21/2007,3/9/2007,2/12/2007,2/26/2007,3/8/2007,3/10/2007,4/7/2007,6/29/2011,12/14/2010,8/19/2011,10/1/2011,11/16/2011,1/9/2012,2/21/2012,4/8/2012,5/15/2012,7/4/2012,8/25/2007,2/21/2008,8/19/2008,2/15/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01004081,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00001,SP00005,Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression,,OREY,Human Immunodeficiency Virus (HIV) Infections,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Beulah N,Chetan K,Terrell p,Mary H,Federico L,Donovan H,In Bellini †,Tiffiny K,Naren G,Ross S,Rima Y ,Mara A,Donovan H,Gertrudis T,Remedios Z,Clarice N,Mara A,Jeanene Y,Mary H,,,Spain,16.57633497,14.91870147,All,"18 Years and older ¬† (Adult, Older Adult)",267,256,247,242,21,16,5/21/2005,12/14/2005,10/18/2005,11/14/2005,10/20/2005,10/27/2005,1/25/2006,5/13/2006,6/4/2006,2/4/2008,8/8/2007,12/20/2007,5/1/2008,6/12/2008,7/27/2008,8/30/2008,10/8/2008,11/11/2008,12/21/2008,4/25/2006,10/22/2006,4/20/2007,10/17/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00337467,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00018,SP00005,A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen,,,HIV Infections,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Quentin N,Geralyn K,Chetan K,Mee M,Aleta H,Garnet T,Anthony P,Kandace p,Clarice N,Federico L,Dinah R,Tammara F,Doreen T,Hee Y,Clarice N,John G,James y,Terrell p,Anthony P,,,"Local Institution, Hobson City, Alabama, United States|Local Institution, Montgomery, Alabama, United States|Local Institution, Phoenix, Arizona, United States|Local Institution, Little Rock, Arkansas, United States|Local Institution, Bakersfield, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, San Francisco, California, United States|Local Institution, San Mateo, California, United States|Local Institution, Tarzana, California, United States|Local Institution, West Hollywood, California, United States|Local Institution, Norwalk, Connecticut, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Atlantis, Florida, United States|Local Institution, Fort Lauderdale, Florida, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Miami Beach, Florida, United States|Local Institution, Miami, Florida, United States|Local Institution, North Miami, Florida, United States|Local Institution, Orlando, Florida, United States|Local Institution, Plantation, Florida, United States|Local Institution, Safety Harbor, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Decatur, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Local Institution, Louisville, Kentucky, United States|Local Institution, New Orleans, Louisiana, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Springfield, Massachusetts, United States|Local Institution, Berkley, Michigan, United States|Local Institution, Jackson, Mississippi, United States|Local Institution, St. Louis, Missouri, United States|Local Institution, Las Vegas, Nevada, United States|Local Institution, East Orange, New Jersey, United States|Local Institution, Hillsborough, New Jersey, United States|Local Institution, Jersey City, New Jersey, United States|Local Institution, Brooklyn, New York, United States|Local Institution, Mt. Vernon, New York, United States|Local Institution, New York, New York, United States|Local Institution, Valhalla, New York, United States|Local Institution, Greenville, North Carolina, United States|Local Institution, Huntersville, North Carolina, United States|Local Institution, Winston Salem, North Carolina, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Columbia, South Carolina, United States|Local Institution, Dallas, Texas, United States|Local Institution, Galveston, Texas, United States|Local Institution, Harlingen, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Hampton, Virginia, United States|Local Institution, Santruce, Puerto Rico",39.99033712,35.99130341,All,"60 Years and older ¬† (Adult, Older Adult)",279,266,248,213,4,31,4/3/2001,8/21/2001,7/1/2001,7/28/2001,7/8/2001,7/10/2001,9/28/2001,12/16/2001,1/6/2002,5/23/2005,4/21/2005,11/7/2005,2/1/2006,3/20/2006,5/2/2006,6/9/2006,7/21/2006,9/12/2006,10/15/2006,1/6/2002,7/5/2002,1/1/2003,6/30/2003,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00135395,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00021,SP00005,A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy,,,HIV Infections,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Mara A,Naren G,Tamesha T,Jerold Goo †,Xochitl D,Chetan K,Federico L,Mac L,Mary H,John G,Geralyn K,Perter K,Selizabeth F,Frank T,Ngan D,Suzie K,Remedios Z,Perter K,Mara A,,,"Local Institution, Phoenix, Arizona, United States|Local Institution, West Hollywood, California, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Altamonte Springs, Florida, United States|Local Institution, Ft. Lauderdale, Florida, United States|Local Institution, Miami, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Minneapolis, Minnesota, United States|Local Institution, St. Louis, Missouri, United States|Local Institution, East Orange, New Jersey, United States|Local Institution, New York, New York, United States|Local Institution, Huntersville, North Carolina, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Columbia, South Carolina, United States|Local Institution, Fort Worth, Texas, United States|Local Institution, Houston, Texas, United States",46.04373047,41.43935743,All,up to 5 Years ¬† (Child),264,260,249,149,74,26,8/4/2002,12/11/2002,10/21/2002,11/22/2002,10/23/2002,11/6/2002,1/12/2003,4/9/2003,4/17/2003,11/22/2004,6/29/2004,11/13/2004,3/1/2005,4/29/2005,6/23/2005,8/19/2005,10/10/2005,11/9/2005,1/3/2006,5/5/2003,11/1/2003,4/29/2004,10/26/2004,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00067782,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00024,SP00005,A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C,,,Hepatic Cirrhosis|Liver Fibrosis,,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,In Bellini †,Patria R,Quentin N,Corrine U,In Bellini †,Selizabeth F,Frank T,Mary H,Remedios Z,Mary H,Kala R,In Bellini †,Mary H,Tien C,Mara A,Lyman W,Jerold Goo †,Marceline R,Corrine U,,,"The Texas Liver Institute, San Antonio, Texas, United States",71.99246379,64.79321741,All,"Child, Adult, Older Adult",262,254,250,75,166,9,5/17/2015,12/13/2015,9/28/2015,10/23/2015,9/21/2015,10/16/2015,3/3/2016,7/14/2016,8/3/2016,6/28/2018,4/22/2018,7/28/2018,12/10/2018,2/5/2019,3/17/2019,5/16/2019,6/18/2019,8/14/2019,9/17/2019,4/13/2016,10/10/2016,4/8/2017,10/5/2017,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03420768,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00036,SP00005,A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen,,,HIV Infections,,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Cross-Sectional,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Jene M,Suzie K,Anthony P,Mary H,Terisa Sikora †,Xochitl D,Kala R,John G,Jeanene Y,Livia Pacheo †,Mary H,Mee M,John G,Dalton E,Quentin N,Stephan T,Jene M,In Bellini †,Tamesha T,,,"Local Institution, Phoenix, Arizona, United States|Vista Medical Partners, Beverly Hills, California, United States|AIDS Healthcare Foundation, Beverly Hills, California, United States|AltaMed Health Services Corporation, Los Angeles, California, United States|Kaiser Permanente, Los Angeles, California, United States|Synergy Hematology and Oncology Medical Associates, Los Angeles, California, United States|Orange Coast Medical Group, Newport Beach, California, United States|Alameda County Medical Center, Oakland, California, United States|East Bay AIDS Center, Oakland, California, United States|Desert Medical Group, Palm Springs, California, United States|Martin M. Mass, MD, San Francisco, California, United States|Wellspring Medical Group, San Francisco, California, United States|San Mateo Medical Center, San Mateo, California, United States|Stanford University Medical Center, Stanford, California, United States|Denver Public Health, Denver, Colorado, United States|Local Institution, Denver, Colorado, United States|Dupont Circle Physicians Group, P.C., Washington, District of Columbia, United States|South Florida Clinical Research, Atlantis, Florida, United States|Daniel A. Warner, MD, PA, Daytona Beach, Florida, United States|Gary J. Richmond, MD, PA, Fort Lauderdale, Florida, United States|Biogenomx Research Institute, LLC/CHC1-AP, Hollywood, Florida, United States|AIDS Healthcare Foundation, Jacksonville, Florida, United States|Albert Canas MD, PA, Miami Beach, Florida, United States|Steinhart Medical Associates, Miami, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Care Resource, Inc., Miami, Florida, United States|Associates in Infectious Diseases, Port St. Lucie, Florida, United States|Health Positive, Safety Harbor, Florida, United States|Bach & Godofsky, MD, PA, Sarasota, Florida, United States|Edward W. Braun, MD PA, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Grady Ponce de Leon Infectious Disease Clinic, Atlanta, Georgia, United States|Atlanta ID Group, Atlanta, Georgia, United States|Infectious Disease Solutions, Atlanta, Georgia, United States|Infectious Disease Group of Atlanta, Atlanta, Georgia, United States|Family Healthcare of Atlanta, PC, Atlanta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Investious Diseases Associates, Riverdale, Georgia, United States|Southern Illinois University of Medicine, Springfield, Illinois, United States|University of Iowa Healthcare, Iowa City, Iowa, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Chase Brexton Health Services, Baltimore, Maryland, United States|University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States|St. Agnes Health Care, Inc., Baltimore, Maryland, United States|Calvert Internal Medicine Group, Prince Frederick, Maryland, United States|Tufts New England Medical Center, Boston, Massachusetts, United States|Fenway Community Health, Boston, Massachusetts, United States|The Research Institute, Springfield, Massachusetts, United States|Be Well Medical Center, Berkley, Michigan, United States|Michaigan State Adult Medicine Clinic, Lansing, Michigan, United States|Charles P. Craig, M.D., P.C., Ypsilanti, Michigan, United States|Central West Clinical Research, Inc., St. Louis, Missouri, United States|Garden State Infectious Disease Associates, Voorhees, New Jersey, United States|Philip S. Smith, MD, Cornwall, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Beth Israel Medical Center, New York, New York, United States|Ricky K. Hsu, MD, PC, New York, New York, United States|Ronald Grossman, MD, New York, New York, United States|AIDS Community Research Initiative of America, New York, New York, United States|James Jones, MD, New York, New York, United States|New York Medical College, Valhalla, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Local Institution, Charlotte, North Carolina, United States|Fairgrove Primary Health, Hickory, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Metro Heath Medical Center, Cleveland, Ohio, United States|The University of Toledo, Toledo, Ohio, United States|The Research and Education Group, Portland, Oregon, United States|Kaiser Permanente Northwest Region, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Univeristy Speciality Clinics, Columbia, South Carolina, United States|Greenville Hospital System, Greenville, South Carolina, United States|Nicholaos C. Bellos, MD, Dallas, Texas, United States|Amelia Court HIV Research, Dallas, Texas, United States|Planned Parenthood Center of El Paso, El Paso, Texas, United States|Tarrant Country Infectious Disease Associates, Fort Worth, Texas, United States|Valley AIDS Council, Harlingen, Texas, United States|Therapeutic Concepts, P.A., Houston, Texas, United States|Diversified Medical Pratices, PA, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Medical Associates of Central Virginia, Lynchburg, Virginia, United States|Richmond AIDS Consortium, Richmond, Virginia, United States|Daniel R. Coulston, MD, Spokane, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",32.76142728,29.48528456,All,9 Years to 12 Years ¬† (Child),278,273,251,242,21,12,8/22/2005,3/16/2006,1/3/2006,1/31/2006,1/3/2006,1/17/2006,6/15/2006,7/26/2006,8/7/2006,3/15/2009,1/31/2009,7/29/2009,9/1/2009,10/12/2009,11/13/2009,1/9/2010,3/5/2010,4/20/2010,6/6/2010,7/16/2006,1/12/2007,7/11/2007,1/7/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00135447,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00040,SP00005,Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir,,,HIV Infections,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Anthony P,Suk T,Clarice N,Naren G,Remedios Z,Federico L,John G,Jerold Goo †,Stephan T,Donovan H,Perter K,Remedios Z,Tammara F,Harry A,Selizabeth F,Tamesha T,Kandace p,John G,,,"Local Institution, Phoenix, Arizona, United States|Local Institution, Bakersfield, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, San Francisco, California, United States|Local Institution, Miami, Florida, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, New York, New York, United States|Local Institution, Cincinnati, Ohio, United States|Local Institution, Portland, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Columbia, South Carolina, United States|Local Institution, Dallas, Texas, United States|Local Institution, Hamilton, Ontario, Canada|Local Institution, Montreal, Quebec, Canada",76.36066046,68.72459441,All,18 Years to 64 Years ¬† (Adult),276,265,252,165,56,31,11/5/2003,4/21/2004,2/20/2004,3/20/2004,2/17/2004,3/2/2004,6/2/2004,10/16/2004,10/22/2004,7/6/2005,8/5/2005,3/20/2006,5/1/2006,6/28/2006,8/15/2006,9/25/2006,11/21/2006,1/5/2007,2/6/2007,8/29/2004,2/25/2005,8/24/2005,2/20/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00120393,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00051,SP00005,The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine,,,HIV Infections,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Hee Y,Mary H,Kala R,Naren G,In Bellini †,John G,Mara A,Mee M,Kala R,Mary H,Patria R,Patria R,Mee M,Otis Thode †,Doreen T,Mac L,John G,Dinah R,John G,,,"Harbor UCLA Med Ctr, Torrance, California, United States|Univ of South Florida, Tampa, Florida, United States|SUNY at Stony Brook / Division of Infectious Diseases, Stony Brook, New York, United States|Houston Clinical Research Network / Div of Montrose Clinic, Houston, Texas, United States|Univ of Utah / School of Medicine / Div of Infect Dis, Salt Lake City, Utah, United States|Sunnybrook Health Science Ctr, North York, Ontario, Canada|Montreal Gen Hosp / Div of Clin Immuno and Allergy, Montreal, Quebec, Canada|Univ of Puerto Rico School of Medicine, San Juan, Puerto Rico",78.22974993,70.40677494,All,"18 Years and older ¬† (Adult, Older Adult)",265,259,253,189,39,25,5/20/1994,10/23/1994,9/5/1994,10/2/1994,8/19/1994,9/12/1994,2/3/1995,4/28/1995,5/9/1995,9/26/1997,4/12/1997,10/16/1997,12/1/1997,1/18/1998,3/13/1998,4/15/1998,5/31/1998,7/2/1998,8/26/1998,3/11/1995,9/7/1995,3/5/1996,9/1/1996,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00002371,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00052,SP00005,Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s),,,HIV Infections,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Lyman W,Harry A,Otis Thode †,Suzie K,Dalton E,Anthony P,Xochitl D,Garnet T,James y,Perter K,Rima Y ,Otis Thode †,Xochitl D,Louann C,Garnet T,Suzie K,Suk T,Garnet T,Chetan K,,,"Cooper Green Hosp, Birmingham, Alabama, United States|Phoenix Body Positive, Phoenix, Arizona, United States|East Bay AIDS Ctr, Berkeley, California, United States|Saint Francis Mem Hosp / HIV Care Unit, San Francisco, California, United States|Kaiser Foundation Hospital, San Francisco, California, United States|San Francisco Veterans Administration Med Ctr, San Francisco, California, United States|Harbor UCLA Med Ctr, Torrance, California, United States|Beacon Clinic / Boulder Community Hosp, Boulder, Colorado, United States|IDC Research Initiative, Altamonte Springs, Florida, United States|Larry Bush, Atlantis, Florida, United States|Community Health Care, Fort Lauderdale, Florida, United States|South Beach Medical Associates, Miami Beach, Florida, United States|Florida ID Group, Orlando, Florida, United States|Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States|Univ of Hawaii, Honolulu, Hawaii, United States|Sky Blue, Boise, Idaho, United States|Infectious Disease of Indiana, Indianapolis, Indiana, United States|Univ of Kansas School of Medicine, Wichita, Kansas, United States|Univ of Kentucky Med Ctr, Lexington, Kentucky, United States|Community Research Initiative, Brookline, Massachusetts, United States|Univ of Massachusetts, Worcester, Massachusetts, United States|Southampton Healthcare Inc, St Louis, Missouri, United States|Steven Zell, Reno, Nevada, United States|VAMC New Jersey Healthcare System, East Orange, New Jersey, United States|North Jersey Community Research Initiative, Newark, New Jersey, United States|Albany Med College, Albany, New York, United States|Erie County Med Ctr, Buffalo, New York, United States|North Shore Univ Hosp, Manhasset, New York, United States|Community Health Network, Rochester, New York, United States|Jemsek Clinic, Huntersville, North Carolina, United States|Oregon Health Sciences Univ, Portland, Oregon, United States|Research & Education Group, Portland, Oregon, United States|Mark Watkins, Philadelphia, Pennsylvania, United States|Univ of South Carolina School of Medicine, Columbia, South Carolina, United States|North Texas Center for AIDS & Clinical Research, Dallas, Texas, United States|Nicholas Bellos, Dallas, Texas, United States|Houston Clinical Research Network, Houston, Texas, United States|Infectious Diseases Associates of Houston, Houston, Texas, United States|Claudia Rodriguez MD, Buenos Aires, Argentina|Elida Pallone MD, Buenos Aires, Argentina|Fundacion Huesped, Buenos Aires, Argentina|Hospital Italiano, Buenos Aires, Argentina|CAICI, Rosario Santa Fe, Argentina|Alfred Hosp, Prahan, Australia|Prahran Market Clinic, South Yarra, Australia|Saint Vincent's Hosp Med Centre, Sydney, Australia|Taylors Square Clinic, Sydney, Australia|Inst of Tropical Medicine, Antwerpe, Belgium|CHU Saint Pierre, Brussels, Belgium|Cliniques Universitaires Saint Luc, Bruxelles, Belgium|University Hospital Gent, Gent, Belgium|Domaine Universitaire Du SART-TILMAN, Liege, Belgium|Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil|Hospital Nossa Senhora da Conceicao-GCH, Porto Alegre, Brazil|Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil|Toronto Hosp, Toronto, Ontario, Canada|Clinique Medicale du Quartier Latin, Montreal, Quebec, Canada|Dr Roger P Leblanc, Montreal, Quebec, Canada|Montreal Gen Hosp / Div of Clin Immuno and Allergy, Montreal, Quebec, Canada|Fundacion Arriaran, Santiago, Chile|Hosp Sotero de Rio, Santiago, Chile|Hopital Hotel Dieu de Lyon, Lyon, France|Services des Maladies Infectieuses, Paris Cedex 12, France|CHU De Bicetre, Paris, France|Hopital Cochin - Port Royal, Paris, France|Hopital Gustave Dron, Tourcoing, France|Ospedale S Orsola, Bologna, Italy|Immunoligia Universita Cagliari, Cagliari, Italy|Reparto di Malattie Infettive, Corso Svizzera, Italy|Ospedale Luigi Sacco Cargnel, Milano, Italy|Ospedale S Raffaele, Milano, Italy|Ospedale degli Infermi, Rimini, Italy|Cat All Immun Clin, Roma, Italy|Ospedale Amedeo de Savoia, Torino, Italy|Ospedale Amedeo di Savoia, Torino, Italy|Hospital 1 ro de Octubre, Mexico City, Mexico|Hospital General, Mexico City, Mexico|Hospital Regional, Mexico City, Mexico|Instituto Nacional de la Nutricion, Mexico City, Mexico|Univ Medical Center Utrecht, CX Utrecht, Netherlands|Hosp Guillermo Almenara-Medicina 1, Lima, Peru|Hosp Nacional Cayetano Heredia, Lima, Peru|San Cristobal Hosp, Coto Laurel, Ponce, Puerto Rico|Clinical Research Puerto Rico Inc, San Juan, Puerto Rico|Hosp Clinic, Barcelona, Spain|Hospital Germans Trias I Pujol, Barcelona, Spain|Hosp de Basurto / Enfermedades Infecciosas, Bilboa, Spain|Hosp Reina Sofia, Cordoba, Spain|Hosp Carlos III, Madrid, Spain|Hosp Ramon y Cajal, Madris, Spain|Hosp Nuestra Senora de Covadonga, Oviedo, Spain|Hosp Virgen Del Rocio, Sevilla, Spain|Whittal Street Clinic, Birmingham, United Kingdom|Royal Liverpool Univ Hosp, Liverpool, United Kingdom|Aurora Hospital|Department of Infection & Tropical Medicine|Klinicka Chorobzkaznych AM",54.66309184,49.19678266,All,"15 Years and older ¬† (Child, Adult, Older Adult)",285,274,254,219,11,24,10/28/2001,5/12/2002,3/17/2002,4/11/2002,3/11/2002,4/4/2002,6/22/2002,7/26/2002,8/3/2002,1/7/2003,2/5/2003,5/28/2003,9/1/2003,10/28/2003,12/18/2003,2/5/2004,3/17/2004,4/22/2004,6/13/2004,10/1/2002,3/30/2003,9/26/2003,3/24/2004,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00028301,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00102,SP00005,Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment,,DCE,Psoriasis,,I&I,,,,,,Industry,Not yet recruiting,Phase 4,Observational,,Observational Model: Other|Time Perspective: Cross-Sectional,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Chetan K,Naren G,John G,Mary H,Jeanene Y,Suzie K,Quentin N,Xochitl D,Beulah N,Jene M,Marcelina X,Doreen T,Terisa Sikora †,Naren G,Terrell p,Anthony P,Stephan T,In Bellini †,Remedios Z,,,"Local Institution, Morrisville, North Carolina, United States",68.69804177,61.82823759,All,"18 Years and older ¬† (Adult, Older Adult)",279,276,255,173,64,18,6/29/2018,12/25/2018,11/1/2018,12/9/2018,11/13/2018,11/21/2018,3/27/2019,7/5/2019,7/18/2019,6/18/2021,7/14/2021,12/10/2021,2/17/2022,4/7/2022,5/12/2022,6/20/2022,8/6/2022,9/8/2022,10/25/2022,5/20/2019,11/16/2019,5/14/2020,11/10/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05065762,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00106,SP00005,"A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis",,,Multiple Sclerosis (MS),,Neurology,,,,,,Industry,Not yet recruiting,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Otis Thode †,Selizabeth F,Donovan H,Livia Pacheo †,Hee Y,Lilla Stilson †,Doreen T,Selizabeth F,Lucie P,Aleta H,Anthony P,Suk T,Dalton E,Xochitl D,Marcelina X,Dinah R,James y,Tamesha T,Otis Thode †,,,"Local Institution, Ann Arbor, Michigan, United States|Local Institution, London, United Kingdom",29.87960548,26.89164493,All,24 Years to 40 Years ¬† (Adult),276,269,256,245,20,9,4/12/2018,10/18/2018,8/6/2018,9/22/2018,9/1/2018,9/4/2018,11/30/2018,4/15/2019,5/9/2019,6/20/2021,6/1/2021,2/12/2022,3/20/2022,4/26/2022,6/2/2022,7/7/2022,8/12/2022,9/16/2022,10/24/2022,3/3/2019,8/30/2019,2/26/2020,8/24/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05064436,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00125,SP00005,A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants,,,Healthy Volunteers,,,,,,,,Industry,Not yet recruiting,Phase 1,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Mac L,Suzie K,Mary H,John G,Suzie K,Anthony P,Dinah R,Patria R,Corrine U,Suzie K,Geralyn K,Naren G,Xochitl D,Tiffiny K,Otis Thode †,Garnet T,Mara A,Lyman W,Mara A,,,,62.97919193,56.68127274,All,"20 Years and older ¬† (Adult, Older Adult)",288,279,257,122,119,16,10/19/2016,3/28/2017,2/16/2017,3/5/2017,2/2/2017,2/25/2017,6/8/2017,10/29/2017,11/26/2017,7/22/2021,4/27/2021,10/30/2021,12/28/2021,2/23/2022,3/30/2022,5/11/2022,6/15/2022,7/21/2022,9/19/2022,8/24/2017,2/20/2018,8/19/2018,2/15/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05051553,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00133,SP00005,A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF),,EQUAL-AF,Atrial Fibrillation,,Cardiovascular,,,,,,Industry,Recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Dalton E,Lavina S,Corrine U,Louann C,Dalton E,Jaquelyn H,Remedios Z,Frank T,Remedios Z,Jerold Goo †,Patria R,Patria R,Mary H,Harry A,Perter K,Xochitl D,Selizabeth F,Aleta H,Marceline R,,,"Local Institution, Swansea, United Kingdom",62.98604408,56.68743967,All,"18 Years and older ¬† (Adult, Older Adult)",274,262,258,85,159,14,1/21/2018,7/4/2018,5/10/2018,6/22/2018,5/31/2018,6/4/2018,8/5/2018,10/20/2018,11/6/2018,12/18/2020,2/16/2021,9/30/2021,11/1/2021,12/7/2021,2/4/2022,3/19/2022,5/6/2022,6/30/2022,8/6/2022,12/1/2018,5/30/2019,11/26/2019,5/24/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05044533,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00144,SP00005,A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus,,LUCENCE,Non-Small Cell Lung Cancer,,Oncology,,,,,,Industry,Recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Hee Y,Livia Pacheo †,Mary H,Terisa Sikora †,James y,James y,Quentin N,Lucie P,Garnet T,Federico L,Lyman W,James y,Naren G,John G,Tien C,Marcelina X,James y,Frank T,Terisa Sikora †,,,"Local Institution, Athens, Greece",98.14894621,88.33405159,All,"50 Years and older ¬† (Adult, Older Adult)",278,265,259,177,59,23,4/17/2021,11/28/2021,9/9/2021,10/12/2021,9/10/2021,10/3/2021,1/6/2022,5/27/2022,6/7/2022,8/4/2025,12/12/2024,4/26/2025,9/15/2025,10/28/2025,12/25/2025,2/9/2026,3/30/2026,5/5/2026,6/5/2026,4/1/2022,9/28/2022,3/27/2023,9/23/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05034926,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00156,SP00005,A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan,,,Non-Valvular Atrial Fibrillation (NVAF),,,,,,,,Industry,Recruiting,Phase 2,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Federico L,Tammara F,Tamesha T,Suzie K,Jerold Goo †,Quentin N,Mary H,Naren G,Anthony P,Doreen T,Terisa Sikora †,Stephan T,Selizabeth F,Liberty A,John G,John G,Selizabeth F,In Bellini †,Frank T,,,"Local Institution, Tokyo, Japan",83.34334627,75.00901164,All,18 Years to 50 Years ¬† (Adult),274,268,260,180,53,27,1/25/2019,7/10/2019,5/6/2019,6/4/2019,4/29/2019,5/21/2019,10/9/2019,3/3/2020,3/20/2020,8/30/2021,2/13/2021,8/21/2021,9/30/2021,11/21/2021,12/27/2021,1/26/2022,3/18/2022,4/25/2022,6/11/2022,11/17/2019,5/15/2020,11/11/2020,5/10/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05027061,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00168,SP00005,A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis,,,"Dermatitis, Atopic",,I&I,,,,,,Industry,Recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Mary H,Selizabeth F,Liberty A,Jerold Goo †,Lavina S,Kandace p,Ross S,Tiffiny K,Perter K,Lucie P,Marcelina X,Suzie K,Frank T,Terisa Sikora †,Suzie K,Frank T,Clarice N,Rima Y ,Naren G,,,"Local Institution, Los Angeles, California, United States|San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States|Local Institution, Skokie, Illinois, United States|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, East Melbourne, Victoria, Australia|Local Institution, Linz, Austria|Local Institution, Calgary, Alberta, Canada|Local Institution, London, Ontario, Canada|Local Institution, Markham, Ontario, Canada|Local Institution, Berlin, Germany|Local Institution, Berlin, Germany|Local Institution, Bochum, Germany|Local Institution, Bonn, Germany|Local Institution, Dresden, Germany|Local Institution, Gera, Germany|Local Institution, Hannover, Germany|Local Institution, Kiel, Germany|Local Institution, Munich, Germany|Local Institution, Osnabr√ºck, Germany|Local Institution, Selters, Germany|Local Institution, Bydgoszcz, Poland|Local Institution, Warsaw, Poland|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Las Palmas De GC, Spain|Local Institution, Madrid, Spain",99.99044533,89.9914008,All,"18 Years and older ¬† (Adult, Older Adult)",296,286,261,116,126,19,3/18/2019,7/29/2019,6/2/2019,6/25/2019,6/5/2019,6/18/2019,10/15/2019,3/10/2020,4/6/2020,3/22/2022,3/27/2022,9/20/2022,10/23/2022,12/1/2022,1/15/2023,3/14/2023,5/2/2023,6/27/2023,7/29/2023,12/15/2019,6/12/2020,12/9/2020,6/7/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05014438,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00183,SP00005,A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer,,,Non-Small Cell Lung Cancer,,Oncology,,,,,,Industry,Not yet recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Suzie K,Mary H,Lyman W,Terisa Sikora †,Stephan T,John G,Kandace p,Louann C,Anthony P,John G,Tammara F,Stephan T,Selizabeth F,Jeanene Y,Frank T,Jaquelyn H,Mara A,Naren G,Federico L,,,,10.63772865,9.573955784,All,"Child, Adult, Older Adult",271,266,262,106,140,16,6/17/2019,11/30/2019,10/3/2019,11/11/2019,10/2/2019,10/22/2019,3/18/2020,6/15/2020,6/20/2020,2/27/2023,8/1/2023,12/9/2023,2/22/2024,3/29/2024,5/7/2024,6/7/2024,7/28/2024,9/13/2024,11/8/2024,4/19/2020,10/16/2020,4/14/2021,10/11/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05005273,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00184,SP00005,A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma,,RELATIVITY-098,Melanoma,,Oncology,,,,,,Industry,Not yet recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Selizabeth F,Mary H,Liberty A,Clarice N,Chetan K,Jeanene Y,Ngan D,Stephan T,Ngan D,Ngan D,Frank T,Xochitl D,Lavina S,Frank T,Christian G,Anthony P,Doreen T,Ngan D,Perter K,,,"Local Institution, Pensacola, Florida, United States|Local Institution, Fridley, Minnesota, United States|Local Institution, Charlotte, North Carolina, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Houston, Texas, United States|Local Institution, Fairfax, Virginia, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Buenos Aires, Distrito Federal, Argentina|Local Institution, Ciudad Aut√≥noma de Buenos Aires, Distrito Federal, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Waratah, New South Wales, Australia|Local Institution, Wollstonecraft, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Ballarat Central, Victoria, Australia|Local Institution, North Melbourne, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Graz, Austria|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Li√®ge, Belgium|Local Institution, Wilrijk, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Recoleta, Metropolitana, Chile|Local Institution, Aalborg, Denmark|Local Institution, Aarhus N, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense C, Denmark|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Local Institution, Dijon, France|Local Institution, Marseille, France|Local Institution, Nantes, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Toulouse Cedex, France|Local Institution, Villejuif, France|Local Institution, Buxtehude, Germany|Local Institution, Dresden, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Gera, Germany|Local Institution, Hannover, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, L√ºbeck, Germany|Local Institution, Munich, Germany|Local Institution, Tuebingen, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Athina, Greece|Local Institution, Piraeus, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Afula, Israel|Local Institution, Jerusalem, Israel|Local Institution, Ramag Gan, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Perugia, Italy|Local Institution, Siena, Italy|Local Institution, Ciudad de M√©xico, Distrito Federal, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Mexico, Nuevo LEON, Mexico|Local Institution, Oaxaca, Mexico|Local Institution, Lorenskog, Norway|Local Institution, Oslo, Norway|Local Institution, Stavanger, Norway|Local Institution, Brasov, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Floresti/ Cluj, Romania|Local Institution, Iasi, Romania|Local Institution, Badajoz, Spain|Local Institution, Donostia, Spain|Local Institution, Granada, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain|Local Institution, Goteborg, Sweden|Local Institution, Lund, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Basel, Switzerland|Local Institution, Chur, Switzerland|Local Institution, Z√ºrich-Flughafen, Switzerland",10.01732688,9.015594194,All,"18 Years and older ¬† (Adult, Older Adult)",286,276,263,127,115,21,7/4/2023,11/22/2023,10/7/2023,10/22/2023,9/29/2023,10/14/2023,2/17/2024,5/16/2024,5/30/2024,4/16/2025,12/13/2024,6/19/2025,7/29/2025,8/30/2025,10/29/2025,11/29/2025,1/19/2026,2/27/2026,4/25/2026,4/11/2024,10/8/2024,4/6/2025,10/3/2025,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05002569,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00186,SP00005,Taste Assessment of Ozanimod,,,Healthy Volunteers,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Xochitl D,Lyman W,Clarice N,Marcelina X,James y,Liberty A,Jene M,Geralyn K,Harry A,Terisa Sikora †,Perter K,James y,Terisa Sikora †,John G,Naren G,Suk T,Chetan K,Kala R,Corrine U,,,"Senopsys LLC, Woburn, Massachusetts, United States",21.82999589,19.6469963,All,"18 Years and older ¬† (Adult, Older Adult)",273,270,264,110,135,19,8/26/2016,3/9/2017,1/23/2017,2/20/2017,1/15/2017,2/4/2017,3/24/2017,5/27/2017,6/14/2017,7/21/2021,3/6/2021,6/1/2021,10/17/2021,11/26/2021,12/26/2021,1/31/2022,3/18/2022,5/17/2022,6/21/2022,8/3/2017,1/30/2018,7/29/2018,1/25/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05001152,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00235,SP00005,"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants",,,Healthy Volunteers,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Kandace p,Lavina S,Remedios Z,Lilla Stilson †,Frank T,Jaquelyn H,Lilla Stilson †,Clarice N,Clarice N,Lucie P,Perter K,Tiffiny K,Chetan K,Suk T,Anthony P,John G,Dinah R,Suzie K,Ross S,,,"Local Institution, Cypress, California, United States",48.48046695,43.63242026,All,3 Years to 8 Years ¬† (Child),283,274,265,235,9,21,6/29/2016,12/12/2016,10/12/2016,11/11/2016,10/12/2016,10/28/2016,2/4/2017,5/9/2017,5/18/2017,12/5/2020,2/7/2021,8/10/2021,11/8/2021,12/31/2021,2/24/2022,4/8/2022,5/30/2022,7/22/2022,9/15/2022,4/26/2017,10/23/2017,4/21/2018,10/18/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04965402,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00236,SP00005,A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants,,,Healthy Volunteers,,,,,,,,Industry,Recruiting,Phase 1,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Garnet T,Lucie P,Dalton E,Kala R,Xochitl D,Marceline R,Suzie K,Marceline R,Otis Thode †,Clarice N,John G,Naren G,Selizabeth F,Xochitl D,Terrell p,Donovan H,Tamesha T,Mara A,,,"Quotient Sciences, Mere Way, Ruddington Fields, Ruddington, Nottingham, United Kingdom",85.24834695,76.72351226,All,18 Years to 45 Years ¬† (Adult),277,271,266,125,118,23,3/28/2019,9/3/2019,7/18/2019,8/10/2019,7/7/2019,7/25/2019,11/1/2019,12/9/2019,12/27/2019,3/31/2021,1/24/2021,3/31/2021,8/24/2021,10/19/2021,12/1/2021,1/24/2022,3/12/2022,4/28/2022,6/5/2022,1/21/2020,7/19/2020,1/15/2021,7/14/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04965389,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00259,SP00005,"A Study to Assess the Effect of Itraconazole, Phenytoin, and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants",,,Healthy Participants,,,,,,,,Industry,Recruiting,Phase 1,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Lavina S,Suzie K,Selizabeth F,Anthony P,Lyman W,Kandace p,Quentin N,Selizabeth F,Donovan H,Jeanene Y,Beulah N,Mara A,Rima Y ,Jaquelyn H,Gertrudis T,Lavina S,Quentin N,John G,Jerold Goo †,,,"Local Institution, Berlin, New Jersey, United States",94.56491245,85.10842121,All,"Child, Adult, Older Adult",290,278,267,200,31,36,10/19/2016,2/24/2017,1/3/2017,1/27/2017,1/8/2017,1/19/2017,3/4/2017,4/17/2017,5/9/2017,7/4/2021,5/8/2021,10/24/2021,1/18/2022,2/27/2022,4/19/2022,6/12/2022,7/25/2022,8/26/2022,10/23/2022,7/18/2017,1/14/2018,7/13/2018,1/9/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04956627,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00268,SP00005,A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants,,,Healthy Participants,,,,,,,,Industry,Recruiting,,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Lavina S,James y,Ngan D,Naren G,Selizabeth F,Xochitl D,Marcelina X,Quentin N,Otis Thode †,Mara A,Mary H,Lilla Stilson †,Jene M,Tammara F,Jaquelyn H,Chetan K,Tien C,Remedios Z,Tiffiny K,,,"Local Institution, Austin, Texas, United States",27.92381912,25.13143721,All,"16 Years to 19 Years ¬† (Child, Adult)",307,293,268,97,154,17,6/15/2017,11/14/2017,8/31/2017,10/6/2017,9/2/2017,9/25/2017,11/27/2017,1/4/2018,1/30/2018,11/27/2021,6/1/2021,8/10/2021,12/28/2021,2/24/2022,4/20/2022,6/4/2022,7/16/2022,9/7/2022,10/19/2022,3/24/2018,9/20/2018,3/19/2019,9/15/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04949269,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00272,SP00005,A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors,,,Advanced Solid Tumors,,Oncology,,,,,,Industry,Not yet recruiting,Early Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Rima Y ,Quentin N,Aleta H,Selizabeth F,Dalton E,Doreen T,Tammara F,Doreen T,Ngan D,Suk T,Jene M,Frank T,Mary H,Jaquelyn H,Jeanene Y,Ross S,Hee Y,Patria R,Garnet T,,,"Local Institution, Atlanta, Georgia, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Hackensack, New Jersey, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Houston, Texas, United States|Local Institution, Edmonton, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montr√©al, Quebec, Canada",75.33395469,67.80055922,All,"18 Years and older ¬† (Adult, Older Adult)",292,285,269,238,7,24,12/23/2021,6/22/2022,4/27/2022,6/3/2022,4/30/2022,5/16/2022,6/27/2022,8/31/2022,9/23/2022,11/24/2022,1/23/2023,10/12/2023,11/13/2023,12/26/2023,2/10/2024,4/4/2024,5/9/2024,6/25/2024,7/29/2024,11/12/2022,5/11/2023,11/7/2023,5/5/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04943900,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00275,SP00005,A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants,,,Healthy Participants,,,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Anthony P,Mee M,Frank T,Clarice N,Corrine U,Frank T,Marcelina X,Livia Pacheo †,Marcelina X,Jerold Goo †,Lilla Stilson †,Anthony P,Otis Thode †,Doreen T,John G,Kandace p,Dinah R,Anthony P,Louann C,,,"Local Institution, Austin, Texas, United States",91.76115782,82.58504204,All,40 Years to 49 Years ¬† (Adult),296,286,270,220,13,37,11/18/2016,5/1/2017,2/17/2017,3/27/2017,2/27/2017,3/15/2017,5/2/2017,6/7/2017,6/27/2017,10/7/2020,1/19/2021,6/13/2021,9/8/2021,10/12/2021,11/23/2021,12/25/2021,2/20/2022,3/22/2022,5/1/2022,9/11/2017,3/10/2018,9/6/2018,3/5/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04941755,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00296,SP00005,A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Frank T,Otis Thode †,Mac L,Doreen T,Livia Pacheo †,Quentin N,Selizabeth F,Louann C,Lilla Stilson †,Aleta H,Mara A,Louann C,Tiffiny K,Doreen T,Jerold Goo †,James y,Remedios Z,Perter K,Aleta H,,,"Innovative Clinical Research Institute, Whittier, California, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Northside Hospital,Inc.- Central Research Department, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Summit Medical Group, Florham Park, New Jersey, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg, Virginia, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Calvary Central Districts Hospital, Elizabeth Vale, South Australia, Australia|Breast Cancer Research Centre - WA, Nedlands, Western Australia, Australia|Local Institution, Liege, Belgium|Local Institution, Namur, Belgium|Local Institution, Wilrijk, Belgium|Centre Leon Berard, Lyon Cedex 08, France|Centre de Cancerologie du Grand Montpellier, Montpellier, France|Institut Claudius Regaud, TOULOUSE Cedex 9, France|Local Institution, Bonn, Germany|Local Institution, Erlangen, Germany|Klinik Essen-Mitte, Essen, Germany|Local Institution, Moenchengladbach, Germany|Local Institution, Saarbruecken, Germany|Clinical Research Puerto Rico, Manati, Puerto Rico|Ponce Medical School Foundation, Ponce, Puerto Rico|Fundacion De Investigacion, San Juan, Puerto Rico|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Hospital Clinico Universitario De Valencia, Valencia, Spain",14.04339539,12.63905585,All,"18 Years and older ¬† (Adult, Older Adult)",299,287,271,94,165,12,2/24/2016,8/28/2016,6/11/2016,7/27/2016,6/24/2016,7/9/2016,10/19/2016,3/5/2017,3/28/2017,1/9/2021,1/4/2021,5/3/2021,7/27/2021,9/5/2021,11/2/2021,12/22/2021,2/2/2022,3/16/2022,5/15/2022,1/5/2017,7/4/2017,12/31/2017,6/29/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04075604,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00298,SP00005,Combination Study of BMS-754807 and Herceptin¬Æ in Patients With Advanced or Metastatic Her-2-positive Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 1|Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Mara A,Beulah N,Beulah N,Gertrudis T,Tiffiny K,Jerold Goo †,Selizabeth F,Mary H,Anthony P,Beulah N,Mary H,Harry A,Quentin N,Corrine U,Tien C,Liberty A,Ross S,Terisa Sikora †,Corrine U,,,"Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Geelong, Victoria, Australia|Local Institution, Brussels, Belgium|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Budapest, Hungary|Local Institution, Miskolc, Hungary|Local Institution, Newcastle Upon Tyne, Tyne And Wear, United Kingdom",75.90730299,68.31657269,Female,"16 Years to 120 Years ¬† (Child, Adult, Older Adult)",303,292,272,246,11,15,3/16/2009,9/7/2009,6/17/2009,7/25/2009,6/19/2009,7/11/2009,12/8/2009,4/17/2010,4/26/2010,11/24/2010,3/9/2011,6/18/2011,11/1/2011,12/14/2011,1/30/2012,3/27/2012,5/19/2012,7/4/2012,8/15/2012,1/7/2010,7/6/2010,1/2/2011,7/1/2011,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00788333,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00301,SP00005,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Livia Pacheo †,Mary H,Quentin N,Tamesha T,Lucie P,Frank T,Marcelina X,Mary H,John G,Aleta H,Mara A,Naren G,Mara A,Lavina S,Lucie P,John G,Tammara F,Chetan K,John G,,,"Comprehensive Cancer Center, Palm Springs, California, United States|Northwest Oncology & Hematology Associates, Coral Spring, Florida, United States|Florida Cancer Research Institute, Davie, Florida, United States|Medical Specialists Of Palm Beaches, Lake Worth, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|University Medical Center, Inc, Louisville, Kentucky, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Albert Einstein Cancer Center, Bronx, New York, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Providence Cancer Center, Spokane, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Wien, Austria|Local Institution, Bordeaux, France|Local Institution, Saint Herblain, France|Local Institution, Duesseldorf, Germany|Local Institution, Erlangen, Germany|Local Institution, Jena, Germany|Local Institution, New Delhi, Delhi, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Trivandrum, Kerala, India|Local Institution, Pune, Maharashtra, India|Local Institution, Bhopal, India|Local Institution, Hyderabad, India|Local Institution, Mumbai, India|Local Institution, Vellore, India|Local Institution, Bologna, Italy|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Callao, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Cebu City, Philippines|Local Institution, Davao City, Philippines|Local Institution, Quezon City, Philippines|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Jaen, Spain|Local Institution, Lleida, Spain|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Nottingham, Nottinghamshire, United Kingdom|Local Institution, Coventry, Warwickshire, United Kingdom",26.18229875,23.56406887,Female,18 Years to 45 Years ¬† (Adult),302,294,273,183,62,28,9/16/2006,4/26/2007,3/6/2007,3/17/2007,3/4/2007,3/11/2007,4/11/2007,8/11/2007,8/23/2007,6/26/2009,2/27/2009,10/24/2009,12/1/2009,1/20/2010,3/9/2010,4/27/2010,6/25/2010,8/19/2010,10/8/2010,9/7/2007,3/5/2008,9/1/2008,2/28/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00455533,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00302,SP00005,Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Lyman W,Dinah R,Harry A,Otis Thode †,Tammara F,Christian G,Tammara F,Anthony P,Quentin N,John G,Beulah N,Ross S,Mary H,Aleta H,Mary H,Tammara F,Patria R,Anthony P,Rima Y ,,,"Compassionate Cancer Care Medical Group, Inc, Fountain Valley, California, United States|Compassionate Cancer Care Medical Group Inc, Riverside, California, United States|Pennsylvania Oncology/Hematology Associates, Philadelphia, Pennsylvania, United States|The West Clinic, Memphis, Tennessee, United States|Local Institution, Hradec Kralove, Czech Republic|Local Institution, Prague 5, Czech Republic|Local Institution, Lille, France|Local Institution, Paris Cedex 13, France|Local Institution, Saint-Cloud Cedex, France|Local Institution, Dublin, Ireland|Local Institution, Gdansk, Poland|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Opole, Poland|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Torrevieja, Spain|Local Institution, Vasteras, Sweden|Local Institution, Chelmsford, Essex, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Coventry, Warwickshire, United Kingdom",86.57703687,77.91933319,All,"18 Years and older ¬† (Adult, Older Adult)",297,292,274,214,30,30,6/14/2008,10/31/2008,9/1/2008,10/6/2008,9/24/2008,9/27/2008,2/24/2009,4/19/2009,5/16/2009,1/16/2011,8/2/2010,12/7/2010,3/1/2011,4/28/2011,6/8/2011,7/19/2011,8/27/2011,10/5/2011,11/16/2011,3/26/2009,9/22/2009,3/21/2010,9/17/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00767520,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00303,SP00005,Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC),,,,,Oncology,,,,,,Industry,Unknown status,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Selizabeth F,Lyman W,Terrell p,Beulah N,Lyman W,Selizabeth F,Harry A,Mee M,Frank T,Anthony P,Jeanene Y,Tamesha T,Stephan T,Donovan H,Clarice N,John G,Terrell p,Lucie P,Lavina S,,,"Local Institution, Barcelona, Spain",33.3164906,29.98484154,All,"18 Years and older ¬† (Adult, Older Adult)",285,279,275,200,42,33,2/6/2017,9/1/2017,7/16/2017,8/17/2017,7/14/2017,7/31/2017,10/15/2017,11/24/2017,12/12/2017,8/25/2018,6/24/2018,12/31/2018,3/28/2019,5/4/2019,6/9/2019,7/15/2019,9/7/2019,10/22/2019,12/15/2019,1/27/2018,7/26/2018,1/22/2019,7/21/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03425825,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00318,SP00005,A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy,,,,,Oncology,,,,,,Industry,Recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Jerold Goo †,Anthony P,Harry A,John G,Stephan T,Kandace p,Selizabeth F,Marceline R,Louann C,Suzie K,Quentin N,Tammara F,Mary H,Kandace p,Chetan K,Livia Pacheo †,Chetan K,Remedios Z,Tamesha T,,,"Local Institution, Paris Cedex 5, France",17.25725116,15.53152604,All,"18 Years and older ¬† (Adult, Older Adult)",303,292,276,236,10,30,9/15/2020,3/3/2021,12/17/2020,1/8/2021,12/16/2020,1/3/2021,3/21/2021,7/25/2021,8/5/2021,5/16/2025,2/5/2025,8/9/2025,9/15/2025,10/15/2025,12/10/2025,1/10/2026,2/9/2026,4/2/2026,6/1/2026,7/2/2021,12/29/2021,6/27/2022,12/24/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04500535,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00334,SP00005,Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 1|Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Mary H,Doreen T,Suk T,Gertrudis T,Tamesha T,Jaquelyn H,In Bellini †,Frank T,Selizabeth F,Chetan K,Clarice N,Gertrudis T,Geralyn K,Louann C,Rima Y ,Hee Y,James y,John G,John G,,,"University of Chicago, Chicago, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Hematology-Oncology Associates Of Rockland, Nyack, New York, United States|Duke University, Durham, North Carolina, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States",96.26148075,86.63533267,Male,"18 Years and older ¬† (Adult, Older Adult)",308,301,277,210,34,33,7/13/2008,11/18/2008,9/19/2008,10/24/2008,9/24/2008,10/13/2008,12/18/2008,4/12/2009,5/7/2009,8/4/2011,7/3/2011,12/17/2011,2/1/2012,3/31/2012,5/23/2012,7/14/2012,9/3/2012,10/13/2012,11/23/2012,4/11/2009,10/8/2009,4/6/2010,10/3/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00439270,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00364,SP00005,"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer",,,,,Oncology,,,,,,Industry,Recruiting,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug A,,,,,,,,,,,,,,,,,,,Louann C,Suk T,Xochitl D,Suk T,In Bellini †,Suzie K,Terrell p,Mee M,Ross S,Liberty A,Jerold Goo †,Aleta H,Hee Y,Aleta H,Jene M,Geralyn K,Terisa Sikora †,Lyman W,Lilla Stilson †,,,"University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States|Local Institution, Concord, California, United States|Marin Cancer Care, Inc, Greenbrae, California, United States|Local Institution, Los Angeles, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Bennett Cancer Center, Stamford, Connecticut, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Local Institution, Orlando, Florida, United States|Sacred Heart Medical Group, Pensacola, Florida, United States|Tallahassee Memorial Cancer Center, Tallahassee, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Northside Hospital,Inc.- Central Research Department, Atlanta, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States|Local Institution, Louisville, Kentucky, United States|New England Cancer Specialists, Scarborough, Maine, United States|American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States|HCA Midwest Division, Kansas City, Missouri, United States|Local Institution, Flemington, New Jersey, United States|Summit Medical Group, Florham Park, New Jersey, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Local Institution, Charlotte, North Carolina, United States|Local Institution, Durham, North Carolina, United States|Local Institution, Winston-Salem, North Carolina, United States|Local Institution, Canton, Ohio, United States|Local Institution, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Portland, Oregon, United States|Tennessee Oncology, PLLC - SCRI - PPDS, Chattanooga, Tennessee, United States|Local Institution, Knoxville, Tennessee, United States|Ft. Worth Center For Cancer Blood Disorders, Fort Worth, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Local Institution, Fairfax, Virginia, United States|Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Local Institution, Seattle, Washington, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma Beunos Aires, Buenos Aires, Argentina|Hospital Britanico De Buenos Aires, Ciudad Aut√≥noma de Buenos Aires, Buenos Aires, Argentina|Local Institution, La Plata, Buenos Aires, Argentina|Local Institution, R√≠o Cuarto, Cordoba, Argentina|Local Institution, Rosario, Santa FE, Argentina|Clinica Adventista Belgrano, Buenos Aires, Argentina|Instituto Medico Especialazado Alexander Fleming, Caba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, La Rioja, Argentina|Local Institution, Viedma, Argentina|Mater Hospital, North Sydney, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Royal Brisbane and Womens Hospital, Herston, Queensland, Australia|Calvary Central Districts Hospital, Elizabeth Vale, South Australia, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Ballarat Base Hospital, North Ballarat, Victoria, Australia|Universitaetsklinik F. Frauenheilkunde / Geburtshilfe, Graz, Austria|Med. Universitaet Innsbruck, Innsbruck, Austria|Landeskrankenhaus-Universitaetsklinik fuer Innere Medizin III, Salzburg, Austria|Medizinische Universitaet Wien, Wien, Austria|Medizinische Universitaet Wien, Wien, Austria|Grand H√¥pital de Charleroi, Charleroi, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|UZ Gent-Medical oncology, Gent, Belgium|UZ Brussel, Jette, Belgium|CHU de Li√®ge, Liege, Belgium|Oncocentro Servico Medicos e Hospitalares Ltda, Fortaleza, Ceara, Brazil|Hospital Sirio Libanes, Brasilia, Distrito Federal, Brazil|Local Institution, Goiania, Goias, Brazil|Universidade Federal De Minas Gerais, Belo Horizonte - Mg, Minas Gerais, Brazil|Local Institution, Juiz de Fora, Minas Gerais, Brazil|Associacao Hospital de Caridade Ijui, Ijui, RIO Grande DO SUL, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre - Hospital Santa Rita, Port Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital Sao Lucas Da Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Santa Cruz do Sul, RIO Grande DO SUL, Brazil|Fundacao Pio Xii Hosp Cancer De Barretos, Barretos, Sao Paulo, Brazil|Faculdade De Medicina Do Abc, Santo Andre, SAO Paulo, Brazil|Local Institution, S√£o Paulo, SAO Paulo, Brazil|COI Clinicas Oncologicas Integradas SA, Rio de Janeiro, Brazil|Centro de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Thunder Bay, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Centre Hospitalier de l'Universit√© de Montr√©al-Breast Cancer, Montr√©al, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Local Institution, La Serena, Coquimbo, Chile|Centro de Investigacion Clinica Bradford Hill, Santiago de Chile, Metropolitana, Chile|Hospital Clinico Pontificia Universidad Catolica De Chile, Santiago Region Metropolitana, Metropolitana, Chile|Oncocentro Apys, Vina del Mar, Valparaiso, Chile|Local Institution, Bengbu, Anhui, China|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Xiamen, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Shjiazhuang, Hebei, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Wuhan, Hubei, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, XiAn, Shan1xi, China|Local Institution, Jinan, Shandong, China|Local Institution, Qingdao, Shandong, China|Local Institution, YanTai, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Chengdu, China|Local Institution, Colombia, Bogota, Colombia|Local Institution, Barranquilla, Colombia|Local Institution, Bogot√°, Colombia|Local Institution, Cali, Colombia|Local Institution, Floridablanca, Colombia|Local Institution, Monteria, Colombia|Local Institution, Pereira, Colombia|Local Institution, Rionegro, Antioquia, Colombia|Local Institution, Chomutov, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Komplexni onkologicke centrum, Novy Jicin, Czechia|Onkologicka klinika, Olomouc, Czechia|Radioterapeuticka a onkologicka klinika FNKV, Praha 10, Czechia|Local Institution, Aarhus N, Denmark|Local Institution, Herlev, Denmark|Local Institution, Kobenhavn O, Denmark|Local Institution, Naestved, Denmark|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Bayonne, France|Chu Jean Minjoz, Besancon, France|Hopital Morvan, Brest, France|Centre Jean Perrin, Clermont-ferrand, France|Clinique Victor Hugo, Le Mans, France|Hopital Prive Jean Mermoz, Lyon, France|Institut du Cancer de Montpellier, Montpellier Cedex 5, France|Hopital Europeen Georges Pompidou, Paris, France|H√¥pital Priv√© Des C√¥tes d'Armor, Plerin, France|Institut De Cancerologie De L Ouest, Saint Herblain Cedex, France|Local Institution, Strasbourg, France|Centre Hospitalier intercommunal de Toulon La Seyne sur Mer, Toulon, France|Institut Gustave Roussy, Villejuif, France|Helios Klinikum Berlin-Buch, Berlin, Germany|Local Institution, Berlin, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum Essen, Essen, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|Agaplesion Diakonieklinikum, Hamburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum d. Saarlandes, Homburg, Germany|Universitaetsklinikum Koeln, Koeln, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Evang. Krankenhaus Bethesda, Moenchengladbach, Germany|Klinikum der Universitaet Muenchen, Muenchen, Germany|Uni Frauenklinikum Suedstadt, Rostock, Germany|CaritasKlinikum Saarbruecken., Saarbruecken, Germany|MVZ-Onkologie Velbert GbR, Velbert, Germany|Universitaetsklinikum Wuerzburg, W√ºrzburg, Germany|Local Institution, Hong Kong, Hong Kong|St. James'S Hospital, Dublin 8, Dublin, Ireland|Local Institution, Cork, Ireland|Beaumont Hospital, Dublin, Ireland|Local Institution, Bergamo, Italy|Local Institution, Brindisi, Italy|Local Institution, Catania, Italy|Azienda Ospedaliero-Universitaria Mater Domini, Catanzaro, Italy|Local Institution, Milano, Italy|Azienda Ospedaliero Universitaria Federico II di Napoli, Napoli, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Fondazione Irccs - Policlinico San Matteo, Pavia, Italy|Local Institution, Prato, Italy|Local Institution, Roma, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Tijuana, BAJA California, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Campeche, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, Colima, Mexico|Local Institution, Oaxaca, Mexico|Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Local Institution, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Oddzial Dzienny Chemioterapii, Koszalin, Poland|Local Institution, Krakow, Poland|Klinika Onkologii CZMP, Lodz, Poland|Local Institution, Opole, Poland|Klinika Nowotworow Piersi i Chirurgii Rekonstrukcyjnej, Warszawa, Poland|Local Institution, Lisboa, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Ponce Medical School Foundation, Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Bucharest, Romania|Local Institution, Bucuresti, Romania|Local Institution, Craiova, Romania|Local Institution, Floresti, Romania|Local Institution, Suceava, Romania|Local Institution, Krasnodar, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Sochi, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Elche (alicante), Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Sevilla, Spain|University Hospital Basel, Basel, Switzerland|CHUV, Lausanne, Switzerland|Onkologiezentrum Thun-Berner Oberland Spital Sts Ag, Thun, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Tainan City, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Adana, Turkey|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Swansea, Glamorgan, United Kingdom|The Christie NHS Foundation Trust, Withington, Manchester, United Kingdom|Local Institution, Coventry, United Kingdom|Local Institution, Headington, United Kingdom|Local Institution, London, United Kingdom",19.61323969,17.65191572,All,"18 Years and older ¬† (Adult, Older Adult)",310,300,278,123,131,24,6/21/2029,2/2/2030,11/27/2029,12/27/2029,11/28/2029,12/12/2029,5/5/2030,10/2/2030,10/27/2030,12/13/2031,9/17/2031,2/3/2032,6/20/2032,7/30/2032,9/2/2032,10/26/2032,12/11/2032,1/13/2033,3/1/2033,6/10/2030,12/7/2030,6/5/2031,12/2/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04109066,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00405,SP00005,"Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada",,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Ngan D,Terisa Sikora †,Gertrudis T,Chetan K,Suzie K,Christian G,Liberty A,In Bellini †,Jene M,Mara A,Aleta H,Xochitl D,Frank T,Dalton E,Mara A,Otis Thode †,Stephan T,Perter K,Lyman W,,,,33.06988259,29.76289433,All,"18 Years and older ¬† (Adult, Older Adult)",310,305,279,168,89,22,6/21/2012,1/9/2013,11/11/2012,12/21/2012,11/28/2012,12/7/2012,3/10/2013,5/7/2013,6/6/2013,3/18/2016,4/14/2016,9/22/2016,12/6/2016,1/9/2017,3/3/2017,4/4/2017,5/19/2017,7/17/2017,9/8/2017,6/5/2013,12/2/2013,5/31/2014,11/27/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02705833,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00408,SP00005,A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread,,,,,Oncology,,,,,,Industry,Recruiting,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Dalton E,Naren G,Otis Thode †,Harry A,Frank T,Quentin N,Otis Thode †,Suk T,Doreen T,Mee M,Geralyn K,Chetan K,Lilla Stilson †,Lavina S,In Bellini †,Suzie K,Tammara F,Selizabeth F,Mary H,,,"Hoag Memorial Hospital Presbyterian, Los Angeles, California, United States|Usc Norris Cancer Center And Hospital, Los Angeles, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Local Institution, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Chicago, Illinois, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Laura And Isaac Perlmutter Cancer Center, New York, New York, United States|Local Institution, Uniondale, New York, United States|Local Institution, Cleveland, Ohio, United States|University Of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Local Institution, Salt Lake City, Utah, United States",93.67974539,84.31177085,All,"18 Years and older ¬† (Adult, Older Adult)",297,285,280,119,148,13,11/22/2019,5/18/2020,4/2/2020,4/30/2020,3/31/2020,4/16/2020,6/29/2020,9/4/2020,9/25/2020,8/21/2023,11/25/2023,4/22/2024,6/30/2024,8/6/2024,9/20/2024,10/20/2024,11/29/2024,1/8/2025,2/7/2025,10/13/2020,4/11/2021,10/8/2021,4/6/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04132817,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00424,SP00005,A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Mara A,Perter K,John G,James y,Geralyn K,Geralyn K,Perter K,Jene M,Corrine U,Naren G,Mara A,Lyman W,Mara A,Mara A,Aleta H,Terrell p,Ross S,Donovan H,John G,,,"Ucsf-Comprehensive Cancer Center, San Francisco, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Dana-Farber Cancer Inst, Boston, Massachusetts, United States|Montefiore Medical Center, Bronx, New York, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Local Institution, Paris, France|Local Institution, Toulouse Cedex 3, France|Local Institution, Modena, Italy|Local Institution, Barcelona, Spain|Local Institution, Lleida, Spain",20.53499514,18.48149562,Female,"19 Years and older ¬† (Adult, Older Adult)",307,295,281,218,40,23,6/5/2006,11/12/2006,9/30/2006,10/21/2006,9/19/2006,10/11/2006,3/2/2007,7/8/2007,8/6/2007,3/20/2008,12/13/2007,6/22/2008,9/1/2008,10/1/2008,11/1/2008,12/10/2008,1/20/2009,2/23/2009,3/29/2009,4/9/2007,10/6/2007,4/3/2008,9/30/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00371254,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00470,SP00005,A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer,,,,,Oncology,,,,,,Industry,Recruiting,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Donovan H,Kandace p,Clarice N,Mara A,Lucie P,Liberty A,Lyman W,Marceline R,Lilla Stilson †,Dinah R,Lavina S,Naren G,In Bellini †,Dinah R,Patria R,John G,Terrell p,Frank T,Suzie K,,,"Local Institution, Mobile, Alabama, United States|Alaska Urological Associates, Apc, Anchorage, Alaska, United States|Local Institution, Phoenix, Arizona, United States|Local Institution, Scottsdale, Arizona, United States|Local Institution, Tucson, Arizona, United States|Local Institution, Tucson, Arizona, United States|St. Bernards Medical Center, Jonesboro, Arkansas, United States|UCLA Medical Center, Los Angeles, California, United States|University of California, Irvine, Orange, California, United States|Desert Hematology Oncology Medical Group Inc. - Main Office, Rancho Mirage, California, United States|Torrance Health Association DBA Cancer Care Associates, Redondo Beach, California, United States|The Urology Center of Colorado, Denver, Colorado, United States|VA Connecticut Healthcare System, West Haven, Connecticut, United States|Local Institution, Washington, District of Columbia, United States|Memorial Regional Cancer Center, Hollywood, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Orlando Health Inc., UF Health Cancer Center, Orlando, Florida, United States|Woodlands Medical Specialists, PA, Pensacola, Florida, United States|Local Institution, Port Saint Lucie, Florida, United States|Cleveland Clinic, Weston, Florida, United States|Blood Marrow Transplant Group of Georgia at Northside Hospital (Cumming), Atlanta, Georgia, United States|Local Institution, Marietta, Georgia, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Local Institution, Fairway, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|Maryland Oncology Hematology, Clinton, Maryland, United States|Local Institution, Boston, Massachusetts, United States|GU Research Network/Urology Cancer Center, Omaha, Nebraska, United States|Local Institution, East Brunswick, New Jersey, United States|Summit Medical Group, Florham Park, New Jersey, United States|Local Institution, Ridgewood, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|New York Cancer and Blood Specialists, Port Jefferson Station, New York, United States|Local Institution, Poughkeepsie, New York, United States|Ohio State University, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|MidLantic urology, Bala-Cynwyd, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates CHOA, Charleston, South Carolina, United States|Local Institution, Myrtle Beach, South Carolina, United States|West Cancer Center, Memphis, Tennessee, United States|Texas Oncology, P.A., Austin, Texas, United States|Local Institution, Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|(USOR) Texas Oncology, P.A., Houston, Texas, United States|University of Texas MD Anderson Cancer Clinic, Houston, Texas, United States|Urology San Antonio P.A., San Antonio, Texas, United States|The University of Texas Health Science Center at Tyler DBA UT Health East Texas Hope Cancer Center, Tyler, Texas, United States|Local Institution, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Spokane, Washington, United States|Hospital Privado de Comunidad, Mar del Plata, Buenos Aires, Argentina|Local Institution, Buenos Aires, Distrito Federal, Argentina|Clinica Viedma, Viedma, RIO Negro, Argentina|Local Institution, Rosario, Santa FE, Argentina|Centro de Investigacion Pergamino SA - Clinica Pergamino, Buenos Aires, Argentina|IDIM-Instituto de Diagnostico e Investigaciones Metabolicas, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Fundacion Richardet Longo FRL, Cordoba, Argentina|Gosford Hospital, Gosford, New South Wales, Australia|Lismore Base hospital, Lismore, New South Wales, Australia|Adventist HealthCare, Wahroonga, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Integrated Clinical Oncology Network Pty Ltd (ICON), South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Adelaide Oncology and Haematology, North Adelaide, South Australia, Australia|Psehog Pty Ltd, Frankston, Victoria, Australia|Cabrini Haematology and Oncology Centre, Malvern, Victoria, Australia|Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria|Uniklinikum Salzburg Universitatsklinik fur Urologie und Andrologie, Salzburg, Austria|Local Institution, Vienna, Austria|Medizinische Universtaet Wien, Vienna, Austria|Krankenhaus Barmherzige Brueder Wien, Wien, Austria|Hopital Universitaire Erasme, Anderlecht, Belgium|Az Sint-Jan-Campus Sint-Jan, Brugge, Belgium|AZ Sint-Lucas, Gent, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Local Institution, Kortrijk, Belgium|Az Turnhout Campus Sint-Elizabeth, Turnhout, Belgium|GZA St. Augustinus, Wilrijk, Belgium|Local Institution, Belo Horizonte, Minas Gerais, Brazil|PERSONAL Oncologia de Precisao e Personalizada, Belo Horizonte, Minas Gerais, Brazil|Instituto de Oncologia do Parana - IOP, Curitiba, Parana, Brazil|Local Institution, Curitiba, Parana, Brazil|Liga Norte Riograndense Contra o Cancer, Natal, RIO Grande DO Norte, Brazil|Hospital de Caridade de Ijui, Ijui, RIO Grande DO SUL, Brazil|Hospital Moinhos de Vento, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Mae de Deus, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Universidade Estadual De Campinas Unicamp, Campinas, SAO Paulo, Brazil|FMABC - Cepho, Santo Andre, SAO Paulo, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose Do Rio Preto, SAO Paulo, Brazil|Real e Benemrita Associao Portuguesa de Beneficencia Portuguesa de Sao Paulo, So Paulo, SAO Paulo, Brazil|Centro de Tratamento de Tumores Botafogo - CTTB, Rio de Janeiro, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|William Osler Health System, Brampton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Quebec, Canada|Clinica Oncologica IRAM, Santiago, Metropolitana, Chile|Bradford Hill Centro de Investigacion Clinica, Santiago, Metropolitana, Chile|Oncocentro Apys, Vina del Mar, Valparaiso, Chile|Local Institution, Beijing Shi, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Baoding Shi, Hebei, China|Local Institution, Harbin Shi, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Wuhan, Hubei, China|Local Institution, Wuhan, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang Shi, Jiangxi, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xian Shi, Shan3xi, China|Local Institution, Jinan, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu City, Sichuan, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Masaryk Memorial Cancer Institute, Brno, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|University Hospital Ostrava, Ostrava, Czechia|Local Institution, Prague 2, Czechia|Local Institution, Prague 8 - Liben, Czechia|Thomayerova nemocnice, Prague, Czechia|Institut de Cancerologie de l Ouest, Angers Cedex 02, France|Clinique Pasteur - CFRO, Brest, France|Hopital Prive Toulon Hyeres, Hyeres, France|Clinique Victor Hugo, Le Mans, France|Centre Oscar Lambret, Lille, France|Hopital Saint Eloi, Montpellier, France|Local Institution, Nimes Cedex 9, France|Hopital Europeen Georges Pompidou, Paris, France|Hospices Civils de Lyon - Centre hospitalier Lyon Sud, Pierre Benite Cedex, France|ICANS-Institut de cancerologie Strasbourg Europe, Strasbourg, France|Institut Gustave-Roussy, Villejuif Cedex, France|Local Institution, Berlin, Germany|Local Institution, Bonn, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Local Institution, Emmendingen, Germany|Universitaetsklinikum Erlangen, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Hamburg, Germany|Local Institution, Hamburg, Germany|InVO - Ins f Versforschung Onkologie GbR, Koblenz, Germany|Local Institution, Koeln, Germany|Local Institution, Luebeck, Germany|Local Institution, Magdeburg, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Local Institution, Munich, Germany|Local Institution, Nuertingen, Germany|Local Institution, Tuebingen, Germany|Local Institution, Shatin, NEW Territories, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Haifa, Israel|Local Institution, Petach tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Tel Hashomer Ramat Gan, Israel|Local Institution, Zefat, Israel|Guz City Clinical Hospital #57, Benevento, Italy|ASST Papa Giovanni XXIII, Bergamo, Italy|A.O.U. Policlinico Sant Orsola-Malpighi, Bologna, Italy|Asst Spedali Civili Di Brescia, Brescia, Italy|ASST Istituti Ospitalieri, Cremona, Italy|Local Institution, Milano, Italy|Istituto Europeo di Oncologia, Milan, Italy|Local Institution, Modena, Italy|IRCCS Istituto Nazionale dei tumori Fondazione G. Pascale, Napoli, Italy|A.O.U. San Luigi Gonzaga, Orbassano, Italy|Institut Mutualiste Montsouris, Parma, Italy|Local Institution, Parma, Italy|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Terni, Italy|Ospedale Santa Chiara, Trento, Italy|Nagoya City University Hospital, Nagoya-shi, Aichi, Japan|Akita University Hospital, Akita-Shi, Akita, Japan|Hirosaki University Hospital, Hirosaki-Shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Toho University - Sakura Hospital Medical Center, Sakura Shi, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama-Shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Sapporo Medical University Hospital, Sapporo shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Yokohama City University Medical Center, Yokohama-shi, Kanagawa, Japan|Kumamoto Medical Center, Kumamoto Shi, Kumamoto, Japan|Kyoto Prefectural University of Medicine, Kyoto-shi, Kyoto, Japan|Nagasaki University Hospital (NUH), Nagasaki Shi, Nagasaki, Japan|Nara Medical University Hospital, Kashihara city, Nara, Japan|Niigata University Medical and Dental Hospital, Niigata shi, Niigata, Japan|Okayama University Hospital, Okayama city, Okayama, Japan|Local Institution, Osaka Sayama, Osaka, Japan|Osaka International Cancer Institute, Osaka shi, Osaka, Japan|Osaka University Hospital, Suita, Osaka, Japan|Hamamatsu University Hospital, Hamamatsu Shi, Shizuoka, Japan|Keio University Hospital, Shinjuku-Ku, Tokyo, Japan|Wakayama Medical University Hospital, Wakayama Shi, Wakayama, Japan|Yamaguchi University Hospital, Ube-shi, Yamaguchi, Japan|Toyama University Hospital, Toyama, Japan|Local Institution, Daejeon, Korea, Republic of|Local Institution, Incheon, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Songnam-si, Korea, Republic of|Local Institution, Yangsan Si, Korea, Republic of|Local Institution, Ciudad de Mexico, Distrito Federal, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Morelia, Michoacan, Mexico|Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V., Aguascalientes, Mexico|Local Institution, Hamilton, New Zealand|Local Institution, Palmerston North, New Zealand|Local Institution, Tauranga, New Zealand|Szpital Wojewodzki im. M. Kopernika w Koszalinie, Koszalin, Poland|WWCOiT Copernicus Memorial Hospital, Lodz, Poland|Centrum Onkologii Ziemi Lubelskiej im. w. Jana z Dukli, Lublin, Poland|Clinical Research Center Spolka z ograniczona odpowiedzialnoscia Medic-R Sp.k., Poznan, Poland|Local Institution, Warsaw, Poland|Szpital Grochowski im. dr med. Rafala Masztaka Sp. z o.o, Warszawa, Poland|Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico|Fundacion de Investigacion, San Juan, Puerto Rico|Institutul Oncologic Bucuresti IOB, Bucharest, Romania|Prof. Dr. Al.Chiricuta Oncologic Institute Cluj Napoca, Cluj Napoca, Romania|Institutul Oncologic Prof. Dr. I. Chiricuta, Cluj, Romania|Spitalul Clinic Judetean de Urgenta Constanta, Constanta, Romania|Centrul de Oncologie Sf. Nectarie, Craiova, Romania|Local Institution, Timisoara, Romania|SBHI Arkhangelsk Region - Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Russian Federation|Local Institution, Ivanovo, Russian Federation|SAHI Republican Clinical Oncology Dispensary of MoH of RT, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Sechenov University, Moscow, Russian Federation|P.A. Herzen Moscow Oncology Research Institute, Moscow, Russian Federation|FSBI National Medical Research Radiology Center NMRRC - A. Tsyb Medical Radiological Research Centre, Obninsk, Russian Federation|Budgetary Healthcare Institution of Omsk Region &quot,Clinical Oncological Dispensary&quot,, Omsk, Russian Federation|Local Institution, Ryazan, Russian Federation|Andros Clinic LLC, Saint-Petersburg, Russian Federation|Russian Scientific Centre of Radiology and Surgical Technologies n.a. acad. M.A., Saint-Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|ICO Badalona, Barcelona, Spain|Institut Catala D 39 Oncologia Duran I Reynals, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|HULA, Lugo, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital MD Anderson, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Althaia Xarxa Assistencial De Manresa, Manresa, Spain|Corporacio Sanitaria Parc Tauli, Sabadell, Spain|Local Institution, Niaosng, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Adana, Turkey|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Edirne, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Izmir, Turkey|Local Institution, Malatya, Turkey|University College London Hospitals NHS Foundation Trust, London, Greater London, United Kingdom|Local Institution, Guildford, United Kingdom|Local Institution, Lancaster, United Kingdom|Local Institution, Leicester, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|The Royal Marsden Nhs Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Mount Vernon Hospital, Northwood, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Local Institution, Oxford, United Kingdom|Local Institution, Preston, United Kingdom|Local Institution, Southampton, United Kingdom",10.48345779,9.435112014,Male,"18 Years to 70 Years ¬† (Adult, Older Adult)",297,289,282,252,11,19,11/20/2019,5/29/2020,3/29/2020,5/15/2020,4/13/2020,4/27/2020,6/25/2020,9/29/2020,10/23/2020,12/21/2023,12/18/2023,3/5/2024,7/10/2024,8/26/2024,10/10/2024,11/16/2024,12/28/2024,2/1/2025,3/7/2025,10/24/2020,4/22/2021,10/19/2021,4/17/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04100018,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00484,SP00005,Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Perter K,Gertrudis T,Clarice N,Doreen T,Doreen T,Gertrudis T,Lucie P,Otis Thode †,Xochitl D,Suzie K,Naren G,Donovan H,Kala R,Ross S,Xochitl D,Remedios Z,Suzie K,Tiffiny K,Tamesha T,,,"Ucsf-Comprehensive Cancer Center, San Francisco, California, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Dana-Farber Cancer Inst, Boston, Massachusetts, United States|Montefiore Medical Center, Bronx, New York, United States|University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Local Institution, Haedo, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Bruxelles, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Dijon Cedex, France|Local Institution, Paris, France|Local Institution, Saint Herblain Cedex, France|Local Institution, Toulouse Cedex 3, France|Local Institution, Modena, Italy|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Barcelona, Spain|Local Institution, Lleida, Spain|Local Institution, Madrid, Spain",86.26632075,77.63968868,Female,"18 Years to 80 Years ¬† (Adult, Older Adult)",307,298,283,236,8,39,4/19/2004,10/23/2004,8/24/2004,9/15/2004,8/31/2004,9/4/2004,1/30/2005,5/9/2005,5/29/2005,8/13/2008,7/27/2008,1/21/2009,3/1/2009,3/31/2009,5/15/2009,6/18/2009,8/17/2009,10/8/2009,11/8/2009,3/3/2005,8/30/2005,2/26/2006,8/25/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00371345,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00519,SP00005,"Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer",,,,,Oncology,,,,,,Industry,Recruiting,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Gertrudis T,Chetan K,Lilla Stilson †,Jeanene Y,Federico L,Naren G,Terisa Sikora †,Otis Thode †,Frank T,Patria R,Anthony P,Quentin N,Ross S,Frank T,Lucie P,Lilla Stilson †,Lucie P,Jaquelyn H,Perter K,,,"Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Local Institution, Fresno, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, West Haven, Connecticut, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Local Institution, Newnan, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Local Institution, Zion, Illinois, United States|Local Institution, Louisville, Kentucky, United States|Minnesota Oncology Hematology (Minneapolis) - USOR, Minneapolis, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Center Of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology Pc, Albany, New York, United States|Local Institution, Lake Success, New York, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Local Institution, New York, New York, United States|Northwest Cancer Specialists, P.C., Tigard, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Oncology, PA - Central Austin Cancer Center, Austin, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, Gosford, New South Wales, Australia|Local Institution, Wahroonga, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Local Institution, Clayton, Victoria, Australia|Medizinische Universtaet Wien, Wien, Austria|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|Local Institution, Aalborg, Denmark|Local Institution, Aarhus N, Denmark|Local Institution, Kobenhavn O, Denmark|Local Institution, Odense, Denmark|Local Institution, Bordeaux, France|Local Institution, Clermont-ferrand, France|Centre Leon Berard, Lyon, France|Local Institution, Marseille Cedex 9, France|Local Institution, Nice, France|Local Institution, Quimper Cedex, France|Local Institution, Strasbourg Cedex, France|Local Institution, Villejuif, France|Staedtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany|Universitatsklinikum Carl Gustav Carus, Dresden, Germany|Georg August Universitaet Goettingen, Goettingen, Germany|Marien Hospital Herne, Herne, Germany|Universitaetsklinikum Jena, Jena, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum Grosshadern, Munich, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Studienpraxis Urologie, Nuertingen, Germany|Urologische Praxis, Rostock, Germany|Uniklinik Tuebingen, Tuebingen, Germany|Urologische Gemeinschaftspraxis Dres Stammel U. Garcia, Wesel, Germany|Local Institution, Arezzo, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Parma, Italy|Local Institution, Terni, Italy|Oddzial Dzienny Chemioterapii, Koszalin, Poland|Local Institution, Krakow, Poland|Local Institution, Warszawa, Poland|Local Institution, Badajoz, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Santiago Compostela, Spain",82.3444846,74.11003614,Male,"18 Years and older ¬† (Adult, Older Adult)",304,292,284,202,42,40,10/18/2020,4/10/2021,2/22/2021,3/15/2021,3/1/2021,3/5/2021,6/3/2021,7/10/2021,8/9/2021,11/1/2022,6/18/2022,3/1/2023,4/12/2023,5/25/2023,7/21/2023,8/26/2023,9/29/2023,11/9/2023,1/2/2024,9/1/2021,2/28/2022,8/27/2022,2/23/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02985957,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00521,SP00005,Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Chetan K,Mara A,Stephan T,Xochitl D,Selizabeth F,Chetan K,Mary H,Mara A,Garnet T,Anthony P,Hee Y,Mary H,Naren G,Donovan H,Tien C,Mary H,Lucie P,Lavina S,Mara A,,,,7.144629014,6.430166112,All,"18 Years and older ¬† (Adult, Older Adult)",319,312,285,269,13,3,12/30/2003,7/21/2004,5/20/2004,7/3/2004,6/12/2004,6/15/2004,10/8/2004,2/13/2005,2/22/2005,5/24/2008,2/14/2008,8/22/2008,11/1/2008,12/20/2008,1/28/2009,3/14/2009,4/18/2009,6/15/2009,7/30/2009,12/12/2004,6/10/2005,12/7/2005,6/5/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00971867,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00525,SP00005,Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC),,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Suzie K,Selizabeth F,Gertrudis T,Ngan D,Doreen T,Selizabeth F,Frank T,Kala R,Dalton E,Terisa Sikora †,Dalton E,Marceline R,Geralyn K,Mara A,Doreen T,Jaquelyn H,Hee Y,Corrine U,Naren G,,,"Consultants In Blood Disorders & Cancer, Louisville, Kentucky, United States",65.95402689,59.3586242,All,"18 Years and older ¬† (Adult, Older Adult)",300,292,286,265,7,14,6/6/2003,11/8/2003,9/3/2003,10/12/2003,9/14/2003,9/27/2003,1/23/2004,4/6/2004,4/22/2004,3/12/2008,2/12/2008,6/7/2008,10/1/2008,11/3/2008,12/21/2008,2/19/2009,4/16/2009,5/27/2009,7/25/2009,3/25/2004,9/21/2004,3/20/2005,9/16/2005,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00651508,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00536,SP00005,Observational Study for Lung Cancer Patients Treated With Nivolumab,,,,,Oncology,,,,,,Industry,Unknown status,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Gertrudis T,Tamesha T,Mary H,Suzie K,Livia Pacheo †,Selizabeth F,Gertrudis T,Liberty A,Aleta H,Clarice N,Harry A,Ross S,Corrine U,Kandace p,Mara A,John G,Marcelina X,Chetan K,Lyman W,,,"Local Institution, Fontaine Les Dijon, France",96.19536743,86.57583069,All,70 Years to 80 Years ¬† (Older Adult),316,311,287,94,180,13,5/14/2015,11/14/2015,8/24/2015,10/1/2015,9/12/2015,9/16/2015,12/10/2015,4/1/2016,4/8/2016,3/11/2020,10/11/2019,3/3/2020,4/30/2020,5/31/2020,7/2/2020,8/28/2020,10/20/2020,11/27/2020,1/1/2021,3/14/2016,9/10/2016,3/9/2017,9/5/2017,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03382496,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00537,SP00005,Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Clarice N,Terisa Sikora †,Mara A,John G,Selizabeth F,John G,Mara A,Geralyn K,In Bellini †,Doreen T,Naren G,Chetan K,Mary H,Aleta H,Terrell p,Naren G,Ross S,Selizabeth F,Lilla Stilson †,,,,39.85576127,35.87018514,Female,"18 Years and older ¬† (Adult, Older Adult)",320,305,288,115,156,17,1/23/2003,7/4/2003,4/20/2003,5/15/2003,4/29/2003,5/8/2003,7/26/2003,11/3/2003,11/13/2003,12/21/2004,10/7/2004,5/29/2005,7/1/2005,8/17/2005,9/26/2005,10/27/2005,12/12/2005,1/12/2006,2/13/2006,11/4/2003,5/2/2004,10/29/2004,4/27/2005,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01023204,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00545,SP00005,Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Jerold Goo †,Jaquelyn H,Jaquelyn H,Kala R,Geralyn K,Kala R,Donovan H,Rima Y ,Mac L,Tammara F,Frank T,Aleta H,Tamesha T,James y,Chetan K,Dinah R,Federico L,Marcelina X,Remedios Z,,,,15.78669317,14.20802386,All,"18 Years and older ¬† (Adult, Older Adult)",316,301,289,252,9,28,5/29/2003,12/30/2003,10/28/2003,12/5/2003,11/6/2003,11/22/2003,1/22/2004,3/25/2004,4/6/2004,8/15/2005,3/16/2005,8/16/2005,12/1/2005,1/24/2006,2/23/2006,3/26/2006,5/16/2006,6/30/2006,8/23/2006,5/20/2004,11/16/2004,5/15/2005,11/11/2005,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01024101,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00557,SP00005,An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers,,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 4,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Mara A,Tamesha T,Jene M,Lyman W,Harry A,Suk T,Otis Thode †,Marceline R,Dalton E,Hee Y,Perter K,Garnet T,Dinah R,Lucie P,Lucie P,Aleta H,Terrell p,Jene M,John G,,,"Alabama Oncology, Birmingham, Alabama, United States|Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Marin Cancer Care, Inc, Greenbrae, California, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Ucla, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Va San Diego Healthcare System, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Affiliates - Ocala, Ocala, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Kentucky One Health St. Joseph East Cancer Center, Lexington, Kentucky, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Minnesota Oncology Hematology, PA, Edina, Minnesota, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|St. Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Cancer Care Specialists, Reno, Nevada, United States|Essex Oncology Of North Jersey P.A., Belleville, New Jersey, United States|Summit Medical Group, Florham Park, New Jersey, United States|Saint Barnabas Medical Cancer Center, Livingston, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Dumc, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Tennessee Oncology, PLLC - SCRI - PPDS, Chattanooga, Tennessee, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Texas Oncology, PA - South Austin Cancer Center, Austin, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology-Longview, Longview, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology Cancer Care And Research Center, Waco, Texas, United States|Virginia Cancer Specialists, Pc, Fairfax, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Valley Medical Center, Renton, Washington, United States|Medical Oncology Associates, Spokane, Washington, United States|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Centro Medico San Roque, Tucuman, Argentina|Local Institution, Gent, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, Greenfield Park, Quebec, Canada|Hopital Du Sacre-Coeur De Montreal, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|Centro Internacional de Estudios Clinicos, Recoleta, Santiago De Chile, Chile|Fundacion Arturo Lopez Perez, Santiago, Chile|Komplexni onkologicke centrum, Novy Jicin, Czechia|Onkologicka klinika VFN a 1. LF UK, Praha 2, Czechia|Local Institution, Bordeaux, France|Local Institution, Dijon Cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Pessac cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulon Cedex, France|Local Institution, Frankfurt, Germany|Local Institution, Gera, Germany|Local Institution, Kassel, Germany|Local Institution, Loewenstein, Germany|Local Institution, Wiesbaden, Germany|Sotiria General Hospital, Athens, Greece|Metropolitan Hospital, N. Faliro, Greece|Papageorgiou General Hospital, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Genova, Italy|IRST Meldola, Meldola, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Ospedale Degli Infermi, Rimini, Italy|Local Institution, Siena, Italy|Azienda Ospedaliera Santa Maria Terni, Terni, Italy|Local Institution, Monterrey, NL, Mexico|Local Institution, Groningen, Netherlands|Local Institution, Rotterdam, Netherlands|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Oddzial Wewnetrzny, Sucha Beskidzka, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|Focus Lab Plus SRL, Bucuresti, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, A Coru√±a, Spain|Local Institution, Barcelona, Spain|Local Institution, Jaen, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda - Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|University Hospital Basel, Basel, Switzerland|University Hospital Zuerich, Zuerich, Switzerland|Local Institution, Antalya, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Leicester, Leicestershire, United Kingdom|Local Institution, Edinburgh, Midlothian, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Wirral, United Kingdom",44.97763656,40.4798729,All,,315,311,290,265,12,13,10/19/2017,5/23/2018,3/8/2018,4/18/2018,3/20/2018,3/30/2018,5/23/2018,10/15/2018,10/26/2018,7/31/2021,9/28/2021,12/20/2021,5/5/2022,6/18/2022,7/24/2022,9/1/2022,10/20/2022,11/19/2022,12/24/2022,9/26/2018,3/25/2019,9/21/2019,3/19/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02869789,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00559,SP00005,Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Garnet T,James y,Beulah N,Mara A,Ngan D,Naren G,John G,Quentin N,Stephan T,Naren G,In Bellini †,In Bellini †,Kala R,Terisa Sikora †,Mac L,Frank T,Terisa Sikora †,Garnet T,Tiffiny K,,,"Local Institution, Nagoya, Aichi, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Toshima-ku, Tokyo, Japan",6.69776182,6.027985638,Female,,312,304,291,99,179,13,9/15/2003,4/21/2004,2/5/2004,3/16/2004,2/13/2004,3/1/2004,5/28/2004,7/8/2004,7/15/2004,1/12/2008,6/28/2007,1/30/2008,3/31/2008,5/2/2008,6/15/2008,7/17/2008,8/26/2008,10/10/2008,11/20/2008,8/28/2004,2/24/2005,8/23/2005,2/19/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00971945,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT00971945/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT00971945/SAP_001.pdf"
BigPharma Sponsor,BigPharma Sponsor,ST00561,SP00005,Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 1|Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Rima Y ,Remedios Z,Tiffiny K,Lavina S,Jaquelyn H,Louann C,John G,Louann C,Marceline R,Louann C,Jaquelyn H,Mary H,Perter K,Terrell p,Ngan D,Jaquelyn H,Tiffiny K,Lilla Stilson †,Terrell p,,,"The Angeles Clinic and Research Institute, Los Angeles, California, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Josephine Ford Cancer Center-Downriver, Brownstown, Michigan, United States|Henry Ford Medical Center-Fairlane, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Henry Ford Medical Center-West Bloomfield, West Bloomfield, Michigan, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States",58.75212623,52.87691361,Male,,305,299,292,222,41,29,11/9/2005,5/18/2006,3/29/2006,4/25/2006,4/3/2006,4/16/2006,8/18/2006,11/6/2006,11/19/2006,4/26/2009,1/18/2009,5/28/2009,9/1/2009,10/1/2009,11/25/2009,1/15/2010,3/7/2010,4/23/2010,6/14/2010,10/13/2006,4/11/2007,10/8/2007,4/5/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00323882,,,,,,
BigPharma Sponsor,BigPharma Sponsor,ST00564,SP00005,Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Frank T,John G,Lyman W,In Bellini †,Mary H,Hee Y,Anthony P,Terrell p,Marceline R,Lilla Stilson †,Mary H,John G,James y,Mary H,Kala R,Rima Y ,Hee Y,Kala R,Patria R,,,,93.77792157,84.40012941,All,,319,307,293,160,108,25,4/11/2003,10/16/2003,8/30/2003,9/26/2003,9/2/2003,9/7/2003,1/15/2004,5/17/2004,5/23/2004,2/23/2006,1/1/2006,6/9/2006,10/1/2006,11/19/2006,12/30/2006,2/22/2007,4/12/2007,5/20/2007,6/26/2007,3/5/2004,9/1/2004,2/28/2005,8/27/2005,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00855764,,,,,,
Celgene,Celgene,ST00103,SP00006,Positron Emission Tomography (PET) Imaging Study to Evaluate Enzyme Availability in the Central Nervous System Before and After CC-97489 Administration in Healthy Participants,,,Healthy Volunteers,,,,,,,,Industry,Not yet recruiting,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Chetan K,John G,Chetan K,Hee Y,Dalton E,Mary H,Stephan T,Lavina S,Suzie K,Frank T,In Bellini †,Gertrudis T,Beulah N,Dinah R,Xochitl D,Jene M,Jaquelyn H,Quentin N,Kandace p,,,"UZ Leuven, Leuven, Belgium",35.76003853,32.18403468,All,45 Years to 60 Years ¬† (Adult),310,301,294,233,15,46,4/4/2018,10/11/2018,7/21/2018,8/31/2018,8/1/2018,8/20/2018,8/22/2018,8/26/2018,9/8/2018,2/15/2022,1/30/2022,6/9/2022,9/6/2022,11/1/2022,12/31/2022,2/17/2023,4/7/2023,6/4/2023,7/20/2023,2/16/2019,8/15/2019,2/11/2020,8/9/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05065541,,,,,,
Celgene,Celgene,ST00153,SP00006,Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-Œ≤ or No Disease Modifying Therapy,,,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",,Neurology,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Jene M,Selizabeth F,In Bellini †,Perter K,Marceline R,Mary H,Federico L,Frank T,Marcelina X,Mary H,Anthony P,Frank T,Stephan T,Xochitl D,Selizabeth F,Garnet T,Perter K,Selizabeth F,Mary H,,,,91.08945123,81.98050611,All,"20 Years and older ¬† (Adult, Older Adult)",315,302,295,127,147,21,1/6/2018,5/13/2018,3/29/2018,4/18/2018,3/21/2018,4/12/2018,4/17/2018,4/19/2018,5/15/2018,3/6/2021,7/13/2021,11/2/2021,2/28/2022,4/26/2022,5/26/2022,7/5/2022,8/25/2022,9/29/2022,11/10/2022,10/9/2018,4/7/2019,10/4/2019,4/1/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05028634,,,,,,
Celgene,Celgene,ST00198,SP00006,Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis,,,Eosinophilic Esophagitis,,,,,,,,Industry,Recruiting,Phase 1,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Corrine U,Frank T,Kala R,Lyman W,Otis Thode †,Tien C,Anthony P,Tiffiny K,Lilla Stilson †,John G,Ngan D,Naren G,Gertrudis T,Quentin N,Terrell p,Garnet T,Suzie K,Beulah N,,,"AES - DRS - Simon Williamson Clinic, PC - Birmingham, Birmingham, Alabama, United States|AES - DRS - Central Phoenix Medical Clinic, LLC, Phoenix, Arizona, United States|Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Del Sol Research Management, Tucson, Arizona, United States|MetroHealth Medical Center, Tucson, Arizona, United States|OM Research, Lancaster, California, United States|Gastrointestinal Biosciences, Los Angeles, California, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|Alliance Clinical Research, LLC, Poway, California, United States|Precision Research Institute, LLC, San Diego, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Rocky Mountain Pediatric Gastroenterology, Denver, Colorado, United States|Western States Clinical Research Inc, Wheat Ridge, Colorado, United States|Connecticut Clinical Research Foundation, Bristol, Connecticut, United States|University of Connecticut, Farmington, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|Gastro Florida, Clearwater, Florida, United States|Nature Coast Clinical Research LLC, Inverness, Florida, United States|ENCORE Borland-Groover Clinical Research, Jacksonville, Florida, United States|A Plus Research Inc, Miami, Florida, United States|Med-Care Research, North Miami Beach, Florida, United States|AES - DRS - Synexus Clinical Research US, Inc. - Orlando, Orlando, Florida, United States|Arnold Palmer Hospital For Children, Orlando, Florida, United States|Gastroenterology Consultants of Central Florida - CAR, Orlando, Florida, United States|Advanced Medical Research Center, Port Orange, Florida, United States|US Associates in Research Inc, Sweetwater, Florida, United States|Emory University, Atlanta, Georgia, United States|Gastroenterology Associates Of Central Georgia LLC, Macon, Georgia, United States|Grand Teton Research Group PLLC, Idaho Falls, Idaho, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Summit Digestive and Liver Disease Specialists - Chicago - CAR, Oakbrook Terrace, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Gastroenterology Health Partners PLLC, New Albany, Indiana, United States|Iowa Digestive Disease Center, Clive, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Tri-State Gastroentrology Associates, Florence, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Gastroenterology Associates LLC, Baton Rouge, Louisiana, United States|Clinical Trials Management LLC, Metairie, Louisiana, United States|Ochsner Children's Health Center, New Orleans, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Digestive Disease Associates, PA, Catonsville, Maryland, United States|Woodholme Gastroenterology Associates, Glen Burnie, Maryland, United States|Meritus Medical Center, Hagerstown, Maryland, United States|Tufts - New England Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Greater Boston Gastroenterology PC, Framingham, Massachusetts, United States|FC Research LLC, South Dartmouth, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|UMASS Memorial Hospital, Worcester, Massachusetts, United States|Troy Gastroenterology, Troy, Michigan, United States|Gastroenterology Associates of Western Michigan PLC, Wyoming, Michigan, United States|Minnesota Gastroenterology, Plymouth, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|GI Associates and Endoscopy Center-GI Clinical Research Department, Flowood, Mississippi, United States|Mid America Gastrointestinal Consultants, Kansas City, Missouri, United States|Washington University Siteman Cancer Center, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Advanced Research Institute - Reno, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Atlantic Research Center LLC, Ocean City, New Jersey, United States|New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|NYU Langone Medical Center, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Hill Medical Center, Syracuse, New York, United States|Syracuse VA Medical Center, Syracuse, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Clinical Research of Charlotte, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Medication Management LLC, Greensboro, North Carolina, United States|Atlantic Medical Group - Kinston - CAR, Kinston, North Carolina, United States|Dayton Gastroenterology, Inc, Beavercreek, Ohio, United States|Consultants for Clinical Research, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|AES - DRS - Synexus Clinical Research US, Inc. - Columbus, Columbus, Ohio, United States|Optimed Research Ltd, Columbus, Ohio, United States|Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|AES - DRS - Synexus Clinical Research US, Inc. - Anderson, Anderson, South Carolina, United States|Prisma Health - Upstate, Greenville, South Carolina, United States|ClinSearch LLC, Chattanooga, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States|Texas Digestive Disease Consultants Dallas, Dallas, Texas, United States|AES - DRS - Synexus Clinical Research US, Inc. - Dallas, Dallas, Texas, United States|Childrens Medical Center, Dallas, Texas, United States|Cook Childrens Medical Center, Fort Worth, Texas, United States|Houston Endoscopy and Research Center, Houston, Texas, United States|Digestive Health Associates of Texas (DHAT), Rockwell, Texas, United States|Southern Star Research Institute LLC, San Antonio, Texas, United States|Texas Digestive Disease Consultants - Southlake, Southlake, Texas, United States|Ogden Clinic Gastrenterology - CAR, Ogden, Utah, United States|University of Utah Primary Children's Medical Center, Salt Lake City, Utah, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|University of Vermont Medical Center Gastro, Burlington, Vermont, United States|Emeritas Research Group, Leesburg, Virginia, United States|Blue Ridge Medical Research, Lynchburg, Virginia, United States|McGuire Veterans Affairs Medical Center, Richmond, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|Velocity Clinical Research - Spokane - ERN - PPDS, Spokane, Washington, United States|Vancouver Clinic Inc PS, Vancouver, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|Aurora Saint Lukes Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Gastroenterology Associates, PC - Casper - CAR, Casper, Wyoming, United States|University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|South Edmonton Gastroenterology, Edmonton, Alberta, Canada|GI Research Institute, Vancouver, British Columbia, Canada|PerCuro Clinical Research LTD, Victoria, British Columbia, Canada|Ottawa Allergy Research Corporation, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Toronto Digestive Disease Associates Inc, Vaughan, Ontario, Canada|Staedisches Klinikum Brandenburg, Brandenburg an der Havel, Germany|AES - DRS - Synexus Frankfurt Research Centre, Frankfurt am Main, Germany|Klinikum Garmisch-Partenkirchen Gmbh, Garmisch-Partenkirchen, Germany|Facharztzentrum Eppendorf, Hamburg, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|EUGASTRO GmbH, Leipzig, Germany|Gastroenterologische Gemeinschaftspraxis Mainz, Mainz, Germany|Klinikum rechts der Isar der Technischen Universitaet Muenchen, Munchen, Germany|Rambam Medical Center, Haifa, Israel|Edith Wolfson Medical Center, Holon, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|Shamir Medical Center - Assaf Harofeh, Zerifin, Israel|Ospedale Policlinico San Martino, Genova, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milano, Italy|AOU dell'Universit√† degli Studi della Campania Luigi Vanvitelli, Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Azienda Policlinico Umberto I, Rome, Italy|Yamagata University Hospital, Yamagata, Japan|Vitamed Galaj i Cichomski sp.j., Bydgoszcz, Poland|AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Czestochowie, Czestochowa, Poland|AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdansku, Gdansk, Poland|AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Katowicach, Katowice, Poland|AES - DRS - Synexus Polska Sp. Z o.o. Oddzial w Lodzi, L√≥dz, Poland|TWOJA PRZYCHODNIA Medical Centre of Szczecin LLC, Szczecin, Poland|WIP Warsaw IBD Point, Warsaw, Poland|Centrum Zdrowia MDM, Warszawa, Poland|AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Poland|AES - DRS - Synexus Polska Sp. z o.o. Oddzial we Wroclawiu, Wroclaw, Poland|Akademicki Szpital Kliniczny im. Jana Mikulicza-Radeckiego, Wroclaw, Poland|Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska, Wroclaw, Poland|Centro Hospitalar de Lisboa Central - Hospital de Santo Ant√≥nio dos Capuchos, Lisboa, Portugal|Centro Hospitalar Lisboa Central- Hospital Dona Estef√¢nia, Lisboa, Portugal|Centro Hospitalar do Porto - Hospital de Santo Ant√≥nio, Porto, Portugal|Centro Hospitalar de S√£o Jo√£o, E.P.E., Porto, Portugal|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Costa del Sol, Marbella, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Chuv Bh-04, Lausanne, Switzerland|Kantonsspital Liestal, Liestal, Switzerland|Belfast Health and Social Care Trust, Belfast Northern Ireland, United Kingdom|AES - DRS - Synexus Midlands Clinical Research Centre, Birmingham, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|AES - DRS - Synexus Wales Clinical Research Centre, Cardiff, United Kingdom|AES - DRS - NW Consortium Lancashire, Chorley, United Kingdom|AES - DRS - Synexus Hexham Clinical Research Centre, Hexam, United Kingdom|AES - DRS - NW Consortium Merseyside, Liverpool, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom|AES - DRS - NW Consortium Manchester, Manchester, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",21.03917322,18.9352559,All,"22 Years to 80 Years ¬† (Adult, Older Adult)",329,318,296,275,7,14,11/24/2024,4/7/2025,2/25/2025,3/17/2025,2/24/2025,3/5/2025,3/18/2025,3/22/2025,4/7/2025,4/16/2026,11/8/2025,5/29/2026,8/1/2026,9/13/2026,10/29/2026,12/10/2026,1/20/2027,3/16/2027,5/3/2027,9/1/2025,2/28/2026,8/27/2026,2/23/2027,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04991935,,,,,,
Celgene,Celgene,ST00212,SP00006,Connect¬Æ Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study,,,"Lymphoma, Non-Hodgkin|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular|Lymphoma, B-Cell",,Oncology,,,,,,Industry,Not yet recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Lavina S,Marcelina X,Jaquelyn H,Anthony P,Harry A,Doreen T,Mary H,Anthony P,Perter K,Louann C,Xochitl D,Suzie K,Ross S,Jerold Goo †,Donovan H,Tammara F,Mary H,Naren G,Suzie K,,,,65.92669786,59.33402807,All,"18 Years and older ¬† (Adult, Older Adult)",333,319,297,256,14,27,3/30/2026,9/2/2026,6/14/2026,7/24/2026,6/18/2026,7/9/2026,7/17/2026,7/19/2026,8/6/2026,9/29/2028,11/10/2028,3/31/2029,7/31/2029,9/7/2029,10/28/2029,12/14/2029,1/31/2030,3/10/2030,4/25/2030,1/5/2027,7/4/2027,12/31/2027,6/28/2028,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04982471,,,,,,
Celgene,Celgene,ST00219,SP00006,Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants,,,Healthy Volunteers,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Otis Thode †,Mee M,Mee M,Beulah N,John G,Harry A,Ngan D,Rima Y ,Naren G,Terrell p,Otis Thode †,Gertrudis T,Anthony P,In Bellini †,Chetan K,Xochitl D,Stephan T,Chetan K,Livia Pacheo †,,,"Anaheim Clinical Trials, Anaheim, California, United States",17.12608315,15.41347483,All,"up to 75 Years ¬† (Child, Adult, Older Adult)",315,303,298,153,122,23,7/14/2017,12/20/2017,11/1/2017,11/29/2017,10/22/2017,11/10/2017,11/13/2017,11/15/2017,11/25/2017,10/5/2021,1/9/2022,6/18/2022,8/2/2022,9/21/2022,10/31/2022,12/13/2022,2/11/2023,4/11/2023,5/12/2023,5/9/2018,11/5/2018,5/4/2019,10/31/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04978298,,,,,,
Celgene,Celgene,ST00221,SP00006,"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM).",,,Multiple Myeloma,,Oncology,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Tiffiny K,John G,John G,Ross S,Anthony P,Lucie P,Mary H,Ngan D,Donovan H,Stephan T,Mee M,Kandace p,Marceline R,Suk T,Selizabeth F,Lilla Stilson †,Frank T,Suzie K,Tien C,,,"Advent Health, Orlando, Florida, United States|Florida Cancer Specialists North Region Sarah Cannon Research, Saint Petersburg, Florida, United States|Emory University, Atlanta, Georgia, United States|Hematology-Oncology Clinic, Baton Rouge, Louisiana, United States|Center for Cancer And Blood Disorders, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|UMASS Memorial Hospital, Worcester, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Summit Medical Group Overlook Oncology Center, Summit, New Jersey, United States|NYU Winthrop Hospital, Mineola, New York, United States|New York University School of Medicine, New York, New York, United States|New York - Presbyterian/Weill Cornell Medical Center, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States|West Penn Allegheny Lupus Center of Excellence, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|UT Southwestern Simmons Cancer Center, Dallas, Texas, United States|University Of Wisconsin, Madison, Wisconsin, United States|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Dept Of Oncology, Bedford Park, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Epworth Hospital, East Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Perth Blood Institute, West Perth, Western Australia, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|St Vincent's Hospital Melbourne, Fitzroy, Australia|The Canberra Hospital, Garran, Australia|Medical University of Graz, Graz, Austria|Innsbruck Medical University, Innsbruck, Austria|Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria|Universitatsklinik der PMU, Salzburg, Austria|University Hospital St. Poelten, St Polten, Austria|Medizinische Universitaet Wien, Vienna, Austria|Wilhelminenspital der Stadt Wien, Wien, Austria|AZ Sint-Jan AV Brugge, Brugge, Belgium|Institut Jules Bordet, Brussel, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Centre Hospitalier de Jolimont-Lobbes, La Louvi√®re-(Haine St-Paul), Belgium|Centre Hospitalier Universitaire de Liege, Liege, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Memorial University of NewfoundlandDr. H Bliss Murphy Cancer Center, St John's, Newfoundland and Labrador, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve Rosemont dba CIUSSS de lEst de lIle de Montreal, Montreal, Quebec, Canada|The Ottawa Hospital - General Campus, Ottawa, Quebec, Canada|University of Saskatchewan, Saskatoon, Saskatchewan, Canada|CHUQ, Quebec, Canada|Peking University Third Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|Beijing Chaoyang Hospital Capital Medical University, Chaoyang District, China|Guangdong General Hospital, Guangzhou, China|The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou City, China|The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China|The First Affiliated Hospital of Harbin Medical University, Harbin, China|Shanghai Chang Zheng Hospital, Shanghai, China|Ruijin Hospital Shanghai Jiaotong University, Shanghai, China|Shengjing Hospital Of China Medical University, Shenyang, China|Institution of Hematology & Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, China|Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China|Xijing Hospital, Xian, China|Fakultni Nemocnice Brno, Brno, Czechia|Fakultni Nemocnice Ostrava, Ostrava-Poruba, Czechia|Vseobecna Fakultni Nemocnice v Praze, Prague 2, Czechia|Aalborg Universitetshospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Odense University Hospital, Odense, Denmark|Sealand University Hospital, Roskilde, Denmark|Vejle Hospital, Vejle, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Oulu University Hospital, Oulu, Finland|Turku University Hospital, Turku, Finland|CH Argenteuil Victor Dupouy, Argenteuil, France|Hopital Henri Mondor, Creteil, France|Centre Hospitalier Departemental de Vendee, La Roche -Sur-Yon - Cedex 9, France|CHRU de Lille France, Lille Cedex, France|CHU Montpellier- Hopital Lapeyronie, Montpellier Cedex 5, France|CHU de Nancy - Hopital Brabois- Service d'Hematologie et DE medecine Interne, 7eme etage, Nancy Cedex, France|CHRU Nantes, Nantes, France|Hopital Saint-Louis, Paris Cedex, France|Hopital Saint Antoine, Paris, France|CHU Bordeaux, Pessac, France|Centre Hospitalier Lyon-Sud, Pierre-Benite CEDEX, France|CHU La Miletrie, Poitiers Cedex, France|CHRU Rennes, Rennes, France|CLCC H BecquerelHematology, Rouen, France|Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse Cedex 9, France|Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany|Universitaetsklinik Hamburg - Eppendorf, Hamburg, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitaetsklinikum Muenster, Munster, Germany|Universitaetsklinikum Wuerzburg, Wuerzburg, Germany|Alexandra General Hospital of Athens, Athens, Greece|Georgios Papanikolaou General Hospital of Thessaloniki, Thessaloniki, Greece|Cork University Hospital, Cork, Ireland|Beaumont Hospital, Dublin 9, Ireland|St James Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Rambam Medical Center, Haifa, Israel|A.O.U. di Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy|Universit√† di Catania- Presidio Ospedaliero Ferrarotto, Catania, Italy|Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Milano, Italy|A.O.U. Maggiore della Carit√†, Novara, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|Azienda Ospedaliera S. Andrea - Universit√† La Sapienza, Roma, Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo FG, Italy|Azienda Ospedaliera S Maria di Terni, Terni, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Italy|Aomori Prefectural Central Hospital, Aomori, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|Kameda Medical Center, Kamogawa, Japan|University Hospital Kyoto Prefectural University of Medicine, Kyoto-City, Japan|Matsuyama Red Cross Hospital, Matsuyama, Japan|Aichi Cancer Center, Nagoya, Japan|Nagoya City University Hospital, Nagoya, Japan|Okayama Medical Center, Okayama, Japan|Kindai University Hospital, Osaka-Sayama, Japan|Osaka City University Hospital, Osaka, Japan|Sapporo Hokuyu Hospital, Sapporo, Japan|Tohoku University Hospital, Sendai, Japan|Japan Red Cross Medical Center, Shibuya-ku, Japan|NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan|Toyohashi Municipal Hospital, Toyohashi, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|National Cancer Center, Gyeonggi-do, Korea, Republic of|Hwasun Chonnam National University Hospital, Hwasun-gun, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul - Saint Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Vrije Universiteit Medisch Centrum (VUMC), Amsterdam, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Haukeland University Hospital, Bergen, Norway|Oslo Universitetssykehus HF Ulleval, Oslo, Norway|Trondheim university hospital, Trondheim, Norway|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Uniwersytet Jagiellonski Collegium Medicum, Krakow, Poland|Szpital Specjalistyczny im. Jedrzeja Sniadeckiego w Nowym Saczu, Nowy Sacz, Poland|Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznan, Poland|Specjalistyczny Szpital im. dra Alfreda Sokolowskiego, Walbrzych, Poland|Centrum Onkologii-Instytut im.Marii Sklodowskiej-Curie, Warszawa, Poland|Uniwersytecki Szpital Kliniczny, Wroclaw, Poland|Centro Hospital e Universitario de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa, Francisco Gentil, Lisboa, Portugal|Champalimaud Cancer Center, Lisboa, Portugal|Hospital Center of Lisbon North E.P.E - Hospital Pulido Valente, Lisboa, Portugal|Ipo Instituto Portugues De Oncologia Porto, Porto, Portugal|Centro Hospitalar de Sao Joao, EPE, Porto, Portugal|City Clinical Hospital 52, Moscow, Russian Federation|State Institution Hematological Research, Centre of Russian Academy of Medical Science, Moscow, Russian Federation|Moscow State Healthcare Institution City clinical hospital n.a. S.P.Botkin, Moscow, Russian Federation|Novosibirsk State Medical University, Novosibirsk, Russian Federation|Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Vall D hebron, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital San Pedro de Alcantara, Caceres, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital de La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital Universitario Virgen de La Arrixaca, Murcia, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Universitario de Salamanca - Hospital Clinico, Salamanca, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Medicinkliniken, Boras, Sweden|Sahlgrenska University Hospital Department of Hematology and Coagulation, Goteborg, Sweden|Helsingborg hospital, Helsingborg, Sweden|Lund University Hosptial, Lund, Sweden|Akademiska Hospital Uppsala, Uppsala, Sweden|Kantonsspital Graubunden, Chur, Switzerland|Chang Gung Medical Foundation, Kaohsiung Memorial Hospital, Niao-Sung Hsiang Kaohsiung County, Taiwan|China Medical University Hospital, Taichung City, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiana, Taiwan|National Taiwan University Hospital, Taipei, Zhongzheng Dist., Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation, Linkou Memorial Hospital, Taoyuan City, Taiwan|Ankara University Medical Faculty, Ankara, Turkey|Gazi Universitesi, Besevler Ankara, Turkey|Ege University Medical Faculty, Izmir, Turkey|Ondokuz Mayis University Medical Faculty, Samsun, Turkey|Belfast City Hospital, Belfast Northern Ireland, United Kingdom|University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom|Kent and Canterbury Hospital, Canterbury Kent, United Kingdom|Victoria Hospital Blackpool, Lancashire Blackpool, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|University College London Hospitals NHS Foundation Trust - University College Hospital, London, United Kingdom|Guy's and St Thomas' Hospital - London, London, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Oxford University Hospitals NHS Foundation Trust-Churchill Hospital-Cancer and Haematology Centre, Oxford, United Kingdom|Queen Alexandra Hospital - Portsmouth, Portsmouth, United Kingdom|Royal Cornwall Hospitals Trust, Truro, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",33.89499375,30.50549438,All,30 Years to 60 Years ¬† (Adult),319,313,299,166,107,26,7/7/2020,12/30/2020,11/17/2020,11/27/2020,11/17/2020,11/22/2020,12/2/2020,12/5/2020,12/15/2020,2/15/2024,7/28/2023,12/27/2023,5/17/2024,6/25/2024,8/24/2024,10/17/2024,11/24/2024,1/1/2025,2/28/2025,5/21/2021,11/17/2021,5/16/2022,11/12/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04975997,,,,,,
Celgene,Celgene,ST00223,SP00006,Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma,,,Multiple Myeloma,,Oncology,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Christian G,Lyman W,Aleta H,Stephan T,Clarice N,Donovan H,Dinah R,Frank T,Tamesha T,Liberty A,Rima Y ,Stephan T,Lilla Stilson †,Clarice N,Christian G,Aleta H,Otis Thode †,Mary H,Jene M,,,"University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Wake Forest Univ. Cancer center, Winston-Salem, North Carolina, United States|Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin, United States",12.67831151,11.41048036,All,"12 Years to 18 Years ¬† (Child, Adult)",328,319,300,119,158,23,7/12/2022,12/11/2022,10/16/2022,11/7/2022,10/11/2022,10/31/2022,11/14/2022,11/16/2022,11/24/2022,3/14/2025,6/25/2025,12/18/2025,2/10/2026,3/18/2026,5/14/2026,6/14/2026,7/20/2026,9/11/2026,10/14/2026,4/29/2023,10/26/2023,4/23/2024,10/20/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04975399,,,,,,
Celgene,Celgene,ST00227,SP00006,Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs),,,Myelodysplastic Syndromes|Beta-thalassemia,,,,,,,,Industry,Not yet recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Cross-Sectional,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Doreen T,Perter K,Xochitl D,Frank T,Ngan D,Suk T,Mara A,Gertrudis T,Anthony P,Ngan D,Marcelina X,Kandace p,Otis Thode †,Garnet T,Lyman W,In Bellini †,Perter K,Dinah R,Geralyn K,,,,17.88775103,16.09897593,All,18 Years to 35 Years ¬† (Adult),329,315,301,221,56,24,8/1/2020,3/10/2021,1/16/2021,1/31/2021,1/10/2021,1/25/2021,2/2/2021,2/7/2021,3/2/2021,6/22/2022,3/1/2022,6/24/2022,9/30/2022,11/29/2022,1/11/2023,3/8/2023,4/8/2023,5/20/2023,6/27/2023,7/24/2021,1/20/2022,7/19/2022,1/15/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04973280,,,,,,
Celgene,Celgene,ST00255,SP00006,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.",,,Healthy Volunteers,,,,,,,,Industry,Not yet recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug F,,,,,,,,,,,,,,,,,,,Mary H,Louann C,Harry A,Christian G,Frank T,Naren G,James y,Quentin N,Selizabeth F,Quentin N,Marceline R,Donovan H,Marceline R,Anthony P,Tammara F,Gertrudis T,Jaquelyn H,Tamesha T,In Bellini †,,,"Collaborative Neuroscience Network, LLC, Long Beach, California, United States",59.42927419,53.48634677,All,"18 Years and older ¬† (Adult, Older Adult)",333,329,302,158,128,16,4/14/2018,8/29/2018,7/19/2018,8/3/2018,7/21/2018,7/24/2018,8/7/2018,8/8/2018,8/19/2018,3/8/2021,3/5/2021,9/14/2021,11/4/2021,12/25/2021,2/16/2022,4/3/2022,6/2/2022,7/22/2022,9/5/2022,1/20/2019,7/19/2019,1/15/2020,7/13/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04958291,,,,,,
Celgene,Celgene,ST00263,SP00006,Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes,,,"Leukemia, Myeloid, Acute|Myelodysplastic Syndromes",,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Marceline R,John G,Frank T,Suzie K,Patria R,Ngan D,Tiffiny K,Selizabeth F,Liberty A,Mary H,Remedios Z,Rima Y ,Terisa Sikora †,Federico L,Selizabeth F,Tien C,Ngan D,Mara A,Suk T,,,"University of California San Diego Moores Cancer Center, La Jolla, California, United States|Northwestern University School of Medicine, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington Univ School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Vall d¬¥Hebron University Hospital, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain",6.143143397,5.528829057,All,"18 Years and older ¬† (Adult, Older Adult)",329,324,303,231,47,25,12/25/2024,5/29/2025,3/24/2025,4/28/2025,3/29/2025,4/13/2025,4/28/2025,5/2/2025,5/30/2025,10/27/2026,12/25/2026,4/12/2027,9/2/2027,10/24/2027,12/22/2027,2/20/2028,4/3/2028,5/7/2028,6/17/2028,10/10/2025,4/8/2026,10/5/2026,4/3/2027,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04951778,,,,,,
Celgene,Celgene,ST00270,SP00006,A Study of CC-99677 in Participants With Active Ankylosing Spondylitis,,AS SpA axSpA,"Spondylitis, Ankylosing",,,,,,,,Industry,Recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Frank T,In Bellini †,Lyman W,Frank T,Dinah R,Hee Y,Terrell p,Tammara F,Harry A,Quentin N,Liberty A,Anthony P,Suzie K,Anthony P,Jene M,Rima Y ,John G,Harry A,Mara A,,,"Arizona Arthritis & Rheumatology Research - Flagstaff, Flagstaff, Arizona, United States|Arizona Arthritis & Rheumatology Research, PLLC - Gilbert, Gilbert, Arizona, United States|Arizona Arthritis & Rheumatology Research, PLLC - Phoenix, Phoenix, Arizona, United States|Arizona Arthritis & Rheumatology Research - Tucson, Tucson, Arizona, United States|Medvin Clinical Research, Covina, California, United States|Desert Medical Advances, Palm Desert, California, United States|Robin K. Dore, MD., Inc., Tustin, California, United States|Southwest Florida Clinical Research Center, Tampa, Florida, United States|The Alliance for Multispecialty Resarch (AMR) Whichita East, Wichita, Kansas, United States|Shores Rheumatology, Saint Clair Shores, Michigan, United States|The Center for Rheumatology, Albany, New York, United States|Joint and Muscle Research Institute, Charlotte, North Carolina, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Oregon Health and Science University - Knight Cardiovascular Institute, Portland, Oregon, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|Precision Comprehensive Clinical Research Solutions, Colleyville, Texas, United States|Pioneer Research Solutions, Cypress, Texas, United States|Precision Comprehensive Clinical Research Solutions - Fort Worth, Fort Worth, Texas, United States|Southwest Rheumatology Research, LLC, Mesquite, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Alberta, Edmonton, Alberta, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Revmaclinic, Brno, Czechia|CCR Ostrava, Ostrava, Czechia|Vesalion s.r.o., Ostrava, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|CCR Czech as, Pardubice, Czechia|CCR Prague, s.r.o., Praha 3, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Thomayerova Hospital, Praha 4, Czechia|Revmatologie, Praha, Czechia|Medical Plus s.r.o., Uhersk√© Hradi≈°te, Czechia|Charite, Campus Benjamin Franklin, Medizinische Klinik III, Bielfeld, Germany|Friedrich-Alexander-Universi√§t Erlangen N√ºrnberg, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie und Immunologie (CIRI), Frankfurt am Main, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|Nasz Lekarz Osrodek Badan Klinicznych, Bydgoszcz, Poland|Szpital Uniwersytecki nr 2 im. J.Biziela, Bydgoszcz, Poland|Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka partnerska, Elblag, Poland|Silmedic Sp. z o.o., Katowice, Poland|Malopolskie Badania Kliniczne Sp. z.o.o Sp k, Krakow, Poland|Centrum Medyczne Plejady, Krakow, Poland|Niepubliczny Zaklad Opieki Zdrowotnej REUMED, Lublin, Poland|Twoja Przychodnia Centrum Medyczne Nowa Sol, Nowa Sol, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|RCMed Oddzial Sochaczew, Sochaczew, Poland|Ars Rheumatica-Centrum Reumatologii, Warsaw, Poland|Centrum Medyczne Oporow, Wroclaw, Poland|Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed SRL, Brasov, Romania|SC Centrul Medical Sana SRL, Bucuresti, Romania|Spitalul Clinic Sfanta Maria, Bucuresti, Romania|Spitalul Clinic*, Bucuresti, Romania|Spitalul Euroclinic, Bucuresti, Romania|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|City Clinical Hospital No 7 - Kazan, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|LLC Medical Center Rheuma-Med, Kemerovo, Russian Federation|Klinika na Maroseyke, LLC, Moscow, Russian Federation|Orenburg Regional Clinical Hospital, Orenburg, Russian Federation|Republican Hospital na VA Baranov, Petrozavodsk, Russian Federation|State Institution of Healthcare Regional Clinical Hospital, Saratov, Russian Federation|Smolensk Regional Clinical Hospital, Smolensk, Russian Federation|City Hospital #40, St. Petersburg, Russian Federation|State Autonomous Healthcare Institution of Yaroslavl Oblast Clinical Hospital 3, Yaroslavl, Russian Federation|University Hospital La Coruna, A Coru√±a, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital de Merida, Merida, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Spain|Hospital Clinico Universitario De Santiago De Compostela, Santiago De Compostela, Spain|Hospital Virgen del Rocio Servicio de Hematologia, Sevilla, Spain|Sakarya University, Adapazari, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Ibn Sina University Hospital (Ankara √úniversitesi ƒ∞bni Sina Hastanesi), Ankara, Turkey|Trakya University Medical Faculty, Edirne, Turkey|Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey|Ege Universitesi Medical Faculty, Izmir, Turkey|Izmir Katip Celebi Universitesi - Ataturk Education Research Hospital, Karabaglar, Turkey|Karadeniz Teknik Universitesi, Trabzon, Turkey",48.63082108,43.76773897,All,18 Years to 40 Years ¬† (Adult),335,329,304,201,81,22,10/2/2018,4/10/2019,1/25/2019,2/28/2019,2/8/2019,2/16/2019,3/2/2019,3/5/2019,4/4/2019,5/28/2023,3/24/2023,7/14/2023,11/22/2023,1/9/2024,2/20/2024,4/13/2024,5/15/2024,6/15/2024,7/18/2024,8/15/2019,2/11/2020,8/9/2020,2/5/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04947579,,,,,,
Celgene,Celgene,ST00310,SP00006,Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Tamesha T,Perter K,Liberty A,James y,Christian G,Naren G,In Bellini †,Ngan D,Lucie P,Dalton E,Federico L,Naren G,Tamesha T,Rima Y ,Terisa Sikora †,Clarice N,Mary H,In Bellini †,Mary H,,,"Breastlink Med Group, Long Beach, California, United States|Hematology/Oncology P.C. Carl & Dorothy Bennet Cancer Center, Stamford, Connecticut, United States|Washington Hospital Center, Washington, District of Columbia, United States|Lombardi Cancer Center Georgetown University Hospital, Washington, District of Columbia, United States|Florida Cancer Institute, Hudson, Florida, United States|Gulf Coast Oncology Associates, Saint Petersburg, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Gerogia Cancer Specialist, Atlanta, Georgia, United States|Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Southwest Regional Cancer Center, Austin, Texas, United States|Swedish Medical Center Cancer Institute Research, Seattle, Washington, United States",95.48471713,85.93624542,Female,"18 Years and older ¬† (Adult, Older Adult)",344,331,305,176,97,32,12/6/2003,5/13/2004,3/12/2004,4/26/2004,3/13/2004,4/6/2004,4/9/2004,4/11/2004,4/22/2004,8/31/2008,1/16/2008,5/25/2008,10/1/2008,11/18/2008,12/30/2008,1/29/2009,3/6/2009,5/1/2009,6/30/2009,10/3/2004,4/1/2005,9/28/2005,3/27/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00093145,,,,,,
Celgene,Celgene,ST00322,SP00006,First Line Therapy for Patients With Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Chetan K,Louann C,Suzie K,Jaquelyn H,James y,Selizabeth F,Jerold Goo †,Frank T,Mary H,Selizabeth F,Terisa Sikora †,Louann C,Tammara F,Otis Thode †,Mee M,Donovan H,Christian G,Marceline R,Liberty A,,,"BC Cancer Agency-Burnaby, Burnaby, British Columbia, Canada|Lions Gate Hospital, North Vancouver, British Columbia, Canada|B.C.C.A Vancouver Island Center, Victoria, British Columbia, Canada|Dr. H. Bliss Murphy Cancer Center, St. Johns, Newfoundland and Labrador, Canada|The Royal Victoria Hospital, Barrie, Ontario, Canada|London Regional Cancer Centre, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto Synnybrook Cancer Centre, Toronto, Ontario, Canada|Windsor Regional Hospital, Windsor, Ontario, Canada|Hospital de la Cite-de-la Sante-de-Laval, Laval, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal-Hotel-Dieu, Montreal, Quebec, Canada|McGill University, Montreal, Quebec, Canada|CHA: Saint Sacrement Hospital, Quebec, Canada",68.0778558,61.27007022,Female,"18 Years and older ¬† (Adult, Older Adult)",329,314,306,155,135,16,1/25/2009,6/19/2009,4/25/2009,5/17/2009,4/15/2009,5/9/2009,5/19/2009,5/24/2009,6/1/2009,9/27/2012,4/13/2012,8/22/2012,12/11/2012,2/3/2013,3/31/2013,5/27/2013,7/11/2013,8/25/2013,10/10/2013,11/5/2009,5/4/2010,10/31/2010,4/29/2011,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00456846,,,,,,
Celgene,Celgene,ST00329,SP00006,ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug E,,,,,,,,,,,,,,,,,,,In Bellini †,John G,Otis Thode †,Beulah N,Perter K,In Bellini †,Gertrudis T,Jeanene Y,Anthony P,Kala R,Terisa Sikora †,Anthony P,Quentin N,Mee M,Frank T,Jaquelyn H,Marcelina X,Jerold Goo †,Hee Y,,,"Melbourne, Florida, United States|Ocoee, Florida, United States|Niles, Illinois, United States|Terre Haute, Indiana, United States|Columbia, Maryland, United States|Westminister, Maryland, United States|Saint Joseph, Missouri, United States|Rochester, New York, United States|Bedford, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Odessa, Texas, United States|San Antonio, Texas, United States|Tyler, Texas, United States|Fairfax, Virginia, United States|Norfolk, Virginia, United States|Salem, Virginia, United States|Burien, Washington, United States|Edmonds, Washington, United States|Vancouver, Washington, United States",79.69331409,71.72398268,Female,"18 Years and older ¬† (Adult, Older Adult)",332,325,307,144,139,24,10/28/2004,3/24/2005,1/18/2005,2/9/2005,1/3/2005,1/27/2005,1/30/2005,1/31/2005,2/9/2005,4/7/2009,1/16/2009,5/29/2009,9/1/2009,10/6/2009,11/25/2009,1/6/2010,2/10/2010,4/10/2010,5/17/2010,7/26/2005,1/22/2006,7/21/2006,1/17/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00394082,,,,,,
Celgene,Celgene,ST00330,SP00006,Abraxane in Treatment of Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Cross-Sectional,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Suzie K,Rima Y ,Kandace p,Tammara F,Hee Y,Perter K,Quentin N,Naren G,Frank T,Dinah R,Jene M,Anthony P,Tiffiny K,Suk T,Garnet T,Remedios Z,Jene M,Mara A,Stephan T,,,"LKH Feldkirch, Feldkirch, Austria|Medical University Graz, Graz, Austria|Medical University Innsbruck, Innsbruck, Austria|LKH Leoben, Leoben, Austria|KH Barmherzige Schwestern Linz, Linz, Austria|LKH Salzburg, Salzburg, Austria|LKH St. P√∂lten, St. P√∂lten, Austria|LKH Steyr, Steyr, Austria|Medical University Vienna, Vienna, Austria|KH SMZ Ost, Vienna, Austria|LKH V√∂cklabruck, V√∂cklabruck, Austria|Klinikum Wels, Wels, Austria|LKH Wr. Neustadt, Wr. Neustadt, Austria",87.7953205,79.01578845,All,"18 Years and older ¬† (Adult, Older Adult)",349,338,308,132,162,14,10/31/2010,6/22/2011,3/30/2011,4/29/2011,4/2/2011,4/24/2011,5/8/2011,5/11/2011,6/9/2011,3/15/2015,5/6/2015,10/10/2015,2/28/2016,4/17/2016,5/20/2016,7/3/2016,8/6/2016,9/11/2016,10/17/2016,10/21/2011,4/18/2012,10/15/2012,4/13/2013,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02555696,,,,,,
Celgene,Celgene,ST00338,SP00006,"Phase II Trial Comparing ABI-007 (Abraxane¬Æ, Nab¬Æ-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer",,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Otis Thode †,Jeanene Y,Remedios Z,Mara A,In Bellini †,Tamesha T,Mac L,Mee M,Jeanene Y,Chetan K,Perter K,Lyman W,Selizabeth F,Dalton E,Beulah N,Mara A,Harry A,Mee M,Dinah R,,,"Study Sites in Russia and the Ukraine, Kiev, Ukraine",69.45207624,62.50686861,Female,"20 Years and older ¬† (Adult, Older Adult)",342,336,309,166,112,31,12/20/2005,6/7/2006,4/6/2006,5/7/2006,4/10/2006,4/24/2006,4/27/2006,4/30/2006,5/23/2006,8/9/2007,5/13/2007,12/26/2007,3/1/2008,4/8/2008,5/8/2008,7/3/2008,8/11/2008,10/8/2008,11/17/2008,10/21/2006,4/19/2007,10/16/2007,4/13/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00274456,,,,,,
Celgene,Celgene,ST00358,SP00006,"A Phase I/II Study of ABI-007 (Abraxane¬Æ, Nab¬Æ-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer",,,,,Oncology,,,,,,Industry,Terminated,Phase 1|Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Mara A,Perter K,Frank T,Frank T,Naren G,Stephan T,Jeanene Y,Suzie K,Suk T,Mara A,Marcelina X,In Bellini †,Lavina S,In Bellini †,Aleta H,Jaquelyn H,Tiffiny K,Jeanene Y,Jerold Goo †,,,"City of Hope Comprehensive Cancer Care Center, Duarte, California, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",47.2482751,42.52344759,All,"18 Years to 120 Years ¬† (Adult, Older Adult)",341,326,310,264,7,39,10/27/2005,2/28/2006,1/1/2006,2/3/2006,1/12/2006,1/28/2006,2/6/2006,2/10/2006,3/1/2006,3/7/2007,5/27/2007,11/17/2007,2/1/2008,3/27/2008,5/17/2008,7/6/2008,8/20/2008,9/30/2008,11/28/2008,7/27/2006,1/23/2007,7/22/2007,1/18/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00140140,,,,,,
Celgene,Celgene,ST00366,SP00006,Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 1|Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Terrell p,Ross S,Suk T,Marcelina X,John G,Harry A,Beulah N,Federico L,Otis Thode †,Rima Y ,Tiffiny K,Tamesha T,Frank T,Ross S,Lucie P,Naren G,Geralyn K,Lilla Stilson †,Perter K,,,"University of Alabama at Birmingham Comprehensive Cancer Ctr, Birmingham, Alabama, United States|Scottsdale Healthcare/Virginia Pipe Cancer Institute, Scottsdale, Arizona, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States|Virigina Piper Cancer Institute, Minneapolis, Minnesota, United States|South Texas Oncology & Hematology, San Antonio, Texas, United States",70.18412554,63.16571298,All,"Child, Adult, Older Adult",345,337,311,169,121,21,3/24/2006,10/16/2006,8/31/2006,10/1/2006,9/1/2006,9/13/2006,9/19/2006,9/23/2006,10/8/2006,9/10/2007,11/17/2007,5/15/2008,9/1/2008,10/8/2008,11/16/2008,1/3/2009,2/20/2009,4/4/2009,5/27/2009,3/12/2007,9/8/2007,3/6/2008,9/2/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00398086,,,,,,
Celgene,Celgene,ST00378,SP00006,Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Mara A,Chetan K,Terrell p,Perter K,Mary H,Anthony P,Chetan K,Selizabeth F,Federico L,Mary H,Gertrudis T,Patria R,Terrell p,Jaquelyn H,John G,Remedios Z,Chetan K,Mara A,Tiffiny K,,,"Hematology Oncology Associates, Phoenix, Arizona, United States|Northern AZ Hematology and Oncology Assoc, Sedona, Arizona, United States|Arizona Oncology, Tucson, Arizona, United States|City of Hope Cancer Center, Duarte, California, United States|Southwest Cancer Center - Escondido, Escondido, California, United States|Scripps Cancer Center - Clinical Research, La Jolla, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|The Angeles Clinc and Research Institute, Los Angeles, California, United States|University of Southern California, Los Angeles, California, United States|Prostate Oncology Specialists, Marina Del Rey, California, United States|Stanford University Medical Center, Stanford, California, United States|Rocky Mountain Cancer Centers-Colorado Springs Circle, Colorado Springs, Colorado, United States|Washington Cancer Institute, Washington, District of Columbia, United States|Melbourne Internal Medicine Associates, Melbourne, Florida, United States|Advanced Medical Specialties, Miami, Florida, United States|Florida Cancer Institute - New Hope, New Port Richey, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Centers of Florida, P.A.- West Gore Street, Orlando, Florida, United States|South Florida Oncology - Hematology, Tamarac, Florida, United States|Palm Beach Cancer Institute, LLC, West Palm Beach, Florida, United States|Cancer Care and Hematology Specialists of Chicagoland, Niles, Illinois, United States|Lutheran General Hospital, Park Ridge, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Hematology and Oncology Specialist, LLC, Metairie, Louisiana, United States|Maryland Oncology Hematology PA, Columbia, Maryland, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Summit Medical Group Overlook Oncology Center, Berkeley Heights, New Jersey, United States|Hematology-Oncology Associates of NNJ, P, Morristown, New Jersey, United States|Hematology Oncology Associates of South Jersey, Mount Holly, New Jersey, United States|New York Oncology Hematology P.C., Albany, New York, United States|Columbia Univ Medical Center, New York, New York, United States|Weill Cornell Medical College Dr. Feldman's Office, New York, New York, United States|New Bern Cancer Care, New Bern, North Carolina, United States|Cancer Centers of North Carolina, Raleigh, North Carolina, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Northwest Cancer Specialists-Tualatin, Tualatin, Oregon, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Cancer Center of the Carolinas, Greer, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Cookeville Regional Medical Center, Cookeville, Tennessee, United States|Sarah Cannon Research Institute UK, Nashville, Tennessee, United States|Texas Oncology, P.A.-Amarillo, Amarillo, Texas, United States|Texas Oncology-Arlington South, Arlington, Texas, United States|Texas Oncology, PA, Austin, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, P.A.-Fort Worth, Fort Worth, Texas, United States|Longview Cancer Center, Longview, Texas, United States|Allison Cancer Center, Midland, Texas, United States|Texas Oncology, P.A. - Paris, Paris, Texas, United States|Southlake Oncology, Southlake, Texas, United States|Texas Oncology, P.A. - Tyler, Tyler, Texas, United States|Texas Oncology Deke Slayton Cancer Center, Webster, Texas, United States|Texas Oncology-Texoma Cancer Center, Wichita Falls, Texas, United States|Veterans Education and Research Association of Northern New England, Inc., White River Junction, Vermont, United States|Cancer Outreach Associates, Abingdon, Virginia, United States|Fairfax Northern Virginia Hematology Oncology, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., Roanoke, Virginia, United States|Columbia Basin Hematology and Oncology, Kennewick, Washington, United States|VA Puget Sound HCS Seattle Division, Seattle, Washington, United States|Evergreen Hematology and Oncology, Spokane, Washington, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Flinders Medical Centre, Bedford Park, Australia|Chris O'Brien Lifehouse, Camperdown, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Port Macquarie Base Hospital, Port Macquarie, Australia|Redcliffe Hospital, Redcliffe, Australia|Royal North Shore Hospital, St Leonards, Australia|Newcastle Calvary Mater Hospital, Waratah, Australia|Westmead Hospital, Westmead, Australia|Border Medical Oncology, Wodonga, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Medical University of Graz, Graz, Austria|Landeskrankenhaus Salzburg, Salzburg, Austria|Krankenhaus der Barmherzigen Brueder, Vienna, Austria|Medizinische Universitat Wien, Vienna, Austria|ZNA Middelheim, Antwerpen, Belgium|Hopital Erasme, Brussels, Belgium|Edith Cavell Clinic, Bruxelles, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|The Health Institute for Men CMX Research Inc, Toronto, Ontario, Canada|Les Urologues Specialises, Montreal, Quebec, Canada|Krajska zdravotni, a.s. Nemocnice Chomutov, o.z., Chomutov, Czechia|Fakultni nemocnice Motol, Prague 5, Czechia|Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad La, Usti Nad Labem, Czechia|Arhus Universitets hospital, Aarhus C, Denmark|Herlev Hospital, Herlev, Denmark|Rigshospitalet University Hospital, Kobenhavn, Denmark|Odense Universitetshospital, Odense C, Denmark|CRLCC Paul Papin, Angers 49, France|Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, France|Centre Georges Francois Leclerc, Dijon Cedex, France|Clinique Victor Hugo, Le Mans, France|Centre Oscar Lambret, Lille 59, France|Centre Leon Berard, Lyon, France|Clinique de Valdegour, Nimes, France|CHU de Poitiers, Poitiers Cedex, France|Centre Eugene Marquis, Rennes Cedex, France|CRLCC Centre Rene Gauducheau, Saint Herblain 44, France|Institut de Cancerologie de la Loire, Saint Priest En Jaroz, France|Hopital Civil de Strasbourg, Strasbourg, France|CHRU Hopital Bretonneau, Tours Cedex, France|Institut Gustave Roussy, Villejuif, France|Vivantes Klinikum am Urban, Berlin, Germany|Medizinisches Zentrum Bonn-Friedensplatz, Bonn, Germany|Diakonissenkrankenhaus Dessau gGmbH, Dessau-Rosslau, Germany|Universitaetsklinikum Duesseldorf, Duesseldorf, Germany|Krankenhaus Nordwest, Frankfurt a.M., Germany|Onkologische Praxis Freiburg, Freiburg, Germany|Universitatsklinikum Hamburg-Eppendorf / IVDP, Hamburg, Germany|IORC- Innovation Onkologie Research and Consulting GmbH, Hamburg, Germany|Praxis fuer Haematologie und Onkologie Koblenz, Koblenz, Germany|Vituro GmbH & Co KG, Leipzig, Germany|TU M√ºnchen - Klinikum rechts der Isar, M√ºnchen, Germany|Universitaetsklinikum Muenster, M√ºnster, Germany|University-Hospital T√ºbingen, Tuebingen, Germany|Universitatsklinikum Ulm, Ulm, Germany|Alexandra General Hospital of Athens, Athens, Greece|Agioi Anargyroi Hospital, Athens, Greece|University Hospital of Larissa, Larissa, Greece|Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece|Fovarosi Onkirmanyzat Peterfy S.Utcai Korhaz-Rend.Int es Baleseti Kozp., Budapest, Hungary|Fovarosi Onkormanyzat Bajcsy-Zsilinszky Korhaz es Rendelointezet, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Hungary|Pecsi Tudomanyegytem Altalanos Orvostudomanyi Kar, Pecs, Hungary|The Soroka University Medical Center, Beer Sheva, Israel|Rambam Health Care Campus, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Assaf Harofeh Medical Center, Zerifin, Israel|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy|Ordine Mauriziano, Candiolo, Italy|Azienda Ospedaliera Istituti Ospitalieri di Cremona, Cremona, Italy|Ospedale Vito Fazzi, Lecce, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy|Ospedale di Mirano, Mirano (VE), Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Ospedale degli Infermi di Rimini, Rimini, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Miserico, Udine, Italy|Hospital Angeles Lindavista, D.f, Df, Mexico|Consultorio de Especialidad en Urologia Privado, Durango, DGO, Mexico|Hospital Fatima, Sinaloa, SIN, Mexico|Consultorio Privado- Dr Jose Arturo Rodriguez Rivera, Zapopan, JAL, Mexico|VU University Medical Center VU Medisch Centrum, Amsterdam, Netherlands|Ziekenhuis Rijnstate, Arhem, Netherlands|Amphia Ziekenhuis Molengracht, Breda, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Gemini Ziekenhuis, Den Helder, Netherlands|Albert Schweitzer Ziekenhuis Amstelwijck, Dordrecht, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Twee Steden Ziekenhuis Tilburg, Tilburg, Netherlands|VieCuri Medisch Centrum Venlo, Venlo, Netherlands|Isala Klinieken, Zwolle, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Regionalny Osrodek Onkologiczny WSS im. M. Kopernika, Lodz, Poland|ZOZ MSWiA z Warminsko- Mazurskim Centrum Onkologii, Olsztyn, Poland|NZOZ Olsztynski Osr. Onkologiczny Kopernik Sp.z o.o, Olsztyn, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku, Rybnik, Poland|Centrum Onkologii-Instytut im.Marii Sklodowskiej-Curie, Warszawa, Poland|4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ, Wroclaw, Poland|Moscow Oncology Clinical Dispensary 1, Moscow, Russian Federation|Medical Radiology Research Centre RAMS, Obninsk, Russian Federation|State Institution of Heath Omsk Regional Oncology Dispensary, Omsk, Russian Federation|Russian Scientific Center for Radiology and Surgical Technol, St. Petersburg, Pesochny Vlg Saint Petersburg, Russian Federation|NSHI Dorozhnaya Clinical Hospital of OAO Russian Railways, Rostov-on-Don, Russian Federation|Oncology Dispensary 2 of Krasnodar Region, Sochi, Russian Federation|Yaroslavl Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|Groote Schuur Hospital, Cape Town, W Cape, South Africa|The Oncology Centre Durban, Durban, KZ-Natal, South Africa|Westridge Medical Centre, Durban, KZ-Natal, South Africa|Netcare Oncology and Interventional Centre, Goodwood, W Cape, South Africa|Dr. H. Malan, Polokwane, South Africa|Pretoria Urology Hospital, Pretoria, South Africa|Hospital del Mar, Barcelona, Spain|Hospital Dur√°n i Reynals - Instituto Catal√†n de Oncolog√¨a ICO, Hospitalet de Llobregat, Barcelona, Spain|Hospital Arnau de Vilanova, L√©rida, Spain|Hospital 12 de Octobre, Madrid, Spain|HCU Virgen de la Victoria, Malaga, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Mutua de Terrassa, Terrassa (Barcelona), Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Lanssjukhuset Ryhov, J√∂nk√∂ping, Sweden|Norrlands Universitetssjukhus, Ume√•, Sweden|Centrallasarettet Vasteras, V√§ster√•s, Sweden|Clatterbridge Centre for Oncology NHS Trust, Bebington, Wirral, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Guy's and St Thomas' Hospital - London, London, United Kingdom|St George's Hospital, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Christie NHS Trust Hospital, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Northern Lincolnshire and Goole Hospitals NHS Foundation Trust, Scunthorpe, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom",43.82250412,39.44025371,Male,"18 Years and older ¬† (Adult, Older Adult)",327,319,312,132,154,26,7/27/2007,12/25/2007,10/29/2007,11/12/2007,10/21/2007,11/7/2007,11/14/2007,11/15/2007,11/22/2007,11/2/2011,4/18/2011,9/15/2011,1/13/2012,2/28/2012,4/13/2012,5/20/2012,6/27/2012,8/16/2012,10/6/2012,5/5/2008,11/1/2008,4/30/2009,10/27/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00988208,,,,,,
Celgene,Celgene,ST00413,SP00006,Treatment of Pancreatic Cancer With Abraxane,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Cross-Sectional,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Stephan T,Perter K,Lyman W,Frank T,Selizabeth F,Geralyn K,Kandace p,Ross S,Ross S,Kandace p,Mary H,Aleta H,Mara A,Kandace p,Lucie P,Xochitl D,Terisa Sikora †,Anthony P,Chetan K,,,"BHB Eisenstadt, Eisenstadt, Austria|LKH Feldkirch, Feldkirch, Austria|Medical University Graz, Graz, Austria|Medical University Innsbruck, Innsbruck, Austria|KH Elisabethinen Klagenfurt, Klagenfurt, Austria|LKH Klagenfurt, Klagenfurt, Austria|KH Krems, Krems, Austria|LKH Leoben, Leoben, Austria|KH Barmherzige Schwestern Linz, Linz, Austria|LKH Salzburg, Salzburg, Austria|LKH St. P√∂lten, St. P√∂lten, Austria|LKH Steyr, Steyr, Austria|Medical University Vienna, Vienna, Austria|KH St. Josephs, Vienna, Austria|KH Hanusch, Vienna, Austria|LKH V√∂cklabruck, V√∂cklabruck, Austria|Klinikum Wels, Wels, Austria|LKH Wr. Neustadt, Wr. Neustadt, Austria|KH Zams, Zams, Austria",13.65925847,12.29333262,All,"Child, Adult, Older Adult",330,318,313,177,107,29,6/20/2017,11/2/2017,8/28/2017,9/27/2017,9/6/2017,9/21/2017,10/5/2017,10/10/2017,11/2/2017,2/23/2020,2/12/2020,6/30/2020,9/7/2020,10/12/2020,11/25/2020,12/26/2020,2/13/2021,3/30/2021,5/6/2021,3/20/2018,9/16/2018,3/15/2019,9/11/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02555813,,,,,,
Celgene,Celgene,ST00417,SP00006,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Clarice N,Jerold Goo †,Anthony P,Anthony P,Tamesha T,Rima Y ,Christian G,Otis Thode †,Kandace p,Suzie K,Marceline R,Stephan T,Quentin N,Gertrudis T,Anthony P,Kala R,Liberty A,Louann C,Jene M,,,"Birmingham, Alabama, United States|Sedona, Arizona, United States|Denver, Colorado, United States|Torrington, Connecticut, United States|Indianapolis, Indiana, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|Saint Louis, Missouri, United States|Henderson, Nevada, United States|Raleigh, North Carolina, United States|Eugene, Oregon, United States|Greenville, South Carolina, United States|Austin, Texas, United States|Bedford, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Fort Worth, Texas, United States|Fredericksburg, Texas, United States|Houston, Texas, United States|Longview, Texas, United States|McAllen, Texas, United States|Tyler, Texas, United States|Waco, Texas, United States|Fairfax, Virginia, United States|Norfolk, Virginia, United States|Vancouver, Washington, United States",93.54620387,84.19158348,Female,"18 Years and older ¬† (Adult, Older Adult)",349,338,314,233,56,25,9/3/2003,1/18/2004,11/29/2003,12/28/2003,12/9/2003,12/19/2003,12/21/2003,12/24/2003,1/17/2004,9/1/2006,7/5/2006,12/9/2006,3/1/2007,4/24/2007,5/24/2007,6/28/2007,8/24/2007,10/2/2007,11/19/2007,6/16/2004,12/13/2004,6/11/2005,12/8/2005,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00394251,,,,,,
Celgene,Celgene,ST00565,SP00006,"A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPŒ±, in Subjects With Advanced Solid and Hematologic Cancers",,,,,Oncology,,,,,,Industry,Recruiting,Phase 1,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Lucie P,Mary H,Mary H,Patria R,Lucie P,John G,James y,Ngan D,Suzie K,Jeanene Y,Xochitl D,Ross S,Chetan K,Naren G,Tamesha T,Kala R,Quentin N,Quentin N,Kala R,,,"University of Alabama Birmingham, Birmingham, Alabama, United States|HonorHealth Research Institute, Scottsdale, Arizona, United States|UC Davis Medical Center, Sacramento, California, United States|Rocky Mountain Cancer Centers, LLP [Aurora-COAU], Aurora, Colorado, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYU Langone Laura and Isaac Perlmutter Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Providence Cancer Center/Earle A. Chiles Res. Inst., Portland, Oregon, United States|University of Pittsburgh Medical Center - Cancer Pavilion, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|US Oncology Research, Irving, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Austin Health - Austin Hospital, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University Health Center, Montreal, Quebec, Canada|Institut Bergonie, Borddeaux Cedex, France|Hotel Dieu CHU Nantes, Nantes Cedex 01, France|CLCC H BecquerelHematology, Rouen, France|Gustave Roussy, Villejuif CEDEX, France|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Universitario de Salamanca - Hospital Clinico, Salamanca, Spain",91.53060939,82.37754845,All,,351,338,315,146,145,24,8/16/2020,1/14/2021,11/14/2020,12/2/2020,11/18/2020,11/24/2020,12/3/2020,12/5/2020,12/15/2020,8/15/2022,2/26/2022,7/16/2022,11/8/2022,12/21/2022,1/21/2023,3/14/2023,4/24/2023,6/10/2023,7/26/2023,5/23/2021,11/19/2021,5/18/2022,11/14/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03783403,,,,,,
Gilead Sciences,Gilead Sciences,ST00003,SP00009,Gilead Sustained Virologic Response (SVR) Registry,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,John G,Perter K,Xochitl D,Tammara F,Mee M,Ngan D,Aleta H,Anthony P,John G,Marcelina X,Marceline R,Suzie K,Mac L,Christian G,In Bellini †,Beulah N,Gertrudis T,Marcelina X,Liberty A,,,"Birmingham Gastroenterology Associates, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Digestive Health Specialists of the Southeast, PA, Dothan, Alabama, United States|Mayo Clinic, Phoenix, Arizona, United States|The University of Arizona, Tucson, Arizona, United States|Advanced Clinical Research Institute, LLC, Anaheim, California, United States|Franco Felizarta, MD, Bakersfield, California, United States|Southern California Liver Centers, Coronado, California, United States|West Coast Clinical Trials, LLC, Costa Mesa, California, United States|Scripps Clinic Medical Group, La Jolla, California, United States|eStudySite, La Mesa, California, United States|Long Beach VA Medical Center, Long Beach, California, United States|Ruane Clinical Research Group, Los Angeles, California, United States|National Research Institute, Los Angeles, California, United States|Anthony Mills MD, Inc, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Kaiser Permanente, Los Angeles, California, United States|Veterans Administration Wadsworth Medical Center, Los Angeles, California, United States|eStudySite, Oceanside, California, United States|Stanford University, Palo Alto, California, United States|Huntington Medical Research Institutes, Pasadena, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|University of California Davis Medical Center, Sacramento, California, United States|UC Davis Medical Center, Sacramento, California, United States|University of California at San Diego, San Diego, California, United States|Research and Education, Inc., San Diego, California, United States|Medical Associates Research Group, Inc., San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|University of California San Diego, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|Quest Clinical Research, San Francisco, California, United States|Kaiser Permanente Center, San Francisco, California, United States|Silicon Valley Research Institute, San Jose, California, United States|Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|South Denver Gastroenterology, Englewood, Colorado, United States|Gastroenterology Center of Connecticut, Hamden, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Whitman-Walker Health, Washington, District of Columbia, United States|Capital Medical Associates, P.C., Washington, District of Columbia, United States|Bach and Godofsky Infectious Diseases, Bradenton, Florida, United States|University of Miami - Dept of Neurology, Coral Gables, Florida, United States|University of Florida Hepatology Research at CTRB, Gainesville, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Advanced Research Institute, New Port Richey, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Internal Medicine Specialists, Orlando, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States|Saint Joseph's Hospital, Tampa, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|South Florida Center of Gastroenterology, P.A., Wellington, Florida, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Digestive Healthcare of Georgia, Atlanta, Georgia, United States|Atlanta Medical Center, Atlanta, Georgia, United States|Dekalb Gastroenterology Associates, LLC, Decatur, Georgia, United States|Infectious Disease Specialists of Atlanta, PC, Decatur, Georgia, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|The Queen's Medical Center-Liver Center, Honolulu, Hawaii, United States|Ruth M. Rothstein CORE Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Graves-Gilbert Clinic, Bowling Green, Kentucky, United States|Delta Research Partners, LLC, Bastrop, Louisiana, United States|Medical Development Centers, LLC, Baton Rouge, Louisiana, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Digestive Disease Associates, PA, Baltimore, Maryland, United States|University of Maryland, College Park, Maryland, United States|Johns Hopkins University, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Community Research Initiative of New England, Boston, Massachusetts, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|The Research Institute, Springfield, Massachusetts, United States|Partners in Internal Medicine, PC, Worcester, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Minnesota Gastroenterology, Saint Paul, Minnesota, United States|Digestive Health Specialists, Tupelo, Mississippi, United States|Kansas City Research Institute, LLC, Kansas City, Missouri, United States|The Kansas City Free Health Clinic, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|ID Care, Inc., Hillsborough, New Jersey, United States|Atlantic Research Affiliates, LLC, Morristown, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|The Gastroenterology Group of South Jersey, Vineland, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Southwest C.A.R.E. Center, Santa Fe, New Mexico, United States|Binghamton Gastroenterology Associates, PC, Binghamton, New York, United States|Bronx Veteran's Affairs Medical Center, Bronx, New York, United States|Northwell Health, Manhasset, New York, United States|Northwell Health, Manhasset, New York, United States|Concorde Medical Group PLLC, New York, New York, United States|Weill Cornell Medical College of Cornell Univeristy, New York, New York, United States|St. Luke's Roosevelt Hospital, New York, New York, United States|Columbia Presbyterian Hospital, Columbia University, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of Rochester, Rochester, New York, United States|Westchester Digestive Disease Group, Yonkers, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Carolinas Center for Liver Disease, Statesville, North Carolina, United States|Digestive Health Specialists, PA, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Options Health Research LLC, Tulsa, Oklahoma, United States|Schleinitz Research and Gastroenterology LLC, Medford, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Network Office of Research and Innovation, Allentown, Pennsylvania, United States|Regional Gastroenterology Associates of Lancaster, Ltd., Lancaster, Pennsylvania, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Philadelphia FIGHT, Philadelphia, Pennsylvania, United States|University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States|UPMC Center For Liver Diseases, Pittsburgh, Pennsylvania, United States|Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Memphis Gastroenterology Group, Germantown, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|The Frist Clinic, Nashville, Tennessee, United States|Nashville Medical Research Institute, Nashville, Tennessee, United States|Quality Medical Research, PLLC, Nashville, Tennessee, United States|The North Texas Clinical Research Institute, Arlington, Texas, United States|Central Texas Clinical Research, LLC, Austin, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor Endocrine Center, Dallas, Texas, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|Southwest Infectious Disease Clinical Research, Inc, Dallas, Texas, United States|Therapeutic Concepts, PA, Houston, Texas, United States|Kelsey Research Foundation, Houston, Texas, United States|Research Specialists of Texas, Houston, Texas, United States|St. Luke's Health Baylor College of Medicine Medical Center, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|CHI Health Reseach Center, Houston, Texas, United States|Gastroenterology Consultants PLC, Live Oak, Texas, United States|The Texas Liver Institute, San Antonio, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States|PRA Health Sciences, Salt Lake City, Utah, United States|Metropolitan Research, Annandale, Virginia, United States|Inova Fairfax Hospital Center for Liver Diseases, Falls Church, Virginia, United States|Liver Institute of Virginia, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Canberra Specialist Centre, Canberra, Australian Capital Territory, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|East Sydney Doctors, Darlinghurst, New South Wales, Australia|Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia|St Vincent's Public Hospital Sydney, Darlinghurst, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders University, Bedford Park, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Footscray Hospital, Footscray, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Greenslopes Private Hospital, Greenslopes, Australia|Royal Brisbane & Women's Hospital, Herston, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Royal Perth Hospital, Perth, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Medizinische Universit√§t Graz, Graz, Styria, Austria|Medizinische Universit√§t Wien, Wien, Vienna, Austria|Wilhelminenspital der Stadt Wien, Wien, Vienna, Austria|Ziekenhuis Netwerk Antwerpen Campus Stuivenberg, Antwerpen, Belgium|Cliniques Universitaires Saint Luc, Brussels, Belgium|Universit√© Libre de Bruxelles H√¥pital Erasme, Brussels, Belgium|AZ Groeninge Kortrijk, Kortrijk, Belgium|University of Calgary Liver Unit, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Liver and Intestinal Research Center, Vancouver, British Columbia, Canada|GIRI GI Research Institute, Vancouver, British Columbia, Canada|Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|Vancouver Infectious Disease Research and Care Centre, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Centre Hospitalier de L'Universite de Montreal (CHUM), Montreal, Quebec, Canada|Slezska nemocnice v Opave, Infekcni oddeleni, Opava, Czechia|Remedis, s.r.o., Praha 4, Czechia|Klin med, s.r.o., Praha 6, Czechia|West Tallinn Central Hospital, Talinn, Estonia|Tartu University Hospital, Tartu, Estonia|Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, Auvergne, France|H√¥pital Henri Mondor, CRETEIL Cedex, Ile-de-france, France|H√¥pital Saint-Antoine, Paris Cedex 12, Ile-de-france, France|H√¥pital Saint-Antoine, Paris cedex 12, Ile-de-france, France|CHU Piti√©-Salp√™tri√®re, Paris Cedex 13, Ile-de-france, France|H√¥pital Bichat-Claude Bernard, Paris cedex 18, Ile-de-france, France|H√¥pital Tenon, Paris Cedex 20, Ile-de-france, France|H√¥pital Paul Brousse, Villejuif Cedex, Ile-de-france, France|Hopitaux De Brabois, Vandoeuvre-les-Nancy, Limousin, Lorraine, France|Centre Hospitalier Universitaire (CHU) De Limoges - Hopital Dupuytren, Limoges Cedex, Limousin, France|CIC Hopital Purpan, Toulouse, Midi-pyrenees, France|CIC Hopital Purpan, Toulouse, Midi-pyrenees, France|H√¥pital Claude Huriez- Service d'H√©pato-Gastroent√©rologie, Lille, NORD Pas-de-calais, France|H√¥pital-Saint Joseph, Service D'H√©pato-Gastroent√©rologie, Marseille cedex 08, Provence Alpes COTE D'azur, France|H√¥pital de I¬¥Archet 2, Nice, Provence Alpes COTE D'azur, France|Centre Hospitalier Universitaire de Grenoble, Cedex 9, Rhone-alpes, France|Hopital Beaujon, Clichy Cedex, France|Hopital Saint-Eloi, Montpellier, France|CHU de Nice - H√¥pital l'Archet, Nice cedex 3, France|H√¥pital Cochin, Paris, Cedex 14, France|H√¥pital Saint Louis, Paris, France|H√¥pital la Piti√© Salp√™tri√®re, Paris, France|Centre Hospitalier Universitaire Bordeaux H√¥pital Haut-L√©v√™que, Pessac Cedex, France|Hopital Pontchaillou, Rennes Cedex 9, France|C.H.U. Strasbourg, Strasbourg, France|PraxisZentrum f√ºr Gastroenterologie und Endokrinologie, Freiburg im Breisgau, Baden-wuerttemberg, Germany|Albert-Ludwigs-Universit√§t, Freiburg, Baden-wuerttemberg, Germany|Medizinische Universit√§tsklinik IV (Krehl Klinik) Abt. Gastroenterologie und Infektionskrankhen, Heidelberg, Baden-wuerttemberg, Germany|Medizinische Klinik und Poliklinik III, M√ºnchen, Bayern, Germany|Infektiologikum Frankfurt, Frankfurt am Main, Hessen, Germany|Universit√§tsklinikum Frankfurt, Frankfurt am Main, Hessen, Germany|Medizinisches Versorgungszentrum, D√ºsseldorf, Nordrhein-westfalen, Germany|Universit√§tsklinikum D√ºsseldorf, D√ºsseldorf, Nordrhein-westfalen, Germany|Universit√§tsklinikum Essen, Essen, Nordrhein-westfalen, Germany|Gastroenterologische Gemeinschaftspraxis, Herne, Nordrhein-westfalen, Germany|Klinikum der Universit√§t zu K√∂ln, K√∂ln, Nordrhein-westfalen, Germany|Centrum f√ºr Interdisziplin√§re Medizin, Muenster, Nordrhein-westfalen, Germany|Leber- and Studienzentrum am Checkpoint, Berlin, Germany|EPIMED GmbH, Berlin, Germany|Charit√© Universit√§tsmedizin Berlin, Berlin, Germany|Zentrum f√ºr Infektiologie Berlin Prenzlauer Berg GmbH, Berlin, Germany|Universit√§ts Bonn, Bonn, Germany|Universit√§tsklinikum Frankfurt, Frankfurt, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Gastroenterologische Gemeinschaftspraxis Kiel Preetzer, Kiel, Germany|University of Leipzig, Leipzig, Germany|Mainz University, Mainz, Germany|Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Azienda Ospedaliera di Bologna - Policlinico S. Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera S. Orsola - Malpighi, Bologna, Italy|Ente Ospedaliero Ospedali Galliera di Genova, Genova, Italy|Ospedale San Raffaele-IRCCS, Centro San Luigi - San Raffaele Turro, Unit√† Operativa di Malattie Infettive, Milano, Italy|Azienda Ospedaliera - Polo Universitario Luigi Saco, Milano, Italy|Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milano, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera Padova, U.O.C. Cardiologia, Padova, Italy|Azienda Ospedaliera-universitaria Policlinico P. Giaccone, Palermo, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Instituto Nationale Per Le Malattie Infettive ""Lazzaro Spallanzani"", Roma, Italy|Fondazione Policlinico Tor Vergata, Roma, Italy|Azienda Ospedaliera Citt√† della Salute e della Scienza di Torino, Torino, Italy|Academisch Medisch Centrum, Amsterdam, Noord-holland, Netherlands|Leiden Universitair Medisch Centrum, Leiden, Zuid-holland, Netherlands|Erasmus Medisch Centrum, Rotterdam, Zuid-holland, Netherlands|Universitair Medisch Centrum Sint Radboud, Nijmegen, Netherlands|Auckland Clinical Studies Limited, Grafton, Auckland, New Zealand|Auckland City Hospital, Grafton, Auckland, New Zealand|Bay of Plenty Clinical School, Tauranga, BAY OF Plenty, New Zealand|Wellington Hospital, Newtown, WGN, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Urosurgery, Hamilton, New Zealand|Centrum Badan Klinicznych, Wroclaw, Dolnoslaskie, Poland|SP ZOZ Wojew√≥dzki Szpital Zakazny, Warszawa, Mazowieckie, Poland|Wojew√≥dzki Szpital Specjalistyczny im. Kazimierza Dluskiego w Bialymstoku, Bialystok, Podlaskie, Poland|Szpital Specjalistyczny w Chorzowie, Chorz√≥w, Slaskie, Poland|ID Clinic Arkadiusz Pisula, Myslowice, Slaskie, Poland|Spzoz Wojewodzki Specjalistyczny Szpital im. W. Bieganskiego W Lodzi, Lodz, Poland|Fundacion De Investigacion De Diego, San Juan, Puerto Rico|Clinical Research Puerto Rico, San Juan, Puerto Rico|Hospital Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Cl√≠nico Universitario Virgen de la Victoria, M√°laga, Malaga, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Mara√±on, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Ram√≥n y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Universitario Nuestra Se√±ora de Valme, Sevilla, Spain|Hospital Universitario Nuestra Se√±ora de Valme, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Sahlgrenska Universitetssjukhuset, √ñstra Sjukhus, G√∂teborg, Sweden|Sk√•nes Universitetssjukhus i Lund, Lund, Sweden|Sk√•nes Universitetssjukhus,, Malm√∂, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|University of Birmingham and Queen Elizabeth Hospital Birmingham, Birmingham, England, United Kingdom|Bristol Royal Infirmary, Bristol, England, United Kingdom|St George Hospital, London, England, United Kingdom|Chelsea and Westminster Hospital NHS Foundation Trust, London, England, United Kingdom|Guy's and Saint Thomas NHS Foundation Trust, London, England, United Kingdom|Imperial College Healthcare NHS Trust, London, England, United Kingdom|King's College Hospital, London, England, United Kingdom|Royal Free London NHS Foundation Trust, London, England, United Kingdom|North Manchester General Hospital, Manchester, England, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, England, United Kingdom|John Radcliffe Hospital, Oxford, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Queen Alexandra Hospital, Portsmouth, England, United Kingdom|Southampton University Hospitals NHS Trust, Southampton General Hospital, Southampton, England, United Kingdom",23.30329884,20.97296895,All,"18 Years and older ¬† (Adult, Older Adult)",345,332,316,240,30,46,8/7/2027,1/25/2028,11/19/2027,12/21/2027,11/28/2027,12/1/2027,12/11/2027,11/28/2014,12/17/2014,5/13/2016,7/19/2016,2/19/2017,3/28/2017,5/5/2017,6/15/2017,7/18/2017,9/6/2017,10/24/2017,12/8/2017,5/29/2028,11/25/2028,5/24/2029,11/20/2029,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01457755,,,,,,
Gilead Sciences,Gilead Sciences,ST00004,SP00009,A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Kala R,Tamesha T,Anthony P,Geralyn K,Tien C,John G,Dalton E,John G,Chetan K,Otis Thode †,Perter K,Aleta H,John G,John G,Tiffiny K,Otis Thode †,Mara A,Suzie K,Kandace p,,,"Birmingham Gastroenterology Associates, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Digestive Health Specialists, Dothan, Alabama, United States|Mayo Clinic, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Advanced Clinical Research Institute, LLC, Anaheim, California, United States|Franco Felizarta, MD, Bakersfield, California, United States|Southern California Medical Group, Coronado, California, United States|West Coast Clinical Trials, LLC, Costa Mesa, California, United States|UC Davis Medical Center, Davis, California, United States|Kaiser Permanente Institute for Health Research, La Jolla, California, United States|Scripps Clinic, La Jolla, California, United States|University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|Kaiser Permanente of Colorado, Los Angeles, California, United States|Peter J. Ruane, MD, Inc., Los Angeles, California, United States|8631 West 3rd Street, Los Angeles, California, United States|California Liver Institute, Los Angeles, California, United States|Anthony Mills MD, Inc, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Veterans Administration Wadsworth Medical Center, Los Angeles, California, United States|eStudySite, Oceanside, California, United States|Stanford University, Palo Alto, California, United States|660 South Fair Oaks Avenue, Pasadena, California, United States|UC Davis Medical Center, Sacramento, California, United States|University of California San Diego, San Diego, California, United States|Research and Education, Inc., San Diego, California, United States|Medical Associates Research Group, Inc., San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|Quest Clinical Research, San Francisco, California, United States|University of California, San Francisco School of Medicine, San Francisco, California, United States|San Francisco General Hospital, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|San Jose Gastroenterology, San Jose, California, United States|Silicon Valley Research Institute, San Jose, California, United States|Los Angeles BioMedical Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado, Aurora, Colorado, United States|South Denver Gastroenterology, Englewood, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Whitman Walker Clinic, Washington, District of Columbia, United States|Capital Medical Associates, P.C., Washington, District of Columbia, United States|Pointe West Infectious Diseases d/b/a Bach and Godofsky Infectious Diseases, Bradenton, Florida, United States|University of Florida, Gainesville, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Advanced Research Institute, New Port Richey, Florida, United States|Orlando Immunology Center-, Orlando, Florida, United States|Internal Medicine Specialists, Orlando, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States|St. Joseph's Comprehensive Research Institute, Tampa, Florida, United States|Saint Joseph's Hospital, Tampa, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|South Florida Center of Gastroenterology, P.A., Wellington, Florida, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Digestive Healthcare of Georgia, Atlanta, Georgia, United States|Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Medical College of Wisconsin, Chicago, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Graves-Gilbert Clinic, Bowling Green, Kentucky, United States|Medical Development Centers, LLC, Baton Rouge, Louisiana, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Digestive Disease Associates, PA, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Community Research Initiative of New England, Boston, Massachusetts, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|The Research Institute, Springfield, Massachusetts, United States|Partners in Internal Medicine, PC, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Minnesota Gastroenterology, P.A., Plymouth, Minnesota, United States|200 1st st SW, Rochester, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Minnesota Gastroenterology, P.A., Saint Paul, Minnesota, United States|Digestive Health Specialists, Tupelo, Mississippi, United States|Kansas City Gastroenterology and Hepatology, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Impact Clinical Trials, Las Vegas, Nevada, United States|ID Care, Inc., Hillsborough, New Jersey, United States|Research Center at Affiliates in Gastroenterology, Morristown, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|The Gastroenterology Group of South Jersey, Vineland, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Southwest C.A.R.E. Center, Santa Fe, New Mexico, United States|Binghamton Gastroenterology Associates, Johnson City, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Concorde Medical Group PLLC, New York, New York, United States|Weill Medical College of Cornell Univeristy, New York, New York, United States|St. Luke's Roosevelt Hospital, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|Saint Luke's-Roosevelt Hospital Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Westchester Medical Center, Yonkers, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Digestive Health Specialists, PA, Winston-Salem, North Carolina, United States|Options Health Research LLC, Tulsa, Oklahoma, United States|Schleinitz Research and Gastroenterology LLC, Medford, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Network Office of Research and Innovation, Allentown, Pennsylvania, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Regional Gastroenterology Associates of Lancaster, Ltd., Lancaster, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Philadelphia FIGHT, Philadelphia, Pennsylvania, United States|Philadelphia FIGHT, Philadelphia, Pennsylvania, United States|University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States|UPMC Center For Liver Diseases, Pittsburgh, Pennsylvania, United States|Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|University Gastroenterology, Providence, Rhode Island, United States|Gastroenterology Center of the MidSouth, P.C., Germantown, Tennessee, United States|Memphis Gastroenterology Group, Germantown, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|Nashville Medical Research Institute, Nashville, Tennessee, United States|Nashville Gastrointestinal Specialists, Inc, Nashville, Tennessee, United States|Quality Medical Research, PLLC, Nashville, Tennessee, United States|The North Texas Research Institute, Arlington, Texas, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Austin Hospital, Austin, Texas, United States|Central Texas Clinical Research, LLC, Austin, Texas, United States|Nicholaos C. Bellos, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Methodist Transplant Physicians, Dallas, Texas, United States|Therapeutic Concepts, PA, Houston, Texas, United States|Kelsey Research Foundation, Houston, Texas, United States|Research Specialists of Texas, Houston, Texas, United States|St. Luke's Episcopal Hospital, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|St. Luke's Health Baylor College of Medicine Medical Center, Houston, Texas, United States|Alamo Medical Research, San Antonio, Texas, United States|The Texas Liver Institute, San Antonio, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|University of Utah Pediatric Pulmonology, Salt Lake City, Utah, United States|PRA Health Sciences, Salt Lake City, Utah, United States|Metropolitan Research, Fairfax, Virginia, United States|Inova Fairfax Hospital Center for Liver Diseases, Falls Church, Virginia, United States|Liver Institute of Virginia, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Liver Institute of Virginia, Bon Secours Health System, Richmond, Virginia, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Wisconsin Hospital and Clinic, Madison, Wisconsin, United States|Canberra Specialist Centre, Canberra, Australian Capital Territory, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|102 Burton Street, Darlinghurst, New South Wales, Australia|East Sydney Doctors, Darlinghurst, New South Wales, Australia|St Vincent's Public Hospital Sydney, Darlinghurst, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Greenslopes Private Hospital, Woolloongabba, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Footscray Hospital, Footscray, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Alfred Hospital - Infectious Disease Unit, Melbourne, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Monash Medical Centre, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|St Vincent's University Hospital, Fitzroy, Australia|Royal Brisbane & Women's Hospital, QLD, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Medizinische Universit√§t Graz, Graz, Styria, Austria|Wilhelminenspital der Stadt Wien, Wien, Vienna, Austria|Vancouver Infectious Disease Research and Care Centre, Vancouver, British Columbia, Canada|Inspiration Research Limited, Toronto, Ontario, Canada|University of Calgary, Calgary, Canada|University of Alberta, Edmonton, Canada|Hopital Saint-Luc du CHUM, Montreal, Canada|Toronto General Hospital, Toronto, Canada|Toronto Western Hospital, Toronto, Canada|LAIR Centre, Vancouver, Canada|Gordon & Leslie Diamond Health Care Centre, Vancouver, Canada|University of British Colombia, Vancouver, Canada|GIRI GI Research Institute, Vancouver, Canada|University of Manitoba, Health Sciences Center, Winnipeg, Canada|Remedis, s.r.o., Nest√°tn√≠ zdravotnick√© zar√≠zen√≠, Vladim√≠rova 10, Praha 4, Czechia|Klinmed, s.r.o., Praha 6, Czechia|West Tallinn Central Hospital, Talinn, Estonia|Tartu University Hospital, Tartu, Estonia|H√¥pital Haut-L√©v√™que, CHU Bordeaux, Pessac Cedex, Aquitaine, France|Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, Auvergne, France|H√¥pital Henri Mondor, CRETEIL Cedex, Ile-de-france, France|Service Maladies Infectieuses, Paris Cedex 12, Ile-de-france, France|H√¥pital Saint-Antoine, Paris cedex 12, Ile-de-france, France|H√¥pital Bichat-Claude Bernard, Paris cedex 18, Ile-de-france, France|H√¥pital La Piti√© Salp√©tri√®re, Service des Maladies Infectieuses, Paris, Ile-de-france, France|Service des Maladies de l'Appareil Digestif et de la nutrition, Lille, NORD Pas-de-calais, France|H√¥pital Claude Huriez- Service d'H√©pato-Gastroent√©rologie, Lille, NORD Pas-de-calais, France|H√¥pital-Saint Joseph, Service D'H√©pato-Gastroent√©rologie, Marseille cedex 08, Provence Alpes COTE D'azur, France|H√¥pital de I¬¥Archet 2, Nice, Provence Alpes COTE D'azur, France|Centre Hospitalier Universitaire de Grenoble, Cedex 9, Rhone-alpes, France|Hopital Beaujon, clichy Cedex, France|Hopital Saint-Eloi, Montpellier, France|CHU de Nice - H√¥pital l'Archet, Nice cedex 3, France|H√¥pital Saint Louis, Services des Maladies Infectieuses, Paris, France|Hopital Pitie-Salpetriere, Paris, France|Hopital Pontchaillou, Rennes Cedex 9, France|C.H.U. Strasbourg - H√¥pital Hautpierre - H√©matologie, Strasbourg, France|CHU de Nancy, Vandoeuvre, France|Bertoldstrasse 48, Freiburg im Breisgau, Baden-wuerttemberg, Germany|Albert-Ludwigs-Universit√§t, Freiburg, Baden-wuerttemberg, Germany|Medizinische Universit√§tsklinik IV (Krehl Klinik) Abt. Gastroenterologie und Infektionskrankhen, Heidelberg, Baden-wuerttemberg, Germany|Infektiologikum, Frankfurt am Main, Hessen, Germany|Universit√§tsklinikum Frankfurt, Frankfurt am Main, Hessen, Germany|CRC Hannover, Hannover, Niedersachsen, Germany|Medizinisches Versorgungszentrum, D√ºsseldorf, Nordrhein-westfalen, Germany|Universit√§tsklinikum D√ºsseldorf, D√ºsseldorf, Nordrhein-westfalen, Germany|Medizinisches Zentrum - Klinik f√ºr Gastroenterologie und Hepatologie, Essen, Nordrhein-westfalen, Germany|Gastroenterologische Gemeinschaftspraxis, Herne, Nordrhein-westfalen, Germany|Klinik f√ºr Gastroenterologie und Hepatologie am Abdominalzentrum, K√∂ln, Nordrhein-westfalen, Germany|Leber- and Studienzentrum am Checkpoint, Berlin, Germany|Charite Campus Virchow-Klinikum, Berlin, Germany|Seestrasse 13, Berlin, Germany|MIB Dienstleistung GmbH, Berlin, Germany|Universit√§tsklinikum Bonn, Bonn, Germany|Center for HIV and Hepatogastroenterology, Dusseldorf, Germany|Klinikum der Johann Wolfgang Goethe Universitaet, Frankfurt, Germany|Klinikum der Johann Wolfgang-Goethe-Universit√§t, Frankfurt, Germany|Universit√§tsklinikum Frankfurt, Frankfurt, Germany|Medizinische Universitatsklinik, Freiburg, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Institut f√ºr interdisziplin√§re Medizin Studien GmbH an der Asklepiosklinik Saint Georg, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Klinikum der Universit√§t Heidelberg, Heidelberg, Germany|Gastroenterologische Gemeinschaftspraxis Kiel, Kiel, Germany|University of Leipzig, Leipzig, Germany|Johannes Gutenberg University Hospital, Mainz, Germany|Mainz University, Mainz, Germany|Klinikum Innenstadt der LMU Munchen, Muenchen, Germany|Universit√§tsklinikum W√ºrzburg - Med Klinik und Poliklinik, Wurzburg, Germany|Universit√§tsklinik W√ºrzburg, W√ºerzburg, Germany|Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Foggia, Italy|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Azienda Ospedaliera di Bologna - Policlinico S. Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera S. Orsola - Malpighi, Bologna, Italy|Ente Ospedaliero Ospedali Galliera di Genova, Genova, Italy|Ospedale San Raffaele-IRCCS, Centro San Luigi - San Raffaele Turro, Unit√† Operativa di Malattie Infettive, Milano, Italy|Azienda Ospedaliera, Milano, Italy|Dipartimento Polispecialistico - Malattie Infetive, Milano, Italy|Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milano, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera Padova, U.O.C. Cardiologia, Padova, Italy|Azienda Ospedaliera-universitaria Policlinico P. Giaccone, Palermo, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive - Epatologia, Roma, Italy|Fondazione Policlinico Tor Vergata, Roma, Italy|Azienda Ospedaliera Citt√† della Salute e della Scienza di Torino, Torino, Italy|Academisch Medisch Centrum, Amsterdam, Noord-holland, Netherlands|Leiden Universitair Medisch Centrum, Leiden, Zuid-holland, Netherlands|Erasmus Medisch Centrum, Rotterdam, Zuid-holland, Netherlands|Universitair Medisch Centrum Sint Radboud, Nijmegen, Netherlands|Auckland Clinical Studies Limited, Grafton, Auckland, New Zealand|Middlemore Hospital, Grafton, Auckland, New Zealand|Auckland City Hospital, Grafton, Auckland, New Zealand|Bay of Plenty Clinical School, Tauranga, BAY OF Plenty, New Zealand|Wellington Hospital, Newton, WGN, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital (District Health Board), Hamilton, New Zealand|Urosurgery, Hamilton, New Zealand|Wellington Hospital, Wellington, New Zealand|Centrum Badan Klinicznych Osrodek Badan Wczesnej Fazy, Wroclaw, Dolnoslaskie, Poland|NZOZ Centrum Badan Klinicznych, Wroclaw, Dolnoslaskie, Poland|Oddzial Dzienny, Warszawa, Mazowieckie, Poland|SP ZOZ Wojew√≥dzki Szpital Zakazny, Warszawa, Mazowieckie, Poland|Wojew√≥dzki Szpital Specjalistyczny im. Kazimierza Dluskiego w Bialymstoku, Bialystok, Podlaskie, Poland|Szpital Specjalistyczny w Chorzowie, Chorz√≥w, Slaskie, Poland|ID Clinic, Myslowice, Slaskie, Poland|SP ZOZ Wojewodzki Szpital Zakazny w Warszawie, Chorzow, Poland|Wojewodzki Specjalistyczny Szpital im. W. Bieganskiego, Lodz, Poland|NZOZ Pol-SaNa-Med, Myslowice, Poland|Chattanooga Hem/Oncology Ass (SCRI), San Juan, Puerto Rico|Fundacion De Investigacion De Diego, San Juan, Puerto Rico|Clinical Research Puerto Rico, San Juan, Puerto Rico|C / Manuel de Falla, Majadahonda, Madrid, Spain|Hospital Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Mara√±on, Madrid, Spain|Hospital Moncloa, Servicio de Enfermedades Infecciosas, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Paseo de la Castellana n¬∫ 261, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Nuestra Se√±ora de Valme, Sevilla, Spain|Hospital Universitario Nuestra Se√±ora de Valme, Sevilla, Spain|Avenida Tres Cruces s/n, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Sahlgrenska Universitetssjukhuset, √ñstra sjukhuset, G√∂teborg, Vastra Gotaland, Sweden|Sahlgrenska Universitetssjukhuset, √ñstra Sjukhus, G√∂teborg, Sweden|Sk√•nes Universitetssjukhus, Lund, Sweden|Sk√•nes Universitetssjukhus i Lund, Lund, Sweden|Sk√•nes Universitetssjukhus, Malm√∂, Malm√∂, Sweden|Karolinska Universitetssjukhuset Solna, Solna, Sweden|University of Birmingham and Queen Elizabeth Hospital Birmingham, Birmingham, England, United Kingdom|Southampton University Hospitals NHS Trust, Southampton General Hospital, Hampshire, England, United Kingdom|Westminster Bridge Road, London, England, United Kingdom|Chelsea and Westminster Hospital NHS Foundation Trust, London, England, United Kingdom|Guy's and Saint Thomas NHS Foundation Trust, London, England, United Kingdom|Imperial College Healthcare NHS Trust, London, England, United Kingdom|King's College Hospital, London, England, United Kingdom|St George Hospital, London, England, United Kingdom|North Manchester General Hospital, Manchester, England, United Kingdom|Queen's Medical Centre Campus, Nottingham, England, United Kingdom|John Radcliffe Hospital, Oxford, England, United Kingdom|Marlborough Street, Bristol, United Kingdom|Derriford Hospital, Plymouth, United Kingdom",62.06694633,55.8602517,All,"12 Years and older ¬† (Child, Adult, Older Adult)",345,337,317,175,119,23,6/29/2027,1/31/2028,12/4/2027,12/30/2027,11/20/2027,12/10/2027,12/20/2027,12/10/2015,1/6/2016,9/11/2017,6/18/2017,2/23/2018,4/9/2018,6/5/2018,7/29/2018,9/8/2018,10/26/2018,12/8/2018,1/31/2019,6/7/2028,12/4/2028,6/2/2029,11/29/2029,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01457768,,,,,,
Gilead Sciences,Gilead Sciences,ST00006,SP00009,Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB,,FINITE CHB,Chronic Hepatitis B,,Virology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Remedios Z,Stephan T,Garnet T,Ngan D,John G,Lilla Stilson †,Ross S,Jaquelyn H,Xochitl D,Stephan T,Selizabeth F,Mary H,Garnet T,Mee M,Doreen T,Naren G,Otis Thode †,John G,Mary H,,,"Leberzentrum am Checkpoint, Berlin, Germany|Charite CVK, Berlin, Germany|Zentrum f√ºr HIV und Hepatitis, Duesseldorf, Germany|J.W. Goethe Universitaetsklinikum, Frankfurt, Germany|ifi Studien und Projekte GmbH, Hamburg, Germany|Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Gastroenterologische Gemeinschaftspraxis, Herne, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Gemeinschaftspraxis Gastroenterologie, Leverkusen, Germany|Klinikum der LMU Grosshadern, Muenchen, Germany|Universitaetsklinikum Ulm, Ulm, Germany",63.74119328,57.36707395,All,18 Years to 45 Years ¬† (Adult),356,348,318,290,4,24,9/30/2027,3/19/2028,12/29/2027,2/7/2028,1/22/2028,1/25/2028,2/4/2028,11/14/2012,12/2/2012,8/17/2015,11/21/2015,5/5/2016,7/28/2016,9/18/2016,11/7/2016,12/7/2016,1/14/2017,2/19/2017,4/2/2017,7/23/2028,1/19/2029,7/18/2029,1/14/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01320943,,,,,,
Gilead Sciences,Gilead Sciences,ST00008,SP00009,A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection,,,Hepatitis C Virus Infection,,Virology,,,,,,Industry,"Active, not recruiting",,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Kala R,Perter K,Beulah N,Tien C,Ross S,Liberty A,Beulah N,Doreen T,Patria R,John G,John G,Jerold Goo †,James y,Tien C,Kandace p,Corrine U,Clarice N,Anthony P,Tien C,,,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Scripps Clinic Medical Group, La Jolla, California, United States|V.A. Long Beach Medical Center, Long Beach, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Kaiser Permanente Medical Center, Los Angeles, California, United States|Tarrant County ID Associates, Los Angeles, California, United States|The Liver Center, Pasadena, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|Kaiser Permanente, San Diego, California, United States|Medical Associates Research Group, San Diego, California, United States|Quest Clinical Research, San Francisco, California, United States|University of California at San Francisco Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Whitman-Walker Health, Washington, District of Columbia, United States|UF Hepatology Research at CTRB, Gainesville, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|South Florida Center of Gastroenterology, Wellington, Florida, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|Atlanta Medical Center, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|Delta Research Partners, Monroe, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Digestive Disease Associates, PA, Catonsville, Maryland, United States|Johns Hopkins Hospital/University, Lutherville, Maryland, United States|Community Research Initiative of New England, Boston, Massachusetts, United States|BIDMC Liver Center, Boston, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Minnesota Gastroenterology, PA, Saint Paul, Minnesota, United States|Kansas City Research Institute, LLC, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|ID Care, Inc, Hillsborough, New Jersey, United States|Southwest CARE Center, Santa Fe, New Mexico, United States|Binghamton Gastroenterology Associates, PC, Binghamton, New York, United States|North Shore Health Inc., Manhasset, New York, United States|Columbia University Medical Center, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|New York University Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|Gastroenterology Center of the MidSouth, P.C., Germantown, Tennessee, United States|Nashville Gastrointestinal Specialists, Inc., Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The North Texas Clinical Research Institute, Arlington, Texas, United States|Baylor Endocrine Center, Dallas, Texas, United States|North Texas Research Institute, Dallas, Texas, United States|St. Luke's Episcopal Hospital, Houston, Texas, United States|The Texas Liver Institute, San Antonio, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|INOVA Fairfax Hospital, Annandale, Virginia, United States|Bon Secours St. Mary's Hospital of Richmond, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Kirby Institute, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|St Vincents Hospital Sydney, Fitzroy, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Monash Medical Centre Clayton Campus, Melbourne, Victoria, Australia|The Alfred Hospital, Prahran, Victoria, Australia|Fiona Stanley Hospital, Fremantle, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|University of Calgary, Calgary, Alberta, Canada|GI Research Institute, Vancouver, British Columbia, Canada|Vancouver Infectious Disease Research and Care Centre, Vancouver, British Columbia, Canada|London Health Sciences Centre - University Campus, London, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CRCHUM, Montr√©al, Quebec, Canada|University of Alberta, Edmonton, Canada|H√¥pital Pontchaillou, Rennes, Bretagne, France|Hopital de La Piti√©-Salp√™tri√®re, Paris, Ile De France, France|CHU Montpellier - Hopital St. Eloi, Montpellier Cedex 05, Languedoc-Rousillon, France|H√¥pital Universitaire Dupuytren, Limoges Cedex, Limousin, France|Hopital Purpan, Toulouse, Midi-Pyrenees, France|Hopital Saint Joseph, Marseille Cedex 08, Provence Alpes Cote D'Azur, France|Groupe Hospitalier Archet I Et II, Nice Cedex 3, Provence Alpes Cote D'Azu, France|Hopital Haut Leveque, Bordeaux, France|CHU Estaing, Clermont Ferrand, France|H√¥pital Beaujon, Clichy, France|Hopital Henri Mondor, Creteil Cedex, France|CHU de Grenoble- Hopital Michallon, Grenoble Cedex 9, France|Hopital Cochin, Paris, Cedex 14, France|Hopital Tenon, Paris, France|H√¥pital de la Croix Rousse, Paris, France|H√¥pitaux Universitaires de Strasbourg, Strasbourg, France|CHU de Nancy-Hopital Brabois Adulte, Vandoeuvre les Nancy, France|H√¥pital Paul Brousse, Villejuif, France|Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany|Universit√§tsklinikum Hamburg-Eppendorf, Hamburg, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitatsklinikum Koln, Koln, Germany|Technische Universit√§t M√ºnchen, M√ºcheln, Germany|Azienda Ospedaliera Ospedale Niguarda C√† Granda, Milano, Italy|Fondazione IRCCS C√† Granda Ospedale Maggiore Policlinico, Milano, Italy|Ospedale Casa Sollievo Della Sofferenza IRCCS, San Giovanni Rotondo, Italy|Azienda Ospedaliera Citt√† della Salute e della Scienza di Torino, Torino, Italy|Auckland Clinical Studies Ltd, Auckland, North Island, New Zealand|Waikato Hospital, Hamilton, North Island, New Zealand|Christchurch Hospital, Christchurch, South Island, New Zealand|Fundacion de Investigation de Diego, San Juan, Puerto Rico|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Virgen de Valme, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Barts Health NHS Trust, London, England, United Kingdom|Kings College Hospital, London, England, United Kingdom|St Georges University of London, London, England, United Kingdom|North Manchester General Hospital, Manchester, England, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, England, United Kingdom|Gartnavel General Hospital, Glasgow, Scotland, United Kingdom|Queen Alexandra Hospital, Portsmouth, United Kingdom",29.64747059,26.68272353,All,"18 Years to 65 Years ¬† (Adult, Older Adult)",362,349,319,264,9,46,9/10/2027,3/28/2028,1/24/2028,2/27/2028,1/30/2028,2/9/2028,2/19/2028,11/8/2019,12/5/2019,2/10/2022,4/19/2022,8/14/2022,1/1/2023,2/25/2023,4/10/2023,5/31/2023,7/29/2023,9/26/2023,11/4/2023,8/7/2028,2/3/2029,8/2/2029,1/29/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02292706,,,,,,
Gilead Sciences,Gilead Sciences,ST00039,SP00009,ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla,,ONCE,HIV Infections,,Virology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Mac L,Dinah R,John G,Perter K,Gertrudis T,Corrine U,Marcelina X,Marcelina X,Xochitl D,Tammara F,Lucie P,Anthony P,Ross S,Marceline R,Jerold Goo †,Suzie K,Mac L,Remedios Z,Lilla Stilson †,,,"Gilead Sciences, Cambridge, United Kingdom",76.74496253,69.07046628,All,"Child, Adult, Older Adult",341,330,320,301,23,4,4/10/2028,10/29/2028,9/3/2028,10/3/2028,9/17/2028,9/19/2028,9/29/2028,11/9/2005,11/29/2005,11/28/2009,2/22/2010,7/20/2010,11/1/2010,12/17/2010,2/2/2011,3/17/2011,4/20/2011,6/3/2011,7/26/2011,3/18/2029,9/14/2029,3/13/2030,9/9/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00615745,,,,,,
Gilead Sciences,Gilead Sciences,ST00055,SP00009,Safety Study of Once a Day ART and Opiate Substitute.,,3OD,HIV Infections,,Virology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Jaquelyn H,Garnet T,Harry A,Dalton E,Clarice N,Mary H,Patria R,Liberty A,Mary H,Ngan D,Naren G,Lucie P,Federico L,Mary H,Lilla Stilson †,Frank T,Christian G,Dalton E,Dalton E,,,"Gilead Sciences, Munich, Germany",37.30323541,33.57291187,All,"18 Years and older ¬† (Adult, Older Adult)",346,342,321,134,173,14,6/13/2028,1/6/2029,10/19/2028,12/1/2028,11/3/2028,11/17/2028,11/27/2028,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/13/1900,4/2/1900,5/24/1900,7/15/1900,9/5/1900,11/2/1900,5/16/2029,11/12/2029,5/11/2030,11/7/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00324688,,,,,,
Gilead Sciences,Gilead Sciences,ST00057,SP00009,Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial,,COOL,HIV Infections,,Virology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),,,,,,Drug C,,,,,,,,,,,,,,,,,,,Stephan T,Mary H,Otis Thode †,Kala R,Anthony P,Stephan T,Federico L,Garnet T,In Bellini †,Terrell p,Corrine U,Louann C,Mee M,Aleta H,Mary H,Suk T,Kala R,Tammara F,Clarice N,,,"France and French West Indies, Paris, France",18.95659129,17.06093216,All,"45 Years to 80 Years ¬† (Adult, Older Adult)",345,340,322,303,16,3,8/6/2028,1/5/2029,11/16/2028,12/12/2028,11/26/2028,11/30/2028,12/10/2028,12/5/2001,12/15/2001,7/6/2004,10/21/2004,4/20/2005,6/1/2005,7/24/2005,9/6/2005,10/17/2005,12/11/2005,1/17/2006,3/8/2006,5/29/2029,11/25/2029,5/24/2030,11/20/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00643968,,,,,,
Gilead Sciences,Gilead Sciences,ST00063,SP00009,"GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection",,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,John G,Lyman W,Beulah N,Tien C,Rima Y ,Beulah N,Mary H,Lyman W,Ross S,Frank T,Doreen T,Marceline R,Terisa Sikora †,Ross S,Ngan D,Perter K,Dinah R,Suk T,Mary H,,,"University of Arizona, Tucson, Arizona, United States|Advanced Clinical Research Institute, LLC, Anaheim, California, United States|California Liver Institute, Beverly Hills, California, United States|SCTI Research Foundation Liver Center, Coronado, California, United States|University of California, San Diego, La Jolla, California, United States|Lightsource Medical, Los Angeles, California, United States|Medical Associates Research Group, Inc., San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|San Jose Gastroenterology, San Jose, California, United States|Whitman Walker Clinic, Washington, District of Columbia, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|University of Miami, Center for Liver Diseases, Miami, Florida, United States|Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mercy Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Henry Ford Health System, Novi, Michigan, United States|Montefiore Medical Center, Bronx, New York, United States|Weill Medical College of Cornell Univeristy, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|Gastro One, Germantown, Tennessee, United States|Southwest Infectious Disease Clinical Research, Inc, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Therapeutic Concepts, PA, Houston, Texas, United States|The University of Texas Health Sciences Center at Houston, Houston, Texas, United States|Alamo Medical Research, Ltd., San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Bon Secours St. Mary's Hospital of Richmond, Inc., Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Leber- and Studienzentrum am Checkpoint, Berlin, Germany|Charite - Universitatsmedizin Berlin Campus Virchow-Klinikum, Berlin, Germany|Universit√§tsklinikum Bonn, Bonn, Germany|Center for HIV and Hepatogastroenterology, D√ºsseldorf, Germany|Klinikum der Johann Wolfgang Goethe Universitaet, Frankfurt, Germany|Medizinische Universitatsklinik, Freiburg, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Klinikum der Universit√§t Heidelberg, Heidelberg, Germany|Gastroenterologisch-Hepatologisches Zentrum Kiel, Kiel, Germany|Universit√§tsklinikum Leipzig, Leipzig, Germany|Johannes Gutenberg University Hospital, Mainz, Germany|Klinikum Innenstadt der LMU Munchen, Muenchen, Germany|Universit√§tsklinikum W√ºrzburg - Med Klinik und Poliklinik, W√ºrzburg, Germany",87.53580517,78.78222465,All,"18 Years to 79 Years ¬† (Adult, Older Adult)",366,350,323,172,130,21,9/2/2028,2/16/2029,12/30/2028,1/19/2029,12/31/2028,1/9/2029,1/19/2029,4/20/2011,5/2/2011,1/29/2012,3/27/2012,10/21/2012,1/1/2013,2/16/2013,4/15/2013,5/30/2013,7/12/2013,8/22/2013,9/21/2013,7/8/2029,1/4/2030,7/3/2030,12/30/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01435226,,,,,,
Gilead Sciences,Gilead Sciences,ST00064,SP00009,"GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection",,,Chronic Genotype 1a or 1b HCV Infection,,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Anthony P,In Bellini †,In Bellini †,Mac L,Livia Pacheo †,Patria R,John G,Suzie K,Doreen T,Louann C,Gertrudis T,Anthony P,Kala R,Frank T,Mary H,Suzie K,Mee M,Corrine U,John G,,,"California Liver Institute, Beverly Hills, California, United States|SCTI Research Foundation Liver Center, Coronado, California, United States|Scripps Clinic, La Jolla, California, United States|University of California, San Diego, La Jolla, California, United States|Kaiser Permanente Medical Center, Los Angeles, California, United States|Lightsource Medical, Los Angeles, California, United States|Medical Associates Research Group, Inc., San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|University of Miami, Center for Liver Diseases, Miami, Florida, United States|Orlando Immunology Center (ACH), Orlando, Florida, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deconess Medical Center, Boston, Massachusetts, United States|The Research Institute, Springfield, Massachusetts, United States|Henry Ford Health System, Novi, Michigan, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|Gastro One, Germantown, Tennessee, United States|The North Texas Research Institute, Arlington, Texas, United States|The University of Texas Medical Branch, Galveston, Texas, United States|The University of Texas Health Sciences Center at Houston, Houston, Texas, United States|Alamo Medical Research, San Antonio, Texas, United States|Inova Fairfax Hospital Center for Liver Diseases, Falls Church, Virginia, United States|Bon Secours St. Mary's Hospital of Richmond, Inc., Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Calgary, Calgary, Alberta, Canada|University Of Alberta Hospital, Edmonton, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Gordon & Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|University of British Columbia, Vancouver, British Columbia, Canada|GIRI GI Research Institute, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|London Health Sciences Centre, London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Toronto General Hospital, University Health Network, Toronto, Ontario, Canada|Toronto General Hospital, University Health Network, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Hospital Saint-Luc DU CHUM, Montreal, Quebec, Canada|Clinical Research Puerto Rico Inc, San Juan, Puerto Rico",63.43068093,57.08761284,All,"13 Years to 19 Years ¬† (Child, Adult)",366,354,324,313,25,14,8/3/2028,2/16/2029,12/24/2028,1/18/2029,1/3/2029,1/10/2029,1/20/2029,11/17/2009,12/10/2009,8/7/2012,5/13/2012,9/6/2012,1/1/2013,2/9/2013,3/31/2013,5/29/2013,7/27/2013,9/24/2013,11/16/2013,7/9/2029,1/5/2030,7/4/2030,12/31/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01434498,,,,,,
Gilead Sciences,Gilead Sciences,ST00065,SP00009,"Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection",,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Otis Thode †,Remedios Z,Mary H,Lucie P,Selizabeth F,Lucie P,Liberty A,Jene M,Terisa Sikora †,Mary H,John G,Mara A,Suzie K,Anthony P,Doreen T,Marceline R,Patria R,Lavina S,Jene M,,,"Digestive Health Specialists of the Southeast, Dothan, Alabama, United States|Alabama Liver and Digestive Specialists, Montgomery, Alabama, United States|California Liver Institute, Beverly Hills, California, United States|Scripps Clinic, La Jolla, California, United States|University of California Davis Medical Center, Sacramento, California, United States|RESEARCH and EDUCATION, INC, San Diego, California, United States|Medical Associates Research Group, San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|University of Colorado Denver, Aurora, Colorado, United States|South Denver Gastroenterology, Englewood, Colorado, United States|Bach and Godofsky Infectious Diseases, Bradenton, Florida, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|South Florida Center of Gastroenterology, LLC, Wellington, Florida, United States|Emory University, Infectious Disease Clinic, Atlanta, Georgia, United States|Digestive Healthcare of Georgia, Atlanta, Georgia, United States|Dekalb Gastroenterology, Decatur, Georgia, United States|Gastrointestinal Specialists of Georgia PC, Marietta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|Digestive Disease Associates, PA, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Partners in Internal Medicine, P.C., Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Gastrointestinal Associates, PA, Jackson, Mississippi, United States|Digestive Health Specialists, PA, Tupelo, Mississippi, United States|ID Care 105, Hillsborough, New Jersey, United States|Atlantic Research Affiliates, LLC, Morristown, New Jersey, United States|Southwest CARE Center, Santa Fe, New Mexico, United States|Binghamton Gastroenterology, Binghamton, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Concorde Medical Group, New York, New York, United States|Cornell University Gastroenterology & Hepatology, New York, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|University Gastroenterology, Providence, Rhode Island, United States|Memphis Gastroenterology Group, Germantown, Tennessee, United States|Columbia Medical Group, The Frist Clinic, Nashville, Tennessee, United States|Nashville Medical Research Institute, Nashville, Tennessee, United States|Nashville Gastrointestinal Specialists, Inc, Nashville, Tennessee, United States|The North Texas Research Institute, Arlington, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Kelsey Research Foundation, Houston, Texas, United States|Research Specialists of Texas, Houston, Texas, United States|Metropolitan Research, Fairfax, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Liver Institute of Virginia, Richmond, Virginia, United States|Virginia Mason Medical Center, Digestive Disease Institute, Seattle, Washington, United States|Fundacion de Investigacion de Diego, San Juan, Puerto Rico",46.30895686,41.67806117,All,"18 Years and older ¬† (Adult, Older Adult)",339,332,325,219,77,29,10/11/2028,3/10/2029,12/27/2028,1/18/2029,1/3/2029,1/11/2029,1/21/2029,11/1/2011,11/30/2011,12/16/2012,7/11/2012,10/13/2012,3/1/2013,4/23/2013,6/12/2013,7/16/2013,9/1/2013,10/23/2013,12/9/2013,7/10/2029,1/6/2030,7/5/2030,1/1/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01371578,,,,,,
Gilead Sciences,Gilead Sciences,ST00066,SP00009,GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Chetan K,Tamesha T,Perter K,James y,Naren G,Gertrudis T,Dinah R,Suk T,Beulah N,Mary H,Aleta H,Gertrudis T,Aleta H,Remedios Z,Lavina S,Lavina S,Tiffiny K,Jerold Goo †,Gertrudis T,,,"Tucson, Arizona, United States|Beverly Hills, California, United States|Coronado, California, United States|Costa Mesa, California, United States|San Diego, California, United States|Aurora, Colorado, United States|Englewood, Colorado, United States|Bradenton, Florida, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Burlington, Massachusetts, United States|Kansas City, Missouri, United States|Forest Hills, New York, United States|Manhasset, New York, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Fairfax, Virginia, United States|Herston, Queensland, Australia|San Juan, Puerto Rico",71.26508222,64.138574,All,"18 Years and older ¬† (Adult, Older Adult)",345,339,326,118,188,20,9/1/2028,2/25/2029,12/22/2028,1/24/2029,1/5/2029,1/12/2029,1/22/2029,8/3/2008,8/13/2008,11/24/2012,8/21/2012,4/19/2013,6/1/2013,7/10/2013,8/18/2013,10/14/2013,11/13/2013,1/12/2014,3/11/2014,7/11/2029,1/7/2030,7/6/2030,1/2/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01356160,,,,,,
Gilead Sciences,Gilead Sciences,ST00067,SP00009,"GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection",,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Otis Thode †,Hee Y,Perter K,Remedios Z,Tiffiny K,Livia Pacheo †,John G,Doreen T,Terrell p,Liberty A,Beulah N,Perter K,Dinah R,Mee M,Marcelina X,Louann C,John G,Suk T,Ross S,,,"Birmingham Gastroenterology Associates, P.C., Birmingham, Alabama, United States|Digestive Health Specialists of the Southeast, Dothan, Alabama, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Southern California Liver Centers, Coronado, California, United States|UCSF Fresno Medical Education Program (MEP), Fresno, California, United States|Stanford University School of Medicine, Palo Alto, California, United States|University of California San Diego, San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|UCSF, San Francisco, California, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|Bach and Godofsky Infectious Diseases, Bradenton, Florida, United States|University of Florida - Gainesville, Gainesville, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States|Gastrointestinal Specialists of Georgia PC, Marietta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Private Practice, Opelousas, Louisiana, United States|Johns Hopkins University, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Gastrointestinal Associates, PA, Jackson, Mississippi, United States|University of New Mexico, Albuquerque, New Mexico, United States|Mount Sinai Medical Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Gastro One, Germantown, Tennessee, United States|Memphis Gastroenterology Group, Germantown, Tennessee, United States|Columbia Medical Group, The Frist Clinic, Nashville, Tennessee, United States|Nashville Gastrointestinal Specialists, Inc, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|Research Specialists of Texas, Houston, Texas, United States|Alamo Medical Research, San Antonio, Texas, United States|Lifetree Clinical Research, LC, Salt Lake City, Utah, United States|Inova Fairfax Hospital - Center for Liver Diseases, Falls Church, Virginia, United States|Liver Institute of Virginia, Bon Secours Health System, Newport News, Virginia, United States|Fundacion de Investigacion de Diego, San Juan, Puerto Rico",40.07152724,36.06437452,All,"18 Years and older ¬† (Adult, Older Adult)",339,335,327,191,112,24,8/26/2028,3/13/2029,12/18/2028,1/29/2029,1/2/2029,1/13/2029,1/23/2029,12/6/2010,12/21/2010,4/5/2012,3/5/2012,7/23/2012,10/1/2012,11/26/2012,1/17/2013,3/6/2013,4/29/2013,6/6/2013,7/11/2013,7/12/2029,1/8/2030,7/7/2030,1/3/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01353248,,,,,,
Gilead Sciences,Gilead Sciences,ST00068,SP00009,"A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys¬Æ and Copegus¬Æ With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C",,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Tien C,Mary H,Anthony P,John G,Patria R,Mary H,Louann C,Kala R,Donovan H,Mary H,Clarice N,Anthony P,Otis Thode †,Jene M,Frank T,Quentin N,Otis Thode †,Harry A,Beulah N,,,"Digestive Health Specialists of the Southeast, Dothan, Alabama, United States|Alabama Liver and Digestive Specialists, Montgomery, Alabama, United States|Mayo Clinic, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Pacific Oaks Medical Group, Beverly Hills, California, United States|eStudySite, Chula Vista, California, United States|Scripps Clinic, La Jolla, California, United States|eStudySite, La Mesa, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Synergy Clinical Research Center, National City, California, United States|eStudySite, Oceanside, California, United States|RESEARCH and EDUCATION, INC, San Diego, California, United States|Medical Associates Research Group, San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|San Francisco Veterans Affairs Medical Center, San Francisco, California, United States|University of Colorado Denver, Aurora, Colorado, United States|South Denver Gastroenterology, Englewood, Colorado, United States|Washington Hospital Center, Washington, District of Columbia, United States|Bach and Godofsky Infectious Diseases, Bradenton, Florida, United States|Avail Clinical Research, LLC, Deland, Florida, United States|University of Florida, Gainesville, Florida, United States|Palmetto Research, Hialeah, Florida, United States|University of Miami, Miami, Florida, United States|Scientific Clinical Research, Inc c/o Segal Institute for Clinical Research, North Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Florida Hospital, Orlando, Florida, United States|South Florida Center of Gastroenterology, LLC, Wellington, Florida, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|Emory University, Infectious Disease Clinic, Atlanta, Georgia, United States|Liver Center of Atlanta, Atlanta, Georgia, United States|Dekalb Gastroenterology, Decatur, Georgia, United States|Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|IGRF, Indianapolis, Indiana, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|Digestive Disease Associates, PA, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Partners in Internal Medicine, P.C., Worcester, Massachusetts, United States|Henry Ford Health System-Columbus center, Novi, Michigan, United States|MN Gastroenterology, P.A., Plymouth, Minnesota, United States|Gastrointestinal Associates, PA, Jackson, Mississippi, United States|Digestive Health Specialists, PA, Tupelo, Mississippi, United States|Saint Louis University, St. Louis, Missouri, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|ID Care 105, Hillsborough, New Jersey, United States|Atlantic Research Affiliates, LLC, Morristown, New Jersey, United States|University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States|UNM Health Sciences Center, Albuquerque, New Mexico, United States|Binghamton Gastroenterology, Binghamton, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Concorde Medical Group, New York, New York, United States|NYU Hepatology Associates, New York, New York, United States|Cornell University Gastroenterology & Hepatology, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Consultants for Clinical, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|Memphis Gastroenterology Group, Germantown, Tennessee, United States|James H. Quillen VA Medical Center, Mountain Home, Tennessee, United States|Columbia Medical Group, The Frist Clinic, Nashville, Tennessee, United States|The North Texas Research Institute, Arlington, Texas, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Kelsey Research Foundation, Houston, Texas, United States|Advanced Liver Therapies, Houston, Texas, United States|Research Specialists of Texas, Houston, Texas, United States|Amcare Research Inc., Houston, Texas, United States|Alamo Medical Research, San Antonio, Texas, United States|Brooke Army Medical Center, San Antonio, Texas, United States|Metropolitan Research, Fairfax, Virginia, United States|Liver Institute of Virginia, Bon Secours, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Virginia Mason Medical Center, Digestive Disease Institute, Seattle, Washington, United States|University of Wisconsin Hospital & Clinics, Madison, Wisconsin, United States|Landeskrankenhaus Graz West, Graz, Austria|Medizinische Universit√§t Graz, Graz, Austria|LKH Innsbruck, Innsbruck, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria|AKH der Stadt Wien, Vienna, Austria|Wilhelminenspital der Stadt Wien, Vienna, Austria|Ziekenhuis Netwerk Antwerpen, Antwerpen, Belgium|ULB Erasme, Brussels, Belgium|UCL Saint Luc, Brussels, Belgium|UZ Antwerp, Edegem, Belgium|Centre Hospitalier Universitaire Sart Tilman Li√®ge, Li√®ge, Belgium|Beaujon Hospital, Clichy, France|Henri Mondor Hospital, Cr√©teil, France|H√¥pital de la Croix Rousse, Lyon, France|Saint Joseph Hospital, Marseille, France|H√¥pital de I¬¥Archet 2, Service H√©patologie, Nice, France|Centre Hospitalier R√©gional d'Orl√©ans, H√¥pital de la Source, Orl√©ans, France|H√¥pital Cochin, Paris, France|Groupe Hospitalier du Haut Leveque, Pessac, France|Centre Hospitalier Universitaire de Strasbourg - H√¥pital Civil, Strasbourg, France|Nancy University Hospital Center, Vandoeuvre, France|Charite University Medicine, Berlin, Germany|Leber- und Studienzentrum am Checkpoint, Berlin, Germany|University Hospital Bonn, Bonn, Germany|University Hospital Essen, Essen, Germany|Klinikum der Johann Wolfgang Goethe-Universit√§t, Frankfurt/M, Germany|University Hospital Freiburg, Freiburg, Germany|Asklepios Klinik Sankt Georg, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|University hospital Heidelberg, Heidelberg, Germany|University Hospital Leipzig, Leipzig, Germany|Johannes Gutenberg University Hospital, Mainz, Germany|Academisch Medisch Centrum Universiteit Van Amsterdam, Amsterdam, Netherlands|Radaboud University Nijmegen Medical Centre (UMC St Radboud), Nijmegen, Netherlands|Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Wojewodzki Szpital Specjalistyczny im. K. Dluskiego Oddzial Obserwacyjno-Zakazny, Bialystok, Poland|Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza Browicza Oddzia≈Ç Obserwacyjno-Zakazny, Bydgoszcz, Poland|Szpital Specjalistyczny w Chorzowie, Chorzow, Poland|Niepubliczny Zak≈Çad Opieki Zdrowotnej ""Pol-SaNa-Med"" Sp. z o.o., Czelad≈∫, Poland|Wojewodzki Szpital Zespolony w Kielcach, Kielce, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wojewodzki Specjalistyczny Szpital im. Dr Wl. Bieganskiego w Lodzi, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin, Poland|Radomski Szpital Specjalistyczny im. Dr Tytusa Chalubinskiego Oddzial obserwacyjno-zakazny z odcinkiem jednego dnia leczenia chorob watroby, Radom, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Wojewodzki Szpital Zakazny Oddzial Dzienny, Warszawa, Poland|Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Warszawa, Poland|Wojew√≥dzki Szpital Specjalistyczny im. J. Gromkowskiego, Wroc≈Çaw, Poland|Queen Elizabeth Hospital, Birmingham, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|Barts and The London Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Kings College Hospital, London, United Kingdom|Chelsea and Westminster Hospital, London, United Kingdom|Saint Mary's Hosptial, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Derriford Hospital, Plymouth, United Kingdom",80.08986551,72.08087896,All,"6 Months to 80 Years ¬† (Child, Adult, Older Adult)",361,352,328,273,21,34,10/10/2028,3/1/2029,12/24/2028,1/24/2029,1/1/2029,1/14/2029,1/24/2029,7/6/2009,7/30/2009,5/2/2012,6/14/2012,10/25/2012,1/1/2013,2/28/2013,4/28/2013,6/22/2013,7/30/2013,9/23/2013,11/22/2013,7/13/2029,1/9/2030,7/8/2030,1/4/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01271790,,,,,,
Gilead Sciences,Gilead Sciences,ST00069,SP00009,"A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys¬Æ and Copegus¬Æ in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C",,,Chronic Hepatitis C Infection,,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug A,,,,,,,,,,,,,,,,,,,Harry A,Mary H,Jerold Goo †,Suk T,In Bellini †,John G,Perter K,Dalton E,Mary H,Perter K,Marcelina X,Frank T,Lucie P,Suzie K,Clarice N,Chetan K,Beulah N,Suzie K,Kandace p,,,"Mayo Clinic, Phoenix, Arizona, United States|Advanced Clinical Research Institute, Anaheim, California, United States|Scripps Clinic, La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Medical Associates Research Group, San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|South Denver Gastroenterology, Englewood, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Miami Center for Liver Diseases, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Bach and Godofsky Infectious Diseases, Sarasota, Florida, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|Emory University, Infectious Disease Clinic, Atlanta, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|Johns Hopkins University, Lutherville, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Southwest CARE Center, Santa Fe, New Mexico, United States|North Shore University Hospital, Great Neck, New York, United States|Concorde Medical Group, New York, New York, United States|Cornell University Gastroenterology & Hepatology, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|University Gastroenterology, Providence, Rhode Island, United States|Memphis Gastroenterology Group, Germantown, Tennessee, United States|The North Texas Research Institute, Arlington, Texas, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Alamo Medical Research, San Antonio, Texas, United States|Metropolitan Research, Fairfax, Virginia, United States|Liver Institute of Virginia, Bon Secours, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Virginia Mason Medical Center, Digestive Disease Institute, Seattle, Washington, United States|Medizinische Universit√§t Graz, Graz, Austria|LKH Innsbruck, Innsbruck, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria|AKH der Stadt Wien, Vienna, Austria|Wilhelminenspital der Stadt Wien, Vienna, Austria|SGS - Clinical Pharmacology Unit Antwerpen, Antwerpen, Belgium|ULB Erasme, Brussels, Belgium|UCL Saint Luc, Brussels, Belgium|UZ Antwerp, Edegem, Belgium|CHU Sart Tilman, Liege, Belgium|Heritage Medical Research Clinic, Calgary, Alberta, Canada|University of Alberta, Division of Gastroenterology, Edmonton, Alberta, Canada|Downtown ID Clinic, Vancouver, British Columbia, Canada|Gordon & Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|GI Research Institute, Vancouver, British Columbia, Canada|John Buhler Research Centre, Winnipeg, Manitoba, Canada|London Health Sciences Centre, London, Ontario, Canada|Ottawa Hospital, Division of Infectious Diseases, Ottawa, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|University Hospital Brno, Brno, Czech Republic|Melnik Hospital, Melnik, Czech Republic|University Hospital Plzen, Plzen, Czech Republic|Klinmed, s.r.o., Prague, Czech Republic|Institute of Clinic and Experimental Medicine, Prague, Czech Republic|Association of Physicians for Infection Diseases, Usti Nad labem, Czech Republic|Beaujon Hospital, Clichy, France|Henri Mondor Hospital, Cr√©teil, France|Claude Huriez Hospital, Lille, France|Hotel Dieu Hospital, Lyon, France|Saint Joseph Hospital, Marseille, France|Nancy University Hospital Center, Vandoeuvre, France|Charite University Medicine, Berlin, Germany|University Hospital Bonn, Bonn, Germany|University Hospital Essen, Essen, Germany|Klinikum der Johann Wolfgang Goethe-Universit√§t, Frankfurt/M, Germany|University Hospital Freiburg, Freiburg, Germany|Ifi - Institut fuer Interdisziplinaere Medizin - Studien und Projekte GmbH, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|University hospital Heidelberg, Heidelberg, Germany|University Hospital Leipzig, Leipzig, Germany|Johannes Gutenberg University Hospital, Mainz, Germany|Ludwig-Maximilians-University Munich, M√ºnchen, Germany|Epatologia, Azienda Ospedaliero ""Spedali Civili"", Brescia, Italy|U.O. Gastroenterologia 1 - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|Medicina Generale - Azienda Ospedaliera di Padova, Padova, Italy|U. O. C. di Gastroenterologia - Azienda Ospedaliero-Universitaria Policlinico Paolo Giaccone, Palermo, Italy|Unit√† di Malattie Infettive ed Epatologia, Azienda Ospedaliero-Universitaria, Parma, Italy|Gastroepatologia - Azienda Ospedaliero-Universitaria S. Giovanni Battista, Torino, Italy|Wojewodzki Szpital Specjalistyczny im. K. Dluskiego Oddzial Obserwacyjno-Zakazny, Bialystok, Poland|Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza Browicza Oddzia≈Ç Obserwacyjno-Zakazny, Bydgoszcz, Poland|Szpital Specjalistyczny w Chorzowie, Chorzow, Poland|Niepubliczny Zaklad Opieki Zdrowotnej ""Pol-SaNa-Med"" Spolka z ograniczona odpowiedzialnoscia, Czeladz, Poland|Wojewodzki Szpital Zespolony w Kielcach, Kielce, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wojewodzki Specjalistyczny Szpital im. Dr Wl. Bieganskiego w Lodzi, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin, Poland|Radomski Szpital Specjalistyczny im. Dr Tytusa Chalubinskiego Oddzial obserwacyjno-zakazny z odcinkiem jednego dnia leczenia chorob watroby, Radom, Poland|Samodzielny Publiczny Wojewodzki Szpital Zespolony w Szczecinie, Szczecin, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Wojewodzki Szpital Zakazny Oddzial Dzienny, Warszawa, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Wojewodzki Szpital Zakazny Oddzia≈Ç X, Warszawa, Poland|Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Warszawa, Poland|EMC Instytut Medyczny S.A., Wroclaw, Poland|Hospital Universitari Vall d'Hebr√≥n, Barcelona, Spain|Hospital Cl√≠nico Universitario San Cecilio, Granada, Spain|Hospital Universitario Ram√≥n y Cajal, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain|Hospital Universitario Ntra. Sra. de Valme, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Queen Elizabeth Hospital, Birmingham, United Kingdom|North Manchester General Hospital, Greater Manchester, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|Barts and The London Hospital, London, United Kingdom|University College London Hospital, London, United Kingdom|Kings College Hospital, London, United Kingdom|Chelsea and Westminster Hospital, London, United Kingdom|Institute of Cellular Medicine (Hepatology), Newcastle Upon Tyne, United Kingdom|Derriford Hospital, Plymouth, United Kingdom",79.86523728,71.87871355,All,18 Years to 45 Years ¬† (Adult),351,335,329,289,10,30,8/19/2028,3/1/2029,12/20/2028,1/21/2029,1/4/2029,1/15/2029,1/25/2029,7/18/2009,8/1/2009,3/6/2012,4/23/2012,9/1/2012,1/1/2013,2/28/2013,4/29/2013,6/24/2013,7/31/2013,9/18/2013,11/8/2013,7/14/2029,1/10/2030,7/9/2030,1/5/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01225380,,,,,,
Gilead Sciences,Gilead Sciences,ST00070,SP00009,"Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection",,,HCV Infection,,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Doreen T,In Bellini †,Kandace p,Terrell p,Lucie P,John G,Remedios Z,Hee Y,Beulah N,Anthony P,Dalton E,John G,Naren G,Mee M,Marcelina X,James y,Mac L,John G,Chetan K,,,"Anaheim, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|San Clemente, California, United States|San Diego, California, United States|San Diego, California, United States|San Francisco, California, United States|Englewood, Colorado, United States|Miami, Florida, United States|North Miami Beach, Florida, United States|Orlando, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Bowling Green, Kentucky, United States|Baton Rouge, Louisiana, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|St. Louis, Missouri, United States|Cedar Knolls, New Jersey, United States|Johnson City, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Plainview, New York, United States|Syracuse, New York, United States|Asheville, North Carolina, United States|Durham, North Carolina, United States|High Point, North Carolina, United States|Cincinatti, Ohio, United States|Cincinnati, Ohio, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Germantown, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Annandale, Virginia, United States|Fairfax, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Bruxelles, Belgium|Bruxelles, Belgium|Ghent, Belgium|Leuven, Belgium|Liege, Belgium|Berlin, Germany|Frankfurt, Germany|Hamburg, Germany|Hannover, Germany|Koln, Germany|Munchen, Germany|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Bialystok, Poland|Bydgoszcz, Poland|Chorzow, Poland|Czeladz, Poland|Krakow, Poland|Warszawa, Poland|Santurce, Puerto Rico|Birmingham, United Kingdom|London, United Kingdom|London, United Kingdom",81.53630198,73.38267178,All,18 Years to 62 Years ¬† (Adult),354,338,330,149,158,23,10/9/2028,2/26/2029,1/4/2029,2/5/2029,1/12/2029,1/16/2029,1/26/2029,10/17/2004,11/1/2004,2/9/2009,12/12/2008,4/28/2009,7/1/2009,8/5/2009,9/5/2009,10/24/2009,12/22/2009,1/22/2010,3/1/2010,7/15/2029,1/11/2030,7/10/2030,1/6/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00743795,,,,,,
Gilead Sciences,Gilead Sciences,ST00076,SP00009,"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection",,,Hepatitis C Virus Infection,,Virology,,,,,,Industry,Completed,Phase 1,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug A,,,,,,,,,,,,,,,,,,,Suk T,Tiffiny K,Rima Y ,Quentin N,Kala R,Selizabeth F,Mary H,In Bellini †,Federico L,Chetan K,Remedios Z,Gertrudis T,Naren G,Mee M,Anthony P,Mara A,Chetan K,Marceline R,Donovan H,,,"Costa Mesa, California, United States|DeLand, Florida, United States|Orlando, Florida, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Berlin, New Jersey, United States|Marlton, New Jersey, United States|Philadelphia, Pennsylvania, United States|Knoxville, Tennessee, United States|San Antonio, Texas, United States|San Juan, Puerto Rico",69.59496883,62.63547195,All,19 Years to 55 Years ¬† (Adult),351,337,331,216,89,26,9/22/2028,3/19/2029,1/25/2029,2/21/2029,2/7/2029,2/13/2029,2/23/2029,10/3/2012,11/2/2012,6/29/2014,4/16/2014,10/30/2014,12/22/2014,2/15/2015,4/9/2015,6/3/2015,7/24/2015,9/14/2015,10/21/2015,8/12/2029,2/8/2030,8/7/2030,2/3/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02185794,,,,,,
Gilead Sciences,Gilead Sciences,ST00078,SP00009,Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C,,,Post-transplant Hepatitis C,,Virology,,,,,,Industry,Approved for marketing,,Expanded Access,,,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Suzie K,Naren G,Ngan D,Aleta H,Kala R,Doreen T,Ross S,James y,Marceline R,Otis Thode †,Dalton E,Suzie K,Mary H,Frank T,Louann C,Suzie K,Corrine U,Terrell p,Dinah R,,,,7.409009219,6.668108297,All,"18 Years and older ¬† (Adult, Older Adult)",349,341,332,258,36,38,8/26/2028,3/19/2029,1/18/2029,2/20/2029,1/31/2029,2/15/2029,2/25/2029,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/3/1900,3/23/1900,4/23/1900,6/21/1900,7/25/1900,9/17/1900,8/14/2029,2/10/2030,8/9/2030,2/5/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01779518,,,,,,
Gilead Sciences,Gilead Sciences,ST00079,SP00009,"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection",,,Hepatitis C Virus Infection,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Doreen T,In Bellini †,Kala R,Liberty A,Suzie K,Mary H,Aleta H,Patria R,Anthony P,Louann C,Ross S,Mac L,Lyman W,Kandace p,Perter K,Lilla Stilson †,Suzie K,Hee Y,Xochitl D,,,"Cairo, Egypt|Cairo, Egypt|Mansourah, Egypt|Shibin Al Kawm, Egypt",14.28107618,12.85296856,All,18 Years to 38 Years ¬† (Adult),350,338,333,183,118,32,11/3/2028,3/24/2029,1/18/2029,3/6/2029,2/2/2029,2/17/2029,2/27/2029,7/24/2012,7/30/2012,7/20/2016,4/18/2016,10/8/2016,11/11/2016,1/1/2017,2/27/2017,4/15/2017,6/4/2017,7/8/2017,9/3/2017,8/16/2029,2/12/2030,8/11/2030,2/7/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02487030,,,,,,
Gilead Sciences,Gilead Sciences,ST00080,SP00009,Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection,,,Hepatitis C Virus Infection,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Mary H,Donovan H,Mee M,Stephan T,Geralyn K,Mac L,Lyman W,Aleta H,Terrell p,John G,Beulah N,Mara A,Jaquelyn H,Tiffiny K,Garnet T,John G,In Bellini †,Federico L,Kala R,,,"Tallinn, Estonia|Tartu, Estonia|Ekaterinburg, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Samara, Russian Federation|St. Petersburg, Russian Federation|St.petersburg, Russian Federation|Stavropol, Russian Federation|Tyumen, Russian Federation",40.56190007,36.50571006,All,"Child, Adult, Older Adult",357,350,334,141,175,18,10/16/2028,4/16/2029,2/7/2029,3/6/2029,2/11/2029,2/18/2029,2/28/2029,3/27/2015,4/17/2015,2/22/2016,6/7/2015,12/21/2015,3/30/2016,5/10/2016,6/21/2016,8/2/2016,9/30/2016,11/1/2016,12/23/2016,8/17/2029,2/13/2030,8/12/2030,2/8/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02472886,,,,,,
Gilead Sciences,Gilead Sciences,ST00081,SP00009,Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection,,,Hepatitis C Virus Infection,,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Suk T,Garnet T,Christian G,Harry A,Lilla Stilson †,Ngan D,Mary H,Frank T,Tamesha T,Terisa Sikora †,Kala R,Rima Y ,Aleta H,Selizabeth F,Mac L,Mee M,Tiffiny K,Patria R,Mara A,,,"Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Vancouver, British Columbia, Canada|Vancouver, British Columbia, Canada|Brampton, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Vaughan, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec, Canada",20.08038271,18.07234444,All,"20 Years to 80 Years ¬† (Adult, Older Adult)",365,354,335,209,90,36,8/31/2028,3/28/2029,2/10/2029,3/5/2029,2/5/2029,2/19/2029,3/1/2029,4/13/2014,5/11/2014,6/4/2015,4/17/2015,7/29/2015,12/1/2015,1/21/2016,3/5/2016,4/28/2016,6/25/2016,8/6/2016,9/25/2016,8/18/2029,2/14/2030,8/13/2030,2/9/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02413593,,,,,,
Gilead Sciences,Gilead Sciences,ST00082,SP00009,Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection,,,Chronic HCV Infection,,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Chetan K,Lucie P,Corrine U,Corrine U,Terisa Sikora †,John G,Louann C,Otis Thode †,John G,Mary H,Liberty A,Dinah R,Mary H,Terisa Sikora †,Lucie P,Naren G,Terrell p,Rima Y ,Patria R,,,"San Antonio, Texas, United States",89.97680679,80.97912611,All,"18 Years and older ¬† (Adult, Older Adult)",357,353,336,227,83,26,10/18/2028,4/4/2029,1/23/2029,3/13/2029,1/31/2029,2/21/2029,3/3/2029,6/17/2012,7/2/2012,1/31/2014,6/9/2013,1/15/2014,4/1/2014,5/30/2014,7/26/2014,9/8/2014,11/6/2014,12/22/2014,2/5/2015,8/20/2029,2/16/2030,8/15/2030,2/11/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01984294,,,,,,
Gilead Sciences,Gilead Sciences,ST00083,SP00009,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ¬± Ribavirin for the Treatment of HCV (ION-3),,,Chronic Hepatitis C Virus,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Chetan K,Mary H,Suzie K,Naren G,Selizabeth F,Corrine U,Beulah N,In Bellini †,Louann C,In Bellini †,Mee M,Federico L,John G,Tamesha T,Jene M,James y,Naren G,Harry A,Otis Thode †,,,"Birmingham, Alabama, United States|La Jolla, California, United States|Los Angeles, California, United States|Palo Alto, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Englewood, Colorado, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Wellington, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Bowling Green, Kentucky, United States|Baton Rouge, Louisiana, United States|Baltimore, Maryland, United States|Lutherville, Maryland, United States|Boston, Massachusetts, United States|Novi, Michigan, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Albuquerque, New Jersey, United States|Berlin, New Jersey, United States|Hillsborough, New Jersey, United States|Santa Fe, New Mexico, United States|Binghamton, New York, United States|Manhasset, New York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Fayetteville, North Carolina, United States|Statesville, North Carolina, United States|Winston-Salem, North Carolina, United States|Philadelphia, Pennsylvania, United States|Providence, Rhode Island, United States|Germantown, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Fairfax, Virginia, United States|Falls Church, Virginia, United States|Newport News, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States",80.47288104,72.42559293,All,"up to 18 Years ¬† (Child, Adult)",357,352,337,194,110,33,9/1/2028,4/3/2029,1/28/2029,2/27/2029,2/8/2029,2/22/2029,3/4/2029,11/30/2009,12/21/2009,2/22/2013,4/3/2013,8/18/2013,12/1/2013,1/3/2014,2/21/2014,4/1/2014,5/4/2014,6/22/2014,7/27/2014,8/21/2029,2/17/2030,8/16/2030,2/12/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01851330,,,,,,
Gilead Sciences,Gilead Sciences,ST00084,SP00009,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ¬± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection,,ION-2,Chronic Hepatitis C Virus,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Louann C,Patria R,Harry A,Beulah N,Selizabeth F,Stephan T,Suzie K,Ngan D,Frank T,Kala R,Lyman W,Doreen T,Ross S,Marcelina X,Livia Pacheo †,Tammara F,Beulah N,Ngan D,John G,,,"Phoenix, Arizona, United States|Tucson, Arizona, United States|La Jolla, California, United States|Los Angeles, California, United States|Palo Alto, California, United States|San Diego, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Englewood, Colorado, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Bowling Green, Kentucky, United States|Baton Rouge, Louisiana, United States|Baltimore, Maryland, United States|Lutherville, Maryland, United States|Boston, Massachusetts, United States|Springfield, Massachusetts, United States|Detroit, Michigan, United States|Rochester, Minnesota, United States|Saint Louis, Minnesota, United States|Saint Paul, Minnesota, United States|Kansas City, Missouri, United States|Berlin, New Jersey, United States|Hillsborough, New Jersey, United States|Albuquerque, New Mexico, United States|Santa Fe, New Mexico, United States|Binghamton, New York, United States|Manhasset, New York, United States|New York, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Fayetteville, North Carolina, United States|Statesville, North Carolina, United States|Winston-Salem, North Carolina, United States|Philadelphia, Pennsylvania, United States|Providence, Rhode Island, United States|Germantown, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Fairfax, Virginia, United States|Newport News, Virginia, United States|Norfolk, Virginia, United States",13.77873414,12.40086072,All,18 Years to 40 Years ¬† (Adult),377,365,338,212,84,42,10/12/2028,4/24/2029,2/4/2029,3/7/2029,2/14/2029,2/23/2029,3/5/2029,3/12/2011,3/19/2011,5/18/2013,1/22/2013,6/24/2013,11/1/2013,12/22/2013,1/24/2014,3/2/2014,4/7/2014,5/11/2014,6/25/2014,8/22/2029,2/18/2030,8/17/2030,2/13/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01768286,,,,,,
Gilead Sciences,Gilead Sciences,ST00085,SP00009,Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ¬± Ribavirin in HCV Genotype 1 Subjects,,,Chronic Hepatitis C Virus,,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Mary H,Jene M,John G,Tien C,John G,Livia Pacheo †,Mary H,Garnet T,Lavina S,Selizabeth F,Quentin N,John G,Jene M,Stephan T,Tamesha T,Selizabeth F,Chetan K,Doreen T,Beulah N,,,"San Antonio, Texas, United States",87.36710763,78.63039687,All,"10 Years to 18 Years ¬† (Child, Adult)",352,346,339,261,28,50,11/7/2028,4/2/2029,2/10/2029,3/8/2029,2/3/2029,2/24/2029,3/6/2029,5/18/2009,5/23/2009,4/7/2013,11/22/2012,2/20/2013,7/1/2013,8/8/2013,9/21/2013,11/5/2013,12/27/2013,2/14/2014,3/29/2014,8/23/2029,2/19/2030,8/18/2030,2/14/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01726517,,,,,,
Gilead Sciences,Gilead Sciences,ST00086,SP00009,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV,,,Chronic Hepatitis C Virus,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Stephan T,Mary H,Lilla Stilson †,Stephan T,Frank T,Marcelina X,Lavina S,Tiffiny K,Jerold Goo †,John G,Louann C,Otis Thode †,Mara A,Mary H,John G,Federico L,Mac L,Clarice N,Mac L,,,"Birmingham, Alabama, United States|La Jolla, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Palo Alto, California, United States|Sacramento, California, United States|San Diego, California, United States|Aurora, Colorado, United States|Englewood, Colorado, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|Wellington, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Baltimore, Maryland, United States|Lutherville, Maryland, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Rochester, Minnesota, United States|Saint Paul, Minnesota, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Hillsborough, New Jersey, United States|Albuquerque, New Mexico, United States|Santa Fe, New Mexico, United States|Bronx, New York, United States|Manhasset, New York, United States|New York, New York, United States|Asheville, North Carolina, United States|Chapel Hill, North Carolina, United States|Durham, North Carolina, United States|Fayetteville, North Carolina, United States|Statesville, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Germantown, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Fairfax, Virginia, United States|Falls Church, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|CHRU Lille, France|Clichy, France|Creteil, France|La Tronche, France|Lyon, France|Marseille, France|Nice, France|Paris, France|Berlin, Germany|Dusseldorf, Germany|Essen, Germany|Frankfurt, Germany|Freiburg, Germany|Hamburg, Germany|Hannover, Germany|Koln, Germany|Mainz, Germany|Bologna, Italy|Brescia, Italy|Milan, Italy|Padova, Italy|Palermo, Italy|Roma, Italy|San Giovanni Rotondo, Italy|Torino, Italy|San Juan, Puerto Rico|Barcelona, Spain|Madrid, Spain|Malaga, Spain|Santander, Spain|Sevilla, Spain|Birmingham, Wstmid, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Plymouth, United Kingdom",25.76838714,23.19154843,All,"40 Years to 80 Years ¬† (Adult, Older Adult)",374,370,340,220,82,38,11/5/2028,4/8/2029,2/1/2029,3/15/2029,2/9/2029,2/25/2029,3/7/2029,2/2/2011,2/19/2011,1/17/2014,5/25/2013,12/14/2013,3/1/2014,4/26/2014,6/10/2014,7/17/2014,9/5/2014,10/31/2014,11/30/2014,8/24/2029,2/20/2030,8/19/2030,2/15/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01701401,,,,,,
Gilead Sciences,Gilead Sciences,ST00088,SP00009,Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3,,,Hepatitis C,,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Selizabeth F,Louann C,Mary H,Garnet T,Livia Pacheo †,Otis Thode †,Marceline R,Dalton E,Clarice N,Otis Thode †,Garnet T,Ross S,Kandace p,Louann C,Mee M,Selizabeth F,Perter K,Jene M,Perter K,,,"Alamo Medical Research, San Antonio, Texas, United States",63.29736847,56.96763162,All,"18 Years and older ¬† (Adult, Older Adult)",374,363,341,304,8,29,9/17/2028,4/4/2029,2/1/2029,3/13/2029,2/7/2029,2/28/2029,3/10/2029,11/17/2010,11/27/2010,1/15/2013,2/3/2013,5/27/2013,9/1/2013,10/3/2013,11/14/2013,12/25/2013,2/14/2014,4/13/2014,6/7/2014,8/27/2029,2/23/2030,8/22/2030,2/18/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01808248,,,,,,
Gilead Sciences,Gilead Sciences,ST00089,SP00009,Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies,,,Chronic Hepatitis C,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Kala R,Louann C,Christian G,Selizabeth F,Mary H,Clarice N,Harry A,Lucie P,Mara A,Kala R,Selizabeth F,Doreen T,Frank T,Federico L,Federico L,Perter K,Mara A,Tamesha T,Jerold Goo †,,,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Franco Felizarta, MD, Bakersfield, California, United States|Arrowhead Regional Medical Center, Colton, California, United States|Southern California Transplantation Institute, Research Foundation Liver Center, Coronado, California, United States|eStudy Site, La Mesa, California, United States|Kaiser Permanente, Los Angeles, California, United States|Lightsource Medical/Peter J. Ruane MD, Inc., Los Angeles, California, United States|California Liver Institute, Los Angeles, California, United States|Anthony Mills MD, Inc., Los Angeles, California, United States|eStudySite, Oceanside, California, United States|University of California Davis Medical Center, Sacramento, California, United States|University of California, San Diego, California, United States|Resarch and Education, Inc., San Diego, California, United States|Medical Associates Research Group, San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|Quest Clinical Research, San Francisco, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|South Denver Gastroenterology, PC, Englewood, Colorado, United States|Whitman-Walker Health, Washington, District of Columbia, United States|Pointe West Infectious Diseases d/b/a Bach and Godofsky Infectious Diseases, Bradenton, Florida, United States|University of Florida, Gainesville, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|University of Miami Center for Liver Diseases, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Internal Medicine Specialists, Orlando, Florida, United States|Advanced Research Institute, Trinity, Florida, United States|South Florida Center of Gastroenterology, PA., Wellington, Florida, United States|Atlanta Gastroenterology Associates, LLC, Atlanta, Georgia, United States|Digestive Healthcare of Georgia, Atlanta, Georgia, United States|Gastointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|Digestive Disease Associates, PA, Baltimore, Maryland, United States|Johns Hopkins University, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Infectious Disease and The Research Institute, Springfield, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Orlando Clinical, Novi, Michigan, United States|Minnesota Gastroenterology, P.A., St. Paul, Minnesota, United States|Kansas City Gastroenterology and Hepatology, Kansas City, Missouri, United States|ID Care, Inc., Hillsborough, New Jersey, United States|AGA Clinical Research Associates, LLC, Township, New Jersey, United States|The Gastroenterology Group of South Jersey, Vineland, New Jersey, United States|Binghamton Gastroenterology Associates, PC, Binghamton, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Clinical Study Center of Asheville, LLC, Asheville, North Carolina, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Carolinas Center for Liver Disease, Statesville, North Carolina, United States|Digestive Health Specialists, PA, Winston Salem, North Carolina, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|Gastro One, Germantown, Tennessee, United States|Memphis Gastroenterology Group, PC, Germantown, Tennessee, United States|Nashville Medical Research Institute, Nashville, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Annette C. and Harold C. Simmons Transplant Center, Dallas, Texas, United States|Research Specialists of Texas, Houston, Texas, United States|Alamo Medical Research, San Antonio, Texas, United States|Metropolitan Research, Fairfax, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Bon Secours Saint Mary's Hospital of Richmond, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Gallipoli Medical Research Foundation, Greenslopes, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Monash Medical Centre, Melbourne, Victoria, Australia|B2 Clinic, Fremantle, Western Australia, Australia|Canberra Hospital, Australian Capital Territory, Australia|St. Vincent's Hospital, Fitzroy, Australia|Royal Brisbane & Women's Hospital, Herston, Australia|St George Hospital, Kogarah, Australia|Royal Prince Alfred Hospital, Camperdown, NSW, Australia|Royal Perth Hospital, Perth Western Australia, Australia|Princess Alexandra Hospital, State of Queensland, Australia|Box Hill Hospital, Victoria, Australia|Medizinische Universit√§t Graz, Graz, Austria|Medizinische Universit√§t Wien, Vienna, Austria|Wilhelminenspital, Wien, Austria|University of Calgary, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Vancouver Infectious Disease Research and Care Centre, Vancouver, British Columbia, Canada|Gastrointestinal Research Institute (GIRI), Vancouver, British Columbia, Canada|John Buhler Research Center, Winnipeg, Manitoba, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Toronto Digestive Diseases Associates, Inc, Vaughan, Ontario, Canada|Hopital St. Luc, Montreal, Quebec, Canada|Gordon & Leslie Diamond Health Care Centre, Vancouver, Canada|Remedis s.r.o., Nest√°tn√≠ zdravotnick√© zar√≠zen√≠, Praha 4, Czech Republic|West Tallinn Central Hospital, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France|CHU Estaing, Clermont-Ferrand, France|H√¥pital Beaujon, Clichy, France|H√¥pital Henri Mondor, Creteil Cedex, France|H√¥pital Claude Huriez- Service d'H√©pato-Gastroent√©rologie, Lille, France|H√¥pital Saint Joseph, Marseille, France|Hopital Saint Eloi, Montpellier, France|Service Hepatologie, Nice, France|H√¥pital Saint-Antoine, Paris Cedex 12, France|Groupe Hospitalier Piti√©-Salp√©tri√®re, Paris Cedex 13, France|H√¥pital Haut-L√©v√™que, CHU Bordeaux, Pessac Cedex, France|Centre Hospitalier Universitare de Rennes, H√¥pital Pontchaillou, Rennes Cedex 9, France|Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France|Hopital de I'Archet 2, Vandoeuvre-les-Nancy, France|Leber- und Studienzentrum am Checkpoint, Berlin, Germany|Campus Virchow Klinikum, Berlin, Germany|Universit√§tsklinikum Bonn, Bonn, Germany|Universit√§tsklinikum D√ºsseldorf, D√ºsseldorf, Germany|Klinikum und Fachbereich Medizin Johann Wolfgang Goethe-Universit√§t Frankfurt am Main, Frankfurt am Main, Germany|PraxisZentrum f√ºr Gastroenterologie und Endokrinologie, Freiburg im Breisgau, Germany|Asklepios Klinik Sankt Georg Hamburg, Hamburg, Germany|Universit√§tsklinikum Hamburg Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Medizinische Universit√§tsklinik IV (Krehl Klinik) Abt. Gastroenterologie und Infektionskrankheiten, Heidelberg, Germany|Gastroenterologische Gemeinschaftspraxis, Herne, Germany|Leberstudienzentrum Kiel, Kiel, Germany|Universit√§tsklinikum Leipzig, Leipzig, Germany|Centrum fur Interdisziplinare Medizin, Muenster, Germany|Klinikum der Universit√§t M√ºnchen, Munich, Germany|Universitatsklinikum Wurzburg, Wurzburg, Germany|Casa Sollievo della Sofferenza Hospital, San Giovanni Rotonda, Foggia, Italy|Ospedale S. Annunziata, Florence, Italy|Ente Ospedaliero Ospedali Galliera di Genova, Genoa, Italy|Fondazione IRCCS CA Granada - Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan, Italy|Azienda Ospedaliera de Padova, Padova, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Fondazione PTV - Policlinico Tor Vergata, Roma, Italy|I.N.M.I L. Spallanzani IRCCS, Rome, Italy|Azienda Ospedaliero Universitaria S. Giovanni Battista di Torino, Turin, Italy|Academisch Medisch Centrum, Amsterdam, Netherlands|Radboud University Nijmegen Medical Centre (UMC St Radboud), Nijmegen, Netherlands|Academic Hospital Rotterdam Erasmus Medical Center, Rotterdam, Netherlands|Auckland Clinical Studies, Grafton, Auckland, New Zealand|Tauranga Hospital, Tauranga, BOP, New Zealand|Wellington Hospital, Newtown, WGN, New Zealand|Auckland City Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Waikato Hospital, Hamilton, New Zealand|Klinika Chorob Zakaznych i Hep, Bialystok, Poland|Oddzial Kliniczny Chorob Zakaznych, Chorzow, Poland|WSSzpital im.Dr.Wj.Bieganskieg, Lodz, Poland|ID Clinic, Myslowice, Poland|Sp Zoz Wojew√≥dzki Szpital, Warsaw, Poland|Fundacion De Investigacion De Diego, San Juan, Puerto Rico|Hospital Casa de la Maternidad, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Carlos III, Madrid, Spain|Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain|Hospital Clinico Universitario Virgen de la Victoria, Malaga, Spain|Hospital Universitario Nuestra Se√±ora de Valme, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Sahlgrenska University Hospital, G√∂teborg, Sweden|Sk√•nes Universitetssjukhus, Malm√∂, Malmo, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|The Liver Unit, Paddington, London, United Kingdom|University of Birmingham, Birmingham, United Kingdom|Southampton University Hospital, Hampshire, United Kingdom|London Royal Hospital, GHU, London, United Kingdom|King's College Hospital, London, United Kingdom|Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom|Royal Free Hospital and University College London Hospital, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Nottingham University Hospitals-NHS, Nottingham, United Kingdom",46.65325526,41.98792974,All,"18 Years and older ¬† (Adult, Older Adult)",380,365,342,291,19,32,11/14/2028,4/27/2029,2/7/2029,3/7/2029,2/12/2029,3/2/2029,3/12/2029,4/10/2011,4/24/2011,4/19/2014,1/12/2014,8/12/2014,10/1/2014,11/21/2014,1/17/2015,3/11/2015,4/29/2015,6/13/2015,7/30/2015,8/29/2029,2/25/2030,8/24/2030,2/20/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01625338,,,,,,
Gilead Sciences,Gilead Sciences,ST00090,SP00009,Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION),,FUSION,Chronic Hepatitis C,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug A,,,,,,,,,,,,,,,,,,,Tamesha T,Lucie P,Jene M,Jeanene Y,Garnet T,Mary H,Suk T,Marcelina X,Lavina S,Suk T,Kandace p,Lyman W,Federico L,John G,James y,Christian G,Selizabeth F,Anthony P,Corrine U,,,"SCTI Research Foundation, Coronado, California, United States|Kaiser Permanente, Los Angeles, California, United States|Peter J. Ruane, MD, Inc., Los Angeles, California, United States|Anthony Mills MD, Inc., Los Angeles, California, United States|UCSD Antiviral Research Center, San Diego, California, United States|Medical Associates Research Group, Inc., San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|Quest Clinical Research, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|South Denver Gastroenterology, PC, Englewood, Colorado, United States|Whitman Walker Clinic, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Borland-Groover Clinic Baptist, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Advanced Research Institute, New Port Richey, Florida, United States|Orlando Immunology Center (ACH), Orlando, Florida, United States|Internal Medicine Specialists, Orlando, Florida, United States|South Florida Center of Gastroenterology, P.A., Wellington, Florida, United States|Digestive Healthcare of Georgia, Atlanta, Georgia, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|Graves-Gilbert Clinic, Bowling Green, Kentucky, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|Johns Hopkins University, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The Research Institute, Springfield, Massachusetts, United States|Henry Ford Health System, Novi, Michigan, United States|Minnesota Gastroenterology, P.A., Minneapolis, Minnesota, United States|Kansas City Gastroenterology and Hepatology, Kansas City, Missouri, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|ID Care, Hillsborough, New Jersey, United States|Southwest C.A.R.E. Center, Santa Fe, New Mexico, United States|Binghamton Gastroenterology Associates, Binghamton, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Digestive Health Specialists, PA, Winston-Salem, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Gastro One, Germantown, Tennessee, United States|Nashville Gastrointestinal Specialists, Inc, Nashville, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Southwest Infectious Disease Clinical Research, Inc., Dallas, Texas, United States|Alamo Medical Research, San Antonio, Texas, United States|Metropolitan Research, Fairfax, Virginia, United States|Inova Fairfax Hospital Center for Liver Diseases, Falls Church, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Bon Secours St. Mary's Hospital of Richmond, Inc., Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Calgary, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Gordon & Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|University of British Columbia, Vancouver, British Columbia, Canada|(G.I.R.I.) Gastrointestinal Research Institute, Vancouver, British Columbia, Canada|University of Manitoba Health Sciences Center, Winnipeg, Manitoba, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Hopital St. Luc, Montreal, Quebec, Canada|Auckland Clinical Studies Limited, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Clinical Research Puerto Rico Inc, San Juan, Puerto Rico|Fundacion De Investigacion De Diego, San Juan, Puerto Rico",73.14726067,65.8325346,All,"18 Years to 65 Years ¬† (Adult, Older Adult)",368,360,343,227,71,45,11/15/2028,4/11/2029,2/26/2029,3/9/2029,2/20/2029,3/3/2029,3/13/2029,5/3/2010,5/14/2010,10/10/2012,5/23/2012,9/8/2012,2/1/2013,3/26/2013,4/26/2013,5/27/2013,7/7/2013,8/31/2013,10/25/2013,8/30/2029,2/26/2030,8/25/2030,2/21/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01604850,,,,,,
Gilead Sciences,Gilead Sciences,ST00091,SP00009,"Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon",,POSITRON,Chronic Hepatitis C,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Lucie P,Otis Thode †,Lavina S,Gertrudis T,Mary H,Christian G,Kala R,Mee M,Patria R,Dalton E,Frank T,Livia Pacheo †,Ross S,Jeanene Y,Suzie K,Doreen T,Frank T,Xochitl D,,,"University of Alabama Birmingham, Birmingham, Alabama, United States|SCTI Research Foundation Liver Center, Coronado, California, United States|Kaiser Permanente, Los Angeles, California, United States|Lightspeed Medical, Los Angeles, California, United States|Anthony Mills MD, Inc., Los Angeles, California, United States|Medical Associates Research Group, San Diego, California, United States|UCSD Antiviral Research Center, San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|Quest Clinical Research, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|South Denver Gastroenterology, Englewood, Colorado, United States|Whitman Walker Clinic, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|University of Miami, Center for Liver Diseases, Miami, Florida, United States|Advanced Research Institute, New Port Richey, Florida, United States|Orlando Immunology Center (ACH), Orlando, Florida, United States|Internal Medicine Specialists, Orlando, Florida, United States|South Florida Center of Gastroenterology, P.A., Wellington, Florida, United States|Digestive Healthcare of Georgia, Atlanta, Georgia, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|Graves-Gilbert Clinic, Bowling Green, Kentucky, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|Johns Hopkins University, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The Research Institute, Springfield, Massachusetts, United States|Henry Ford Health System, Novi, Michigan, United States|Minnesota Gastroenterology, P.A., St. Paul, Minnesota, United States|Kansas City Gastroenterology and Hepatology, Kansas City, Missouri, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|ID Care, Hillsborough, New Jersey, United States|Binghamton Gastroenterology Associates, Binghamton, New York, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Duke University, Durham, North Carolina, United States|Digestive Health Specialists, PA, Winston-Salem, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|Gastro One, Germantown, Tennessee, United States|Nashville Gastrointestinal Specialists, Inc, Nashville, Tennessee, United States|Southwest Infectious Disease Clinical Research, Inc., Dallas, Texas, United States|Therapeutic Concepts, PA, Houston, Texas, United States|Alamo Medical Research, San Antonio, Texas, United States|Metropolitan Research, Fairfax, Virginia, United States|Inova Fairfax Hospital Center for Liver Diseases, Falls Church, Virginia, United States|Liver Institute of Virginia, Bon Secours St.Mary's, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Westmead Hospital, Westmead,, New South Wales, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|St. Vincent's Hospital, Melbourne, Australia|Monash Medical Centre, Melbourne, Australia|University of Calgary, Calgary, Alberta, Canada|Gordon & Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|(G.I.R.I.) Gastrointestinal Research Institute, Vancouver, British Columbia, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|CHUM - The Research Centre, Montreal, Quebec, Canada|Auckland Clinical Studies Limited, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Clinical Research Puerto Rico Inc, San Juan, Puerto Rico|Fundacion De Investigacion De Diego, San Juan, Puerto Rico",27.07178472,24.36460625,All,21 Years to 55 Years ¬† (Adult),391,377,344,225,81,38,9/29/2028,4/26/2029,2/16/2029,3/21/2029,2/10/2029,3/4/2029,3/14/2029,12/28/2010,1/18/2011,4/1/2012,2/11/2012,9/18/2012,11/1/2012,12/5/2012,1/15/2013,3/5/2013,4/17/2013,5/17/2013,7/9/2013,8/31/2029,2/27/2030,8/26/2030,2/22/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01542788,,,,,,
Gilead Sciences,Gilead Sciences,ST00093,SP00009,"Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection",,NEUTRINO,Chronic Hepatitis C,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Anthony P,Dalton E,Selizabeth F,Otis Thode †,Suzie K,Mara A,Mee M,John G,Jerold Goo †,Dalton E,Frank T,Garnet T,Perter K,Christian G,Selizabeth F,Lavina S,Tien C,Donovan H,Mary H,,,"University of Alabama Birmingham, Birmingham, Alabama, United States|SCTI Research Foundation, Coronado, California, United States|Kaiser Permanente, Los Angeles, California, United States|Peter J. Ruane, MD, Inc., Los Angeles, California, United States|Anthony Mills MD, Inc., Los Angeles, California, United States|University of California San Diego, San Diego, California, United States|Medical Associates Research Group, Inc., San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|Quest Clinical Research, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|South Denver Gastroenterology, PC, Englewood, Colorado, United States|Whitman Walker Clinic, Washington, District of Columbia, United States|Capital Medical Associates, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Borland-Groover Clinic Baptist, Jacksonville, Florida, United States|University of Miami Center for Liver Diseases, Miami, Florida, United States|Advanced Research Institute, New Port Richey, Florida, United States|Orlando Immunology Center (ACH), Orlando, Florida, United States|Internal Medicine Specialists, Orlando, Florida, United States|South Florida Center of Gastroenterology, P.A., Wellington, Florida, United States|Digestive Healthcare of Georgia, Atlanta, Georgia, United States|Infectious Disease Specialist of Atlanta, Decatur, Georgia, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|Graves-Gilbert Clinic, Bowling Green, Kentucky, United States|Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States|Johns Hopkins University, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The Research Institute, Springfield, Massachusetts, United States|Henry Ford Health System, Novi, Michigan, United States|Minnesota Gastroenterology, P.A., St. Paul, Minnesota, United States|Kansas City Gastroenterology and Hepatology, Kansas City, Missouri, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|ID Care, Hillsborough, New Jersey, United States|Southwest C.A.R.E. Center, Santa Fe, New Mexico, United States|Binghamton Gastroenterology Associates, Binghamton, New York, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Digestive Health Specialists, PA, Winston-Salem, North Carolina, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Gastro One, Germantown, Tennessee, United States|Nashville Gastrointestinal Specialists, Inc, Nashville, Tennessee, United States|Southwest Infectious Disease Clinical Research, Inc., Dallas, Texas, United States|Research Specialists of Texas, Houston, Texas, United States|Alamo Medical Research, San Antonio, Texas, United States|Metropolitan Research, Fairfax, Virginia, United States|Inova Fairfax Hospital Center for Liver Diseases, Falls Church, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Bon Secours St. Mary's Hospital of Richmond, Inc., Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Fundacion De Investigacion De Diego, San Juan, Puerto Rico",78.20878692,70.38790823,All,"18 Years and older ¬† (Adult, Older Adult)",387,371,345,320,28,3,10/13/2028,4/18/2029,2/5/2029,3/19/2029,3/2/2029,3/6/2029,3/16/2029,4/23/2011,5/12/2011,3/30/2012,4/25/2012,8/20/2012,1/1/2013,2/15/2013,3/21/2013,5/16/2013,6/30/2013,8/6/2013,9/17/2013,9/2/2029,3/1/2030,8/28/2030,2/24/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01641640,,,,,,
Gilead Sciences,Gilead Sciences,ST00094,SP00009,Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection,,,Hepatitis C Virus,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Livia Pacheo †,Perter K,Rima Y ,Remedios Z,Tamesha T,Patria R,Mary H,Selizabeth F,Naren G,Chetan K,Perter K,Hee Y,Terisa Sikora †,Donovan H,Jerold Goo †,Jaquelyn H,Stephan T,Lyman W,Jeanene Y,,,"Cairo, Egypt|Mansoura, Egypt",45.18369365,40.66532429,All,"15 Years to 39 Years ¬† (Child, Adult)",376,371,346,135,184,27,9/10/2028,4/22/2029,2/20/2029,3/16/2029,2/12/2029,3/7/2029,3/17/2029,12/30/2010,1/17/2011,9/20/2013,8/3/2013,2/21/2014,5/1/2014,6/4/2014,7/21/2014,9/8/2014,10/15/2014,11/25/2014,1/14/2015,9/3/2029,3/2/2030,8/29/2030,2/25/2031,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01838590,,,,,,
Gilead Sciences,Gilead Sciences,ST00176,SP00009,Study to Evaluate the Safety and Tolerability of GS-1811 as Monotherapy and in Combination With Pembrolizumab in Adults With Advanced Solid Tumors,,,Advanced Solid Tumor,,Oncology,,,,,,Industry,Recruiting,Not Applicable,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Tammara F,Lyman W,James y,Quentin N,Livia Pacheo †,Anthony P,Naren G,Tamesha T,Suk T,Quentin N,Mary H,Suk T,Remedios Z,Lilla Stilson †,Terrell p,Selizabeth F,Gertrudis T,Remedios Z,Doreen T,,,"Mary Crowley Cancer Research, Dallas, Texas, United States|NEXT Oncology, San Antonio, Texas, United States",29.84171422,26.8575428,All,"18 Years and older ¬† (Adult, Older Adult)",364,360,347,250,67,30,3/27/2021,8/31/2021,7/16/2021,8/9/2021,7/10/2021,7/30/2021,8/10/2021,8/15/2021,9/2/2021,6/26/2023,8/8/2023,3/17/2024,5/1/2024,6/26/2024,7/29/2024,9/7/2024,10/29/2024,12/16/2024,2/7/2025,1/26/2022,7/25/2022,1/21/2023,7/20/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05007782,,,,,,
Gilead Sciences,Gilead Sciences,ST00178,SP00009,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies",,,Solid Malignancies,,,,,,,,Industry,Recruiting,,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Christian G,Stephan T,Liberty A,John G,Tammara F,Anthony P,Beulah N,Louann C,Suzie K,Xochitl D,Mary H,James y,Mara A,Lilla Stilson †,Chetan K,Federico L,Louann C,Perter K,Tien C,,,"START Midwest, Grand Rapids, Michigan, United States|START Mountain Region, Grand Rapids, Michigan, United States|START San Antonio, San Antonio, Texas, United States",92.81287748,83.53158973,All,65 Years to 90 Years ¬† (Older Adult),371,366,348,291,15,42,9/29/2024,3/19/2025,1/13/2025,2/22/2025,1/19/2025,2/2/2025,2/13/2025,2/16/2025,2/22/2025,8/10/2026,10/13/2026,12/3/2026,5/1/2027,6/13/2027,8/10/2027,9/21/2027,11/2/2027,12/28/2027,2/9/2028,8/1/2025,1/28/2026,7/27/2026,1/23/2027,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05006794,,,,,,
Gilead Sciences,Gilead Sciences,ST00195,SP00009,Study to Assess Safety and Efficacy of Lenacapavir and Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection,,PURPOSE 1,Pre-Exposure Prophylaxis of HIV Infection,,,,,,,,Industry,Recruiting,Phase 1,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",,,,,,Drug A,,,,,,,,,,,,,,,,,,,Harry A,Dinah R,Xochitl D,Christian G,Suzie K,Ross S,Mary H,Naren G,Naren G,Federico L,Naren G,Mee M,Quentin N,Beulah N,Perter K,Lyman W,In Bellini †,Livia Pacheo †,Lilla Stilson †,,,"Madibeng Centre for Research, Brits, South Africa|Wits Reproductive Health & HIV Institute (Wits RHI), Johannesburg, South Africa",31.78097743,28.60287968,Female,"18 Years to 130 Years ¬† (Adult, Older Adult)",375,363,349,138,189,22,7/24/2019,2/6/2020,12/17/2019,1/18/2020,12/26/2019,1/3/2020,1/10/2020,1/14/2020,2/10/2020,4/17/2023,5/11/2023,1/20/2024,3/1/2024,4/5/2024,5/12/2024,6/15/2024,8/3/2024,9/16/2024,11/6/2024,7/1/2020,12/28/2020,6/26/2021,12/23/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04994509,,,,,,
Gilead Sciences,Gilead Sciences,ST00254,SP00009,Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Adults With Metastatic Triple-Negative Breast Cancer,,,Triple-Negative Breast Cancer,,Oncology,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Tammara F,Naren G,Mara A,Anthony P,Anthony P,Anthony P,Gertrudis T,Ngan D,Lavina S,Tiffiny K,Corrine U,Dinah R,Lucie P,Corrine U,Chetan K,Selizabeth F,Lyman W,Harry A,Selizabeth F,,,,68.1358089,61.32222801,All,"18 Years to 75 Years ¬† (Adult, Older Adult)",383,373,350,237,70,43,7/20/2022,1/9/2023,10/30/2022,12/3/2022,11/7/2022,11/22/2022,11/29/2022,11/30/2022,12/24/2022,12/9/2023,9/15/2023,2/7/2024,6/1/2024,7/6/2024,8/25/2024,10/12/2024,11/26/2024,1/8/2025,3/2/2025,5/21/2023,11/17/2023,5/15/2024,11/11/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04958785,,,,,,
Gilead Sciences,Gilead Sciences,ST00323,SP00009,Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Tamesha T,Kandace p,Tamesha T,Mary H,In Bellini †,Jeanene Y,Tamesha T,Dinah R,Christian G,Naren G,Lilla Stilson †,Anthony P,Mary H,Mary H,Aleta H,Mary H,Liberty A,Selizabeth F,Kala R,,,"Memorial Sloan-Kettering Cancer Center, New York, New York, United States",29.09029313,26.18126382,All,"18 Years and older ¬† (Adult, Older Adult)",369,357,351,253,48,50,9/1/2012,1/10/2013,11/24/2012,12/23/2012,11/21/2012,12/3/2012,12/7/2012,12/11/2012,12/30/2012,6/23/2014,5/13/2014,8/29/2014,12/1/2014,1/22/2015,3/17/2015,5/2/2015,6/18/2015,7/27/2015,9/20/2015,6/1/2013,11/28/2013,5/27/2014,11/23/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01270698,,,,,,
Gilead Sciences,Gilead Sciences,ST00382,SP00009,A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer,,,,,Oncology,,,,,,Industry,Withdrawn,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Mary H,Donovan H,Marceline R,Federico L,Mary H,John G,Otis Thode †,Livia Pacheo †,Anthony P,Hee Y,Suzie K,Mac L,Suzie K,Harry A,Corrine U,Lilla Stilson †,John G,Frank T,Liberty A,,,,63.35517533,57.0196578,All,"7 Years and older ¬† (Child, Adult, Older Adult)",394,381,352,259,58,35,5/17/2012,1/7/2013,10/30/2012,11/18/2012,10/17/2012,11/8/2012,11/15/2012,11/16/2012,11/27/2012,4/9/2015,10/12/2014,6/8/2015,8/1/2015,9/25/2015,10/25/2015,12/9/2015,2/2/2016,3/5/2016,5/1/2016,5/7/2013,11/3/2013,5/2/2014,10/29/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01915472,,,,,,
Gilead Sciences,Gilead Sciences,ST00403,SP00009,Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 1|Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Mary H,John G,Tammara F,Jaquelyn H,Lilla Stilson †,Clarice N,Mary H,Tammara F,Gertrudis T,Aleta H,Tamesha T,Jaquelyn H,Beulah N,Mara A,Mary H,Naren G,Mara A,Aleta H,Stephan T,,,"Christiana Care Health Services, Newark, Delaware, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Herbert Werthem College of Medicine/Jackson North Medical Center, Miami, Florida, United States|Moffit Cancer Center, Tampa, Florida, United States|Winship Cancer Institute/Emory University Hospital, Atlanta, Georgia, United States|Goshen Cancer Center, Goshen, Indiana, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|Mt. Sinai Medical Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Thomas Jefferson University Medical Center, Philadelphia, Pennsylvania, United States",48.88319326,43.99487393,All,"18 Years and older ¬† (Adult, Older Adult)",386,381,353,217,108,28,9/2/2009,1/29/2010,11/21/2009,12/21/2009,12/4/2009,12/13/2009,12/23/2009,12/25/2009,1/7/2010,12/6/2012,12/11/2012,3/17/2013,7/1/2013,8/11/2013,9/16/2013,11/12/2013,12/14/2013,1/24/2014,3/6/2014,6/11/2010,12/8/2010,6/6/2011,12/3/2011,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00603863,,,,,,
Gilead Sciences,Gilead Sciences,ST00441,SP00009,Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer,,,,,Oncology,,,,,,Industry,Withdrawn,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Chetan K,Ross S,Ngan D,Mara A,Terrell p,Jaquelyn H,Federico L,Kandace p,Doreen T,Tiffiny K,Christian G,Tammara F,Naren G,Beulah N,Anthony P,Perter K,Otis Thode †,Mac L,Mara A,,,,43.45169899,39.10652909,All,"18 Years and older ¬† (Adult, Older Adult)",377,373,354,214,114,26,11/19/2012,6/7/2013,4/16/2013,5/2/2013,4/20/2013,4/24/2013,5/7/2013,5/12/2013,6/11/2013,12/26/2015,12/15/2015,4/13/2016,8/1/2016,9/11/2016,10/28/2016,12/11/2016,1/18/2017,2/27/2017,4/23/2017,10/21/2013,4/19/2014,10/16/2014,4/14/2015,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02161679,,,,,,
Gilead Sciences,Gilead Sciences,ST00469,SP00009,Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer Triple-Negative Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Frank T,Lucie P,Anthony P,Christian G,Mara A,Christian G,Aleta H,Selizabeth F,Lavina S,Lyman W,John G,Garnet T,Terisa Sikora †,John G,Aleta H,John G,Dinah R,Harry A,Perter K,,,"Southern Cancer Center, 29653 Anchor Cross Blvd, Daphne, Alabama, United States|Souther Cancer Center, 3719 Dauphin St., 5 Floor, Mobile, Alabama, United States|Southern Cancer Center, 3 Mobile Infirmary Circle, Mobile, Alabama, United States|Southern Cancer Center, 6701 Airport Blvd., Bldg B, Terace Level, Mobile, Alabama, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Mayo Clinic Hospital, Scottsdale, Arizona, United States|UCLA Jonsson Comprehensive Cancer Center, 1411 S. Garfield Ave Suite 200, Alhambra, California, United States|UCLA Jonsson Comprehensive Cancer Center, 201. S. Buena Vista St Suite 200, Burbank, California, United States|UCLA Jonsson Comprehensive Cancer Center, Laguna Hills, California, United States|UCLA Jonsson Comprehensive Cancer Center, 200 UCLA Medical Plaza, Los Angeles, California, United States|UCLA Jonsson Comprehensive Cancer Center, 625 South Fair Oaks Avenue Suite 320, Pasadena, California, United States|University of California, San Francisco (UCSF) - Innovation, Technology & Alliances, 1600 Divisadero Street, San Francisco, California, United States|UCLA Jonsson Comprehensive Cancer Center, 2020 Santa Monica Boulevard, Santa Monica, California, United States|Rocky Mountain Cancer Centers, 1700 South Potomac Street, Aurora, Colorado, United States|University of Colorado Hospital - Anschutz Cancer Pavilion, 1665 Aurora Court, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, 4715 Arapahoe Ave, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, 2312 N. Nevada Avenue, Suite 400, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, 1800 Williams St., Denver, Colorado, United States|Rocky Mountain Cancer Centers, 4700 E. Hale Parkway, Suite 400, Denver, Colorado, United States|Rocky Mountain Cancer Centers, 499 E Hampden Ave Suite 450, Englewood, Colorado, United States|Rocky Mountain Cancer Centers, 11750 West 2nd Place, Suite 1-100, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, 22 West Dry Creek Circle, Littleton, Colorado, United States|Rocky Mountain Cancer Centers, 10103 Ridge Gate Parkway, Suite G-01, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers, 2030 W Mountain View Avenue, Ste. 210, Longmont, Colorado, United States|Rocky Mountain Cancer Centers, 9397 Crown Crest Blvd., Suite 421, Parker, Colorado, United States|Rocky Mountain Cancer Centers, 3676 Parker Blvd., Suite 350, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers, 8820 Huron Street, Thornton, Colorado, United States|Yale School Of Medicine, New Haven, Connecticut, United States|Norwalk Hospital, 34 Maple Street, Norwalk, Connecticut, United States|Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Florida Cancer Specialists & Research Institute, 601 E. Altamonte Drive, Altamonte Springs, Florida, United States|Florida Cancer Specialist, Bonita Springs, Florida, United States|Florida Cancer Specialists, Bradenton, Florida, United States|Florida Cancer Specialists & Research Institute, 403 S. King Ave, Brandon, Florida, United States|Florida Cancer Specialists, Cape Coral, Florida, United States|Florida Cancer Specialists & Research Institute, 3280 McMullen Booth road, Clearwater, Florida, United States|Sylvester Comprehensive Cancer Center, Coral Gables, Florida, United States|Florida Cancer Specialists & Research Institute, 224 Memorial medical Parway, Daytona Beach, Florida, United States|Sylvester Comprehensive Cancer Center, Deerfield Beach, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists & Research Institute, 6420 W Newberry Road Est Wing, Gainesville, Florida, United States|Florida Cancer Specialists & Research Institute, 100 Highland Avenue, Largo, Florida, United States|Florida Cancer Specialists & Research Institute, 521 N. Lecanto Highway, Lecanto, Florida, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Baptist Health Medical Group Oncology, LLC, Miami, Florida, United States|Florida Cancer Specialists, Naples, Florida, United States|Florida Cancer Specialists & Research Institute, 8763 River Crossing Blvd, New Port Richey, Florida, United States|Florida Cancer Specialists & Research Institute, 1630 SE 18th ST, Ocala, Florida, United States|Florida Cancer Specialists & Research Institute, 765 Image Way, Orange City, Florida, United States|Orlando Regional Medical Center, Orlando, Florida, United States|Florida Cancer Specialists & Research Institute, 70 W Gore Street, Orlando, Florida, United States|Florida Cancer Specialists & Research Institute - 325 Clyde Morris, Ormond Beach, Florida, United States|Sylvester Comprehensive Cancer Center, Plantation, Florida, United States|Florida Cancer Specialists, Port Charlotte, Florida, United States|Florida Cancer Specialists & Research Institute, 1201 Fifth Avenue North, Saint Petersburg, Florida, United States|Florida Cancer Specialists & Research Institute, 560 Jackson St, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialists & Research Institute, 7154 Medical Center Drive, Spring Hill, Florida, United States|Florida Cancer Specialists & Research Institute, 3402 W Dr. Martin Luther King Jr Boulevard, Tampa, Florida, United States|Florida Cancer Specialists & Research Institute, 4100 Waterman Way, Tavares, Florida, United States|Florida Cancer Specialists & Research Institute, 1400 US highway 441 N, The Villages, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Florida Cancer Specialists & Research Institute - 3730 7th Terrace, Vero Beach, Florida, United States|Florida Cancer Specialists & Research Institute, 1037 State Road 7 Bldg B, Wellington, Florida, United States|Florida Cancer Specialists & Research Institute1309 N Flagler Dr, West Palm Beach, Florida, United States|Florida Cancer Specialists & Research Institute, 2100 Glenwood Drive, Winter Park, Florida, United States|Atlanta Cancer Center - Alpharetta, Alpharetta, Georgia, United States|University Cancer & Blood Center, 3320 Old Jefferson Rd, Athens, Georgia, United States|GCS/Annex, Atlanta, Georgia, United States|Atlanta Cancer Care - Atlanta, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|GCS/Canton, Canton, Georgia, United States|Atlanta Cancer Care - Conyers, Conyers, Georgia, United States|Atlanta Cancer Care - Cumming, Cumming, Georgia, United States|Atlanta Cancer Care - Decatur, Decatur, Georgia, United States|GCS/Stemmer, Decatur, Georgia, United States|Atlanta Cancer Care - Stockbridge, Jonesboro, Georgia, United States|GCS/Macon, Macon, Georgia, United States|GCS/Kennestone, Marietta, Georgia, United States|GCS/Northside, Sandy Springs, Georgia, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|University of Chicago Medical Center 5841 S. Maryland Ave, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center at Silver Cross Hospital 1900 Silver Cross Blvd, New Lenox, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Orland Park - UCMC Center for Advanced Care 14290 South LaGrange Rd, Orland Park, Illinois, United States|MidAmerica Division Inc. c/o Menorah Medical Center, Overland Park, Kansas, United States|University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion, Westwood, Kansas, United States|Maryland Oncology Hematology, Bethesda, Maryland, United States|Maryland Oncology Hematology, Brandywine, Maryland, United States|Maryland Oncology Hematology, Clinton, Maryland, United States|Maryland Oncology Hematology, Columbia, Maryland, United States|Maryland Oncology Hematology, Rockville, Maryland, United States|Maryland Oncology Hematology, Silver Spring, Maryland, United States|Maryland Oncology Hematology, Silver Spring, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Mass General - North Shore Cancer Center ( NSCC ), Danvers, Massachusetts, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Minnesota Oncology Hematology P.A., Coon Rapids, Minnesota, United States|Suburban Imaging Northwest, Coon Rapids, Minnesota, United States|Suburban Imaging, Coon Rapids, Minnesota, United States|Mercy Hospital - Unity Campus AHL, Fridley, Minnesota, United States|Minnesota Oncology Hematology P.A., Fridley, Minnesota, United States|Minnesota Oncology Hematology P.A., Minneapolis, Minnesota, United States|Abbot Northwestern Hospital, Minneapolis, Minnesota, United States|Virginia G. Piper Cancer Center at HonorHealth, Minneapolis, Minnesota, United States|Mayo Clinic - 200 First Street SW, Rochester, Minnesota, United States|Washington University School of Medicine in St. Louis, Creve Coeur, Missouri, United States|MidAmerica Division Inc. c/o Menorah Medical Center, Independence, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States|Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States|Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States|Nebraska Cancer Specialists - Midwest Cancer Center - Papillion, Omaha, Nebraska, United States|Nebraska Cancer Specialists - Midwest Cancer Center - Paillion, Omaha, Nebraska, United States|Nebraska Cancer Specialists- Midwest Cancer Center- Papillion, Papillion, Nebraska, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|New York Oncology Hematology, P.C., Clifton Park, New York, United States|North Shore Hematology Oncology Associates., PC, 235 North Belle Mead Road, East Setauket, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|North Shore Hematology Oncology Associates., PC, 285 Sills Road Building 16, Patchogue, New York, United States|UNC Health Care System, Chapel Hill, North Carolina, United States|The Ohio State University Wexner Medical Center, 460 W 10th Ave, Columbus, Ohio, United States|The Ohio State University Wexner Medical Center, 1145 Olentangy River Road, Columbus, Ohio, United States|Providence Medical Group, Portland, Oregon, United States|UPMC Hillman Cancer Center Mountainview Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|UPMC Hillman Cancer Center UPMC East, Monroeville, Pennsylvania, United States|UPMC Hillman Cancer Center Upper Saint Clair, Pittsburgh, Pennsylvania, United States|Allegheny-Singer Research Institute, 320 East North Avenue, Pittsburgh, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center UPMC Passavant, Pittsburgh, Pennsylvania, United States|Tennessee Oncology - Chattanooga Oncology & Hematology Associates, Chattanooga, Tennessee, United States|Tennesee Oncology - PLLC, Chattanooga, Tennessee, United States|Tenesse Oncology - PLLC, Cleveland, Tennessee, United States|Tennessee Oncology, LLC, Dickson, Tennessee, United States|Tennessee Ocology, LLC, Franklin, Tennessee, United States|Tennessee Oncology, LLC, Gallatin, Tennessee, United States|West Cancer Center, 7945 Wolf River Blvd, Germantown, Tennessee, United States|Tennessee Oncology, LLC, Hermitage, Tennessee, United States|Tennessee Oncology, LLC, Lebanon, Tennessee, United States|Tennessee Oncology, LLC, Murfreesboro, Tennessee, United States|Sarah Cannon Cancer Institute/Tennessee Oncology, Nashville, Tennessee, United States|Tennessee Oncology, LLC, Nashville, Tennessee, United States|Vanderbilt Breast Cancer Center at One Hundred Oaks 719 Thompson Lane, Suite 25000, Nashville, Tennessee, United States|Tennessee Ocology, LLC, Nashville, Tennessee, United States|Tennessee Oncology, LLC, Nashville, Tennessee, United States|Tenessee Oncology, Nashville, Tennessee, United States|Henry-Joyce Cancer Clinic 1301 Medical Center Drive 1903 The Vanderbilt Clinic Nashville, TN 37232, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Tennessee Oncology, LLC, Shelbyville, Tennessee, United States|Center for Cancer and Blood Disorders, Arlington, Texas, United States|Center for Cancer and Blood Disorders, Burleson, Texas, United States|Texas Oncology- Medical City Dallas Building D, Dallas, Texas, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, Denton, Texas, United States|Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Houston Methodist Hospital - 6565 Fannin St, Houston, Texas, United States|Texas Oncology-Longview Cancer Center, Longview, Texas, United States|Texas Oncology, Plano, Texas, United States|US Oncology, Tyler, Texas, United States|Center for Cancer and Blood Disorders, Weatherford, Texas, United States|Virginia Cancer Specialists, PC, Alexandria, Virginia, United States|Virginia Cancer Specialists, PC, Arlington, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United States|Virginia Oncology Associates, Chesapeake, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Cancer Specialists, PC, Gainesville, Virginia, United States|Virginia Oncology Associates, Hampton, Virginia, United States|Virginia Cancer Specialists, PC, Leesburg, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Low Moor, Virginia, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Virginia Oncology Associates, P.C., Norfolk, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Roanoke, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Salem, Virginia, United States|Virginia Oncology Associates, Virginia Beach, Virginia, United States|Virginia Cancer Specialists, PC, Woodbridge, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Wytheville, Virginia, United States|Swedish Cancer Institute, Edmonds, Washington, United States|Swedish Cancer Institute, Issaquah, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Universitair Zlekenhuis Brussel, Brussels, Belgium|Institut Jules Bordet, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|Clinique et Maternite Sainte-Elisabeth, Namur, Belgium|Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Jewish General Hospital, 3755 C√¥te-Sainte-Catherine, Montr√©al, Quebec, Canada|Jewish General Hospital, 3755 C√¥te-Sainte-Catherine, Qu√©bec, Quebec, Canada|Centre de Lutte Contre le Cancer - Institut de Cancerologie de l'Ouest - Paul Papin, Angers, France|CHU Besan√ßon - H√¥pital Jean Minjoz, Besan√ßon, France|Institut R√©gional du Cancer de Montpellier, Montpellier, France|Institut Curie, Paris, France|Centre Eug√®ne Marquis, Rennes Cedex, France|Florence Lerebours, Saint-Cloud, France|CHU de Nantes - H√¥pital Nord Laennec, Saint-Herblain, France|Institut Claudius Regaud, Toulouse, France|Gustave Roussy, Villejuif, France|H√§matologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany|Praxis f√ºr interdisziplin√§re Onkologie & H√§matologie GbR, Freiburg im Breisgau, Germany|Facharztzentrum Eppendorf, Hamburg, Germany|Institut f√ºr Versorgungsforschung in der Onkologie, Koblenz, Germany|Praxis f√ºr H√§matologie und Internistische Onkologie, Velbert, Germany|Hospital Teresa Herrera, As Xubias, 84, A Coru√±a, Spain|Hospital Quir√≥n Barcelona, Plaza Alfonso Com√≠n 5, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Carrer del Mas Casanovas, 90, Barcelona, Spain|Institut Catala d'Oncologia Hospitalet, Avenida Gran Via 199-203, Hospitalet de Llobregat, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Complexo Hospitalario Universitario de Santiago (CHUS) - Hospital Clinco Universaitario, Santiago De Compostela, Spain|Hospital Universitario Virgen del Roc√≠o, Sevilla, Spain|Colchester Hospital University NHS Foundation Trust - Colchester General Hospital, Turner Road, Colchester, ESS, United Kingdom|The Arden Cancer Centre- University Hospital Coventry, Coventry, United Kingdom|County Durham and Darlington NHS Foundation Trust - University Hospital of North Durham, Durham, United Kingdom|The Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom|The County Hospital, Wye Valley NHS Trust, Hereford, United Kingdom|The Royal Free London NHS Foundation Trust - The Royal Free Hospital, Pond Street Oncology & Haematology Clinical Trials Unit Dept. of Academic Oncology, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom|Plymouth Hospitals NHS Trust - Derriford Hospital, Plymouth, United Kingdom|Taunton and Somerset NHS Foundation Trust - Musgrove Park Hospital, Musgrove Park Hospital, Taunton, United Kingdom|The Mid Yorkshire Hospitals NHS Trust - Pinderfields Hospital, Wakefield, United Kingdom",46.01908713,41.41717841,All,"18 Years and older ¬† (Adult, Older Adult)",375,366,355,243,83,29,9/1/2016,4/10/2017,2/12/2017,3/10/2017,2/4/2017,2/22/2017,2/24/2017,2/27/2017,3/15/2017,12/4/2019,8/2/2019,12/25/2019,3/11/2020,4/14/2020,6/12/2020,7/26/2020,8/28/2020,10/22/2020,11/21/2020,8/21/2017,2/17/2018,8/16/2018,2/12/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02574455,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02574455/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02574455/SAP_001.pdf"
Gilead Sciences,Gilead Sciences,ST00569,SP00009,Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Suzie K,Suzie K,Anthony P,Jaquelyn H,Jene M,Frank T,Perter K,Patria R,Suzie K,Mary H,Frank T,Lavina S,Suzie K,Lucie P,Christian G,Remedios Z,Rima Y ,Chetan K,Geralyn K,,,"HonorHealth Research Institute, Avondale, Arizona, United States|Arizona Oncology Associates, PC, Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|University of California, San Diego Moores Cancer Center, La Jolla, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|UCLA Department of Medicine - Hematology/Oncology, Los Angeles, California, United States|University of California, Irvine Medical Center-Chao Family Comprehensive Cancer Center, Orange, California, United States|Southern California Permanente Medical Group, San Diego, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|University of Colorado, Aurora, Colorado, United States|Yale University Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Orlando Health, Inc., Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Inc., Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|The University of Kansas Cancer Center, Westwood, Kansas, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Mercy Medical Center, Medical Oncology & Hematology, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Summit Medical Group, Florham Park, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Laura and Isaac Perlmutter Cancer Center/NYU Langone Health, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The Ohio State University, Columbus, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|The West Clinic, PC dba West Cancer Center, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States|Texas Oncology-Denton South, Denton, Texas, United States|Houston Methodist Hospital/Houston Methodist Cancer Center, Houston, Texas, United States|Texas Oncology-Longview Cancer Center, Longview, Texas, United States|UT Health San Antonio - Mays Cancer Center, San Antonio, Texas, United States|Virginia Cancer Specialists, Arlington, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc. DBA Blue Ridge Cancer Care, Salem, Virginia, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|Chirec Cancer Institute, Brussels, Belgium|Institut Jules Bordet, Brussels, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|CHU UCL Namur/Site Sainte Elisabeth, Namur, Belgium|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Centre Hospitalier de L'Universite de Montreal - H√¥pital Notre-Dame, Montr√©al, Canada|Centre Hospitalier Universitaire de Sherbrooke - Fleurimont, Sherbrooke, Canada|Hopital de Mercy, Ars-Laquenexy, France|Institut Sainte Catherine, Avignon, France|H√¥pital Jean-Minjoz, Besan√ßon, France|Centre Georges-Francois Leclerc, Dijon, France|Centre Leon Berard, Lyon, France|Institut R√©gional du Cancer de Montpellier, Montpellier, France|Institut Curie, Paris, France|Hospices Civils de Lyon, Pierre-B√©nite, France|Institut de Canc√©rologie Lucien Neuwirth, Saint-Priest-en-Jarez, France|Institut Claudius Regaud, Toulouse, France|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Gynakologisches Zentrum Bonn, Bonn, Germany|Marienhospital Bottrop, Bottrop, Germany|St√§dtisches Klinikum Dessau, Dessau, Germany|Universit√§tsklinikum Erlangen, Erlangen, Germany|Kliniken Essen-Mitte, Essen, Germany|Centrum f√ºr H√§matologie und Onkologie Bethanien, Frankfurt, Germany|Onkologische Schwerpunktpraxis Eppendorf, Hamburg, Germany|Gynakologisch-Onkologische Praxis Hannover, Hannover, Germany|DIAKOVERE Krankenhaus gGmbH Henriettenstift - Standort Kirchrode, Hannover, Germany|Nationales Centrum f√ºr Tumorerkrankungen - Heidelberg, Heidelberg, Germany|Praxisklinik f√ºr H√§matologie und Onkologie Koblenz, Koblenz, Germany|Universit√§tsmedizin Mannheim, Mannheim, Germany|Klinikum Mutterhaus der Borrom√§erinnen, Trier, Germany|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Ospedale di Desio, Desio, Italy|Ospedale Vito Fazzi di Lecce, Lecce, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza, Italy|Azienda Unit√† Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto, Piacenza, Italy|IFO Istituto Nazionale dei Tumori Regina Elena, Rome, Italy|Antoni van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Medisch Centrum Haaglanden Antoniushove, Leidschendam, Netherlands|Maastricht UMC+, Maastricht, Netherlands|Complejo Hospitalario Universitario A Coruna, A Coru√±a, Spain|Hospital Quir√≥nsalud Barcelona Instituto Oncologico Baselga, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de la Santa Creu I Sant Pau, Barcelona, Spain|Hospital Provincial de Castell√≥n, Castill√≥n, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Instituto Oncologico Bureau (IOB), Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario de Santiago de Compostela, Santiago De Compostela, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Royal Cornwall Hospital NHS Trust, Cornwell, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Barts Health NHS Trust, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom",20.58764166,18.52887749,All,,380,364,356,227,91,38,1/4/2017,5/23/2017,3/12/2017,4/26/2017,3/13/2017,4/7/2017,4/10/2017,4/15/2017,4/30/2017,6/22/2021,2/18/2021,9/13/2021,11/1/2021,12/3/2021,1/23/2022,3/14/2022,4/17/2022,6/3/2022,7/23/2022,10/4/2017,4/2/2018,9/29/2018,3/28/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03901339,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00002,SP00010,Long-term Follow-up Study to Evaluate Durability of Sustained Virologic Response (SVR) in Previous GSK3228836 Study Participants (B-Sure),,,Hepatitis B,,Virology,,,,,,Industry,Not yet recruiting,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Tamesha T,Lavina S,Hee Y,Patria R,Jeanene Y,Mac L,Doreen T,Garnet T,Chetan K,Marceline R,Donovan H,Harry A,Naren G,Jerold Goo †,Perter K,Mara A,Mara A,Frank T,Terrell p,,,,72.33440005,65.10096004,All,20 Years to 40 Years ¬† (Adult),392,378,357,109,228,20,8/10/2027,1/10/2028,10/31/2027,12/13/2027,11/13/2027,11/27/2027,12/7/2027,5/7/2020,6/5/2020,6/17/2022,10/4/2021,5/10/2022,7/22/2022,9/2/2022,10/28/2022,12/24/2022,2/22/2023,3/31/2023,5/19/2023,5/25/2028,11/21/2028,5/20/2029,11/16/2029,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04954859,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00056,SP00010,Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects,,,HIV-1,,Virology,,,,,,Industry,Terminated,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Tammara F,Suzie K,Ross S,Perter K,Perter K,Quentin N,Ross S,Marcelina X,Lyman W,In Bellini †,Tiffiny K,Terrell p,Suzie K,Christian G,Garnet T,Jerold Goo †,Marcelina X,Selizabeth F,Ngan D,,,"GSK Clinical Trials Call Center, Darlinghurst, New South Wales, Australia|GSK Clinical Trials Call Center, Carlton, Victoria, Australia|GSK Clinical Trials Call Center, Brussels, Belgium|GSK Clinical Trials Call Center, Vancouver, British Columbia, Canada|GSK Clinical Trials Call Center, Hamilton, Ontario, Canada|GSK Clinical Trials Call Center, Ottawa, Ontario, Canada|GSK Clinical Trials Call Center, Toronto, Ontario, Canada|GSK Clinical Trials Call Center, Toronto, Ontario, Canada|GSK Clinical Trials Call Center, Montreal, Quebec, Canada|GSK Clinical Trials Call Center, Montreal, Quebec, Canada|GSK Clinical Trials Call Center, Saint-Foy, Quebec, Canada|GSK Clinical Trials Call Center, Lagny sur Marne, France|GSK Clinical Trials Call Center, Paris, France|GSK Clinical Trials Call Center, Paris, France|GSK Clinical Trials Call Centre, Paris, France|GSK Clinical Trials Call Center, Saint Denis, France|GSK Clinical Trials Call Center, Strasburg, France|GSK Clinical Trials Call Center, Toulon, France|GSK Clinical Trials Call Center, Vanouvre Les Nancy, France|GSK Clinical Trials Call Center, Hamburg, Germany|GSK Clinical Trials Call Center, Athens, Greece|GSK Clinical Trials Call Center, Athens, Greece|GSK Clinical Trials Call Center, Athens, Greece|GSK Clinical Trials Call Center, Piraeus, Greece|GSK Clinical Trials Call Center, Liguria, Italy|GSK Clinical Trials Call Center, Lombardia, Italy|GSK Clinical Trials Call Center, Romagna, Italy|GSK Clinical Trials Call Center, Rome, Italy|GSK Clinical Trials Call Centre, Torino, Italy|GSK Clinical Trials Call Center, Toscana, Italy|GSK Clinical Trials Call Center, Toscana, Italy|GSK Clinical Trials Call Center, Veneto, Italy|GSK Clinical Trials Call Center, Barcelona, Spain|GSK Clinical Trials Call Center, Jerez de la Frontera, Spain|GSK Clinical Trials Call Center, Madrid, Spain|GSK Clinical Trials Call Center, Madrid, Spain|GSK Clinical Trials Call Center, Madrid, Spain|GSK Clinical Trials call Center, Birmingham, United Kingdom|GSK Clinical Trials Call Center, Brighton, United Kingdom|GSK Clinical Trials Call Center, London, United Kingdom|GSK Clinical Trials Call Center, London, United Kingdom|GSK Clinical Trials Call Center, London, United Kingdom",94.38508173,84.94657356,All,"Child, Adult, Older Adult",384,377,358,167,165,26,7/15/2028,1/11/2029,11/4/2028,12/4/2028,11/3/2028,11/18/2028,11/28/2028,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/19/1900,4/5/1900,5/6/1900,6/7/1900,8/4/1900,9/19/1900,5/17/2029,11/13/2029,5/12/2030,11/8/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00144833,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00058,SP00010,A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B,,,"Hepatitis B, Chronic",,Virology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Lavina S,Jeanene Y,Lyman W,Lyman W,Patria R,Tiffiny K,Chetan K,Chetan K,Beulah N,Remedios Z,Tien C,Perter K,Mac L,Mary H,Jaquelyn H,Garnet T,Geralyn K,Mara A,Kala R,,,"GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Chiba, Japan|GSK Investigational Site, Ehime, Japan|GSK Investigational Site, Ehime, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hiroshima, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Nagasaki, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tottori, Japan",32.05278931,28.84751038,All,"18 Years and older ¬† (Adult, Older Adult)",382,371,359,115,227,17,7/18/2028,2/3/2029,11/21/2028,12/25/2028,11/26/2028,12/8/2028,12/18/2028,4/26/2017,5/6/2017,8/24/2018,4/2/2018,9/6/2018,12/28/2018,2/10/2019,4/1/2019,5/16/2019,7/15/2019,9/3/2019,10/31/2019,6/6/2029,12/3/2029,6/1/2030,11/28/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03258710,,,,,,"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03258710/SAP_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03258710/Prot_002.pdf"
GlaxoSmithKline,GlaxoSmithKline,ST00061,SP00010,Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB),,B-Together,Hepatitis B,,Virology,,,,,,Industry,Recruiting,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Xochitl D,Patria R,Selizabeth F,Jene M,Garnet T,Dalton E,Mary H,Rima Y ,Louann C,Clarice N,Frank T,Beulah N,Kandace p,Dinah R,John G,Louann C,Doreen T,Suzie K,Jaquelyn H,,,"GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Changchun, Jilin, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Hangzhou, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Baggiovara (MO), Emilia-Romagna, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Monza (MB), Lombardia, Italy|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Fukui, Japan|GSK Investigational Site, Gifu, Japan|GSK Investigational Site, Hiroshima, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Nagasaki, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Daegu, Korea, Republic of|GSK Investigational Site, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Ulsan, Korea, Republic of|GSK Investigational Site, Lancut, Poland|GSK Investigational Site, Lublin, Poland|GSK Investigational Site, Myslowice, Poland|GSK Investigational Site, Barnaul, Russian Federation|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Krasnojarsk, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Samara, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Ennerdale, Gauteng, South Africa|GSK Investigational Site, Johannesburg, Gauteng, South Africa|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, M√°laga, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle-upon-Tyne, United Kingdom|GSK Investigational Site, Nottingham, United Kingdom|GSK Investigational Site, Plymouth, United Kingdom",17.04607715,15.34146943,All,"4 Years to 18 Years ¬† (Child, Adult)",375,369,360,189,150,21,7/24/2028,2/13/2029,12/4/2028,1/13/2029,12/20/2028,12/29/2028,1/8/2029,3/23/2021,4/15/2021,12/29/2022,11/23/2022,4/26/2023,6/15/2023,7/26/2023,9/1/2023,10/16/2023,12/11/2023,1/22/2024,2/25/2024,6/27/2029,12/24/2029,6/22/2030,12/19/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04676724,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00062,SP00010,A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB),,B-Clear,Hepatitis B,,Virology,,,,,,Industry,"Active, not recruiting",Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Doreen T,Lavina S,John G,Dalton E,Naren G,Anthony P,Harry A,Lilla Stilson †,Tammara F,Tiffiny K,Lavina S,Mary H,Perter K,Mary H,Louann C,Frank T,Mee M,Terisa Sikora †,Selizabeth F,,,"GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Decatur, Georgia, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Sliven, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Victoria, British Columbia, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Regina, Saskatchewan, Canada|GSK Investigational Site, Qu√©bec, Canada|GSK Investigational Site, Wuhan, Hubei, China|GSK Investigational Site, Shenyang, Liaoning, China|GSK Investigational Site, Chongqing, Sichuan, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Guangzhou, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Clichy Cedex, France|GSK Investigational Site, Cr√©teil cedex, France|GSK Investigational Site, Limoges cedex, France|GSK Investigational Site, Lyon cedex 04, France|GSK Investigational Site, Nice cedex 3, France|GSK Investigational Site, Strasbourg, France|GSK Investigational Site, Erlangen, Bayern, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Pokfulam, Hong Kong|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Chiba, Japan|GSK Investigational Site, Ehime, Japan|GSK Investigational Site, Hiroshima, Japan|GSK Investigational Site, Hiroshima, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Ishikawa, Japan|GSK Investigational Site, Ishikawa, Japan|GSK Investigational Site, Kagawa, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Miyagi, Japan|GSK Investigational Site, Nagasaki, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Daegu, Korea, Republic of|GSK Investigational Site, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Ulsan, Korea, Republic of|GSK Investigational Site, Johor Bahru, Malaysia|GSK Investigational Site, Kuala Lumpur, Malaysia|GSK Investigational Site, Makati City, Philippines|GSK Investigational Site, Quezon City, Philippines|GSK Investigational Site, Lancut, Poland|GSK Investigational Site, Lublin, Poland|GSK Investigational Site, Myslowice, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Brasov, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Cluj Napoca, Romania|GSK Investigational Site, Cluj-Napoca, Romania|GSK Investigational Site, Craiova, Romania|GSK Investigational Site, Galati, Romania|GSK Investigational Site, Iasi, Romania|GSK Investigational Site, Timisoara, Romania|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Kaliningrad, Russian Federation|GSK Investigational Site, Krasnodar, Russian Federation|GSK Investigational Site, Krasnojarsk, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, Samara, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Port Elizabeth, Eastern Cape, South Africa|GSK Investigational Site, Bloemfontein, Free State, South Africa|GSK Investigational Site, Ennerdale, Gauteng, South Africa|GSK Investigational Site, Lenasia Johannesburg, Gauteng, South Africa|GSK Investigational Site, Durban, KwaZulu- Natal, South Africa|GSK Investigational Site, Kwaguqa Emalahleni, Mpumalanga, South Africa|GSK Investigational Site, Bloemfontein, South Africa|GSK Investigational Site, Vosloorus Ext 2, South Africa|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, M√°laga, Spain|GSK Investigational Site, Pontevedra, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Changhua, Taiwan|GSK Investigational Site, Kaohsiung, Taiwan|GSK Investigational Site, Taichung, Taiwan|GSK Investigational Site, Tainan, Taiwan|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Chiangmai, Thailand|GSK Investigational Site, Phitsanulok, Thailand|GSK Investigational Site, Songkla, Thailand|GSK Investigational Site, Nottingham, Nottinghamshire, United Kingdom|GSK Investigational Site, Crumpsall, Manchester, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle-upon-Tyne, United Kingdom|GSK Investigational Site, Plymouth, United Kingdom",10.64978222,9.584803995,All,"18 Years and older ¬† (Adult, Older Adult)",408,394,361,268,58,35,8/6/2028,2/6/2029,12/15/2028,1/14/2029,12/12/2028,12/31/2028,1/10/2029,8/23/2018,9/6/2018,4/6/2021,7/17/2021,11/25/2021,3/8/2022,4/7/2022,5/27/2022,7/18/2022,8/28/2022,10/20/2022,12/9/2022,6/29/2029,12/26/2029,6/24/2030,12/21/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04449029,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00107,SP00010,Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma,,DREAMM 14,Multiple Myeloma,,Oncology,,,,,,Industry,Not yet recruiting,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Jene M,Gertrudis T,In Bellini †,Ngan D,Anthony P,Selizabeth F,Kala R,Jene M,John G,Lavina S,Jerold Goo †,Perter K,Suzie K,Terisa Sikora †,Terisa Sikora †,Remedios Z,Rima Y ,Suzie K,Geralyn K,,,,6.858516762,6.172665085,All,"18 Years and older ¬† (Adult, Older Adult)",393,382,362,223,106,33,7/27/2021,2/19/2022,12/19/2021,1/20/2022,1/8/2022,1/12/2022,1/17/2022,1/20/2022,1/29/2022,12/28/2023,11/20/2023,3/23/2024,8/2/2024,9/28/2024,11/7/2024,12/11/2024,1/25/2025,3/7/2025,4/30/2025,7/11/2022,1/7/2023,7/6/2023,1/2/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05064358,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00115,SP00010,A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above,,,Respiratory Syncytial Virus Infections,,Virology,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Rima Y ,Lucie P,Dinah R,Lavina S,Lucie P,Mary H,Frank T,Mary H,Beulah N,Donovan H,James y,Geralyn K,Kandace p,Frank T,Lyman W,Perter K,Federico L,Clarice N,Federico L,,,,19.91569568,17.92412611,All,"18 Years and older ¬† (Adult, Older Adult)",396,391,363,177,156,30,6/17/2017,2/8/2018,11/19/2017,12/23/2017,12/6/2017,12/12/2017,12/21/2017,12/22/2017,12/30/2017,6/19/2021,7/12/2021,11/19/2021,2/8/2022,3/15/2022,5/7/2022,6/25/2022,8/7/2022,10/5/2022,12/2/2022,6/10/2018,12/7/2018,6/5/2019,12/2/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05059301,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00128,SP00010,A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine,,,Herpes Zoster,,,,,,,,Industry,Not yet recruiting,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Livia Pacheo †,Suk T,Lucie P,Louann C,Tammara F,Mary H,Liberty A,Garnet T,Kala R,Frank T,Mary H,Chetan K,Anthony P,Frank T,Naren G,Suzie K,Frank T,Ngan D,Tamesha T,,,,10.72235,9.650115003,All,"18 Years and older ¬† (Adult, Older Adult)",409,395,364,156,184,24,11/30/2017,6/8/2018,3/21/2018,5/1/2018,4/13/2018,4/18/2018,5/2/2018,5/7/2018,5/24/2018,2/16/2022,11/18/2021,7/3/2022,8/4/2022,9/13/2022,10/29/2022,12/26/2022,2/19/2023,4/9/2023,6/2/2023,10/15/2018,4/13/2019,10/10/2019,4/7/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05047770,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00132,SP00010,A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.,,,Respiratory Syncytial Virus Infections,,,,,,,,Industry,Recruiting,Not Applicable,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,,,,,Drug A,,,,,,,,,,,,,,,,,,,Anthony P,Perter K,Rima Y ,Clarice N,James y,Terrell p,Federico L,Kandace p,Lilla Stilson †,Clarice N,Dinah R,Mee M,Mac L,Donovan H,Harry A,Suzie K,Marcelina X,Rima Y ,Jaquelyn H,,,"GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Stockbridge, Georgia, United States|GSK Investigational Site, Peoria, Illinois, United States|GSK Investigational Site, Springfield, Missouri, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Truro, Nova Scotia, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Mirabel, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Espoo, Finland|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Jarvenpaa, Finland",58.90357872,53.01322085,Female,"18 Years and older ¬† (Adult, Older Adult)",398,391,365,270,54,41,9/29/2016,4/27/2017,2/28/2017,3/29/2017,3/10/2017,3/21/2017,3/30/2017,4/4/2017,5/4/2017,1/27/2021,4/21/2021,8/2/2021,12/23/2021,1/24/2022,3/15/2022,5/4/2022,6/24/2022,7/27/2022,9/8/2022,9/17/2017,3/16/2018,9/12/2018,3/11/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05045144,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00134,SP00010,"A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants",,,Heart Failure,,Cardiovascular,,,,,,Industry,Not yet recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Corrine U,Mac L,Christian G,Lilla Stilson †,Jerold Goo †,Tien C,Mary H,Suzie K,Anthony P,Frank T,Frank T,Liberty A,Ross S,Marcelina X,Hee Y,James y,Jene M,Clarice N,Ngan D,,,,72.74054348,65.46648913,All,"50 Years and older ¬† (Adult, Older Adult)",388,373,366,308,0,58,7/31/2017,2/6/2018,12/16/2017,1/14/2018,12/23/2017,12/31/2017,1/8/2018,1/10/2018,2/4/2018,7/18/2022,12/28/2021,6/11/2022,8/18/2022,9/20/2022,10/29/2022,12/28/2022,2/22/2023,4/4/2023,5/6/2023,6/29/2018,12/26/2018,6/24/2019,12/21/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05044325,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00159,SP00010,"A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers",,,Tobacco Use Disorder,,,,,,,,Industry,Recruiting,Early Phase 1,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Naren G,Mac L,Marcelina X,Aleta H,Anthony P,Frank T,Lyman W,Patria R,Stephan T,Mary H,Jaquelyn H,Mary H,Frank T,Selizabeth F,Lyman W,Chetan K,Lavina S,John G,Naren G,,,"GSK Investigational Site, Springfield, Missouri, United States",87.02882223,78.32594,All,5 Years to 5 Years ¬† (Child),408,392,367,311,8,48,8/21/2016,1/31/2017,12/17/2016,1/5/2017,12/12/2016,12/23/2016,1/2/2017,1/5/2017,1/15/2017,6/19/2021,2/21/2021,7/7/2021,10/25/2021,12/20/2021,2/18/2022,3/21/2022,5/14/2022,7/4/2022,8/9/2022,6/21/2017,12/18/2017,6/16/2018,12/13/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05024747,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00161,SP00010,A Bioequivalence Study of a New Paracetamol Oral Suspension 24mg/ml Compared to the Marketed Paracetamol Oral Suspension (Panadol Baby and Infant 24mg/ml) in Healthy Adult Subjects,,,Pain,,I&I,,,,,,Industry,Completed,Not Applicable,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Frank T,Tamesha T,Anthony P,Garnet T,Frank T,Corrine U,Beulah N,Lavina S,Jaquelyn H,Beulah N,Jeanene Y,Mara A,Lucie P,John G,Suzie K,James y,Lyman W,Frank T,Naren G,,,"QUINTA-ANALYTICA s.r.o., Prague, Czechia",45.21186614,40.69067953,All,"18 Years and older ¬† (Adult, Older Adult)",408,398,368,171,173,24,2/10/2017,8/10/2017,6/27/2017,7/20/2017,6/13/2017,7/2/2017,7/12/2017,7/16/2017,7/29/2017,4/14/2021,11/26/2020,7/29/2021,9/8/2021,10/19/2021,12/8/2021,1/9/2022,2/21/2022,4/7/2022,6/1/2022,12/29/2017,6/27/2018,12/24/2018,6/22/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05022810,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00214,SP00010,"A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers",,,Respiratory Syncytial Virus Infections,,,,,,,,Industry,Recruiting,Phase 1,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Anthony P,Lilla Stilson †,Suzie K,Mara A,Chetan K,Naren G,Liberty A,Otis Thode †,Kandace p,Quentin N,Clarice N,Chetan K,Lavina S,Lavina S,Mara A,Otis Thode †,Rima Y ,Selizabeth F,Doreen T,,,"GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Dothan, Alabama, United States|GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Covington, Louisiana, United States|GSK Investigational Site, Lafayette, Louisiana, United States|GSK Investigational Site, Slidell, Louisiana, United States|GSK Investigational Site, Missoula, Montana, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, Grapevine, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, League City, Texas, United States|GSK Investigational Site, Plano, Texas, United States|GSK Investigational Site, Weatherford, Texas, United States|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Kingston, Ontario, Canada|GSK Investigational Site, Qu√©bec, Canada|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Soweto, Gauteng, South Africa|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain",48.34391477,43.50952329,Female,25 Years to 60 Years ¬† (Adult),392,384,369,131,215,23,7/3/2017,11/30/2017,10/1/2017,11/3/2017,10/5/2017,10/21/2017,11/5/2017,11/7/2017,11/17/2017,5/16/2022,9/10/2021,1/30/2022,6/20/2022,7/24/2022,9/4/2022,10/19/2022,12/7/2022,1/26/2023,3/19/2023,4/19/2018,10/16/2018,4/14/2019,10/11/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04980391,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00222,SP00010,"Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis",,,"Dermatitis, Atopic",,I&I,,,,,,Industry,Not yet recruiting,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,James y,Chetan K,Chetan K,Patria R,Gertrudis T,Tien C,Suzie K,Kala R,Lucie P,Stephan T,Dinah R,Frank T,Mara A,Suzie K,Doreen T,In Bellini †,Aleta H,Corrine U,Mara A,,,,87.15584272,78.44025845,All,"18 Years and older ¬† (Adult, Older Adult)",414,403,370,185,160,25,9/11/2018,2/11/2019,12/18/2018,1/11/2019,12/28/2018,1/6/2019,1/8/2019,1/10/2019,1/25/2019,4/1/2022,3/18/2022,10/10/2022,1/2/2023,2/13/2023,4/10/2023,5/13/2023,6/26/2023,7/26/2023,9/15/2023,7/5/2019,1/1/2020,6/29/2020,12/26/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04975438,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00230,SP00010,Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment,,,Hepatitis B,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Patria R,Mary H,Livia Pacheo †,Mac L,Xochitl D,Selizabeth F,Doreen T,Kandace p,Chetan K,John G,John G,Christian G,Suzie K,Marceline R,John G,Beulah N,Anthony P,Mee M,Mary H,,,,40.39936711,36.35943039,All,,400,393,371,129,217,25,7/5/2018,1/1/2019,11/13/2018,11/29/2018,10/29/2018,11/19/2018,11/21/2018,11/22/2018,12/16/2018,4/30/2022,12/19/2021,3/16/2022,7/18/2022,9/5/2022,10/26/2022,12/8/2022,1/21/2023,3/9/2023,4/11/2023,5/18/2019,11/14/2019,5/12/2020,11/8/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04971928,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00231,SP00010,"Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis",,,Systemic Lupus Erythematosus,,,,,,,,Industry,Not yet recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Ross S,Patria R,Suk T,Garnet T,Stephan T,Tammara F,Jaquelyn H,Liberty A,Kandace p,Marcelina X,Doreen T,Corrine U,Stephan T,Mary H,Mary H,Hee Y,Patria R,Stephan T,Lyman W,,,,80.37050539,72.33345485,All,"18 Years and older ¬† (Adult, Older Adult)",415,408,372,246,83,43,9/20/2019,2/22/2020,12/17/2019,1/25/2020,12/17/2019,1/11/2020,1/23/2020,1/26/2020,2/25/2020,3/4/2022,2/26/2022,7/14/2022,11/1/2022,12/26/2022,2/5/2023,3/23/2023,5/14/2023,6/16/2023,7/20/2023,7/9/2020,1/5/2021,7/4/2021,12/31/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04971590,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00234,SP00010,Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE),,SPHERE,Hypereosinophilic Syndrome,,,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Lavina S,Mara A,Suzie K,Perter K,Clarice N,Terisa Sikora †,Remedios Z,Remedios Z,Chetan K,James y,Lavina S,Patria R,John G,In Bellini †,Jaquelyn H,Suzie K,Livia Pacheo †,Terrell p,Corrine U,,,,87.8612882,79.07515938,All,"18 Years and older ¬† (Adult, Older Adult)",402,396,373,196,140,37,8/19/2021,3/12/2022,1/28/2022,2/17/2022,2/2/2022,2/9/2022,2/22/2022,2/25/2022,3/20/2022,6/7/2024,12/19/2023,7/17/2024,9/23/2024,11/1/2024,12/30/2024,2/7/2025,3/17/2025,4/26/2025,5/26/2025,8/8/2022,2/4/2023,8/3/2023,1/30/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04965636,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00241,SP00010,A Real-World Evidence Study to Evaluate Oral Health Related Quality of Life Using an Anti-Sensitivity Toothpaste,,,Dentin Sensitivity,,,,,,,,Industry,Recruiting,,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Mac L,Patria R,Clarice N,Liberty A,Chetan K,Doreen T,Ross S,Beulah N,Harry A,Liberty A,In Bellini †,Lyman W,Lilla Stilson †,Mee M,Dinah R,Terrell p,Mara A,Mary H,Marcelina X,,,"GSK Investigational Site, Orlando, Florida, United States",60.77169408,54.69452467,All,18 Years to 45 Years ¬† (Adult),418,401,374,192,151,31,7/15/2020,11/28/2020,10/4/2020,11/11/2020,10/4/2020,10/26/2020,11/1/2020,11/5/2020,11/16/2020,9/19/2021,7/3/2021,2/26/2022,4/24/2022,6/15/2022,8/12/2022,9/18/2022,11/12/2022,12/29/2022,2/9/2023,4/24/2021,10/21/2021,4/19/2022,10/16/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04964063,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00242,SP00010,A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy Adult Participants Under Fasting Conditions,,,Healthy Volunteers,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Naren G,Anthony P,Lavina S,Beulah N,Stephan T,Otis Thode †,Selizabeth F,Liberty A,Mara A,Perter K,Xochitl D,Marcelina X,Dinah R,Remedios Z,Beulah N,Suk T,Tammara F,Quentin N,Kala R,,,,63.53364356,57.18027921,All,"18 Years to 65 Years ¬† (Adult, Older Adult)",403,389,375,361,52,38,11/16/2017,5/26/2018,4/10/2018,5/6/2018,4/18/2018,4/25/2018,5/2/2018,5/5/2018,5/30/2018,6/22/2021,4/12/2021,12/4/2021,1/18/2022,2/22/2022,4/21/2022,6/13/2022,8/3/2022,9/20/2022,11/15/2022,10/22/2018,4/20/2019,10/17/2019,4/14/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04964050,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00261,SP00010,Long-term Follow-up Study to Evaluate Durability of Sustained Virologic Response (SVR) in Previous GSK3228836 Study Participants (B-Sure),,,Hepatitis B,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Naren G,Suzie K,Harry A,Jene M,Mary H,Lavina S,Tiffiny K,Tien C,Donovan H,Anthony P,Suzie K,Dalton E,John G,Naren G,Otis Thode †,Garnet T,Aleta H,Selizabeth F,Frank T,,,,54.97472088,49.4772488,All,"5 Years to 18 Years ¬† (Child, Adult)",397,380,376,354,38,16,8/26/2018,1/14/2019,11/27/2018,12/21/2018,12/8/2018,12/10/2018,12/25/2018,12/28/2018,1/26/2019,6/21/2022,10/14/2021,5/5/2022,7/22/2022,9/20/2022,10/28/2022,12/27/2022,2/7/2023,3/17/2023,4/26/2023,6/8/2019,12/5/2019,6/2/2020,11/29/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04954859,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00264,SP00010,An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ‚â• 18 Years of Age in the United States and Europe.,,,Herpes Genitalis,,Virology,,,,,,Industry,Recruiting,Not Applicable,Observational,,Observational Model: Other|Time Perspective: Prospective,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Dinah R,Anthony P,Marcelina X,Mac L,Lyman W,Mara A,Naren G,Hee Y,Chetan K,Dalton E,Stephan T,Kandace p,Corrine U,Chetan K,Mara A,Marcelina X,Suk T,Jeanene Y,Frank T,,,"GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Plantation, Florida, United States|GSK Investigational Site, Smyrna, Georgia, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Lawrenceville, New Jersey, United States|GSK Investigational Site, Oulu, Finland|GSK Investigational Site, Bron, France|GSK Investigational Site, Nantes Cedex 1, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Saint Etienne Cedex 02, France|GSK Investigational Site, Toulouse Cedex 9, France|GSK Investigational Site, Palermo, Sicilia, Italy|GSK Investigational Site, Alcorcon, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Marbella, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, London, United Kingdom",8.845459209,7.960913288,All,"18 Years and older ¬† (Adult, Older Adult)",408,403,377,185,166,26,8/2/2021,1/8/2022,11/5/2021,12/14/2021,11/13/2021,12/1/2021,12/8/2021,12/11/2021,12/17/2021,9/6/2023,4/17/2023,8/29/2023,11/9/2023,12/13/2023,1/31/2024,3/27/2024,4/27/2024,6/7/2024,7/16/2024,5/30/2022,11/26/2022,5/25/2023,11/21/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04950712,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00265,SP00010,A Clinical Study to Evaluate the Efficacy of a Stannous Fluoride Dentifrice in the Relief of Dentinal Hypersensitivity in a Chinese Population,,,Dentin Sensitivity,,,,,,,,Industry,Recruiting,Not Applicable,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug F,,,,,,,,,,,,,,,,,,,Remedios Z,Chetan K,Geralyn K,Suk T,Tien C,Stephan T,Lyman W,Chetan K,Louann C,Doreen T,Hee Y,Federico L,Lavina S,Perter K,Doreen T,Anthony P,Jeanene Y,Suzie K,Ross S,,,"GSK Investigational Site, Shanghai, China",35.03275959,31.52948363,All,18 Years to 40 Years ¬† (Adult),401,382,378,234,98,46,3/4/2018,10/13/2018,8/23/2018,9/3/2018,8/8/2018,8/28/2018,9/5/2018,9/10/2018,9/16/2018,9/17/2021,2/18/2021,6/13/2021,10/29/2021,12/11/2021,1/15/2022,2/20/2022,4/17/2022,5/21/2022,6/25/2022,2/24/2019,8/23/2019,2/19/2020,8/17/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04950465,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00266,SP00010,Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN),,,Pruritus,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug G,,,,,,,,,,,,,,,,,,,Chetan K,Gertrudis T,Harry A,Mee M,Stephan T,Anthony P,Harry A,Suzie K,Mee M,Stephan T,John G,Jene M,Naren G,Doreen T,Lavina S,Suzie K,John G,Corrine U,Aleta H,,,,44.41658502,39.97492652,All,"18 Years and older ¬† (Adult, Older Adult)",407,389,379,340,6,33,8/28/2020,3/14/2021,2/5/2021,2/23/2021,1/20/2021,2/10/2021,2/24/2021,2/26/2021,3/17/2021,10/19/2022,8/8/2022,4/6/2023,5/16/2023,6/26/2023,8/23/2023,10/14/2023,11/16/2023,12/30/2023,2/16/2024,8/9/2021,2/5/2022,8/4/2022,1/31/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04950127,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00294,SP00010,Breast Cancer With Over-expression of erbB2-BRAINSTORM,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Dalton E,Marcelina X,Lyman W,John G,Anthony P,Jene M,Kandace p,Anthony P,Mac L,Perter K,James y,Patria R,Geralyn K,Naren G,Frank T,Geralyn K,Xochitl D,In Bellini †,Dinah R,,,"GSK Investigational Site, Pasay City, Philippines|GSK Investigational Site, Quezon City, Philippines|GSK Investigational Site, Quezon City, Philippines|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Chiangmai, Thailand",16.25939203,14.63345283,Female,"18 Years and older ¬† (Adult, Older Adult)",421,416,380,238,116,26,12/4/2009,6/23/2010,4/3/2010,4/29/2010,4/10/2010,4/24/2010,4/30/2010,5/4/2010,5/12/2010,1/21/2011,10/22/2010,3/7/2011,6/3/2011,7/6/2011,8/22/2011,9/21/2011,10/24/2011,12/7/2011,1/27/2012,10/21/2010,4/19/2011,10/16/2011,4/13/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01064349,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00340,SP00010,Brain Metastasis in Breast Cancer Patients,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Hee Y,Jeanene Y,Louann C,Jaquelyn H,Livia Pacheo †,Geralyn K,Perter K,Tien C,Rima Y ,John G,Liberty A,Liberty A,Liberty A,Corrine U,Dalton E,Chetan K,Mary H,Anthony P,Stephan T,,,,90.47496542,81.42746888,Female,"50 Years to 120 Years ¬† (Adult, Older Adult)",422,416,381,255,76,50,10/27/2010,3/11/2011,1/18/2011,2/9/2011,1/6/2011,1/29/2011,2/1/2011,2/3/2011,3/2/2011,3/16/2013,11/22/2012,4/26/2013,8/1/2013,9/23/2013,11/18/2013,12/24/2013,2/15/2014,3/30/2014,5/6/2014,7/28/2011,1/24/2012,7/22/2012,1/18/2013,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01077648,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00351,SP00010,Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Only|Time Perspective: Retrospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Selizabeth F,Naren G,Tammara F,Lucie P,Selizabeth F,Otis Thode †,Mary H,Xochitl D,Ross S,Doreen T,Livia Pacheo †,Louann C,Chetan K,Mara A,Otis Thode †,Donovan H,Otis Thode †,Mara A,Ross S,,,,78.05851833,70.2526665,Female,"18 Years and older ¬† (Adult, Older Adult)",397,392,382,200,143,39,1/4/2008,7/8/2008,5/11/2008,6/3/2008,5/12/2008,5/19/2008,5/28/2008,5/30/2008,6/14/2008,1/25/2011,8/22/2010,1/31/2011,4/1/2011,5/7/2011,6/6/2011,7/23/2011,8/23/2011,10/19/2011,11/19/2011,11/15/2008,5/14/2009,11/10/2009,5/9/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01328028,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00385,SP00010,Cross-sectional Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Cervical Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Only|Time Perspective: Cross-Sectional,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Dalton E,Ross S,Jaquelyn H,Patria R,Perter K,Xochitl D,Garnet T,Kandace p,Jene M,Gertrudis T,Ross S,Anthony P,John G,Ngan D,Xochitl D,Dalton E,Chetan K,Tiffiny K,Patria R,,,,73.18797236,65.86917512,Female,"18 Years and older ¬† (Adult, Older Adult)",428,412,383,332,12,39,3/11/2007,8/14/2007,6/11/2007,7/11/2007,6/18/2007,7/5/2007,7/17/2007,7/21/2007,8/17/2007,11/19/2009,11/22/2009,8/2/2010,9/1/2010,10/7/2010,11/29/2010,1/2/2011,2/18/2011,4/16/2011,6/12/2011,1/1/2008,6/29/2008,12/26/2008,6/24/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01221987,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00386,SP00010,A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Frank T,Donovan H,Naren G,Federico L,Tiffiny K,Kala R,Jeanene Y,Quentin N,Gertrudis T,Mary H,Xochitl D,Geralyn K,Rima Y ,Dalton E,James y,Gertrudis T,Anthony P,Gertrudis T,Jeanene Y,,,"GSK Investigational Site, Chiba, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Shizuoka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan",57.87873473,52.09086126,All,"18 Years to 75 Years ¬† (Adult, Older Adult)",416,404,384,181,176,27,6/7/2011,11/12/2011,9/1/2011,10/9/2011,8/30/2011,9/21/2011,9/24/2011,9/25/2011,10/9/2011,3/17/2014,11/26/2013,3/3/2014,7/1/2014,8/4/2014,9/17/2014,11/12/2014,12/31/2014,2/13/2015,3/21/2015,3/19/2012,9/15/2012,3/14/2013,9/10/2013,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01943864,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00429,SP00010,Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Tien C,Suk T,Geralyn K,Selizabeth F,Dalton E,Marcelina X,Harry A,Tiffiny K,Federico L,Naren G,Gertrudis T,Selizabeth F,Mee M,In Bellini †,Mara A,Ngan D,Jerold Goo †,Chetan K,Lavina S,,,"GSK Investigational Site, LaJolla, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Newport Beach, California, United States|GSK Investigational Site, Engelwood, Colorado, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Lakeland, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Hinsdale, Illinois, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Debrecen, Hungary",14.89245829,13.40321246,Female,"18 Years and older ¬† (Adult, Older Adult)",423,404,385,352,4,29,8/25/2002,3/19/2003,1/18/2003,2/7/2003,1/28/2003,1/30/2003,2/9/2003,2/12/2003,3/6/2003,11/1/2007,3/2/2007,10/6/2007,12/1/2007,1/1/2008,2/11/2008,4/2/2008,5/23/2008,7/16/2008,9/3/2008,7/29/2003,1/25/2004,7/23/2004,1/19/2005,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00267488,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00464,SP00010,A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer,,,,,Oncology,,,,,,Industry,Withdrawn,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Stephan T,Frank T,Frank T,Marcelina X,Patria R,Federico L,Selizabeth F,Dinah R,Tamesha T,John G,Tien C,Liberty A,Mac L,Dalton E,Stephan T,Jene M,Doreen T,Xochitl D,Beulah N,,,,20.36146138,18.32531524,All,"Child, Adult, Older Adult",436,423,386,168,191,27,12/17/2010,6/23/2011,4/20/2011,5/22/2011,4/24/2011,5/14/2011,5/20/2011,5/24/2011,6/13/2011,8/15/2013,7/30/2013,2/23/2014,4/1/2014,5/14/2014,6/19/2014,8/14/2014,10/2/2014,11/24/2014,1/3/2015,11/10/2011,5/8/2012,11/4/2012,5/3/2013,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02034097,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00486,SP00010,Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Selizabeth F,Tiffiny K,Otis Thode †,Patria R,Tammara F,Lucie P,Mara A,Ross S,Harry A,Quentin N,Mac L,Suzie K,Livia Pacheo †,In Bellini †,Suzie K,Mary H,Otis Thode †,Suzie K,Chetan K,,,,33.07579725,29.76821752,Female,"18 Years and older ¬† (Adult, Older Adult)",433,415,387,222,137,28,11/2/2001,5/18/2002,2/19/2002,3/31/2002,3/1/2002,3/19/2002,3/27/2002,4/1/2002,4/27/2002,4/2/2005,8/3/2005,11/7/2005,4/1/2006,5/12/2006,7/6/2006,9/3/2006,10/6/2006,11/7/2006,12/28/2006,9/15/2002,3/14/2003,9/10/2003,3/8/2004,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00078572,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00492,SP00010,Study Of Ispinesib In Subjects With Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,John G,Mary H,Geralyn K,Perter K,Dinah R,Marceline R,Perter K,Clarice N,Stephan T,Jene M,Aleta H,Ross S,Ngan D,Selizabeth F,Lucie P,Christian G,Naren G,Donovan H,Suk T,,,"GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Bandar Tun Razak, Cheras, Malaysia|GSK Investigational Site, Bandar Tun Razak, Cheras, Malaysia|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Southampton, Hampshire, United Kingdom|GSK Investigational Site, Manchester, Lancashire, United Kingdom|GSK Investigational Site, Newcastle Upon Tyne, Northumberland, United Kingdom|GSK Investigational Site, London, United Kingdom",2.320021593,2.088019434,All,"18 Years and older ¬† (Adult, Older Adult)",403,399,388,210,152,26,3/3/2003,10/13/2003,7/18/2003,8/30/2003,7/26/2003,8/17/2003,8/28/2003,8/31/2003,9/30/2003,4/8/2006,11/5/2005,7/9/2006,8/25/2006,10/19/2006,11/27/2006,1/7/2007,3/8/2007,5/1/2007,6/5/2007,2/13/2004,8/11/2004,2/7/2005,8/6/2005,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00089973,,,,,,
GlaxoSmithKline,GlaxoSmithKline,ST00515,SP00010,Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Perter K,In Bellini †,Hee Y,Livia Pacheo †,Lucie P,Mara A,Louann C,Mary H,Tamesha T,John G,Ross S,Quentin N,Mee M,Mac L,Otis Thode †,Mara A,In Bellini †,Mary H,Mary H,,,"GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Zion, Illinois, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Campbelltown, New South Wales, Australia|GSK Investigational Site, Liverpool, New South Wales, Australia|GSK Investigational Site, Randwick, New South Wales, Australia|GSK Investigational Site, South Brisbane, Queensland, Australia|GSK Investigational Site, Bedford Park, South Australia, Australia|GSK Investigational Site, Box Hill, Victoria, Australia|GSK Investigational Site, Ringwood East, Victoria, Australia|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Bayonne, France|GSK Investigational Site, Lille Cedex, France|GSK Investigational Site, Paris cedex 13, France|GSK Investigational Site, Ramat Gan, Israel|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Girona, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Sfax, Tunisia|GSK Investigational Site, Sfax, Tunisia|GSK Investigational Site, Tunis, Tunisia|GSK Investigational Site, Tunis, Tunisia|GSK Investigational Site, London, United Kingdom",76.63843023,68.97458721,All,"18 Years and older ¬† (Adult, Older Adult)",401,394,389,141,227,21,4/5/2004,9/18/2004,8/1/2004,8/19/2004,7/26/2004,8/6/2004,8/18/2004,8/19/2004,9/2/2004,5/19/2006,2/24/2006,8/16/2006,11/1/2006,12/17/2006,1/19/2007,2/22/2007,3/31/2007,5/18/2007,6/30/2007,2/2/2005,8/1/2005,1/28/2006,7/27/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00111787,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00009,SP00011,An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin),,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Clarice N,Hee Y,Mee M,Mac L,Geralyn K,Liberty A,Ross S,Remedios Z,Rima Y ,Otis Thode †,Suk T,John G,Garnet T,Stephan T,Louann C,Jeanene Y,Stephan T,Mary H,Mary H,,,"Neuilly-sur-seine, France",1.981607089,1.78344638,All,"18 Years to 65 Years ¬† (Adult, Older Adult)",431,423,390,236,125,29,10/12/2027,4/16/2028,1/25/2028,3/11/2028,2/1/2028,2/20/2028,3/1/2028,8/25/2010,9/4/2010,10/30/2012,8/30/2012,3/14/2013,6/1/2013,7/12/2013,8/25/2013,10/3/2013,11/24/2013,1/9/2014,3/5/2014,8/18/2028,2/14/2029,8/13/2029,2/9/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01200225,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00010,SP00011,A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a),,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Ngan D,Patria R,Anthony P,Kandace p,Ngan D,Xochitl D,Frank T,James y,Jeanene Y,Selizabeth F,Suzie K,Terrell p,Aleta H,Mee M,Suzie K,Beulah N,Remedios Z,Mac L,Naren G,,,"Most, Czech Republic",97.14794909,87.43315418,All,"5 Years to 18 Years ¬† (Child, Adult)",435,427,391,249,102,40,10/29/2027,4/13/2028,1/31/2028,3/4/2028,1/30/2028,2/21/2028,3/2/2028,9/5/2010,9/15/2010,9/11/2013,5/16/2013,9/30/2013,1/1/2014,2/9/2014,3/28/2014,5/15/2014,7/3/2014,8/29/2014,10/2/2014,8/19/2028,2/15/2029,8/14/2029,2/10/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01585324,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00012,SP00011,A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Na√Øve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin),,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Selizabeth F,James y,John G,Naren G,Dinah R,Kandace p,Patria R,Xochitl D,Frank T,Mara A,Mary H,Marcelina X,Anthony P,Frank T,Donovan H,Liberty A,Selizabeth F,Tien C,Clarice N,,,"Salvador, BA, Brazil|Vitoria, ES, Brazil|Juiz de Fora, MG, Brazil|Rio de Janeiro, RJ, Brazil|Rio de Janeiro, RJ, Brazil|Joinville, SC, Brazil|Sao Jose Do Rio Preto, SC, Brazil|Botucatu, SP, Brazil|Campinas, SP, Brazil|Campinas, SP, Brazil|Santos, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sorocaba, SP, Brazil",4.125859691,3.713273722,All,"18 Years and older ¬† (Adult, Older Adult)",441,429,392,256,103,33,10/31/2027,4/4/2028,2/10/2028,3/16/2028,2/2/2028,2/27/2028,3/8/2028,9/12/2009,10/3/2009,12/28/2011,2/1/2012,6/14/2012,11/1/2012,12/4/2012,1/11/2013,3/9/2013,4/10/2013,5/27/2013,6/26/2013,8/25/2028,2/21/2029,8/20/2029,2/16/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01447420,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00013,SP00011,An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Na√Øve Patients With Chronic Hepatitis C Genotype 1,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Ngan D,Naren G,Quentin N,Chetan K,Doreen T,Stephan T,John G,Mee M,Jene M,Frank T,Marcelina X,In Bellini †,Anthony P,Garnet T,Donovan H,Gertrudis T,Dinah R,Lilla Stilson †,Mac L,,,"Bydgoszcz, Poland|Bytom, Poland|Chorzow, Poland|Ciechanow, Poland|Debica, Poland|Katowice, Poland|Koszalin, Poland|Lancut, Poland|Lodz, Poland|Mielec, Poland|Pulawy, Poland|Radom, Poland|Walbrzych, Poland|Warszawa, Poland",92.12577857,82.91320071,All,"18 Years and older ¬† (Adult, Older Adult)",409,397,393,182,190,21,9/16/2027,4/6/2028,2/4/2028,3/12/2028,2/6/2028,2/29/2028,3/10/2028,9/27/2011,10/4/2011,7/5/2014,5/22/2014,9/20/2014,1/1/2015,2/26/2015,4/19/2015,6/2/2015,8/1/2015,9/10/2015,10/30/2015,8/27/2028,2/23/2029,8/22/2029,2/18/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01750216,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00015,SP00011,INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.,,,HIV Infections,,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Lyman W,Doreen T,Jerold Goo †,Christian G,Tiffiny K,Gertrudis T,Gertrudis T,Harry A,Christian G,Ngan D,Dinah R,Lyman W,Selizabeth F,Tamesha T,Marcelina X,Harry A,Tamesha T,Tien C,Corrine U,,,"Aulnay Sous Bois, France|Basse-terre, France|Bordeaux, France|Boulogne, France|Caen, France|Colmar, France|Fort-de-france, France|Garches, France|La Roche Sur Yon, France|Le Kremlin Bic√™tre, France|Levallois Perret, France|Lyon, France|Marseille, France|Nantes, France|Nice, France|Nimes, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Pessac, France|Pointe √Ä Pitre, France|Poitiers, France|Pontoise, France|Rouen, France|Saint Pierre, France|Saint-denis, France|Toulouse, France|Tourcoing, France",15.18988677,13.6708981,All,"40 Years to 65 Years ¬† (Adult, Older Adult)",419,413,394,369,20,5,10/13/2027,4/22/2028,2/16/2028,3/15/2028,2/16/2028,3/3/2028,3/13/2028,9/22/2008,10/17/2008,8/2/2010,10/7/2010,3/3/2011,6/1/2011,7/11/2011,8/27/2011,10/4/2011,11/17/2011,1/6/2012,2/20/2012,8/30/2028,2/26/2029,8/25/2029,2/21/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00615134,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00016,SP00011,An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Terminated,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Perter K,Lilla Stilson †,Mee M,Louann C,Ngan D,Anthony P,Anthony P,Anthony P,Suk T,Christian G,Quentin N,Selizabeth F,James y,James y,Dalton E,Lavina S,John G,Selizabeth F,Lucie P,,,"La Jolla, California, United States|Long Beach, California, United States|Sacramento, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Englewood, Colorado, United States|Bradenton, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Marietta, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|New Orleans, Louisiana, United States|Detroit, Michigan, United States|Kansas City, Missouri, United States|Lebanon, New Hampshire, United States|Hillsborough, New Jersey, United States|Newark, New Jersey, United States|Manhasset, New York, United States|New York, New York, United States|New York, New York, United States|Providence, Rhode Island, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Newport News, Virginia, United States|Richmond, Virginia, United States|Vancouver, Washington, United States|Darlinghurst, New South Wales, Australia|Kingswood, New South Wales, Australia|Sydney, New South Wales, Australia|Westmead, New South Wales, Australia|Greenslopes, Queensland, Australia|Herston, Queensland, Australia|Woolloongabba, Queensland, Australia|Adelaide, South Australia, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Wien, Austria|Salvador, BA, Brazil|Porto Alegre, RS, Brazil|Ribeirao Preto, SP, Brazil|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Vancouver, British Columbia, Canada|Vancouver, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Winnipeg, Manitoba, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Clichy, France|Creteil, France|Lille, France|Marseille, France|Montpellier, France|Montpellier, France|Nice, France|Paris, France|Paris, France|Pessac, France|Rennes, France|Toulouse, France|Vandoeuvre-les-nancy, France|Berlin, Germany|Berlin, Germany|Frankfurt Am Main, Germany|Hamburg, Germany|Hannover, Germany|Muenchen, Germany|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Torino, Piemonte, Italy|Bari, Puglia, Italy|Pisa, Toscana, Italy|Guadalajara, Mexico|Guadalajara, Mexico|Monterrey, Mexico|Christchurch, New Zealand|Dunedin, New Zealand|Grafton, New Zealand|Bydgoszcz, Poland|Chorzow, Poland|Lodz, Poland|Myslowice, Poland|Warszawa, Poland|Warszawa, Poland|Wroc≈Çaw, Poland|≈Åodz, Poland|San Juan, Puerto Rico|Bratislava, Slovakia|Badalona, Barcelona, Spain|Santander, Cantabria, Spain|Palma de Mallorca, Islas Baleares, Spain|La Coruna, La Coru√±a, Spain|La Laguna, Tenerife, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Pontevedra, Spain|Sevilla, Spain|Valencia, Spain|Dorset, United Kingdom|Dundee, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Nottingham, United Kingdom",91.18732329,82.06859096,All,18 Years to 60 Years ¬† (Adult),444,432,395,145,228,22,11/23/2027,4/25/2028,2/21/2028,3/10/2028,3/1/2028,3/5/2028,3/15/2028,3/20/2014,4/6/2014,10/1/2014,7/18/2014,1/27/2015,4/1/2015,5/18/2015,7/4/2015,8/17/2015,10/9/2015,11/16/2015,12/18/2015,9/1/2028,2/28/2029,8/27/2029,2/23/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01168856,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00017,SP00011,"POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).",,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Frank T,Livia Pacheo †,John G,Louann C,Tammara F,Lucie P,Mary H,Suzie K,Terrell p,Aleta H,Terisa Sikora †,John G,Perter K,Mac L,Tammara F,Liberty A,Mary H,Tamesha T,Patria R,,,"Brasilia, DF, Brazil|Vitoria, ES, Brazil|Sao Luis, MA, Brazil|Rio de Janeiro, RJ, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Campinas, SP, Brazil|Campinas, SP, Brazil|Ribeirao Preto, SP, Brazil|Santo Andre, SP, Brazil|Sao Paulo, SP, Brazil|Sorocaba, SP, Brazil",66.71439904,60.04295913,All,"18 Years to 80 Years ¬† (Adult, Older Adult)",423,412,396,218,147,31,9/27/2027,4/13/2028,2/9/2028,3/17/2028,2/14/2028,3/6/2028,3/16/2028,5/6/2008,5/21/2008,3/24/2010,1/12/2010,9/8/2010,11/1/2010,12/15/2010,1/29/2011,3/1/2011,4/27/2011,5/28/2011,7/23/2011,9/2/2028,3/1/2029,8/28/2029,2/24/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00700401,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00023,SP00011,"A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6",,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Terminated,Phase 3,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Marcelina X,Tiffiny K,Terrell p,Dinah R,Otis Thode †,Suzie K,Christian G,Selizabeth F,In Bellini †,Tien C,Mara A,Terrell p,Corrine U,Suk T,Frank T,Kala R,Geralyn K,Dinah R,Livia Pacheo †,,,"Antwerpen, Belgium|Antwerpen, Belgium|Brugge, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Charleroi, Belgium|Edegem, Belgium|Gent, Belgium|Gilly, Belgium|Haine-saint-paul, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liege, Belgium|Namur, Belgium|Roeselare, Belgium|Yvoir, Belgium",2.161315816,1.945184235,All,"50 Years to 75 Years ¬† (Adult, Older Adult)",413,404,397,330,17,50,3/17/2028,8/28/2028,6/10/2028,7/20/2028,6/29/2028,7/6/2028,7/16/2028,3/29/2007,4/10/2007,4/21/2008,8/29/2007,2/26/2008,6/1/2008,7/2/2008,8/18/2008,10/17/2008,12/10/2008,1/26/2009,2/27/2009,1/2/2029,7/1/2029,12/28/2029,6/26/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02791256,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00025,SP00011,An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Tien C,Beulah N,Marceline R,Mara A,Mac L,Kala R,Selizabeth F,Stephan T,Stephan T,Mary H,Selizabeth F,Lucie P,James y,Donovan H,John G,Dinah R,Tien C,Mara A,Louann C,,,"Mhat - Pleven; Clinic of Gastroenterology, Pleven, Bulgaria|Umhat St. Georgi; Clinical of Gastroenterology, Plovdiv, Bulgaria|MHAT Tokuda Hospital Sofia; Department of Gastroenterology at Clinic of Internal Deseases, Sofia, Bulgaria|UMHAT Alexandrovska EAD; Gastroenterology, Sofia, Bulgaria|Mhat Queenjoanna; Clinic of Gastroenterology, Sofia, Bulgaria|Military Medical Academy; Gastroenterology, Sofia, Bulgaria|Mhat St. Ivan Rilski; Clinic of Gastroenterology, Sofia, Bulgaria|Mhat St. Zagora; Clinical of Gastroenterology, Stara Zagora, Bulgaria|Mhat Sveta Marina; Clinic of Gastroenterology, Varna, Bulgaria",3.055435616,2.749892055,All,"18 Years to 80 Years ¬† (Adult, Older Adult)",410,404,398,309,55,34,4/3/2028,8/22/2028,7/16/2028,7/31/2028,7/4/2028,7/22/2028,8/1/2028,11/28/2009,12/9/2009,11/20/2013,12/23/2013,3/18/2014,7/31/2014,9/7/2014,10/26/2014,11/27/2014,1/1/2015,2/23/2015,4/22/2015,1/18/2029,7/17/2029,1/13/2030,7/12/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01392742,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00027,SP00011,A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Rima Y ,Mee M,Frank T,Stephan T,Aleta H,Christian G,Naren G,Tammara F,Ross S,Mara A,Hee Y,Frank T,Lavina S,Jerold Goo †,Mary H,Federico L,Tamesha T,Tien C,Jene M,,,"Mexico City, Mexico",11.32012787,10.18811508,Male,18 Years to 45 Years ¬† (Adult),440,433,399,394,59,54,4/8/2028,9/10/2028,8/2/2028,8/17/2028,8/2/2028,8/9/2028,8/19/2028,9/3/2004,9/14/2004,4/8/2006,9/8/2005,2/17/2006,7/1/2006,8/25/2006,10/23/2006,12/5/2006,1/15/2007,3/1/2007,4/13/2007,2/5/2029,8/4/2029,1/31/2030,7/30/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00475072,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00028,SP00011,PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-na√Øve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Naren G,Patria R,John G,Marcelina X,John G,Hee Y,Clarice N,Ngan D,In Bellini †,Chetan K,Hee Y,Federico L,Mara A,Suzie K,In Bellini †,Mac L,Perter K,Gertrudis T,Louann C,,,"Birmingham, Alabama, United States|Birmingham, Alabama, United States|Birmingham, Alabama, United States|Dothan, Alabama, United States|Fresno, California, United States|La Jolla, California, United States|Lancaster, California, United States|Loma Linda, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Clemente, California, United States|San Diego, California, United States|San Francisco, California, United States|San Mateo, California, United States|Torrance, California, United States|Aurora, Colorado, United States|Hartford, Connecticut, United States|Gainesville, Florida, United States|Maitland, Florida, United States|Orlando, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Macon, Georgia, United States|Marietta, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Lexington, Kentucky, United States|Baton Rouge, Louisiana, United States|New Orleans, Louisiana, United States|Opelousas, Louisiana, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Springfield, Massachusetts, United States|Springfield, Massachusetts, United States|Worcester, Massachusetts, United States|Detroit, Michigan, United States|Grand Rapids, Michigan, United States|Jackson, Mississippi, United States|Tupelo, Mississippi, United States|St Louis, Missouri, United States|St Louis, Missouri, United States|Topeka, Missouri, United States|Lebanon, New Hampshire, United States|Egg Harbour Township, New Jersey, United States|Hackensack, New Jersey, United States|Hillsborough, New Jersey, United States|Roseland, New Jersey, United States|Voorhees, New Jersey, United States|Albuquerque, New Mexico, United States|Bayside, New York, United States|Catskill, New York, United States|Flushing, New York, United States|New York, New York, United States|New York, New York, United States|Poughkeepsie, New York, United States|Syracuse, New York, United States|Asheville, North Carolina, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Fayetteville, North Carolina, United States|Rocky Mount, North Carolina, United States|Winston-salem, North Carolina, United States|Winston-salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Portland, Oregon, United States|Portland, Oregon, United States|Camp Hill, Pennsylvania, United States|DuBois, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Bristol, Tennessee, United States|Chattanooga, Tennessee, United States|Germantown, Tennessee, United States|Kingsport, Tennessee, United States|Nashville, Tennessee, United States|West Nashville, Tennessee, United States|Dallas, Texas, United States|Galveston, Texas, United States|Harlingen, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Fairfax, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Huntington, West Virginia, United States|Casper, Wyoming, United States|Santurce, Puerto Rico",38.73950228,34.86555205,All,"18 Years and older ¬† (Adult, Older Adult)",449,430,400,370,9,21,4/30/2028,9/21/2028,7/27/2028,8/30/2028,7/22/2028,8/13/2028,8/23/2028,2/18/2009,3/20/2009,11/23/2010,10/20/2010,5/31/2011,8/1/2011,9/29/2011,10/30/2011,12/26/2011,2/14/2012,3/24/2012,5/6/2012,2/9/2029,8/8/2029,2/4/2030,8/3/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01066819,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00029,SP00011,PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-na√Øve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a),,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Christian G,Suzie K,Terisa Sikora †,Lilla Stilson †,Marceline R,Livia Pacheo †,Terrell p,Suzie K,Suzie K,Doreen T,Jerold Goo †,Patria R,Tiffiny K,Otis Thode †,Suk T,Otis Thode †,Anthony P,Lyman W,Mary H,,,"Gratwein, Austria|Graz, Austria|Innsbruck, Austria|Linz, Austria|Linz, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Salvador, BA, Brazil|Goiania, GO, Brazil|Belo Horizonte, MG, Brazil|Belem, PA, Brazil|Recife, PE, Brazil|Recife, PE, Brazil|Rio de Janeiro, RJ, Brazil|Rio de Janeiro, RJ, Brazil|Rio de Janeiro, RJ, Brazil|Porto Alegre, RS, Brazil|Rio Grande, RS, Brazil|Botucatu, SP, Brazil|Campinas, SP, Brazil|Campinas, SP, Brazil|Ribeirao Preto, SP, Brazil|Santos, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Kelowna, British Columbia, Canada|Nanaimo, British Columbia, Canada|New Westminster, British Columbia, Canada|Prince George, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Winnipeg, Manitoba, Canada|St John's, Newfoundland and Labrador, Canada|Barrie, Ontario, Canada|Brampton, Ontario, Canada|Etobicoke, Ontario, Canada|Guelph, Ontario, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|North Bay, Ontario, Canada|Oakville, Ontario, Canada|Oshawa, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Scarborough, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Windsor, Ontario, Canada|Levis, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec City, Quebec, Canada|Quebec City, Quebec, Canada|Quebec City, Quebec, Canada|Saint-jean Sur Richelieu, Quebec, Canada|St-charles Borromee, Quebec, Canada|Osijek, Croatia|Pula, Croatia|Split, Croatia|Zadar, Croatia|Zagreb, Croatia|Agen, France|Aix En Provence, France|Albi, France|Amiens, France|Angers, France|Annecy, France|Antibes, France|Argenteuil, France|Argenteuil, France|Aulnay Sous Bois, France|Aulnay Sous Bois, France|Bastia, France|Beaumont, France|Beausoleil, France|Beauvais, France|Besancon, France|Besancon, France|Beziers, France|Beziers, France|Bordeaux, France|Bordeaux, France|Boulogne Billancourt, France|Bourgoin Jallieu, France|Caen, France|Chambery, France|Clermont Ferrand, France|Clichy, France|Colmar, France|Cornebarrieu, France|Creil, France|Creteil, France|Creteil, France|Dijon, France|Dijon, France|Druex, France|Evreux, France|Frejus, France|Freyming Merlebach, France|Grasse, France|Grenoble, France|Herouville St Clair, France|Hyeres, France|La Rochelle, France|La Valette du Var, France|Lagny Sur Marne, France|Le Chesnay, France|Le Havre, France|Le Kremlin Bicetre, France|Lille, France|Limoges, France|Lomme, France|Lorient, France|Lyon, France|Lyon, France|Lyon, France|Marseille, France|Marseille, France|Marseille, France|Marseille, France|Marseille, France|Martigues, France|Meaux, France|Melun, France|Menton, France|Metz, France|Metz, France|Monaco, France|Montauban, France|Montpellier, France|Montpellier, France|Mulhouse, France|Muret, France|Nanterre, France|Nantes, France|Nantes, France|Nice, France|Nice, France|Nimes, France|Nimes, France|Ollioules, France|Orange, France|Orleans, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Perigueux, France|Perpignan, France|Pessac, France|Poissy, France|Poitiers, France|Pont a Mousson, France|Reims, France|Rennes, France|Rouen, France|Saint Laurent Du Var, France|Sete, France|St Dizier, France|St Jean De Verges, France|St Mande, France|Ste Maxime, France|Strasbourg, France|Tarbes, France|Toulon, France|Toulouse, France|Toulouse, France|Toulouse, France|Toulouse, France|Tourcoing, France|Valenciennes, France|Vandoeuvre-les-nancy, France|Villejuif, France|Ajka, Hungary|Bekescsaba, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Debrecen, Hungary|Eger, Hungary|Gyor, Hungary|Gyula, Hungary|Kaposvar, Hungary|Kecskemet, Hungary|Kistarcsa, Hungary|Miskolc, Hungary|Miskolc, Hungary|Ny√≠regyh√°za, Hungary|Pecs, Hungary|Pecs, Hungary|Szeged, Hungary|Szekszard, Hungary|Szolnok, Hungary|Szombathely, Hungary|Sz√©kesfeh√©rv√°r, Hungary|Tatab√°nya, Hungary|Zalaegerszeg, Hungary|Zalaegerszeg, Hungary|Skopje, Macedonia, The Former Yugoslav Republic of|Chihuahua, Mexico|Chihuahua, Mexico|Culiacan, Mexico|Guadalajara, Mexico|Hermosillo, Mexico|Mexicali, Mexico|Mexico City, Mexico|Mexico DF, Mexico|Monterrey, Mexico|Puebla, Mexico|Puebla, Mexico|Casablanca, Morocco|Casablanca, Morocco|Rabat, Morocco|Bydgoszcz, Poland|Lodz, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Arad, Romania|Brasov, Romania|Brasov, Romania|Brasov, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Cluj Napoca, Romania|Cluj-napoca, Romania|Constanta, Romania|Constanta, Romania|Constanta, Romania|Iasi, Romania|Iasi, Romania|Sector 2, Romania|Targu-Mures, Romania|Timisoara, Romania|Timisoara, Romania|Belgrade, Serbia|NIS, Serbia|Novi Sad, Serbia|Celje, Slovenia|Ljubljana, Slovenia|Maribor, Slovenia|Novo Mesto, Slovenia|Eskilstuna, Sweden|Halmstad, Sweden|Huddinge, Sweden|Linkoeping, Sweden|Lund, Sweden|Oerebro, Sweden",39.56800195,35.61120176,All,19 Years to 44 Years ¬† (Adult),425,413,401,153,228,20,4/23/2028,9/18/2028,8/4/2028,8/29/2028,8/7/2028,8/15/2028,8/25/2028,8/9/2009,8/20/2009,7/21/2010,9/5/2010,3/11/2011,7/1/2011,8/23/2011,10/2/2011,11/25/2011,1/5/2012,2/7/2012,3/27/2012,2/11/2029,8/10/2029,2/6/2030,8/5/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01070550,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00030,SP00011,PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-na√Øve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Dinah R,Aleta H,Perter K,Remedios Z,Federico L,Terisa Sikora †,Mara A,Selizabeth F,Terisa Sikora †,Tien C,Naren G,Lyman W,Gertrudis T,Clarice N,Stephan T,Dinah R,John G,Frank T,Marcelina X,,,"Aalst, Belgium|Antwerpen, Belgium|Antwerpen, Belgium|Brugge, Belgium|Brussels, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Charleroi, Belgium|Edegem, Belgium|Genk, Belgium|Gent, Belgium|Gilly (Charleroi), Belgium|Godinne, Belgium|Haine-Saint-Paul, Belgium|Kortrijk, Belgium|Leuven, Belgium|Li√®ge, Belgium|Namur, Belgium|Oostende, Belgium|Roeselare, Belgium|Seraing, Belgium|Sijsele, Belgium|Tielt, Belgium|Verviers, Belgium|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Pescara, Abruzzo, Italy|Catanzaro, Calabria, Italy|Vibo Valentia, Calabria, Italy|Barra, Campania, Italy|Benevento, Campania, Italy|Gragnano, Campania, Italy|Napoli, Campania, Italy|Napoli, Campania, Italy|Napoli, Campania, Italy|Napoli, Campania, Italy|Napoli, Campania, Italy|Napoli, Campania, Italy|Napoli, Campania, Italy|Nola, Campania, Italy|Bologna, Emilia-Romagna, Italy|Ferrara, Emilia-Romagna, Italy|Parma, Emilia-Romagna, Italy|Basovizza (TS), Friuli-Venezia Giulia, Italy|Udine, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Savona, Liguria, Italy|Brescia, Lombardia, Italy|Busto Arsizio, Lombardia, Italy|Cremona, Lombardia, Italy|Lecco, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Monza, Lombardia, Italy|Saronno, Lombardia, Italy|Treviglio, Lombardia, Italy|Fermo, Marche, Italy|Isernia, Molise, Italy|Alessandria, Piemonte, Italy|Asti, Piemonte, Italy|Biella, Piemonte, Italy|Novara, Piemonte, Italy|Torino, Piemonte, Italy|Torino, Piemonte, Italy|Bisceglie, Puglia, Italy|Brindisi, Puglia, Italy|Casarano, Puglia, Italy|Castellana Grotte, Puglia, Italy|Foggia, Puglia, Italy|Galatina, Puglia, Italy|Taranto, Puglia, Italy|Cagliari, Sardegna, Italy|Catania, Sicilia, Italy|Comiso, Sicilia, Italy|Palermo, Sicilia, Italy|Arezzo, Toscana, Italy|Firenze, Toscana, Italy|Grosseto, Toscana, Italy|Bolzano, Trentino-Alto Adige, Italy|Trento, Trentino-Alto Adige, Italy|Perugia, Umbria, Italy|Mestre (VE), Veneto, Italy|Padova, Veneto, Italy|Treviso, Veneto, Italy|Venezia, Veneto, Italy|Verona, Veneto, Italy|London, United Kingdom",46.818465,42.1366185,All,"18 Years to 70 Years ¬† (Adult, Older Adult)",425,417,402,318,33,51,3/30/2028,10/11/2028,8/3/2028,9/1/2028,7/25/2028,8/16/2028,8/26/2028,3/2/2006,3/30/2006,9/25/2010,6/3/2010,10/10/2010,3/1/2011,4/3/2011,5/24/2011,7/23/2011,8/29/2011,9/29/2011,11/8/2011,2/12/2029,8/11/2029,2/7/2030,8/6/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01066793,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00031,SP00011,An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a),,,"Hepatitis D, Chronic",,Virology,,,,,,Industry,Terminated,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Jaquelyn H,Geralyn K,Liberty A,Mee M,Xochitl D,Geralyn K,Ngan D,Remedios Z,Anthony P,Lyman W,Louann C,Terrell p,Marceline R,Dalton E,Harry A,Stephan T,Otis Thode †,Naren G,Marceline R,,,"Bucharest, Romania",22.4744589,20.22701301,All,"Child, Adult, Older Adult",454,436,403,156,229,18,2/19/2028,9/16/2028,7/29/2028,8/25/2028,7/29/2028,8/17/2028,8/27/2028,5/15/2013,6/1/2013,9/25/2014,7/27/2014,10/8/2014,3/1/2015,4/17/2015,6/16/2015,7/20/2015,9/16/2015,10/30/2015,12/29/2015,2/13/2029,8/12/2029,2/8/2030,8/7/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01861444,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00034,SP00011,"Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection",,,HIV Infections,,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Chetan K,Gertrudis T,Lucie P,Mee M,Liberty A,Ross S,Otis Thode †,Mee M,John G,Xochitl D,Jaquelyn H,Federico L,Frank T,Tien C,Ngan D,Harry A,Dinah R,Anthony P,Terisa Sikora †,,,"Aix En Provence, France|Angers, France|Annecy, France|Argenteuil, France|Auch, France|Aulnay Sous Bois, France|Avignon, France|Basse-terre, France|Besancon, France|Bobigny, France|Bordeaux, France|Bordeaux, France|Boulogne, France|Bourg En Bresse, France|Caen, France|Carpentras, France|Cayenne, France|Cayenne, France|Colmar, France|Corbeil-essonnes, France|Creteil, France|Fort-de-france, France|Garches, France|Kourou, France|La Roche Sur Yon, France|Lagny-sur-marne, France|Levallois Perret, France|Lyon, France|Lyon, France|Macon, France|Mantes La Jolie, France|Marseille, France|Marseille, France|Marseille, France|Marseille, France|Matoury, France|Montpellier, France|Nantes, France|Nice, France|Nimes, France|Niort, France|Orleans, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|PAU, France|Perpignan, France|Pessac, France|Pointe √Ä Pitre, France|Pontoise, France|Quimper, France|Rennes, France|Rouen, France|Saint Pierre, France|Saint-denis, France|Saint-denis, France|Saint-dizier, France|Strasbourg, France|Suresnes, France|Toulon, France|Toulouse, France|Toulouse, France|Tours, France|Valenciennes, France|Vandoeuvre-les-nancy, France|Villejuif, France",19.56065761,17.60459184,All,"18 Years and older ¬† (Adult, Older Adult)",427,421,404,144,244,16,4/13/2028,10/18/2028,7/31/2028,9/12/2028,8/8/2028,8/29/2028,9/8/2028,5/17/2006,5/31/2006,7/4/2007,7/27/2007,11/20/2007,3/1/2008,4/4/2008,5/18/2008,6/30/2008,8/27/2008,10/3/2008,11/28/2008,2/25/2029,8/24/2029,2/20/2030,8/19/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02733419,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00035,SP00011,A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Frank T,Anthony P,Kala R,Quentin N,Donovan H,Jeanene Y,Mary H,Patria R,Mary H,Lilla Stilson †,Marceline R,John G,Corrine U,Ross S,Marcelina X,Perter K,Suzie K,John G,Kala R,,,"La Jolla, California, United States|Long Beach, California, United States|Sacramento, California, United States|San Diego, California, United States|Aurora, Colorado, United States|Orlando, Florida, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|New Orleans, Louisiana, United States|Detroit, Michigan, United States|Manhasset, New York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Medford, Oregon, United States|Providence, Rhode Island, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Darlinghurst, New South Wales, Australia|Kingswood, New South Wales, Australia|Westmead, New South Wales, Australia|Adelaide, South Australia, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Wien, Austria|Porto Alegre, RS, Brazil|Ribeirao Preto, SP, Brazil|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Vancouver, British Columbia, Canada|Vancouver, British Columbia, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|La Tronche, France|Paris, France|Paris, France|Pessac, France|Vandoeuvre-les-nancy, France|Berlin, Germany|Essen, Germany|Kiel, Germany|T√ºbingen, Germany|Napoli, Campania, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Pisa, Toscana, Italy|Guadalajara, Mexico|Guadalajara, Mexico|Bydgoszcz, Poland|Czeladz, Poland|Kielce, Poland|Warszawa, Poland|≈Åodz, Poland|San Juan, Puerto Rico|Badalona, Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Sevilla, Spain|Birmingham, United Kingdom|Dundee, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom",75.36294701,67.82665231,All,"8 Years and older ¬† (Child, Adult, Older Adult)",461,445,405,123,265,17,4/28/2028,10/9/2028,8/11/2028,9/8/2028,8/24/2028,8/30/2028,9/9/2028,5/27/2009,6/21/2009,9/20/2012,4/12/2012,8/25/2012,1/1/2013,3/2/2013,4/20/2013,6/14/2013,7/30/2013,8/30/2013,9/30/2013,2/26/2029,8/25/2029,2/21/2030,8/20/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01331850,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00037,SP00011,"A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C",,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Perter K,Lilla Stilson †,Terisa Sikora †,Ross S,Liberty A,Lyman W,Jaquelyn H,Stephan T,James y,Naren G,Mee M,Frank T,Kala R,Chetan K,Perter K,Garnet T,Suzie K,Selizabeth F,Livia Pacheo †,,,"Graz, Austria|Innsbruck, Austria|Linz, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Dortmund, Germany|Frankfurt am Main, Germany|Hamburg, Germany|Hannover, Germany|Oberhausen, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Kaposvar, Hungary|Pecs, Hungary|Bialystok, Poland|Bydgoszcz, Poland|Chorzow, Poland|Lublin, Poland|Wroc≈Çaw, Poland|≈Åodz, Poland|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Constanta, Romania|Timisoara, Romania|Vigo, Pontevedra, Spain|Baracaldo, Vizcaya, Spain|Granada, Spain|Zaragoza, Spain",28.11060073,25.29954066,All,"19 Years and older ¬† (Adult, Older Adult)",429,413,406,351,4,51,5/30/2028,11/2/2028,8/21/2028,9/23/2028,8/21/2028,9/5/2028,9/15/2028,9/19/2010,10/11/2010,10/13/2013,9/15/2013,4/12/2014,6/1/2014,7/3/2014,8/16/2014,9/29/2014,11/21/2014,1/16/2015,2/20/2015,3/4/2029,8/31/2029,2/27/2030,8/26/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01591460,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00041,SP00011,ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Ngan D,Mary H,Ngan D,Jaquelyn H,Rima Y ,Lavina S,Selizabeth F,John G,Beulah N,Tien C,Jeanene Y,Selizabeth F,John G,Aleta H,Mara A,Lavina S,Naren G,Frank T,John G,,,"Birmingham, Alabama, United States|Mobile, Alabama, United States|Anchorage, Alaska, United States|Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Little Rock, Arkansas, United States|La Jolla, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Palo Alto, California, United States|Sacramento, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|San Francisco, California, United States|San Francisco, California, United States|San Luis Obispo, California, United States|Littleton, Colorado, United States|Farmington, Connecticut, United States|Bradenton, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pensacola, Florida, United States|Tampa, Florida, United States|Wellington, Florida, United States|Atlanta, Georgia, United States|Austell, Georgia, United States|Honolulu, Hawaii, United States|Boise, Idaho, United States|Moline, Illinois, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Iowa City, Iowa, United States|Baton Rouge, Louisiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Burlington, Massachusetts, United States|Worcester, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Plymouth, Minnesota, United States|St Louis, Missouri, United States|Albuquerque, New Mexico, United States|Bayside, New York, United States|Binghamton, New York, United States|Bronx, New York, United States|Manhasset, New York, United States|New York, New York, United States|New York, New York, United States|Williamsville, New York, United States|Chapel Hill, North Carolina, United States|Durham, North Carolina, United States|Fayetteville, North Carolina, United States|Statesville, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Hershey, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Cranston, Rhode Island, United States|Providence, Rhode Island, United States|Germantown, Tennessee, United States|Dallas, Texas, United States|Dallas, Texas, United States|Fort Sam Houston, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|White River Junction, Vermont, United States|Charlottesville, Virginia, United States|Chesapeake, Virginia, United States|Falls Church, Virginia, United States|Richmond, Virginia, United States|Bellevue, Washington, United States|Kirkland, Washington, United States|Puyallup, Washington, United States|Seattle, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States|Madison, Wisconsin, United States|Cheyenne, Wyoming, United States|Adelaide, Australia|Brisbane, Australia|Kingswood, Australia|Melbourne, Australia|Woolloongabba, Australia|Edmonton, Alberta, Canada|Downsview, Ontario, Canada|Mississauga, Ontario, Canada|Clichy, France|Creteil, France|La Tronche, France|Marseille, France|Nice, France|Rennes, France|Strasbourg, France|Toulouse, France|Vandoeuvre-les-nancy, France|Berlin, Germany|D√ºsseldorf, Germany|Freiburg, Germany|Hannover, Germany|Homburg/saar, Germany|Kiel, Germany|Bergamo, Italy|Bologna, Italy|Milano, Italy|Napoli, Italy|Pavia, Italy|Pisa, Italy|Otahuhu, New Zealand|Ponce, Puerto Rico|San Juan, Puerto Rico|San Juan, Puerto Rico|Santurce, Puerto Rico|Badalona, Spain|Barakaldo, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Sevilla, Spain|Valencia, Spain",93.21343844,83.8920946,All,"18 Years to 90 Years ¬† (Adult, Older Adult)",418,413,407,164,213,30,5/2/2028,11/24/2028,9/19/2028,10/12/2028,9/13/2028,9/29/2028,10/9/2028,11/17/2002,12/3/2002,8/31/2005,5/5/2005,11/25/2005,3/1/2006,4/10/2006,6/8/2006,7/18/2006,9/11/2006,10/27/2006,12/17/2006,3/28/2029,9/24/2029,3/23/2030,9/19/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00077636,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00043,SP00011,REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Frank T,Dalton E,Mee M,Marcelina X,Mac L,John G,Anthony P,Beulah N,Chetan K,Lyman W,Suzie K,Aleta H,Chetan K,Chetan K,Beulah N,Jerold Goo †,Federico L,Kandace p,Naren G,,,"Mobile, Alabama, United States|Scottsdale, Arizona, United States|Los Angeles, California, United States|Pasadena, California, United States|San Diego, California, United States|Ukiah, California, United States|Farmington, Connecticut, United States|Bradenton, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Savannah, Georgia, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Des Moines, Iowa, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Kansas City, Missouri, United States|St Louis, Missouri, United States|Florham Park, New Jersey, United States|Albuquerque, New Mexico, United States|Williamsville, New York, United States|Lancaster, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Cranston, Rhode Island, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Richmond, Virginia, United States|Bruxelles, Belgium|Gent, Belgium|Leuven, Belgium|Rio de Janeiro, Brazil|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Clichy, France|Creteil, France|Lille, France|Lyon, France|Marseille, France|Montpellier, France|Paris, France|Pessac, France|Toulouse, France|Berlin, Germany|Bochum, Germany|Bonn, Germany|D√ºsseldorf, Germany|D√ºsseldorf, Germany|Erlangen, Germany|Frankfurt Am Main, Germany|Freiburg, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Homburg/saar, Germany|Kassel, Germany|Kiel, Germany|K√∂ln, Germany|Mainz, Germany|Muenchen, Germany|Oberhausen, Germany|Wuerzburg, Germany|Alexandroupolis, Greece|Athens, Greece|Athens, Greece|Thessaloniki, Greece|Bari, Italy|Bologna, Italy|Milano, Italy|Padova, Italy|Palermo, Italy|Roma, Italy|Torino, Italy|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Alicante, Spain|Barcelona, Spain|Granada, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|M√°laga, Spain|Santander, Spain|Sevilla, Spain|Valencia, Spain|Goeteborg, Sweden|Huddinge, Sweden|Lund, Sweden|Z√ºrich, Switzerland|Ankara, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Birmingham, United Kingdom",78.34815966,70.5133437,All,"20 Years to 65 Years ¬† (Adult, Older Adult)",444,438,408,179,196,33,6/9/2028,11/28/2028,9/22/2028,10/23/2028,9/26/2028,10/8/2028,10/18/2028,11/10/2003,12/3/2003,7/16/2007,7/26/2007,12/19/2007,5/1/2008,6/30/2008,8/29/2008,9/30/2008,11/25/2008,12/26/2008,1/29/2009,4/6/2029,10/3/2029,4/1/2030,9/28/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00087646,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00045,SP00011,A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Mara A,Perter K,Anthony P,Naren G,Lucie P,Mary H,John G,Mary H,Suk T,Harry A,Beulah N,Mary H,Ross S,Garnet T,Suk T,Marceline R,Patria R,Suk T,,,"Phoenix, Arizona, United States|Long Beach, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Diego, California, United States|San Diego, California, United States|Aurora, Colorado, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Orlando, Florida, United States|Lombard, Illinois, United States|New Orleans, Louisiana, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Manhasset, New York, United States|New York, New York, United States|Asheville, North Carolina, United States|Chapel Hill, North Carolina, United States|Medford, Oregon, United States|Lancaster, Pennsylvania, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Vancouver, Washington, United States|Milwaukee, Wisconsin, United States|Kingswood, New South Wales, Australia|Adelaide, South Australia, Australia|Heidelberg, Victoria, Australia|Wien, Austria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Clichy, France|Marseille, France|Montpellier, France|Paris, France|Frankfurt Am Main, Germany|Hamburg, Germany|Napoli, Campania, Italy",40.11992619,36.10793357,All,"18 Years and older ¬† (Adult, Older Adult)",433,418,409,182,197,30,5/5/2028,11/16/2028,9/28/2028,11/2/2028,10/7/2028,10/13/2028,10/23/2028,12/23/2010,1/11/2011,11/22/2011,4/5/2011,8/30/2011,1/1/2012,2/13/2012,3/28/2012,5/9/2012,7/6/2012,8/8/2012,9/20/2012,4/11/2029,10/8/2029,4/6/2030,10/3/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00963885,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00046,SP00011,"A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4",,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Kandace p,Beulah N,Suk T,Anthony P,Mara A,Otis Thode †,Jeanene Y,Suk T,Mara A,Mara A,Mara A,Mara A,Liberty A,Chetan K,Lilla Stilson †,Tamesha T,Selizabeth F,Livia Pacheo †,Mara A,,,"Birmingham, Alabama, United States|La Jolla, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|Washington, District of Columbia, United States|Bradenton, Florida, United States|Gainesville, Florida, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Lutherville, Maryland, United States|Kansas City, Missouri, United States|Newark, New Jersey, United States|New York, New York, United States|Hershey, Pennsylvania, United States|Providence, Rhode Island, United States|Columbia, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Sydney, New South Wales, Australia|Greenslopes, Queensland, Australia|Herston, Queensland, Australia|Woolloongabba, Queensland, Australia|Fitzroy, Victoria, Australia|Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Perth, Western Australia, Australia|Wien, Austria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Vancouver, British Columbia, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Creteil, France|La Tronche, France|Lille, France|Nice, France|Paris, France|Paris, France|Pessac, France|Vandoeuvre-les-nancy, France|Berlin, Germany|Frankfurt Am Main, Germany|Freiburg, Germany|Hannover, Germany|Muenchen, Germany|Ulm, Germany|Bologna, Emilia-Romagna, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Pisa, Toscana, Italy|Santurce, Puerto Rico|Badalona, Barcelona, Spain|La Coruna, La Coru√±a, Spain|Barcelona, Spain|Barcelona, Spain|Granada, Spain|Madrid, Spain|Sevilla, Spain|Valencia, Spain|London, United Kingdom|London, United Kingdom",11.32123085,10.18910777,All,"18 Years and older ¬† (Adult, Older Adult)",449,431,410,255,115,40,7/2/2028,11/14/2028,9/16/2028,10/28/2028,9/22/2028,10/14/2028,10/24/2028,3/2/2010,3/11/2010,2/26/2011,4/26/2011,11/2/2011,2/1/2012,3/18/2012,4/17/2012,6/15/2012,8/2/2012,9/5/2012,10/23/2012,4/12/2029,10/9/2029,4/7/2030,10/4/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00869661,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00047,SP00011,A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Otis Thode †,Jene M,Chetan K,Dalton E,Harry A,Terisa Sikora †,Federico L,John G,Corrine U,Aleta H,Aleta H,Donovan H,Garnet T,Anthony P,Mac L,Quentin N,Lavina S,Lucie P,Clarice N,,,"Birmingham, Alabama, United States|La Jolla, California, United States|Lancaster, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Sacramento, California, United States|Sacramento, California, United States|San Diego, California, United States|Torrance, California, United States|Aurora, Colorado, United States|Jacksonville, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Marietta, Georgia, United States|Honolulu, Hawaii, United States|Baton Rouge, Louisiana, United States|Opelousas, Louisiana, United States|Boston, Massachusetts, United States|Tupelo, Mississippi, United States|St Louis, Missouri, United States|St Louis, Missouri, United States|Egg Harbour Township, New Jersey, United States|Hackensack, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Syracuse, New York, United States|Asheville, North Carolina, United States|Chapel Hill, North Carolina, United States|Winston-salem, North Carolina, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Kingsport, Tennessee, United States|Fort Sam Houston, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Fairfax, Virginia, United States|Richmond, Virginia, United States|Darlinghurst, Australia|Fremantle, Australia|Melbourne, Australia|Nedlands, Australia|Sydney, Australia|Graz, Austria|Innsbruck, Austria|Linz, Austria|Oberndorf, Austria|Wien, Austria|Wien, Austria|Antwerpen, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Gent, Belgium|Kortrijk, Belgium|Liege, Belgium|Brasilia, Brazil|Campinas, Brazil|Campinas, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Ribeirao Preto, Brazil|Rio de Janeiro, Brazil|Santo Andre, Brazil|Sao Luis, Brazil|Sao Paulo, Brazil|Sorocaba, Brazil|Vitoria, Brazil|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Hamilton, Ontario, Canada|Mississauga, Ontario, Canada|Berlin, Germany|Berlin, Germany|Bonn, Germany|D√ºsseldorf, Germany|D√ºsseldorf, Germany|Frankfurt Am Main, Germany|Freiburg, Germany|Giessen, Germany|Hamburg, Germany|Heidelberg, Germany|Jena, Germany|Kiel, Germany|K√∂ln, Germany|Mainz, Germany|M√ºnchen, Germany|Offenburg, Germany|T√ºbingen, Germany|ULM, Germany|Guadalajara, Mexico|Guadalajara, Mexico|Mexicali, Mexico|Mexico City, Mexico|Mexico Df, Mexico|Puebla, Mexico|Santurce, Puerto Rico|Lausanne, Switzerland|Lugano, Switzerland|St. Gallen, Switzerland|Z√ºrich, Switzerland",51.83272556,46.64945301,All,"18 Years and older ¬† (Adult, Older Adult)",441,427,411,189,196,26,6/2/2028,12/14/2028,9/23/2028,10/23/2028,9/23/2028,10/15/2028,10/25/2028,9/27/2007,10/20/2007,12/11/2011,7/25/2011,3/3/2012,5/1/2012,5/31/2012,7/16/2012,9/5/2012,10/13/2012,12/1/2012,1/23/2013,4/13/2029,10/10/2029,4/8/2030,10/5/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00623428,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00048,SP00011,A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug A,,,,,,,,,,,,,,,,,,,Donovan H,Chetan K,John G,Jene M,Gertrudis T,Dinah R,Ross S,John G,Beulah N,James y,Tien C,Donovan H,Lucie P,Stephan T,Remedios Z,Perter K,Mary H,Tien C,Tamesha T,,,"Littleton, Colorado, United States|Chicago, Illinois, United States|Shreveport, Louisiana, United States|Detroit, Michigan, United States|Kansas City, Missouri, United States|San Antonio, Texas, United States|Chesapeake, Virginia, United States|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|London, Ontario, Canada|Creteil, France|Nice, France|Rennes, France|Berlin, Germany|Hamburg, Germany|Hannover, Germany|Napoli, Campania, Italy|Milano, Lombardia, Italy|Firenze, Toscana, Italy|Ponce, Puerto Rico|Santander, Cantabria, Spain|Palma de Mallorca, Islas Baleares, Spain|Pontevedra, Spain|Valencia, Spain",55.49064468,49.94158021,All,up to 10 Years ¬† (Child),425,418,412,242,124,46,5/14/2028,11/17/2028,10/6/2028,10/23/2028,9/22/2028,10/16/2028,10/26/2028,11/19/2010,12/15/2010,7/15/2013,5/11/2013,8/9/2013,1/1/2014,2/22/2014,4/21/2014,6/3/2014,7/31/2014,9/21/2014,11/4/2014,4/14/2029,10/11/2029,4/9/2030,10/6/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01482403,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00049,SP00011,A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C,,,Hepatitis C,,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Lucie P,Rima Y ,Perter K,Marcelina X,Lucie P,Lyman W,Anthony P,Tamesha T,Remedios Z,Marcelina X,Perter K,Mary H,Dinah R,In Bellini †,Chetan K,Suzie K,Livia Pacheo †,John G,Mee M,,,"Birmingham Gastro Associates, P.C., Birmingham, Alabama, United States|VA Long Beach Healthcare System, Long Beach, California, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States|UCSD Antiviral Research Center, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|Gastroenterology Group of Naples, Naples, Florida, United States|John Hopkins Hospital, Lutherville, Maryland, United States|Metrowest Medical Center, Framingham, Massachusetts, United States|Saint Louis University Gastroenterology & Hepatology; Clinical Research Unit, Saint Louis, Missouri, United States|Weill Cornell Medical College, New York, New York, United States|Carolina'S Center For Liver Disease, Statesville, North Carolina, United States|Uni of Cincinnati College of Medicine; Div. of Digestive Diseases, Cincinnati, Ohio, United States|Baylor Uni Medical Center; Division Of Hepatology/Transplantation; Annette C. and Harold C. Simmons, Dallas, Texas, United States|McGuire; Veteran Affairs Med Ctr, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Gordon & Leslie Diamond Health Care Centre; Dept. of Medicine - Division of Gastroenterology, Vancouver, British Columbia, Canada|GI Research Institute; Gastroenterology & Hepatology, Vancouver, British Columbia, Canada|Percuro Clinical Research Ltd., Victoria, British Columbia, Canada|Winnipeg Regional Health Authority; Section of Hepatology, Winnipeg, Manitoba, Canada|University Health Network - Toronto Western Hospital; Hepatology, Toronto, Ontario, Canada|Toronto Digest. Disease Asso., Woodbridge, Ontario, Canada|McGill University, Montreal Chest Institute; Viral and other Infectious, Montreal, Quebec, Canada|Hopital Claude Huriez;Gastro Enterologie, Lille, France|Fondation Hopital Saint Joseph; Gastro-Enterologie, Marseille, France|Hopital Purpan;Gastro Enterologie Hepatologie, Toulouse, France|Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I, Frankfurt Am Main, Germany|Uniklinik Freiburg; Abteilung Innere Medizin II, Freiburg, Germany|Universit√§ts Klinikum; Schleswig-Holstein Kiel, Kiel, Germany|UNI DEGLI STUDI - POLICLINICA S. ORSOLA; Dipartimento Malattie dell'Apparato Digerente e Medicina In, Bologna, Emilia-Romagna, Italy|ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA; Divisione Malattie Infettive, Milano, Lombardia, Italy|Ospedale Cisanello - Az. Osp. Pisana; Unit√† Operativa Di Gastroenterologia Ed Epatologia, Pisa, Toscana, Italy|Hospital Universitario de Canarias; Servicio de Digestivo, La Laguna, Tenerife, Spain|Hospital Universitari Vall d'Hebron; Departamento de Enfermedades Infecciosas, Barcelona, Spain|Hospital Clinic I Provincial; Servicio de Digestivo, Barcelona, Spain|Hospital Carlos III; Laboratorio de Biologia Molecular, Madrid, Spain|Royal Bournemouth Hospital, Gastroenterology, Dorset, United Kingdom|King'S College Hospital; Institute of Liver Studies, London, United Kingdom|St George's Hospital, London, United Kingdom|Imperial College Healthcare NHS Trust; Hepatology Clinical Research Facility, London, United Kingdom",51.47306678,46.3257601,All,"18 Years and older ¬† (Adult, Older Adult)",446,429,413,184,209,20,6/8/2028,11/16/2028,9/18/2028,10/26/2028,9/23/2028,10/17/2028,10/27/2028,8/31/2011,9/23/2011,7/31/2013,5/17/2013,9/11/2013,1/31/2014,3/30/2014,5/17/2014,7/16/2014,8/17/2014,10/16/2014,11/23/2014,4/15/2029,10/12/2029,4/10/2030,10/7/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01482390,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00050,SP00011,A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Mary H,Kandace p,John G,Ross S,Mara A,Marceline R,Ross S,Mary H,Marcelina X,Lavina S,Marcelina X,James y,In Bellini †,Perter K,John G,Naren G,Quentin N,Lavina S,Lucie P,,,"Phoenix, Arizona, United States|La Jolla, California, United States|Long Beach, California, United States|Sacramento, California, United States|San Diego, California, United States|San Diego, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Englewood, Colorado, United States|Bradenton, Florida, United States|Gainesville, Florida, United States|Miami, Florida, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Plymouth, Minnesota, United States|Bronx, New York, United States|Manhasset, New York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Hershey, Pennsylvania, United States|Providence, Rhode Island, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Fort Sam Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Fairfax, Virginia, United States|Richmond, Virginia, United States|Adelaide, Australia|Greenslopes, Australia|Melbourne, Australia|Sydney, Australia|Sydney, Australia|Wien, Austria|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Vancouver, British Columbia, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Clichy, France|Creteil, France|Marseille, France|Paris, France|Paris, France|Pessac, France|Vandoeuvre-les-nancy, France|Berlin, Germany|Frankfurt Am Main, Germany|Freiburg, Germany|Hamburg, Germany|Hannover, Germany|K√∂ln, Germany|Bologna, Italy|Napoli, Italy|Torino, Italy|Santurce, Puerto Rico|Badalona, Spain|Barcelona, Spain|Madrid, Spain|Sevilla, Spain|Valencia, Spain",8.866707579,7.980036821,All,"18 Years and older ¬† (Adult, Older Adult)",442,421,414,345,30,39,7/4/2028,11/23/2028,10/17/2028,11/5/2028,10/9/2028,10/24/2028,11/3/2028,5/15/2008,5/22/2008,11/5/2009,3/14/2009,11/25/2009,1/1/2010,2/21/2010,4/7/2010,5/27/2010,7/13/2010,9/11/2010,10/17/2010,4/22/2029,10/19/2029,4/17/2030,10/14/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00517439,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00053,SP00011,A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 4,Interventional,,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Harry A,Doreen T,Federico L,Frank T,John G,Clarice N,Marcelina X,Chetan K,Chetan K,Hee Y,Federico L,Federico L,Livia Pacheo †,Mac L,Lyman W,Jaquelyn H,Gertrudis T,Clarice N,Suzie K,,,"Birmingham, Alabama, United States|Huntsville, Alabama, United States|Anchorage, Alaska, United States|Phoenix, Arizona, United States|Fresno, California, United States|La Jolla, California, United States|Lancaster, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|San Luis Obispo, California, United States|San Marcos, California, United States|Ventura, California, United States|Aurora, Colorado, United States|Englewood, Colorado, United States|Washington, District of Columbia, United States|Washington, District of Columbia, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|North Miami Beach, Florida, United States|Sarasota, Florida, United States|Atlanta, Georgia, United States|Austell, Georgia, United States|Marietta, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Winfield, Illinois, United States|Indianapolis, Indiana, United States|Des Moines, Iowa, United States|Iowa City, Iowa, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|Baton Rouge, Louisiana, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Detroit, Michigan, United States|Ypsilanti, Michigan, United States|Plymouth, Minnesota, United States|Kansas City, Missouri, United States|St Louis, Missouri, United States|St Louis, Missouri, United States|Lebanon, New Hampshire, United States|Egg Harbour Township, New Jersey, United States|Vineland, New Jersey, United States|Bronx, New York, United States|Manhasset, New York, United States|New York, New York, United States|New York, New York, United States|Rochester, New York, United States|Williamsville, New York, United States|Yonkers, New York, United States|Asheville, North Carolina, United States|Chapel Hill, North Carolina, United States|Fayetteville, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Lancaster, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Cranston, Rhode Island, United States|Providence, Rhode Island, United States|Columbia, South Carolina, United States|Germantown, Tennessee, United States|West Nashville, Tennessee, United States|Dallas, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Fort Sam Houston, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Annandale, Virginia, United States|Charlottesville, Virginia, United States|Chesapeake, Virginia, United States|Fairfax, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Tacoma, Washington, United States|Vancouver, Washington, United States|Casper, Wyoming, United States|Cheyenne, Wyoming, United States|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Gent, Belgium|Leuven, Belgium|Caixa, Brazil|Campinas, Brazil|Juiz de Fora, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Salvador, Brazil|Sao Jose Do Rio Preto, Brazil|Sao Paulo, Brazil|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Kolding, Denmark|Odense, Denmark|Clermont-ferrand, France|Clichy, France|Lille, France|Lyon, France|Rouen, France|Strasbourg, France|Berlin, Germany|Bonn, Germany|D√ºsseldorf, Germany|Frankfurt Am Main, Germany|Freiburg, Germany|Giessen, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Kiel, Germany|K√∂ln, Germany|T√ºbingen, Germany|Bekescsaba, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyor, Hungary|Gyula, Hungary|Pecs, Hungary|Szombathely, Hungary|Amsterdam, Netherlands|Leiden, Netherlands|Rotterdam, Netherlands|Bydgoszcz, Poland|Chorzow, Poland|Kielce, Poland|Lodz, Poland|Warszawa, Poland|Wroclaw, Poland|Ponce, Puerto Rico|San Juan, Puerto Rico|Santurce, Puerto Rico|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Cluj-napoca, Romania|Constanta, Romania|Iasi, Romania|Timisoara, Romania|Jaloslave, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Samara, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|Stavropol, Russian Federation|Stockholm, Sweden|Uppsala, Sweden|London, United Kingdom|London, United Kingdom|London, United Kingdom|Newcastle Upon Tyne, United Kingdom|Plymouth, United Kingdom|Southampton, United Kingdom",31.64575683,28.48118115,All,"12 Years to 21 Years ¬† (Child, Adult)",431,422,415,266,115,34,5/25/2028,1/3/2029,10/13/2028,11/16/2028,10/19/2028,11/10/2028,11/20/2028,12/27/2005,1/4/2006,6/20/2008,7/26/2008,1/30/2009,4/1/2009,5/28/2009,6/29/2009,8/8/2009,10/2/2009,11/1/2009,12/27/2009,5/9/2029,11/5/2029,5/4/2030,10/31/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00394277,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00054,SP00011,A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).,,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 4,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Marceline R,Aleta H,Tien C,Kala R,Aleta H,Kandace p,Liberty A,Naren G,Mee M,Frank T,Stephan T,Mary H,Chetan K,Geralyn K,Anthony P,Mary H,Chetan K,Naren G,Garnet T,,,"La Jolla, California, United States|Long Beach, California, United States|San Diego, California, United States|San Diego, California, United States|Farmington, Connecticut, United States|Bradenton, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Wellington, Florida, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Boston, Massachusetts, United States|St Louis, Missouri, United States|Manhasset, New York, United States|Chapel Hill, North Carolina, United States|Statesville, North Carolina, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Richmond, Virginia, United States|Santurce, Puerto Rico",92.6551704,83.38965336,All,"18 Years and older ¬† (Adult, Older Adult)",471,454,416,240,133,43,7/24/2028,1/4/2029,11/6/2028,11/30/2028,11/11/2028,11/16/2028,11/26/2028,3/14/2004,4/1/2004,5/17/2005,3/29/2005,7/18/2005,12/1/2005,1/16/2006,3/11/2006,5/1/2006,6/5/2006,7/17/2006,8/19/2006,5/15/2029,11/11/2029,5/10/2030,11/6/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00077649,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00130,SP00011,"A Study of Atezolizumab Compared With Platinum Doublet Chemotherapy for PD-L1 Highly Expressed, Chemotherapy-Na√Øve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer",,,Non-Small Cell Lung Cancer,,Oncology,,,,,,Industry,Not yet recruiting,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Liberty A,James y,Federico L,Stephan T,Lilla Stilson †,Suk T,Kala R,Mara A,Tiffiny K,Jerold Goo †,Lyman W,John G,Doreen T,Mary H,Jaquelyn H,Jene M,Jerold Goo †,Remedios Z,Dinah R,,,"Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China|Beijing Chest Hospital; Oncology Department, Beijing, China|Beijing Tiantan Hospital,Capital Medical University, Beijing, China|Xuanwu Hospital, Capital Medical University, Beijing, China|Hunan Cancer Hospital, Changsha City, China|The Third Xiangya Hospital Of Central South University, Changsha, China|Changzhou First People's Hospital, Changzhou, China|Sichuan Cancer Hospital, Chengdu City, China|Daping Hospital of Third Military Medical University, Chongqing, China|Fujian Cancer Hospital, Fuzhou, China|The First Affilicated Hospital, Sun Yat-sen University, Guangzhou City, China|Nanfang Hospital, Southern Medical University, Guangzhou, China|Sir Run Run Shaw Hospital Zhejiang University, Hangzhou City, China|The Second Affiliated Hospital, Zhejiang University, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|The First Affiliated Hospital of Anhui Medical University, Hefei, China|Anhui Province Cancer Hospital, Hefei, China|Shandong Cancer Hospital, Jinan, China|The First Affiliated Hospital Of Jinzhou Medical University, Jinzhou City, China|Yunnan Cancer Hospital, Kunming, China|Linyishi Cancer Hospital, Linyi City, China|Linyi people's hospital, Linyi, China|Nanjing Chest Hospital, Nanjing City, China|Nanjing First Hospital, Nanjing City, China|Shanghai Chest Hospital, Shanghai, China|Changhai Hospital of Shanghai, Shanghai, China|Cancer Hospital of Shantou University Medical College, Shantou, China|Shanxi Baiqiuen Hospital, Taiyuan, China|Tianjin Medical University General Hospital, Tianjin, China|Tianjin Cancer Hospital, Tianjin, China|Tumor Center,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China|Xuzhou Central Hospital, Xuzhou, China",83.52549582,75.17294624,All,"18 Years and older ¬† (Adult, Older Adult)",437,430,417,322,56,39,11/13/2020,4/20/2021,1/29/2021,3/11/2021,2/14/2021,2/24/2021,2/28/2021,3/5/2021,3/28/2021,8/7/2023,6/14/2023,1/1/2024,3/31/2024,4/30/2024,6/6/2024,8/1/2024,9/19/2024,10/30/2024,12/22/2024,8/23/2021,2/19/2022,8/18/2022,2/14/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05047250,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00174,SP00011,A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemotherapy in Participants With Locally Advanced Rectal Cancer,,,Rectal Neoplasms|Rectal Cancer,,Oncology,,,,,,Industry,Not yet recruiting,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Naren G,Anthony P,Mary H,Kandace p,Rima Y ,Jerold Goo †,Naren G,Beulah N,Anthony P,Jerold Goo †,Liberty A,Federico L,Tiffiny K,James y,Hee Y,Perter K,Frank T,Federico L,Dalton E,,,"The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China|Zhongshan Hospital Fudan University, Shanghai, China|First Hospital of China Medical University, Shenyang, China",13.37804153,12.04023737,All,"18 Years to 80 Years ¬† (Adult, Older Adult)",462,456,418,240,154,24,6/3/2020,11/4/2020,8/30/2020,9/25/2020,9/1/2020,9/15/2020,9/24/2020,9/29/2020,10/21/2020,1/28/2023,11/5/2022,3/19/2023,6/30/2023,8/21/2023,10/13/2023,12/1/2023,12/31/2023,2/21/2024,3/29/2024,3/14/2021,9/10/2021,3/9/2022,9/5/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05009069,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00215,SP00011,"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma",,,Lymphoma,,Oncology,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,In Bellini †,In Bellini †,Marcelina X,Selizabeth F,Selizabeth F,Suzie K,Marceline R,John G,Beulah N,Doreen T,Mac L,Dinah R,Christian G,Suzie K,Louann C,Aleta H,Anthony P,Chetan K,Chetan K,,,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|Yale School of Medicine, New Haven, Connecticut, United States|University of Iowa, Iowa City, Iowa, United States|University of Maryland, Baltimore, Maryland, United States|University of Minnesota, Minneapolis, Minnesota, United States|Morristown Medical Center;Hematology-Oncology Assoc, Morristown, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Baylor University Medical Center, Dallas, Texas, United States",25.14483129,22.63034816,All,6 Months to 5 Years ¬† (Child),448,438,419,395,28,4,11/9/2020,4/8/2021,2/6/2021,3/12/2021,2/24/2021,3/5/2021,3/15/2021,3/18/2021,4/17/2021,3/22/2024,3/12/2024,10/18/2024,12/10/2024,1/29/2025,3/25/2025,5/15/2025,6/25/2025,8/1/2025,9/19/2025,9/1/2021,2/28/2022,8/27/2022,2/23/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04980222,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00243,SP00011,A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus,,ALLEGORY,Systemic Lupus Erythematosus,,,,,,,,Industry,Recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Marceline R,Marcelina X,In Bellini †,Ross S,Otis Thode †,Federico L,Mary H,Ross S,Ngan D,Livia Pacheo †,Mac L,Suzie K,Lyman W,Harry A,Rima Y ,Mara A,Dinah R,Frank T,Jaquelyn H,,,"University of Alabama; Kirklin Clinic, Birmingham, Alabama, United States|St Joseph Heritage Healthcare; Rheumatology, Fullerton, California, United States|University of Colorado Denver, Barbara Davis Center, Center For Clinical Research, Aurora, Colorado, United States|Denver Arthritis Clinic, Denver, Colorado, United States|Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States|Rheumatology Associates of Central Florida, Orlando, Florida, United States|Adventhealth Medical Group - Tampa - IM/Rheumatology, Tampa, Florida, United States|Arthritis & Rheumatology of Georgia, Atlanta, Georgia, United States|Uni of Michigan Health System, Ann Arbor, Michigan, United States|Suny Downstate Medical Center; Rheumatology, Brooklyn, New York, United States|Northwell Health Division of Rheumatology, Great Neck, New York, United States|Columbia University Medical Center; Division of Rheumatology, New York, New York, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|University of Pittsburgh Medical Center (UPMC); UPMC Lupus Center of Excellence, Pittsburgh, Pennsylvania, United States|Amarillo Center For Clinical Research, Amarillo, Texas, United States|Prolato Clinical Research Center, Houston, Texas, United States|Organizacion Medica de Investigacion, Buenos Aires, Argentina|DOM Centro de Reumatolog√≠a, Ciudad Aut√≥noma de Buenos Aires, Argentina|Centro de Investigaciones M√©dicas Tucuman; REUMATHOLOGY, San Miguel, Argentina|Ser Servicos Especializados Em Reumatologia, Salvador, BA, Brazil|Santa Casa de Misericordia; de Belo Horizonte, Belo Horizonte, MG, Brazil|Hospital das Clinicas - UFMG, Belo Horizonte, MG, Brazil|Centro Mineiro de Pesquisa - CMIP, Juiz de Fora, MG, Brazil|Centro de Estudos em Terapias Inovadoras - CETI, Curtiba, PR, Brazil|Hospital das Clinicas - FMUSP Ribeirao Preto; Reumatologia, Ribeirao Preto, SP, Brazil|Centro Multidisciplinar de Estudos Cl√≠nicos - CEMEC*X*, Sao Bernardo Do Campo, SP, Brazil|AACD - Lar Escola S√£o Francisco, Sao Paulo, SP, Brazil|Hopital La Cavale Blanche; Rhumatologie, Brest, France|Ch Pitie Salpetriere; Medecine Interne I, Paris, France|HOPITAL COCHIN; Internal Medicine Department, Paris, France|H√¥pital Sud - CHU de Rennes Service interne, Rennes, France|Hopital Hautepierre; Rhumatologie, Strasbourg, France|Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy|Asst Degli Spedali Civili Di Brescia; Reumatologia Ed Immunologia Clinica, Brescia, Lombardia, Italy|IRCCS S. Raffaele; U.O. Immunologia, Reumatologia, Allergologia e Malattie Rare, Milano, Lombardia, Italy|A.O. Universitaria Pisana, Pisa, Toscana, Italy|Azienda Ospedaliero-Universitaria Di Ferrara Arcispedale Santanna; Reumatologia, Cona (Ferrara), Veneto, Italy|Uni Di Padova; Divisione Di Rheumatologia, Padova, Veneto, Italy|Centro de Investigacion Alberto Bazzoni S.A. de C.V., Torreon, Coahuila, Mexico|Centro de Investigaci√≥n de Tratamientos Innovadores de Sinaloa (CITI), Culiac√°n Rosales, Sinaloa, Mexico|Unidad de Reumatologia Rehabilitacion Integral; Centro Medico Del Angel, Mexicali, Mexico|Centro de Investigaci√≥n y Tratamiento Reumatol√≥gico S.C., Mexico, DF, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Mexico|Middlemore Hospital; Dept of Rheumatology, Auckland, New Zealand|Wellington Hospital, Wellington, New Zealand|Hogar Cl√≠nica San Juan de Dios, Arequipa, Peru|Cl√≠nica San Juan Bautista CSJB; UNIDAD DE INVESTIGACION EN REUMATOLOGIA E INMUNOLOGIA CSJB, Lima, Peru|Instituto del Cerebro y la Columna Vertebral SAC, Lima, Peru|Instituto de Ginecolog√≠a y Reproducci√≥n, Lima, Peru|Clinica El Golf, San Isidro, Peru|Clinica Peruana Americana, Trujillo, Peru|Szpital Uniwersytecki; nr 2 im. Dr J. Biziela; Klinika Reumatologii i Ukladowych Chorob, Bydgoszcz, Poland|Med-Roz Niepubliczny Zak≈Çad Opieki Zdrowotnej, Karwiany, Poland|Twoja Przychodnia Centrum Medyczne Nowa Sol, Nowa S√≥l, Poland|Prywatna Praktyka Lekarska; Prof.UM dr hab.med Pawel Hryc, Poznan, Poland|Ortopedyczno-Rehabilitacyjny Szpital Kliniczny im. Wiktora Degi UM; Katedra i Klinika Reumatologii, Poznan, Poland|Medycyna Kliniczna, Warszawa, Poland|Rheuma Medicus Zaklad Opieki Zdrowotnej, Warszawa, Poland|State Autonomous Healthcare Institution of Yaroslavl region ""Clinical Hospital 9"", Yaroslavl, Jaroslavl, Russian Federation|Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova, Moscow, Moskovskaja Oblast, Russian Federation|Ooo ""Firma Oris"", Moskva, Moskovskaja Oblast, Russian Federation|Center of Family Medicine LC, Yekaterinburg, Sankt Petersburg, Russian Federation|OOO New Clinic, Pyatigorsk, Stavropol, Russian Federation|SBHI of Yaroslavl Region Clinical Hospital #3, Yaroslavl, Volgograd, Russian Federation|Scient Res Med Ctr Your Health, Kazan, Russian Federation|SBEI of HPI The 1st Moscow State Medical University n.a. I.M. Sechenov of MOH of RF, Moscow, Russian Federation|City Clinical Hospital # 52, Moscow, Russian Federation|Vladimirskiy Regional Scientific Research Inst., Moscow, Russian Federation|Ryazan State Medical University Named after I.P.Pavlov, Ryazan, Russian Federation|FGBU ""Federal Medical and Research Center named after V.A.Almazov"" Russian Ministry of Health, Sankt-Petersburg, Russian Federation|NIH ""Departmental Hospital on Station Smolensk of OJSC ""Russian Railways"", Smolensk, Russian Federation|Republican clinical hospital named after G.G. Kuvatov, UFA, Russian Federation|Volgograd state medical university, Volgograd, Russian Federation|Panorama Medical Center; Rheumatology, Cape Town, South Africa|TREAD Research, Cape Town, South Africa|Winelands Medical Research; Medical Research, Cape Town, South Africa|Precise Clinical Solutions (Pty) Ltd, Chatsworth, South Africa|Metropolitan Clinical Research Institute, Polokwane, South Africa|Greenacres Hospital, Port Elizabeth, South Africa|Emmed Research, Pretoria, South Africa|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Medicina Interna, Santiago de Compostela, LA Coru√±a, Spain|Hospital Meixoeiro, Vigo, Pontevedra, Spain|Hospital de Basurto; Servicio de Reumatologia, Bilbao, Vizcaya, Spain|Hospital Universitario Vall d'Hebron; Servicio de Medicina Interna, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona; Enfermedades Autoinmmunes, Barcelona, Spain|Hospital General Universitario Gregorio Mara√±on; Servicio de Reumatolog√≠a, Madrid, Spain|Addenbrooke'S Hospital; Rheumatology Research Unit, Cambridge, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Chapel Allerton Hospital; Leeds Institution of Rheumatology Medicine, Leeds, United Kingdom|Aintree University Hospitals NHS Foundation Trust, Liverpool, United Kingdom|Royal Free Hospital; Department of Rheumatology, London, United Kingdom|Guy's Hospital; Louise Coote Lupus Unit, London, United Kingdom|Manchester Royal Infirmary; Kellgren Centre for Rheumatology, Manchester, United Kingdom|Lancashire Teaching Hospitals NHS Foundation Trust; Lancashire Clinical Research Facility, Preston, United Kingdom",12.47258497,11.22532647,All,"18 Years and older ¬† (Adult, Older Adult)",459,440,420,132,269,19,3/25/2021,8/31/2021,6/29/2021,8/1/2021,6/21/2021,7/14/2021,7/23/2021,7/28/2021,8/24/2021,2/10/2025,2/5/2025,8/6/2025,11/30/2025,1/27/2026,3/17/2026,4/16/2026,5/28/2026,7/24/2026,8/23/2026,1/10/2022,7/9/2022,1/5/2023,7/4/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04963296,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00244,SP00011,"A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis",,,Generalized Myasthenia Gravis,,Neurology,,,,,,Industry,Not yet recruiting,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Chetan K,Livia Pacheo †,Aleta H,Stephan T,Suk T,Xochitl D,Perter K,Selizabeth F,Terisa Sikora †,Mary H,Perter K,Lilla Stilson †,Ngan D,Rima Y ,Hee Y,John G,Frank T,John G,Tamesha T,,,"HonorHealth Neurology, Scottsdale, Arizona, United States|Keck School of Medicine of USC, Los Angeles, California, United States|University of California Irvine - Manchester Pavilion, Orange, California, United States|SC3 Research Group, Inc, Pasadena, California, United States|Medical Faculty Associates Inc., Washington, District of Columbia, United States|University of Florida Jacksonville Physicians Inc. (UFJPI), Jacksonville, Florida, United States|University of Chicago Hospital, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics; Department of Neurology, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University School of Medicine; Department of Neurology, Saint Louis, Missouri, United States|University at Buffalo / SUNY; UBMD Neurology, Buffalo, New York, United States|Neurological Institute of New York, New York, New York, United States|NeuroScience Research Center, Canton, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Mercy Neurology Clinic, Moore, Oklahoma, United States|Hospital Italiano; Neurology, Caba, Argentina|Hospital Ramos Mej√≠a, Caba, Argentina|Hospital Britanico, Ciudad Autonoma Bs As, Argentina|Centro de Investigaciones M√©dicas Tucuman; REUMATHOLOGY, San Miguel, Argentina|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Box Hill Hospital; Department of Neurology, Box Hill, Victoria, Australia|Instituto de Neurologia de Curitiba, Curitiba, PR, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital das Clinicas - UNICAMP, Campinas, SP, Brazil|Faculdade de Medicina do ABC - FMABC, Santo Andre, SP, Brazil|Hospital Sao Paulo, Sao Paulo, SP, Brazil|University of Calgary; Heritage Medical Research Clinic, Calgary, Alberta, Canada|Toronto General Hospital, Toronto, Ontario, Canada|MUCH - Montreal Neurological Institute & Hospital, Montreal, Quebec, Canada|Beijing Tongren Hospital, Beijing, China|Beijing Tiantan Hospital,Capital Medical University, Beijing, China|Xuanwu Hospital, Capital Medical University, Beijing, China|Xiangya Hospital Central South University, Changsha City, China|West China Hospital - Sichuan University, Chengdu City, China|Sir Run Run Shaw Hospital, Hangzhou, China|The First Affiliated Hospital Of Shandong First Medical University, Jinan, China|Huashan Hospital, Fudan University, Shanghai City, China|The First Hospital of Shanxi Medical University, Taiyuan, China|Tianjin Medical University General Hospital, Tianjin, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China|Tangdu Hospital, Xi'an, China|Aarhus Universitetshospital; Neurologisk Klinik, Aarhus N, Denmark|Rigshospitalet; Neurologisk Klinik, K√∏benhavn √ò, Denmark|APHP Raymond Poincare, Garches, France|Hopital Timone Adultes; Neurologie Mal Neuro Musculaires, Marseille, France|CHU de Nantes - Hotel Dieu, Nantes, France|CHU Nice - H√¥pital Pasteur 2; SYST NERVEUX PERIPHERIQUE MUSCLE, Nice, France|Hopital de la Pitie Salpetriere, Paris, France|CHU Bordeaux, Pessac, France|St. Josef-Hospital, Klinik f√ºr Neurologie, Bochum, Germany|Universit√§tsklinikum Essen (A√∂R); Klinik f√ºr Neurologie, Essen, Germany|Univerist√§tsklinikum Leipzig; Klinik und Poliklinik f√ºr Neurologie, Leipzig, Germany|Universit√§tsklinikum M√ºnster; Klinik und Poliklinik f√ºr Neurologie, M√ºnster, Germany|Azienda Ospedaliera A. Cardarelli; Dipartimento medico polispecialistico, Napoli, Campania, Italy|A.O. Sant'Andrea; UOC Neurologia, Dip. di Neuroscienze, Salute Mentale e Organi di Senso (NESMOS), Roma, Lazio, Italy|Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari, Milano, Lombardia, Italy|IRCCS Istituto Neurologico C. Mondino-Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla, Pavia, Lombardia, Italy|A.R.N.A.S. Civico Di Cristina Benfratelli; U.O.C. Neurologia con Stroke Unit, Palermo, Sicilia, Italy|Ospedale C√† Foncello; S.C Neurologia, Treviso, Veneto, Italy|Chiba University Hospital; Neurology, Chiba-shi, Chiba, Japan|General Hanamaki Hospital; Neurology, Hanamaki, Iwate, Japan|Hiroshima University Hospital, Hiroshima, Japan|Sapporo Medical University Hospital; Neurology, Hokkaido, Japan|NHO Hokkaido Medical Center, Hokkaido, Japan|Kagawa University Hospital; Neurology, Kagawa, Japan|St. Marianna University School of Medicine Hospital, Kanagawa, Japan|Saitama Medical Center; Neurology, Kawagoe-shi, Saitama, Japan|Nagasaki Kawatana Medical Center; Neurology, Nagasaki, Japan|International University of Health and Welfare Narita Hospital; Neurology, Narita, Chiba, Japan|Kindai University Hospital; Neurology, Osaka, Japan|Osaka Toneyama Medical Center; Neurology, Osaka, Japan|Dokkyo Medical University Saitama Medical Center; Neurology, Saitama, Japan|Tokyo Women's Medical University Hospital; Neurology, Shinjuku-ku, Japan|Seirei Hamamatsu General Hospital, Shizuoka, Japan|Osaka University Hospital; Neurology, Suita, Japan|Tokyo Medical And Dental University, Medical Hospital; Neurology, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsangnam-do, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Amsterdam UMC Location AMC, Amsterdam, Netherlands|LUMC, Leiden, Netherlands|Klinika Neurologii Doros≈Çych, Uniwersyteckie Centrum Kliniczne, Gda≈Ñsk, Poland|Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii K, Krakow, Poland|Zespol Poradni Specjalistycznych - Poradnia Neurologiczna; Szpital Uniwersytecki w Krakowie, Krak√≥w, Poland|Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak., Lublin, Poland|FSBHI Siberian Clinical Center of the Federal Medical and Biological Agency, Krasnoyarsk, Krasnojarsk, Russian Federation|National Center of Social Significant Disease, Sankt-peterburg, Leningrad, Russian Federation|Research Center of Neurology; Neurology Department #5, Moskva, Moskovskaja Oblast, Russian Federation|Krasnoyarsk State Medical Academy, Krasnoyarsk, Russian Federation|Novosibirsk State Regional Clinical Hospital, Novosibirsk, Russian Federation|Samara Regional Clinical Hospital named after V.D. Seredavina, Samara, Russian Federation|Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation|Hospital Universitari de Bellvitge; Servicio de Neurologia, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital de Donostia Unidad Demencias; Consultas de Neurolog√≠a, San Sebastian, Guipuzcoa, Spain|Hospital Universitario Infanta Sofia; Servicio de Neurologia, San Sebastian de los Reyes, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Neurolog√≠a, Pamplona, Navarra, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain|Hospital General Universitario Gregorio Mara√±on; Servicio de Neurologia, Madrid, Spain|Clinica Universitaria Navarra; Servicio Neurologia, Madrid, Spain|Hospital Universitario la Fe; Servicio de Neurologia, Valencia, Spain|Taipei Veterans General Hospital-Neurology, Taipei, Taiwan|Chang Gung Medical Foundation Linkou Branch, Taoyuan City, Taiwan|Hacettepe University Medical Faculty; Neurology, Ankara, Turkey|Ege University Medical Faculty, Izmir, Turkey|Kocaeli University Hospital; Department of Neurology, Kocaeli, Turkey|Ondokuz Mayis Univ. Med. Fac.; Neurology, Samsun, Turkey|Karadeniz Tecnical Uni. Med. Fac.; Neurology, Trabzon, Turkey",91.62856072,82.46570465,All,"12 Years and older ¬† (Child, Adult, Older Adult)",468,450,421,203,184,34,10/11/2018,4/10/2019,2/9/2019,3/10/2019,2/17/2019,2/19/2019,2/24/2019,3/1/2019,3/9/2019,4/24/2023,11/6/2022,3/11/2023,7/14/2023,8/24/2023,10/23/2023,12/4/2023,1/21/2024,2/29/2024,4/18/2024,8/18/2019,2/14/2020,8/12/2020,2/8/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04963270,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00248,SP00011,"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)",,,Early Breast Cancer,,Oncology,,,,,,Industry,Recruiting,,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Patria R,Selizabeth F,Tamesha T,Mara A,Perter K,Mac L,John G,Jene M,Lavina S,Lavina S,Corrine U,Suk T,Gertrudis T,Louann C,Dinah R,Mac L,Livia Pacheo †,In Bellini †,Frank T,,,"CBCC Global Research Inc., at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Cancer and Blood Specialty Clinic, Fountain Valley, California, United States|UCLA Hematology/Oncology, Santa Monica, California, United States|Torrance Memorial Physician Network/Cancer Care, Torrance, California, United States|Valley Breast Care and Women's Health Center, Van Nuys, California, United States|Stamford Hospital; Clincal Trials Office - 1st Fl - Bennett Cancer Cente, Stamford, Connecticut, United States|Cancer Center of Kansas - Kingman, Kingman, Kansas, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Ballarat Oncology & Haematology, Wendouree, Victoria, Australia|Metropolitan General Hospital, Cholargos, Greece|Olympion Clinic, Patras, Greece|Hospital Universitario de Jaen, Jaen, Spain",27.7467509,24.97207581,All,"50 Years and older ¬† (Adult, Older Adult)",474,458,422,383,0,39,4/16/2024,10/18/2024,8/15/2024,9/2/2024,8/8/2024,8/20/2024,8/23/2024,8/24/2024,9/20/2024,5/25/2025,5/6/2025,9/29/2025,12/19/2025,2/14/2026,3/24/2026,5/2/2026,6/18/2026,7/19/2026,9/2/2026,2/16/2025,8/15/2025,2/11/2026,8/10/2026,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04961996,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00311,SP00011,"Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer",,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Gertrudis T,Tamesha T,Tammara F,Livia Pacheo †,Rima Y ,In Bellini †,Anthony P,Tiffiny K,Livia Pacheo †,John G,John G,Naren G,Frank T,In Bellini †,Mary H,John G,Doreen T,Donovan H,Chetan K,,,"Ironwood Cancer & Research Centers, Chandler, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|USC/Westside Cancer Ctr, Beverly Hills, California, United States|City of Hope, Duarte, California, United States|Kaiser Permanente San Diego - Los Angeles, Los Angeles, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|UC Irvine Medical Center, Orange, California, United States|Stanford University, Palo Alto, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Lynn Cancer Institute/Boca Raton Regional Hospital, Boca Raton, Florida, United States|Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Illinois Cancer Care, Peoria, Illinois, United States|Associates in Oncology/Hematology P.C., Rockville, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute.., Detroit, Michigan, United States|HCA Midwest Division, Kansas City, Missouri, United States|Urology Cancer Center & GU Research Network, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, United States|Hackensack Univ Medical Center; John Theurer Cancer Ctr, Hackensack, New Jersey, United States|Cleveland Clinic, Cleveland, Ohio, United States|Northwest Cancer Specialists, P.C., Tigard, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Charleston Oncology, P .A, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Texas Oncology - Memorial City, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Macquarie University Hospital, Macquarie Park, New South Wales, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Monash Medical Centre; Oncology, Clayton, Victoria, Australia|Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia|Eastern Health; GU - Oncology, Melbourne, Victoria, Australia|LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung f√ºr Onkologie, Graz, Austria|Ordensklinikum Linz Elisabethinen; Abteilung f√ºr Urologie und Andrologie, Linz, Austria|Landeskrankenhaus Salzburg; Universit√§tsklinik f√ºr Urologie und Andrologie der PMU, Salzburg, Austria|UZ Gent, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|CHU Sart-Tilman, Li√®ge, Belgium|Hospital Luxemburgo; Oncologia, Belo Horizonte, MG, Brazil|Liga Norte Riograndense Contra O C√¢ncer, Natal, RN, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, Canada|Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, Canada|Sunnybrook Research Institute, Toronto, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Hopital Sacre-Coeur Research Centre, Montreal, Quebec, Canada|CHU de Qu√©bec - Universit√© Laval - H√¥tel-Dieu de Qu√©bec, Quebec, Canada|Beijing Friendship Hospital Affiliated of Capital University of Medical Science, Beijing Shi, China|Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing City, China|Jiangsu Cancer Hospital, Nanjing City, China|Fudan University Shanghai Cancer Center, Shanghai City, China|Zhongshan Hospital Fudan University, Shanghai, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China|Clinica CIMCA, San Jose, Costa Rica|ICIMED Instituto de Investigaci√≥n en Ciencias M√©dicas, San Jos√©, Costa Rica|Aarhus Universitetshospital, Urologisk Afd. K, Aarhus N, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|ICO Paul Papin; Oncologie Medicale., Angers, France|Centre Francois Baclesse; Oncologie, Caen, France|Centre Jean Perrin, Clermont Ferrand, France|CHD Vend√©e, La Roche Sur Yon, France|Hopital Claude Huriez; Urologie, Lille, France|Institut r√©gional du Cancer Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Institut de cancerologie du Gard, Nimes, France|Institut Mutualiste Montsouris; Oncologie, Paris, France|CHU Poitiers, Poitiers, France|Hopital d'Instruction des Armees de Begin, Saint-Mande, France|Hopital Foch; Oncologie, Suresnes, France|Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France|Alexandras Hospital; Dept. of Clin. Therapeutics, Athens Uni School of Medicine, Athens, Greece|IASO General Hospital of Athens, Athens, Greece|University Hospital of Patras Medical Oncology, Patras, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Semmelwies University of Medicine; Urology Dept., Budapest, Hungary|Orszagos Onkologiai Intezet; ""C"" Belgy√≥gy√°szati-Onkol√≥giai √©s Klinikai Farmakol√≥giai Oszt√°ly, Budapest, Hungary|Uzsoki Utcai Korhaz, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont ; Department of Oncology, Debrecen, Hungary|B-A-Z County Hospital, Miskolc, Hungary|Cork University Hospital, Cork, Ireland|Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital; Oncology Day Unit, Dublin, Ireland|Mater Misericordiae Uni Hospital; Oncology, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|Rambam Health Care Campus; Oncology, Haifa, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Belinson Medical Center, Division of Oncology, Petach Tikva, Israel|Chaim Sheba medical center, Oncology division, Ramat Gan, Israel|ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico, Napoli, Campania, Italy|I.R.S.T Srl IRCCS; Oncologia Medica, Meldola, Emilia-Romagna, Italy|A.O. Universitaria Policlinico Di Modena; Oncologia, Modena, Emilia-Romagna, Italy|Azienda Ospedaliera San Camillo Forlanini; Oncologia Medica, Roma, Lazio, Italy|A.O. Istituti Ospitalieri - Cremona; S.C. Oncologia, Cremona, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|A.O. San Carlo Borromeo; U.O.C. Oncologia, Milano, Lombardia, Italy|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|Ospedale Area Aretina Nord; U.O.C. Oncologia, Arezzo, Toscana, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Ospedale di Trento-Presidio Ospedaliero Santa Chiara; Oncologia Medica, Trento, Trentino-Alto Adige, Italy|Nagoya University Hospital, Aichi, Japan|Hirosaki University Hospital, Aomori, Japan|National Cancer Center East, Chiba, Japan|Toho University Sakura Medical Center, Chiba, Japan|Gunma University Hospital, Gunma, Japan|National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan|Kanazawa University Hospital, Ishikawa, Japan|Yokohama City University Medical Center, Kanagawa, Japan|Kitasato University Hospital, Kanagawa, Japan|Kochi Medical School Hospital, Kochi, Japan|Kumamoto University Hospital, Kumamoto, Japan|University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Kindai University Hospital, Osaka, Japan|Toranomon Hospital, Tokyo, Japan|Nippon Medical School Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Keio University Hospital, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Yamaguchi University Hospital, Yamaguchi, Japan|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Centro Medico Culiacan SA de CV; Consultorio Medico 303 B, Culiacan, Sinaloa, Mexico|Medical Care & Research, M√©rida, Yucatan, Mexico|Consultorio de Especialidad en Urologia Privado, Durango, Mexico|Hospital Angeles Mocel, Mexico City, Mexico|Sykehuset √òstfold Kalnes; Onkologisk seksjon, Gr√•lum, Norway|Akershus universitetssykehus HF, L√∏renskog, Norway|SPZOZ Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarawskiego, Opole, Poland|Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; Klinika Nowotworow Ukladu Moczowego, Warszawa, Poland|Szpital Grochowski im. dr med. Rafa≈Ça Masztaka Sp. z o.o., Warszawa, Poland|Dolnoslaskie Centrum Onkologii, Wroc≈Çaw, Poland|Woj. Wielospec. Centrum Onkologii i Traumatologii, ≈Å√≥d≈∫, Poland|HUC; Servico de Urologia e Transplantacao Renal, Coimbra, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Altai Regional Oncological Center, Barnaul, Russian Federation|Blokhin Cancer Research Center; Urological Dept, Moscow, Russian Federation|Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation|P.A. Herzen Oncological Inst. ; Oncology, Moscow, Russian Federation|Privolzhsk Regional Medical Center, Nizhny Novgorod, Russian Federation|Institut Catala d¬¥Oncologia Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, C√≥rdoba, Cordoba, Spain|Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Clinic i Provincial; Servicio de Urolog√≠a, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia, Barcelona, Spain|Hospital General Universitario Gregorio Mara√±on; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|KAOHSIUNG MEDICAL UNI CHUNG-HO HOSPITAL; Dept. Of Urology, Kaohsiung, Taiwan|China Medical University Hospital; Urology, Taichung, Taiwan|Taichung Veterans General Hospital; Division of Urology, Taichung, Taiwan|Chang Gung Memorial Hospital-LinKou; Urology, Taoyuan, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Maharaj Nakorn Chiangmai Hospital; Department of Surgery/ Urology unit, Chiangmai, Thailand|Royal Blackburn Hospital, Blackburn, United Kingdom|Addenbrookes Nhs Trust; Oncology Clinical Trials Unit, Cambridge, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Mount Vernon & Watford Trust Hospital; Dept. of Clinical Oncology, Northwood, United Kingdom|Royal Marsden Hospital; Institute of Cancer Research, Sutton, United Kingdom|Royal Wolverhampton hospital; McHale Building, Wolverhampton, United Kingdom",81.61279758,73.45151782,Male,"18 Years and older ¬† (Adult, Older Adult)",459,451,423,146,251,26,5/26/2015,12/8/2015,10/1/2015,11/2/2015,10/6/2015,10/24/2015,10/28/2015,10/29/2015,11/25/2015,2/2/2020,6/7/2019,12/11/2019,3/16/2020,4/24/2020,6/20/2020,8/19/2020,10/8/2020,11/23/2020,1/13/2021,4/21/2016,10/18/2016,4/16/2017,10/13/2017,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03072238,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00350,SP00011,Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy,,,,,Oncology,,,,,,Industry,Recruiting,Phase 4,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Suk T,Gertrudis T,Jene M,Mara A,Ross S,Mary H,Corrine U,Liberty A,Lavina S,Geralyn K,Lilla Stilson †,Lucie P,Geralyn K,Selizabeth F,Gertrudis T,Liberty A,Naren G,Xochitl D,Mary H,,,"UCSF Comp Canc Ctr, San Francisco, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Yale Cancer Center; Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology, Saint Louis, Missouri, United States|Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion, New York, New York, United States|Sarah Cannon Cancer Center, Arrington, Tennessee, United States|Centre Leon Berard; Service Oncologie Medicale, Lyon, France|Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse, France|Seoul National University Hospital; Department of Oncology, Seoul, Korea, Republic of|Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology, Seoul, Korea, Republic of|Clinica Universitaria de Navarra; Servicio de oncolog√≠a, Pamplona, Navarra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Barts Hospital; Institute of Cancer, London, United Kingdom",33.47025742,30.12323167,All,"18 Years and older ¬† (Adult, Older Adult)",442,429,424,193,193,38,8/13/2016,2/10/2017,12/8/2016,1/13/2017,12/17/2016,1/6/2017,1/13/2017,1/15/2017,2/7/2017,9/8/2021,5/1/2021,9/3/2021,12/31/2021,2/28/2022,4/17/2022,5/23/2022,6/25/2022,8/23/2022,10/14/2022,7/5/2017,1/1/2018,6/30/2018,12/27/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03333655,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00374,SP00011,A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Cross-Sectional,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Garnet T,Harry A,Perter K,Quentin N,Louann C,Dinah R,Mary H,Christian G,Marceline R,Christian G,Tammara F,Mary H,Ngan D,Dalton E,Corrine U,Garnet T,Tammara F,Chetan K,Mee M,,,"Bludesch, Austria",64.86322631,58.37690368,All,"18 Years and older ¬† (Adult, Older Adult)",462,440,425,311,52,62,8/13/2012,1/11/2013,11/9/2012,12/12/2012,11/16/2012,11/29/2012,12/2/2012,12/5/2012,12/21/2012,8/27/2014,2/20/2014,6/9/2014,11/1/2014,12/27/2014,2/25/2015,4/17/2015,5/20/2015,6/28/2015,8/21/2015,5/28/2013,11/24/2013,5/23/2014,11/19/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02595450,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00420,SP00011,An Observational Study of Kadcyla Safety in Breast Cancer,,,,,Oncology,,,,,,Industry,Recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Naren G,In Bellini †,Anthony P,Jeanene Y,Anthony P,Gertrudis T,Tiffiny K,John G,Hee Y,Marcelina X,Anthony P,Gertrudis T,Tamesha T,Harry A,Dalton E,Garnet T,Mac L,Chetan K,Frank T,,,"Inje University Busan Paik Hospital, Busan, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Inje university Haeundae Paik Hospital, Busan, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Yeungnam University Medical Center; Surgical Department of Breast and Internal Secretion, Daegu, Korea, Republic of|The Catholic University of Korea Daejeon ST. Mary's Hospital, Daejeon, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Uijeongbu St. Mary's Hospital, Gyeonggi-do, Korea, Republic of|Hallym University Sacred Heart Hospital, Gyeonggi-do, Korea, Republic of|Soonchunhyang University Bucheon Hospital, Gyeonggi-do, Korea, Republic of|Bucheon St Mary's hospital, Gyeonggi-do, Korea, Republic of|St. Vincent's Hospital, Gyeonggi-do, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsangnam-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Catholic Kwandong University International St. Mary'S Hospital., Incheon, Korea, Republic of|Chonbuk National Uni Hospital, Jeollabuk-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Presbyterian Medical Center, Jeonju-si, Korea, Republic of|Wonkwang University School of Medicine & Hospital, Jeonlabuk-do, Korea, Republic of|NHIC Ilsan Hospital, Kyonggi-do, Korea, Republic of|Korea Cancer Center Hospital of Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Gangdong Kyung Hee University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|ChungAng University Hospital, Seoul, Korea, Republic of|Yeouido St. Mary's Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of|Ajou University Hospital, Suwon City, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of",26.0630162,23.45671458,All,"18 Years and older ¬† (Adult, Older Adult)",485,468,426,376,11,39,8/7/2016,2/15/2017,11/29/2016,1/5/2017,12/10/2016,12/22/2016,12/24/2016,12/29/2016,1/20/2017,12/10/2020,2/24/2021,7/5/2021,10/31/2021,12/13/2021,1/12/2022,3/8/2022,4/14/2022,5/22/2022,6/23/2022,6/20/2017,12/17/2017,6/15/2018,12/12/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02305641,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00421,SP00011,A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.,,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug F,,,,,,,,,,,,,,,,,,,Terisa Sikora †,John G,Suk T,Jerold Goo †,Naren G,Ngan D,Lavina S,Chetan K,Geralyn K,Dinah R,Patria R,Ngan D,Harry A,Lucie P,John G,Remedios Z,Mee M,Mary H,Perter K,,,"USA Mitchell Cancer Institute, Mobile, Alabama, United States|Highlands Oncology Group, Springdale, Arkansas, United States|UCLA, Los Angeles, California, United States|Kaiser Permanente-SCPMG; Oncology Research, San Diego, California, United States|Stanford Cancer Center, Stanford, California, United States|Kaiser Permanente - Franklin, Denver, Colorado, United States|Stamford Hospital; BCC, MOHR, Stamford, Connecticut, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Memorial Healthcare System - Memorial Regional Hospital, Hollywood, Florida, United States|Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Nancy N. and J.C. Lewis Cancer & Research Pavillion -St. Josephs / Candler Health System-CCD PRIME, Savannah, Georgia, United States|Rush University, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Ochsner Health System, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Medstar Franklin Square Medical Center, Baltimore, Maryland, United States|St. Joseph Mercy Hospital; Cancer Care Center., Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States|CHI Health Saint Francis; Oncology, Grand Island, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack Univ Med Ctr, Hackensack, New Jersey, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Kaiser Permanente - Portland, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Charleston Oncology, P .A, Charleston, South Carolina, United States|Greenville Health System; Cancer Center, Greenville, South Carolina, United States|The West Clinic; West Cancer Center, Germantown, Tennessee, United States|Vanderbilt Univ Medical Ctr, Nashville, Tennessee, United States|Fundaci√≥n CENIT para la Investigaci√≥n en Neurociencias, Buenos Aires, Argentina|Inst. Angel Roffo; Haematology, Buenos Aires, Argentina|Hospital Britanico, Ciudad Autonoma Bs As, Argentina|Instituto Medico Rio Cuarto, Cordoba, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Fundaci√≥n Scherbovsky, Mendoza, Argentina|Macquarie University Hospital, Macquarie Park, New South Wales, Australia|Mid North Coast Cancer Institute, Port Macquarie, New South Wales, Australia|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Monash Health Monash Medical Centre, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia|Sunshine Hospital; Oncology Research, St Albans, Victoria, Australia|St John of God Hospital; Bendat Cancer Centre, Subiaco, Western Australia, Australia|Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. F√ºr Gyn√§kologie, Innsbruck, Austria|Ordensklinikum Linz Barmherzige Schwestern; Interne 1 - H√§mato-Onkologie, Linz, Austria|Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU, Salzburg, Austria|Medizinische Universit√§t Wien; Univ.Klinik f√ºr Innere Medizin I, Wien, Austria|AZ Maria Middelares, Gent, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|Hospital Sao Rafael - HSR, Salvador, BA, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, SP, Brazil|Inst. Brasileiro de Controle Ao Cancer; Oncologia Clinica / Quimioterapia, Sao Paulo, SP, Brazil|MHAT Nadezhda, Sofia, Bulgaria|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|Fraser Valley Centre British Columbia Cancer Agency, Surrey, British Columbia, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|Royal Victoria Hospital, Barrie, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Centre de Sante & de Services Sociaux de Chicoutimi; Recherche Clinique Oncologie, Chicoutimi, Quebec, Canada|St Mary's Hospital Center, Montreal, Quebec, Canada|McGill University; Glen Site; Oncology, Montreal, Quebec, Canada|Jewish General Hospital; Research Unit, Montr√©al, Quebec, Canada|Hopital du Saint Sacrement, Quebec City, Quebec, Canada|the First Hospital of Jilin University, Changchun, China|Guangdong Provincial Traditional Chinese Medicine Hospital, Guangzhou City, China|Harbin Medical University Cancer Hospital, Harbin, China|Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China|Liaoning cancer Hospital & Institute, Shenyang, China|Tianjin Medical University Cancer Institute & Hospital, Tianjing, China|Clinica del Country, Bogota, Colombia|Onc√≥logos de Occidente, Pereira, Colombia|Clinica CIMCA, San Jose, Costa Rica|Oncotech S.A., San Jos√©, Costa Rica|Masaryk≈Øv onkologick√Ω √∫stav; Klinika komplexn√≠ onkologick√© p√©ƒçe, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Herlev Hospital; Afdeling for Kr√¶ftbehandling, Herlev, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|Docrates Cance Center, Helsinki, Finland|KYS Sadesairaala; Syopatautien poliklinikka, Kuopio, Finland|VAASAN KESKUSSAIRAALA; Onkologian poliklinikka, Vaasa, Finland|Centre Oscar Lambret; Senologie, Lille, France|Centre Eugene Marquis; Service d'oncologie, Rennes, France|Agioi Anargyroi Cancer Hospital; 2Nd Oncology Dept., Kifisia, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Tuen Mun Hospital; Clinical Onc, Hong Kong, Hong Kong|Prince of Wales Hospital; Department of Clinical Onocology, Shatin, Hong Kong|Sahyadri Super Specialty Hospital Hadapsar, Pune, Maharashtra, India|Shaare Zedek Medical Center, Jerusalem, Israel|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|ASU FC S. M. DELLA MISERICORDIA; Oncologia, Udine, Friuli-Venezia Giulia, Italy|ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica, Brescia, Lombardia, Italy|ASST DI LECCO; Oncologia Medica, Lecco, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1, Milano, Lombardia, Italy|IRCCS Istituto Clinico Humanitas; Oncologia, Rozzano, Lombardia, Italy|Ospedale Civile; Unita Operativa Di Oncologia Medica, Livorno, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Aichi Cancer Center Hospital, Aichi, Japan|Chiba Cancer Center, Chiba, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Gunma Prefectural Cancer Center, Gunma, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|Hiroshima University Hospital, Hiroshima, Japan|National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan|Hyogo College of Medicine Hospital, Hyogo, Japan|St. Marianna University School of Medicine Hospital, Kanagawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Kumamoto Shinto General Hospital, Kumamoto, Japan|Okayama University Hospital, Okayama, Japan|Naha-nishi Clinic, Okinawa, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Osaka International Cancer Institute, Osaka, Japan|Saitama Cancer Center, Saitama, Japan|St. Luke's International Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Showa University Hospital, Tokyo, Japan|Kyungpook National University Medical Center, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Investigacion Oncofarmaceutica, La Paz, BAJA California SUR, Mexico|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Christus Muguerza Clinica Vidriera, Monterrey, Nuevo LEON, Mexico|Auckland City Hospital, Cancer and Blood Research, Auckland, New Zealand|Tauranga Hospital, Clinical Trials Unit; BOP Clinical School, Tauranga, New Zealand|Wellington Regional Hospital; Clinical Trials Unit, Wellington, New Zealand|Centro Medico Monte Carmelo, Arequipa, Peru|Instituto Regional de Enfermedades Neoplasicas, Arequipa, Peru|Unidad de Investigaci√≥n Oncologica; Hospital Nacional Daniel Alcides Carrion, Lima, Peru|Cl√≠nica San Gabriel; Unidad de Investigaci√≥n Oncol√≥gica de la Cl√≠nica San Gabriel, Lima, Peru|Hospital Arzobispo Loayza, Lima, Peru|Oncosalud Sac; Oncolog√≠a, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Instituto Regional de Enfermedades Neoplasicas - IREN Norte, Trujillo, Peru|Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice; Centr.Diagn.i Lecz.Chor.Piersi, Gliwice, Poland|Szpital Uniwersytecki w Krakowie, Oddzia≈Ç Kliniczny Kliniki Onkologii, Krak√≥w, Poland|Wielkopolskie Centrum Onkologii, Poznan, Poland|Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie; Klinika Nowotworow Piersi i Chirurgii Rekonstr, Warszawa, Poland|Instyt. Centrum Zdrowia Matki Polki; Klinika Chirurgii Onk. Chor√≥b Piersi z Podod. Onko Klinicznej, ≈Å√≥d≈∫, Poland|Hospital da Luz; Departamento de Oncologia Medica, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|Hospital Beatriz Angelo; Departamento de Oncologia, Loures, Portugal|Centro Hospitalar do Porto - Hospital de Santo Ant√≥nio; Oncologia, Porto, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Oncology Center Sf. Nectarie, Craiova, Romania|University —Ålinic of headaches, Moscow, Moskovskaja Oblast, Russian Federation|SBIH ""Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"", Moskva, Moskovskaja Oblast, Russian Federation|Fed State Budgetary Inst ""N.N. Blokhin Med Center of Oncology"" MHRF, Moskva, Moskovskaja Oblast, Russian Federation|FSAI Treatment and rehabilitation Centre Ministry of Health; Clinical research and chemotherapy., Moskva, Moskovskaja Oblast, Russian Federation|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|P.A. Gertsen Cancer Research Inst. ; Chemotherapy Dept, Moscow, Russian Federation|Limited Liability Company ""RC Medical"", Novosibirsk, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|National Cancer Centre; Medical Oncology, Singapore, Singapore|National Hospital; Oncotherapy Dept, Bloemfontein, South Africa|Cancercare, George, South Africa|Wits Clinical Research, Johannesberg, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa|Cancercare, Port Elizabeth, South Africa|Wilgers Oncology Centre, Pretoria, South Africa|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon de La Plana, Castellon, Spain|Complejo Hospitalario Universitario A Coru√±a (CHUAC); Servicio de Oncologia, La Coruna, LA Coru√±a, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Cl√≠nic i Provincial; Servicio de Hematolog√≠a y Oncolog√≠a, Barcelona, Spain|Hospital General Universitario Gregorio Mara√±on; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Cl√≠nico San Carlos; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncolog√≠a, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Cl√≠nico Universitario de Valencia; Servicio de Oncolog√≠a, Valencia, Spain|Universit√§tsspital Basel; Frauenklinik, Basel, Switzerland|Universit√§tsspital Z√ºrich; Klinik f√ºr Gyn√§kologie, Z√ºrich, Switzerland|China Medical University Hospital; Surgery, Taichung, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan|Chang Gung Memorial Hosipital at Linkou, Taoyuan City, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial, Chiang Mai, Thailand|Khonkaen Hospital, Khonkaen, Thailand|Songklanagarind Hospital; Department of Oncology, Songkhla, Thailand|Memorial Ankara Hastanesi, Ankara, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey|SI Institute of general&urgent surgery n/a Zaytseva V.T NAMSU; Purulent Surgery department, Kharkiv, Kharkiv Governorate, Ukraine|Regional Oncology Center; Department of Mammology, Chernigiv, Ukraine|Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipropetrovsk, Ukraine|ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department, Kryvyi Rih, Ukraine|MI Kyiv Regional Council Kyiv Regional Oncological Dispensary; Department of Mammology, Kyiv, Ukraine|Municipal Institution Odesa Regional Clinical Hospital, Odesa, Ukraine|RCI Sumy Regional Clinical Oncological Dispensary, Sumy, Ukraine|University Hospital Bristol, Bristol, United Kingdom|BEATSON WEST OF SCOTLAND CANCER CENTRE; Clinical Research Unit - Level 1, Glasgow, United Kingdom|Royal Lancaster Infirmary, Morecambe Bay Hospitals Nhs Trust, Lancaster, United Kingdom|The Royal Marsden Hospital, Fulham, London, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Poole General Hospital; Oncology Research Park View House, Poole, United Kingdom|Musgrove Park Hospital; Department Clinical Research, Beacon Centre, Somerset, United Kingdom",94.37134346,84.93420912,All,"18 Years and older ¬† (Adult, Older Adult)",469,462,427,149,256,22,12/18/2023,6/26/2024,5/7/2024,5/28/2024,5/8/2024,5/23/2024,6/6/2024,6/7/2024,7/5/2024,4/27/2025,2/7/2025,9/1/2025,10/10/2025,11/27/2025,1/26/2026,2/25/2026,4/23/2026,6/16/2026,7/25/2026,11/19/2024,5/18/2025,11/14/2025,5/13/2026,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04177108,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00427,SP00011,An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Doreen T,Liberty A,Tiffiny K,Naren G,Mara A,Anthony P,Marcelina X,Kandace p,Garnet T,Lilla Stilson †,Kandace p,Quentin N,Frank T,Chetan K,Doreen T,Mara A,Kandace p,Ross S,Chetan K,,,"Banska Bystrica, Slovakia|Bratislava, Slovakia|Bratislava, Slovakia|Kosice, Slovakia|Martin, Slovakia|Nitra, Slovakia|Poprad, Slovakia|Presov, Slovakia|Ruzomberok, Slovakia",5.334577505,4.801119754,All,"18 Years and older ¬† (Adult, Older Adult)",484,468,428,256,124,48,9/8/2011,1/22/2012,12/4/2011,12/29/2011,11/17/2011,12/11/2011,12/24/2011,12/26/2011,1/2/2012,7/26/2014,9/9/2014,11/16/2014,4/1/2015,5/16/2015,7/7/2015,8/20/2015,9/29/2015,11/13/2015,12/29/2015,6/8/2012,12/5/2012,6/3/2013,11/30/2013,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01442155,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00430,SP00011,An Observational Study of Herceptin SC Safety in Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Mara A,Aleta H,Mary H,Rima Y ,Marcelina X,Kala R,Xochitl D,Aleta H,Xochitl D,Christian G,Terisa Sikora †,Anthony P,Remedios Z,Kala R,Tien C,Ross S,Harry A,Patria R,Chetan K,,,"Pusan National University Hospital, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Myongji Hospital, Gyeonggi-do, Korea, Republic of|Hallym University Sacred Heart Hospital, Gyeonggi-do, Korea, Republic of|Ajou University Medical Center, Gyeonggi-do, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsangnam-do, Korea, Republic of|Gyeongsang National University Hospital, Gyeongsangnam-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Wonkwang University School of Medicine & Hospital, Jeonlabuk-do, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Inje University, Sanggye-Paik Hospital, Seoul, Korea, Republic of|Korea Cancer Hospital of Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Cheil General Hospital & Women's Healthcare Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|ChungAng University Hospital, Seoul, Korea, Republic of|Borame Medical Center, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Miz Medi Hospital, Seoul, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of",85.66894876,77.10205389,All,"18 Years to 75 Years ¬† (Adult, Older Adult)",453,437,429,259,142,28,10/8/2017,3/13/2018,1/13/2018,2/21/2018,2/2/2018,2/4/2018,2/15/2018,2/19/2018,3/8/2018,11/22/2019,5/5/2019,12/16/2019,1/31/2020,3/10/2020,4/17/2020,5/25/2020,7/2/2020,8/12/2020,9/27/2020,8/3/2018,1/30/2019,7/29/2019,1/25/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02305628,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00431,SP00011,A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer,,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Suk T,Garnet T,Perter K,Beulah N,Otis Thode †,Quentin N,Christian G,Gertrudis T,Corrine U,Selizabeth F,Hee Y,Mary H,Lucie P,Geralyn K,James y,Aleta H,Mary H,Christian G,Tammara F,,,"Pacific Shores Medical Group, Long Beach, California, United States|St Vincents Hospital; Cardiopulmonary transplant Ambulatory Care Dept, Darlinghurst, New South Wales, Australia|Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Institut de Cancerologie de l Ouest, Angers, France|Institut Bergonie, Bordeaux, France|Centre Georges Francois Leclerc, Dijon, France|Institut Curie, Paris, France|Gustave Roussy, Villejuif CEDEX, France|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz., Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Direcci√≥n M√©dica, Madrid, Spain|Hospital Universitario Virgen del Roc√≠o, Sevilla, Spain|Barts Cancer Institute, London, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",69.5314897,62.57834073,All,"18 Years and older ¬† (Adult, Older Adult)",475,465,430,288,96,46,5/23/2019,11/7/2019,9/7/2019,10/22/2019,9/13/2019,10/4/2019,10/16/2019,10/18/2019,11/9/2019,8/12/2022,1/4/2022,7/20/2022,10/29/2022,12/14/2022,1/17/2023,3/12/2023,4/21/2023,6/16/2023,8/6/2023,4/1/2020,9/28/2020,3/27/2021,9/23/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03800836,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00432,SP00011,Observational Study of Pertuzumab Safety in Participants With Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,John G,Ngan D,Jaquelyn H,Clarice N,Rima Y ,Mara A,Federico L,Anthony P,Marcelina X,Mary H,Ross S,Lucie P,Marceline R,Frank T,Chetan K,Christian G,Chetan K,Jene M,Donovan H,,,"Inje university Haeundae Paik Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|National Health Insurance Service Ilsan Hospital, Gyeonggi-do, Korea, Republic of|Hallym University Sacred Heart Hospital, Gyeonggi-do, Korea, Republic of|Soonchunhyang University Bucheon Hospital, Gyeonggi-do, Korea, Republic of|St. Vincent's Hospital, Gyeonggi-do, Korea, Republic of|Ajou University Medical Center, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea Bucheon St. Mary's Hospital, Gyeonggi-do, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsangnam-do, Korea, Republic of|Catholic Univ. of Incheon St.Mary's Hospital, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Gil Hospital. Gachon University, Incheon, Korea, Republic of|Catholic Kwandong University International St. Mary'S Hospital., Incheon, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Wonkwang University School of Medicine & Hospital, Jeonlabuk-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Inje University, Sanggye-Paik Hospital, Seoul, Korea, Republic of|Korea Cancer Center Hospital of Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Gangdong Kyung Hee University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|ChungAng University Hospital, Seoul, Korea, Republic of|Yeouido St. Mary's Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of",39.49560659,35.54604593,All,"18 Years to 72 Years ¬† (Adult, Older Adult)",446,439,431,279,112,40,3/19/2016,8/21/2016,6/16/2016,7/17/2016,6/21/2016,6/27/2016,7/7/2016,7/10/2016,7/24/2016,3/18/2020,6/3/2020,12/20/2020,3/8/2021,5/1/2021,6/9/2021,8/5/2021,9/24/2021,10/26/2021,12/9/2021,12/24/2016,6/22/2017,12/19/2017,6/17/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02266173,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00438,SP00011,A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer Treatment,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Mara A,Selizabeth F,Terrell p,Chetan K,Suk T,Jerold Goo †,Naren G,Naren G,Donovan H,Suk T,In Bellini †,Otis Thode †,Kandace p,Suzie K,Chetan K,Marceline R,Geralyn K,Federico L,Mac L,,,"Centre Francois Baclesse; Oncologie, Caen, France|Centre Jean Perrin; Oncologie, Clermont Ferrand, France|Hopital Prive Jean Mermoz; Cancerologie, Lyon, France|Hopital Saint Louis; Oncologie Medicale, Paris, France|Institut du Cancer Coulancy Reims, Reims, France",10.66920898,9.602288083,Female,"30 Years to 80 Years ¬† (Adult, Older Adult)",456,445,432,322,51,59,9/21/2015,4/25/2016,2/4/2016,3/22/2016,2/19/2016,3/4/2016,3/15/2016,3/18/2016,4/16/2016,6/26/2018,8/6/2018,12/15/2018,4/19/2019,5/19/2019,6/26/2019,8/25/2019,10/3/2019,11/28/2019,1/19/2020,8/31/2016,2/27/2017,8/26/2017,2/22/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03558490,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00449,SP00011,A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 1|Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug H,,,,,,,,,,,,,,,,,,,Doreen T,Patria R,Marcelina X,Suk T,Tammara F,Suzie K,James y,Terisa Sikora †,Suzie K,Chetan K,Corrine U,Suk T,Dinah R,Dinah R,Christian G,Tiffiny K,John G,Mary H,Terisa Sikora †,,,"MD Anderson Cancer Center, Houston, Texas, United States|Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia|Honv√©delmi Miniszt√©rium √Ållami Eg√©szs√©g√ºgyi K√∂zpont; Onkol√≥giai Oszt√°ly; Pharmacy, Budapest, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz; Onkoradiol√≥gia, Ny√≠regyh√°za, Hungary|P√©csi Tudom√°nyegyetem; Klinikai K√∂zpont Onkoter√°pi√°s Int√©zet, P√©cs, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet; Megyei Onkologiai Kozpont, Szolnok, Hungary|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain",19.56227574,17.60604817,All,"18 Years to 99 Years ¬† (Adult, Older Adult)",477,463,433,411,39,17,5/14/2018,11/24/2018,9/14/2018,10/26/2018,10/4/2018,10/8/2018,10/22/2018,10/23/2018,11/1/2018,8/6/2020,6/4/2020,10/27/2020,2/4/2021,3/23/2021,5/18/2021,7/16/2021,8/31/2021,10/11/2021,11/15/2021,4/6/2019,10/3/2019,3/31/2020,9/27/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04298918,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00450,SP00011,A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Suzie K,Livia Pacheo †,Donovan H,Beulah N,Garnet T,Marceline R,Kandace p,Tiffiny K,Chetan K,Mara A,Suzie K,Terisa Sikora †,Anthony P,Mary H,Kala R,Lucie P,Donovan H,Jeanene Y,Anthony P,,,"Klinikum Augsburg; Institut f√ºr Pathologie, Augsburg, Germany|Sozialstiftung Bamberg; Institut f√ºr Pathologie, Bamberg, Germany|Klinikum Bayreuth, Bayreuth, Germany|Institut f√ºr Pathologie, Zytologie & Molekularpathologie in Bergisch Gladbach, Bergisch Gladbach, Germany|Gemeinschaftspraxis; Institut f√ºr Pathologie am Evangelischen Waldkrankenhaus, Berlin - Spandau, Germany|Gemeinschaftspraxis f√ºr Pathologie Stefan Berger, J√∂rg Linke und Ellen Fietze, Berlin, Germany|Vivantes Klinikum Neuk√∂lln; Fachbereich Pathologie, Berlin, Germany|HELIOS Klinikum Emil von Behring Klinik f.Pneumologie Onkologie u.Infektiologie, Berlin, Germany|Praxis am St. Agnes-Hospital Bocholt, Bocholt, Germany|Institut f√ºr Pathologie und Zytologie an der Augusta-Kranken-Anstalt, Bochum, Germany|Universit√§tsklinikum Bonn; Zentrum f√ºr Pathologie Pathologisches Institut, Bonn, Germany|Klinikum Coburg GmbH - Institut f√ºr Pathologie, Coburg, Germany|St√§dtisches Klinikum Dessau; Institut f√ºr Pathologie, Dessau-Ro√ülau, Germany|Gemeinschaftspraxis f√ºr Pathologie Dr. Dykgers, Dr. Langwieder, Dr. Rees, Dortmund, Germany|St√§dtisches Klinikum Dresden; Institut f√ºr Pathologie ""Georg Schmorl"" (Friedrichstadt), Dresden, Germany|Evangelisches Krankenhaus BETHESDA zu Duisburg GmbH; Institut f√ºr Pathologie, Duisburg, Germany|Krankenhaus D√ºren gem. GmbH; Institut und Praxisgemeinschaft f√ºr Pathologie, D√ºren, Germany|Universit√§tsklinikum Erlangen; Pathologisches Institut, Erlangen, Germany|OptiPath Gemeinschaftspraxis f√ºr Pathologie, Frankfurt, Germany|Universit√§tsklinikum Freiburg Institut f.Pathologie, Freiburg, Germany|Pathologische Institut Friedrichshafen/Bodensee (Gemeinschaftspraxis f√ºr Pathologie und Zytologie), Friedrichshafen, Germany|Institut f√ºr Pathologie, MVZ am Lukaskrankenhaus, Grevenbroich, Germany|Klinikum Oberberg; Pathologisches Institut Kreiskrankenhaus Gummersbach, Gummersbach, Germany|Klinik am Eichert; Institut f√ºr Pathologie, G√∂ppingen, Germany|Universit√§tsklinikum G√∂ttingen, Institut f√ºr Pathologie, G√∂ttingen, Germany|Pathologisches Institut am Allg. KH Stadt Hagen; Stambolis, Wolf von Rh√ºden, Ruwe, Hagen, Germany|Universit√§tsklinikum Halle (Saale), Institut f√ºr Pathologie, Halle/Saale, Germany|Kath. Marienkrankenhaus gGmbH, Hamburg, Germany|Fach√§rzte Dres Tiemann & Schulte Partnerschaft; Institut f√ºr H√§matopathologie Hamburg, Hamburg, Germany|Gemeinschaftspraxis f√ºr Pathologie Hamm, Dres. Diebold/Niemann, Hamm, Germany|Gemeinschaftspraxis Dr. Hartmut Fitz, Dr. Sebastian Blasius und PD Dr. Christian August, Hanau, Germany|Dres. Wolfgang Beschow Eckehardt Kupsch Herbert Radner u.w., Hannover, Germany|Medizinische Hochschule Hannover, Klinik f√ºr Frauenheilkunde und Geburtshilfe, Hannover, Germany|Pathologisches Institut, Heidelberg, Germany|Institut f√ºr Pathologie Hildesheim, Hildesheim, Germany|Gemeinschaftspraxis f√ºr Pathologie Ingolstadt Dr. K√∂nig, Dr. Popp, Prof. Dr. Adam, Ingolstadt, Germany|Universit√§tsklinikum Jena; Institut f√ºr Pathologie, Jena, Germany|St√§dtisches Klinikum Karlsruhe gGmbH; Pathologisches Institut, Karlsruhe, Germany|Institut F√ºr Pathologie Nordhessen, Kassel, Germany|Institut f√ºr Pathologie Kassel, Kassel, Germany|Institut f√ºr Pathologie, Universit√§sklinikum Schleswig-Holstein, Kiel, Germany|Klinikum Konstanz gGmbH, Institut und Praxis f√ºr Pathologie, Konstanz, Germany|Institut f. Pathologie, der Univers. K√∂ln, K√∂ln, Germany|Kliniken der Stadt K√∂ln gGmbH Krankenhaus Merheim, K√∂ln, Germany|Gemeinschaftspraxis f√ºr Pathologie L√ºbeck; Turzynski, Lebeau, Gocht, Leuenroth, L√ºbeck, Germany|Universit√§tsklinikum Magdeburg; Institut f√ºr Pathologie und Neuropathologie, Magdeburg, Germany|Klinikum Magdeburg GmbH, Magdeburg, Germany|Klinikum Mannheim; Pathologisches Institut, Mannheim, Germany|Institut f√ºr Pathologie, M√ºhlhausen, Germany|Pathologie M√ºnchen-Nord, M√ºnchen, Germany|Institut f√ºr Pathologie der Universit√§t M√ºnster, Albert Schweitzer Campus, Geb√§ude D17, M√ºnster, Germany|Institut f√ºr Pathologie am Clemenshospital M√ºnster, M√ºnster, Germany|Dietrich Bonhoeffer Kliniken Neubrandenburg, Institut f√ºr Pathologie, Neubrandenburg, Germany|Zentrum f√ºr Pathologie, Zytologie und Molekularpathologie Neuss, Neuss, Germany|Evangelisches Krankenhaus Oberhausen GmbH, Institut f.Pathologie, Oberhausen, Germany|Pathocom - Gemeinschaftspraxis Bischofsstra√üe Osnabr√ºck, Osnabr√ºck, Germany|Pathologisches Institut Recklinghausen, Recklinghausen, Germany|Klinikum am Steinenberg / Ermstalklinik, Reutlingen, Germany|Diakoniekrankenhaus Institut f.Pathologie, Rotenburg, Germany|Leopoldina Krankenhaus der Stadt Schweinfurt GmbH; Pathologie, Schweinfurt, Germany|HELIOS Klinikum Schwerin; Frauenklinik, Schwerin, Germany|Gemeinschaftspraxis PD Dr.med. Meinald Schultz und Dr.med. Petra L√ºders, Stendal, Germany|Robert-Bosch-Krankenhaus; Pathologisches Institut, Stuttgart, Germany|Gemeinschaftspraxis f√ºr Pathologie Weiden; am Klinikum Weiden; Giedl, Stelter und Meier, Weiden, Germany",34.95863421,31.46277079,All,"18 Years and older ¬† (Adult, Older Adult)",482,460,434,317,73,44,11/30/2012,5/23/2013,3/25/2013,4/22/2013,3/17/2013,4/2/2013,4/13/2013,4/16/2013,4/24/2013,10/1/2017,6/3/2017,11/29/2017,2/28/2018,4/2/2018,5/2/2018,6/23/2018,8/19/2018,10/17/2018,12/6/2018,9/29/2013,3/28/2014,9/24/2014,3/23/2015,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02666261,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00451,SP00011,A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,,,,Drug H,,,,,,,,,,,,,,,,,,,Quentin N,Patria R,Tiffiny K,Chetan K,Terisa Sikora †,Frank T,Jaquelyn H,Stephan T,Rima Y ,John G,Tiffiny K,Liberty A,Tamesha T,Tiffiny K,Tiffiny K,Marceline R,Tien C,Ngan D,Ngan D,,,"Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States|USC Norris Cancer Center, Los Angeles, California, United States|USC Norris Cancer Center; USC Oncology Hematology Newport Beach, Newport Beach, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|Christiana Care Health Srvcs; Helen F Graham Can Center, Newark, Delaware, United States|Orlando Health Inc., Orlando, Florida, United States|Atlanta Cancer Care, Alpharetta, Georgia, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Mercy Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute; GYN Oncology, Boston, Massachusetts, United States|Minnesota Oncology Minneapolis, Minneapolis, Minnesota, United States|Summit Medical Group; MD Anderson Cancer Center, Florham Park, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Duke Cancer Center, Durham, North Carolina, United States|Northwest Cancer Specialists, Portland, Oregon, United States|Faris Research, Greenville, South Carolina, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Cabrini Medical Centre; Oncology, Malvern, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung f√ºr Onkologie, Graz, Austria|Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. F√ºr Gyn√§kologie, Innsbruck, Austria|Klinikum Klagenfurt; Abt. f. H√§matologie u. internistische Onkologie, Klagenfurt, Austria|Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1, Linz, Austria|Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU, Salzburg, Austria|Medizinische Universit√§t Wien; Univ.Klinik f√ºr Innere Medizin I, Wien, Austria|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, SP, Brazil|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre), Kelowna, British Columbia, Canada|BC Cancer - Victoria, Victoria, British Columbia, Canada|Juravinski Cancer Clinic; Clinical Trials Department, Hamilton, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Hopital du Saint Sacrement, Quebec City, Quebec, Canada|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Universit√† degli Studi della Campania Luigi Vanvitelli; Divsione Di Oncologia Medica, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Azienda Unit√† Sanitaria Locale di Reggio Emilia/IRCCS, Reggio Emilia, Emilia-Romagna, Italy|Ospedale San Raffaele S.r.l., Milano, Lombardia, Italy|ASST DI MONZA; Oncologia Medica, Monza, Lombardia, Italy|Istituto Clinico Humanitas, Rozzano (MI), Lombardia, Italy|Fondazione del Piemonte per l'Oncologia (IRCCS), Candiolo, Piemonte, Italy|Ospedale San Vincenzo Taormina :Divisione di Oncologia Medica, Taormina, Sicilia, Italy|Ospedale Civile - Livorno, Livorno, Toscana, Italy|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Okayama University Hospital, Okayama, Japan|Ajou University Medical Center, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Cl√≠nico Universitario de Valencia; Servicio de Oncolog√≠a, Valencia, Spain|China Medical University Hospital; Surgery, Taichung, Taiwan|National Cheng Kung Uni Hospital; Dept of Hematology and Oncology, Tainan, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|National Taiwan Uni Hospital; Dept of Oncology, Taipei, Taiwan|Mackay Memorial Hospital; Dept of Surgery, Taipei, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Srinagarind Hospital; Medical Oncology Unit, Khon Kaen, Thailand|The Royal Marsden Hospital; Dept of Medicine, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Royal Marsden Hosp NHS Fnd; Medicine - Breast Unit, Sutton, United Kingdom",24.39777198,21.95799478,All,"Child, Adult, Older Adult",486,471,435,166,246,23,3/7/2019,9/12/2019,6/28/2019,7/31/2019,7/17/2019,7/25/2019,7/29/2019,8/1/2019,8/12/2019,7/14/2022,9/11/2022,1/7/2023,4/30/2023,6/19/2023,8/4/2023,9/29/2023,10/29/2023,12/13/2023,1/12/2024,1/21/2020,7/19/2020,1/15/2021,7/14/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04060862,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00456,SP00011,Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Control|Time Perspective: Cross-Sectional,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Suzie K,Gertrudis T,Frank T,Ross S,Liberty A,Chetan K,Mara A,Tamesha T,Lilla Stilson †,Kandace p,Stephan T,Federico L,Lavina S,Perter K,John G,Ross S,Tamesha T,Selizabeth F,Liberty A,,,"Ankara University Medical Faculty, Ankara, Turkey|Istanbul University Istanbul Medical Faculty, Istanbul, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Dokuz Eylul University Medical Faculty, Izmir, Turkey",32.11804378,28.9062394,Female,"45 Years and older ¬† (Adult, Older Adult)",458,453,436,174,240,22,7/7/2012,1/27/2013,11/20/2012,12/15/2012,11/11/2012,12/6/2012,12/21/2012,12/23/2012,1/15/2013,6/21/2014,2/14/2014,7/28/2014,10/1/2014,11/17/2014,1/6/2015,2/11/2015,4/11/2015,6/1/2015,7/18/2015,6/4/2013,12/1/2013,5/30/2014,11/26/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02580799,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00457,SP00011,Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Dinah R,Lyman W,Mara A,In Bellini †,Geralyn K,Dinah R,John G,Tamesha T,Patria R,Dinah R,Suk T,Corrine U,Terisa Sikora †,Tiffiny K,Jeanene Y,Federico L,Jerold Goo †,Doreen T,Quentin N,,,"King Fahad Specialist Hospital; Oncology, Dammam, Saudi Arabia|King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia|National Guard King Abdulaziz Medical City; Oncology, Riyadh, Saudi Arabia",93.14468494,83.83021645,All,"45 Years and older ¬† (Adult, Older Adult)",495,476,437,270,121,46,5/14/2016,11/5/2016,9/6/2016,10/2/2016,9/7/2016,9/16/2016,9/25/2016,9/29/2016,10/16/2016,3/18/2019,1/23/2019,5/14/2019,9/17/2019,11/16/2019,1/5/2020,2/29/2020,4/12/2020,5/23/2020,6/30/2020,3/15/2017,9/11/2017,3/10/2018,9/6/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02954471,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00460,SP00011,"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer",,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug F,,,,,,,,,,,,,,,,,,,Lyman W,Terisa Sikora †,Marceline R,Remedios Z,Geralyn K,Gertrudis T,Tammara F,Marcelina X,Jerold Goo †,Otis Thode †,Frank T,Geralyn K,Ross S,Ngan D,Tamesha T,Lavina S,Aleta H,Anthony P,Beulah N,,,"UCSD Moores Cancer Center, La Jolla, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|USC Norris Cancer Center; USC Oncology Hematology Newport Beach, Newport Beach, California, United States|Kaiser Permanente - Oakland, Oakland, California, United States|Kaiser Permanente - Roseville, Roseville, California, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente - San Francisco (2238 Geary), San Francisco, California, United States|UCSF Comprehensive Cancer Ctr, San Francisco, California, United States|K. Permanente - San Jose, San Jose, California, United States|Kaiser Permanente - San Leandro, San Leandro, California, United States|K. Permanente - Santa Clara, Santa Clara, California, United States|Kaiser Permanente - South San Francisco, South San Francisco, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|K. Permanente - Walnut Creek, Walnut Creek, California, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|University of Maryland, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center; MSK Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center at Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center - Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center at Westchester, Harrison, New York, United States|Memorial Sloan Kettering, New York, New York, United States|Memorial Sloan Kettering Cancer Center at Nassau, Uniondale, New York, United States|West Clinic, Germantown, Tennessee, United States|Texas Oncology, P.A., Dallas, Texas, United States|UT Southwestern Medical Center; Simmons Comprehensive Cancer Center, Simmons Pharmacy, Dallas, Texas, United States|Oncology Consultants PA, Houston, Texas, United States|Fundaci√≥n CENIT para la Investigaci√≥n en Neurociencias, Buenos Aires, Argentina|Hosp Provincial D. Centenarios; Oncology Dept, Rosario, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Westmead Hospital; Medical Oncology, Wentworthville, New South Wales, Australia|Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia|Cabrini Medical Centre; Oncology, Malvern, Victoria, Australia|Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit, Bull Creek, Western Australia, Australia|Cliniques Universitaires St-Luc, Bruxelles, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Santa Casa de Misericordia de Salvador, Salvador, BA, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital do C√¢ncer de Londrina, Londrina, PR, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Faculdade de Medicina do ABC - FMABC, Santo Andre, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, Chile|Clinica CIMCA, San Jose, Costa Rica|ICIMED Instituto de Investigaci√≥n en Ciencias M√©dicas, San Jos√©, Costa Rica|Masaryk≈Øv onkologick√Ω √∫stav; Klinika komplexn√≠ onkologick√© p√©ƒçe, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|CHU Besan√ßon - H√¥pital Jean Minjoz, Besan√ßon Cedex, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|ICM; Medecine B3, Montpellier cedex 5, France|Centre Catherine De Sienne, Nantes, France|APHP - Hospital Saint Louis, Paris, France|Institut Jean Godinot; Oncologie Medicale, Reims CEDEX, France|Onkologische Schwerpunktpraxis Kurf√ºrstendamm, Berlin, Germany|Praxis f√ºr Interdisziplin√§re Onkologie und H√§matologie GbR, Freiburg, Germany|Universit√§tsklinikum Hamburg-Eppendorf; Frauenklinik, Hamburg, Germany|Universit√§tsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe, Homburg/Saar, Germany|Praxis Dr.med. Katja Ziegler-L√∂hr, K√∂ln, Germany|Dres. Andreas K√∂hler und Roswitha Fuchs, Langen, Germany|M√ºhlenkreiskliniken; Johannes Wesling Klinikum Minden; Klinik f√ºr Frauenheilkunde und Geburtshilfe, Minden, Germany|Oncologianova GmbH - Gesellschaft f√ºr Innovationen in der Onkologie, Recklinghausen, Germany|Universit√§tsfrauen- und Poliklinik am Klinikum Suedstadt, Rostock, Germany|Universit√§tsklinikum W√ºrzburg; Frauenklinik, W√ºrzburg, Germany|Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, Greece|Agioi Anargyroi; 3Rd Dept. of Medical Oncology, Athens, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Orszagos Onkologial Intezet; Onkologiai Osztaly X, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly, Miskolc, Hungary|Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, Hungary|Hetenyi Geza County Hospital; Onkologiai Kozpont, Szolnok, Hungary|Zala County Hospital ICU, Zalaegerszeg, Hungary|Indraprastha Apollo Hospitals, New Delhi, Delhi, India|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, India|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unit√† Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Ospedale Santa Maria Annunziata; Oncologia, Bagno a Ripoli, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Aichi Cancer Center Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|National Hospital Organization Kyushu Cancer Center;Breast Oncology, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Hyogo College of Medicine Hospital, Hyogo, Japan|St. Marianna University School of Medicine Hospital, Kanagawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Kumamoto Shinto General Hospital, Kumamoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Kinki University Hospital, Faculty of Medicine; Surgery, Osaka, Japan|Saitama Cancer Center, Breast Oncology, Saitama, Japan|Shizuoka Cancer Center, Shizuoka, Japan|National Cancer Center Hospital, Tokyo, Japan|St. Luke's International Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Showa University Hospital; Breast Surgery, Tokyo, Japan|National Cancer Center, Goyang-si, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Centro Medico Dalinde, Cdmx, Mexico CITY (federal District), Mexico|Centro M√©dico Zambrano Hellion, Monterrey, Nuevo LEON, Mexico|Merida   Investigacion Clinica, M√©rida, Yucatan, Mexico|Consultorio de Medicina Especializada; Dentro de Condominio San Francisco, Mexico City, Mexico|Clinical Hospital; Oncology Department, Bitola, North Macedonia|PHI University Clinic of Radiotherapy and Oncology; Breast malignancy, Skopje, North Macedonia|PHI University Clinic of Radiotherapy and Oncology; Malignant diseases of thorax, Skopje, North Macedonia|Centro Medico Monte Carmelo, Arequipa, Peru|Hospital Daniel Alcides Carrion, Callao, Peru|Cl√≠nica San Gabriel; Unidad de Investigaci√≥n Oncol√≥gica de la Cl√≠nica San Gabriel, Lima, Peru|Hospital Nacional Cayetano Heredia; Ocolog√≠a; Servicio de Hematolog√≠a Oncolog√≠a M√©dica, Lima, Peru|Oncosalud Sac; Oncolog√≠a, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Instituto Regional de Enfermedades Neoplasicas - IREN Norte, Trujillo, Peru|Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice; III Klin. Radioter. i Chemioter., Gliwice, Poland|Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie; Klinika Nowotworow Piersi i Chirurgii Rekonstr, Warszawa, Poland|Instyt. Centrum Zdrowia Matki Polki; Klinika Chirurgii Onk. Chor√≥b Piersi z Podod. Onko Klinicznej, ≈Å√≥d≈∫, Poland|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Arhangelsk, Russian Federation|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moskva, Moskovskaja Oblast, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|SBIH Kaluga Region Clinical Oncology Dispensary, Kaluga, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|Federal State Institution, Moscow Research Oncology Institute n.a. P.A. Hertzen; Oncourology, Moscow, Russian Federation|FSI Rostov research oncological institute of MoH and SD of RF; PAD, Rostov-on-Don, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon de La Plana, Castellon, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, C√≥rdoba, Cordoba, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coru√±a, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clinic Barcelona; Servicio de oncologia, Barcelona, Spain|Hospital de Donostia; Servicio de Oncologia, Guipuzcoa, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clinico Universitario; Oncologia, Valencia, Spain|Chi Mei Medical Center Liou Ying Campus, Liuying Township, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan|Ankara City Hospital, Ankara, Turkey|Dicle Uni Medical Faculty; Internal Medicine, Diyarbakir, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Prof. Dr. Cemil Tascioglu City Hospital; Med Onc, Istanbul, Turkey|Katip Celebi University Ataturk Training and Research Hospital; Oncology, Izmir, Turkey|Sakarya University Medical School; Medical Oncology, Sakarya, Turkey|Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipropetrovsk, Ukraine|Kyiv City Clinical Oncological Center, Day Hospital Department for Oncological patients, Kiev, Ukraine|National Cancer Institute MOH of Ukraine, Kiev, Ukraine|Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine|Velindre Cancer Centre, Cardiff, United Kingdom|University Hospital coventry; Oncology Department, Coventry, United Kingdom|The Beatson West of Scotland Cancer Centre; Cancer Clinical Trials Unit, Glasgow, United Kingdom|Royal Marsden Hospital - London, London, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom",94.17307183,84.75576465,All,"18 Years and older ¬† (Adult, Older Adult)",472,463,438,230,169,39,9/9/2019,2/6/2020,12/5/2019,1/2/2020,12/13/2019,12/24/2019,12/26/2019,12/29/2019,1/4/2020,7/23/2021,3/18/2021,9/15/2021,12/22/2021,1/29/2022,2/28/2022,4/23/2022,6/1/2022,7/14/2022,9/4/2022,6/21/2020,12/18/2020,6/16/2021,12/13/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03337724,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00463,SP00011,A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1),,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Mara A,Federico L,Ross S,Lavina S,Gertrudis T,Chetan K,Frank T,Donovan H,Donovan H,Perter K,Lavina S,Louann C,Quentin N,Anthony P,Kala R,Harry A,Perter K,John G,Rima Y ,,,"University of Alabama At Birmingham, Birmingham, Alabama, United States|Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Arizona Oncology - HOPE Wilmot, Tucson, Arizona, United States|UCLA, Los Angeles, California, United States|The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Kaiser Permanente - San Marcos, San Marcos, California, United States|Stanford Cancer Center, Stanford, California, United States|Kaiser Permanente; Oncology Clinical Trials, Vallejo, California, United States|Rocky Mountain Cancer Center - Aurora, Aurora, Colorado, United States|University Of Colorado, Aurora, Colorado, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Yale Cancer Center ; Medical Oncology, New Haven, Connecticut, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Mayo Clinic Cancer Center, Jacksonville, Florida, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|University of Chicago; Hematology/Oncology, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Indiana University Health; Goshen Center for Cancer Care, Goshen, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Massachusetts General Hospital;Oncology, Boston, Massachusetts, United States|Dana Farber Cancer Inst. ; Dept. of Medical Oncology, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Harvard Medical School; Department of Medicine, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Minneapolis, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Urology Cancer Center & GU Research Network, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, P.C., Albany, New York, United States|NYU Langone Medical Center, New York, New York, United States|Mount Sinai School of Medicine - Tisch Cancer Institute, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Case Western Reserve Univ; Hem/Onc, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Kimmel Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Ctr for Cancer and Blood Disorders, Fort Worth, Texas, United States|Texas Oncology - Houston (Gessner), Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates - Lake Wright Cancer Center, Norfolk, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Bcca - Cancer Center Southern Interior, Kelowna, British Columbia, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, Canada|The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|APHP - Hospital Saint Louis, Paris, France|Hopital Foch; Oncologie, Suresnes, France|Institut Gustave Roussy; Oncologie Medicale, Villejuif, France|Charit√© - Universit√§tsmedizin Berlin; CC 8: Chirurgische Medizin; Klinik f√ºr Urologie, Berlin, Germany|Universit√§tsklinikum D√ºsseldorf; Urologische Klinik, D√ºsseldorf, Germany|Universit√§tsklinikum Freiburg; Chirurgische Klinik; Abteilung Urologie, Freiburg, Germany|Universit√§tsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II, Hamburg, Germany|Klinikum rechts der Isar der TU M√ºnchen; Urologische Klinik und Poliklinik, M√ºnchen, Germany|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia, Arezzo, Toscana, Italy|The Netherlands Cancer Institute - Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital General Universitario Gregorio Mara√±on; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|University Hospital Birmingham The Cancer Centre, Queen Elizabeth Hospital, Birmingham, United Kingdom|Barts and The London, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom",38.94281121,35.04853008,All,"18 Years and older ¬† (Adult, Older Adult)",480,467,439,348,48,43,9/5/2010,2/1/2011,11/19/2010,12/31/2010,11/29/2010,12/12/2010,12/27/2010,12/30/2010,1/6/2011,12/10/2014,10/22/2014,4/18/2015,5/31/2015,7/13/2015,9/4/2015,10/17/2015,12/6/2015,1/8/2016,3/4/2016,6/10/2011,12/7/2011,6/4/2012,12/1/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02951767,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00466,SP00011,"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer",,,,,Oncology,,,,,,Industry,Recruiting,Phase 2|Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug I,,,,,,,,,,,,,,,,,,,Perter K,Mee M,Beulah N,Louann C,Terrell p,Aleta H,Suzie K,Tien C,Beulah N,Selizabeth F,Stephan T,Doreen T,Jaquelyn H,Kala R,Ngan D,Aleta H,Tamesha T,Marceline R,Tamesha T,,,"Arizona Oncology Associates, PC-CASA, Tucson, Arizona, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|Kaiser Permanente;Clinical Trials Department, Denver, Colorado, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States|Memorial Healthcare System - Memorial Regional Hospital, Hollywood, Florida, United States|Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, United States|SCRI Florida Cancer Specialists PAN, Tallahassee, Florida, United States|SCRI Florida Cancer Specialists East, West Palm Beach, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Univ of Chicago, Chicago, Illinois, United States|Maryland Oncology Hematology; Maryland Oncology Hematology, Silver Spring, Silver Spring, Maryland, United States|Massachusetts General Hospital., Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|HCA Midwest Division, Kansas City, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Providence Portland Medical Center; Providence Oncology and Hematology Clinic Westside, Portland, Oregon, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Tech University Health Sciences Center; Department of Internal Medicine, El Paso, Texas, United States|The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, United States|Texas Oncology, P.A. - McAllen; South Texas Cancer Center-McAllen, McAllen, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology, P.A. - Tyler; Tyler Cancer Center, Tyler, Texas, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Macquarie University Hospital, Macquarie Park, New South Wales, Australia|Westmead Hospital; Medical Oncology and Pallative Care, Westmead, New South Wales, Australia|Southern Medical Day Care Centre, Wollongong, New South Wales, Australia|Cairns Base Hospital; Cancer Care Centre, Cairns, Queensland, Australia|Mater Adult Hospital; Oncology, South Brisbane, Queensland, Australia|Townsville Hospital; Haematology and Oncology, Townsville, Queensland, Australia|Princess Alexandra Hospital; Cancer Trials Unit, Woolloongabba, Queensland, Australia|Western Health, Fitzroy, Victoria, Australia|Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|Austin Health; Cancer Clinical Trial Centre, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia|Universit√§tsklinikum St. P√∂lten; Klinische Abteilung f√ºr Innere Medizin 1, St. P√∂lten, Austria|Cliniques Universitaires St-Luc, Bruxelles, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Fraser Valley Centre British Columbia Cancer Agency, Surrey, British Columbia, Canada|Royal Victoria Hospital, Barrie, Ontario, Canada|London Regional Cancer Program, London Health Sciences Centre, Baines Centre, London, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Hopital du Saint Sacrement, Quebec City, Quebec, Canada|Centre Hospitalier Regional De Rimouski, Rimouski, Quebec, Canada|Beijing Cancer Hospital, Beijing, China|The First Hospital of Jilin University, Changchun City, China|West China Hospital, Sichuan University, Chengdu, China|The First Affiliated Hospital, Chongqing Medical University, Chongqing, China|The First People's Hospital of Foshan, Foshan, China|Fujian Medical University Union Hospital, Fuzhou City, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department, Hangzhou City, China|Harbin Medical University Cancer Hospital, Harbin, China|Anhui Provincial Hospital, Hefei, China|Shandong Cancer Hospital, Jinan, China|Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China|Fudan University Shanghai Cancer Center; Medical Oncology, Shanghai City, China|Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province), Shijiazhuang, China|Tianjin Cancer Hospital, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China|Hubei Cancer Hospital, Wuhan, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China|Henan Cancer Hospital, Zhengzhou, China|Herlev Hospital; Afdeling for Kr√¶ftbehandling, Herlev, Denmark|Vejle Sygehus; Onkologisk Afdeling, Vejle, Denmark|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Centre Jean Perrin Centre Regional de Lutte Contre Le Cancer D auvergne, Clermont-ferrand, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|Centre Oscar Lambret; Senologie, Lille, France|Hopital Dupuytren; Oncologie Medicale, Limoges, France|Hopital Prive Jean Mermoz; Cancerologie, Lyon, France|Institut r√©gional du Cancer Montpellier, Montpellier, France|Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France|Vivantes Klinikum Am Urban Klinik f√ºr Innere Medizin H√§matologie und Onkologie, Berlin, Germany|Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters, Berlin, Germany|Gyn√§kologisches Zentrum Bonn, Bonn, Germany|Universit√§tsklinikum ""Carl Gustav Carus"" der Technischen Universit√§t Dresden, Dresden, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik f√ºr Senologie / Brustzentrum, Essen, Germany|Nationales Centrum f√ºr Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany|St. Elisabeth Krankenhaus K√∂ln GmbH; Gyn√§kologie und Geburtshilfe, Koeln, Germany|Helios Klinikum Krefeld; Zentrum f√ºr ambulante gyn√§kologische Onkologie (ZAGO), Krefeld, Germany|Universit√§tsklinikum Leipzig; Klinik und Poliklinik f√ºr Frauenheilkunde, Leipzig, Germany|Universit√§tsklinikum Mannheim; Frauenklinik, Mannheim, Germany|Klinik & Poliklinik f√ºr Frauenheilkunde und Geburtshilfe, Campus Innenstadt, M√ºnchen, Germany|St. Vincenz-Krankenhaus Paderborn; Haus 3 Frauenklinik, Paderborn, Germany|Oncologianova GmbH - Gesellschaft f√ºr Innovationen in der Onkologie, Recklinghausen, Germany|Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie, Trier, Germany|Universit√§tsfrauenklinik Ulm; Abteilung Gyn√§kologie, Ulm, Germany|Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine, Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|Metropolitan Hospital; Dept. of Oncology, Pireaus, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Prince of Wales Hospital; Department of Clinical Onocology, Shatin, Hong Kong|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, Hungary|Uzsoki Utcai Korhaz; Onkoradiol√≥giai Oszt√°ly, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont ; Department of Oncology, Debrecen, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet; Megyei Onkologiai Kozpont, Szolnok, Hungary|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, Italy|A.O. Universitaria Di Parma, Parma, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera Univ di Udine; Oncologia Medica, Udine, Friuli-Venezia Giulia, Italy|Policlinico Universitario ""Agostino Gemelli""; U.O.C. Oncologia Medica, Roma, Lazio, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina, Brescia, Lombardia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|Ospedale Santa Maria Annunziata; Oncologia, Bagno a Ripoli, Toscana, Italy|Azienda Ospedaliero Universitaria Pisana; Unita Operativa Oncologia Medica 2, Pisa, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Pusan National University Hospital, Busan, Korea, Republic of|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Kyungpook National University Medical Center, Daegu, Korea, Republic of|Soon Chun Hyang University Cheonan Hospital, Dongnam-gu, Cheonan-si, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Borame Medical Center, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Auckland City Hospital; Clinical Oncology, Auckland, New Zealand|Christchurch Hospital NZ, Christchurch, New Zealand|Waikato Hospital; Dept of Medical Oncology, Hamilton, New Zealand|Palmerston North Hospital; Regional Cancer Treatment Service, Palmerston North, New Zealand|Centrum Onkologii im. Prof. Franciszka ≈Åukaszczyka; Ambulatorium Chemioterapii, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gda≈Ñsk, Poland|Narodowy Instytut Onkologii Odzia≈Ç w Gliwicach; Centrum Diagnostyki i Leczenia Chor√≥b Piersi, Gliwice, Poland|Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, Poland|Centrum Terapii Wspolczesnej J.M.Jasnorzewska Spolka Komandytowo-Akcyjna, Lodz, Poland|Opolskie Centrum Onkologii; Onkologia Kliniczna z Odcinkiem Dziennym, Opole, Poland|Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii, Otwock, Poland|Lecznice Citomed Sp. z o.o., Torun, Poland|Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr, Warszawa, Poland|Wojskowy Instytut Medyczny; Klinika Onkologii, Warszawa, Poland|Dolno≈õlƒÖskie Centrum Onkologii; Oddzia≈Ç Onkologii Klinicznej i Chemioterapii, Wroc≈Çaw, Poland|Centro Clinico Champalimaud; Oncologia Medica, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|Centro Hospitalar do Porto - Hospital de Santo Ant√≥nio; Oncologia, Porto, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Moscow Clinical Scientific Center, Moscow, Moskovskaja Oblast, Russian Federation|MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy, Moscow, Moskovskaja Oblast, Russian Federation|LLC Medscan, Moskva, Moskovskaja Oblast, Russian Federation|Clinical Hospital Lapino (LLC Haven), Yudino, Moskovskaja Oblast, Russian Federation|Medical Clinic ""AB Medical group"", Saint Petersburg, Sankt Petersburg, Russian Federation|Blokhin Cancer Research Center; Out-Patients Dept, Moscow, Russian Federation|Regional Oncology Dispensary; Dept of Chemotherapy, Novgorod Veliky, Russian Federation|Volgograd Regional Clinical Oncology Dispensary, Volgograd, Russian Federation|Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clinic de Barcelona. Unidad de Nuevas Terapias;Oncology Department, Barcelona, Spain|Insituto Catal√°n de Oncologia (ICO), Barcelona, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Hospital General Universitario Gregorio Mara√±on; Servicio de Oncologia, Madrid, Spain|Clinica Universidad de Navarra-Madrid, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Kaohsiung Medical Uni Chung-Ho Hospital; Dept of Surgery, Kaohsiung, Taiwan|Chi-Mei Medical Centre; Hematology & Oncology, Tainan, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan|Tri-Service General Hospital, Division of General Surgery, Taipei, Taiwan|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial, Chiang Mai, Thailand|Chulabhorn Hospital; Medical Oncology, Lak Si, Thailand|Songklanagarind Hospital; Department of Oncology, Songkhla, Thailand|Adana Baskent University Hospital; Medical Oncology, Adana, Turkey|Gulhane Training and Research Hospital, Ankara, Turkey|Ege University Medical Faculty; Medical Oncology Department, Bornova, ƒ∞ÃázmiÃár, Turkey|Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey|Prof. Dr. Cemil Tascioglu City Hospital; Med Onc, Istanbul, Turkey|Kartal Dr Lutfi Kirdar Sehir Hastanesi; Medical Oncology Department, Istanbul, Turkey|SI Institute of general&urgent surgery n/a Zaytseva V.T NAMSU; Purulent Surgery department, Kharkiv, Kharkiv Governorate, Ukraine|Municipal Institution SubCarpathian Clinical Oncological Centre; Surgical department#2, Ivano-Frankivsk, KIEV Governorate, Ukraine|Uzhhorod Central City Clinical Hospital, Uzhhorod, KIEV Governorate, Ukraine|City Clinical Hospital #4, Dnipropetrovsk, Ukraine|ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department, Kryvyi Rih, Ukraine|Kyiv City Clinical Oncological Center, Kyiv, Ukraine|RCI Sumy Regional Clinical Oncological Dispensary, Sumy, Ukraine|Bristol Royal Infirmary, Bristol, United Kingdom|Princess Alexandra Hospital; Oncology Department, Harlow, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|Barts Health NHS Trust; Cancer Research Delivery Group, London, United Kingdom|St Georges University Hospitals NHS Foundation Trust, London, United Kingdom|Royal Marsden Hospital - Fulham; Oncology Department, London, United Kingdom|Maidstone Hospital; Kent Oncology Centre, Maidstone, United Kingdom|Christie Foundation Trust, Manchester, United Kingdom|Mount Vernon Hospital; Mount Vernon Cancer Centre, Northwood, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Churchill Hospital; Department of Oncology, Oxford, United Kingdom|Peterborough City Hospital, Edith Cavell Campus; Oncology Department, Peterborough, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Marsden Hosp NHS Fnd; Medicine - Breast Unit, Sutton, United Kingdom",94.65551413,85.18996272,All,"18 Years and older ¬† (Adult, Older Adult)",456,445,440,303,87,50,1/22/2021,9/3/2021,7/6/2021,7/29/2021,6/22/2021,7/14/2021,7/20/2021,7/23/2021,7/30/2021,12/23/2024,12/26/2024,5/21/2025,9/19/2025,10/24/2025,12/10/2025,1/15/2026,2/15/2026,3/29/2026,5/10/2026,1/10/2022,7/9/2022,1/5/2023,7/4/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04191499,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00467,SP00011,A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Quentin N,Beulah N,Garnet T,James y,Perter K,Mac L,Naren G,Doreen T,Jene M,Suk T,Corrine U,Hee Y,Naren G,Jeanene Y,Frank T,Patria R,John G,Dalton E,Suzie K,,,"Aschersleben, Germany|Dessau, Germany|Fulda, Germany|Leipzig, Germany|Leipzig, Germany|Marburg, Germany|Weiden, Germany",74.91538252,67.42384427,All,"18 Years and older ¬† (Adult, Older Adult)",463,454,441,262,133,46,3/27/2007,9/10/2007,6/27/2007,7/30/2007,7/4/2007,7/24/2007,7/27/2007,7/28/2007,8/6/2007,6/24/2009,5/27/2009,11/10/2009,1/1/2010,2/4/2010,3/28/2010,5/26/2010,7/23/2010,9/17/2010,10/22/2010,1/20/2008,7/18/2008,1/14/2009,7/13/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02013765,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00471,SP00011,A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Mac L,Doreen T,Mee M,Louann C,Lyman W,Lucie P,Louann C,Ngan D,Donovan H,John G,Mary H,Remedios Z,Ross S,John G,Aleta H,Suzie K,Ross S,Jerold Goo †,Beulah N,,,"Aschersleben, Germany|Dessau, Germany|Fulda, Germany|Leipzig, Germany|Leipzig, Germany|Marburg, Germany|Weiden, Germany",77.6054737,69.84492633,All,"18 Years and older ¬† (Adult, Older Adult)",490,473,442,188,218,36,7/6/2005,1/1/2006,10/31/2005,12/10/2005,11/9/2005,11/20/2005,12/1/2005,12/2/2005,12/19/2005,1/25/2009,3/7/2009,9/24/2009,1/1/2010,2/4/2010,3/22/2010,5/17/2010,6/21/2010,8/8/2010,9/26/2010,5/19/2006,11/15/2006,5/14/2007,11/10/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02006667,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00473,SP00011,A Study of Pertuzumab in Participants With Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Perter K,Aleta H,Kandace p,Tammara F,Dalton E,Tien C,Mara A,Hee Y,Aleta H,Chetan K,Quentin N,Ross S,Kala R,Tien C,Mary H,Stephan T,Lavina S,John G,Ross S,,,"Camperdown, Australia|Fitzroy, Australia|Geelong, Australia|Namur, Belgium|Helsinki, Finland|Tampere, Finland|Hamburg, Germany|Herne, Germany|M√ºnchen, Germany|Milano, Italy|Parma, Italy|Amsterdam, Netherlands|Barcelona, Spain|Barcelona, Spain|Valencia, Spain|Edinburgh, United Kingdom|London, United Kingdom|Manchester, United Kingdom",5.302411132,4.772170019,Female,"18 Years and older ¬† (Adult, Older Adult)",472,456,443,137,282,24,5/10/2001,11/9/2001,9/11/2001,10/27/2001,9/23/2001,10/9/2001,10/15/2001,10/19/2001,10/25/2001,8/25/2004,9/3/2004,12/10/2004,4/1/2005,5/12/2005,6/19/2005,7/25/2005,9/22/2005,11/21/2005,1/13/2006,4/7/2002,10/4/2002,4/2/2003,9/29/2003,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02491892,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00475,SP00011,To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Marceline R,Perter K,John G,Mary H,Jerold Goo †,Mary H,Mac L,Naren G,Tiffiny K,Rima Y ,Hee Y,Christian G,Tien C,John G,Lilla Stilson †,Marcelina X,Tiffiny K,Corrine U,John G,,,"Bayonne, France|Beziers, France|Bourg En Bresse, France|Colmar, France|Dijon, France|Hyeres, France|La Tronche, France|Le Mans, France|Limoges, France|Lyon, France|Marseille, France|Montbeliard, France|Montfermeil, France|Nice, France|Nimes, France|Paris, France|Pierre Benite, France|Saint Herblain, France|Strasbourg, France|Toulouse, France|Vannes, France",89.43487996,80.49139196,Female,"18 Years and older ¬† (Adult, Older Adult)",490,483,444,307,77,60,8/25/2008,3/17/2009,1/5/2009,2/8/2009,1/5/2009,1/21/2009,1/28/2009,2/2/2009,2/11/2009,7/23/2011,3/5/2011,8/10/2011,12/1/2011,1/19/2012,2/24/2012,3/31/2012,5/17/2012,6/18/2012,7/30/2012,7/20/2009,1/16/2010,7/15/2010,1/11/2011,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02846428,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00477,SP00011,An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat),,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Mary H,Jeanene Y,Donovan H,Jaquelyn H,Stephan T,Mary H,Xochitl D,Chetan K,Xochitl D,Mara A,Suzie K,Naren G,Ngan D,Anthony P,Mara A,John G,Terisa Sikora †,Aleta H,Jene M,,,"Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyor, Hungary|Gyula, Hungary|Kaposvar, Hungary|Ny√≠regyh√°za, Hungary|Pecs, Hungary|Szeged, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Szekszard, Hungary|Szolnok, Hungary|Szombathely, Hungary|Tatab√°nya, Hungary|Veszprem, Hungary|Zalaegerszeg-Pozva, Hungary",61.60034209,55.44030788,All,"18 Years and older ¬† (Adult, Older Adult)",475,470,445,153,269,23,11/6/2007,5/8/2008,2/21/2008,4/4/2008,2/25/2008,3/18/2008,3/23/2008,3/24/2008,4/14/2008,3/24/2009,3/28/2009,11/26/2009,1/1/2010,2/4/2010,3/23/2010,5/5/2010,6/21/2010,7/21/2010,9/10/2010,9/14/2008,3/13/2009,9/9/2009,3/8/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02553850,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00485,SP00011,A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Livia Pacheo †,Anthony P,Geralyn K,Liberty A,John G,John G,Gertrudis T,Tiffiny K,Beulah N,Suzie K,Selizabeth F,Ross S,Tammara F,Donovan H,Mary H,Livia Pacheo †,Dinah R,Perter K,Mary H,,,"Salzburg, Austria",88.28157416,79.45341674,Female,"18 Years and older ¬† (Adult, Older Adult)",477,457,446,219,205,22,1/2/2003,8/14/2003,5/20/2003,7/1/2003,6/14/2003,6/16/2003,6/27/2003,6/29/2003,7/26/2003,11/22/2007,8/13/2007,12/31/2007,4/1/2008,5/25/2008,7/23/2008,9/16/2008,11/11/2008,12/24/2008,2/18/2009,12/13/2003,6/10/2004,12/7/2004,6/5/2005,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02005549,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00487,SP00011,Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Tamesha T,Mee M,Jaquelyn H,Hee Y,Ngan D,Dinah R,Perter K,Christian G,Geralyn K,Lilla Stilson †,Gertrudis T,Federico L,Mac L,Geralyn K,Remedios Z,John G,Geralyn K,Mary H,Jaquelyn H,,,"Beijing Hospital, Beijing City, China|The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA), Beijing, China|Beijing Cancer Hospital, Beijing, China|the First Hospital of Jilin University, Changchun, China|Jilin Cancer Hospital, Changchun, China|Changzhou First People's Hospital, Changzhou, China|West China Hospital, Sichuan University, Chengdu, China|Fujian Medical University Union Hospital, Fuzhou City, China|Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department, Hangzhou City, China|The Second Affiliated Hospital of Zhejiang University College, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Jiangsu Cancer Hospital, Nanjing City, China|Jiangsu Province Hospital, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai City, China|Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital), Shanghai, China|Liaoning cancer Hospital & Institute, Shenyang, China|Tianjin Cancer Hospital, Tianjin, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China",12.02999611,10.8269965,All,"18 Years and older ¬† (Adult, Older Adult)",493,472,447,173,250,24,2/2/2017,7/3/2017,5/15/2017,5/30/2017,4/28/2017,5/20/2017,5/24/2017,5/28/2017,6/11/2017,2/1/2018,2/6/2018,9/6/2018,11/23/2018,12/23/2018,2/4/2019,3/31/2019,5/28/2019,7/16/2019,9/14/2019,11/16/2017,5/15/2018,11/11/2018,5/10/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03084939,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00490,SP00011,An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC),,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Suzie K,Lilla Stilson †,Quentin N,Anthony P,James y,Aleta H,Jene M,Perter K,Jerold Goo †,Rima Y ,Ngan D,Hee Y,Frank T,Chetan K,Harry A,Jaquelyn H,Jaquelyn H,Suzie K,Kala R,,,"Brighton, United Kingdom|Cardiff, United Kingdom|Maidstone, United Kingdom|Nottingham, United Kingdom",94.41732408,84.97559167,Female,"18 Years to 70 Years ¬† (Adult, Older Adult)",484,470,448,397,0,51,4/15/2011,9/17/2011,7/1/2011,8/2/2011,7/18/2011,7/21/2011,8/1/2011,8/3/2011,8/28/2011,7/17/2012,6/9/2012,10/31/2012,2/1/2013,3/23/2013,5/21/2013,7/19/2013,8/24/2013,10/19/2013,12/10/2013,1/17/2012,7/15/2012,1/11/2013,7/10/2013,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02658461,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00491,SP00011,Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen,,,,,Oncology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Jaquelyn H,Aleta H,Patria R,Ross S,Jene M,Perter K,Perter K,Lyman W,Dalton E,Tiffiny K,Patria R,Anthony P,Xochitl D,Doreen T,Remedios Z,Mee M,Stephan T,Gertrudis T,Anthony P,,,"Yashoda Hospital, Hyderabad, Andhra Pradesh, India|Rajiv Gandhi Cancer Institute & Research Center, New Delhi, Delhi, India|Manipal Hospital; Department of Oncology, Bangalore, Karnataka, India|Jehangir Clinical Development Centre Pvt. Ltd; Cancer Research Room, Pune, Maharashtra, India|MAX Balaji Hospital, Delhi, India|Dr. GVN Cancer Institute; Medical Oncology, Trichy, India",64.5071681,58.05645129,Female,"18 Years and older ¬† (Adult, Older Adult)",475,454,449,337,46,66,2/26/2018,7/28/2018,5/10/2018,6/13/2018,6/4/2018,6/6/2018,6/16/2018,6/21/2018,7/19/2018,4/7/2021,12/1/2020,4/1/2021,6/24/2021,7/30/2021,9/9/2021,10/30/2021,12/16/2021,2/4/2022,3/6/2022,12/3/2018,6/1/2019,11/28/2019,5/26/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02419742,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00493,SP00011,Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study,,,,,Oncology,,,,,,Industry,"Active, not recruiting",,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Clarice N,Remedios Z,Christian G,Geralyn K,Aleta H,Perter K,Selizabeth F,James y,Louann C,Harry A,Mara A,Doreen T,Mary H,Tien C,Anthony P,Terisa Sikora †,John G,Tammara F,Ross S,,,"Kent & Canterbury Hospital, Canterbury, United Kingdom|Chesterfield Royal Hospital, Chesterfield, United Kingdom|Castle Hill Hospital; The Queens Centre for Oncology and Haematology, Cottingham, United Kingdom|Hairmyres Hospital; Oncology Dept, East Kilbride, United Kingdom|Queen Elizabeth Hospital, Gateshead, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|Forth Valley Royal Hospital ; Oncology Department, Larbert, United Kingdom|Queen Elizabeth Hospital, London, United Kingdom|Royal Marsden Hospital; Dept of Med-Onc, London, United Kingdom|Charing Cross Hospital; Medical Oncology., London, United Kingdom|Macclesfield District General Hospital, Macclesfield, United Kingdom|Maidstone Hospital; Kent Oncology Centre, Maidstone, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|James Cook University Hospital; Oncology and Radiology, Middlesbrough, United Kingdom|Northampton General Hospital NHS Trust;Oncology Unit, Northampton, United Kingdom|Mount Vernon & Watford Trust Hospital; Dept. of Clinical Oncology, Northwood, United Kingdom|Norfolk & Norwich University Hospital; Oncology Department, Norwich, United Kingdom|Nottingham City Hospital; Oncology, Nottingham, United Kingdom|Derriford Hospital; Plymouth Oncology Centre, Plymouth, United Kingdom|Royal Preston Hosp; Rosemere Cancer Ctr, Preston, United Kingdom|North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, United Kingdom|Scarborough General Hospital, Scarborough, United Kingdom|Royal Shrewsbury Hospitals Nhs Trust; Oncology, Shrewsbury, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom|Singleton Hospital; Pharmacy, Swansea, United Kingdom|Great Western Hospital, Swindon Cancer Research Unit; Osprey Unit Level 3, Swindon, United Kingdom|Royal Cornwall Hospital; Dept of Clinical Oncology, Truro, United Kingdom|Pinderfields Hospital; Clinical Research Team, Rowan House, Wakefield, United Kingdom|Yeovil District Hospital; Macmillan Unit, Yeovil, United Kingdom|Airedale General Hospital; Oncology, York, United Kingdom",18.2242874,16.40185866,All,"18 Years and older ¬† (Adult, Older Adult)",499,487,450,218,189,43,12/28/2018,6/30/2019,4/26/2019,6/6/2019,5/20/2019,5/25/2019,6/7/2019,6/9/2019,6/19/2019,4/9/2022,6/9/2022,1/20/2023,3/24/2023,5/11/2023,7/1/2023,8/25/2023,10/21/2023,12/9/2023,2/5/2024,11/21/2019,5/19/2020,11/15/2020,5/14/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02393924,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00495,SP00011,A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA),,,,,Oncology,,,,,,Industry,"Active, not recruiting",,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Louann C,Otis Thode †,Livia Pacheo †,Mary H,Ngan D,Lucie P,Kala R,Lucie P,Jaquelyn H,Marceline R,Naren G,Stephan T,Mary H,Otis Thode †,Suzie K,Ross S,Otis Thode †,Tien C,Kala R,,,"Lkh-Univ. Klinikum Graz; Klinik F√ºr Gyn√§kologie, Graz, Austria|LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung f√ºr Onkologie, Graz, Austria|Klinikum Klagenfurt; Abt. f. H√§matologie u. internistische Onkologie, Klagenfurt, Austria|LKH Hochsteiermark; Abt. f√ºr H√§mato-Onkologie, Leoben, Austria|Ordensklinikum Linz Elisabethinen ; I. INTERNE ABT., Linz, Austria|A.√ñ. Krankenhaus Der Barmherzigen Schwestern Ried; Interne Abtl., Ried-innkreis, Austria|A.√ñ. Lhk Villach; Abt. F√ºr Gyn√§kologie, Villach, Austria|Landesklinikum Wiener Neustadt; Innere Medizin, H√§matologie u. internistische Onkologie, Wiener Neustadt, Austria|Medizinische Universit√§t Wien; Univ.Klinik f√ºr Frauenheilkunde - Klinik f√ºr Gyn√§kologie, Wien, Austria|Medizinische Universit√§t Wien; Univ.Klinik f√ºr Innere Medizin I, Wien, Austria|Hanusch-Krankenhaus; Geburtshilfliche und Gyn√§kologische Abteilung, Wien, Austria|Multiprofile Hospital for Active Treatment Central Onco Hospital OOD, Plovdiv, Bulgaria|Complex Oncological Center - Plovdiv, EOOD, Plovdiv, Bulgaria|Mdozs - Russe, Ruse, Bulgaria|MHAT Nadezhda, Sofia, Bulgaria|Tokuda Hospital; Medical Oncology Department, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD, Sofia, Bulgaria|SHATOD - Sofia, Sofia, Bulgaria|Complex Oncology Center-Burgas; Medical Oncology, Sofia, Bulgaria|District Oncology Dispensary; Dept of Chimiotherapy, Stara Zagora, Bulgaria|District Oncology Dispensary Wit Stationary, Varna, Bulgaria|Comprehensive Oncology Center - Vratsa, Vratza, Bulgaria|A.O. Universitaria Policlinico Di Modena; Oncologia, Modena, Emilia-Romagna, Italy|RCCS - Centro di Riferimento; Oncologia Medica B, Aviano (PN), Friuli-Venezia Giulia, Italy|Ospedale S. Maria Goretti; Divisione Di Oncologia Medica, Latina, Lazio, Italy|Ospedale S.S. Trinit√† Nuovo; Divisione Oncologia, Sora, Lazio, Italy|Ospedale Belcolle Di Viterbo; Oncologia, Viterbo, Lazio, Italy|Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina, Brescia, Lombardia, Italy|A.O.U. Ospedali Riuniti Umberto I-G.M.Lancisi-G.Salesi Ancona;S.O.D. MED.Interna-Clinica Oncologica, Ancona, Marche, Italy|Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica, Ponderano (BI), Piemonte, Italy|Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica, Bari, Puglia, Italy|Ospedale Barletta - Mons. Dimiccoli; Dip. Oncologia, Barletta, Puglia, Italy|Ospedale Cannizzaro, Oncologia, Catania, Sicilia, Italy|Casa Di Cura Di Alta Specialita La Maddalena; Dept. Oncologico Di Iii Livello, Palermo, Sicilia, Italy|Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia, Firenze, Toscana, Italy|Ospedale San Luca; Oncologia, Lucca, Toscana, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Sant'Andrea Delle Fratte (PG), Umbria, Italy|Ospedale Civile; Oncologia Medica, Camposampiero, Veneto, Italy|Azienda Ospedaliero Universitaria di Ferrara - U.O. Di Oncologia, Cona (FE), Veneto, Italy|Azienda ULSS 21 Ospedale Mater Salutis; Dip. di Oncologia, Legnago (VR), Veneto, Italy|A.O.U. Integrata Verona - Policlinico G.B. Rossi; Oncologia Medica - Dip. di Medicina, Verona, Veneto, Italy|Hospital Garcia de Orta; Servico de Oncologia Medica, Almada, Portugal|IPO de Coimbra; Servico de Oncologia Medica, Coimbra, Portugal|Hospital Santo Antonio dos Capuchos;Servico de Oncologia Medica, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|Hospital Beatriz Angelo; Departamento de Oncologia, Loures, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|""Filantropia"" Clinical Hospital; Gynecological Oncology, Bucharest, Romania|Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, Bucuresti, Romania|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania|Cluj-Napoca Emergency Clinical County Hospital; Medical Oncology, Cluj-Napoca, Romania|Centrul de Oncologie Sfantul Nectarie, Craiova, Romania|Oncomed SRL, Timisoara, Romania",93.13738688,83.82364819,All,"18 Years and older ¬† (Adult, Older Adult)",472,456,451,259,146,46,5/2/2020,9/25/2020,7/8/2020,8/18/2020,7/29/2020,8/3/2020,8/16/2020,8/17/2020,8/24/2020,5/14/2024,4/7/2024,7/21/2024,12/18/2024,2/2/2025,3/23/2025,5/19/2025,7/6/2025,8/6/2025,10/3/2025,1/30/2021,7/29/2021,1/25/2022,7/24/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02913456,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00498,SP00011,A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug E,,,,,,,,,,,,,,,,,,,John G,Dinah R,Clarice N,Liberty A,Quentin N,Patria R,Lucie P,Mary H,Hee Y,Lilla Stilson †,Terrell p,John G,Anthony P,In Bellini †,Livia Pacheo †,Mary H,Jeanene Y,Ngan D,Jene M,,,"Adelaide, Australia|Brisbane, Australia|Camperdown, Australia|Geelong, Australia|Melbourne, Australia|Melbourne, Australia|Perth, Australia|Southport, Australia|Porto Alegre, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Calgary, Alberta, Canada|Ottawa, Ontario, Canada|Quebec, Canada|San Jose, Costa Rica|Turku, Finland|Besancon, France|Grenoble, France|Marseille, France|Paris, France|Pierre Benite, France|Rennes, France|Athens, Greece|Heraklion, Greece|Patras, Greece|Guatemala City, Guatemala|Legnago, Italy|Noale, Italy|Rozzano, Italy|Trento, Italy|Treviglio, Italy|Distrito Federal, Mexico|Merida, Mexico|Monterrey, Mexico|Monterrey, Mexico|Panama City, Panama|Gdansk, Poland|Szczecin, Poland|Barcelona, Spain|Lerida, Spain|Sabadell, Barcelona, Spain|Zaragoza, Spain|Karlstad, Sweden|V√§ster√•s, Sweden|Ipswich, United Kingdom|Leeds, United Kingdom|Manchester, United Kingdom|Northwood, United Kingdom|Oxford, United Kingdom|Southampton, United Kingdom|Weston Super Mare, United Kingdom",64.56016005,58.10414404,Female,"18 Years and older ¬† (Adult, Older Adult)",468,461,452,280,132,40,9/23/2002,3/20/2003,1/29/2003,3/8/2003,2/9/2003,2/16/2003,2/27/2003,2/28/2003,3/7/2003,7/13/2005,7/18/2005,10/25/2005,3/1/2006,4/8/2006,5/13/2006,7/10/2006,8/11/2006,9/20/2006,10/20/2006,8/15/2003,2/11/2004,8/9/2004,2/5/2005,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02748213,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00499,SP00011,Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Patria R,Tamesha T,Marcelina X,Otis Thode †,Anthony P,Frank T,Selizabeth F,Otis Thode †,Marceline R,Livia Pacheo †,Lavina S,Suk T,Patria R,Kala R,Lyman W,John G,Christian G,Geralyn K,Jeanene Y,,,"Rajiv Gandhi Cancer Institute & Research Center, New Delhi, Delhi, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, Mumbai, Maharashtra, India|Jehangir Clinical Development Centre Pvt. Ltd; Cancer Research Room, Pune, Maharashtra, India|Christian Medical College & Hospital; Medicine, Vellore, Tamil NADU, India|Indo-American Cancer Hospital & Research Center, Hyderabad, Telangana, India|TATA Medical Centre; Medical Oncology, Kolkata, WEST Bengal, India|M S Ramaiah Memorial Hospital, Bangalore, India|MAX Balaji Hospital, Delhi, India",59.36231206,53.42608085,All,"18 Years and older ¬† (Adult, Older Adult)",508,486,453,425,45,17,2/15/2016,8/27/2016,7/3/2016,7/31/2016,7/19/2016,7/26/2016,8/4/2016,8/5/2016,8/22/2016,8/27/2018,1/27/2018,6/11/2018,9/26/2018,11/8/2018,12/10/2018,1/29/2019,3/8/2019,5/2/2019,6/14/2019,1/22/2017,7/21/2017,1/17/2018,7/16/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02445586,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02445586/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02445586/SAP_001.pdf"
Hoffmann-La Roche,Hoffmann-La Roche,ST00505,SP00011,An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Ngan D,Patria R,Dinah R,Livia Pacheo †,Naren G,Jeanene Y,Suzie K,Stephan T,Anthony P,Mee M,Lyman W,Chetan K,Doreen T,Christian G,Mee M,Frank T,Quentin N,Stephan T,Beulah N,,,"Abbottabad, Pakistan|Faisalabad, Pakistan|Gujranwala, Pakistan|Hyderabad, Pakistan|Islamabad, Pakistan|Islamabad, Pakistan|Karachi, Pakistan|Karachi, Pakistan|Karachi, Pakistan|Lahore, Pakistan|Lahore, Pakistan|Multan, Pakistan|Peshwar, Pakistan|Rawalpindi, Pakistan|Rawalpindi, Pakistan",70.13243352,63.11919017,Female,"18 Years to 70 Years ¬† (Adult, Older Adult)",502,487,454,230,185,39,7/17/2012,2/4/2013,12/4/2012,1/10/2013,12/16/2012,12/21/2012,1/4/2013,1/9/2013,1/20/2013,6/15/2014,6/6/2014,12/14/2014,2/1/2015,3/16/2015,4/18/2015,5/18/2015,6/25/2015,8/17/2015,9/26/2015,6/19/2013,12/16/2013,6/14/2014,12/11/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01725386,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00506,SP00011,A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,James y,Tamesha T,Marcelina X,Chetan K,Marcelina X,Kandace p,Frank T,John G,Suzie K,Mary H,Naren G,Mary H,Otis Thode †,Mara A,Jaquelyn H,Mary H,Anthony P,Hee Y,Tiffiny K,,,"CHINESE ACADEMY OF MEDICAL SCIENCE; CANCER INST. & HOSPITAL; Medical ward, Beijing, China|Beijing Cancer Hospital, Beijing, China|Chinese PLA General Hospital, Beijing, China|the First Hospital of Jilin University, Changchun, China|Changzhou First People's Hospital, Changzhou, China|West China Hospital, Sichuan University, Chengdu, China|Fuzhou General Hospital, PLA Nanjing Military Area Command, Fuzhou, China|Guangdong General Hospital, Guangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Shandong Cancer Hospital, Jinan, China|Jiangsu Cancer Hospital, Nanjing City, China|Jiangsu province hospital; surgery on galactophore, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai City, China|First Hospital of China Medical University, Shenyang, China|Liaoning cancer Hospital & Institute, Shenyang, China|Zhejiang Cancer Hospital, Zhejiang, China",58.97228165,53.07505348,All,"18 Years to 95 Years ¬† (Adult, Older Adult)",508,492,455,176,259,20,9/26/2014,3/14/2015,1/19/2015,2/3/2015,1/18/2015,1/28/2015,2/6/2015,2/10/2015,2/23/2015,7/6/2017,9/18/2017,2/16/2018,6/27/2018,8/19/2018,9/18/2018,11/6/2018,12/17/2018,1/28/2019,3/16/2019,7/27/2015,1/23/2016,7/21/2016,1/17/2017,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02896855,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02896855/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02896855/SAP_001.pdf"
Hoffmann-La Roche,Hoffmann-La Roche,ST00507,SP00011,H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Beulah N,Anthony P,Jeanene Y,Corrine U,Mee M,Hee Y,Mac L,Frank T,Clarice N,Mary H,Garnet T,Tien C,Gertrudis T,Rima Y ,Mary H,Perter K,Frank T,Chetan K,Anthony P,,,"Algiers, Algeria|Annaba, Algeria|Blida, Algeria|Mascara, Algeria|Oran, Algeria|Sidi Belabes, Algeria|Tizi Ouzou, Algeria|Agadir, Morocco|Casablanca, Morocco|Casablanca, Morocco|Casablanca, Morocco|Casablanca, Morocco|Casablanca, Morocco|Fes, Morocco|Marrakech, Morocco|Rabat, Morocco|Rabat, Morocco|Rabat, Morocco|Rabat, Morocco",50.54112907,45.48701617,All,"18 Years and older ¬† (Adult, Older Adult)",479,466,456,428,40,12,10/10/2008,4/12/2009,2/1/2009,3/13/2009,2/6/2009,2/21/2009,3/8/2009,3/13/2009,4/4/2009,3/19/2012,7/14/2012,12/13/2012,2/1/2013,3/25/2013,5/10/2013,6/19/2013,7/22/2013,9/10/2013,10/21/2013,8/20/2009,2/16/2010,8/15/2010,2/11/2011,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01991340,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00508,SP00011,A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Control|Time Perspective: Cross-Sectional,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Christian G,Terisa Sikora †,Clarice N,Mee M,Kala R,Jeanene Y,Tamesha T,Gertrudis T,Beulah N,Perter K,Anthony P,Aleta H,Ngan D,Otis Thode †,Patria R,Naren G,Tammara F,Dinah R,John G,,,"Hospital Provincial de Castellon; Servicio de Oncologia, Castellon de La Plana, Castellon, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, C√≥rdoba, Cordoba, Spain|Hospital de Donostia.; Servicio de Oncolog√≠a Radioter√°pica, San Sebasti√°n, Guipuzcoa, Spain|Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario A Coru√±a (CHUAC); Servicio de Oncologia, La Coruna, LA Coru√±a, Spain|Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia, Las Palmas de Gran Canaria, LAS Palmas, Spain|Hospital Quiron Barcelona; Servicio de Oncologia, Barcelona, Spain|Hospital Universitario Virgen de las Nieves; Servicio de Oncologia, Granada, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Complejo Asistencial Universitario de Leon; Servicio de Oncologia, Leon, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia, Lerida, Spain|Hospital Lucus Augusti; Servicio de Oncologia, Lugo, Spain|Hospital Universitario de la Princesa; Servicio de Oncologia, Madrid, Spain|Centro Oncologico MD Anderson Internacional; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Oncologia, Murcia, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia, Murcia, Spain|Hospital de Navarra; Servicio de Oncologia, Navarra, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, Spain|Hospital General de Segovia; Servicio de Oncologia, Segovia, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia, Valencia, Spain|Hospital Universitario Dr. Peset; Servicio de Oncologia, Valencia, Spain|Complejo Hospitalario Zamora- H. Virgen de la Concha; Servicio Oncologia, Zamora, Spain",22.80222377,20.5220014,All,"18 Years and older ¬† (Adult, Older Adult)",502,496,457,170,270,17,8/7/2014,2/17/2015,1/5/2015,1/27/2015,1/4/2015,1/17/2015,1/27/2015,1/31/2015,2/25/2015,7/13/2018,3/7/2018,8/2/2018,12/3/2018,1/27/2019,3/26/2019,5/9/2019,6/29/2019,8/20/2019,9/29/2019,7/16/2015,1/12/2016,7/10/2016,1/6/2017,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02613208,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02613208/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02613208/SAP_001.pdf"
Hoffmann-La Roche,Hoffmann-La Roche,ST00512,SP00011,A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2),,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Quentin N,Louann C,Mary H,Terisa Sikora †,Mary H,Selizabeth F,Suzie K,Lavina S,Perter K,Terrell p,Garnet T,Mee M,Suzie K,Kandace p,Mary H,Remedios Z,Kala R,Chetan K,,,"University of Alabama At Birmingham, Birmingham, Alabama, United States|Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Arizona Oncology - HOPE Wilmot, Tucson, Arizona, United States|UCLA, Los Angeles, California, United States|The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Kaiser Permanente - San Marcos, San Marcos, California, United States|Stanford Cancer Center, Stanford, California, United States|Kaiser Permanente; Oncology Clinical Trials, Vallejo, California, United States|Rocky Mountain Cancer Center - Aurora, Aurora, Colorado, United States|University Of Colorado, Aurora, Colorado, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Yale Cancer Center ; Medical Oncology, New Haven, Connecticut, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Mayo Clinic Cancer Center, Jacksonville, Florida, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|University of Chicago; Hematology/Oncology, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Indiana University Health; Goshen Center for Cancer Care, Goshen, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Massachusetts General Hospital;Oncology, Boston, Massachusetts, United States|Dana Farber Cancer Inst. ; Dept. of Medical Oncology, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Harvard Medical School; Department of Medicine, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Minneapolis, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Urology Cancer Center & GU Research Network, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, P.C., Albany, New York, United States|NYU Langone Medical Center, New York, New York, United States|Mount Sinai School of Medicine - Tisch Cancer Institute, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Case Western Reserve Univ; Hem/Onc, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Kimmel Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Ctr for Cancer and Blood Disorders, Fort Worth, Texas, United States|Texas Oncology - Houston (Gessner), Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates - Lake Wright Cancer Center, Norfolk, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Bcca - Cancer Center Southern Interior, Kelowna, British Columbia, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, Canada|The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|APHP - Hospital Saint Louis, Paris, France|Hopital Foch; Oncologie, Suresnes, France|Institut Gustave Roussy; Oncologie Medicale, Villejuif, France|Charit√© - Universit√§tsmedizin Berlin; CC 8: Chirurgische Medizin; Klinik f√ºr Urologie, Berlin, Germany|Universit√§tsklinikum D√ºsseldorf; Urologische Klinik, D√ºsseldorf, Germany|Universit√§tsklinikum Freiburg; Chirurgische Klinik; Abteilung Urologie, Freiburg, Germany|Universit√§tsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II, Hamburg, Germany|Klinikum rechts der Isar der TU M√ºnchen; Urologische Klinik und Poliklinik, M√ºnchen, Germany|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia, Arezzo, Toscana, Italy|The Netherlands Cancer Institute - Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital General Universitario Gregorio Mara√±on; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|University Hospital Birmingham The Cancer Centre, Queen Elizabeth Hospital, Birmingham, United Kingdom|Barts and The London, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom",5.991020269,5.391918242,All,"Child, Adult, Older Adult",498,489,458,354,68,36,12/1/2012,5/2/2013,2/16/2013,3/19/2013,2/18/2013,3/6/2013,3/13/2013,3/17/2013,4/4/2013,7/1/2014,9/2/2014,1/13/2015,5/31/2015,7/7/2015,8/8/2015,9/23/2015,11/14/2015,12/17/2015,2/9/2016,9/2/2013,3/1/2014,8/28/2014,2/24/2015,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02108652,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00513,SP00011,A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,"Active, not recruiting",,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Lilla Stilson †,In Bellini †,Terisa Sikora †,Quentin N,Louann C,Gertrudis T,Lilla Stilson †,Mee M,Patria R,Liberty A,Donovan H,Aleta H,Terrell p,Jene M,Suzie K,Remedios Z,Tamesha T,John G,Kandace p,,,"ARETAIEION UNIVERSITY HOSPITAL; oncology unit, Athens, Greece|IASO General Hospital of Athens, Athens, Greece",70.80985397,63.72886858,All,"18 Years and older ¬† (Adult, Older Adult)",492,471,459,357,51,51,6/11/2022,1/3/2023,10/24/2022,11/25/2022,10/24/2022,11/14/2022,11/18/2022,11/19/2022,12/17/2022,3/18/2024,12/22/2023,5/31/2024,9/30/2024,11/10/2024,12/18/2024,1/27/2025,3/26/2025,4/27/2025,6/16/2025,5/13/2023,11/9/2023,5/7/2024,11/3/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02595762,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00514,SP00011,"A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread",,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,John G,John G,Lilla Stilson †,Tiffiny K,Lavina S,Liberty A,Tammara F,Beulah N,Ross S,Livia Pacheo †,Livia Pacheo †,Frank T,Tiffiny K,Selizabeth F,Donovan H,Chetan K,Mee M,Mary H,Otis Thode †,,,"Mercy Hospital, a Campus of Plantation General Hospital, Miami, Florida, United States|Cancer Specialists of North Florida, Orange Park, Florida, United States|Florida Hospital Cancer Inst, Orlando, Florida, United States|Florida Cancer Research Institute, Plantation, Florida, United States|Cancer Treatment Centers of America, Newnan, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Montefiore Einstein Cancer Center, Bronx, New York, United States|Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Mater Adult Hospital, South Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia|St John of God Murdoch Hospital; Oncology West, Murdoch, Western Australia, Australia|Clinique Edith Cavell, Bruxelles, Belgium|AZ Sint Lucas (Sint Lucas), Gent, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|AZ Sint Augustinus Veurne, Veurne, Belgium|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Multiscan s.r.o., Pardubice, Czechia|Centre Oscar Lambret, Lille, France|Centre R√©gional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque, Montpellier, France|Hopital Tenon, Paris, France|Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer, Rennes, France|Chaim Sheba Medical Center, Ramat Gan, Israel|Azienda Ospedaliero Universitaria Seconda Universit√† Degli Studi Di Napoli, Napoli, Campania, Italy|A.O.U Policlinico S. Orsola Malpighi di Bologna U.O di Medicina Interna Borghi - Pad.2, Bologna, Emilia-Romagna, Italy|Centro Di Riferimento Oncologico; SOC Oncologia Medica C, Aviano, Friuli-Venezia Giulia, Italy|Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria - Polo Oncologico, Pisa, Toscana, Italy|National Cancer Center; Medical Oncology, Gyeonggi-do, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Yonsei University Health System/Severance Hospital, Seoul, Korea, Republic of|Riga East Clinical University Hospital Latvian Oncology Centre, Riga, Latvia|Pauls Stradins Clinical University Hospital, Rƒ´ga, Latvia|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania|Oncology Center Sf. Nectarie, Craiova, Romania|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Organizaci√≥n Sanitaria Integrada Bilbao Basurto, Bilbao, Vizcaya, Spain|Hospital Universitario Infanta Cristina; Servicio de Oncologia, Badajoz, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Fundacion Jimenez Diaz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Nefrologia, Madrid, Spain|Hosp. Regional Univ. de Malaga - Hospital Materno Infantil; Hospital Materno Infantil de Malaga, Malaga, Spain|Chang Gung Memorial Hospital, Kaohsiung Country, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|Nuffield Health Bournemouth Hospital, Bournemouth, United Kingdom|Mount Vernon Hospital, Middlesex, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, United Kingdom",47.40920091,42.66828082,All,"18 Years and older ¬† (Adult, Older Adult)",485,466,460,340,71,49,3/3/2014,9/27/2014,8/2/2014,9/6/2014,8/11/2014,8/23/2014,9/3/2014,9/4/2014,9/23/2014,9/9/2017,12/17/2017,5/12/2018,8/10/2018,9/15/2018,10/26/2018,12/7/2018,1/12/2019,3/4/2019,4/30/2019,2/19/2015,8/18/2015,2/14/2016,8/12/2016,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02322814,,,,,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02322814/Prot_SAP_000.pdf"
Hoffmann-La Roche,Hoffmann-La Roche,ST00516,SP00011,An Observational Study to Register the Incidence of Breast Cancer and Current Clinical Care Patterns in Kenya,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Kala R,Selizabeth F,Geralyn K,Gertrudis T,Terisa Sikora †,Corrine U,Xochitl D,Mara A,Suzie K,Jerold Goo †,Mary H,In Bellini †,Hee Y,Suzie K,Quentin N,Perter K,Geralyn K,Gertrudis T,Mary H,,,"University of Nairobi School of Medicine; Internal Medicine and Therapeutics, Nairobi, Kenya",69.60530198,62.64477178,Female,"21 Years and older ¬† (Adult, Older Adult)",490,484,461,257,176,28,12/8/2017,6/12/2018,3/21/2018,5/4/2018,4/9/2018,4/19/2018,5/1/2018,5/4/2018,5/23/2018,3/21/2019,3/7/2019,7/9/2019,12/6/2019,1/7/2020,2/8/2020,4/2/2020,5/9/2020,6/21/2020,8/14/2020,10/16/2018,4/14/2019,10/11/2019,4/8/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01484483,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00518,SP00011,A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Frank T,John G,Remedios Z,Lavina S,Christian G,Gertrudis T,Lucie P,Donovan H,Naren G,Gertrudis T,Jene M,Jeanene Y,Geralyn K,Jene M,Ngan D,Otis Thode †,Jaquelyn H,Mary H,Suk T,,,"Wien, Austria|Muenchen, Germany|Bologna, Emilia-Romagna, Italy|Carpi, Emilia-Romagna, Italy|Udine, Friuli-Venezia Giulia, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Varese, Lombardia, Italy|San Giovanni Rotondo, Puglia, Italy|Sassari, Sardegna, Italy|Pisa, Toscana, Italy|Trento, Trentino-Alto Adige, Italy|Bellunoi, Veneto, Italy|Castelfranco Veneto, Veneto, Italy|Mirano, Veneto, Italy|Santorso, Veneto, Italy|Vicenza, Veneto, Italy|Lisboa, Portugal|Kazan, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|St Petersburg, Russian Federation|Terrassa, Barcelona, Spain|Jerez de La Frontera, Cadiz, Spain|San Sebastian, Guipuzcoa, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Valencia, Spain|Zaragoza, Spain",36.38103078,32.74292771,Female,"Child, Adult, Older Adult",519,497,462,205,234,23,9/29/2009,2/19/2010,12/31/2009,1/22/2010,12/25/2009,1/12/2010,1/16/2010,1/21/2010,2/10/2010,12/8/2011,10/12/2011,3/13/2012,7/1/2012,8/6/2012,9/15/2012,10/27/2012,12/4/2012,1/31/2013,3/6/2013,7/11/2010,1/7/2011,7/6/2011,1/2/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01998906,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00524,SP00011,AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Ross S,Remedios Z,Lyman W,Tamesha T,John G,Tiffiny K,Federico L,Suk T,Mary H,Mary H,Mary H,Chetan K,Jene M,Anthony P,Suzie K,Garnet T,Mac L,Christian G,Frank T,,,"Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Debrecen, Hungary|Eger, Hungary|Gyor, Hungary|Gyula, Hungary|Kaposvar, Hungary|Kecskemet, Hungary|Kistarcsa, Hungary|Miskolc, Hungary|Ny√≠regyh√°za, Hungary|Pecs, Hungary|Salg√≥tarj√°n, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Szekszard, Hungary|Szentes, Hungary|Szolnok, Hungary|Szombathely, Hungary|Tatab√°nya, Hungary|Veszprem, Hungary|Zalaegerszeg, Hungary",42.12929641,37.91636677,All,"18 Years to 75 Years ¬† (Adult, Older Adult)",506,490,463,305,104,54,8/13/2009,3/21/2010,1/4/2010,2/2/2010,1/5/2010,1/27/2010,2/6/2010,2/7/2010,2/19/2010,8/1/2011,6/10/2011,12/2/2011,3/1/2012,4/6/2012,5/30/2012,7/16/2012,9/14/2012,10/27/2012,11/28/2012,7/26/2010,1/22/2011,7/21/2011,1/17/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01777932,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00526,SP00011,A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 1|Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Clarice N,Terrell p,Geralyn K,Naren G,Remedios Z,Doreen T,Aleta H,Lavina S,Donovan H,Clarice N,Mary H,Jene M,Liberty A,Louann C,Naren G,Tiffiny K,Marceline R,Terrell p,Ngan D,,,"Madrid, Spain",15.89930105,14.30937095,Female,"18 Years to 75 Years ¬† (Adult, Older Adult)",476,470,464,403,18,43,6/21/2004,12/17/2004,10/2/2004,11/11/2004,10/18/2004,10/25/2004,10/31/2004,11/3/2004,11/18/2004,3/26/2009,11/9/2008,6/7/2009,9/1/2009,10/13/2009,11/28/2009,1/17/2010,2/26/2010,4/14/2010,5/17/2010,4/23/2005,10/20/2005,4/18/2006,10/15/2006,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02015676,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00527,SP00011,"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)",,,,,Oncology,,,,,,Industry,Recruiting,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Suk T,Ross S,Mac L,Frank T,Mara A,Remedios Z,Perter K,Dinah R,Harry A,Corrine U,Dalton E,Kala R,Clarice N,Beulah N,Tammara F,Perter K,John G,Dalton E,Mary H,,,"CBCC Global Research Inc., at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Cancer and Blood Specialty Clinic, Fountain Valley, California, United States|UCLA Hematology/Oncology, Santa Monica, California, United States|Torrance Memorial Physician Network/Cancer Care, Torrance, California, United States|Valley Breast Care and Women's Health Center, Van Nuys, California, United States|Stamford Hospital; Clincal Trials Office - 1st Fl - Bennett Cancer Cente, Stamford, Connecticut, United States|Cancer Center of Kansas - Kingman, Kingman, Kansas, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Ballarat Oncology & Haematology, Wendouree, Victoria, Australia|Metropolitan General Hospital, Cholargos, Greece|Olympion Clinic, Patras, Greece|Hospital Universitario de Jaen, Jaen, Spain",3.159313393,2.843382053,All,"18 Years to 90 Years ¬† (Adult, Older Adult)",507,493,465,274,160,31,10/15/2021,3/20/2022,1/22/2022,2/20/2022,1/27/2022,2/1/2022,2/10/2022,2/14/2022,2/27/2022,4/1/2025,3/17/2025,10/18/2025,12/19/2025,1/18/2026,3/19/2026,5/3/2026,6/26/2026,8/18/2026,9/24/2026,7/31/2022,1/27/2023,7/26/2023,1/22/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04961996,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00532,SP00011,Non-Interventional Study of Xeloda (Capecitabine) in Patients With Gastric Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Doreen T,Selizabeth F,Garnet T,Suzie K,Dalton E,Federico L,Liberty A,Tamesha T,Mary H,John G,Chetan K,Jeanene Y,Rima Y ,Donovan H,Corrine U,Stephan T,Lucie P,Perter K,Harry A,,,"Mannheim, Germany",96.22645087,86.60380578,All,75 Years and older ¬† (Older Adult),493,481,466,168,275,23,10/10/2008,5/20/2009,3/18/2009,4/2/2009,3/13/2009,3/25/2009,3/30/2009,4/2/2009,4/25/2009,5/1/2012,2/17/2012,9/6/2012,12/1/2012,1/19/2013,3/17/2013,4/29/2013,6/4/2013,7/31/2013,9/9/2013,9/21/2009,3/20/2010,9/16/2010,3/15/2011,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02274376,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00533,SP00011,A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Quentin N,Tamesha T,Naren G,Perter K,Jeanene Y,Tammara F,Suzie K,Naren G,Chetan K,Perter K,Chetan K,Patria R,Donovan H,Terrell p,Corrine U,Beulah N,Anthony P,Tiffiny K,Suzie K,,,"Bangor, United Kingdom|Cottingham, United Kingdom|Exeter, United Kingdom|Grimsby, United Kingdom|Harrogate, United Kingdom|Plymouth, United Kingdom|Portsmouth, United Kingdom|Preston, United Kingdom|Somerset, United Kingdom|Wolverhampton, United Kingdom",77.30046994,69.57042294,Female,"18 Years and older ¬† (Adult, Older Adult)",524,505,467,358,44,65,4/2/2012,10/6/2012,7/31/2012,9/6/2012,8/14/2012,8/23/2012,8/28/2012,8/30/2012,9/7/2012,11/1/2015,2/11/2015,10/14/2015,12/1/2015,1/25/2016,3/1/2016,3/31/2016,5/10/2016,7/5/2016,8/21/2016,2/19/2013,8/18/2013,2/14/2014,8/13/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01094184,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00535,SP00011,A Study of Pertuzumab in Participants With Prostate Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Rima Y ,Frank T,Jaquelyn H,Marcelina X,Anthony P,Kala R,Mee M,Naren G,Suk T,Christian G,Mac L,Quentin N,Chetan K,Mac L,Mary H,Hee Y,Suk T,Selizabeth F,Selizabeth F,,,"Lyon, France|Montpellier, France|Berlin, Germany|Parma, Italy|Roma, Italy|Rotterdam, Netherlands|Barcelona, Spain|Valencia, Spain|Cardiff, United Kingdom|Sutton, United Kingdom|Weston Super Mare, United Kingdom",10.72805197,9.655246776,Male,"18 Years and older ¬† (Adult, Older Adult)",516,500,468,232,199,37,5/11/2002,10/23/2002,8/10/2002,9/5/2002,8/9/2002,8/25/2002,9/4/2002,9/6/2002,9/15/2002,7/10/2005,12/31/2004,7/18/2005,9/1/2005,10/8/2005,12/5/2005,1/13/2006,3/10/2006,4/27/2006,6/4/2006,2/21/2003,8/20/2003,2/16/2004,8/14/2004,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02480010,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00540,SP00011,XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Gertrudis T,Terrell p,John G,Mary H,Suzie K,Aleta H,Tammara F,Selizabeth F,Rima Y ,Mara A,Ross S,Mac L,Doreen T,Jene M,Tiffiny K,Selizabeth F,Selizabeth F,Chetan K,Perter K,,,"Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyula, Hungary|Kaposv√°r, Hungary|Kecskemet, Hungary|Miskolc, Hungary|Ny√≠regyh√°za, Hungary|Szeged, Hungary|Szombathely, Hungary|Veszprem, Hungary|Zalaegerszeg, Hungary",43.25321081,38.92788973,All,"18 Years to 80 Years ¬† (Adult, Older Adult)",525,503,469,245,184,40,1/30/2010,7/26/2010,5/22/2010,6/4/2010,5/6/2010,5/30/2010,6/12/2010,6/17/2010,7/2/2010,10/8/2014,4/22/2014,9/9/2014,12/1/2014,1/13/2015,3/9/2015,5/7/2015,6/14/2015,7/19/2015,8/28/2015,11/26/2010,5/25/2011,11/21/2011,5/19/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01777945,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00544,SP00011,A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC),,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Xochitl D,Corrine U,Gertrudis T,Suzie K,Lyman W,John G,Garnet T,Suzie K,Selizabeth F,Louann C,James y,Remedios Z,Naren G,Jeanene Y,Garnet T,Dinah R,Tammara F,Tammara F,Mary H,,,"Onze Lieve Vrouwziekenhuis Aalst, Aalst, Belgium|Imeldaziekenhuis, Bonheiden, Belgium|AZ Sint Jan, Brugge, Belgium|CHU St Pierre (St Pierre), Brussels, Belgium|AZ Maria Middelares, Gent, Belgium|AZ Sint Lucas (Sint Lucas), Gent, Belgium|UZ Gent, Gent, Belgium|CH Jolimont - Lobbes (Jolimont), Haine-Saint-Paul, Belgium|Clinique Saint-Joseph, Li√®ge, Belgium|CHU Ambroise Par√©, Mons, Belgium|CHR de Namur, Namur, Belgium|AZ Damiaan, Oostende, Belgium|AZ Turnhout Sint Elisabeth, Turnhout, Belgium|Soroka Medical Center; Oncology Dept, Beer Sheva, Israel|Rambam Medical Center; Oncology, Haifa, Israel|Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Western Galilee Hospital; Oncology-Nahariya, Nahariya, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Chaim Sheba medical center, Oncology division, Ramat Gan, Israel|Kaplan Medical Center; Oncology Inst., Rehovot, Israel|Sourasky / Ichilov Hospital; Dept. of Oncology, Tel Aviv, Israel|Assaf Harofeh; Oncology, Zerifin, Israel",86.71861891,78.04675702,All,"30 Years to 80 Years ¬† (Adult, Older Adult)",509,488,470,277,146,47,3/15/2010,10/8/2010,8/25/2010,9/16/2010,8/26/2010,9/4/2010,9/16/2010,9/21/2010,10/10/2010,6/19/2015,1/30/2015,5/16/2015,9/4/2015,10/17/2015,12/2/2015,1/23/2016,3/3/2016,4/5/2016,5/12/2016,3/3/2011,8/30/2011,2/26/2012,8/24/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01926886,,,,,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT01926886/Prot_SAP_000.pdf"
Hoffmann-La Roche,Hoffmann-La Roche,ST00546,SP00011,A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Patria R,Christian G,Hee Y,Terrell p,Jene M,Donovan H,Kala R,Dalton E,Doreen T,Mara A,Jerold Goo †,Lavina S,Selizabeth F,Geralyn K,Donovan H,Gertrudis T,Corrine U,Gertrudis T,Tien C,,,"St George Hospital; Cancer Care Centre, Kogarah, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Newcastle Mater Misericordiae Hospital; Oncology, Waratah, New South Wales, Australia|Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia|Lyell McEwin Hospital, Adelaide, South Australia, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Bendigo Hospital; Oncology, Bendigo, Victoria, Australia|Monash Medical Centre; Oncology, Clayton, Victoria, Australia|Geelong Hospital; Andrew Love Cancer Centre, Geelong, Victoria, Australia|Royal Melbourne Hospital; Hematology and Medical Oncology, Parkville, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|St John of God Murdoch Hospital; Oncology West, Murdoch, Western Australia, Australia",32.53038257,29.27734432,All,,521,511,471,210,235,26,11/26/2011,5/3/2012,2/28/2012,3/20/2012,3/5/2012,3/13/2012,3/19/2012,3/20/2012,4/6/2012,8/16/2016,2/1/2016,8/16/2016,11/4/2016,12/4/2016,1/7/2017,2/16/2017,3/30/2017,5/13/2017,6/25/2017,9/9/2012,3/8/2013,9/4/2013,3/3/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02019277,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00547,SP00011,An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Tamesha T,Quentin N,Rima Y ,Suzie K,Stephan T,Lilla Stilson †,Clarice N,Mary H,Mara A,Mary H,In Bellini †,Garnet T,Anthony P,Livia Pacheo †,Clarice N,Rima Y ,John G,Mary H,Naren G,,,"Uni Hospital Split; Oncology & Radiotherapy, Split, Croatia|General Hospital Varazdin, Varazdin, Croatia",62.26208531,56.03587678,All,,526,512,472,218,222,32,6/27/2014,11/18/2014,10/4/2014,11/4/2014,10/4/2014,10/18/2014,10/29/2014,10/31/2014,11/14/2014,9/27/2015,12/6/2015,7/10/2016,9/14/2016,10/18/2016,12/5/2016,1/10/2017,2/9/2017,3/13/2017,4/16/2017,4/16/2015,10/13/2015,4/10/2016,10/7/2016,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01661153,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00553,SP00011,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug H,,,,,,,,,,,,,,,,,,,Marceline R,Christian G,John G,Perter K,Beulah N,Marcelina X,Naren G,Suk T,Mac L,Terrell p,Clarice N,Perter K,Mary H,Selizabeth F,Aleta H,Liberty A,Lavina S,Geralyn K,Otis Thode †,,,"The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA), Beijing, China|the First Hospital of Jilin University, Changchun, China|Jilin Cancer Hospital, Changchun, China|Fujian Medical University Union Hospital, Fujian, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Shandong Cancer Hospital, Jinan, China|Jiangsu Province Hospital, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai City, China|Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital), Shanghai, China|Zhejiang Cancer Hospital, Zhejiang, China|Henan Cancer Hospital, Zhengzhou, China|Kyungpook National University Medical Center, Daegu, Korea, Republic of|Ajou University Medical Center, Gyeonggi-do, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Taipei Medical University -Shuang Ho Hospital, New Taipei City, Taiwan|China Medical University Hospital; Surgery, Taichung, Taiwan|Mackay Memorial Hospital; Dept of Surgery, Taipei, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Bhumibol Adulyadej Hospital; Medicine, Bangkok, Thailand|Srinagarind Hospital, Khon Kaen University; Surgery, Khon Kaen, Thailand|Songklanagarind Hospital; Department of Surgery, Songkla, Thailand",87.51888273,78.76699446,All,,499,478,473,199,241,33,9/11/2014,2/19/2015,12/3/2014,1/3/2015,12/17/2014,12/27/2014,1/10/2015,1/15/2015,1/31/2015,7/1/2017,3/31/2017,6/14/2017,10/23/2017,12/17/2017,1/28/2018,3/7/2018,4/25/2018,6/5/2018,7/23/2018,6/25/2015,12/22/2015,6/19/2016,12/16/2016,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02586025,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02586025/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02586025/SAP_001.pdf"
Hoffmann-La Roche,Hoffmann-La Roche,ST00554,SP00011,A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Suzie K,Perter K,Lavina S,Otis Thode †,Dalton E,Mara A,Perter K,Harry A,Terrell p,Frank T,Harry A,Suzie K,Gertrudis T,Mary H,Marcelina X,Garnet T,Kandace p,Mee M,Ngan D,,,"Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Besancon, France|Dijon, France|Lille, France|Montpellier, France|Modena, Emilia-Romagna, Italy|Parma, Emilia-Romagna, Italy|Milano, Lombardia, Italy|Barcelona, Spain|Barcelona, Spain|Valencia, Spain|Valencia, Spain|Edinburgh, United Kingdom|Manchester, United Kingdom|Northwood, United Kingdom|Truro, United Kingdom",80.21760133,72.1958412,Female,,494,487,474,384,41,49,2/22/2005,9/23/2005,7/9/2005,8/22/2005,7/27/2005,8/8/2005,8/21/2005,8/25/2005,9/24/2005,12/3/2007,6/13/2007,12/5/2007,2/1/2008,3/23/2008,5/2/2008,6/25/2008,8/21/2008,10/1/2008,11/29/2008,2/4/2006,8/3/2006,1/30/2007,7/29/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01674062,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00555,SP00011,A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Frank T,Hee Y,Ross S,Otis Thode †,Suk T,Dalton E,Dalton E,Suk T,Suk T,Tiffiny K,Frank T,Tammara F,Dalton E,Naren G,James y,Corrine U,Doreen T,Harry A,John G,,,"Centre hospitalo-univerisitaire de Rouiba;Service d'oncologie m√©dicale, Algiers, Algeria|Centre Anti Cancer Beau-fraisier;Service d'oncologie m√©dicale, Algiers, Algeria|CHU Annaba; Service d'Oncologie M√©dicale, Annaba, Algeria|EHS Oncologie Emir Abdelkader Oran; Service d'Oncologie M√©dicale, Oran, Algeria|Clinique Littoral, Casablanca, Morocco|Centre Hospitalier Universitaire Mohamed VI; Oncologie-H√©matologie, Marrakech, Morocco|Institut National D'oncologie Sidi Med Benabdellah, Rabat, Morocco|International Medical Center (IMC), Jeddah, Saudi Arabia|King Khaled Uni Hospital; Oncology, Riyadh, Saudi Arabia|Abderrahmen Mami Hospital; Medical Oncology department, Ariana, Tunisia|Habib Bourguiba Hospital; Oncology department, Sfax, Tunisia|Farhat Hached Hospital; Oncology department, Sousse, Tunisia|Institut Salah Aza√Øz; Service de M√©decine Carcinologique, Tunis, Tunisia|Gazi University Medical Faculty; Department of ƒ∞nternal Medicine, Ankara, Turkey|Akdeniz Univesity Medical Faculty, Antalya, Turkey|Dicle University Faculty of Medicine, Diyarbakir, Turkey|Trakya University Medical Faculty, Edirne, Turkey|Gaziantep Univ. Med. Fac., Gaziantep, Turkey|ƒ∞stanbul √úniversitesi Cerrahpa≈üa Tƒ±p Fak√ºltesi, ƒ∞stanbul, Turkey|Bezmialem Vakif Univ Medical, Istanbul, Turkey|Marmara Uni Faculty of Medicine; Medical Oncology, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sƒ±hhiye, Ankara, Turkey",59.59780504,53.63802453,All,,517,500,475,147,303,25,12/16/2013,4/15/2014,2/15/2014,3/26/2014,3/4/2014,3/16/2014,3/23/2014,3/26/2014,4/13/2014,6/20/2016,5/12/2016,8/5/2016,12/22/2016,1/23/2017,2/23/2017,4/19/2017,5/24/2017,7/7/2017,8/15/2017,9/12/2014,3/11/2015,9/7/2015,3/5/2016,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01964391,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00558,SP00011,HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Naren G,Stephan T,Federico L,Jene M,Suk T,Doreen T,James y,Suk T,Terrell p,Stephan T,Perter K,Naren G,Anthony P,Mara A,Ngan D,Mary H,Chetan K,Perter K,Mary H,,,"AGAPLESION Markus-Krankenhaus, Frankfurt, Germany",81.08016294,72.97214665,Female,,504,496,476,271,154,51,10/2/2016,3/19/2017,1/13/2017,2/14/2017,1/19/2017,1/28/2017,2/2/2017,2/4/2017,3/5/2017,1/22/2020,4/22/2020,9/27/2020,11/25/2020,1/23/2021,3/6/2021,4/18/2021,6/1/2021,7/26/2021,9/17/2021,7/27/2017,1/23/2018,7/22/2018,1/18/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01777958,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00562,SP00011,A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Frank T,Frank T,Jerold Goo †,James y,Stephan T,Ross S,Dinah R,Marcelina X,John G,John G,Donovan H,Christian G,Patria R,James y,Lilla Stilson †,Ngan D,Otis Thode †,Mary H,Tiffiny K,,,"Lkh-Univ. Klinikum Graz; Klinik F√ºr Gyn√§kologie, Graz, Austria|LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung f√ºr Onkologie, Graz, Austria|Lhk Klagenfurt; Abt. F√ºr Gyn√§kologie, Klagenfurt, Austria|LKH Hochsteiermark; Abt. f√ºr Innere Medizin, Leoben, Austria|Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1, Linz, Austria|Lhk Feldkirch; Interne Medizin Abt., Rankweil, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|A. √ñ. Krankenhaus Der Barmherzigen Br√ºder; Abt. F√ºr Chirurgie, St Veit An Der Glan, Austria|A.√ñ. Lhk; Ii. Medizinische Abt. Mit Schwerpunkt Gastr√∂nter. & Onkologie, Steyr, Austria|Lhk V√∂cklabruck; Ii. Interne Abt., V√∂cklabruck, Austria|Klinikum Kreuzschwestern Wels; Iv. Interne Abt., Wels, Austria|Krankenanstalt Rudolfstiftung; I. Med. Abt., Wien, Austria|Medizinische Universit√§t Wien; Univ.Klinik f√ºr Frauenheilkunde - Klinik f√ºr Gyn√§kologie, Wien, Austria|Medizinische Universit√§t Wien; Univ.Klinik f√ºr Innere Medizin I, Wien, Austria|Wilhelminenspital; I. Medizinische Abt., Wien, Austria|ZNA Middelheim, Antwerpen, Belgium|CH EpiCURA Site Louis Caty, Baudour, Belgium|AZ KLINA, Brasschaat, Belgium|AZ Sint Jan, Brugge, Belgium|HIS (Etterbeek Ixelles), Bruxelles, Belgium|Hospital Erasme; Neurologie, Bruxelles, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Antwerpen, Edegem, Belgium|AZ Groeninge (Kennedylaan), Kortrijk, Belgium|CHU Sart-Tilman, Li√®ge, Belgium|Clinique Ste-Elisabeth, Namur, Belgium|Clinique St Pierre asbl, Ottignies, Belgium|AZ Delta (Campus Wilgenstraat), Roeselare, Belgium|AZ Nikolaas (Sint Niklaas), Sint Niklaas, Belgium|AZ Turnhout Sint Elisabeth, Turnhout, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|Studienzentrum Aschaffenburg, Aschaffenburg, Germany|Internist; Praxis F√ºr Haemotologie & Onkologie, Bad Soden, Germany|Brustzentrum Bassum, Bassum, Germany|Onkologische Schwerpunktpraxis Kurf√ºrstendamm, Berlin, Germany|Praxis Dr. Schoenegg, Berlin, Germany|DRK Kliniken Berlin K√∂penick, Frauenklinik, Berlin, Germany|Praxis Dr Geuther, Berlin, Germany|Onkologische Schwerpunktpraxis Bielefeld; Haemotologie & Internistische onkologie, Bielefeld, Germany|Medizinisches Versorgungszentrum Bonn, Bonn, Germany|Universit√§tsklinikum Bonn; Zentrum f√ºr Geburtshilfe und Frauenheilkunde, Bonn, Germany|Med. Versorgungszentrum Filiale Donauw√∂rth Onkologisches Zentrum, Donauw√∂rth, Germany|Onkologisches Zentrum; Oncology, Donauw√∂rth, Germany|St. Johannes Hospital, Dortmund, Germany|Praxis im Elbcenter 1 in Dresden-Pieschen; Dr. med. Thomas Goehler & Dipl.-Med. Steffen Doerfel, Dresden, Germany|BAG Freiberg-Richter, Jacobasch, Illmer, Wolf, Dresden, Germany|Universit√§tsklinikum ""Carl Gustav Carus""; Frauenheilkunde und Geburtshilfe, Dresden, Germany|Universit√§tsklinikum D√ºsseldorf; Frauenklinik, D√ºsseldorf, Germany|Kreisklinik Ebersberg; Abteilung f√ºr Gyn√§kologie & Geburtshilfe, Ebersberg, Germany|Universit√§tsklinikum Erlangen; Frauenklinik, Erlangen, Germany|St Antonius Hospital; Frauenklinik, Eschweiler, Germany|Uniklinik Essen; Gyn√§kologie, Essen, Germany|H√§matologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt am Main, Germany|Praxis f√ºr Interdisziplin√§re Onkologie und H√§matologie GbR, Freiburg, Germany|Klinikum Fulda gAG; Frauenklinik, Fulda, Germany|Klinikum St. Georg GmbH; Franziskus-Hospital Harderberg; Klinik f√ºr Gynaekologie und Geburtshilfe, Georgsmarienh√ºtte, Germany|Wilhelm-Anton-Hospital Klinik f.H√§matologie und internistische Onkologie, Goch, Germany|Martin-Luther-Universit√§t Halle-Wittenberg, Halle, Germany|Universit√§tsklinikum Hamburg-Eppendorf; Frauenklinik, Hamburg, Germany|Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem, Hamburg, Germany|Praxis Harburger Ring, Hamburg, Germany|Iorc-Innovation Onkologie& Research& Consulting Gmbh; Praxis Lerchenfeld Hamburg, Hamburg, Germany|Dres. Sigrun M√ºller-Hagen Mathias Bertram und Ulrich Stein, Hamburg, Germany|SANA Klinikum Hameln-Pyrmont; Frauenklinik / Brustzentrum, Hameln, Germany|Diakovere Henriettenstift, Frauenklinik, Hannover, Germany|Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gyn√§kologische Onkologie, Hannover, Germany|Stiftung Kathol. Krankenhaus Marienhospital Herne Klinik Mitte Frauenklinik, Herne, Germany|Universitaetsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe, Homburg/Saar, Germany|Universit√§tsklinikum Jena; Klinik und Poliklinik f√ºr Frauenheilkunde und Fortpflanzungsmedizin, Jena, Germany|Westpfalz-Klinikum GmbH; Klinik f√ºr Frauenheilkunde und Geburtshilfe, Kaiserslautern, Germany|Gemeinschaftspraxis Dr. Siehl & Dr. Soeling, Kassel, Germany|Systemedic Frauenarzte Pruener Gang, Kiel, Germany|Gemeinschaftspraxis F√ºr Haematologie/Onkologie, K√∂ln, Germany|Uniklinik K√∂ln; Klinik F√ºr Frauenheilkunde, K√∂ln, Germany|Asklepios Klinik; Abt. Gyn√§kologie, Langen, Germany|Klinik Lippe Lemgo; Medizinische Klinik II/Haematoonkologie, Lemgo, Germany|Universit√§tsklinikum Schleswig-Holstein / Campus L√ºbeck; Klinik f√ºr Frauenheilkunde und Geburtshilfe, L√ºbeck, Germany|Onkologische Gemeinschaftspraxis, Magdeburg, Germany|Universit√§tsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde, Mainz, Germany|Universit√§tsklinikum Marburg; Gyn√§kologie, Marburg, Germany|Ev. Krankenhaus, M√ºlheim, Germany|Gemeinschaftspraxis f√ºr H√§matologie und Onkologie, M√ºnster, Germany|Praxis F√ºr Haematologie & Onkologie Dr. B. Otremba, Oldenburg, Germany|Praxis Frau Dr. Schwarz, Oranienburg, Germany|Klinikum Passau; 2. Medizinische Klinik; Onkologie und H√§matologie, Passau, Germany|Krankenhaus Rheinfelden; Frauenklinik, Rheinfelden, Germany|Agaplesion Diakonieklinikum Rotenburg, Rotenburg-wuemme, Germany|Caritas Klinik St. Theresia -Frauenklinik Brustzentrum, Saarbruecken, Germany|Praxis Dr. Wagner, Saarbruecken, Germany|Klinik Saarbr√ºcken Ggmbh; Brustzentrum, Saarbruecken, Germany|DRK Krankenhaus Saarlouis; Kooperatives Brustzentrum, Saarlouis, Germany|Marienkrankenhaus Abt. Gyn√§kologie und Geburtshilfe, Saint Wendel, Germany|MVZ f√ºr H√§matologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken, Stade, Germany|Johanniter-Krankenhaus, Stendal, Germany|Klinik Der Hansestadt Stralsund Gmbh; Frauenklinik, Stralsund, Germany|Klinikum Traunstein, Traunstein, Germany|Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie, Trier, Germany|Katharinen-Hospital gGmbH, Unna, Germany|Kliniken Nordoberpfalz; Klinikum Weiden; Brustzentrum, Weiden, Germany|Gemeinschaftspraxis H√§matologie / Onkologie, Wiesbaden, Germany|Semmelweis Egyetem Onkologiai K√∂zpont, Budapest, Hungary|Municipal Hospital of Uzsoki Utca; Centre of Oncoradiology, Budapest, Hungary|Josa Andras Korhaz; Dept of Oncoradiology, Ny√≠regyh√°za, Hungary|Vas Megyei Markusovszky Korhaz ; Pulmonology, Szombathely, Hungary|Policlinico Ospedaliero Ss Annunziata; U.O. Di Clinica Oncologica, Chieti, Abruzzo, Italy|Ospedale San Carlo; Day Hospital Oncologia Medica, Potenza, Basilicata, Italy|Ospedale Oncologico Regionale; U.O. Oncologia Medica Ed Ematologia, Rionero in Vulture, Basilicata, Italy|Az. Osp. Pugliese; Dh Oncologico, Catanzaro, Calabria, Italy|Az. Osp. Mariano Santo; Centro Oncologico, Cosenza, Calabria, Italy|Azienda Ospedaliera S.G. Moscati; Division of Medical Oncology, Avellino, Campania, Italy|Az. Osp. Cardarelli; Divisione Di Oncologia, Napoli, Campania, Italy|Ist. Uni Federico Ii; Divisione Di Oncologia Medica - Dpt. Di Medicina Interna, Napoli, Campania, Italy|Istituto Tumori Fondazione Pascale; Endocrinologia Oncologica, Napoli, Campania, Italy|Ospedale S. Gennaro; Oncologia Medica, Napoli, Campania, Italy|Az. Osp. S. Orsola Malpighi; Istituto Di Oncologia Seragnoli, Bologna, Emilia-Romagna, Italy|Opspedale Morgagni - Pierantoni; Dept. Di Oncologia Medica, Meldola, Emilia-Romagna, Italy|Ospedale Provinciale Santa Maria delle Croci, Ravenna, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Centro Soc. Oncologico, Azienda Sanitaria Universitaria Integrata Trieste; CENTRO ONCOLOGICO, Trieste, Friuli-Venezia Giulia, Italy|Ospedale S. Maria Goretti; Divisione Di Oncologia Medica, Latina, Lazio, Italy|Ospedale San Giacomo in Augusta; Reparto Oncologia, Roma, Lazio, Italy|Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica, Roma, Lazio, Italy|Azienda Complesso Ospedaliero S. Filippo Neri; Divisione Di Oncologia Medica, Roma, Lazio, Italy|Istituto Regina Elena; Oncologia Medica A, Roma, Lazio, Italy|Policlinico Militare Di Roma; Reparto Di Oncologia, Roma, Lazio, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, Italy|Ospedale S. Andrea Est Felettino; Oncologia Medica, La Spezia, Liguria, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina, Brescia, Lombardia, Italy|Ospedale Di Casalpusterlengo; Day Hospital Oncologico, Casalpusterlengo, Lombardia, Italy|Ospedale Valduce; Dept. Di Oncologia Medica, Como, Lombardia, Italy|ASST DI LECCO; Oncologia Medica, Lecco, Lombardia, Italy|ASST OVEST MILANESE; Oncologia Medica, Legnano, Lombardia, Italy|Az. Osp. Carlo Poma; Divisione Di Oncologia Medica, Mantova, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Asst Santi Paolo E Carlo; Unita Operativa Di Oncologia Medica, Milano, Lombardia, Italy|Fondazione Salvatore Maugeri; Divisione Di Oncologia Medica, Pavia, Lombardia, Italy|Fondazione Salvatore Maugeri; Servizio Di Prevenzione Oncologica, Pavia, Lombardia, Italy|Irccs Policlinico S. Matteo - Uni Pavia; Clinica Medica I Div. Med. Int. Onc. Medica E Gastroent., Pavia, Lombardia, Italy|Ospedale Di Circolo; Centro Di Senologia, Varese, Lombardia, Italy|Ospedale S. Croce Di Fano; Servizio Oncologia, Fano, Marche, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, Italy|Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica, Ponderano (BI), Piemonte, Italy|A.O. Citt√† della Salute e della Scienza - Presidio Molinette; divisione oncologia medica, Torino, Piemonte, Italy|Ospedale Sant'Anna - Uni Di Torino; Unita Di Oncologia Ginecologica, Torino, Piemonte, Italy|Ospedale Vito Fazzi; Div. Oncoematologia, Lecce, Puglia, Italy|IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia, San Giovanni Rotondo, Puglia, Italy|A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia, Cagliari, Sardegna, Italy|Azienda Ospedaliero Universitaria Di Sassari;Oncologia, Sassari, Sardegna, Italy|Centro Catanese Di Oncologia; Oncologia Medica, Catania, Sicilia, Italy|Az. Osp. M. Ascoli G. Di Cristina; Oncologia Medica, Palermo, Sicilia, Italy|La Maddalena Casa Di Cura Di Alta Specialita; Oncologia Chirurgica, Palermo, Sicilia, Italy|Az. Osp. ; Divisione Di Oncologia, Ragusa, Sicilia, Italy|USL 8 Ospedale San Donato; Oncology Endocrinology, Arezzo, Toscana, Italy|Ospedale Santa Maria Annunziata; Oncologia, Bagno a Ripoli, Toscana, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Ospedale Campo Di Marte; Dipartimento Oncologico, Lucca, Toscana, Italy|Azienda Usl 7; Dept. Oncologico, Poggibonsi, Toscana, Italy|Ospedale Santa Chiara; Oncologia Medica, Trento, Trentino-Alto Adige, Italy|Arcispedale S.Anna; Oncologia Medica, Cona (Ferrara), Veneto, Italy|Polo Ospedaliero Santorso, Santorso, Veneto, Italy|Ospedale Civile S. Bortolo; Divisione Di Oncologia, Vicenza, Veneto, Italy|Regionalne Centrum Onkologi; Oddzial Chorob Wewnetrznych I Onkologii, Bydgoszcz, Poland|Oddzial Chemioterapii Szpitala Klinicznego Nr 1 w Poznaniu, Poznan, Poland|Hospital General de Mataro; Servicio de Oncologia, Mataro, Barcelona, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Hospital Regional Universitario Carlos Haya, Malaga, Spain|Hospital de Navarra; Servicio de Oncologia, Navarra, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia, Toledo, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|G√§vle sjukhus onkologkliniken, Gaevle, Sweden|Lanssjukhuset Ryhov; Onkologkliniken, Jonkoping, Sweden|L√§nssjukhuset Kalmar; Oncology, Kalmar, Sweden|Centralsjukhuset Karlstad, Onkologkliniken, Karlstad, Sweden|Uni Hospital Linkoeping; Dept. of Oncology, Link√∂ping, Sweden|Sk√•nes University Hospital, Sk√•nes Department of Onclology, Lund, Sweden|Karolinska Hospital; Oncology - Radiumhemmet, Stockholm, Sweden|L√§nssjukhuset Sundsvall, Onkologkliniken, Sundsvall, Sweden|Norrlands Universitetssjukhus, Ume√•, Cancercentrum; Dept of Oncology, Umea, Sweden|Aberdeen Royal Infirmary; Medical Oncology Dept, Aberdeen, United Kingdom|Belfast City Hospital; Dept of Oncology, Belfast, United Kingdom|Velindre Cancer Centre; Oncology Dept, Cardiff, United Kingdom|Broomfield Hospital; Oncology, Chelmsford, United Kingdom|Ninewells Hospital; Dept of Radiotherapy & Oncology, Dundee, United Kingdom|Royal Devon & Exeter Hospital; Oncology Centre, Exeter, United Kingdom|Glasgow Western Infirmary; Dept of Radiotherapy, Glasgow, United Kingdom|Huddersfield Royal Infirmary, Huddersfield, United Kingdom|Queen Elizabeth Hospital, Kings Lynn, United Kingdom|St Thomas Hospital; Medicine Div., London, United Kingdom|St George'S Hospital; Oncology Research Office /Oncology Opd, London, United Kingdom|Charing Cross Hospital; Medical Oncology., London, United Kingdom|Christie Hospital; Breast Cancer Research Office, Manchester, United Kingdom|James Cook Uni Hospital, Middlesborough, United Kingdom|Newcastle General Hospital, Newcastle Upon Tyne, United Kingdom|Royal Preston Hosptial, Preston, United Kingdom|Oldchurch Hospital, Romford, United Kingdom|Salisbury District General Hospital; Medical Oncology Dept, Salisbury, United Kingdom|Royal Shrewsbury Hospitals Nhs Trust; Oncology, Shrewsbury, United Kingdom|Southampton General Hospital; Medical Oncology, Southampton, United Kingdom|Worthing Hospital; Sussex Oncology Centre, Worthing Breast Unit, Worthing, United Kingdom|Yeovil District Hospital; Macmillan Cancer Unit, Yeovil, United Kingdom|Airedale General Hospital; Oncology, York, United Kingdom",34.11647432,30.70482688,All,,534,514,477,370,38,69,1/6/2014,8/18/2014,6/20/2014,7/10/2014,6/27/2014,7/2/2014,7/16/2014,7/21/2014,8/14/2014,1/12/2016,11/13/2015,4/19/2016,5/31/2016,7/4/2016,8/20/2016,9/29/2016,11/25/2016,1/5/2017,3/1/2017,12/29/2014,6/27/2015,12/24/2015,6/21/2016,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01152606,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00563,SP00011,A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin¬Æ) and Docetaxel (Taxotere¬Æ) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Jene M,Stephan T,Dinah R,Selizabeth F,Louann C,Jeanene Y,Ross S,Liberty A,Frank T,Jene M,Geralyn K,Lavina S,Suk T,Frank T,Perter K,Mara A,Perter K,Liberty A,Frank T,,,,88.20331466,79.38298319,All,,513,506,478,150,307,21,2/28/2009,9/13/2009,7/7/2009,7/27/2009,7/10/2009,7/19/2009,7/30/2009,8/3/2009,8/26/2009,11/13/2009,4/2/2010,7/1/2010,11/1/2010,12/2/2010,1/22/2011,3/2/2011,4/5/2011,5/17/2011,6/21/2011,1/15/2010,7/14/2010,1/10/2011,7/9/2011,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00679341,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00566,SP00011,A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function,,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Mary H,Liberty A,Lilla Stilson †,Mara A,Clarice N,Gertrudis T,John G,John G,Rima Y ,Perter K,Mac L,Garnet T,Hee Y,Garnet T,Doreen T,Frank T,Jaquelyn H,Mara A,Doreen T,,,"Fort Myers, Florida, United States|Detroit, Michigan, United States|Portland, Oregon, United States|Nashville, Tennessee, United States|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Marseille, France|Paris, France|Toulouse, France|Catanzaro, Calabria, Italy|Udine, Friuli-Venezia Giulia, Italy|Barcelona, Spain|Madrid, Spain",14.32648572,12.89383715,All,,503,487,479,313,129,37,11/2/2009,4/7/2010,2/5/2010,3/19/2010,2/18/2010,3/7/2010,3/11/2010,3/16/2010,4/15/2010,12/17/2013,11/6/2013,4/7/2014,9/1/2014,10/5/2014,11/20/2014,12/28/2014,2/4/2015,3/10/2015,4/19/2015,9/3/2010,3/2/2011,8/29/2011,2/25/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01513083,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00568,SP00011,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Kala R,Suzie K,Christian G,Jene M,James y,Kandace p,Anthony P,Mac L,Selizabeth F,Otis Thode †,Jeanene Y,Garnet T,Suzie K,Terisa Sikora †,Marcelina X,Mac L,James y,Donovan H,Mary H,,,"Asl 4 - Osp. San Salvatore; Oncologia Medica, L'aquila, Abruzzo, Italy|Ospedale San Carlo; Day Hospital Oncologia Medica, Potenza, Basilicata, Italy|Campus Universitario S.Venuta; Centro Oncologico T.Campanella, Catanzaro, Calabria, Italy|Az. Osp. ; Divisione Oncologia Medica, Reggio Calabria, Calabria, Italy|Azienda Ospedaliera S.G. Moscati; Division of Medical Oncology, Avellino, Campania, Italy|Presidio Ospedaliero S. Giovanni Di Dio; U.O. Di Oncologia, Frattamaggiore, Campania, Italy|Seconda Universit√† di Napoli;Day Hospital Clinica Oncologia Medica, Napoli, Campania, Italy|Ospedale Bellaria; U.O. Oncologia Medica, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unit√† Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|Ospedale Ramazzini ; Day Hospital Oncologico, Carpi, Emilia-Romagna, Italy|Ospedale Civile; Day Hospital Oncologico, Guastalla, Emilia-Romagna, Italy|Arcispedale Santa Maria Nuova; Oncologia, Reggio Emilia, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia, Udine, Friuli-Venezia Giulia, Italy|Policlinico A. Gemelli-Complesso Integrato Columbus-Radioterapia, Roma, Lazio, Italy|Uni Cattolica Policlinico Gemelli; Oncologia Medica Ist. Medicina Interna, Roma, Lazio, Italy|Ospedale S.G.Calibita Fatebenefratelli; Unit√† Operativa Oncologia, Roma, Lazio, Italy|Villa San Pietro Fatebenefatelli; Divisione Oncologia, Roma, Lazio, Italy|Az. Osp. Uni Ria San Martino; Cliniche Uni Rie Convenzionate U.O. Oncologia Medical, Genova, Liguria, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, Italy|Ospedale Civile S. Andrea; Day Hospital Oncologia, La Spezia, Liguria, Italy|Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina, Brescia, Lombardia, Italy|Casa Di Cura Poliambulanza; Unita Operativa Di Oncologia Medica, Brescia, Lombardia, Italy|Ospedale Valduce;U.O.S. Oncologia Ed Ematologia, Como, Lombardia, Italy|ASST DI LECCO; Oncologia Medica, Lecco, Lombardia, Italy|Az. Osp. Carlo Poma; Divisione Di Oncologia Medica, Mantova, Lombardia, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Fondazione Salvatore Maugeri; Divisione Di Oncologia Medica, Pavia, Lombardia, Italy|Az. Osp. Di Busto P.O. Di Saronno; U.O. Di Oncologia Medica, Saronno, Lombardia, Italy|ASST DI BERGAMO OVEST; Unit√† Operativa di Oncologia Medica, Treviglio, Lombardia, Italy|Ospedale Di Circolo E Fondazione Macchi; Oncologia Medica, Varese, Lombardia, Italy|A.O.U. Ospedali Riuniti Umberto I-G.M.Lancisi-G.Salesi Ancona;S.O.D. MED.Interna-Clinica Oncologica, Ancona, Marche, Italy|Ospedale Di Macerata; Oncologia, Macerata, Marche, Italy|Ospedale San Salvatore Muraglia;Divisone Oncologia, Pesaro, Marche, Italy|Azienda Sanitaria Locale Di Asti-P.O. Cardinal Massaia;Oncologia, Asti, Piemonte, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, Italy|Azienda Sanitaria Ospedaliera s. Croce e Carle; Oncologia Medica, Cuneo, Piemonte, Italy|Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica, Ponderano (BI), Piemonte, Italy|Ospedale Mauriziano Umberto I; Divisione Onco-Ematologia, Torino, Piemonte, Italy|Centro Catanese Di Oncologia; Oncologia Medica, Catania, Sicilia, Italy|Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia, Arezzo, Toscana, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Ospedale della Misericordia; Hospice Terapia del Dolore, Grosseto, Toscana, Italy|Ospedale Nuovo Della Versilia; Divisione Di Oncologia Medica, Lido Di Camaiore, Toscana, Italy|Ospedale Civile; Unita Operativa Di Oncologia Medica, Livorno, Toscana, Italy|Azienda Usl 7; Dept. Oncologico, Poggibonsi, Toscana, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Sant'Andrea Delle Fratte (PG), Umbria, Italy|Presidio Ospedaliero - Usl 13; Servizio Di Oncologia, Castelfranco Veneto, Veneto, Italy|AZ. Usll12 Veneziana-Ospedale Dell'angelo;Oncologia Medica, Mestre, Veneto, Italy|Ospedale Calvi di Noale; U.O. Complessa di Oncologia ed Ematologia Oncologica, Mirano, Veneto, Italy|Ospedale Sacro Cuore Don Calabria; U.O. Di Oncologia, Negrar, Veneto, Italy|Ospedale C√† Foncello - Divisione di Oncologia Medica, Treviso, Veneto, Italy|Ospedale Di Vicenza; Nefrologia, Oncologia Medica, Vicenza, Veneto, Italy",17.07828895,15.37046005,All,,531,509,480,172,287,21,4/1/2013,9/12/2013,7/7/2013,8/3/2013,7/18/2013,7/24/2013,7/26/2013,7/29/2013,8/5/2013,9/10/2015,8/7/2015,1/10/2016,4/5/2016,5/16/2016,6/27/2016,8/6/2016,9/9/2016,11/7/2016,12/19/2016,1/20/2014,7/19/2014,1/15/2015,7/14/2015,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01940497,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT01940497/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT01940497/SAP_001.pdf"
Hoffmann-La Roche,Hoffmann-La Roche,ST00570,SP00011,"A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)",,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Perter K,Beulah N,Selizabeth F,Naren G,Kala R,Aleta H,Jene M,Remedios Z,John G,Selizabeth F,Hee Y,Suk T,In Bellini †,Marcelina X,In Bellini †,Lavina S,Jerold Goo †,Federico L,Suk T,,,"UCLA - Beverly Hills, Beverly Hills, California, United States|UCLA - Burbank, Burbank, California, United States|UCLA Hematology/Oncology-Encino, Encino, California, United States|UCLA Hematology Oncology - Irvine, Irvine, California, United States|UCLA - Laguna Hills, Laguna Hills, California, United States|UCLA - Pasadena, Pasadena, California, United States|UCLA Hemetology Oncology; Porter Ranch, Porter Ranch, California, United States|UCLA Hematology/Oncology-San Luis Obispo, San Luis Obispo, California, United States|UCLA Hematology Oncology-Santa Monica, Santa Monica, California, United States|Torrance Memorial Physician Network/Cancer Care, Torrance, California, United States|UCLA Hem/Onc - Torrance, Torrance, California, United States|UCLA Hematology/Oncology-Santa Clarita, Valencia, California, United States|UCLA; UCLA Hematology Oncology Ventura, Ventura, California, United States|UCLA Hematology Oncology - Westlake, Westlake Village, California, United States|Orlando Health Inc., Orlando, Florida, United States|SCRI Florida Cancer Specialists East, West Palm Beach, Florida, United States|Saint Barnabas Medical Center Cancer Center, Livingston, New Jersey, United States|Tennessee Oncology; Sarah Cannon Research Institute, Nashville, Tennessee, United States|Univ of Wisconsin-Madison; Clinical Science Center, Madison, Wisconsin, United States|Macquarie University Hospital, Macquarie Park, New South Wales, Australia|Westmead Hospital; Medical Oncology and Pallative Care, Westmead, New South Wales, Australia|Hospital do Cancer de Pernambuco - HCP, Recife, PE, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS, Brazil|Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, SP, Brazil|N√∫cleo de Pesquisa S√£o Camilo; ONCOLOGIA CLINICA / QUIMIOTERAPIA, Sao Paulo, SP, Brazil|Universit√§tsklinikum Dresden, Dresden, Germany|LUISENKRANKENHAUS; Senological Oncology, D√ºsseldorf, Germany|UNIVERSITATSKLINIKUM ERLANGEN; Department of Gynecology and Obstetrics, Erlangen, Germany|Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont; Onkoradiologiai Kozpont, Kecskemet, Hungary|Tolna Megyei K√≥rh√°z, Onkol√≥gia, Szeksz√°rd, Hungary|National Cancer Center; Medical Oncology, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital; Internal Medicine, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Szpital Morski Im. Pck; Oncology & Radiotherapy Dept, Gdynia, Poland|COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej, Lublin, Poland|Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Oncology, Warszawa, Poland|DOLNOSLASKIE CENTRUM ONKOLOGII; Oddzial Chirurgii Piersi, Wroc≈Çaw, Poland|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Private Healthcare Institution Clinical Hospital RZhD Medicine, St. Petersburg, Sankt Petersburg, Russian Federation|Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic, Kazan, Tatarstan, Russian Federation|Filial #1 Regional Oncology Dispensary of Nizhniy Novgorod, Nizhny Novgorod, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|FSI ""SRC of Oncology n. a. N.N.Petrov of Rosmedtekhnologiy"", St. Petersburg, Russian Federation|Institutio Catalan De Oncologia, Badalona, Barcelona, Spain|ALTHAIA Xarxa Assistencial de Manresa, Manresa, Barcelona, Spain|Hospital de Jerez de la Frontera; Servicio de Oncologia, Jerez de La Frontera, Cadiz, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Lerida, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitari Sant Joan de Reus; Planta baja, color lila, Reus, Tarragona, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Quir√≥n Dexeus, Barcelona, Spain|Hospital Vall Hebron, Barcelona, Spain|Hospital Universitario Virgen de las Nieves : Hospital General, Granada, Spain|Hospital Clinico San Cecilio, Granada, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Hospital Universitario La Paz, Madrid, Spain|Fundaci√≥n Jimenez D√≠az, Madrid, Spain|Hosp Univ Fundacion Alcorcon, Madrid, Spain|Hospital Universitario Virgen de La Arrixaca, Murcia, Spain|Hospital de Navarra; Servicio de Oncologia, Navarra, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain|National Cheng Kung Uni Hospital; Surgery, Tainan, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan|Regional Oncology Center of Kharkiv Regional Council; Department of Soft Tissues and Breast Cancer, Kharkiv, Kharkiv Governorate, Ukraine|Odesa Regional Clinical Hospital; Department of Thoracic Surgery, Odesa, Kharkiv Governorate, Ukraine|Khmelnytsky Regional Antitumor Center; Department of Breast, Skin, Soft Tissues and Bones Tumors, Khmelnytskyi, Podolia Governorate, Ukraine|Municipal institution Dnipropetrovsk City Multifield Clinical Hospital #4; dept. of Chemotherapy, Dnipropetrovsk, Ukraine|ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department, Kryvyi Rih, Ukraine|Kyiv Regional Oncological Dispensary, Kyiv, Ukraine",40.8089179,36.72802611,Female,,510,496,481,342,75,64,11/18/2019,4/13/2020,1/23/2020,2/29/2020,2/19/2020,2/21/2020,2/23/2020,2/25/2020,3/10/2020,2/14/2021,11/19/2020,5/22/2021,7/6/2021,8/5/2021,9/17/2021,11/7/2021,12/24/2021,1/28/2022,3/12/2022,8/19/2020,2/15/2021,8/14/2021,2/10/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04436744,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00574,SP00011,"A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer",,,,,Oncology,,,,,,Industry,Recruiting,Phase 1,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Xochitl D,Patria R,Lucie P,Jaquelyn H,Clarice N,Garnet T,Suk T,Tien C,Terisa Sikora †,Suzie K,Anthony P,Ngan D,Dalton E,Terrell p,John G,John G,Tamesha T,Stephan T,Geralyn K,,,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Univ of Chicago, Chicago, Illinois, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Magee-Woman's Hospital, Pittsburgh, Pennsylvania, United States|Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States|Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia|Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit, Bull Creek, Western Australia, Australia|Hospital Sao Rafael - HSR, Salvador, BA, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital S√≠rio-Liban√™s, Sao Paulo, SP, Brazil|Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, SP, Brazil|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik f√ºr Senologie / Brustzentrum, Essen, Germany|Nationales Centrum f√ºr Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Arhangelsk, Russian Federation|SBIH ""Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"", Moskva, Moskovskaja Oblast, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moskva, Moskovskaja Oblast, Russian Federation|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coru√±a, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Hospital Cl√≠nico Universitario de Valencia; Servicio de Oncolog√≠a, Valencia, Spain|China Medical University Hospital; Surgery, Taichung, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan",32.66180339,29.39562305,All,,552,529,482,306,116,60,6/6/2019,12/23/2019,10/21/2019,11/14/2019,10/9/2019,10/31/2019,11/15/2019,11/17/2019,12/5/2019,8/29/2021,5/30/2021,1/3/2022,3/15/2022,5/6/2022,6/21/2022,8/6/2022,9/21/2022,11/5/2022,12/17/2022,4/28/2020,10/25/2020,4/23/2021,10/20/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04584112,,,,,,
Hoffmann-La Roche,Hoffmann-La Roche,ST00576,SP00011,"A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer",,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Garnet T,Perter K,Geralyn K,Doreen T,Suzie K,Mary H,Lucie P,Gertrudis T,Tammara F,Marcelina X,Jene M,Otis Thode †,Hee Y,Terisa Sikora †,Remedios Z,Mary H,Frank T,John G,Clarice N,,,"University of South Alabama; Mitchell Cancer Institute, Mobile, Alabama, United States|Marin Specialty Care, Greenbrae, California, United States|California Pacific Medical Center, San Francisco, California, United States|MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington, District of Columbia, United States|Washington Cancer Institute at MedStar Washington Hospital Center., Washington, District of Columbia, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Berkshire Medical Center, Pittsfield, Massachusetts, United States|Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Saint Lukes Hospital Cancer Institute, Kansas City, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Regional Cancer Care Associates LLC - Morristown, Morristown, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|MSKCC @ Commack, Commack, New York, United States|MSKCC @ West Harrison, Harrison, New York, United States|Mount Sinai Beth Israel Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|MSKC @ Rockville, Rockville Centre, New York, United States|Mercy Clinic Oklahoma Communties, Inc, Oklahoma City, Oklahoma, United States|Harrington Cancer Center, Amarillo, Texas, United States|University of Utah; Huntsman Cancer Hospital, Salt Lake City, Utah, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|PeaceHealth St. Joseph Cancer Center, Bellingham, Washington, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Horizon Health Network, Moncton, New Brunswick, Canada|Royal Victoria Hospital, Barrie, Ontario, Canada|Cite de La Sante de Laval; Hemato-Oncologie, Laval, Quebec, Canada|St Mary's Hospital Center, Montreal, Quebec, Canada|Hopital Sacre-Coeur Research Centre, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Herlev Hospital; Afdeling for Kr√¶ftbehandling, Herlev, Denmark|Rigshospitalet; Onkologisk Klinik, K√∏benhavn √ò, Denmark|Vejle Sygehus; Onkologisk Afdeling, Vejle, Denmark|Clinique Victor Hugo; Chimiotherapie, Le Mans, France|Centre Oscar Lambret; Cancerologie Gynecologique, Lille, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Clinique Clementville; Hopital De Jour, Montpellier, France|Centre D'Oncologie de Gentilly; Oncology, Nancy, France|Centre Antoine Lacassagne; Hopital De Jour A2, Nice, France|Institut Curie; Oncologie Medicale, Paris, France|Centre Eugene Marquis; Unite Huguenin, Rennes, France|Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France|Universit√§tsklinikum ""Carl Gustav Carus""; Frauenheilkunde und Geburtshilfe, Dresden, Germany|Dres.Andreas Ammon und Dirk Meyer, G√∂ttingen, Germany|Dres. Andreas K√∂hler und Roswitha Fuchs, Langen, Germany|Klinikum rechts der Isar der TU M√ºnchen; Klinik und Poliklinik f√ºr Frauenheilkunde, M√ºnchen, Germany|Ruppiner Kliniken, Klinik fuer Gynaekologie und Geburtshilfe, Neuruppin, Germany|Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche, Roma, Lazio, Italy|A.O. Citt√† della Salute e della Scienza - Presidio Molinette; divisione oncologia medica, Torino, Piemonte, Italy|Asl Le-Ospedale ""Vito Fazzi"";U.O. Oncologia, Lecce, Puglia, Italy|Casa Di Cura Di Alta Specialita La Maddalena; Dept. Oncologico Di Iii Livello, Palermo, Sicilia, Italy|Ospedale Santa Maria Annunziata; Oncologia, Bagno a Ripoli, Toscana, Italy|Ospedale Della Misericordia; U.O. Di Medicina Ia - Oncologia Medica, Grosseto, Toscana, Italy|Iem-Fucam, D.f., Mexico|Centro de Diagn√≥stico y Tratamiento Integral de Mama, Hospital San Jos√© Tec de Monterrey, Monterrey, Mexico|Haukeland Universitetssjukehus; Klinisk forskningspost, Bergen, Norway|Oslo universitetssykehus HF, Ullev√•l, Kreftsenteret, Oslo, Norway|Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej, Bialystok, Poland|Szpital Uniwersytecki w Krakowie, Oddzia≈Ç Kliniczny Kliniki Onkologii, Krak√≥w, Poland|Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii, Otwock, Poland|Wielkopolskie Centrum Onkologii; im. Marii Sk≈Çodowskiej-Curie, Poznan, Poland|Centro Clinico Champalimaud; Oncologia Medica, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|Hospital Beatriz Angelo; Departamento de Oncologia, Loures, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, C√≥rdoba, Cordoba, Spain|Centro Oncol√≥gico Gallego Jos√© Antonio Quiroga y Pi√±eiro, Servicio de Oncologia, La Coru√±a, Spain|Hospital Universitario de la Princesa; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia, Toledo, Spain|Royal United Hospital; Oncology Department, Bath, United Kingdom|Royal Bournemouth Hospital; Oncology, Bournemouth, United Kingdom|Guys & St Thomas Hospital; Department of Oncology, London, United Kingdom|Royal Marsden Hospital - Fulham; Oncology Department, London, United Kingdom|Freeman Hospital; Northern Centre For Cancer Care, New Castle Upon Tyne, United Kingdom|Churchill Hospital; Oxford Cancer and Haematology Centre, Oxford, United Kingdom|Peterborough City Hospital, Edith Cavell Campus; Oncology Department, Peterborough, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom",53.72581814,48.35323632,All,,529,513,483,176,274,33,10/6/2011,5/3/2012,3/20/2012,4/13/2012,3/30/2012,4/2/2012,4/4/2012,4/5/2012,5/5/2012,1/21/2016,8/12/2015,10/25/2015,3/3/2016,4/11/2016,5/17/2016,6/22/2016,7/26/2016,9/22/2016,10/30/2016,9/29/2012,3/28/2013,9/24/2013,3/23/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02132949,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00005,SP00013,Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427),,APEGIN,"Hepatitis C, Chronic|Hepatitis C",,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Control|Time Perspective: Prospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Dinah R,Garnet T,Marceline R,Tien C,Mee M,Chetan K,Tiffiny K,Jene M,Corrine U,Mac L,Jaquelyn H,John G,Naren G,Anthony P,Quentin N,Aleta H,Frank T,Otis Thode †,Tien C,,,,13.34993044,12.01493739,All,"18 Years to 70 Years ¬† (Adult, Older Adult)",520,513,484,352,81,51,7/26/2027,3/14/2028,1/10/2028,1/22/2028,1/12/2028,1/16/2028,1/26/2028,12/27/2004,1/18/2005,9/6/2008,1/17/2009,6/1/2009,9/1/2009,10/24/2009,12/21/2009,1/31/2010,3/3/2010,4/29/2010,6/25/2010,7/14/2028,1/10/2029,7/9/2029,1/5/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00724854,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00007,SP00013,Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017),,,Hepatitis C,,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Jene M,Suzie K,Kandace p,Doreen T,James y,Dinah R,Garnet T,Tiffiny K,Lucie P,Corrine U,Stephan T,Anthony P,Anthony P,Mara A,Mara A,Tamesha T,Lilla Stilson †,Dalton E,Mary H,,,,61.4546522,55.30918698,All,18 Years to 60 Years ¬† (Adult),537,526,485,266,167,52,8/21/2027,3/21/2028,1/12/2028,2/13/2028,1/23/2028,2/6/2028,2/16/2028,11/3/2019,11/9/2019,6/11/2020,8/11/2020,12/7/2020,3/31/2021,5/27/2021,6/26/2021,8/15/2021,10/7/2021,11/21/2021,12/31/2021,8/4/2028,1/31/2029,7/30/2029,1/26/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01667081,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00011,SP00013,Extended Treatment With PEG-Intron¬Æ and Rebetol¬Æ in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685),,,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Hee Y,Chetan K,Terrell p,Federico L,Mary H,Gertrudis T,Marcelina X,Suk T,Naren G,Jerold Goo †,Dinah R,Otis Thode †,Tiffiny K,Clarice N,Jeanene Y,Hee Y,Tamesha T,Dalton E,Clarice N,,,,76.22565647,68.60309082,All,"18 Years and older ¬† (Adult, Older Adult)",514,495,486,396,16,74,9/5/2027,4/2/2028,2/17/2028,3/9/2028,2/2/2028,2/22/2028,3/3/2028,10/2/2006,10/7/2006,5/19/2007,9/28/2007,1/1/2008,5/1/2008,6/30/2008,8/25/2008,10/8/2008,11/16/2008,1/2/2009,2/22/2009,8/20/2028,2/16/2029,8/15/2029,2/11/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00265395,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00014,SP00013,Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059),,START 4,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Terminated,Phase 4,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Suzie K,Marcelina X,Frank T,Naren G,In Bellini †,In Bellini †,Frank T,Perter K,Jene M,Tiffiny K,Hee Y,Kandace p,Lucie P,Marceline R,Patria R,Donovan H,John G,Patria R,Aleta H,,,,54.72000172,49.24800155,All,"20 Years to 85 Years ¬† (Adult, Older Adult)",554,534,487,288,161,38,11/9/2027,4/5/2028,2/8/2028,3/11/2028,2/9/2028,3/2/2028,3/12/2028,12/17/2011,1/5/2012,4/14/2014,6/6/2014,10/6/2014,1/26/2015,3/20/2015,5/12/2015,7/2/2015,8/20/2015,10/10/2015,11/9/2015,8/29/2028,2/25/2029,8/24/2029,2/20/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01606800,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00019,SP00013,"3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals",,,Hepatitis C,,Virology,,,,,,Industry,Terminated,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Clarice N,Clarice N,Frank T,Frank T,Perter K,Jaquelyn H,Lavina S,Mary H,Remedios Z,Perter K,Liberty A,Lilla Stilson †,Jene M,Ngan D,Gertrudis T,Rima Y ,Liberty A,Jeanene Y,Naren G,,,,91.07296167,81.96566551,All,"18 Years to 75 Years ¬† (Adult, Older Adult)",538,518,488,327,107,54,11/19/2027,4/25/2028,2/26/2028,3/28/2028,2/27/2028,3/21/2028,3/31/2028,10/19/2011,11/2/2011,10/28/2014,5/7/2014,10/7/2014,3/1/2015,4/17/2015,6/7/2015,8/6/2015,9/8/2015,11/3/2015,12/27/2015,9/17/2028,3/16/2029,9/12/2029,3/11/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01721265,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00032,SP00013,Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-na√Øve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209),,,"Hepatitis C, Chronic|Hepatitis C",,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Case-Only|Time Perspective: Retrospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Tammara F,Perter K,Liberty A,Frank T,Dalton E,Kala R,Tien C,Mara A,Tien C,Lucie P,John G,Mac L,Livia Pacheo †,Suzie K,Ross S,Kala R,Liberty A,Chetan K,Mee M,,,,81.37209986,73.23488987,All,"18 Years and older ¬† (Adult, Older Adult)",547,524,489,334,89,66,4/10/2028,10/10/2028,8/11/2028,9/6/2028,8/3/2028,8/19/2028,8/29/2028,11/16/2008,11/23/2008,8/8/2010,12/16/2009,6/7/2010,10/1/2010,11/17/2010,1/9/2011,2/27/2011,4/12/2011,5/13/2011,6/22/2011,2/15/2029,8/14/2029,2/10/2030,8/9/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00724464,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00033,SP00013,Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303),,,"Hepatitis C, Chronic|Insulin Resistance",,Virology,,,,,,Industry,Terminated,Phase 4,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Federico L,Hee Y,Patria R,Dinah R,Marcelina X,Suzie K,Kala R,Marceline R,Mara A,Otis Thode †,Stephan T,Mary H,Harry A,Remedios Z,Mac L,Tammara F,James y,Frank T,Jene M,,,,34.04400943,30.63960848,All,"18 Years and older ¬† (Adult, Older Adult)",515,506,490,455,55,20,4/22/2028,10/15/2028,8/5/2028,9/7/2028,8/12/2028,8/23/2028,9/2/2028,4/17/2007,4/22/2007,11/30/2008,3/3/2009,8/18/2009,10/1/2009,11/15/2009,1/3/2010,2/6/2010,3/8/2010,4/15/2010,6/2/2010,2/19/2029,8/18/2029,2/14/2030,8/13/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00493805,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00038,SP00013,ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632),,ATHENAS,"Hepatitis C, Chronic",,Virology,,,,,,Industry,Terminated,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Tiffiny K,Remedios Z,Aleta H,Mary H,Terrell p,Quentin N,Aleta H,Corrine U,Jeanene Y,Dinah R,Mary H,Tamesha T,Kandace p,Otis Thode †,Perter K,Chetan K,Louann C,Tammara F,Corrine U,,,,42.26140349,38.03526314,All,"20 Years and older ¬† (Adult, Older Adult)",525,515,491,189,274,28,4/6/2028,10/16/2028,8/23/2028,9/20/2028,9/6/2028,9/8/2028,9/18/2028,1/3/2007,1/13/2007,2/3/2010,12/11/2009,8/17/2010,10/1/2010,11/17/2010,1/7/2011,2/12/2011,4/2/2011,5/17/2011,7/9/2011,3/7/2029,9/3/2029,3/2/2030,8/29/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00856024,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00042,SP00013,An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN),,PEGIMPACT,"Hepatitis C, Chronic|Hepatitis C",,Virology,,,,,,Industry,Withdrawn,,Observational,,Observational Model: Case-Only,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Naren G,Harry A,Tiffiny K,Harry A,Hee Y,Terrell p,Federico L,Federico L,Mary H,Stephan T,Beulah N,Mac L,Mara A,Jaquelyn H,Jene M,Mara A,Marceline R,Anthony P,Lavina S,,,,76.81781807,69.13603626,All,"18 Years and older ¬† (Adult, Older Adult)",508,500,492,466,62,36,5/20/2028,11/27/2028,9/14/2028,10/16/2028,9/9/2028,10/1/2028,10/11/2028,1/25/2009,2/22/2009,9/21/2009,6/11/2009,11/15/2009,3/1/2010,4/12/2010,5/13/2010,7/1/2010,8/30/2010,10/5/2010,11/10/2010,3/30/2029,9/26/2029,3/25/2030,9/21/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00704756,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00044,SP00013,Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562),,,"Hepatitis C, Chronic|Hepatitis C Virus",,Virology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Perter K,Lavina S,Livia Pacheo †,Gertrudis T,Rima Y ,Lavina S,Rima Y ,John G,Corrine U,Lavina S,In Bellini †,Federico L,Selizabeth F,Marceline R,Patria R,Selizabeth F,Frank T,Jeanene Y,Tamesha T,,,,26.84811539,24.16330385,All,6 Weeks to 10 Weeks ¬† (Child),525,500,493,300,136,57,4/17/2028,11/21/2028,10/4/2028,10/30/2028,9/24/2028,10/11/2028,10/21/2028,3/3/2009,3/18/2009,12/30/2009,12/5/2009,3/17/2010,8/1/2010,9/26/2010,11/16/2010,12/22/2010,1/31/2011,3/5/2011,4/26/2011,4/9/2029,10/6/2029,4/4/2030,10/1/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00705224,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00101,SP00013,A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRASG12C Mutant Advanced Solid Tumors (MK-1084-001),,,Advanced Solid Tumors,,Oncology,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Naren G,Perter K,Kandace p,Terisa Sikora †,Garnet T,Jaquelyn H,Quentin N,Lucie P,Terrell p,Anthony P,Quentin N,Anthony P,In Bellini †,Terisa Sikora †,Hee Y,Ross S,Naren G,Mac L,Corrine U,,,,22.00642401,19.80578161,All,19 Years to 50 Years ¬† (Adult),540,522,494,376,79,39,11/27/2022,5/9/2023,3/28/2023,4/24/2023,4/2/2023,4/9/2023,4/20/2023,4/25/2023,5/13/2023,12/26/2025,7/6/2025,10/17/2025,2/5/2026,3/10/2026,4/15/2026,5/17/2026,7/7/2026,8/29/2026,9/29/2026,10/6/2023,4/3/2024,9/30/2024,3/29/2025,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05067283,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00109,SP00013,A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007),,,Colorectal Cancer,,Oncology,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Mary H,In Bellini †,Aleta H,Naren G,Suk T,Xochitl D,Dinah R,Hee Y,Garnet T,Gertrudis T,James y,Jene M,Perter K,Perter K,Selizabeth F,Anthony P,Federico L,Naren G,Stephan T,,,,37.0171412,33.31542708,All,"18 Years and older ¬† (Adult, Older Adult)",556,544,495,429,10,56,9/24/2021,2/17/2022,12/27/2021,2/4/2022,12/24/2021,1/18/2022,1/20/2022,1/23/2022,2/5/2022,4/15/2023,7/1/2023,10/9/2023,2/9/2024,3/24/2024,4/28/2024,6/9/2024,7/9/2024,8/13/2024,9/25/2024,7/17/2022,1/13/2023,7/12/2023,1/8/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05064059,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00140,SP00013,A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) (MK-0482-002),,,Relapsed or Refractory Acute Myeloid Leukemia,,,,,,,,Industry,Recruiting,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Frank T,Stephan T,Garnet T,Chetan K,Dinah R,Tien C,Stephan T,Xochitl D,Suzie K,Lyman W,Naren G,Lilla Stilson †,Lilla Stilson †,Clarice N,Geralyn K,Jaquelyn H,John G,Lavina S,Jeanene Y,,,"Hadassah Medical Center ( Site 0100), Jerusalem, Israel",23.95947024,21.56352322,All,"18 Years and older ¬† (Adult, Older Adult)",519,511,496,164,305,27,2/17/2022,7/25/2022,5/13/2022,6/18/2022,5/17/2022,6/10/2022,6/19/2022,6/20/2022,6/30/2022,11/16/2024,12/16/2024,5/13/2025,9/29/2025,11/21/2025,1/17/2026,3/2/2026,4/30/2026,6/23/2026,8/13/2026,12/7/2022,6/5/2023,12/2/2023,5/30/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05038800,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00149,SP00013,A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010),,,Renal Cell Carcinoma,,Oncology,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Federico L,Garnet T,John G,Stephan T,Otis Thode †,Naren G,Gertrudis T,Lilla Stilson †,Lilla Stilson †,Beulah N,Remedios Z,John G,Livia Pacheo †,Louann C,Jaquelyn H,Chetan K,Chetan K,Selizabeth F,Federico L,,,,33.43608804,30.09247923,All,65 Years to 90 Years ¬† (Older Adult),565,546,497,255,199,43,10/1/2023,3/27/2024,2/2/2024,3/3/2024,2/5/2024,2/16/2024,2/19/2024,2/22/2024,3/7/2024,12/31/2024,8/24/2024,1/10/2025,4/25/2025,6/8/2025,8/6/2025,9/23/2025,10/27/2025,12/7/2025,1/20/2026,8/14/2024,2/10/2025,8/9/2025,2/5/2026,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05030506,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00155,SP00013,Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (Factor XI Hemodialysis Study) (MK-2060-007),,,"End-Stage Renal Disease|End-Stage Kidney Disease|Kidney Failure, Chronic",,Metabolic,,,,,,Industry,Recruiting,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Frank T,Anthony P,James y,Liberty A,Suk T,Quentin N,Selizabeth F,Suk T,Xochitl D,Mary H,Naren G,Mara A,Naren G,Mary H,Frank T,Mary H,Kandace p,Chetan K,Suzie K,,,"Citrus Dialysis Center ( Site 0609), Covina, California, United States|La Puente Dialysis Center ( Site 0610), La Puente, California, United States|Academic Medical Research Institute ( Site 0533), Los Angeles, California, United States|Genesis Clinical Research ( Site 0585), Tampa, Florida, United States|Genesis Clinical Research ( Site 0594), Tampa, Florida, United States",93.25704555,83.931341,All,"18 Years to 70 Years ¬† (Adult, Older Adult)",534,528,498,315,141,42,8/25/2018,2/19/2019,12/10/2018,1/26/2019,12/17/2018,1/8/2019,1/19/2019,1/22/2019,2/1/2019,11/19/2022,8/13/2022,2/9/2023,3/27/2023,5/21/2023,6/29/2023,8/25/2023,10/15/2023,11/25/2023,1/22/2024,7/7/2019,1/3/2020,7/1/2020,12/28/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05027074,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00167,SP00013,A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18),,,Advanced or Metastatic Solid Tumors,,Oncology,,,,,,Industry,Not yet recruiting,Phase 1|Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Harry A,Doreen T,Anthony P,Patria R,Jeanene Y,Remedios Z,Mee M,Perter K,Tamesha T,Doreen T,Lavina S,Naren G,Tien C,Mara A,Lucie P,Jene M,John G,Ross S,Frank T,,,,8.592385041,7.733146537,All,"18 Years and older ¬† (Adult, Older Adult)",555,541,499,201,264,34,8/8/2018,3/5/2019,1/11/2019,2/3/2019,12/29/2018,1/23/2019,2/3/2019,2/6/2019,3/4/2019,2/7/2022,4/28/2022,7/18/2022,11/25/2022,1/17/2023,3/6/2023,4/15/2023,5/16/2023,7/8/2023,8/13/2023,7/22/2019,1/18/2020,7/16/2020,1/12/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05017012,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00175,SP00013,Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11),,KEYNOTE-C11,Classical Hodgkin Lymphoma,,Oncology,,,,,,Industry,Not yet recruiting,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,John G,Rima Y ,Anthony P,In Bellini †,Mary H,Otis Thode †,Chetan K,Jeanene Y,Mary H,Tien C,Ngan D,Louann C,Louann C,Lilla Stilson †,Otis Thode †,Terisa Sikora †,Stephan T,Dalton E,Dinah R,,,,63.94695368,57.55225831,All,20 Years to 40 Years ¬† (Adult),562,545,500,467,41,8,12/28/2019,5/7/2020,3/26/2020,4/24/2020,3/11/2020,4/5/2020,4/11/2020,4/13/2020,4/21/2020,12/23/2023,9/21/2023,3/1/2024,6/18/2024,7/30/2024,9/16/2024,11/8/2024,12/17/2024,2/4/2025,3/20/2025,10/2/2020,3/31/2021,9/27/2021,3/26/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05008224,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00177,SP00013,MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005),,,Uterine Cervical Neoplasms|Endometrial Neoplasms|Squamous Cell Carcinoma of Head and Neck|Gallbladder Neoplasms|Cholangiocarcinoma|Esophageal Neoplasms|Triple Negative Breast Neoplasms|Hepatocellular Carcinoma,,Oncology,,,,,,Industry,Recruiting,Not Applicable,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Marceline R,Suzie K,In Bellini †,Terrell p,Garnet T,Jerold Goo †,Naren G,Geralyn K,Lavina S,Beulah N,Gertrudis T,John G,John G,Chetan K,Frank T,Mac L,Frank T,Garnet T,Dalton E,,,"Rambam Health Care Campus-Oncology ( Site 1141), Haifa, Israel|Seoul National University Hospital-Internal Medicine ( Site 1312), Seoul, Korea, Republic of|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 1101, Warszawa, Mazowieckie, Poland|Szpital Wojew√≥dzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1104), Koszalin, Zachodniopomorskie, Poland|HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1114), Sevilla, Spain|NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1302), Tainan, Taiwan",57.24565736,51.52109162,All,"18 Years and older ¬† (Adult, Older Adult)",563,537,501,178,293,30,7/10/2022,1/31/2023,12/1/2022,12/26/2022,11/29/2022,12/19/2022,12/25/2022,12/30/2022,1/11/2023,10/27/2024,7/16/2024,11/11/2024,2/19/2025,4/4/2025,5/5/2025,6/16/2025,8/4/2025,9/10/2025,10/19/2025,6/17/2023,12/14/2023,6/11/2024,12/8/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05007106,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00180,SP00013,A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004),,,Hematological Malignancies,,,,,,,,Industry,Not yet recruiting,Phase 1,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Jerold Goo †,Selizabeth F,Perter K,Jene M,Doreen T,Suk T,John G,Louann C,Chetan K,Naren G,Naren G,Suzie K,Rima Y ,Selizabeth F,Terrell p,James y,Xochitl D,Ross S,Naren G,,,,91.58719356,82.4284742,All,"18 Years and older ¬† (Adult, Older Adult)",538,513,502,172,310,20,5/23/2020,12/12/2020,10/2/2020,10/22/2020,10/10/2020,10/14/2020,10/25/2020,10/27/2020,11/25/2020,5/31/2024,1/21/2024,6/15/2024,9/9/2024,11/4/2024,12/7/2024,1/29/2025,3/16/2025,5/14/2025,6/22/2025,4/12/2021,10/9/2021,4/7/2022,10/4/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05005442,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00192,SP00013,Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020),,,Moderate Hepatic Impairment,,,,,,,,Industry,Not yet recruiting,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Kala R,Beulah N,Gertrudis T,Geralyn K,Garnet T,Tammara F,Corrine U,Stephan T,Corrine U,Suk T,Stephan T,Naren G,Gertrudis T,Mara A,Mac L,Frank T,Marceline R,Suzie K,Suk T,,,,35.10123858,31.59111472,All,"18 Years and older ¬† (Adult, Older Adult)",531,523,503,152,322,29,7/11/2019,12/24/2019,10/30/2019,12/6/2019,11/20/2019,11/23/2019,11/26/2019,11/30/2019,12/22/2019,10/24/2021,2/25/2022,6/27/2022,9/19/2022,10/20/2022,12/17/2022,2/7/2023,4/7/2023,5/12/2023,6/26/2023,5/21/2020,11/17/2020,5/16/2021,11/12/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04995484,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00194,SP00013,A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021),,,End Stage Renal Disease|Renal Impairment,,,,,,,,Industry,Not yet recruiting,Phase 3,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Frank T,Mary H,Mary H,Marceline R,Frank T,Perter K,Jene M,Mary H,Christian G,Geralyn K,Clarice N,Mee M,Beulah N,Dinah R,Stephan T,Terisa Sikora †,Mara A,Lilla Stilson †,Hee Y,,,,1.053904374,0.948513937,All,"50 Years and older ¬† (Adult, Older Adult)",564,538,504,413,43,48,1/7/2018,8/8/2018,5/25/2018,6/26/2018,6/12/2018,6/19/2018,6/27/2018,6/28/2018,7/22/2018,10/17/2021,1/6/2022,7/8/2022,9/17/2022,11/9/2022,1/8/2023,2/11/2023,4/8/2023,5/20/2023,7/9/2023,12/16/2018,6/14/2019,12/11/2019,6/8/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04994522,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00213,SP00013,A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006),,,PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS),,,,,,,,Industry,Recruiting,Phase 1|Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Tammara F,Frank T,Rima Y ,Anthony P,Tiffiny K,Xochitl D,Stephan T,Jeanene Y,Livia Pacheo †,Suzie K,Ngan D,Suzie K,Naren G,Marceline R,Livia Pacheo †,Mee M,Suzie K,Anthony P,Patria R,,,"Bundaberg Base Hospital ( Site 0202), Bundaberg, Queensland, Australia",80.73152595,72.65837336,All,"18 Years and older ¬† (Adult, Older Adult)",571,547,505,374,62,69,3/6/2022,8/5/2022,6/22/2022,7/5/2022,6/9/2022,6/27/2022,7/6/2022,7/10/2022,7/19/2022,11/19/2024,1/19/2025,5/9/2025,8/30/2025,10/14/2025,12/7/2025,1/6/2026,2/17/2026,4/8/2026,5/21/2026,12/24/2022,6/22/2023,12/19/2023,6/16/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04980872,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00220,SP00013,Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016),,,"Carcinoma, Hepatocellular|Colorectal Neoplasms|Pancreatic Ductal Adenocarcinoma|Biliary Tract Neoplasms",,Oncology,,,,,,Industry,Recruiting,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Terrell p,Tammara F,Tiffiny K,Mac L,Mac L,Xochitl D,Stephan T,Tiffiny K,Jeanene Y,Ross S,Quentin N,Aleta H,Stephan T,Dalton E,Perter K,Gertrudis T,Tammara F,Gertrudis T,Doreen T,,,"City of Hope Comprehensive Cancer Center ( Site 5002), Duarte, California, United States|Maastricht UMC+-Medical Oncology ( Site 1501), Maastricht, Limburg, Netherlands|Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 1503), Utrecht, Netherlands",53.64906798,48.28416118,All,198 Months to 210 Months ¬† (Child),554,541,506,171,307,28,1/13/2023,9/2/2023,6/14/2023,7/21/2023,6/16/2023,7/5/2023,7/12/2023,7/13/2023,7/19/2023,1/4/2026,10/2/2025,3/19/2026,7/7/2026,9/4/2026,10/26/2026,12/17/2026,1/17/2027,3/17/2027,5/8/2027,1/1/2024,6/29/2024,12/26/2024,6/24/2025,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04976634,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00258,SP00013,Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86),,,Non-Small Cell Lung Cancer,,Oncology,,,,,,Industry,Recruiting,Not Applicable,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Dinah R,Lilla Stilson †,Ross S,Frank T,Jene M,Gertrudis T,Dalton E,Louann C,Jerold Goo †,Perter K,Chetan K,Suk T,Frank T,Doreen T,Stephan T,John G,Livia Pacheo †,Naren G,Jerold Goo †,,,"St. Vincent Frontier Cancer Center ( Site 0058), Billings, Montana, United States|The University of Tennessee Medical Center ( Site 0050), Knoxville, Tennessee, United States|Oncology Consultants, PA ( Site 0052), Houston, Texas, United States|Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 0100), Blacksburg, Virginia, United States|Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0602), Guatemala, Guatemala|Clinica Privada Dr. Rixci Ramirez ( Site 0601), Guatemala, Guatemala|INTERVASC ( Site 0605), Guatemala, Guatemala|Grupo Angeles SA ( Site 0604), Guatemala, Guatemala|Centro Regional de Sub Especialidades M√©dicas SA ( Site 0600), Quetzaltenango, Guatemala|Centrum Onkologii im prof Franciszka Lukaszczyka ( Site 1201), Bydgoszcz, Kujawsko-pomorskie, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warszawa, Mazowieckie, Poland|Przychodnia Lekarska KOMED ( Site 1202), Konin, Wielkopolskie, Poland|Szpital Wojewodzki im. Mikolaja Kopernika ( Site 1200), Koszalin, Zachodniopomorskie, Poland|SPBU Clinic of Advanced medical technologies n.a. N. I. Pirogov ( Site 1406), Saint-Petersburg, Sankt-Peterburg, Russian Federation|National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 1407), Saint-Petersburg, Sankt-Peterburg, Russian Federation|SPb SBHI City Clinical Oncological Dispensary ( Site 1409), Sankt-Peterburg, Russian Federation|H.U. Vall de Hebron ( Site 1600), Barcelona, Spain|Hospital Juan Ramon Jimenez ( Site 1602), Huelva, Spain|Hospital Universitario La Paz ( Site 1601), Madrid, Spain|Taipei Veterans General Hospital ( Site 2106), Taipei, Taiwan|Gulhane Egitim ve Arastirma Hastanesi ( Site 1704), Ankara, Turkey|Ankara Sehir Hastanesi ( Site 1702), Ankara, Turkey|Inonu Universitesi Turgut Ozal Tip Merkezi ( Site 1707), Malatya, Turkey|Communal non profit enterprise Regional Clinical Oncology Center ( Site 1806), Kharkiv, Kharkivska Oblast, Ukraine|Ukrainian Center of Tomotherapy ( Site 1807), Kropyvnytskyi, Kirovohradska Oblast, Ukraine|Medical Center Asklepion LLC ( Site 1804), Khodosivka, Kyivska Oblast, Ukraine|Kyiv City Clinical Oncology Centre ( Site 1809), Kyiv, Kyivska Oblast, Ukraine",48.78884977,43.90996479,All,"18 Years to 65 Years ¬† (Adult, Older Adult)",540,515,507,242,227,38,8/13/2019,3/15/2020,1/19/2020,2/9/2020,1/16/2020,2/4/2020,2/19/2020,2/24/2020,3/19/2020,6/29/2022,7/16/2022,9/18/2022,2/10/2023,4/8/2023,5/8/2023,7/1/2023,8/14/2023,9/18/2023,11/9/2023,8/2/2020,1/29/2021,7/28/2021,1/24/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04956692,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00271,SP00013,A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001),,,Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis,,,,,,,,Industry,Recruiting,,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Kandace p,Stephan T,Suzie K,Harry A,Federico L,John G,Corrine U,Gertrudis T,Mary H,Chetan K,Anthony P,Suzie K,Jerold Goo †,John G,Quentin N,Liberty A,Frank T,Lyman W,Gertrudis T,,,"Catalina Research Institute, LLC ( Site 1939), Montclair, California, United States|Floridian Clinical Research, LLC ( Site 1950), Miami Lakes, Florida, United States|Sensible Healthcare, LLC ( Site 1903), Ocoee, Florida, United States|Lucas Research, Inc ( Site 1930), Morehead City, North Carolina, United States|Texas Clinical Research Institute ( Site 1910), Arlington, Texas, United States|Baylor College of Medicine-Advanced Liver Therapies ( Site 1960), Houston, Texas, United States|American Research Corporation at Texas Liver Institute ( Site 1920), San Antonio, Texas, United States|Clinical Trials of Texas, Inc. ( Site 1906), San Antonio, Texas, United States|Flinders Medical Centre-Hepatology and Liver Transplant Medicine ( Site 0201), Bedford Park, South Australia, Australia|Rambam Health Care Campus-Liver disease unit ( Site 0704), Haifa, Israel|Shaare Zedek Medical Center-Liver Unit ( Site 0703), Jerusalem, Israel|Rabin Medical Center ( Site 0701), Petah-Tikva, Israel|Sheba Medical Center-The Liver Diseases Center ( Site 0700), Ramat Gan, Israel|Humanitas-Medicina interna ed Epatologia ( Site 0800), Rozzano, Lombardia, Italy|Middlemore Clinical Trials ( Site 1000), Auckland, New Zealand|NATIONAL CHENG-KUNG UNI. HOSP.-Liver Research team of National Cheng Kung University Hospital ( Site, Tainan, Taiwan|Ankara University Department of Hematology, Clinical Research Unit ( Site 1603), Ankara, Turkey|Hacettepe Universitesi-internal diseases ( Site 1602), Ankara, Turkey|Gazi Universitesi-gastroenterology ( Site 1605), Ankara, Turkey|L.T. Mala National Institute of Therapy of NAMS of Ukraine-Department of Aging Studies and Prevent, Kharkiv, Kharkivska Oblast, Ukraine",54.67627438,49.20864694,All,"18 Years and older ¬† (Adult, Older Adult)",526,514,508,164,312,32,3/7/2020,8/4/2020,5/29/2020,7/12/2020,6/5/2020,6/23/2020,6/30/2020,7/2/2020,7/21/2020,2/21/2022,4/19/2022,10/8/2022,12/27/2022,2/5/2023,3/16/2023,4/20/2023,6/6/2023,7/27/2023,9/25/2023,12/20/2020,6/18/2021,12/15/2021,6/13/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04944992,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00279,SP00013,Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013),,MOVe-AHEAD,Coronavirus Disease (COVID-19),,Virology,,,,,,Industry,Recruiting,Phase 4,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,,,,,Drug G,,,,,,,,,,,,,,,,,,,Naren G,Dinah R,John G,Livia Pacheo †,Jene M,Marceline R,Naren G,John G,Jaquelyn H,Christian G,Suzie K,Quentin N,Harry A,Patria R,Perter K,Hee Y,Lilla Stilson †,Naren G,Ross S,,,"Cahaba Research, Inc. ( Site 2523), Birmingham, Alabama, United States|The Institute for Liver Health DBA Arizona Clinical Trials ( Site 2484), Mesa, Arizona, United States|The Institute for Liver Health DBA Arizona Clinical Trials ( Site 2448), Tucson, Arizona, United States|Carbon Health ( Site 2515), Carlsbad, California, United States|Marvel Clinical Research ( Site 2490), Huntington Beach, California, United States|National Research Institute ( Site 2452), Los Angeles, California, United States|Valley Clinical Trials Inc. ( Site 2406), Northridge, California, United States|Carbon Health ( Site 2514), Oakland, California, United States|Alta California Medical Group ( Site 2468), Simi Valley, California, United States|Future Innovative Treatments, LLC ( Site 2471), Colorado Springs, Colorado, United States|Emerson Clinical Research Institute ( Site 2457), Washington, District of Columbia, United States|Synergy Healthcare ( Site 2521), Bradenton, Florida, United States|Velocity Clinical Research, Hallandale Beach ( Site 2485), Hallandale Beach, Florida, United States|Indago Research & Health Center, Inc ( Site 2412), Hialeah, Florida, United States|Advanced Research For Health Improvement LLC ( Site 2436), Immokalee, Florida, United States|Clinical Site Partners, LLC d/b/a CSP Miami ( Site 2508), Miami, Florida, United States|Clinical Research Trials of Florida ( Site 2402), Tampa, Florida, United States|Clinical Site Partners, LLC d/b/a CSP Miami ( Site 2425), Winter Park, Florida, United States|Chicago Clinical Research Institute Inc ( Site 2454), Chicago, Illinois, United States|MedPharmics, LLC ( Site 2443), Metairie, Louisiana, United States|Centennial Medical Group ( Site 2435), Elkridge, Maryland, United States|Michigan Center of Medical Research ( Site 2445), Farmington Hills, Michigan, United States|Michigan Center of Medical Research ( Site 2525), Lathrup Village, Michigan, United States|Allina Health Infectious Diseases Research Clinic ( Site 2507), Minneapolis, Minnesota, United States|Mercury Street Medical Group PLLC ( Site 2476), Butte, Montana, United States|ID Care ( Site 2466), Hillsborough, New Jersey, United States|Amici Clinical Research LLC ( Site 2426), Raritan, New Jersey, United States|AXCES Research Group ( Site 2437), Santa Fe, New Mexico, United States|Dayton Clinical Research ( Site 2488), Dayton, Ohio, United States|Cherokee Nation WW Hastings Indian Hospital/Cherokee Nation Health Services ( Site 2459), Tahlequah, Oklahoma, United States|Preferred Clinical Research ( Site 2470), Pittsburgh, Pennsylvania, United States|Velocity Clinical Research-Providence ( Site 2432), Warwick, Rhode Island, United States|Tribe Clinical Research, LLC ( Site 2409), Greenville, South Carolina, United States|TTS Research ( Site 2433), Boerne, Texas, United States|Houston Methodist Hospital ( Site 2463), Houston, Texas, United States|Santa Clara Family Clinic ( Site 2462), Houston, Texas, United States|Crossroads Clinical Research LLC ( Site 2451), Victoria, Texas, United States|TPMG Clinical Research ( Site 2495), Williamsburg, Virginia, United States|Sanatorio de la Trinidad Mitre ( Site 0108), Caba, Buenos Aires, Argentina|Mautalen Salud e Investigacion ( Site 0103), Caba, Buenos Aires, Argentina|Clinica Independencia ( Site 0104), Munro, Buenos Aires, Argentina|Instituto Medico de la Fundacion Estudios Clinicos ( Site 0106), Rosario, Santa Fe, Argentina|CEMIC ( Site 0101), Buenos Aires, Argentina|Funda√ßao de Medicina Tropical Doutor Heitor Vieira Dourado ( Site 0303), Manaus, Amazonas, Brazil|Hospital Nossa Senhora das Gracas ( Site 0310), Curitiba, Parana, Brazil|Funda√ß√£o Faculdade Regional de Medicina de S√£o Jos√© do Rio Preto ( Site 0312), S√£o Jos√© do Rio Preto, Sao Paulo, Brazil|Fundacion Centro de Investigacion Clinica CIC ( Site 0402), Medellin, Antioquia, Colombia|Caja de Compensacion Familiar CAFAM ( Site 0403), Bogota, Distrito Capital De Bogota, Colombia|Fundacion Centro de Investigaciones Clinicas CARDIOMET ( Site 0409), Pereira, Risaralda, Colombia|Instituto Neumologico del Oriente S.A. ( Site 0408), Bucaramanga, Santander, Colombia|Fundacion Valle del Lili ( Site 0405), Cali, Valle Del Cauca, Colombia|CHU de la Reunion - Groupe Hospitalier Sud ( Site 0508), Saint Pierre Cedex, La Reunion, France|Maison de sant√© du Pays Neufchatelois ( Site 0507), Neufchatel-en-Bray, Seine-Maritime, France|Centro de Investigaciones Pediatricas ( Site 0703), Guatemala, Guatemala|Medifarma-98 Kft. ( Site 0808), Nyiregyhaza, Szabolcs-Szatmar-Bereg, Hungary|DRC Gyogyszervizsgalo Kozpont Kft. ( Site 0801), Balatonfured, Veszprem, Hungary|Obudai Egeszsegugyi Centrum - OEC ( Site 0821), Budapest, Hungary|Obudai Egeszsegugyi Centrum - Zalaegerszeg ( Site 0819), Zalaegerszeg, Hungary|IUHW Narita Hospital ( Site 1105), Narita, Chiba, Japan|Den-en-chofu family clinic ( Site 1104), Tokyo, Japan|Centrul Medical Unirea SRL Bucuresti ( Site 1706), Bucaresti, Bucuresti, Romania|Centrul Medical Unirea SRL ( Site 1707), Cluj-Napoca, Cluj, Romania|S.C Materna Care SRL ( Site 1702), Timisoara, Timis, Romania|Centrul Medical Unirea ( Site 1705), Brasov, Romania|Delta Heath Care S.R.L ( Site 1708), Bucuresti, Romania|Centrul Medical Unirea SRL Constanta ( Site 1703), Constanta, Romania|Centrul Medical Unirea SRL IASI ( Site 1701), Iasi, Romania|C.S. Vallcarca-Sant Gervasi ( Site 2000), Barcelona, Spain|Hospital Universitario Infanta Leonor ( Site 2002), Madrid, Spain|Ankara Universitesi Ibni Sina Hastanesi ( Site 2101), Ankara, Turkey|Hacettepe Universitesi Tip Fakultesi ( Site 2102), Ankara, Turkey|Gazi Universitesi Tip Fakultesi Hastanesi ( Site 2106), Ankara, Turkey|Atakent Acibadem Hastanesi ( Site 2103), Istanbul, Turkey|Ege Universitesi Tip Fakultesi Hastanesi ( Site 2105), Izmir, Turkey|Sakarya Universitesi Egitim ve Arastirma Hastanesi ( Site 2107), Sakarya, Turkey|Regional Phthisiopulmonological Center ( Site 2203), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|NPME -Central Clinical Hospital of Ivano-Frankivsk City Council ( Site 2204), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|PCNE Kharkiv City polyclinic 9 of the Kharkiv City Council ( Site 2201), Kharkiv, Kharkivska Oblast, Ukraine|Limited Liability Company Medical center Healthy Happy ( Site 2225), Kyiv, Kyivska Oblast, Ukraine|MNPE Consultative-Diagnostic Centre of Desnyanskyi District of Kyiv ( Site 2205), Kyiv, Kyivska Oblast, Ukraine|Kyiv railway clinical hospital 2 of Branch Health center ( Site 2207), Kyiv, Kyivska Oblast, Ukraine|Municipal Noncommercial Enterprise Lviv 4th City Clinical Hospital ( Site 2200), Lviv, Lvivska Oblast, Ukraine|MNCE -Odesa regional clinical hospital of Odesa regional council ( Site 2226), Odessa, Odeska Oblast, Ukraine|Municipal Enterprise Poltava Regional Clinical Infectious Hospital ( Site 2227), Poltava, Poltavska Oblast, Ukraine|Medical Clinical Investigational Center of Medical Center Health Clinic ( Site 2210), Vinnytsia, Vinnytska Oblast, Ukraine",30.02993891,27.02694502,All,"18 Years to 90 Years ¬† (Adult, Older Adult)",559,541,509,376,79,54,7/27/2019,2/14/2020,11/23/2019,12/30/2019,11/22/2019,12/16/2019,12/19/2019,12/24/2019,1/14/2020,1/12/2022,7/27/2021,2/16/2022,4/3/2022,5/15/2022,6/22/2022,7/31/2022,9/16/2022,11/11/2022,12/17/2022,6/13/2020,12/10/2020,6/8/2021,12/5/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04939428,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00280,SP00013,MK-1654 in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007),,,RSV Infection,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",,,,,,Drug H,,,,,,,,,,,,,,,,,,,Geralyn K,Mary H,Perter K,Federico L,Naren G,Chetan K,Tiffiny K,Tien C,Mara A,Donovan H,Marcelina X,Tien C,Perter K,Anthony P,Otis Thode †,Federico L,Mac L,Gertrudis T,Louann C,,,,10.04254204,9.038287832,All,"18 Years to 80 Years ¬† (Adult, Older Adult)",562,552,510,311,147,52,11/30/2023,4/23/2024,2/16/2024,3/8/2024,2/14/2024,3/2/2024,3/10/2024,3/14/2024,4/11/2024,3/30/2025,1/3/2025,3/27/2025,8/21/2025,9/29/2025,11/8/2025,12/18/2025,1/18/2026,3/14/2026,4/14/2026,8/29/2024,2/25/2025,8/24/2025,2/20/2026,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04938830,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00281,SP00013,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98),,,Small Cell Lung Carcinoma,,Oncology,,,,,,Industry,Recruiting,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Selizabeth F,Anthony P,Tammara F,Corrine U,Patria R,Perter K,Chetan K,Quentin N,Geralyn K,Dinah R,Aleta H,Tiffiny K,Dinah R,Mara A,Garnet T,Christian G,Naren G,Lyman W,Lyman W,,,"Georgia Cancer Specialists ( Site 0156), Atlanta, Georgia, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0172), Omaha, Nebraska, United States|St Francis Cancer Center-Research Office ( Site 0167), Greenville, South Carolina, United States|Virginia Cancer Institute ( Site 0169), Richmond, Virginia, United States|Rambam Health Care Campus-Oncology ( Site 3600), Haifa, Israel|Shaare Zedek Medical Center-Oncology ( Site 3602), Jerusalem, Israel|Meir Medical Center ( Site 3601), Kfar Saba, Israel|Seoul National University Bundang Hospital-Medical Oncology ( Site 4104), Seongnam, Kyonggi-do, Korea, Republic of|Seoul National University Hospital ( Site 4101), Seoul, Korea, Republic of|Asan Medical Center-Lung Cancer Center ( Site 4103), Seoul, Korea, Republic of|Samsung Medical Center ( Site 4100), Seoul, Korea, Republic of|Krasnoyarsk Regional Oncology Dispensary, Named after Krizhanovsky ( Site 3708), Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 3702), Saint Petersburg, Leningradskaya Oblast, Russian Federation|N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( S, Saint Petersburg, Sankt-Peterburg, Russian Federation|Scientific research institution of oncology named after N.N. Petrov-Thoracic oncology ( Site 3704), Sankt-Peterburg, Russian Federation|Instituto Catalan de Oncologia - Hospital Duran i Reynals ( Site 3403), L'Hospitalet de Llobregat, Cataluna, Spain|Hospital Universitari Vall d'Hebron-Oncology ( Site 3401), Barcelona, Spain",60.51750944,54.46575849,All,"18 Years and older ¬† (Adult, Older Adult)",578,552,511,279,195,37,8/7/2022,2/10/2023,12/3/2022,1/4/2023,12/1/2022,12/22/2022,1/3/2023,1/7/2023,1/16/2023,7/11/2026,4/12/2026,8/10/2026,11/2/2026,12/18/2026,2/3/2027,3/16/2027,5/13/2027,6/25/2027,7/29/2027,6/20/2023,12/17/2023,6/14/2024,12/11/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04938817,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00341,SP00013,The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050),,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Jaquelyn H,Gertrudis T,Naren G,Mary H,Tiffiny K,Mee M,Rima Y ,Marceline R,Jaquelyn H,Patria R,Marceline R,Terrell p,Jene M,Mary H,Mara A,Christian G,Tammara F,Terrell p,,,,64.94042106,58.44637895,Female,"18 Years to 120 Years ¬† (Adult, Older Adult)",559,550,512,285,191,36,5/10/2008,12/12/2008,10/9/2008,10/30/2008,10/1/2008,10/20/2008,10/27/2008,10/30/2008,11/20/2008,8/1/2012,4/3/2012,8/1/2012,12/1/2012,1/12/2013,3/8/2013,4/12/2013,6/5/2013,7/19/2013,9/11/2013,4/18/2009,10/15/2009,4/13/2010,10/10/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01220570,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00347,SP00013,A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3),,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Aleta H,Marceline R,Hee Y,Mara A,Jerold Goo †,Suzie K,Lilla Stilson †,Liberty A,Mara A,Dalton E,Chetan K,Frank T,Lilla Stilson †,John G,Mac L,Lilla Stilson †,Frank T,Federico L,Rima Y ,,,,52.71433312,47.44289981,Female,"18 Years and older ¬† (Adult, Older Adult)",550,531,513,310,150,53,8/6/2011,1/9/2012,11/14/2011,12/12/2011,11/17/2011,11/29/2011,12/14/2011,12/19/2011,1/10/2012,9/5/2013,1/14/2013,7/14/2013,10/15/2013,11/22/2013,12/23/2013,2/16/2014,3/28/2014,5/4/2014,6/23/2014,5/27/2012,11/23/2012,5/22/2013,11/18/2013,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01234857,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00362,SP00013,A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014),,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Perter K,Selizabeth F,Terisa Sikora †,Suk T,Mary H,Terrell p,Liberty A,Chetan K,John G,Lyman W,James y,Chetan K,Gertrudis T,Chetan K,John G,James y,Terrell p,Chetan K,Harry A,,,,86.13139956,77.51825961,All,"18 Years and older ¬† (Adult, Older Adult)",551,528,514,448,23,43,12/16/2006,8/2/2007,5/26/2007,6/17/2007,6/7/2007,6/12/2007,6/19/2007,6/21/2007,6/30/2007,3/25/2011,12/19/2010,6/23/2011,8/1/2011,9/23/2011,11/9/2011,1/7/2012,3/6/2012,4/15/2012,5/20/2012,12/9/2007,6/6/2008,12/3/2008,6/1/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00106145,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00401,SP00013,Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009),,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Suk T,Marcelina X,Mary H,Otis Thode †,Suzie K,Livia Pacheo †,Suzie K,Ngan D,Mary H,Lavina S,Lavina S,Mary H,John G,Lucie P,Selizabeth F,Mary H,Suzie K,Chetan K,Marcelina X,,,,58.28169048,52.45352143,Female,"18 Years and older ¬† (Adult, Older Adult)",572,551,515,249,231,35,2/20/2008,8/18/2008,6/15/2008,7/26/2008,6/29/2008,7/15/2008,7/28/2008,7/30/2008,8/17/2008,6/25/2010,5/6/2010,9/10/2010,1/1/2011,2/7/2011,3/29/2011,5/4/2011,6/7/2011,7/7/2011,8/23/2011,1/11/2009,7/10/2009,1/6/2010,7/5/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00736970,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00444,SP00013,Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086),,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Tien C,Marceline R,Hee Y,Mary H,Frank T,Suzie K,Marceline R,Otis Thode †,Remedios Z,Kala R,Kandace p,Tiffiny K,Selizabeth F,Corrine U,Rima Y ,In Bellini †,Donovan H,Perter K,Naren G,,,,70.70581147,63.63523033,All,"20 Years to 70 Years ¬† (Adult, Older Adult)",576,549,516,309,174,33,11/8/2015,4/14/2016,2/16/2016,3/13/2016,2/28/2016,3/4/2016,3/16/2016,3/20/2016,4/9/2016,5/29/2018,7/16/2018,1/5/2019,2/18/2019,4/16/2019,5/17/2019,7/13/2019,8/16/2019,10/10/2019,11/26/2019,8/31/2016,2/27/2017,8/26/2017,2/22/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02447003,,,,,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02447003/Prot_SAP_000.pdf"
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00489,SP00013,"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)",,,,,Oncology,,,,,,Industry,Recruiting,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug I,,,,,,,,,,,,,,,,,,,Rima Y ,Livia Pacheo †,Garnet T,Marcelina X,Doreen T,Doreen T,Perter K,Lavina S,Jerold Goo †,Mary H,Terrell p,Tammara F,Tamesha T,Beulah N,Hee Y,Dalton E,Anthony P,Corrine U,Jaquelyn H,,,"Southern Cancer Center, PC ( Site 8003), Daphne, Alabama, United States|Cancer Treatment Centers of America at Western Regional Medical Center ( Site 0001), Goodyear, Arizona, United States|Arizona Oncology Associates PC- HOPE ( Site 8008), Tucson, Arizona, United States|Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0079), Los Angeles, California, United States|El Camino Hospital Cancer Center ( Site 0004), Mountain View, California, United States|Stanford Cancer Center ( Site 0072), Palo Alto, California, United States|UC Davis Comprehensive Cancer Center ( Site 0073), Sacramento, California, United States|University of Colorado Cancer Center ( Site 0008), Aurora, Colorado, United States|Baptist MD Anderson Cancer Center ( Site 0014), Jacksonville, Florida, United States|Southeastern Regional Medical Center, Inc. ( Site 0075), Newnan, Georgia, United States|The University of Chicago Medical Center ( Site 0080), Chicago, Illinois, United States|Orchard Healthcare Research Inc. ( Site 0020), Skokie, Illinois, United States|Midwestern Regional Medical Center, Inc. ( Site 0077), Zion, Illinois, United States|Goshen Center for Cancer Care ( Site 0021), Goshen, Indiana, United States|MercyOne Waterloo Cancer Center ( Site 0016), Waterloo, Iowa, United States|James Graham Brown Cancer Center ( Site 0022), Louisville, Kentucky, United States|Maryland Oncology Hematology, P.A. ( Site 8007), Bethesda, Maryland, United States|Massachusetts General Hospital ( Site 0024), Boston, Massachusetts, United States|MGH - North Shore Cancer Center ( Site 0081), Danvers, Massachusetts, United States|MGH Newton-Wellesley Hospital's Vernon Cancer Center ( Site 0082), Newton, Massachusetts, United States|Henry Ford Health System ( Site 0028), Detroit, Michigan, United States|Mayo Clinic and Medical School (Rochester) ( Site 0029), Rochester, Minnesota, United States|St. Vincent Frontier Cancer Center ( Site 0033), Billings, Montana, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0039), Omaha, Nebraska, United States|Holy Name Medical Center ( Site 0041), Teaneck, New Jersey, United States|Weill Cornell Medical College ( Site 0043), New York, New York, United States|CTCA Southwestern ( Site 0074), Tulsa, Oklahoma, United States|OHSU Knight Cancer Institute ( Site 0051), Portland, Oregon, United States|Northwest Cancer Specialists, P.C. ( Site 8000), Tigard, Oregon, United States|Geisinger Medical Center ( Site 0052), Danville, Pennsylvania, United States|Fox Chase Cancer Center ( Site 0078), Philadelphia, Pennsylvania, United States|Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0076), Philadelphia, Pennsylvania, United States|Medical University of South Carolina ( Site 0053), Charleston, South Carolina, United States|Tennessee Oncology, PLLC/The Sarah Cannon Research Institute ( Site 7000), Nashville, Tennessee, United States|Texas Oncology-Austin Central ( Site 8004), Austin, Texas, United States|Texas Oncology-Dallas Presbyterian Hospital ( Site 8002), Dallas, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 8009), Dallas, Texas, United States|Texas Oncology-Memorial City ( Site 8012), Houston, Texas, United States|University of Texas-MD Anderson Cancer Center ( Site 0083), Houston, Texas, United States|Texas Oncology- Plano East ( Site 8010), Plano, Texas, United States|Texas Oncology-Tyler ( Site 8006), Tyler, Texas, United States|Bon Secours St. Francis Medical Center Oncology Research ( Site 0064), Midlothian, Virginia, United States|Virginia Oncology Associates ( Site 8001), Norfolk, Virginia, United States|Kadlec Clinic Hematology and Oncology ( Site 0070), Kennewick, Washington, United States|Medical Oncology Associates (Summit Cancer Centers) ( Site 0066), Spokane, Washington, United States|Chris OBrien Lifehouse ( Site 2107), Camperdown, New South Wales, Australia|Royal North Shore Hospital ( Site 2100), Sydney, New South Wales, Australia|Westmead Hospital ( Site 2101), Sydney, New South Wales, Australia|Mater Misericordiae Ltd ( Site 2106), South Brisbane, Queensland, Australia|Frankston Hospital ( Site 2103), Frankston, Victoria, Australia|Peter MacCallum Cancer Centre ( Site 2102), Melbourne, Victoria, Australia|Imelda Ziekenhuis Bonheiden ( Site 0703), Bonheiden, Antwerpen, Belgium|UZ Antwerpen - Medical Oncology ( Site 0709), Edegem, Antwerpen, Belgium|Institut Jules Bordet ( Site 0710), Brussels, Bruxelles-Capitale, Region De, Belgium|Cliniques Universitaires Saint-Luc ( Site 0701), Brussels, Bruxelles-Capitale, Region De, Belgium|CHC MontLegia ( Site 0707), Li√®ge, Liege, Belgium|Jessa Ziekenhuis Campus Virga Jesse ( Site 0704), Hasselt, Limburg, Belgium|CHU UCL Namur Site de Godinne ( Site 0706), Yvoir, Namur, Belgium|AZ Maria Middelares Gent ( Site 0700), Gent, Oost-Vlaanderen, Belgium|UZ Leuven ( Site 0702), Leuven, Vlaams-Brabant, Belgium|AZ Groeninge ( Site 0705), Kortrijk, West-Vlaanderen, Belgium|Hospital Araujo Jorge Associacao de Combate ao Cancer de Goias ( Site 0205), Goiania, Goias, Brazil|Hospital de Caridade de Ijui ( Site 0206), Ijui, Rio Grande Do Sul, Brazil|Associacao Hospitalar Moinhos de Vento ( Site 0201), Porto Alegre, Rio Grande Do Sul, Brazil|Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0202), Porto Alegre, Rio Grande Do Sul, Brazil|CEPON - Centro de Pesquisas Oncologicas ( Site 0208), Florianopolis, Santa Catarina, Brazil|Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 0207), Itajai, Santa Catarina, Brazil|Instituto Nacional de Cancer - INCA HC III ( Site 0200), Rio de Janeiro, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0209), Sao Paulo, Brazil|Clinica de Pesquisas e Ctro de Estudos Onc. Ginecol. e Mamaria Ltda ( Site 0204), Sao Paulo, Brazil|IBCC - Instituto Brasileiro de Controle do Cancer ( Site 0210), Sao Paulo, Brazil|Cross Cancer Institute ( Site 0115), Edmonton, Alberta, Canada|BC Cancer-Vancouver Center ( Site 0116), Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre ( Site 0112), Toronto, Ontario, Canada|CISSS de la Monteregie-Centre ( Site 0108), Greenfield Park, Quebec, Canada|Hopital Maisonneuve-Rosemont CIUSSS de l Est de L Ile de Montreal ( Site 0111), Montreal, Quebec, Canada|Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0114), Montreal, Quebec, Canada|Jewish General Hospital ( Site 0103), Montreal, Quebec, Canada|Centre Hospitalier Regional de Trois-Rivieres ( Site 0106), Trois-Rivi√®res, Quebec, Canada|CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0101), Quebec, Canada|Anhui Provincial Hospital ( Site 3224), Heifei, Anhui, China|Cancer Hospital Chinese Academy of Medical Sciences ( Site 3208), Beijing, Beijing, China|Fujian Medical University Union Hospital-1 Bingfanglou-Oncology ( Site 3207), Fuzhou Fujian, Fujian, China|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ( Site 3213), Guangzhou, Guangdong, China|Fourth Hospital Of Hebei Medical University ( Site 3216), Shijia Zhuang, Hebei, China|Harbin Medical University Cancer Hospital ( Site 3200), Harbin, Heilongjiang, China|Henan Cancer Hospital ( Site 3212), Zhengzhou, Henan, China|Hubei Cancer Hospital ( Site 3211), Wuhan, Hubei, China|Hunan Cancer Hospital ( Site 3214), Changsha, Hunan, China|The First Affiliated Hospital of Zhejiang University ( Site 3203), Hangzhou, Jiangsu, China|The First Hospital of Jilin University ( Site 3201), Changchun, Jilin, China|Ruijin Hosp,Shanghai Jiao Tong University School of Medicine ( Site 3215), Shanghai, Shanghai, China|Fudan University Shanghai Cancer Center ( Site 3205), Shanghai, Shanghai, China|The First Affiliated Hospital of Xi an Jiaotong University ( Site 3220), XI An, Shanxi, China|Tianjin Medical University Cancer Institute & Hospital ( Site 3209), Tianjin, Tianjin, China|Cancer Hospital Affiliated to Xinjiang Medical University ( Site 3219), Urumqi, Xinjiang, China|Zhejiang Provincial People's Hospital ( Site 3225), Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital.... ( Site 3210), Hangzhou, Zhejiang, China|Rodrigo Botero SAS ( Site 0407), Medellin, Antioquia, Colombia|Fundacion Colombiana de Cancerologia Clinica Vida ( Site 0405), Medellin, Antioquia, Colombia|Clinica de la Costa Ltda. ( Site 0400), Barranquilla, Atlantico, Colombia|Oncomedica S.A. ( Site 0401), Monteria, Cordoba, Colombia|Centro de Investigacion Clinica del Country ( Site 0402), Bogota, Distrito Capital De Bogota, Colombia|Fundacion Universitaria Sanitas ( Site 0403), Bogota, Distrito Capital De Bogota, Colombia|Centro Medico Imbanaco de Cali S.A ( Site 0406), Cali, Valle Del Cauca, Colombia|Hospital Metropolitano - Sede Lindora ( Site 4203), San Jos√©, San Jose, Costa Rica|Centre Francois Baclesse ( Site 0927), Caen, Calvados, France|Centre Georges Francois Leclerc ( Site 0920), Dijon, Cote-d Or, France|Institut Claudius Regaud IUCT Oncopole ( Site 0903), Toulouse, Haute-Garonne, France|Institut Curie - Centre Rene Huguenin ( Site 0917), Saint-Cloud, Hauts-de-Seine, France|Centre de Cancerologie du Grand Montpellier ( Site 0925), Montpellier, Herault, France|CHR-METZ-THIONVILLE - Hopital de Mercy ( Site 0919), Metz, Moselle, France|Centre Oscar Lambret ( Site 0911), Lille, Nord, France|Institut Sainte Catherine ( Site 0916), Avignon, Provence-Alpes-Cote-d Azur, France|Centre Jean Perrin ( Site 0909), Clermont Ferrand Cedex, Puy-de-Dome, France|Clinique Victor Hugo ( Site 0906), Le Mans, Sarthe, France|Institut Gustave Roussy ( Site 0926), Villejuif, Val-de-Marne, France|Institut Curie ( Site 0900), Paris, France|Hopital Saint-Louis ( Site 0908), Paris, France|Hopital Tenon ( Site 0914), Paris, France|Medizinische Management GmbH ( Site 1012), Friedrichshafen, Baden-Wurttemberg, Germany|Universitaetsklinikum Erlangen ( Site 1001), Erlangen, Bayern, Germany|Klinikum der Universitaet Muenchen - Grosshadern ( Site 1000), Muenchen, Bayern, Germany|Sana Klinikum Offenbach GmbH ( Site 1002), Offenbach, Hessen, Germany|HELIOS Dr. Horst Schmidt Kliniken Wiesbaden ( Site 1004), Wiesbaden, Hessen, Germany|Gynaekologisch-onkologische Praxis Hannover ( Site 1013), Hannover, Niedersachsen, Germany|Gynaekologisches Zentrum ( Site 1003), Bonn, Nordrhein-Westfalen, Germany|Kliniken Essen Mitte Gmbh Evang. Huyssens Stiftung ( Site 1006), Essen, Nordrhein-Westfalen, Germany|Frauenklinik St. Louise ( Site 1014), Paderborn, Nordrhein-Westfalen, Germany|Caritas Klinikum Saarbruecken St. Theresia ( Site 1009), Saarbruecken, Saarland, Germany|Universitaetsklinikum Carl Gustav Carus ( Site 1008), Dresden, Sachsen, Germany|MVZ Nordhausen gGmbH - Praxis Dr. Grafe ( Site 1005), Nordhausen, Thuringen, Germany|Bacs-Kiskun Megyei Korhaz ( Site 2913), Kecskemet, Bacs-Kiskun, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 2905), Pecs, Baranya, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 2904), Miskolc, Borsod-Abauj-Zemplen, Hungary|Szent Margit Korhaz ( Site 2901), Budapest, Hungary|Orszagos Onkologiai Intezet ( Site 2908), Budapest, Hungary|Uzsoki Utcai Korhaz ( Site 2902), Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 2907), Debrecen, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 2915), Kaposvar, Hungary|Bon Secours Hospital ( Site 1554), Cork, Ireland|St. James s Hospital ( Site 1553), Dublin, Ireland|HaEmek Medical Center ( Site 1712), Afula, Israel|Assuta Ashdod Public ( Site 1704), Ashdod, Israel|Soroka Medical Center ( Site 1701), Beer Sheva, Israel|Rambam Medical Center ( Site 1705), Haifa, Israel|Shaare Zedek Medical Center ( Site 1708), Jerusalem, Israel|Hadassah Ein Karem - Sharett Institute of Oncology ( Site 1700), Jerusalem, Israel|Meir Medical Center ( Site 1710), Kfar-Saba, Israel|Holy Family Hospital ( Site 1711), Nazareth, Israel|Rabin Medical Center ( Site 1702), Petah Tikva, Israel|Chaim Sheba Medical Center. ( Site 1707), Ramat Gan, Israel|Kaplan Medical Center ( Site 1703), Rehovot, Israel|Sourasky Medical Center ( Site 1706), Tel Aviv, Israel|Assuta Medical Center ( Site 1709), Tel Aviv, Israel|Aichi Cancer Center Hospital ( Site 2601), Nagoya, Aichi, Japan|National Cancer Center Hospital East ( Site 2613), Kashiwa, Chiba, Japan|National Hospital Organization Hokkaido Cancer Center ( Site 2607), Sapporo, Hokkaido, Japan|Hyogo College of Medicine Hospital ( Site 2600), Nishinomiya, Hyogo, Japan|Kitasato University Hospital ( Site 2616), Sagamihara, Kanagawa, Japan|Saitama Medical University International Medical Center ( Site 2606), Hidaka, Saitama, Japan|Saitama Cancer Center ( Site 2612), Kitaadachi-gun, Saitama, Japan|Shizuoka Cancer Center Hospital and Research Institute ( Site 2611), Sunto-gun, Shizuoka, Japan|Chiba Cancer Center ( Site 2605), Chiba, Japan|Fukushima Medical University Hospital ( Site 2610), Fukushima, Japan|Hiroshima City Hiroshima Citizens Hospital ( Site 2603), Hiroshima, Japan|Kumamoto University Hospital ( Site 2602), Kumamoto, Japan|National Hospital Organization - Osaka National Hospital - Institute For Clinical Research ( Site 26, Osaka, Japan|Toranomon Hospital ( Site 2608), Tokyo, Japan|The Cancer Institute Hospital of JFCR ( Site 2604), Tokyo, Japan|Showa University Hospital ( Site 2615), Tokyo, Japan|National Cancer Center ( Site 2204), Goyang-si, Kyonggi-do, Korea, Republic of|Asan Medical Center ( Site 2202), Songpagu, Seoul, Korea, Republic of|Seoul National University Hospital ( Site 2200), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 2201), Seoul, Korea, Republic of|Samsung Medical Center ( Site 2203), Seoul, Korea, Republic of|Tauranga Hospital ( Site 2302), Tauranga, Bay Of Plenty, New Zealand|Canterbury Regional Cancer & Blood Services ( Site 2303), Christchurch, Canterbury, New Zealand|Capital & Coast District Health Board - Wellington Hospital ( Site 2301), Wellington, New Zealand|Dolnoslaskie Centrum Onkologii. ( Site 1820), Wroc≈Çaw, Dolnoslaskie, Poland|Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1800), Bydgoszcz, Kujawsko-pomorskie, Poland|Instytut Centrum Zdrowia Matki Polki ( Site 1821), Lodz, Lodzkie, Poland|Mazowiecki Szpital Specjalistyczny im. dr Jozefa Psarskiego ( Site 1814), Ostroleka, Mazowieckie, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warszawa, Mazowieckie, Poland|Mazowiecki Szpital Onkologiczny ( Site 1803), Wieliszew, Mazowieckie, Poland|Bialostockie Centrum Onkologii ( Site 1819), Bialystok, Podlaskie, Poland|Wojewodzkie Centrum Onkologii Copernicus ( Site 1817), Gdansk, Pomorskie, Poland|Szpitale Pomorskie Sp. z o.o. ( Site 1818), Gdynia, Pomorskie, Poland|Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1810), Bielsko-Biala, Slaskie, Poland|Wojewodzki Szpital Specjalistyczny nr 4 w Bytomiu ( Site 1807), Bytom, Slaskie, Poland|Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1801), Gliwice, Slaskie, Poland|Fundacao Champalimaud ( Site 2500), Lisboa, Portugal|CHLN Hospital Santa Maria ( Site 2501), Lisboa, Portugal|Hospital Geral de Santo Antonio ( Site 2503), Porto, Portugal|Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 2502), Porto, Portugal|UPR Comprehensive Cancer Center ( Site 6200), San Juan, Puerto Rico|Arkhangelsk Clinical Oncological Dispensary ( Site 1901), Arkhangelsk, Arkhangel Skaya Oblast, Russian Federation|Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1909), Ufa, Baskortostan, Respublika, Russian Federation|N.N. Blokhin NMRCO ( Site 1908), Moscow, Moskva, Russian Federation|Central Clinical Hospital with outpatient Clinic ( Site 1907), Moscow, Moskva, Russian Federation|Medical Rehabilitation Center ( Site 1912), Moscow, Moskva, Russian Federation|Ryazan Regional Clinical Oncology Dispensary ( Site 1910), Ryazan, Ryazanskaya Oblast, Russian Federation|Railway Hospital of OJSC ( Site 1913), Saint Petersburg, Sankt-Peterburg, Russian Federation|Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1900), Saint Petersburg, Sankt-Peterburg, Russian Federation|Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1903), Kazan, Tatarstan, Respublika, Russian Federation|Tomsk Scientific Research Institute of Oncology ( Site 1905), Tomsk, Tomskaya Oblast, Russian Federation|Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 1363), Hospitalet de Llobregat, Barcelona, Spain|Hospital Teresa Herrera - Chuac ( Site 1358), A Coruna, La Coruna, Spain|Hospital General Universitario Gregorio Maranon ( Site 1367), Madrid, Madrid, Comunidad De, Spain|Hospital Quiron de Madrid ( Site 1351), Pozuelo de Alarcon, Madrid, Spain|Hospital Clinico Universitario de Valencia ( Site 1355), Valencia, Valenciana, Comunitat, Spain|Instituto Oncologico Baselga.Hospital Quiron. ( Site 1352), Barcelona, Spain|Hospital Vall D Hebron ( Site 1357), Barcelona, Spain|Hospital Clinic I Provincial de Barcelona ( Site 1353), Barcelona, Spain|Complejo Hospitalario de Jaen ( Site 1364), Jaen, Spain|Hospital Ruber Internacional ( Site 1370), Madrid, Spain|Hospital Clinico San Carlos ( Site 1354), Madrid, Spain|Hospital Universitario 12 de Octubre ( Site 1356), Madrid, Spain|Hospital Universitario Virgen del Rocio ( Site 1360), Sevilla, Spain|Hospital General Arnau de Vilanova de Valencia ( Site 1369), Valencia, Spain|China Medical University Hospital ( Site 2401), Taichung, Taiwan|National Cheng Kung University Hospital ( Site 2400), Tainan, Taiwan|National Taiwan University Hospital ( Site 2404), Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center ( Site 2403), Taipei, Taiwan|Linkou Chang Gung Memorial Hospital ( Site 2402), Taoyuan, Taiwan|Dnipropetrovsk City Multidiscipline Clinical Hosp. 4 of DRC ( Site 2702), Dnipro, Dnipropetrovska Oblast, Ukraine|MI Kryviy Rih Center of Dnipropetrovsk Regional Council ( Site 2700), Kryviy Rih, Dnipropetrovska Oblast, Ukraine|MI Precarpathian Clinical Oncology Center ( Site 2707), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|Communal non profit enterprise Regional Clinical Oncology Center ( Site 2721), Kharkiv, Kharkivska Oblast, Ukraine|MI KhRC Kherson Regional Oncology Dispensary ( Site 2713), Antonivka Village, Khersonska Oblast, Ukraine|Khmelnitskiy Regional Onkology Dispensary ( Site 2704), Khmelnitskiy, Khmelnytska Oblast, Ukraine|Kyiv City Clinical Oncology Centre ( Site 2716), Kyiv, Kyivska Oblast, Ukraine|MI Odesa Regional Clinical Hospital ( Site 2701), Odesa, Odeska Oblast, Ukraine|MI Odessa Regional Oncological Centre ( Site 2714), Odesa, Odeska Oblast, Ukraine|Medical center of the Limited Liability Company Yulis ( Site 2720), Zaporizhzhia, Zaporizka Oblast, Ukraine|National Cancer Institute of the MoH of Ukraine ( Site 2719), Kyiv, Ukraine|University Hospitals Bristol NHS Foundation Trust ( Site 1503), Bristol, Bristol, City Of, United Kingdom|Colchester General Hospital ( Site 1508), Colchester, Essex, United Kingdom|Barts Health NHS Trust ( Site 1500), London, London, City Of, United Kingdom|Guy's Hospital ( Site 1501), London, London, City Of, United Kingdom|St. Georges University Hospital NHS Foundation Trust ( Site 1505), London, London, City Of, United Kingdom|Nottingham University Hospitals NHS Trust ( Site 1504), Nottingham, United Kingdom|Birmingham & Solihull Heartlands Hospital NHS ( Site 1506), Solihull, United Kingdom|Royal Cornwall Hospital ( Site 1502), Truro, United Kingdom",56.23992923,50.61593631,All,"18 Years to 86 Years ¬† (Adult, Older Adult)",569,552,517,222,266,29,4/8/2026,10/23/2026,8/6/2026,9/13/2026,8/10/2026,8/29/2026,9/4/2026,9/7/2026,9/18/2026,12/23/2030,4/26/2030,9/17/2030,1/24/2031,3/16/2031,5/2/2031,6/2/2031,7/22/2031,8/28/2031,10/19/2031,2/25/2027,8/24/2027,2/20/2028,8/18/2028,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03725059,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00522,SP00013,Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143),,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Mary H,Suk T,Ross S,Louann C,John G,Suzie K,Stephan T,Clarice N,Louann C,Livia Pacheo †,Aleta H,Lilla Stilson †,Dalton E,Dalton E,Lilla Stilson †,Suk T,Tamesha T,Stephan T,Kala R,,,,78.20991119,70.38892008,Female,"50 Years and older ¬† (Adult, Older Adult)",537,527,518,417,55,46,3/24/2010,9/18/2010,7/1/2010,8/4/2010,7/4/2010,7/27/2010,7/29/2010,8/1/2010,8/28/2010,6/2/2011,12/28/2010,9/1/2011,10/1/2011,11/15/2011,1/6/2012,2/28/2012,4/28/2012,6/2/2012,7/16/2012,1/23/2011,7/22/2011,1/18/2012,7/16/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00959582,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00523,SP00013,Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058),,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Lavina S,Federico L,Dinah R,Hee Y,Hee Y,Perter K,Dalton E,Perter K,Christian G,Christian G,Anthony P,Selizabeth F,Ross S,Rima Y ,Patria R,Lavina S,Marceline R,John G,John G,,,,69.16168627,62.24551764,All,"18 Years to 74 Years ¬† (Adult, Older Adult)",546,533,519,492,29,2,12/20/2007,6/30/2008,5/19/2008,6/7/2008,5/12/2008,5/24/2008,6/3/2008,6/6/2008,6/30/2008,4/28/2009,7/2/2009,12/20/2009,4/1/2010,5/30/2010,7/18/2010,8/23/2010,10/1/2010,11/1/2010,12/9/2010,11/20/2008,5/19/2009,11/15/2009,5/14/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00423449,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00551,SP00013,18F-FLT-PET in Breast Cancer (MK-0000-139),,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Frank T,Terrell p,Jene M,Mac L,Donovan H,Anthony P,Frank T,Federico L,Frank T,Selizabeth F,Perter K,Tien C,Corrine U,Selizabeth F,Naren G,Tamesha T,Selizabeth F,James y,Ngan D,,,,9.843278473,8.858950626,Female,,583,572,520,457,16,47,2/24/2009,8/19/2009,6/3/2009,7/2/2009,6/21/2009,6/27/2009,6/29/2009,7/3/2009,7/15/2009,4/1/2011,8/27/2010,3/3/2011,5/24/2011,6/23/2011,8/2/2011,9/19/2011,11/6/2011,12/12/2011,1/20/2012,12/24/2009,6/22/2010,12/19/2010,6/17/2011,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01015131,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00556,SP00013,A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013),,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Suzie K,Patria R,Clarice N,Gertrudis T,Tien C,Jaquelyn H,Ross S,Stephan T,Perter K,Louann C,Mac L,John G,Gertrudis T,Mary H,Donovan H,Rima Y ,Christian G,Lucie P,Frank T,,,,89.62231506,80.66008356,Female,,563,550,521,424,30,67,7/28/2007,2/19/2008,12/24/2007,1/15/2008,12/11/2007,12/29/2007,1/8/2008,1/12/2008,1/31/2008,6/1/2009,5/17/2009,11/13/2009,2/17/2010,4/12/2010,6/10/2010,8/7/2010,9/26/2010,11/24/2010,12/24/2010,6/26/2008,12/23/2008,6/21/2009,12/18/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00759785,,,,,,
Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,ST00575,SP00013,A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007),,,,,Oncology,,,,,,Industry,Not yet recruiting,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Lavina S,Mary H,Patria R,John G,Mary H,Rima Y ,John G,Otis Thode †,Ross S,Terrell p,Naren G,Tiffiny K,Suzie K,Beulah N,Marcelina X,Quentin N,Lavina S,Jerold Goo †,Remedios Z,,,,50.87859717,45.79073745,All,,563,546,522,394,51,77,4/1/2020,8/25/2020,7/10/2020,8/9/2020,7/23/2020,7/26/2020,7/28/2020,8/2/2020,8/16/2020,7/18/2023,6/21/2023,10/6/2023,2/9/2024,4/7/2024,6/5/2024,7/25/2024,9/3/2024,10/23/2024,12/11/2024,1/22/2021,7/21/2021,1/17/2022,7/16/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05064059,,,,,,
Novartis,Novartis,ST00305,SP00014,Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 4,Interventional,,Primary Purpose: Treatment,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Mary H,Suk T,Mee M,Geralyn K,Anthony P,Geralyn K,Naren G,Harry A,Frank T,Frank T,Tien C,Beulah N,Xochitl D,Marcelina X,Mee M,Beulah N,Doreen T,Selizabeth F,Selizabeth F,,,"Alta Bates Comprehensive Cancer Center, Berkeley, California, United States|Long Beach Memorial Breast Center, Long Beach, California, United States|Cancer Research Network, Inc., Hollywood, Florida, United States|Oncology-Hematology Group of South Florida, Miami, Florida, United States|Pharm Research, Pinecrest, Florida, United States|Cancer Research Network Inc., Plantation, Florida, United States|Good Samaritan Medical Center, West Palm Beach, Florida, United States|Illinois Oncology, Ltd., Belleville, Illinois, United States|Joliet Oncology/Hematology Associates, Ltd., Joliet, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Southwest Oncology Association, Lafayette, Louisiana, United States|New Mexico Oncology-Hematology, Albuquerque, New Mexico, United States|Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States|Oncology Partnership Network, Cincinnati, Ohio, United States|Memphis Cancer Center, Memphis, Tennessee, United States|Dial Research Associates, Inc., Nashville, Tennessee, United States|Center for Oncology Research and Treatment, Medical City Hospital, Dallas, Texas, United States|Intermountain Hematology/Oncology Associates, Inc., Salt Lake City, Utah, United States|Cascade Cancer Center, Kirkland, Washington, United States",1.618648871,1.456783984,Female,"26 Years and older ¬† (Adult, Older Adult)",560,549,523,382,93,48,12/17/1996,6/14/1997,4/20/1997,5/4/1997,4/24/1997,4/28/1997,5/7/1997,5/9/1997,5/29/1997,8/7/2001,7/19/2001,12/16/2001,3/1/2002,4/13/2002,5/31/2002,7/7/2002,8/23/2002,10/6/2002,11/30/2002,10/25/1997,4/23/1998,10/20/1998,4/18/1999,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00014638,,,,,,
Novartis,Novartis,ST00325,SP00014,"Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy",,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Clarice N,Chetan K,Rima Y ,Aleta H,John G,Kala R,Frank T,Perter K,Selizabeth F,John G,Perter K,Ngan D,Suzie K,Suzie K,Naren G,Mary H,Xochitl D,Perter K,Federico L,,,"Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Victoria, British Columbia, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Windsor, Ontario, Canada|Novartis Investigative Site, Granby, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Victoriaville, Quebec, Canada|Novartis Investigative Site, Quebec, Canada",30.31280723,27.28152651,Female,"50 Years to 75 Years ¬† (Adult, Older Adult)",569,548,524,222,258,44,7/3/2003,2/9/2004,12/11/2003,12/27/2003,11/26/2003,12/17/2003,12/23/2003,12/28/2003,1/13/2004,10/13/2006,6/10/2006,12/3/2006,3/1/2007,4/30/2007,6/12/2007,7/30/2007,8/29/2007,10/11/2007,12/4/2007,6/14/2004,12/11/2004,6/9/2005,12/6/2005,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00247650,,,,,,
Novartis,Novartis,ST00335,SP00014,Maintaining Bone Strength in Men With Prostate Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Christian G,Kandace p,Mary H,Kandace p,Rima Y ,Tiffiny K,Frank T,Jaquelyn H,Mee M,Beulah N,Rima Y ,Suk T,Xochitl D,Tiffiny K,Marceline R,Naren G,Anthony P,Perter K,Remedios Z,,,"Derby, United Kingdom",21.38550463,19.24695417,Male,"18 Years and older ¬† (Adult, Older Adult)",560,552,525,189,301,35,3/17/2005,10/6/2005,8/9/2005,9/7/2005,8/1/2005,8/25/2005,8/30/2005,9/4/2005,9/29/2005,6/12/2006,8/30/2006,1/14/2007,5/1/2007,6/26/2007,8/23/2007,9/30/2007,10/30/2007,12/28/2007,2/18/2008,2/21/2006,8/20/2006,2/16/2007,8/15/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00391950,,,,,,
Novartis,Novartis,ST00392,SP00014,Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy,,,,,Oncology,,,,,,Industry,Completed,Phase 2|Phase 3,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Suzie K,Clarice N,Lucie P,Marcelina X,Tamesha T,Perter K,Quentin N,Anthony P,John G,Suzie K,Selizabeth F,Liberty A,Dinah R,Naren G,Clarice N,Corrine U,Anthony P,Frank T,Lyman W,,,"Kiel, Germany",57.71146542,51.94031888,Female,"18 Years and older ¬† (Adult, Older Adult)",561,555,526,250,244,32,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/23/1900,4/22/1900,6/1/1900,7/17/1900,9/3/1900,10/18/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00333047,,,,,,
Novartis,Novartis,ST00446,SP00014,Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Xochitl D,Aleta H,Anthony P,Harry A,Louann C,Jeanene Y,Anthony P,Doreen T,Selizabeth F,Suk T,In Bellini †,Suzie K,Dinah R,Terrell p,Suk T,In Bellini †,Jaquelyn H,Jeanene Y,Terrell p,,,"Novartis Investigative Site, Tuebingen, Germany",3.163051751,2.846746576,Male,"18 Years and older ¬† (Adult, Older Adult)",585,572,527,367,87,73,8/25/2005,3/18/2006,1/1/2006,2/1/2006,1/25/2006,1/27/2006,2/1/2006,2/4/2006,2/28/2006,6/30/2010,2/21/2010,9/23/2010,12/1/2010,1/14/2011,2/18/2011,4/10/2011,5/28/2011,7/9/2011,9/7/2011,7/26/2006,1/22/2007,7/21/2007,1/17/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00391690,,,,,,
Pfizer,Pfizer,ST00026,SP00015,"Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients",,,Human Immunodeficiency Virus,,Virology,,,,,,Industry,Withdrawn,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Rima Y ,Kandace p,Suzie K,Tamesha T,Chetan K,Anthony P,James y,Dinah R,Mee M,Mary H,John G,Hee Y,Aleta H,Selizabeth F,Christian G,Selizabeth F,Corrine U,Lilla Stilson †,Tien C,,,,18.07290586,16.26561528,All,"18 Years to 80 Years ¬† (Adult, Older Adult)",553,535,528,213,286,29,3/23/2028,9/27/2028,7/25/2028,8/16/2028,7/22/2028,8/8/2028,8/18/2028,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/25/1900,4/4/1900,5/16/1900,6/24/1900,7/28/1900,9/5/1900,2/4/2029,8/3/2029,1/30/2030,7/29/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00488995,,,,,,
Pfizer,Pfizer,ST00098,SP00015,A Study of PF-07260437 in Advanced or Metastatic Solid Tumors,,C4431001,Ovarian Neoplasms|Endometrial Neoplasms|Breast Neoplasms,,Oncology,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Terrell p,Doreen T,John G,Suzie K,Chetan K,Selizabeth F,Doreen T,Anthony P,Donovan H,Frank T,Terrell p,Marcelina X,Terrell p,Suk T,Perter K,Anthony P,Xochitl D,Suzie K,,,,11.27794525,10.15015073,All,"18 Years and older ¬† (Adult, Older Adult)",596,578,529,447,21,61,1/1/2021,5/27/2021,4/11/2021,5/1/2021,4/7/2021,4/25/2021,5/1/2021,5/4/2021,5/11/2021,7/11/2024,7/13/2024,10/27/2024,2/22/2025,3/30/2025,5/14/2025,7/12/2025,9/10/2025,10/18/2025,11/21/2025,10/22/2021,4/20/2022,10/17/2022,4/15/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05067972,,,,,,
Pfizer,Pfizer,ST00100,SP00015,"A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants",,,Healthy Participants,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Patria R,Selizabeth F,Louann C,Tien C,Tiffiny K,Terisa Sikora †,Marceline R,Naren G,Mee M,Suzie K,Geralyn K,James y,Suk T,Otis Thode †,John G,Anthony P,Mara A,Lavina S,Rima Y ,,,"Research Center of America, Hollywood, Florida, United States",81.3359048,73.20231432,All,18 Years to 30 Years ¬† (Adult),550,544,530,443,9,78,10/30/2017,5/15/2018,2/25/2018,4/5/2018,3/18/2018,3/22/2018,3/30/2018,4/1/2018,4/26/2018,7/5/2021,5/12/2021,8/3/2021,12/15/2021,1/19/2022,3/20/2022,5/12/2022,6/14/2022,7/31/2022,9/11/2022,9/18/2018,3/17/2019,9/13/2019,3/11/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05067439,,,,,,
Pfizer,Pfizer,ST00104,SP00015,PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants,,,Healthy Participants,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Donovan H,Aleta H,Livia Pacheo †,Livia Pacheo †,Remedios Z,Terisa Sikora †,Ngan D,Tamesha T,Mac L,Remedios Z,Lavina S,Anthony P,Mee M,John G,Chetan K,Terisa Sikora †,Terisa Sikora †,Mary H,Livia Pacheo †,,,"Research Centers of America ( Hollywood ), Hollywood, Florida, United States",83.95144439,75.55629995,All,"18 Years and older ¬† (Adult, Older Adult)",587,573,531,165,334,32,2/13/2020,8/27/2020,7/8/2020,8/13/2020,7/22/2020,7/28/2020,8/1/2020,8/4/2020,8/16/2020,4/4/2021,1/26/2021,9/28/2021,11/22/2021,12/29/2021,2/23/2022,4/3/2022,5/15/2022,7/3/2022,8/22/2022,1/24/2021,7/23/2021,1/19/2022,7/18/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05064800,,,,,,
Pfizer,Pfizer,ST00108,SP00015,A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC),,,Healthy,,,,,,,,Industry,Not yet recruiting,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Mary H,Mara A,James y,Quentin N,John G,Livia Pacheo †,Tien C,Suk T,Dalton E,Chetan K,Mara A,Geralyn K,Donovan H,Liberty A,Tiffiny K,Otis Thode †,John G,Remedios Z,Garnet T,,,"Qps-Mra, Llc, South Miami, Florida, United States",60.41177177,54.37059459,Female,"19 Years and older ¬† (Adult, Older Adult)",582,558,532,272,213,47,10/21/2016,4/16/2017,2/26/2017,3/14/2017,2/10/2017,3/5/2017,3/16/2017,3/17/2017,4/16/2017,11/9/2021,4/21/2021,10/29/2021,12/16/2021,2/4/2022,3/7/2022,4/20/2022,6/14/2022,7/26/2022,9/11/2022,9/1/2017,2/28/2018,8/27/2018,2/23/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05064332,,,,,,
Pfizer,Pfizer,ST00110,SP00015,Study of PF-07263689 in Participants With Selected Advanced Solid Tumors,,,Renal Cell Cancer|Melanoma|Non-Small-Cell Lung Cancer|Hepatocellular Cancer|Bladder Cancer|Sarcoma|Head and Neck Cancer|Colorectal Cancer|Ovarian Cancer|Squamous Cell Carcinoma,,Oncology,,,,,,Industry,Not yet recruiting,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Ross S,Kala R,Ngan D,Terrell p,Frank T,Jerold Goo †,Marceline R,Tiffiny K,Louann C,Lucie P,Remedios Z,Perter K,Naren G,Terrell p,Mac L,Kala R,Ngan D,Mac L,Livia Pacheo †,,,,53.54478441,48.19030597,All,"18 Years and older ¬† (Adult, Older Adult)",573,567,533,307,171,55,7/17/2019,1/23/2020,11/6/2019,12/12/2019,11/15/2019,11/29/2019,12/3/2019,12/8/2019,12/27/2019,4/9/2024,11/23/2023,5/17/2024,7/7/2024,8/13/2024,9/29/2024,11/20/2024,1/5/2025,2/26/2025,4/10/2025,5/27/2020,11/23/2020,5/22/2021,11/18/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05061537,,,,,,
Pfizer,Pfizer,ST00111,SP00015,"Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants",,,Healthy,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Lilla Stilson †,Naren G,Mary H,Kala R,Ngan D,Kandace p,Garnet T,Mary H,Hee Y,Christian G,Xochitl D,Selizabeth F,Lilla Stilson †,Remedios Z,Jene M,Anthony P,Rima Y ,Lavina S,Kandace p,,,"Huashan Hospital Fudan University, Shanghai, Shanghai, China",53.28807982,47.95927184,All,"18 Years and older ¬† (Adult, Older Adult)",578,551,534,357,117,60,12/18/2017,5/7/2018,3/16/2018,4/7/2018,3/16/2018,4/1/2018,4/16/2018,4/18/2018,5/4/2018,6/9/2021,3/21/2021,7/13/2021,12/1/2021,1/19/2022,2/20/2022,4/12/2022,5/18/2022,6/24/2022,8/14/2022,9/28/2018,3/27/2019,9/23/2019,3/21/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05061277,,,,,,
Pfizer,Pfizer,ST00114,SP00015,Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing,,,Advanced Malignancies|NSCLC|Ovarian Cancer|Urothelial Cancer|Solid Tumors,,Oncology,,,,,,Industry,Not yet recruiting,Phase 4,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Jerold Goo †,Anthony P,Suzie K,John G,Garnet T,Anthony P,Mara A,Clarice N,Frank T,John G,John G,Anthony P,John G,Mary H,Stephan T,Terrell p,Chetan K,Frank T,Otis Thode †,,,"Japanese Foundation for Cancer Research, Koto, Tokyo, Japan",75.91752904,68.32577614,All,3 Years to 8 Years ¬† (Child),591,573,535,236,253,46,12/20/2021,6/27/2022,5/5/2022,5/27/2022,5/11/2022,5/21/2022,5/27/2022,5/28/2022,6/18/2022,4/10/2025,5/6/2025,9/21/2025,12/31/2025,2/17/2026,3/22/2026,4/30/2026,6/23/2026,8/13/2026,9/20/2026,11/17/2022,5/16/2023,11/12/2023,5/10/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05059522,,,,,,
Pfizer,Pfizer,ST00124,SP00015,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza",,,"Influenza, Human",,Virology,,,,,,Industry,Recruiting,Phase 1,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,,,,,Drug D,,,,,,,,,,,,,,,,,,,John G,Dinah R,Jaquelyn H,Lilla Stilson †,Lucie P,Ross S,Jeanene Y,Lilla Stilson †,Chetan K,Corrine U,John G,Frank T,John G,Dalton E,Patria R,Tamesha T,Stephan T,Mary H,Corrine U,,,"Arizona Heart Rhythm Center, Phoenix, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|The Pain Center of Arizona, Phoenix, Arizona, United States|Inland Valley Cardiovascular Center, Murrieta, California, United States|Artemis Institute for Clinical Research, Riverside, California, United States|Alliance for Multispecialty Research, LLC, Coral Gables, Florida, United States|Casa de Corazon, Miami, Florida, United States|My Cardiologist, South Miami, Florida, United States|Precision Clinical Research, Sunrise, Florida, United States|Centennial Medical Group, Elkridge, Maryland, United States|Meridian Clinical Research, LLC, Omaha, Nebraska, United States|Penn Medicine, Somers Point, New Jersey, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|NYU Langone - Center for the Prevention of Cardiovascular Disease, New York, New York, United States|NYU Langone Health, New York, New York, United States|Rochester General Hospital Infectious Disease, Rochester, New York, United States|Rochester General Hospital, Rochester, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University Global Health Research Unit, Syracuse, New York, United States|Aventiv Research Inc, Columbus, Ohio, United States|Columbus Cardiovascular Associates, Inc, Columbus, Ohio, United States|DM Clinical Research, Houston, Texas, United States|DM Clinical Research, Humble, Texas, United States|Mt Olympus Medical Research, Sugar Land, Texas, United States|DM Clinical Research, Tomball, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|Northwest Heart Center, Tomball, Texas, United States",79.46935092,71.52241582,All,"19 Years to 90 Years ¬† (Adult, Older Adult)",611,584,536,294,197,45,11/21/2017,6/30/2018,5/3/2018,5/18/2018,4/21/2018,5/10/2018,5/15/2018,5/19/2018,6/5/2018,7/7/2021,9/26/2021,2/8/2022,5/30/2022,7/12/2022,8/13/2022,9/20/2022,10/30/2022,12/10/2022,1/18/2023,11/6/2018,5/5/2019,11/1/2019,4/29/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05052697,,,,,,
Pfizer,Pfizer,ST00126,SP00015,"Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants",,,Healthy,,,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Christian G,John G,Lavina S,Geralyn K,Frank T,Frank T,Doreen T,Geralyn K,Garnet T,Rima Y ,Donovan H,Frank T,Mary H,Kala R,Anthony P,Mac L,Anthony P,Suzie K,Tiffiny K,,,,89.32155604,80.38940043,All,"18 Years and older ¬† (Adult, Older Adult)",586,569,537,171,332,34,12/9/2017,6/14/2018,4/6/2018,5/20/2018,4/26/2018,5/6/2018,5/9/2018,5/11/2018,5/19/2018,8/26/2021,4/15/2021,10/24/2021,12/10/2021,1/28/2022,3/9/2022,5/8/2022,6/11/2022,7/21/2022,9/16/2022,11/2/2018,5/1/2019,10/28/2019,4/25/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05050682,,,,,,
Pfizer,Pfizer,ST00129,SP00015,A Post-Exposure Prophylaxis Study of PF-07321332/Ritonavir in Adult Household Contacts of an Individual With Symptomatic COVID-19,,,COVID-19,,Virology,,,,,,Industry,Recruiting,Not Applicable,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Hee Y,Lyman W,Christian G,Corrine U,Mary H,Lilla Stilson †,Xochitl D,Chetan K,Lilla Stilson †,Jaquelyn H,John G,Mara A,Mac L,Donovan H,Frank T,Ngan D,Harry A,Donovan H,Mara A,,,"Lightship, El Segundo, California, United States|MOORE Clinical Research, Inc., Brandon, Florida, United States|Herco Medical and Research Center Inc, Coral Gables, Florida, United States|Qway Research, LLC, Hialeah, Florida, United States|Inpatient Research Clinic, Hialeah, Florida, United States|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States|Global Health Clinical Trials Corp, Miami, Florida, United States|Entrust Clinical Research, Miami, Florida, United States|Reed Medical Research, Miami, Florida, United States|NAPA Research LLC, Pompano Beach, Florida, United States|USPA Advance Concept Medical Research Group LLC, South Miami, Florida, United States|Santos Research Center, CORP, Tampa, Florida, United States|Clinical Site Partners, Inc, Winter Park, Florida, United States|Jackson Medical Mall, Jackson, Mississippi, United States|Lakeland Pharmacy, Branson W., Missouri, United States|Price Cutter, Springfield, Missouri, United States|Walmart, Las Vegas, Nevada, United States|Walgreens, Las Vegas, Nevada, United States|PharmaTex Research, LLC, Amarillo, Texas, United States|St Hope Foundation, Bellaire, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|Epic Medical Research, Red Oak, Texas, United States|International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan|Rakuwakai Otowa Hospital, Kyoto-shi, Kyoto, Japan|Rinku General Medical Center, Izumisano, Osaka, Japan|Denenchofu Family Clinic, Ota, Tokyo, Japan|Tokyo Shinagawa Hospital, Shinagawa-ku, Tokyo, Japan|Sekino Hospital, Toshimaku, Tokyo, Japan|Kyushu Medical Center, Fukuoka, Japan|Advance Medical Research Center, San Juan, Puerto Rico",56.9572472,51.26152248,All,18 Years to 55 Years ¬† (Adult),599,574,538,336,139,63,11/22/2017,6/17/2018,4/11/2018,5/26/2018,5/5/2018,5/8/2018,5/13/2018,5/17/2018,6/11/2018,3/18/2021,3/5/2021,8/3/2021,12/25/2021,2/17/2022,4/11/2022,5/15/2022,7/4/2022,8/17/2022,10/9/2022,11/4/2018,5/3/2019,10/30/2019,4/27/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05047601,,,,,,
Pfizer,Pfizer,ST00136,SP00015,European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies,,EUCHARIS,Metastatic Breast Cancer,,Oncology,,,,,,Industry,Not yet recruiting,Phase 1|Phase 2,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Gertrudis T,James y,Doreen T,Clarice N,Xochitl D,Mara A,Kala R,Terrell p,Liberty A,Terisa Sikora †,Mac L,Lucie P,Tammara F,Mara A,Mac L,Marceline R,Anthony P,Anthony P,Patria R,,,"Pfizer, New York, New York, United States",19.16187112,17.245684,All,"18 Years and older ¬† (Adult, Older Adult)",586,578,539,213,285,41,10/5/2018,2/20/2019,1/6/2019,1/28/2019,1/1/2019,1/11/2019,1/26/2019,1/28/2019,2/7/2019,9/18/2021,9/15/2021,5/6/2022,6/30/2022,8/23/2022,9/27/2022,11/22/2022,12/23/2022,1/25/2023,3/23/2023,7/10/2019,1/6/2020,7/4/2020,12/31/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05043506,,,,,,
Pfizer,Pfizer,ST00139,SP00015,A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults,,,Healthy Participants,,,,,,,,Industry,Recruiting,,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Marceline R,Stephan T,Hee Y,Naren G,Dinah R,Lyman W,James y,Harry A,Suzie K,Perter K,Livia Pacheo †,Suzie K,Rima Y ,Naren G,Garnet T,Dinah R,Naren G,Dinah R,Livia Pacheo †,,,"New Haven Clinical Research Unit, New Haven, Connecticut, United States",81.42313454,73.28082109,All,18 Years to 35 Years ¬† (Adult),606,579,540,229,269,42,10/3/2019,3/9/2020,12/26/2019,2/3/2020,12/30/2019,1/16/2020,1/27/2020,1/29/2020,2/10/2020,9/9/2021,4/20/2021,8/30/2021,11/22/2021,1/20/2022,3/18/2022,4/17/2022,5/24/2022,6/26/2022,8/9/2022,7/14/2020,1/10/2021,7/9/2021,1/5/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05040295,,,,,,
Pfizer,Pfizer,ST00141,SP00015,High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France,,HELIOS-AF,Atrial Fibrillation,,,,,,,,Industry,Not yet recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Mee M,Marcelina X,Rima Y ,Lucie P,Jeanene Y,Quentin N,Chetan K,Donovan H,John G,Quentin N,Dalton E,Terrell p,Mary H,Naren G,Anthony P,John G,Suzie K,Tiffiny K,Beulah N,,,"Pfizer Investigator, London, United Kingdom",7.680364858,6.912328372,All,"Child, Adult, Older Adult",566,547,541,373,126,42,11/16/2019,5/16/2020,2/28/2020,4/7/2020,3/6/2020,3/21/2020,3/24/2020,3/26/2020,4/12/2020,1/13/2022,12/22/2021,5/29/2022,9/2/2022,10/17/2022,12/4/2022,1/29/2023,3/16/2023,4/19/2023,6/7/2023,9/17/2020,3/16/2021,9/12/2021,3/11/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05038228,,,,,,
Pfizer,Pfizer,ST00142,SP00015,"Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants",,,Healthy,,,,,,,,Industry,Not yet recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Lavina S,Jerold Goo †,Mara A,Anthony P,Kandace p,Lucie P,Doreen T,Corrine U,Dinah R,Dinah R,Tamesha T,Marceline R,Chetan K,Liberty A,Jeanene Y,Quentin N,Lilla Stilson †,Christian G,Harry A,,,"Medical Corporation Shinanokai Shinanozaka Clinic, Shinjuku-ku, Tokyo, Japan",59.03573911,53.1321652,All,"6 Years to 25 Years ¬† (Child, Adult)",568,556,542,352,148,42,3/7/2019,8/6/2019,6/26/2019,7/12/2019,6/19/2019,7/2/2019,7/17/2019,7/22/2019,8/7/2019,10/23/2021,7/15/2021,1/24/2022,3/27/2022,4/28/2022,6/2/2022,7/31/2022,9/22/2022,11/17/2022,1/3/2023,12/29/2019,6/26/2020,12/23/2020,6/21/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05037409,,,,,,
Pfizer,Pfizer,ST00143,SP00015,"Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.",,RENOIR,Lower Respiratory Tract Illness,,,,,,,,Industry,Recruiting,Not Applicable,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",,,,,,Drug B,,,,,,,,,,,,,,,,,,,John G,Patria R,Louann C,Chetan K,Stephan T,John G,Rima Y ,Jene M,John G,Doreen T,Mara A,Geralyn K,Otis Thode †,Tamesha T,Livia Pacheo †,Federico L,Terrell p,Otis Thode †,Tiffiny K,,,"Medical Affiliated Research Center, Huntsville, Alabama, United States|Lenzmeier Family Medicine/CCT Research, Glendale, Arizona, United States|Phoenix Clinical LLC., Phoenix, Arizona, United States|Phoenix Clinical LLC, Phoenix, Arizona, United States|Phoenix Clinical, LLC, Phoenix, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|The Pain Center of Arizona, Phoenix, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|Cognitive Clinical Trials, LLC, Phoenix, Arizona, United States|Headlands Research - Scottsdale, Scottsdale, Arizona, United States|Alliance for Multispecialty Research, LLC, Tempe, Arizona, United States|HOPE Research Institute - Tempe, Tempe, Arizona, United States|HOPE Research Institute, Tempe, Arizona, United States|Noble Clinical Research, Tucson, Arizona, United States|The Institute for Liver Health dba Arizona Clinical Trials, Tucson, Arizona, United States|Hope Clinical Research, Canoga Park, California, United States|eStudySite, Chula Vista, California, United States|Benchmark Research, Colton, California, United States|West Coast Research, Dublin, California, United States|Marvel Clinical Research 002, LLC, Huntington Beach, California, United States|Ark Clinical Research, Long Beach, California, United States|Downtown L.A. Research Center, Inc., Los Angeles, California, United States|Providence Clinical Research, North Hollywood, California, United States|Fomat Medical Research, Oxnard, California, United States|Empire Clinical Research, Pomona, California, United States|Paradigm Clinical Research Center, Redding, California, United States|Artemis Institute for Clinical Research, Riverside, California, United States|Benchmark Research, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|California Research Foundation, San Diego, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Lynn Institute of Denver, Aurora, Colorado, United States|Tekton Research, Inc., Longmont, Colorado, United States|Clinical Research Consulting, Milford, Connecticut, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Innovative Research of West Florida, Clearwater, Florida, United States|Nature Coast Clinical Research, Crystal River, Florida, United States|Universal Axon Clinical Research, LLC (Administrative), Doral, Florida, United States|Indago Research & Health Center, Inc, Hialeah, Florida, United States|Doral Medical Research, LLC, Hialeah, Florida, United States|Multi-Specialty Research Associates, Inc., Lake City, Florida, United States|Global Health Research Center, Inc., Miami Lakes, Florida, United States|Optimus U Corporation, Miami, Florida, United States|Advance Medical Research Center, Miami, Florida, United States|Optimus U Corporation, Miami, Florida, United States|Next Phase Research Alliance, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Clinical Site Partners, Inc dba CSP Miami, Miami, Florida, United States|Headlands Research Orlando, Orlando, Florida, United States|Pines Care Research Center, LLC, Pembroke Pines, Florida, United States|IDEAL Clinical Research, Pembroke Pines, Florida, United States|DBC Research USA, Pembroke Pines, Florida, United States|Invictus Clinical Research Group, LLC, Pompano Beach, Florida, United States|Headlands Research Sarasota, Sarasota, Florida, United States|Precision Clinical Research, Sunrise, Florida, United States|Clinical Site Partners, Inc, Winter Park, Florida, United States|Conquest Research, LLC, Winter Park, Florida, United States|Javara Inc, Albany, Georgia, United States|Privia Medical Group Georgia, LLC, Albany, Georgia, United States|Coastal Heritage Clinical Research, Hinesville, Georgia, United States|Javara Inc., Savannah, Georgia, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Privia Medical Group Georgia, LLC, Savannah, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Javara Inc., Thomasville, Georgia, United States|Privia Medical Group Georgia, LLC, Thomasville, Georgia, United States|Snake River Research, PLLC, Idaho Falls, Idaho, United States|Solaris Clinical Research, Meridian, Idaho, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Affinity Health Corp, Oak Brook, Illinois, United States|MOC Research, Mishawaka, Indiana, United States|Velocity Clinical Research Valparaiso, Valparaiso, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Iowa, Iowa City, Iowa, United States|Meridian Clinical Research, LLC, Sioux City, Iowa, United States|Alliance for Multispecialty Research, LLC, Lexington, Kentucky, United States|MedPharmics LLC, Metairie, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Meridian Clinical Research, LLC, Rockville, Maryland, United States|ActivMed Practices & Research, LLC, Beverly, Massachusetts, United States|Michigan Center of Medical Research (MICHMER), Farmington Hills, Michigan, United States|Oakland Medical Research, Troy, Michigan, United States|Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy, Michigan, United States|Saint Louis University, Saint Louis, Missouri, United States|Sundance Clinical Research, Saint Louis, Missouri, United States|Skyline Medical Center, PC/CCT Research, Elkhorn, Nebraska, United States|Quality Clinical Research, Omaha, Nebraska, United States|Wr-Crcn, Llc., Las Vegas, Nevada, United States|Las Vegas Clinical Trials, North Las Vegas, Nevada, United States|ActivMed Practices and Research, LLC., Portsmouth, New Hampshire, United States|Amici Clinical Research LLC, Raritan, New Jersey, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|Meridian Clinical Research, LLC, Binghamton, New York, United States|CHEAR Center LLC, Bronx, New York, United States|Meridian Clinical Research, LLC, Endwell, New York, United States|Drug Trials America, Hartsdale, New York, United States|Corning Center for Clinical Research, Horseheads, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Accellacare - Charlotte, Charlotte, North Carolina, United States|Javara Inc., Charlotte, North Carolina, United States|Tryon Medical Partners, PLLC, Charlotte, North Carolina, United States|Accellacare - Wilmington, Wilmington, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Meridian Clinical Research, Cincinnati, Ohio, United States|Velocity Clinical Research - Cincinnati, Cincinnati, Ohio, United States|Meridian Clinical Research, Cincinnati, Ohio, United States|Aventiv Research Inc, Columbus, Ohio, United States|Tekton Research, Inc., Edmond, Oklahoma, United States|Tekton Research, Inc., Yukon, Oklahoma, United States|Velocity Clinical Research, Grants Pass, Grants Pass, Oregon, United States|Velocity Clinical Research, Medford, Medford, Oregon, United States|Summit Headlands, LLC, Portland, Oregon, United States|Kaiser Permanente Northwest-Center for Health Research, Portland, Oregon, United States|Capital Area Research, LLC, Camp Hill, Pennsylvania, United States|Central Erie Primary Care, Erie, Pennsylvania, United States|West Shore Family Practice, P. C., Mechanicsburg, Pennsylvania, United States|Velocity Clinical Research, Providence, Warwick, Rhode Island, United States|Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States|Accellacare US Inc., d/b/a Accellacare of Knoxville, Knoxville, Tennessee, United States|Clinical Research Associates, Inc., Nashville, Tennessee, United States|Benchmark Research, Austin, Texas, United States|ARC Clinical Research at Wilson Parke, Austin, Texas, United States|Tekton Research, Inc., Austin, Texas, United States|Tekton Research, Inc., Beaumont, Texas, United States|North Texas Infectious Diseases Consultants, Dallas, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|Allure Health at Mt. Olympus Medical Research, Friendswood, Texas, United States|Hany H. Ahmed, MD, Houston, Texas, United States|HG Pediatrics, Houston, Texas, United States|Trio Clinical Trials, LLC, Houston, Texas, United States|Van Tran Family Practice, Houston, Texas, United States|Ventavia Research Group, LLC, Houston, Texas, United States|Centex Studies, Houston, Texas, United States|DM Clinical Research ? CyFair, Houston, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Centex Studies, Houston, Texas, United States|DM Clinical Research, Humble, Texas, United States|Milton Haber, M.D., Laredo, Texas, United States|SMS Clinical Research, Mesquite, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Benchmark Research, San Antonio, Texas, United States|Dynamed Clinical Research, LP d/b/a DM Clinical Research, Sugar Land, Texas, United States|Javara Inc., Sugar Land, Texas, United States|Privia Medical Group Gulf Coast, PLLC, Sugar Land, Texas, United States|Mt Olympus Medical Research, Sugar Land, Texas, United States|Javara Inc., The Woodlands, Texas, United States|Privia Medical Group Gulf Coast, PLLC, The Woodlands, Texas, United States|DM Clinical Research, Tomball, Texas, United States|J. Lewis Research Inc. / Foothill Family Clinic Draper, Draper, Utah, United States|Tanner Clinic, Layton, Utah, United States|J. Lewis Research, Inc. / Jordan River Family Medicine, South Jordan, Utah, United States|Velocity Clinical Research, Salt Lake City, West Jordan, Utah, United States|Suffolk Multispecialty Research, Suffolk, Virginia, United States|Virginia Gastroenterology Clinical Research, Suffolk, Virginia, United States|Sound Medical Research, Port Orchard, Washington, United States|Wenatchee Valley Hospital, Wenatchee, Washington, United States|Allegiance Research Specialists, LLC, Wauwatosa, Wisconsin, United States|Aggarwal and Associates Limited, Brampton, Ontario, Canada|Hamilton Medical Research Group, Hamilton, Ontario, Canada|Manna Research (Mirabel), Mirabel, Quebec, Canada|Alpha Recherche Clinique, Qu√©bec, Quebec, Canada|Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada|Diex Recherche Victoriaville Inc., Victoriaville, Quebec, Canada|Diex Recherche Quebec Inc., Quebec, Canada|Motomachi Takatsuka Naika Clinic, Yokohama, Kanagawa, Japan|Nihonbashi Sakura Clinic, Chuo-ku, Tokyo, Japan|Fukuwa Clinic, Chuo-ku, Tokyo, Japan|Medical Corp. Seikoukai New Medical Research System Clinic, Hachioji-shi, Tokyo, Japan|Oda Clinic, Shinjuku-ku, Tokyo, Japan|Sekino Hospital, Toshima-ku, Tokyo, Japan",27.18988365,24.47089528,All,"18 Years to 65 Years ¬† (Adult, Older Adult)",602,576,543,260,257,26,3/12/2021,9/19/2021,7/8/2021,8/9/2021,6/30/2021,7/23/2021,8/1/2021,8/3/2021,8/13/2021,2/10/2024,10/28/2023,5/13/2024,6/19/2024,8/14/2024,10/9/2024,11/29/2024,1/1/2025,3/2/2025,4/30/2025,1/19/2022,7/18/2022,1/14/2023,7/13/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05035212,,,,,,
Pfizer,Pfizer,ST00146,SP00015,Comirnaty Korea PMS,,,COVID-19|Vaccines|Adverse Effects|SARS-CoV-2|Safety,,Virology,,,,,,Industry,Not yet recruiting,Not Applicable,Observational,,Observational Model: Case-Only|Time Perspective: Prospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Christian G,Tamesha T,Dalton E,Anthony P,John G,Aleta H,Remedios Z,Aleta H,Selizabeth F,Mac L,John G,Hee Y,Tammara F,Tiffiny K,Suzie K,Liberty A,Anthony P,Selizabeth F,John G,,,,39.96890602,35.97201542,All,"18 Years to 65 Years ¬† (Adult, Older Adult)",575,564,544,507,18,19,1/23/2025,7/18/2025,5/28/2025,6/10/2025,5/21/2025,6/2/2025,6/6/2025,6/7/2025,6/29/2025,8/17/2026,7/1/2026,1/2/2027,3/4/2027,4/20/2027,5/20/2027,7/11/2027,8/14/2027,9/30/2027,11/4/2027,11/29/2025,5/28/2026,11/24/2026,5/23/2027,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05032976,,,,,,
Pfizer,Pfizer,ST00147,SP00015,Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants,,,Healthy Participants,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Ngan D,Chetan K,Suzie K,Anthony P,Frank T,Louann C,Marcelina X,Kala R,Christian G,Jeanene Y,Mac L,Otis Thode †,Mary H,Remedios Z,Selizabeth F,Clarice N,Lavina S,Liberty A,Harry A,,,"Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, R√©gion DE, Belgium",71.13041686,64.01737518,All,"18 Years and older ¬† (Adult, Older Adult)",608,590,545,524,61,40,4/25/2019,11/28/2019,9/17/2019,10/29/2019,9/30/2019,10/12/2019,10/15/2019,10/19/2019,11/3/2019,8/30/2021,4/26/2021,8/8/2021,12/5/2021,1/25/2022,3/1/2022,4/20/2022,5/27/2022,7/3/2022,8/24/2022,4/9/2020,10/6/2020,4/4/2021,10/1/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05032950,,,,,,
Pfizer,Pfizer,ST00148,SP00015,Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule,,,Healthy Participants,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Chetan K,Naren G,Stephan T,Naren G,Anthony P,Stephan T,James y,Frank T,Perter K,Lavina S,Lyman W,Tammara F,Mara A,Gertrudis T,Federico L,Geralyn K,Chetan K,Selizabeth F,John G,,,"Pfizer Clinical Research Unit, New Haven, Connecticut, United States",26.35744319,23.72169887,All,"34 Weeks and older ¬† (Child, Adult, Older Adult)",628,599,546,495,33,18,5/3/2019,11/12/2019,8/20/2019,10/8/2019,9/10/2019,9/18/2019,9/21/2019,9/25/2019,10/12/2019,11/10/2021,5/9/2021,10/1/2021,1/4/2022,2/15/2022,3/31/2022,5/23/2022,7/20/2022,9/13/2022,10/25/2022,3/16/2020,9/12/2020,3/11/2021,9/7/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05032690,,,,,,
Pfizer,Pfizer,ST00162,SP00015,Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea,,,Venous Thromboembolism,,,,,,,,Industry,Not yet recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Terisa Sikora †,Suzie K,Quentin N,Tammara F,Liberty A,Otis Thode †,John G,Livia Pacheo †,Mary H,Mary H,Garnet T,Jerold Goo †,Dinah R,Dalton E,Suk T,Clarice N,Dinah R,Quentin N,Mary H,,,"Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Sungkyunkwan University, Suwon-si, Korea, Republic of",87.0487115,78.34384035,All,"18 Years to 70 Years ¬† (Adult, Older Adult)",608,600,547,193,329,25,1/16/2017,6/13/2017,4/14/2017,4/29/2017,4/21/2017,4/23/2017,5/3/2017,5/8/2017,6/7/2017,4/14/2021,1/6/2021,7/23/2021,9/30/2021,11/28/2021,1/2/2022,2/21/2022,4/7/2022,6/1/2022,7/4/2022,10/20/2017,4/18/2018,10/15/2018,4/13/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05022563,,,,,,
Pfizer,Pfizer,ST00164,SP00015,MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma,,MAGNETISMM-5,Multiple Myeloma,,Oncology,,,,,,Industry,Not yet recruiting,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Kala R,Livia Pacheo †,John G,Harry A,Dalton E,Dinah R,Quentin N,Remedios Z,John G,Dinah R,Naren G,Terrell p,Garnet T,Federico L,Corrine U,James y,Mary H,Suk T,Naren G,,,"Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of|Pratia Onkologia Katowice, Katowice, Poland|Centrum Medyczne Pratia Poznan, Skorzewo, Poland",70.85625832,63.77063249,All,4 Months to 50 Months ¬† (Child),584,562,548,402,82,64,7/13/2023,12/23/2023,10/18/2023,11/26/2023,11/4/2023,11/17/2023,11/24/2023,11/27/2023,12/6/2023,4/22/2024,5/2/2024,8/18/2024,12/20/2024,2/15/2025,4/13/2025,5/20/2025,7/8/2025,8/29/2025,10/22/2025,5/15/2024,11/11/2024,5/10/2025,11/6/2025,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05020236,,,,,,
Pfizer,Pfizer,ST00165,SP00015,COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States,,,Immunocompromised|Immunosuppressed|Covid-19|SARS-COV-2|SARS-COV-2 Infection|Breakthrough Infection,,Virology,,,,,,Industry,"Active, not recruiting",Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,John G,Harry A,Xochitl D,In Bellini †,Dalton E,Chetan K,Patria R,Kala R,Tammara F,Lucie P,Tammara F,Remedios Z,Beulah N,Otis Thode †,Tiffiny K,Quentin N,Perter K,Geralyn K,Donovan H,,,"Pfizer Inc., New York, New York, United States",14.30123442,12.87111097,All,"20 Years and older ¬† (Adult, Older Adult)",615,595,549,503,54,8,4/7/2018,10/21/2018,8/13/2018,9/6/2018,8/23/2018,8/27/2018,9/9/2018,9/13/2018,9/28/2018,10/6/2021,6/8/2021,10/27/2021,12/31/2021,2/27/2022,4/9/2022,6/6/2022,8/5/2022,9/7/2022,10/23/2022,2/23/2019,8/22/2019,2/18/2020,8/16/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05020145,,,,,,
Pfizer,Pfizer,ST00169,SP00015,MagnetisMM-9: Study of Elranatamab (PF-06863135) Monotherapy in Participants With Relapsed/Refractory Multiple Myeloma,,,Multiple Myeloma,,Oncology,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Frank T,Kandace p,Mary H,Federico L,Stephan T,Clarice N,Gertrudis T,John G,Mara A,Tammara F,Geralyn K,Chetan K,Naren G,Anthony P,Kala R,Xochitl D,Doreen T,Christian G,Beulah N,,,,63.47262502,57.12536252,All,"18 Years and older ¬† (Adult, Older Adult)",590,572,550,360,135,55,4/11/2019,10/1/2019,8/1/2019,9/3/2019,7/23/2019,8/15/2019,8/26/2019,8/29/2019,9/5/2019,10/23/2022,9/20/2022,4/8/2023,6/27/2023,8/26/2023,10/22/2023,12/3/2023,1/24/2024,3/2/2024,4/22/2024,2/11/2020,8/9/2020,2/5/2021,8/4/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05014412,,,,,,
Pfizer,Pfizer,ST00171,SP00015,Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART),,,Renal Cell Carcinoma,,Oncology,,,,,,Industry,Not yet recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Anthony P,Suzie K,Rima Y ,Geralyn K,Anthony P,Marceline R,Chetan K,Suzie K,Perter K,Anthony P,Selizabeth F,Dalton E,Lavina S,Mee M,Patria R,Frank T,Naren G,Mac L,Perter K,,,,92.07743286,82.86968958,All,18 Years to 50 Years ¬† (Adult),609,589,551,444,44,63,11/1/2016,3/14/2017,1/24/2017,2/21/2017,1/23/2017,2/6/2017,2/13/2017,2/17/2017,3/10/2017,5/8/2021,4/8/2021,10/9/2021,12/31/2021,2/22/2022,4/19/2022,5/26/2022,7/16/2022,8/18/2022,10/5/2022,8/5/2017,2/1/2018,7/31/2018,1/27/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05012865,,,,,,
Pfizer,Pfizer,ST00172,SP00015,Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone,,,Metastatic Breast Cancer,,Oncology,,,,,,Industry,"Active, not recruiting",Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Jene M,Mara A,Jaquelyn H,Hee Y,Garnet T,Tamesha T,Liberty A,Kandace p,Geralyn K,Selizabeth F,Mary H,Jene M,Garnet T,Chetan K,Jeanene Y,Jeanene Y,Mary H,Lyman W,Perter K,,,"Pfizer New York, New York, New York, United States",2.561317077,2.305185369,Female,18 Years to 50 Years ¬† (Adult),594,570,552,348,135,69,8/9/2020,1/28/2021,11/3/2020,12/16/2020,11/11/2020,12/1/2020,12/6/2020,12/9/2020,12/23/2020,3/4/2021,4/3/2021,10/8/2021,12/13/2021,1/19/2022,2/26/2022,4/22/2022,5/28/2022,7/4/2022,8/5/2022,5/30/2021,11/26/2021,5/25/2022,11/21/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05012644,,,,,,
Pfizer,Pfizer,ST00173,SP00015,A Study of PF-07321332/Ritonavir in Non-hospitalized Low-Risk Adult Participants With COVID-19,,,COVID-19,,Virology,,,,,,Industry,Recruiting,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Kala R,Tien C,John G,Tammara F,Tammara F,James y,Frank T,Christian G,Liberty A,Harry A,In Bellini †,John G,Lavina S,Garnet T,Lucie P,Anthony P,Anthony P,Mary H,Frank T,,,"Cahaba Research, Inc., Birmingham, Alabama, United States|Cahaba Research, Inc., Pelham, Alabama, United States|The Institute for Liver Health dba Arizona Clinical Trials, Mesa, Arizona, United States|The Institute for Liver Health dba Arizona Clinical Trials, Tucson, Arizona, United States|KLR Business Group, Inc. dba Arkansas Clinical Research, Little Rock, Arkansas, United States|Lightship, El Segundo, California, United States|Ascada Research, Fullerton, California, United States|Providence Clinical Research, North Hollywood, California, United States|FOMAT Medical Research, Oxnard, California, United States|Optimus Medical Group, San Francisco, California, United States|South Bay Clinical Research Institute, Torrance, California, United States|Future Innovative Treatments, LLC, Colorado Springs, Colorado, United States|MOORE Clinical Research, Inc., Brandon, Florida, United States|Herco Medical and Research Center Inc, Coral Gables, Florida, United States|Advance Clinical Research Group, Cutler Bay, Florida, United States|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States|Unlimited Medical Research Group, LLC, Hialeah Gardens, Florida, United States|Qway Research, LLC, Hialeah, Florida, United States|Savin Medical Group, LLC, Miami Lakes, Florida, United States|LCC Medical Research Institute, LLC, Miami, Florida, United States|Global Health Clinical Trials Corp, Miami, Florida, United States|South Florida Research Center, Inc., Miami, Florida, United States|USPA Advance Concept Medical Research Group LLC, Miami, Florida, United States|Medimpact Clinical & Investigational Center, Miami, Florida, United States|Entrust Clinical Research, Miami, Florida, United States|C'A Research, Miami, Florida, United States|ProLive Medical Research, Corp., Miami, Florida, United States|Omega Research Orlando, LLC, Orlando, Florida, United States|CDC Research Institute, Port Saint Lucie, Florida, United States|Sunrise Research Institute, Sunrise, Florida, United States|Santos Research Center, CORP, Tampa, Florida, United States|Clinical Site Partners, Inc. dba CSP Orlando, Winter Park, Florida, United States|The South Bend Clinic Center for Research, South Bend, Indiana, United States|MedPharmics LLC, Metairie, Louisiana, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Jackson Medical Mall, Jackson, Mississippi, United States|Lakeland Pharmacy, Branson W., Missouri, United States|CVS, Springfield, Missouri, United States|Meridian Clinical Research, LLC, Grand Island, Nebraska, United States|Walmart, Las Vegas, Nevada, United States|Walgreens, Las Vegas, Nevada, United States|Accellacare, Wilmington, North Carolina, United States|Innovo Research: Wilmington Health, Wilmington, North Carolina, United States|PharmaTex Research, LLC, Amarillo, Texas, United States|ARC Clinical Research at William Cannon, Austin, Texas, United States|St Hope Foundation, Bellaire, Texas, United States|Conroe Willis Medical Research, Conroe, Texas, United States|South Texas Clinical Research, Corpus Christi, Texas, United States|SingnatureCare Emergency Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|Tranquility Research, Webster, Texas, United States|Centro M√©dico Viamonte, Caba, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Zarate, Zarate, Buenos Aires, Argentina|Instituto M√©dico de la Fundaci√≥n Estudios Cl√≠nicos (Fundaci√≥n Estudios Cl√≠nicos), Rosario, Santa FE, Argentina|IBPClin - Instituto Brasil de Pesquisa Cl√≠nica, Rio de Janeiro, RJ, Brazil|Caimed S.A.S., Yopal, Casanare, Colombia|Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S, CIREEM S.A.S, Bogota, Cundinamarca, Colombia|Trial Pharma Kft., Bekescsaba, Hungary|Semmelweis University Varosmajori Sziv Es Ergyogyaszati Klinika, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont Infektologiai Klinika, Debrecen, Hungary|Agria-Study Kft., Eger, Hungary|Trial Pharma Kft., Gyula, Hungary|Medifarma-98 Kft., Nyiregyhaza, Hungary|Szent Borbala Korhaz, Tatabanya, Hungary|Fujita Health University Hospital, Toyoake-City, Aichi, Japan|Chiba Aoba Municipal Hospital, Chuo-ku, Chiba, Japan|National Hokkaido Medical Center, Sapporo, Hokkaido, Japan|Rakuwakai Otowa Hospital, Kyoto-shi, Kyoto, Japan|Rinku General Medical Center, Izumisano, Osaka, Japan|Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan|Tokyo Shinagawa Hospital, Shinagawa-ku, Tokyo, Japan|National Center for Global Health and Medicine, Shinjuku City, Tokyo, Japan|Sekino Hospital, Toshimaku, Tokyo, Japan|Kyushu Medical Center, Fukuoka, Japan|Chonnam National University Hospital, Gwangju-si, Kwangju-kwangy?kshi, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Chonnam National University Bitgoeul Hospital, Gwangju, Korea, Republic of|Incheon Medical Center, Incheon, Korea, Republic of|Boramae Medical Center, Seoul, Korea, Republic of|Hospital Taiping, Taiping, Perak, Malaysia|Hospital Seberang Jaya, Perai, Pulau Pinang, Malaysia|Hospital Miri, Miri, Sarawak, Malaysia|Klinik Kesihatan Kuang, Rawang, Selangor, Malaysia|Ponce Medical School Foundation, Inc. CAIMED Center, Ponce, Puerto Rico|Clinical Research Management Group Inc, Ponce, Puerto Rico|Advance Medical Research Center, San Juan, Puerto Rico|Eba Centelles, Centelles, Barcelona [barcelona], Spain|CAP Vicen√ß Papaceit, La Roca del Valles, Barcelona, Spain|Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain|IMED Valencia, Burjassot, Valencia, Spain|Complexo Hospitalario Universitario da Coruna, A Coruna, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario de la Paz, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen de Valme, Sevilla, Spain|Far Eastern Memorial Hospital, New Taipei City, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Siriraj Hospital, Mahidol University, BangkokNoi, Bangkok, Thailand|Riverside Bangkok Hotel, Bangplud, Bangkok, Thailand|Bangkok Centre Hotel, Bangrak, Bangkok, Thailand|Chula Filed hospital, Chulalongkorn University Sport center (Chantanayingyong Gymnasium),, Pathum Wan District,, Bangkok, Thailand|Thai Red Cross Emerging Infectious Diseases (EDI) Clinic, Pathumwan,, Bangkok, Thailand|The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT),, Pathumwan, Bangkok, Thailand|Baiyoke Suite Hotel, Ratchathewi, Bangkok, Thailand|Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University,, Hat Yai, Songkhla, Thailand|Khon Kaen Univerisity Field Hospital, Student Dormitory 26, Khon Kaen University, Khon Kaen, Thailand|Srinagarind Hospital, Khon Kaen, Thailand|Cukurova University Medical Faculty, Balcali, Adana, Turkey|Ankara University Medical Faculty, Ibni-Sina Hospital, Ankara, Turkey|Hacettepe University Medical Faculty Hospital, Ankara, Turkey|Akdeniz Universitesi Hastanesi, Antalya, Turkey|Gaziantep Universitesi Tip Fakultesi Sahinbey Uygulama ve Arastirma Hastanesi, Gaziantep, Turkey|Istanbul Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim Arastirma Hastanesi, Istanbul, Turkey|Istanbul University Istanbul Medical Faculty, Istanbul, Turkey|Istanbul University Cerrahpasa-Cerrahpasa Medical Faculty, Istanbul, Turkey|Medipol Mega University Hospital, Istanbul, Turkey|Acibadem University Atakent Hospital, Istanbul, Turkey|Basaksehir Cam ve Sakura Sehir Hastanesi, Istanbul, Turkey|Izmir Suat Seren Chest Disease and Surgery Training and Research Hospital, Izmir, Turkey|Kocaeli University Medical Faculty, Kocaeli, Turkey|Mersin University Medical Faculty, Mersin, Turkey|Sakarya University Training and Research Hospital, Sakarya, Turkey|Karadeniz Teknik Universitesi Farabi Hastanesi, Trabzon, Turkey",8.650709737,7.785638763,All,"18 Years and older ¬† (Adult, Older Adult)",602,579,553,432,65,56,12/20/2018,6/13/2019,4/10/2019,5/6/2019,4/19/2019,5/1/2019,5/8/2019,5/13/2019,5/26/2019,11/20/2020,2/1/2021,5/28/2021,10/18/2021,11/25/2021,1/13/2022,2/27/2022,4/5/2022,5/18/2022,7/12/2022,10/28/2019,4/25/2020,10/22/2020,4/20/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05011513,,,,,,
Pfizer,Pfizer,ST00182,SP00015,Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332,,,Hepatic Impairment,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Terrell p,Clarice N,Mary H,Doreen T,John G,Mary H,Geralyn K,Garnet T,John G,Donovan H,Chetan K,Mary H,James y,Mac L,Ross S,Jerold Goo †,Aleta H,Chetan K,Rima Y ,,,"Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States",89.23996751,80.31597076,All,21 Years to 60 Years ¬† (Adult),629,600,554,342,153,59,7/20/2018,1/10/2019,10/31/2018,12/3/2018,10/31/2018,11/15/2018,11/18/2018,11/19/2018,12/18/2018,3/18/2021,3/25/2021,7/3/2021,11/30/2021,1/12/2022,2/17/2022,4/18/2022,6/4/2022,7/14/2022,8/27/2022,5/14/2019,11/10/2019,5/8/2020,11/4/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05005312,,,,,,
Pfizer,Pfizer,ST00203,SP00015,Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer,,,Breast Cancer,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 1,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Jaquelyn H,Jeanene Y,James y,Gertrudis T,Patria R,Naren G,Kala R,Mara A,Louann C,Mary H,Otis Thode †,Louann C,Mara A,Lyman W,Kala R,Ngan D,Tien C,Mac L,Clarice N,,,"Pfizer Inc, New York, New York, United States",64.73118509,58.25806658,All,"18 Years and older ¬† (Adult, Older Adult)",607,587,555,349,167,39,4/17/2018,10/1/2018,7/19/2018,8/31/2018,8/11/2018,8/14/2018,8/22/2018,8/25/2018,9/9/2018,4/24/2021,2/18/2021,7/16/2021,9/30/2021,11/10/2021,1/8/2022,2/14/2022,4/1/2022,5/24/2022,7/22/2022,2/10/2019,8/9/2019,2/5/2020,8/3/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04987931,,,,,,
Pfizer,Pfizer,ST00211,SP00015,Korea Post Marketing Surveillance (PMS) Study of Talzenna¬Æ,,,Breast Neoplasms,,Oncology,,,,,,Industry,Not yet recruiting,Not Applicable,Observational,,Observational Model: Case-Only|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Selizabeth F,James y,Gertrudis T,Lavina S,Donovan H,Ngan D,Mary H,Anthony P,Christian G,Naren G,Dinah R,Mara A,Mary H,Mary H,Dinah R,Federico L,Tammara F,Naren G,Mee M,,,,5.423494686,4.881145217,All,9 Years to 15 Years ¬† (Child),612,598,556,274,242,40,5/17/2024,9/29/2024,7/27/2024,8/24/2024,8/16/2024,8/18/2024,8/21/2024,8/22/2024,9/6/2024,3/24/2026,10/3/2025,4/9/2026,6/30/2026,8/11/2026,9/30/2026,11/22/2026,12/24/2026,2/22/2027,4/6/2027,2/14/2025,8/13/2025,2/9/2026,8/8/2026,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04982848,,,,,,
Pfizer,Pfizer,ST00218,SP00015,Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients,,,ALK-positive Non-small-cell Lung Cancer,,Oncology,,,,,,Industry,Recruiting,Not Applicable,Observational,,Observational Model: Case-Only|Time Perspective: Retrospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Lavina S,Jaquelyn H,Frank T,Quentin N,Livia Pacheo †,Frank T,Geralyn K,Tiffiny K,Xochitl D,Mary H,Otis Thode †,Lucie P,Anthony P,Tiffiny K,Marcelina X,Jene M,John G,Hee Y,Patria R,,,"National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai-shi, Osaka-fu, Japan",68.07510545,61.26759491,All,"up to 75 Years ¬† (Child, Adult, Older Adult)",622,598,557,517,49,9,11/18/2018,4/12/2019,2/21/2019,3/13/2019,2/15/2019,3/4/2019,3/18/2019,3/21/2019,4/9/2019,11/20/2021,3/6/2021,8/7/2021,12/31/2021,2/18/2022,4/1/2022,5/6/2022,6/14/2022,8/6/2022,9/5/2022,8/31/2019,2/27/2020,8/25/2020,2/21/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04979988,,,,,,
Pfizer,Pfizer,ST00225,SP00015,"Study to Assess the Pharmacokinetics, Safety and Tolerability of Aztreonam-Avibactam in Healthy Chinese Participants.",,,Healthy,,,,,,,,Industry,Recruiting,Not Applicable,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Lavina S,Anthony P,Dalton E,Aleta H,Naren G,Harry A,Garnet T,Louann C,Doreen T,Suzie K,Aleta H,Stephan T,Suzie K,Perter K,Mac L,Naren G,Geralyn K,Tien C,Dinah R,,,"Huashan Hospital Fudan University, Shanghai, Shanghai, China",62.85230742,56.56707668,All,"18 Years to 99 Years ¬† (Adult, Older Adult)",597,577,558,190,336,32,7/8/2017,2/7/2018,11/15/2017,12/22/2017,11/29/2017,12/12/2017,12/25/2017,12/26/2017,1/12/2018,12/3/2020,12/16/2020,7/20/2021,9/27/2021,11/20/2021,12/30/2021,2/20/2022,4/16/2022,5/26/2022,7/24/2022,6/10/2018,12/7/2018,6/5/2019,12/2/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04973826,,,,,,
Pfizer,Pfizer,ST00233,SP00015,Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules,,,Hypertension|Heart Failure,,Cardiovascular,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Anthony P,Gertrudis T,Mary H,Geralyn K,Chetan K,Naren G,Jeanene Y,Ngan D,Gertrudis T,Xochitl D,Terisa Sikora †,Marceline R,Marceline R,Mara A,Lyman W,Jene M,Remedios Z,Frank T,Quentin N,,,"Clinical Trials of Texas, Inc. (CTT), San Antonio, Texas, United States",32.69738365,29.42764529,All,"18 Years and older ¬† (Adult, Older Adult)",580,569,559,379,139,41,1/10/2020,7/23/2020,5/6/2020,6/17/2020,5/7/2020,6/1/2020,6/13/2020,6/14/2020,7/6/2020,2/18/2021,5/30/2021,10/30/2021,12/17/2021,1/24/2022,3/25/2022,5/4/2022,6/26/2022,8/7/2022,9/9/2022,11/28/2020,5/27/2021,11/23/2021,5/22/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04967443,,,,,,
Pfizer,Pfizer,ST00246,SP00015,Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir,,,Healthy Participant,,,,,,,,Industry,"Active, not recruiting",,Interventional,,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Lilla Stilson †,Mary H,Perter K,Frank T,Mary H,Mary H,James y,James y,Stephan T,Dalton E,Livia Pacheo †,Suk T,James y,John G,Louann C,Tiffiny K,Liberty A,Federico L,Kala R,,,"Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",64.73582722,58.2622445,All,18 Years to 35 Years ¬† (Adult),636,612,560,264,250,46,6/1/2016,11/29/2016,10/2/2016,11/13/2016,10/15/2016,10/26/2016,10/30/2016,11/3/2016,11/23/2016,6/10/2021,1/2/2021,7/28/2021,9/30/2021,11/21/2021,1/13/2022,3/3/2022,5/1/2022,6/13/2022,7/16/2022,4/24/2017,10/21/2017,4/19/2018,10/16/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04962230,,,,,,
Pfizer,Pfizer,ST00247,SP00015,Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants,,,Healthy Participant,,,,,,,,Industry,Recruiting,,Interventional,,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Frank T,Suk T,Ross S,Jaquelyn H,Selizabeth F,Terisa Sikora †,Selizabeth F,Chetan K,Terisa Sikora †,Chetan K,Jaquelyn H,Hee Y,Perter K,Frank T,Mara A,Patria R,Lavina S,Stephan T,Suk T,,,"Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, R√©gion DE, Belgium",58.17681599,52.35913439,All,18 Years to 60 Years ¬† (Adult),593,576,561,552,101,92,6/12/2016,1/3/2017,11/15/2016,12/8/2016,11/20/2016,12/3/2016,12/18/2016,12/20/2016,1/12/2017,12/24/2020,12/22/2020,6/4/2021,10/1/2021,11/18/2021,12/27/2021,1/29/2022,3/13/2022,4/14/2022,6/7/2022,6/1/2017,11/28/2017,5/27/2018,11/23/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04962022,,,,,,
Pfizer,Pfizer,ST00252,SP00015,A Study of PF-07321332/Ritonavir in Nonhospitalized High Risk Adult Participants With COVID-19,,,COVID-19,,Virology,,,,,,Industry,Recruiting,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Remedios Z,Federico L,Kala R,Naren G,Beulah N,Liberty A,Lucie P,Mee M,Ross S,Federico L,Naren G,Anthony P,Mary H,Livia Pacheo †,Corrine U,James y,Selizabeth F,Marcelina X,Chetan K,,,"Cahaba Research Inc, Birmingham, Alabama, United States|Cahaba Research, Inc., Pelham, Alabama, United States|The Institute for Liver Health dba Arizona Clinical Trials, Mesa, Arizona, United States|The Institute for Liver Health dba Arizona Clinical Trials, Tucson, Arizona, United States|KLR Business Group, Inc. dba Arkansas Clinical Research, Little Rock, Arkansas, United States|Hope Clinical Research, Canoga Park, California, United States|Lightship, El Segundo, California, United States|Ascada Research, Fullerton, California, United States|Velocity Clinical Research, San Diego, La Mesa, California, United States|Atella Clinical Research LLC., La Palma, California, United States|Ark Clinical Research, Long Beach, California, United States|American Institute of Research, Los Angeles, California, United States|Providence Clinical Research, North Hollywood, California, United States|FOMAT Medical Research, Oxnard, California, United States|Benchmark Research, Sacramento, California, United States|Optimus Medical Group, San Francisco, California, United States|South Bay Clinical Research Institute, Torrance, California, United States|Hope Clinical Research (COVID Satellite Site), West Hills, California, United States|IMMUNOe Research Centers, Centennial, Colorado, United States|Future Innovative Treatments, LLC, Colorado Springs, Colorado, United States|BRB Health Group DBA Broward Research Center, Aventura, Florida, United States|Xera Med Research, Boca Raton, Florida, United States|Synergy Healthcare, Bradenton, Florida, United States|MOORE Clinical Research, Inc., Brandon, Florida, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Herco Medical and Research Center Inc, Coral Gables, Florida, United States|Advance Clinical Research Group, Cutler Bay, Florida, United States|Beautiful Minds Clinical Research Center, Cutler Bay, Florida, United States|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States|Doral Medical Research,LLC, Doral, Florida, United States|Unlimited Medical Research Group, LLC, Hialeah Gardens, Florida, United States|Qway Research, LLC, Hialeah, Florida, United States|Eastern Research Inc, Hialeah, Florida, United States|Inpatient Research Clinic, Hialeah, Florida, United States|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States|Pro-Care Research Center, Corp., Miami Gardens, Florida, United States|Savin Medical Group, LLC, Miami Lakes, Florida, United States|Nova Life Med Spa, Miami, Florida, United States|LCC Medical Research Institute, LLC, Miami, Florida, United States|Premium Medical Research Corp, Miami, Florida, United States|Global Health Clinical Trials, Miami, Florida, United States|South Florida Research Center, Inc., Miami, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|Medimpact Clinical & Investigational Center, Miami, Florida, United States|Entrust Clinical Research, Miami, Florida, United States|Medical Research of Westchester Inc, Miami, Florida, United States|C'A Research, Miami, Florida, United States|ProLive Medical Research, Corp., Miami, Florida, United States|Reed Medical Research, Miami, Florida, United States|Kendall South Medical Center, Miami, Florida, United States|Clinical Site Partners, Inc d/b/a CSP Miami, Miami, Florida, United States|Coral Research Clinic Corp, Miami, Florida, United States|Omega Research Orlando, LLC, Orlando, Florida, United States|NAPA Research LLC, Pompano Beach, Florida, United States|CDC Research Institute, Port Saint Lucie, Florida, United States|GCP, Global Clinical Professionals, Saint Petersburg, Florida, United States|Accel Research Sites - St. Petersburg Clinical Research Unit, Saint Petersburg, Florida, United States|Professional Urgent Care Services, Saint Petersburg, Florida, United States|USPA Advance Concept Medical Research Group LLC, South Miami, Florida, United States|Sunrise Research Institute, Sunrise, Florida, United States|CBS Laboratory of Tampa, LLC, Tampa, Florida, United States|Santos Research Center, CORP, Tampa, Florida, United States|Clinical Site Partners, Inc. dba CSP Orlando, Winter Park, Florida, United States|Research by Design, LLC, Chicago, Illinois, United States|The South Bend Clinic Day Road Immediate Care Center, Mishawaka, Indiana, United States|The South Bend Clinic Center for Research, South Bend, Indiana, United States|New Orleans Sinus Center (COVID-19 Testing), Marrero, Louisiana, United States|Tandem Clinical Research GI, LLC, Marrero, Louisiana, United States|MedPharmics LLC, Metairie, Louisiana, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Jackson Medical Mall, Jackson, Mississippi, United States|Lakeland Pharmacy, Branson W., Missouri, United States|CVS, Springfield, Missouri, United States|Mercury Street Medical Group, PLLC, Butte, Montana, United States|Meridian Clinical Research, LLC, Grand Island, Nebraska, United States|Quality Clinical Research, Omaha, Nebraska, United States|Walmart, Las Vegas, Nevada, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Walgreens, Las Vegas, Nevada, United States|Certified Research Associates, Cortland, New York, United States|Meridian Clinical Research, LLC, Endwell, New York, United States|NYC Health + Hospitals/Harlem, New York, New York, United States|NYC Health Hospitals/Harlem, New York, New York, United States|Monroe Biomedical Research, Monroe, North Carolina, United States|Accellacare, Wilmington, North Carolina, United States|Innovo Research: Wilmington Health, Wilmington, North Carolina, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Premier Medical Group, Clarksville, Tennessee, United States|PharmaTex Research, LLC, Amarillo, Texas, United States|ARC Clinical Research at William Cannon, Austin, Texas, United States|St Hope Foundation, Bellaire, Texas, United States|Conroe Willis Medical Research, Conroe, Texas, United States|South Texas Clinical Research, Corpus Christi, Texas, United States|Urgent Care Clinical Trials at City Doc McKinney, Dallas, Texas, United States|SignatureCare Emergency Center, Houston, Texas, United States|Trio Clinical Trials, LLC, Houston, Texas, United States|C & R Research Services USA, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|SMS Clinical Research, LLC, Mesquite, Texas, United States|SMS Clinical Research, Mesquite, Texas, United States|LinQ Research, LLC, Pearland, Texas, United States|Epic Medical Research, Red Oak, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|BFHC Research, San Antonio, Texas, United States|Tranquility Research, Webster, Texas, United States|Huntsman Cancer Hospital at the University of Utah, Salt Lake City, Utah, United States|University of Utah Medical Center, Salt Lake City, Utah, United States|TPMG (Tidewater Physicians Multispecialty Group) Clinical Research, Newport News, Virginia, United States|TPMG Research, Newport News, Virginia, United States|Centro Medico Viamonte SRL, Caba, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Zarate, Zarate, Buenos Aires, Argentina|Instituto M√©dico de la Fundaci√≥n Estudios Cl√≠nicos (Fundaci√≥n Estudios Cl√≠nicos), Rosario, Santa FE, Argentina|Clinica Mayo Urgencias Medicas Cruz Blanca SRL, San Miguel de Tucuman, Tucuman, Argentina|Funda√ß√£o de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil|Infection Control Ltda, Belo Horizonte, Minas Gerais, Brazil|School of Medicine Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Hospital Agamenon Magalhaes, Recife, Pernambuco, Brazil|Centro de Estudos e Pesquisas em Mol√©stias Infecciosas, Natal, RIO Grande DO Norte, Brazil|Hospital De Clinicas De Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|IBPClin - Instituto Brasil de Pesquisa Cl√≠nica, Rio de Janeiro, RJ, Brazil|Instituto Nacional de Infectologia Evandro Chagas - INI/FIOCRUZ, Rio de Janeiro, RJ, Brazil|Scentryphar - Pesquisa Cl√≠nica, Campinas, SAO Paulo, Brazil|Centro de Estudos Clinicos do Interior Paulista (CECIP), Jau, SAO Paulo, Brazil|Hospital e Maternidade Celso Pierro - PUC Campinas / Sociedade Campineira de Educa√ß√£o e Instru√ß√£, Campinas, SP, Brazil|Associa√ß√£o Evang√©lica de Campinas - Hospital Samaritano, Campinas, S√ÉO Paulo, Brazil|Instituto de Pesquisa Cl√≠nica de Campinas, Campinas, S√ÉO Paulo, Brazil|Centro de Refer√™ncia e Treinamento DST/AIDS, Sao Paulo, S√ÉO Paulo, Brazil|Clinica de Alergia Martti Antila, Sorocaba, S√ÉO Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Cl√≠nicos, S√£o Bernardo do Campo, S√ÉO Paulo, Brazil|Instituto de Infectologia Emilio Ribas, S√£o Paulo, Brazil|Conjunto Hospitalar do Mandaqui, S√£o Paulo, Brazil|""Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases-Haskovo"" Ltd, Haskovo, Bulgaria|MHAT ""Sv.Ivan. Rilski'' Kozloduy EOOD, Kozloduy, Bulgaria|Diagnostic-Consultative Center I Lom EOOD, Lom, Bulgaria|Multiprofile Hospital for Active Treatment- Sveti Nikolay Chudotvoretz EOOD, Lom, Bulgaria|Medical centre Leo Clinic EOOD, Lovech, Bulgaria|MHAT Heart and Brain EAD, Pleven, Bulgaria|Multi-Profile Hospital for Active treatment ''Plovdiv''AD, Plovdiv, Bulgaria|Multiprofile Hospital for Active Treatment Sveti Ivan Rilski - Razgrad AD, Razgrad, Bulgaria|""Specialized Hospital for Active Treatment of Pneumo-Physiatric Diseases Dr. Dimitar Gramatikov -, Ruse, Bulgaria|UMHAT Medica Ruse OOD, Ruse, Bulgaria|Multiprofile Hospital for Active Treatment - Samokov EOOD, Samokov, Bulgaria|Medical Center-1-Sevlievo EOOD, Sevlievo, Bulgaria|Multiprofile Hospital For Active Treatment Shumen AD, Shumen, Bulgaria|MHAT ""Dr. Ivan Seliminski"" AD, Sliven, Sliven, Bulgaria|Diagnostic-Consultative Center XXII- Sofia –ï–û–ûD, Sofia, Bulgaria|Diagnostic Consultative Center 18 - Sofia EOOD, Sofia, Bulgaria|MHAT ""St. Sofia"" EOOD, Sofia, Bulgaria|Specialized hospital for active treatment in pulmonology and phthisiology ""Stara Zagora"" EOOD, Stara Zagora, Bulgaria|Multiprofile Hospital for Active Treatment Targovishte AD, Targovishte, Bulgaria|Medical center Leo Clinic EOOD, Varna, Bulgaria|Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases Vratsa EOOD, Vratsa, Bulgaria|Hospital Universidad Del Norte, Soledad, Atlantico, Colombia|IPS Medicos Internistas de Caldas, Manizales, Caldas, Colombia|Caimed S.A.S., Yopal, Casanare, Colombia|Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S, CIREEM S.A.S, Bogota, Cundinamarca, Colombia|Trial Pharma Kft., Bekescsaba, Hungary|Semmelweis University Varosmajori Sziv Es Ergyogyaszati Klinika, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont Infektologiai Klinika, Debrecen, Hungary|Agria-Study Kft., Eger, Hungary|Trial Pharma Kft., Gyula, Hungary|Medifarma-98 Kft., Nyiregyhaza, Hungary|AIIMS Raipur, Raipur, Chhattisgarh, India|Unity Hospital, Surat, Gujarat, India|Jupiter Hospital, Vadodara, Gujarat, India|Rhythm Heart Institute, Vadodara, Gujarat, India|BGS Global Institute of Medical Sciences and Hospital, Bangalore, Karnataka, India|Lisie Hospital, Kochi, Kerala, India|St Georges Hospital, Mumbai, Maharashtra, India|Shree Hospital & Critical Care Centre, Nagpur, Maharashtra, India|All India Institute of Medical Sciences Nagpur, Nagpur, Maharashtra, India|Department of Pulmonary Medicine, Navi Mumbai, Maharashtra, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Jehangir Clinical Development Centre Pvt. Ltd, Pune, Maharashtra, India|Sahyadri Clinical Research and Development Center, Pune, Maharashtra, India|Lifepoint Multispeciality Hospital, Pune, Maharashtra, India|Jawahar Lal Nehru Medical College, Ajmer, Rajasthan, India|Apex Hospitals Pvt Ltd, Jaipur, Rajasthan, India|Maharaja Agrasen Superspeciality Hospital, Jaipur, Rajasthan, India|Apollo Hospitals, Chennai, Tamil NADU, India|Sri Ramachandra Hospital, Chennai, Tamil NADU, India|Nil Ratan Sircar Medical College and Hospital, Kolkata, WEST Bengal, India|Aakash Healthcare Private Limited, New Delhi, India|Sardar Patel Medical College, Pavan PURI Bikaner, Rajasthan, India|Fujita Health University Hospital, Toyoake-City, Aichi, Japan|Chiba Aoba Municipal Hospital, Chuo-ku, Chiba, Japan|International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan|National Hokkaido Medical Center, Sapporo, Hokkaido, Japan|Rakuwakai Otowa Hospital, Kyoto-shi, Kyoto, Japan|Rinku General Medical Center, Izumisano, Osaka, Japan|Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan|National Center for Global Health and Medicine, Shinjuku City, Tokyo, Japan|Sekino Hospital, Toshimaku, Tokyo, Japan|Kyushu Medical Center, Fukuoka, Japan|Chonnam National University Hospital, Gwangju-si, Kwangju-kwangy?kshi, Korea, Republic of|Pusan National University Hospital, Busan, Pusan-kwangy?kshi, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Incheon Medical Center, Incheon, Korea, Republic of|Chonnam National University Bitgoeul Hospital, Nam-gu, Korea, Republic of|Boramae Medical Center Department of Internal Medicine, Seoul, Korea, Republic of|Hospital Taiping, Taiping, Perak, Malaysia|Hospital Seberang Jaya, Perai, Pulau Pinang, Malaysia|Hospital Umum Sarawak, Kuching, Sarawak, Malaysia|Hospital Miri, Miri, Sarawak, Malaysia|Clinical Research Institute Saltillo S.A. de C.V., Saltillo, Coahuila, Mexico|Asociacion Mexicana para la Investigacion Clinica A.C. (AMIC), Pachuca de Soto, Hidalgo, Mexico|Instituto Jalisciense de Metabolismo, S.C., Guadalajara, Jalisco, Mexico|JM Research, Cuernavaca, Morelos, Mexico|Christus - Latam Hub Center of Excellence and Innovation Center S.C., Monterrey, Nuevo LEON, Mexico|Eukarya Pharmasite S.C., Monterrey, Nuevo LEON, Mexico|Oaxaca Site Management Organization, Oaxaca de Juarez, Oaxaca, Mexico|InfectoLab Consultorios de Especialidad en Infectologia, Baja California, Tijuana, Mexico|Kohler & Milstein Research S.A. de C.V., Merida, Yucatan, Mexico|Eme Red Hospitalaria, M√©rida, Yucat√°n, Mexico|Centro de Investigacion Clinica Del Pacifico SA de CV, Acapulco, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Instituto de Investigaciones Cl√≠nicas para la Salud, Durango, Mexico|FAICIC Clinical Research, Veracruz, Mexico|Arke SMO S.A. de C.V, Veracruz, Mexico|Sociedad de Metabolismo y Corazon S.C., Veracruz, Mexico|WIP Warsaw IBD Point Profesor Kierkus, Warsaw, Mazowieckie, Poland|KLIMED Marek Klimkiewicz, Bialystok, Poland|Krakowskie Centrum Medyczne, Krakow, Poland|Przychodnia Valeo Medical, Lodz, Poland|IRMED O≈õrodek Bada≈Ñ Klinicznych, Piotrkow Trybunalski, Poland|Tomasz Blicharski Lubelskie Centrum Diagnostyczne, Swidnik, Poland|Centrum Bada≈Ñ Klinicznych Piotr Napora Lekarze Sp√≥≈Çka Partnerska, Wroclaw, Poland|Ponce Medical School Foundation, Inc. CAIMED Center, Ponce, Puerto Rico|Clinical Research Management Group Inc, Ponce, Puerto Rico|Advance Medical Research Center, San Juan, Puerto Rico|Eba Centelles, Centelles, Barcelona [barcelona], Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|CAP Vicen√ß Papaceit, La Roca del Valles, Barcelona, Spain|Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain|IMED Valencia, Burjassot, Valencia, Spain|Complexo Hospitalario Universitario da Coruna, A Coruna, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario de la Paz, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen de Valme, Sevilla, Spain|Far Eastern Memorial Hospital, New Taipei City, Taiwan|China Medical University Hospital, Taichung City, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Bangkok Centre Hotel, Bangrak, Bangkok, Thailand|Chula Filed hospital, Chulalongkorn University Sport center (Chantanayingyong Gymnasium),, Pathum Wan District,, Bangkok, Thailand|Thai Red Cross Emerging Infectious Diseases (EDI) Clinic, Pathumwan,, Bangkok, Thailand|The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT),, Pathumwan, Bangkok, Thailand|Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University,, Hat Yai, Songkhla, Thailand|Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand|Cukurova University Medical Faculty, Balcali, Adana, Turkey|Ankara University Medical Faculty, Ibni-Sina Hospital, Ankara, Turkey|Hacettepe University Medical Faculty Hospital, Ankara, Turkey|Akdeniz Universitesi Hastanesi, Antalya, Turkey|Istanbul University Istanbul Medical Faculty, Fatih / Istanbul, Turkey|Gaziantep Universitesi Tip Fakultesi Sahinbey Uygulama ve Arastirma Hastanesi, Gaziantep, Turkey|Istanbul Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim Arastirma Hastanesi, Istanbul, Turkey|Istanbul University Cerrahpasa-Cerrahpasa Medical Faculty, Istanbul, Turkey|Medipol Mega University Hospital, Istanbul, Turkey|Acibadem University Atakent Hospital, Istanbul, Turkey|Basaksehir Cam ve Sakura Sehir Hastanesi, Istanbul, Turkey|Izmir Suat Seren Chest Disease and Surgery Training and Research Hospital, Izmir, Turkey|Kocaeli University Medical Faculty, Kocaeli, Turkey|Mersin University Medical Faculty, Mersin, Turkey|Sakarya University Training and Research Hospital, Sakarya, Turkey|Karadeniz Teknik Universitesi Farabi Hastanesi, Trabzon, Turkey|Communal non-profit enterprise ""City Clinical Hospital #16"" of Dnipro City Council, Dnipro, Ukraine|Municipal Nonprofit Enterprise ""Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital of, Ivano-Frankivsk, Ukraine|Communal nonprofit enterprise ""Central City Clinical Hospital of Ivano-Frankivsk City Council"", Ivano-Frankivsk, Ukraine|Municipal Nonprofit Enterprise ""City Student Hospital"" of Kharkiv City Council, Kharkiv, Ukraine|Municipal Nonprofit Enterprise of Kharkiv Regional Council ""Regional Clinical Infectious Diseases, Kharkiv, Ukraine|Municipal Non-profit Enterprise ""Oleksandrivska Kyiv City Clinical Hospital"" Of Executive Body Of, Kyiv, Ukraine|Municipal non-commercial enterprise ""Kyiv City Clinical Hospital #1"" Of Executive Body Of the Kyiv, Kyiv, Ukraine|Kyiv Railway Clinical Hospital No.2 of Branch ""Health Center of the Public Joint Stock Company, Kyiv, Ukraine|Polyclinic of Center for Medical Services and Rehabilitation of State Joint-Stock Holding Company, Kyiv, Ukraine|Municipal Nonprofit Enterprise ""Lviv City Clinic Hospital #4"", Lviv, Ukraine|Municipal Enterprise ""Poltava Regional Clinical Infectious Diseases Hospital"" of Poltava Regional, Poltava, Ukraine|Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Tarasove Village, Ukraine|Municipal Non-commercial Enterprise ""Vinnytsia City Clinical Hospital ‚Ññ1"", Vinnytsia, Ukraine|Communal Enterprise ""Hospital #1"" of Zhytomyr City Council, Zhytomyr, Ukraine",10.68329081,9.614961727,All,"Child, Adult, Older Adult",617,604,562,293,229,40,10/23/2016,3/18/2017,1/6/2017,2/4/2017,1/6/2017,1/26/2017,1/30/2017,1/31/2017,2/18/2017,3/28/2021,3/31/2021,6/29/2021,11/26/2021,1/5/2022,2/18/2022,4/5/2022,6/1/2022,7/28/2022,9/3/2022,7/25/2017,1/21/2018,7/20/2018,1/16/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04960202,,,,,,
Pfizer,Pfizer,ST00284,SP00015,Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,"Active, not recruiting",,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Aleta H,Otis Thode †,Ross S,Marceline R,Ngan D,Dinah R,Tien C,Tamesha T,Jene M,Chetan K,John G,Mary H,Frank T,Mee M,Mee M,Donovan H,Doreen T,Donovan H,Jerold Goo †,,,"Pfizer Inc, New York, New York, United States",26.14647651,23.53182886,All,"19 Years to 120 Years ¬† (Adult, Older Adult)",606,599,563,207,320,36,1/11/2020,6/26/2020,4/18/2020,5/20/2020,4/22/2020,5/2/2020,5/4/2020,5/6/2020,5/23/2020,7/11/2021,1/7/2021,8/19/2021,9/30/2021,11/19/2021,12/30/2021,2/22/2022,4/3/2022,5/30/2022,7/18/2022,10/29/2020,4/27/2021,10/24/2021,4/22/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04987931,,,,,,
Pfizer,Pfizer,ST00287,SP00015,"Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer",,,,,Oncology,,,,,,Industry,Completed,Phase 4,Interventional,,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Lucie P,John G,Ngan D,Chetan K,Naren G,Clarice N,Ngan D,Remedios Z,Mary H,John G,Chetan K,In Bellini †,Jerold Goo †,Aleta H,Rima Y ,Lilla Stilson †,Tien C,Mac L,Otis Thode †,,,"Benjamin Carl Forster, North Sydney, New South Wales, Australia|Dr. Alexander Maxwell Menzies, North Sydney, New South Wales, Australia|HPS Pharmacies - North Sydney, North Sydney, New South Wales, Australia|Mater Hospital Sydney, North Sydney, New South Wales, Australia|Professor Frances Mary Boyle, North Sydney, New South Wales, Australia|Royal North Shore Hospital - Clinical Trials Pharmacy, St Leonards, New South Wales, Australia|Royal North Shore Hospital, Dept. of Medical Oncology, St Leonards, New South Wales, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, Australia|River City Pharmacy, Auchenflower, Queensland, Australia|Icon Cancer Care Chermside, Chermside, Queensland, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Icon Cancer Care, Corporate Office, South Brisbane, Queensland, Australia|Icon Cancer Care Southport, Southport, Queensland, Australia|Flinders Medical Centre-Pharmacy Department, Bedford Park, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Monash Health, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre Pharmacy, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Sunshine Hospital Pharmacy, St. Albans, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Pharmacy Department, Murdoch, Western Australia, Australia|Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India|Dr. B.R.A Institute Rotary Cancer Hospital, All India Institue of Medical Sciences, New Delhi, Delhi, India|The Gujarat Cancer & Research Institute, M.P Shah Cancer Hospital, Ahmedabad, Gujarat, India|Manipal Hospital, Bangalore, Karnataka, India|HealthCare Global Enterprises Ltd., Bangalore, Karnataka, India|Kasturba Hospital, Manipal, Karnataka, India|Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, India|Meditrina Institute Of Medical Sciences, Nagpur, Maharashtra, India|Shatabdi Hospital, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Apollo Speciality Hospital, Chennai, Tamilnadu, India",13.42706667,12.08436001,Female,"16 Years and older ¬† (Child, Adult, Older Adult)",585,574,564,534,65,35,3/20/2017,9/4/2017,7/19/2017,8/4/2017,7/18/2017,7/25/2017,8/2/2017,8/7/2017,8/29/2017,3/8/2019,11/26/2018,6/23/2019,7/25/2019,9/2/2019,10/20/2019,11/19/2019,12/27/2019,2/11/2020,3/23/2020,1/21/2018,7/20/2018,1/16/2019,7/15/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02679755,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02679755/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02679755/SAP_001.pdf"
Pfizer,Pfizer,ST00291,SP00015,Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Selizabeth F,Mara A,Mary H,Suzie K,Stephan T,Anthony P,Stephan T,Mee M,Mary H,Mee M,Anthony P,Tiffiny K,Marceline R,Mara A,Jaquelyn H,Beulah N,John G,Mary H,Hee Y,,,"Banner Gateway Medical Center, Gilbert, Arizona, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Highlands Oncology Group, Rogers, Arkansas, United States|PMK Medical Group Inc., dba Ventura County Hematology Oncology Specialists, Camarillo, California, United States|City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States|City of Hope Investigational Drug Services (IDS), Duarte, California, United States|The Oncology Institute of Hope & Innovation, Glendale, California, United States|Glendale Adventist Medical Center, Glendale, California, United States|The Oncology Institute of Hope & Innovation, Long Beach, California, United States|UC Irvine Health, Orange, California, United States|UC Irvine Medical Center, Orange, California, United States|PMK Medical Group Inc., dba Ventura County Hematology Oncology Specialists, Oxnard, California, United States|Emad Ibrahim, MD, INC., Redlands, California, United States|The Oncology Institute of Hope & Innovation, Santa Ana, California, United States|Stanford Cancer Institute, Stanford, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Stanford Women's Cancer Center, Stanford, California, United States|PMK Medical Group Inc., dba Ventura County Hematology Oncology Specialists, Ventura, California, United States|The Oncology Institute of Hope & Innovation, West Covina, California, United States|The Oncology Institute of Hope & Innovation, Whittier, California, United States|ICRI, Whittier, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Englewood, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers, Longmont, Colorado, United States|Rocky Mountain Cancer Centers, Parker, Colorado, United States|Rocky Mountain Cancer Centers, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers, Thornton, Colorado, United States|Innovative Medical Research of South Florida, Inc, Aventura, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Professional Office Building Infusion Pharmacy, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Rush Oak Park Hospital, Oak Park, Illinois, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Summit Medical Group, Berkeley Heights, New Jersey, United States|Summit Medical Group PA, Florham Park, New Jersey, United States|St. Luke's Hospital - Warren Campus, Phillipsburg, New Jersey, United States|St. Luke's Warren Physician Group, Phillipsburg, New Jersey, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Tigard, Oregon, United States|St. Luke's Hematology Oncology Specialists, Allentown, Pennsylvania, United States|St. Luke's Hospital - Allentown Campus, Allentown, Pennsylvania, United States|St. Luke's Hematology Oncology Specialists, Bethlehem, Pennsylvania, United States|St. Luke's Hospital - Bethlehem Campus, Bethlehem, Pennsylvania, United States|St. Luke's Hospital - Miners Campus, Coaldale, Pennsylvania, United States|St Luke's Hospital - Anderson Campus, Easton, Pennsylvania, United States|St. Luke's Hospital - Anderson Campus, Easton, Pennsylvania, United States|UPMC Hillman Cancer Center Mountainview Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|UPMC Cancer Centers East Oxford Drive, Monroeville, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center North Hills at Passavant, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center UPMC Passavant, Pittsburgh, Pennsylvania, United States|St. Luke's Hospital - Quakertown Campus, Quakertown, Pennsylvania, United States|St. Luke's Hospital - Monroe Campus, Stroudsburg, Pennsylvania, United States|UPMC Hillman Cancer Center Uniontown, Uniontown, Pennsylvania, United States|UPMC Hillman Cancer Center Washington, Washington, Pennsylvania, United States|Charleston Hematology Oncology Associates, PA, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Avera Specialty Hospital, Sioux Falls, South Dakota, United States|Brig Center for Cancer Care and Survivorship, Knoxville, Tennessee, United States|Baptist Cancer Center, Memphis, Tennessee, United States|Texas Oncology - Allen, Allen, Texas, United States|Texas Oncology - Austin Midtown, Austin, Texas, United States|Texas Oncology-Austin Central, Austin, Texas, United States|Texas Oncology - South Austin, Austin, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology-Denton South, Denton, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|U.T. MD Anderson Cancer Center, Investigational Pharmacy Services - Unit 376, Houston, Texas, United States|U.T. MD Anderson Cancer Center, Houston, Texas, United States|US Oncology Investigational Products Center (IPC), Irving, Texas, United States|Texas Oncology - McKinney, McKinney, Texas, United States|Texas Oncology - Round Rock, Round Rock, Texas, United States|Virginia Oncology Associates, Chesapeake, Virginia, United States|Virginia Oncology Associates, Hampton, Virginia, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Oncology Associates, Virginia Beach, Virginia, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States|UW Health University Hospital - Pharmaceutical Research Center, Madison, Wisconsin, United States",41.65424463,37.48882017,All,"18 Years and older ¬† (Adult, Older Adult)",604,581,565,209,333,23,11/11/2018,5/30/2019,4/17/2019,5/14/2019,3/30/2019,4/24/2019,5/2/2019,5/7/2019,5/31/2019,6/19/2020,1/25/2020,6/11/2020,9/23/2020,10/24/2020,12/16/2020,1/27/2021,2/27/2021,4/14/2021,5/27/2021,10/21/2019,4/18/2020,10/15/2020,4/13/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03499353,,,,,,
Pfizer,Pfizer,ST00304,SP00015,Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: N/A|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Dinah R,Lavina S,James y,Mee M,Louann C,Livia Pacheo †,Suzie K,Naren G,Gertrudis T,Terisa Sikora †,Suk T,In Bellini †,Frank T,Gertrudis T,Anthony P,Quentin N,Jene M,Mary H,Mary H,,,"Instituto de Oncologia de Rosario, Rosario, Santa FE, Argentina|Sanatorio Guemes, Caba, Argentina|Hospital Italiano de Buenos Aires, Caba, Argentina|Hospital Britanico de Buenos Aires, Caba, Argentina|Instituto Medico Especializado Alexander Fleming, Caba, Argentina|Instituto de Cardiologia y Cirugia Cardiovascular, Santa Fe, Argentina|ISIS Centro Especializado, Santa Fe, Argentina|Hospital Da Cidade De Passo Fundo, Passo Fundo, RIO Grande DO SUL, Brazil|Hospital Sao Lucas da PUCRS / Uniao Brasileira de Educacao e Assistencia, Porto Alegre, RIO Grande DO SUL, Brazil|Oncologia Rede D'Or S.A., Rio de Janeiro, Brazil|IDOR - Instituto D'Or em Pesquisa e Ensino, Rio de Janeiro, Brazil|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, Sao Paulo, Brazil|Cl√≠nica de Pesquisa e Centro de Estudos em Oncologia Ginecol√≥gica e Mam√°ria Ltda, S√£o Paulo, Brazil|Instituto de Cancerologia S.A., Medellin, Antioquia, Colombia|Oncomedica S.A., Monteria, Cordoba, Colombia|Administradora Country, Bogota, Distrito Capital, Colombia|Oncology Center, Bogota, Distrito Capital, Colombia|Imagenes Diagnosticas, Pereira, Risaralda, Colombia|ONCOLOGOS DEL OCCIDENTE S.A.S Sede Pereira Clinica de Alta Tecnologia Maraya, Pereira, Risaralda, Colombia|Fucam A.C., Coyoacan, D.f., Mexico|Instituto Nacional de Cancerologia, Tlalpan, D.f., Mexico|Hospital Maria Auxiliadora, Guadalajara, Jalisco, Mexico|Clinica de Especialidades Medicas Intepro, ONCE Oncologia Especializada, Zapopan, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico",18.44929792,16.60436812,Female,"18 Years and older ¬† (Adult, Older Adult)",597,573,566,286,232,48,7/31/2014,1/31/2015,12/8/2014,1/7/2015,12/19/2014,12/27/2014,1/4/2015,1/8/2015,1/17/2015,9/30/2018,10/1/2018,2/17/2019,5/28/2019,6/28/2019,8/27/2019,10/5/2019,11/22/2019,1/5/2020,2/22/2020,6/25/2015,12/22/2015,6/19/2016,12/16/2016,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02600923,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02600923/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02600923/SAP_001.pdf"
Pfizer,Pfizer,ST00306,SP00015,"Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer",,,,,Oncology,,,,,,Industry,Withdrawn,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Livia Pacheo †,James y,Selizabeth F,Mary H,Perter K,Selizabeth F,Jeanene Y,Lilla Stilson †,Frank T,Doreen T,Jeanene Y,Doreen T,Marcelina X,Aleta H,Louann C,Louann C,Anthony P,Ngan D,Tien C,,,,49.00479948,44.10431953,Female,"18 Years and older ¬† (Adult, Older Adult)",618,603,567,405,85,77,9/30/2007,4/22/2008,3/5/2008,4/5/2008,3/10/2008,3/21/2008,4/3/2008,4/5/2008,4/14/2008,2/17/2011,12/24/2010,4/24/2011,9/1/2011,10/18/2011,11/30/2011,1/21/2012,3/6/2012,4/10/2012,6/1/2012,9/17/2008,3/16/2009,9/12/2009,3/11/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00678626,,,,,,
Pfizer,Pfizer,ST00309,SP00015,Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Anthony P,Federico L,Kandace p,Garnet T,Lavina S,Terisa Sikora †,Rima Y ,Lyman W,Stephan T,Ngan D,Chetan K,Hee Y,In Bellini †,Stephan T,Jeanene Y,Christian G,Patria R,In Bellini †,Marcelina X,,,"Central Hematology Oncology Medical group Inc., Alhambra, California, United States|UCLA Hematology/Oncology - Alhambra, Alhambra, California, United States|CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|UCLA West Medical Pharmacy (Drug Management Only), Los Angeles, California, United States|UCLA West Medical Pharmacy, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCLA West Medical Pharmacy, Los Angeles, California, United States|Drug Management Only: UCLA West Medical Pharmacy, Los Angeles, California, United States|Drug Management Only, Los Angeles, California, United States|Regulatory Managment, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|TORI -US Central Administration (Regulatory Management), Los Angeles, California, United States|TORI -US Central Administration, Los Angeles, California, United States|TORI Central Administration (Regulatory Management), Los Angeles, California, United States|TORI Central Administration (Regulatory Managment Only), Los Angeles, California, United States|TRIO-US Central Administration, Los Angeles, California, United States|UCLA Hematology/Oncology, Los Angeles, California, United States|UCLA, Hematology/Oncology, Los Angeles, California, United States|Westwood Bowyer Clinic, Peter Morton Medical Building, Los Angeles, California, United States|Central Hematology Oncology Medical Group, Inc, Pasadena, California, United States|Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates, Redondo Beach, California, United States|Sansum Santa Barbara Medical Foundation Clinic, Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Santa Monica-UCLA Medical Center and Orthopaedic Hospital, Santa Monica, California, United States|UCLA Hematology Oncology-Santa Monica, Santa Monica, California, United States|UCLA Hematology/Oncology - Santa Clarita, Valencia, California, United States|Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care, Duluth, Georgia, United States|Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care, Lawrenceville, Georgia, United States|Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care, Snellville, Georgia, United States|Illinois Cancer Specialists, Chicago, Illinois, United States|Resurrection Medical Group, Chicago, Illinois, United States|North Shore Oncology-Hematology Associates, Crystal Lake, Illinois, United States|North Shore Hematology Oncology, Highland Park, Illinois, United States|North Shore Oncology-Hematology Associates, Libertyville, Illinois, United States|North Shore Hematology Oncology, Skokie, Illinois, United States|Regulatory Office: Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Texas Oncology-Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Investigational Products Center (IPC), Fort Worth, Texas, United States|US Oncology Research and Clinical Pharmacy, Fort Worth, Texas, United States|Virginia Cancer Specialists, PC, Arlington, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Cancer Specialists, PC, Gainesville, Virginia, United States|Virginia Cancer Specialists, PC, Leesburg, Virginia, United States|Virginia Cancer Specialists, PC, Woodbridge, Virginia, United States|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|CSSS Champlain-Charles-Le Moyne Local HS-0054, Greenfield Park, Quebec, Canada|Centre Paul Papin, CRLCC, ANGERS Cedex 9, France|CHD Vendee, La Roche Sur Yon, France|Gemeinschaftspraxis, Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, Germany|Gemeinschaftspraxis Haematologie-Onkologie, Dresden, Germany|Martin-Luther-Universitaet Halle-Wittenberg, Halle/Saale, Germany|Universitaetsklinik und Poliklinik fuer Gynaekologie, Martin-Luther-Universitaet Halle-Wittenberg, Halle/Saale, Germany|Nationales Centrum fuer Tumorerkrankungen, Heidelberg, Germany|Frauenaerzte Pruener Gang Abts & Partner, Kiel, Germany|Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe Universitaetsklinik Mainz, Mainz, Germany|Onkolog. Gemeinschaftspraxis, Muenchen, Germany|Frauenklinik vom Roten Kreuz, Muenchen, Germany|Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universitaet Muenchen, Muenchen, Germany|Mutterhaus der Borromaeerinnen, Innere Medizin I, Trier, Germany|Szent Margit Korhaz, Onkologia, Budapest, Hungary|Orszagos Onkologiai Intezet, Kemoterapia B, Budapest, Hungary|Fovarosi Onkormanyzat Uzsoki Utcai Korhaz, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz, Onkoradiologia, Gyor, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz √©s Egyetemi Oktato Korhaz, Onkologia, Miskolc, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak es, Nyiregyhaza, Hungary|Markusovszky Egyetemi Oktatokorhaz, Onkoradiologiai Osztaly, Szombathely, Hungary|Bon Secours Hospital, Cork, Ireland|St. James's Hospital, Dublin 8, Ireland|St. Vincent's University Hospital, Dublin, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|Divisione Oncologia Medica Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, Meldola, FC, Italy|M.O. di Oncologia - Azienda USL di Rimini - Ospedale ""Cervesi"", Cattolica, Italy|Ospedale Civile di Faenza Centro Oncologico, Faenza, RA, Italy|Unita' Operativa di Oncologia, Ospedale Civile di Lugo, Lugo, RA, Italy|Ospedale Civile di Ravenna, Ravenna, Italy|Azienda Unita Sanitaria Locale di Rimini, U.O. di Oncologia ed Oncoematologia Ospedale degli Infermi, Rimini, Italy|Ospedale Villa San Pietro, Roma, Italy|National Cancer Center, Center for Breast Cancer, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Federal State Budgetary Scientific Institution, Moscow, Russian Federation|Pyatigorsk Oncology Center, Pyatigorsk, Russian Federation|State Budgetary Healthcare Institution ""Samara Regional Clinical Oncology Dispensary"", Samara, Russian Federation|Republican Clinical Oncology Dispensary of the Ministry of Health of Bashkortostan Republic, Ufa, Russian Federation|Department of Oncotherapy, National Hospital, Bloemfontein, South Africa|Eastleigh Breast Care Centre, Pretoria, South Africa|Ico-Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital General Universitario Vall D'Hebron, Barcelona, Spain|Centro Oncologico de Galicia, La Coru√±a, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Department of Oncology and Medical Radiology, SI ""DMA of MOH, Ukraine, ""MI ""Dnipropetrovsk City, Dnipropetrovsk, Ukraine|Municipal Treatment-and-Prophylactic Institution 'Donetsk City Oncological Dispensary' Radiology dep, Donetsk, Ukraine|Municipal clinical treatment-and-propyilactic institution ""Donetsk regional oncology center',, Donetsk, Ukraine|Kyiv City Clinical Oncologic Center, Kyiv, Ukraine|Lviv State Oncologic Regional Treatment and Diagnostic Centre, Lviv, Ukraine",82.41287437,74.17158694,Female,"18 Years and older ¬† (Adult, Older Adult)",615,589,568,317,198,53,6/25/2010,1/17/2011,11/22/2010,1/4/2011,12/6/2010,12/16/2010,12/24/2010,12/27/2010,1/14/2011,3/13/2013,3/17/2013,7/18/2013,11/29/2013,1/3/2014,2/9/2014,4/10/2014,5/14/2014,6/19/2014,7/22/2014,6/14/2011,12/11/2011,6/8/2012,12/5/2012,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00721409,,,,,,
Pfizer,Pfizer,ST00321,SP00015,Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive,,,,,Oncology,,,,,,Industry,Completed,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Lyman W,Garnet T,Livia Pacheo †,Selizabeth F,Lyman W,Jaquelyn H,Federico L,Mary H,Selizabeth F,Quentin N,Anthony P,Perter K,Suk T,Jerold Goo †,Hee Y,Kandace p,In Bellini †,Marceline R,Dalton E,,,"Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Charleroi, Belgium|Pfizer Investigational Site, Sint-Niklaas, Belgium|Pfizer Investigational Site, Wilrijk, Belgium|Pfizer Investigational Site, Meldola, FC, Italy|Pfizer Investigational Site, Milano, Italy",12.56188849,11.30569964,Female,"18 Years and older ¬† (Adult, Older Adult)",626,599,569,438,80,51,1/30/2008,7/20/2008,5/7/2008,6/3/2008,5/6/2008,5/21/2008,5/31/2008,6/3/2008,6/22/2008,10/9/2010,1/5/2011,4/17/2011,9/1/2011,10/8/2011,11/27/2011,1/22/2012,3/12/2012,5/10/2012,7/5/2012,11/17/2008,5/16/2009,11/12/2009,5/11/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00372424,,,,,,
Pfizer,Pfizer,ST00324,SP00015,Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2|Phase 3,Interventional,,Allocation: Randomized|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Marceline R,Jerold Goo †,Mary H,Tien C,Frank T,Anthony P,Tien C,Corrine U,Mary H,Marceline R,Beulah N,Lucie P,Xochitl D,Federico L,Jeanene Y,James y,Chetan K,Lyman W,John G,,,"Comprehensive Cancer Care Specialists of Boca Raton, Boca Raton, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|St. Vincents Comprehensive Cancer Center, New York, New York, United States",60.07020157,54.06318142,Male,"18 Years and older ¬† (Adult, Older Adult)",616,597,570,423,65,82,4/4/2005,9/29/2005,8/1/2005,8/22/2005,8/8/2005,8/15/2005,8/30/2005,9/2/2005,9/9/2005,3/19/2007,1/6/2007,6/5/2007,9/1/2007,10/5/2007,11/10/2007,12/28/2007,2/9/2008,3/19/2008,5/5/2008,2/11/2006,8/10/2006,2/6/2007,8/5/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00004071,,,,,,
Pfizer,Pfizer,ST00326,SP00015,"Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan",,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Louann C,Geralyn K,Federico L,Chetan K,Stephan T,Louann C,Xochitl D,Xochitl D,Dinah R,Doreen T,Selizabeth F,Tiffiny K,John G,Aleta H,Donovan H,Naren G,Mee M,Doreen T,Dinah R,,,"National Cheng Kung University, Tainan City, Taiwan",95.32856698,85.79571028,All,"18 Years and older ¬† (Adult, Older Adult)",626,611,571,346,187,38,3/15/2015,8/9/2015,5/25/2015,7/6/2015,6/16/2015,6/20/2015,6/30/2015,7/3/2015,8/1/2015,1/7/2017,7/23/2016,1/21/2017,2/28/2017,4/13/2017,6/6/2017,7/19/2017,8/19/2017,10/10/2017,11/20/2017,12/17/2015,6/14/2016,12/11/2016,6/9/2017,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02924584,,,,,,
Pfizer,Pfizer,ST00331,SP00015,Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Primary Purpose: Treatment,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Corrine U,Liberty A,Dalton E,Suzie K,Liberty A,Frank T,Selizabeth F,Terisa Sikora †,Livia Pacheo †,Mary H,Xochitl D,Selizabeth F,Perter K,Remedios Z,Donovan H,Tamesha T,Kala R,Naren G,Frank T,,,"Agouron Pharmaceuticals, Inc., La Jolla, California, United States",26.95698131,24.26128318,Male,"18 Years and older ¬† (Adult, Older Adult)",631,605,572,446,42,84,7/17/1998,1/3/1999,10/27/1998,11/21/1998,10/20/1998,11/12/1998,11/18/1998,11/20/1998,12/10/1998,3/18/2000,6/9/2000,8/26/2000,1/1/2001,2/12/2001,3/17/2001,5/7/2001,6/17/2001,7/31/2001,9/5/2001,5/11/1999,11/7/1999,5/5/2000,11/1/2000,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00003343,,,,,,
Pfizer,Pfizer,ST00339,SP00015,Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Gertrudis T,Chetan K,Mary H,Kala R,Jene M,Anthony P,Mac L,In Bellini †,In Bellini †,Dalton E,Liberty A,Corrine U,Marcelina X,Lucie P,Tammara F,Dalton E,Chetan K,In Bellini †,Selizabeth F,,,"Pfizer Investigational Site, Charleroi, Belgium|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Stockholm, Sweden",76.30076006,68.67068406,Female,"25 Years to 70 Years ¬† (Adult, Older Adult)",587,579,573,359,164,50,12/31/2007,7/3/2008,4/25/2008,6/9/2008,5/16/2008,5/24/2008,6/1/2008,6/3/2008,7/1/2008,5/5/2012,3/28/2012,7/4/2012,12/1/2012,1/23/2013,3/5/2013,4/15/2013,6/2/2013,7/9/2013,9/4/2013,11/20/2008,5/19/2009,11/15/2009,5/14/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01430585,,,,,,
Pfizer,Pfizer,ST00344,SP00015,A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 1,Interventional,,Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Tamesha T,Liberty A,Tammara F,Naren G,Louann C,Donovan H,Louann C,Kala R,James y,Jene M,In Bellini †,Aleta H,Aleta H,Anthony P,Xochitl D,Quentin N,Tiffiny K,Mary H,Naren G,,,"University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama at Birmingham, IDS Pharmacy, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford Cancer Institute, Stanford, California, United States|Stanford Hospital & Clinics-DRUG SHIPMENT ADDRESS only, Stanford, California, United States|Stanford Hospital & Clinics, Stanford, California, United States|Stanford Women's Cancer Center, Stanford, California, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Karmanos Cancer Institute (KCI), Detroit, Michigan, United States|UNC Cancer Hospital Infusion Pharmacy, Chapel Hill, North Carolina, United States|UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Jules Bordet Institut, Bruxelles, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|Instituto Europeo di Oncologia, Milano, Italy|Instituto Catalan de Oncologia de L'Hospitalet de Llobregat(ICO), Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain",54.6755817,49.20802353,Female,18 Years to 40 Years ¬† (Adult),643,626,574,177,374,23,4/5/2014,11/12/2014,9/3/2014,10/18/2014,9/13/2014,9/28/2014,10/11/2014,10/15/2014,11/12/2014,4/13/2015,4/17/2015,9/19/2015,12/24/2015,2/18/2016,4/6/2016,6/1/2016,7/28/2016,9/9/2016,11/8/2016,3/27/2015,9/23/2015,3/21/2016,9/17/2016,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01876251,,,,,,
Pfizer,Pfizer,ST00355,SP00015,Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100),,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Livia Pacheo †,Lilla Stilson †,Otis Thode †,Naren G,Louann C,In Bellini †,Otis Thode †,Marcelina X,Jeanene Y,Anthony P,Kala R,Quentin N,Liberty A,Perter K,John G,Donovan H,Lyman W,Corrine U,Aleta H,,,"Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HAL, Scottsdale, Arizona, United States|Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Sansum Clinic, Santa Barbara, California, United States|Sansum Clinic, Solvang, California, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Montefiore Medical Center - EPC, Bronx, New York, United States|Montefiore Medical Center - Oncology Investigational Services, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Montefiore Medical Center - Centennial, Bronx, New York, United States|NYU Winthrop Hospital, Clinical Trials Center, Mineola, New York, United States|NYU Winthrop Hospital, Gynecologic Oncology, Mineola, New York, United States|NYU Winthrop Hospital, Infusion Center, Mineola, New York, United States|NYU Winthrop Hospital, Research Pharmacy, Mineola, New York, United States|NYU Winthrop Radiology, Mineola, New York, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Shelbyville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|Texas Oncology Bedford, Bedford, Texas, United States|Texas Oncology, Fort Worth, Texas, United States|US Oncology Investigational Product Center (IPC), Irving, Texas, United States|US Oncology Investigational Products Center, Irving, Texas, United States|Texas Onoclogy -San Antonio Medical Center, San Antonio, Texas, United States|Virginia Oncology Associates, Chesapeake, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Oncology Associates, Virginia Beach, Virginia, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|Epworth Foundation trading as Epworth HealthCare, East Melbourne, Victoria, Australia|Epworth HealthCare, Clinical Trials & Research Centre, Richmond, Victoria, Australia|Slade Compounding - Slade Pharmaceuticals, Richmond, Victoria, Australia|CHU-UCL Namur/Site Sainte Elisabeth, Namur, Belgium|Bon Secours Hospital, Cork, Ireland|Istituto Europeo di Oncologia (IEO), Milano, MI, Italy|Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, RM, Italy|Niigata Cancer Center Hospital, Niigata, Japan|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Clinical Trial Pharmacy, Samsung Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Limited Liability Company ""VitaMed"" (LLC ""VitaMed""), Moscow, Russian Federation|Department of Nuclear Medicine and Molecular Imaging, Singapore, Singapore|SingHealth Investigational Medicine Unit, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore|Department of Pathology, Singapore, Singapore|Raffles Hospital, Singapore, Singapore|Raffles Radiology, Singapore, Singapore|Farrer Park Hospital, Singapore, Singapore|Taipei Veterans General Hospital, Taipei, Taiwan|Department of Radiology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan|Division of Pharmacy, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan",65.63195629,59.06876066,Female,"18 Years and older ¬† (Adult, Older Adult)",644,620,575,520,20,35,8/26/2017,4/11/2018,2/2/2018,2/24/2018,1/31/2018,2/13/2018,2/26/2018,2/27/2018,3/21/2018,12/27/2020,4/5/2021,10/3/2021,11/28/2021,1/18/2022,3/17/2022,5/16/2022,6/20/2022,8/8/2022,9/22/2022,8/12/2018,2/8/2019,8/7/2019,2/3/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03642132,,,,,,
Pfizer,Pfizer,ST00367,SP00015,Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole,,,,,Oncology,,,,,,Industry,Not yet recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Anthony P,Perter K,Frank T,Otis Thode †,Jerold Goo †,Federico L,Suzie K,Xochitl D,Tammara F,Stephan T,Suzie K,Rima Y ,Dalton E,Dinah R,Tammara F,Terisa Sikora †,Livia Pacheo †,Donovan H,Naren G,,,"Sagara Hospital, Kagoshima, Japan",44.68746532,40.21871879,Female,"18 Years and older ¬† (Adult, Older Adult)",637,612,576,498,20,58,8/10/2019,1/10/2020,11/8/2019,12/3/2019,10/27/2019,11/16/2019,11/27/2019,11/30/2019,12/9/2019,4/10/2022,5/22/2022,9/5/2022,12/31/2022,2/12/2023,4/11/2023,5/17/2023,7/10/2023,8/27/2023,10/20/2023,5/14/2020,11/10/2020,5/9/2021,11/5/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04735367,,,,,,
Pfizer,Pfizer,ST00371,SP00015,An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer,,,,,Oncology,,,,,,Industry,Recruiting,Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Suzie K,Quentin N,Stephan T,Selizabeth F,Perter K,Ngan D,Terrell p,Selizabeth F,Naren G,Remedios Z,Jerold Goo †,Selizabeth F,Mara A,Selizabeth F,Jerold Goo †,Mary H,Livia Pacheo †,Kala R,Livia Pacheo †,,,"Yuma Regional Medical Center Cancer Center, Yuma, Arizona, United States|Yuma Regional Medical Center Ophthalmology, Yuma, Arizona, United States|Yuma Regional Medical Center, Yuma, Arizona, United States|UCLA Hematology/Oncology, Los Angeles, California, United States|UCLA Stein Eye Center Santa Monica (OPH), Santa Monica, California, United States|UCLA Hematology/Oncology, Santa Monica, California, United States|Eastern Ct Hematology and Oncology Associates, Norwich, Connecticut, United States|Southeast CT Eye Care LLC, Norwich, Connecticut, United States|Florida Cancer Specialist, Altamonte Springs, Florida, United States|Florida Cancer Specialists, Bonita Springs, Florida, United States|Florida Cancer Specialists, Bradenton, Florida, United States|Florida Cancer Specialist, Brandon, Florida, United States|Florida Cancer Specialists, Cape Coral, Florida, United States|Florida Cancer Specialist, Clearwater, Florida, United States|Florida Cancer Specialists, Fleming Island, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialist, Gainesville, Florida, United States|Florida Cancer Specialist, Largo, Florida, United States|Florida Cancer Specialist, Lecanto, Florida, United States|Florida Cancer Specialists, Naples, Florida, United States|Florida Cancer Specialist, New Port Richey, Florida, United States|Florida Cancer Specialist, Ocala, Florida, United States|Florida Cancer Specialist, Orange City, Florida, United States|Florida Cancer Specialist, Orlando, Florida, United States|Florida Cancer Specialists, Port Charlotte, Florida, United States|Florida Cancer Specialist, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialist, Spring Hill, Florida, United States|Florida Cancer Specialists PAN - SCRI - PPDS, Tallahassee, Florida, United States|Florida Cancer Specialist, Tampa, Florida, United States|Florida Cancer Specialist, Tavares, Florida, United States|Florida Cancer Specialist, The Villages, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Florida Cancer Specialist, Winter Park, Florida, United States|Winship Cancer Institute @ Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Winship Cancer Institute @ Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Winship Cancer Institute @ Emory Johns Creek Hospital, Johns Creek, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|MidAmerica Division, Inc. c/o Menorah Medical Center, Overland Park, Kansas, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|The Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston (OCB), Boston, Massachusetts, United States|Ophthalmic Consultants of Boston Inc, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center/East, Boston, Massachusetts, United States|Dana-Farber Cancer Institute - Chestnut Hill, Newton, Massachusetts, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|MidAmerica Division, Inc. c/o Centerpoint Medical Center, Independence, Missouri, United States|MidAmerica Division, Inc., c/o Research Medical Center, Kansas City, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, United States|Siteman Cancer Center - St Peters, Saint Peters, Missouri, United States|Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center - Bergen, Montvale, New Jersey, United States|Metropolitan Eye Care, Paramus, New Jersey, United States|Chilton Medical Center - Cardiovascular Imaging at 242 West Parkway - Echocardiography Dept, Pompton Plains, New Jersey, United States|Montefiore-Einstein Center for Cancer Care, Bronx, New York, United States|Montefiore Medical Center- Department of Ophthalmology & Visual Sciences, Bronx, New York, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center David H Koch Center for Cancer Care, New York, New York, United States|Weill Cornell Eye Associates, New York, New York, United States|Weill Cornell Medical College - New York Presbyterian Hospital, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical Center - New York Presbyterian Hospital, New York, New York, United States|Weill Cornell Medical College - New York Presbyterian Hospital, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Duke Cancer Center, Durham, North Carolina, United States|Ohio State CarePoint East, Columbus, Ohio, United States|The Ohio State University Hospital, Columbus, Ohio, United States|The Ohio State University James Cancer Hospital, Columbus, Ohio, United States|The Ohio State University Medical Center - Thoracic Oncology Clinic, Columbus, Ohio, United States|Ohio State Eye and Ear Institute, Columbus, Ohio, United States|Stefanie Spielman Comprehensive Breast Cancer, Columbus, Ohio, United States|Martha Morehouse Medical Plaza, Columbus, Ohio, United States|Ohio State CarePoint Gahanna, Gahanna, Ohio, United States|Ohio State Outpatient Care Lewis Center, Lewis Center, Ohio, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Providence Cancer Institute Newberg Clinic, Newberg, Oregon, United States|Providence Cancer Institute, Franz Clinic, Portland, Oregon, United States|Providence Oncology and Hematology Care Clinic - Westside, Portland, Oregon, United States|Arnold Palmer Cancer Center, Greensburg, Pennsylvania, United States|UPMC Hillman Cancer Center Monroeville, Monroeville, Pennsylvania, United States|UPMC Eye Center, Eye and Ear Institute, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center Investigational Drug Service, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center - Passavant, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center - Upper St. Clair, Pittsburgh, Pennsylvania, United States|Weaver Eye Associates, York, Pennsylvania, United States|WellSpan Oncology Research, York, Pennsylvania, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Cleveland, Tennessee, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hendersonville, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Shelbyville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|Houston Eye Associates - Gramercy Location, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|Eye associates Northwest, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|AUSL Romagna - Presidio Ospedale ""degli Infermi"" di Faenza, Faenza, Emilia-romagna, Italy|AUSL Romagna - Presidio Ospedale ""Umberto I"" di Lugo, Lugo, Emilia-romagna, Italy|Azienda Policlinico Umberto I, Roma, Lazio, Italy|Istituto Nazionale Dei Tumori, Milano, Lombardia, Italy|Departimento Oncologia Medica, Milan, Lombardia, Italy|Unita Operativa di Oculistica: UO Oncologia Oculare e Immunopatologia oculare, Milan, Lombardia, Italy|Unita Operativa Radiologia, Milan, Lombardia, Italy|UO Anatomia e lstologia Patologica, Milan, Lombardia, Italy|UO Dermatologia e Cosmetologia, Milan, Lombardia, Italy|UO Medicina Nucleare, Milan, Lombardia, Italy|UOC Farmacia, Milan, Lombardia, Italy|S.S.D. Oncologia Polmonare, Orbassano, Torino, Italy|SCDO Cardiologia, Orbassano, Torino, Italy|SCDO Farmacia Ospedaliera, Orbassano, Torino, Italy|SCDU Anatomia Patologica, Orbassano, Torino, Italy|SCDU Oftalmologia, Orbassano, Torino, Italy|SCDU Radiodiagnostica e S.S. Medicina Nucleare, Orbassano, Torino, Italy|Dermatologia Azienda Ospedaliero Universitaria Citt√† della Salute e della Scienza di Torino, Torino, TO, Italy|UO Dermatologia Centro Tumori Cutanei (CTC)- Azienda Ospedaliero, Bologna, Italy|UO di Oftalmologia- Azienda Ospedaliero Universitaria Di Bologna, Bologna, Italy|UO Farmacia Clinica- Azienda Ospedaliero Universitaria Di Bologna, Bologna, Italy|UO Medicina Borghi- Azienda Ospedaliero Universitaria Di Bologna, Bologna, Italy|UO Radiologia Golfieri- Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi, Bologna, Italy|UOC di Anatomia Patologica- Azienda Ospedaliero Universitaria Di Bo logna, Bologna, Italy|AUSL Romagna - Presidio Ospedale ""Cervesi"" di Cattolica, Cattolica, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, Italy|Clinica Oculistica II, 2¬∞ Policlinico Federico II, Napli, Italy|S. C. Farmacia, Napoli, Italy|Farmacia Oncologica, Ravenna, Italy|AUSL Romagna - Presisio Ospedale ""degli Infermi"" di Rimini, Rimini, Italy|National Cancer Center Clinical Pharmacy, Goyang-si, Gyeonggido, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeonnam, Jeonranamdo, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Asan Medical Center - PPDS, Seoul, Korea, Republic of|Samsung Medical Center - PPDS, Seoul, Korea, Republic of|Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Noord-holland, Netherlands|OLVG, locatie Oost; Ophthalmology department, Amsterdam, Netherlands|Ophthalmology department, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Madrid, Spain|Hospital Regional Universitario de Malaga - Hospital General, Malaga, M√°laga, Spain|Hospital Clinic de Barcelona, Badalona, Spain|Hospital del Mar, Barcelona, Spain|CETIR Centro Medico Teknon, Barcelona, Spain|Hospital Quiron Salud Barcelona, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Grupo Cardiologico Corpal (Hospital de la Cruz Roja), Cordoba, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|CETIR, Esplugues de Llobregat, Spain|lnstitut Catala d'Oncologfa_L'Hospitalet, L'Hospitalet, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Centro Hospitalario Integral Privado (CHIP), Malaga, Spain|CERCO, Sevilla, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain",46.04515519,41.44063967,All,"18 Years to 70 Years ¬† (Adult, Older Adult)",610,602,577,405,97,75,1/7/2020,6/30/2020,4/8/2020,5/25/2020,4/19/2020,5/7/2020,5/10/2020,5/13/2020,5/22/2020,9/1/2021,9/18/2021,4/23/2022,6/30/2022,8/11/2022,9/22/2022,10/30/2022,12/20/2022,2/9/2023,3/11/2023,11/3/2020,5/2/2021,10/29/2021,4/27/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03915951,,,,,,
Pfizer,Pfizer,ST00397,SP00015,A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin¬Æ [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02),,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug H,,,,,,,,,,,,,,,,,,,Mary H,Selizabeth F,Marcelina X,Louann C,Garnet T,John G,Lucie P,Clarice N,Mara A,John G,Marceline R,Tamesha T,Livia Pacheo †,Ngan D,Clarice N,Tiffiny K,Remedios Z,Suk T,Christian G,,,"Cancer Center of Central Connecticut, Plainville, Connecticut, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Florida Cancer Research Institute, Boca Raton, Florida, United States|Florida Cancer Research Institute, Plantation, Florida, United States|COIBA - Centro de Oncologia e Investigacion Buenos Aires, Berazategui, Buenos Aires, Argentina|Instituto De Oncologia De Rosario, Rosario, Santa FE, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Sanatorio de la Providencia, C.a.b.a, Argentina|CRIO - Centro Regional Integrado de Oncologia, Fortaleza, CE, Brazil|Associacao de Combate ao Cancer em Goias - Hospital Araujo Jorge, Goiania, GO, Brazil|Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner, Curitiba, Parana, Brazil|Instituto do Cancer de Londrina - Hospital do Cancer de Londrina - HCL, Londrina, Parana, Brazil|Hospital Bruno Born (Sociedade Beneficencia e Caridade de Lajeado), Lajeado, RIO Grande DO SUL, Brazil|Associacao Hospital de Caridade Ijui, Ijui, RS, Brazil|Centro de Pesquisa em Oncologia - Uniao Brasileira de Educacao e Assistencia, Porto Alegre, RS, Brazil|Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral, Itajai, Santa Catarina, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, SAO Paulo, Brazil|Centro de Pesquisas Oncologicas de Santa Catarina - CEPON, Florianopolis, SC, Brazil|Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral, Itajai, SC, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - Faculdade de Medicina do ABC, Santo Andre, SP, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - Faculdade de Medicina do ABC, Santo Andre, SP, Brazil|Clinica Alemana de Temuco, Temuco, Region DE LA Araucania, Chile|Centro de Investigacion Clinica SIM, Temuco, Region DE LA Araucania, Chile|Administrative office, Temuco, Region DE LA Araucania, Chile|Fresenius Kabi Chile Therapia iv, Santiago, RM, Chile|Hospital Clinico Vina Del Mar, Vina del Mar, V Region, Chile|Instituto Oncologico, Clinica Renaca, Vina del Mar, V Region, Chile|Hospital Naval Almirante Nef, V Region, Chile|Instituto Oncologico Clinica Renaca, V Region, Chile|Onkologicka klinika VFN a 1. LF UK, Fakultni poliklinika, Praha 2, Czechia|General Hospital of Chania ""O Agios Georgios"", Chania, Crete, Greece|Interbalkan European Medical Center, Pylaia, Thessaloniki, Greece|General Hospital of Athens ""Hippokration"", Athens, Greece|Bacs-Kiskun Megyei Korhaz, Onkoradiologiai Kozpont, Kecskemet, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz, es Egyetemi Oktatokorhaz, Klinikai Onkologiai es Sugarterapias, Miskolc, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendelointezet, Megyei Onkologiai Kozpont, Szolnok, Hungary|Markusovszky Egyetemi Oktatokorhaz, Szombathely, Hungary|Department of Medicine New Block, Visakhapatnam, Andhra Pradesh, India|Manipal Hospital, Bengaluru, Karnataka, India|Manipal Centre for Clinical Research, Manipal, Karnataka, India|Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, India|Shatabdi Super Speciality Hospital, Nashik, Maharashtra, India|Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Navi Mumbai, Maharashtra, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India|Sahyadri Clinical Research & Development Centre, Pune, Maharashtra, India|Sahyadri Speciality Hospital, Pune, Maharashtra, India|Acharya Harihar Regional Cancer Center, Cuttack, Odisha, India|Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India|Meenakshi Mission Hospital and Research Centre, Madurai, Tamil NADU, India|MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, Telangana, India|National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-Shi, Fukuoka, Japan|Japan Community Health care Organization Kurume General Hospital, Kurume-city, Fukuoka, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kumamoto University Hospital, Kumamoto-city, Kumamoto, Japan|Saitama Cancer Center Hospital, Kitaadachi-gun, Saitama, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan|National Hospital Organization Tokyo Medical Center, Meguro-Ku, Tokyo, Japan|Showa University Hospital, Shinagawa-ku, Tokyo, Japan|Chiba Cancer Center, Chiba, Japan|Hakuaikai Medical Corporation Sagara Hospital, Kagoshima, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Nakanoshima Osaka Breast Clinic, Osaka, Japan|Osaka Breast Clinic, Osaka, Japan|Shizuoka General Hospital, Shizuoka, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|National Cancer Centre, Goyang-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|P.Stradins Clinical University Hospital, Riga, Latvia|Instituto Nacional de Cancerologia, Mexico City, Distrito Federal, Mexico|Consultorio dentro de la Torre Medica Dalinde (Oncologia Medica), Mexico, Distrito Federal, Mexico|Inter Hosp S.A. de C.V. ""Centro Medico Dalinde"", Mexico, Distrito Federal, Mexico|Oaxaca Site Management Organization S.C., Oaxaca, Mexico|Cancerologia de Queretaro S.C., Queretaro, Mexico|Hospital Militar Central, Lima, Peru|INNPARES, Lima, Peru|Resocentro, Lima, Peru|Clinica Anglo Americana, Lima, Peru|Instituto de Oncologia y Radioterapia de la Clinica Ricardo Palma, Lima, Peru|Radiologos S.R.L., Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Siglo XXI, Lima, Peru|Resocentro, Lima, Peru|Siglo XXI, Lima, Peru|Cebu Doctors' University Hospital, Cebu City, Cebu, Philippines|Cardinal Santos Medical Center, San Juan City, Mentro Manila, Philippines|Manila Doctors Hospital, Manila, Metro Manila, Philippines|Veterans Memorial Medical Center, Quezon City, Metro Manila, Philippines|University of Philippines Manila-Philippine General Hospital, Manila, NCR, Philippines|The Medical City, Pasig City, NCR, Philippines|St. Luke's Medical Center, Quezon City, NCR, Philippines|The Research Institute at Perpetual Succor Hospital, Cebu City, Region VII, Philippines|Manila Doctors Hospital, Manila, Philippines|COPERNICUS Podmiot Leczniczy Sp. z o.o. Wojewodzkie Centrum Onkologii, Gdansk, Poland|Szpitale Pomorskie Sp. z o.o. Oddzial Onkologii i Radioterapii, Gdynia, Poland|Centrum Terapii Wspolczesnej, Lodz, Poland|SPZOZ MSW z Warminsko-Mazurskim Centrum Onkologii w Olsztynie, Oddzial Kliniczny Chemioterapii, Olsztyn, Poland|MRUKMED. Lekarz Beata Madej Mruk i Partner. Sp. p. Oddzial nr 1 w Rzeszowie, Rzeszow, Poland|Magodent Sp. z o.o. Oddzial Onkologii Klinicznej/Chemioterapii, Warszawa, Poland|Hospital de Braga, Braga, Portugal|Hospital CUF Descobertas, Lisboa, Portugal|Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Cluj, Romania|S.C. Medisprof S.R.L, Cluj-Napoca, Cluj, Romania|Centrul de Oncologie Sf. Nectarie, Craiova, Dolj, Romania|SC Oncolab SRL, Oncologie, Craiova, Jud Dolj, Romania|Spitalul Universitar de Urgenta, Departamentul Oncologie Medicala, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania|Spitalul Judetean de Urgenta ""Sf.Ioan cel Nou"", Sectia Oncologie, Suceava, Romania|Spitalul Clinic Municipal de Urgenta Timisoara, Sectia Clinica Oncologie Medicala, Timisoara, Romania|Republic Clinical Hospital of Emergency Care, Grozny, Chechenkaya Republic, Russian Federation|State Healthcare Institution Kursk Regional Oncological Dispensary of the Healthcare Committee, Kislino Settlement, Kursk, Russian Federation|State Budgetary Healthcare Institution ""Leningrad Regional Oncological Dispensary"", Kuzmolovo, Vsevolozhskiy, Leningrad Region, Russian Federation|FSBSI Russian Cancer Research Center n.a. N.N.Blokhin, Moscow, NAP, Russian Federation|GBUZ of Perm region ""Perm regional oncology dispensary"", Perm, NAP, Russian Federation|Federal State Budgetary Institution ¬øNational Medical Research Oncology Centre named after N.N., Saint-Petersburg, Pos.pesochny, Russian Federation|State Healthcare Institution, Republican Clinical Oncology Dispensary of the Ministry of, Ufa, Republic OF Bashkortostan, Russian Federation|GBUZ Republican Clinical Hospital n.a. G.F. Kuvatova, Ufa, Republic OF Baskortostan, Russian Federation|Republican Clinical Oncology Dispensary of the Ministry of Healthcare of Baskortostan Republic, Ufa, Republic OF Baskortostan, Russian Federation|State Budgetary Healthcare Institution ''Republic Oncological Dispensary'', Petrozavodsk, Republic OF Karelia, Russian Federation|State budget institution of healthcare of Mordovia Republic ""Republic Oncology Dispensary"", Saransk, Republic OF Mordovia, Russian Federation|Rostov Research Institute of Oncology, Rostov-on-Don, Rostov Region, Russian Federation|Private medical institution Euromedservice, Pushkin, Saint Petersburg, Russian Federation|Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncology), Poselok Pesochny, Saint-petersburg, Russian Federation|LLC Medekspert, Kislovodsk, Stavropol Region, Russian Federation|Federal State Budgetary Healthcare Institution of ""Clinical Hospital #101 of Federal Medical and, Lermontov, Stavropol Region, Russian Federation|Centre of Specialized kinds of Medical Care of Pyatigorsk city, Pyatigorsk, Stavropol Region, Russian Federation|State Budgetary Healthcare Institution of Stavropol Region Pyatigorsk Oncology Dispensary, Pyatigorsk, Stavropol Region, Russian Federation|LLC Novaya Clinica, Pyatigorsk, Stavropol Region, Russian Federation|Pyatigorsk City Hospital #2, Pyatigorsk, Stavropol Region, Russian Federation|Stavropol Regional Hospital for War Veterans, Pyatigorsk, Stavropol Region, Russian Federation|State Budgetary Healthcare Institution Volgograd Regional Clinical Oncology Dispensary, Volzhskiy, Volgograd Region, Russian Federation|GBUZ Arkhangelsk Regional Clinical Oncological dispensary, Arkhangelsk, Russian Federation|State Budgetary Healthcare Institution ""Chelyabinsk Regional Clinical Oncological Dispensary"", Chelyabinsk, Russian Federation|""Regional Budgetary Healthcare Institution """"Ivanovo Regional Oncology Dispensary"""""", Ivanovo, Russian Federation|SBIH of Kaluga Region ""Kaluga Regional Clinical Oncology Dispensary"", Kaluga, Russian Federation|GBUZ ""Regional Oncology Dispensary #2"", Magnitogorsk, Russian Federation|Federal State Budgetary Institution ""Russian Oncological Scientific Center n.a. N.N. Blokhin"" of, Moscow, Russian Federation|LLC VitaMed, Moscow, Russian Federation|LLC VitaMed, Moscow, Russian Federation|State Budgetary Healthcare Institution ""Nizhniy Novgorod Regional Oncological Dispensary"", Nizhniy Novgorod, Russian Federation|""BIH of Omsk Region """"Clinical oncological dispensary"""""", Omsk, Russian Federation|Budgetary Institution of Healthcare of Orel region ""Orel oncological dispensary"", Orel, Russian Federation|SBEI HPE RyazSMU of MoH of the Russian Federation based on SBI of Ryazan Region ""Regional CLinical, Ryazan, Russian Federation|SBEI of HPE ""First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation|SBI ""North-Western State Medical University n.a. I. I. Mechnikov"" of the MoH of the Russian, Saint-Petersburg, Russian Federation|Non-state healthcare agency Road Clinical Hospital PLC Russian Railways, Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Healthcare Institution ""Oncological Dispensary of Moscow District"", Saint-Petersburg, Russian Federation|Non-State Healthcare Institution ""Road Clinical Hospital at Saratov II Station"", Saratov, Russian Federation|State Budgetary Healthcare Institution of Stavropol region ""Stavropol regional clinical oncology, Stavropol, Russian Federation|Institute for Oncology and Radiology of Serbia, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinic of Oncology-Clinical Center Nis, Nis, Serbia|Oncology Institute of Vojvodina, Sremska Kamenica, Serbia|Onkologicky ustav sv. Alzbety, s.r.o., Bratislava, Slovakia|Narodny Onkologicky Ustav, Bratislava, Slovakia|GVI Oncology, Langenhoven Drive Oncology Centre, Port Elizabeth, Eastern CAPE, South Africa|wits Clinical Research, Joannesburg, Gauteng, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|Sandton Oncology Centre, Johannesburg, Gauteng, South Africa|*Department of Medical Oncology, University of Pretoria & Steve Biko Academic Hospitals Complex, Pretoria, Gauteng, South Africa|Eastleigh Breast Care Centre, Pretoria, Gauteng, South Africa|Cape Town Oncology Trials, Kraaifontein, Western CAPE, South Africa|GVI Rondebosch Oncology Centre-Rondebosch Medical Centre, Rondebosch, Western CAPE, South Africa|National Cancer Institute, Ratchathewi, Bangkok, Thailand|Udonthani Cancer Hospital, Amphur Muang, Udonthani, Thailand|Faculty of Medicine, Chulongkorn University, Medical Oncology Unit, Bangkok, Thailand|Baskent University School of Medicine Adana Hospital, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Uludag Universitesi Tip Fakultesi Ic Hastaliklari Anabilim Dali, Bursa, Turkey|Dicle University Medical Faculty, Diyarbakir, Turkey|Gaziantep University Medical Faculty, Gaziantep, Turkey|Istanbul Universitesi Onkoloji Enstitusu, Istanbul, Turkey|Municipal Institution ""Chernivtsi Regional Clinical Oncology Center"", Outpatient Department, Chernivtsi, Ukraine|Municipal Non-Profit Enterprise City Clinical Hospital No.4of Dnipro Regional Council, Department of, Dnipro, Ukraine|SI Institute of Medical Radiology n.a.S.P. Ilrygoriev of National Academy of Medical Science of, Kharkiv, Ukraine|Communal Non-Profit Enterprise ""Regional Center of Oncology"", Kharkiv, Ukraine|Khmelnytskyi Regional Oncologic Dispensary, Khmelnytskyi, Ukraine|Municipal Enterprise 'Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council', Kryvyi Rih, Ukraine|Municipal Non-Profit Enterprise of Kyiv Regional Council ""Kyiv Regional Oncology Dispensary"", Kyiv, Ukraine|Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine|Municipal Institution Odesa Regional Clinical Hospital, Mammology Center, Odesa, Ukraine|Zakarpattia Regional Clinical Oncological Center, Uzhgorod, Ukraine|Municipal Non-profit Enterprise Podilsk Regional Oncology Centre of Vinnytsia Regional Council, Vinnytsia, Ukraine",50.23975532,45.21577979,Female,"18 Years and older ¬† (Adult, Older Adult)",603,586,578,477,14,87,12/2/2011,5/24/2012,3/22/2012,4/27/2012,3/23/2012,4/12/2012,4/23/2012,4/25/2012,5/20/2012,10/16/2015,11/29/2015,7/25/2016,8/24/2016,9/26/2016,10/29/2016,11/28/2016,1/3/2017,2/6/2017,4/4/2017,10/9/2012,4/7/2013,10/4/2013,4/2/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01989676,,,,,,
Pfizer,Pfizer,ST00398,SP00015,Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Selizabeth F,Donovan H,Doreen T,Clarice N,Beulah N,Jerold Goo †,Kala R,Lyman W,Lyman W,Livia Pacheo †,In Bellini †,Suzie K,James y,Frank T,Lucie P,Aleta H,John G,Doreen T,Chetan K,,,"Agouron Pharmaceuticals, Inc., La Jolla, California, United States",12.35825297,11.12242767,All,"18 Years and older ¬† (Adult, Older Adult)",610,588,579,199,357,23,11/16/1997,5/21/1998,3/9/1998,4/7/1998,3/16/1998,3/28/1998,4/7/1998,4/11/1998,4/20/1998,7/14/2000,11/15/2000,2/15/2001,7/1/2001,8/9/2001,9/18/2001,11/17/2001,12/27/2001,1/29/2002,3/29/2002,9/24/1998,3/23/1999,9/19/1999,3/17/2000,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00004199,,,,,,
Pfizer,Pfizer,ST00406,SP00015,"Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer",,,,,Oncology,,,,,,Industry,Unknown status,Phase 1,Interventional,,Masking: None (Open Label)|Primary Purpose: Other,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Rima Y ,Kandace p,Tammara F,Federico L,Lyman W,Jaquelyn H,Kala R,Christian G,Perter K,Terisa Sikora †,Naren G,Mary H,Otis Thode †,Beulah N,James y,Jerold Goo †,Suk T,In Bellini †,Perter K,,,"Beijing Cancer Hospital/Oncology department, Beijing, Beijing, China|Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China|Guangdong General Hospital/Department of Breast Surgery, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|The first hospital of jilin university, Changchun, Jilin, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China",4.491759116,4.042583205,Female,"18 Years and older ¬† (Adult, Older Adult)",619,607,580,306,221,53,12/11/2015,5/15/2016,3/28/2016,4/25/2016,3/22/2016,4/9/2016,4/11/2016,4/15/2016,5/11/2016,1/28/2018,11/15/2017,3/11/2018,7/31/2018,9/15/2018,11/8/2018,1/3/2019,2/8/2019,3/29/2019,5/15/2019,10/6/2016,4/4/2017,10/1/2017,3/30/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02499146,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02499146/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02499146/SAP_001.pdf"
Pfizer,Pfizer,ST00407,SP00015,Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,,,,Drug E,,,,,,,,,,,,,,,,,,,Frank T,Geralyn K,Geralyn K,Christian G,Corrine U,Tien C,Patria R,Suzie K,Terisa Sikora †,John G,Tiffiny K,Tammara F,Otis Thode †,Mara A,James y,James y,John G,Hee Y,Mary H,,,"Pfizer Investigational Site, La Plata, Buenos Aires, Argentina|Pfizer Investigational Site, Santa Fe, Argentina|Pfizer Investigational Site, Wollongong, New South Wales, Australia|Pfizer Investigational Site, East Bentleigh, Victoria, Australia|Pfizer Investigational Site, Frankston, Victoria, Australia|Pfizer Investigational Site, Fremantle, Western Australia, Australia|Pfizer Investigational Site, St. Poelten, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Liege, Belgium|Pfizer Investigational Site, Sarajevo, Bosnia and Herzegovina|Pfizer Investigational Site, Goi√¢nia, GO, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Santo Andr√©, SP, Brazil|Pfizer Investigational Site, Ruse, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Stara Zagora, Bulgaria|Pfizer Investigational Site, Varna, Bulgaria|Pfizer Investigational Site, Oshawa, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Medellin, Antioquia, Colombia|Pfizer Investigational Site, Pasto, Narino, Colombia|Pfizer Investigational Site, Nicosia, Cyprus|Pfizer Investigational Site, Brno, Czech Republic|Pfizer Investigational Site, Nova Ves Pod Plesi, Czech Republic|Pfizer Investigational Site, Pribram, Czech Republic|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Bochum, Germany|Pfizer Investigational Site, Esslingen, Germany|Pfizer Investigational Site, Frankfurt, Germany|Pfizer Investigational Site, Halle, Germany|Pfizer Investigational Site, Hannover, Germany|Pfizer Investigational Site, Moenchengladbach, Germany|Pfizer Investigational Site, Oldenburg, Germany|Pfizer Investigational Site, Regensburg, Germany|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Kowloon, Hong Kong|Pfizer Investigational Site, Tuen Mun, New Territories, Hong Kong|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Debrecen, Hungary|Pfizer Investigational Site, Debrecen, Hungary|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Mumbai, Maharashtra, India|Pfizer Investigational Site, Mumbai, Maharashtra, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Vellore, Tamil Nadu, India|Pfizer Investigational Site, Dublin 24, Ireland|Pfizer Investigational Site, Dublin, Ireland|Pfizer Investigational Site, Dublin, Ireland|Pfizer Investigational Site, Galway, Ireland|Pfizer Investigational Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Pfizer Investigational Site, Daegu, Korea, Republic of|Pfizer Investigational Site, Incheon, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Acapulco, Guerrero, Mexico|Pfizer Investigational Site, Ciudad Obregon, Sonora, Mexico|Pfizer Investigational Site, Forde, Norway|Pfizer Investigational Site, Tonsberg, Norway|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Porto, Portugal|Pfizer Investigational Site, Porto, Portugal|Pfizer Investigational Site, Santa Maria da Feira, Portugal|Pfizer Investigational Site, √âvora, Portugal|Pfizer Investigational Site, Cluj-Napoca, Cluj, Romania|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Saint Petersburg, Russian Federation|Pfizer Investigational Site, Saint Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Sremska Kamenica, Serbia|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Observatory, South Africa|Pfizer Investigational Site, Panorama, South Africa|Pfizer Investigational Site, Parktown, South Africa|Pfizer Investigational Site, Port Elizabeth, South Africa|Pfizer Investigational Site, Sandton, South Africa|Pfizer Investigational Site, Elche, Alicante, Spain|Pfizer Investigational Site, Santander, Cantabria, Spain|Pfizer Investigational Site, Mostoles, Madrid, Spain|Pfizer Investigational Site, Alicante, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Zaragoza, Spain|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Uppsala, Sweden|Pfizer Investigational Site, Changhua, Taiwan|Pfizer Investigational Site, Chiayi County, Taiwan|Pfizer Investigational Site, Kaohsiang Hsien, Taiwan|Pfizer Investigational Site, Kaohsiung, Taiwan|Pfizer Investigational Site, Kwei-Shan, Taoyuan, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Rachathevee, Bangkok, Thailand|Pfizer Investigational Site, Muang, Chiang Mai, Thailand|Pfizer Investigational Site, Muang, Khon Kaen, Thailand|Pfizer Investigational Site, Bangkok, Thailand|Pfizer Investigational Site, Cherkasy, Ukraine|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Kyiv, Ukraine|Pfizer Investigational Site, Lviv, Ukraine|Pfizer Investigational Site, Uzhgorod, Ukraine|Pfizer Investigational Site, Northwood, Middlesex, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom",67.21289661,60.49160695,All,"18 Years and older ¬† (Adult, Older Adult)",664,637,581,442,86,53,9/10/2005,4/10/2006,1/22/2006,2/19/2006,1/25/2006,2/11/2006,2/23/2006,2/24/2006,3/13/2006,6/30/2009,6/21/2009,1/10/2010,3/1/2010,4/15/2010,5/19/2010,7/2/2010,8/8/2010,10/4/2010,11/25/2010,8/10/2006,2/6/2007,8/5/2007,2/1/2008,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00457691,,,,,,
Pfizer,Pfizer,ST00411,SP00015,Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Suzie K,Dalton E,Selizabeth F,Terrell p,Ngan D,Quentin N,Naren G,John G,Dinah R,Stephan T,Otis Thode †,Dalton E,Federico L,Selizabeth F,Jene M,Livia Pacheo †,Anthony P,Perter K,Mee M,,,"Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|New England Medical Center Hospital, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Raleigh Hematology/Oncology Associates - Wake Practice, Raleigh, North Carolina, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|West Clinic, P.C., Memphis, Tennessee, United States|Southwest Regional Cancer Center, Austin, Texas, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada|BC Cancer Agency, Vancouver, British Columbia, Canada|British Columbia Cancer Agency - Vancouver Island Cancer Centre, Victoria, British Columbia, Canada|Ottawa Regional Cancer Center - General Division, Ottawa, Ontario, Canada|Mount Sinai Hospital - Toronto, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada",22.78618339,20.50756505,All,"18 Years and older ¬† (Adult, Older Adult)",642,629,582,448,56,78,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/26/1900,4/2/1900,5/26/1900,7/22/1900,9/15/1900,11/12/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00005093,,,,,,
Pfizer,Pfizer,ST00414,SP00015,Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100),,,,,Oncology,,,,,,Industry,Terminated,Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Suzie K,Suk T,Tiffiny K,Ngan D,Rima Y ,Lucie P,Tamesha T,Dalton E,Chetan K,Frank T,Mary H,Jerold Goo †,Perter K,Quentin N,Naren G,Suk T,Clarice N,Garnet T,Otis Thode †,,,"Alabama Oncology, Alabaster, Alabama, United States|Alabama Oncology, Bessemer, Alabama, United States|Alabama Oncology, Bruno Cancer Center, Birmingham, Alabama, United States|Alabama Oncology, Birmingham, Alabama, United States|Alabama Oncology, Birmingham, Alabama, United States|Alabama Oncology, Birmingham, Alabama, United States|Alabama Oncology, Birmingham, Alabama, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HAL, Scottsdale, Arizona, United States|Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States|Arizona Oncology Associates, PC-HOPE, Tucson, Arizona, United States|Arizona Oncology Associates, PC-HOPE, Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Highlands Oncology Group, Rogers, Arkansas, United States|Oso HomeCare, Irvine, California, United States|Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States|Medical Center, Cedars-Sinai, Los Angeles, California, United States|Gynecologic Oncology Associates, Newport Beach, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Hematology-Oncology Medical Group of Orange County, Orange, California, United States|Medical Oncology Care Associates, Orange, California, United States|St. Joseph Hospital of Orange, Orange, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|UC Irvine Health, Orange, California, United States|University of California, Irvine/UC Irvine Health, Orange, California, United States|California Pacific Medical Center - Medical Office Building, San Francisco, California, United States|California Pacific Medical Center - Van Ness Campus, San Francisco, California, United States|California Pacific Medical Center - Davies Campus, San Francisco, California, United States|Bryan Hemming Cancer Care Center - California Pacific Medical Center, San Francisco, California, United States|California Pacific Medical Center - Pacific Heights Outpatient Pharmacy, San Francisco, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|California Pacific Medical Center-Research Institute, San Francisco, California, United States|Palo Alto Medical Foundation Group, San Francisco, California, United States|Sansum Clinic, Santa Barbara, California, United States|Sansum Clinic, Solvang, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|C/O Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Johns Hopkins Sibley Memorial Hospital, Washington, District of Columbia, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|UHEALTH Deerfield Beach, Deerfield Beach, Florida, United States|University of Miami Hospital and Clinics, Miami, Florida, United States|Orlando Health Gynecological Cancer Center, Orlando, Florida, United States|Orlando Health UF Health Cancer Center, Orlando, Florida, United States|Orlando Health, Inc., Orlando, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Investigational Drug Service, Emory University Clinic, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Rcca Md Llc, Bethesda, Maryland, United States|Rcca Md Llc, Germantown, Maryland, United States|SKCCC at Johns Hopkins, Green Spring Station, Lutherville, Maryland, United States|Women's Health Specialists of Montgomery County, Rockville, Maryland, United States|Holy Cross Resource Center, Silver Spring, Maryland, United States|Maryland Oncology Hematology, Silver Spring, Maryland, United States|Holy Cross Hospital, Pharmacy, Silver Spring, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Maryland Oncology Hematology, Wheaton, Maryland, United States|Massachusetts General Hospital Attn: Svetlana Rashkova, RPh, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center Attn: Nisha Sharma, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute Attn: Vasilika Koci, PharmD, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mercy Ministry Office, Chesterfield, Missouri, United States|Mercy - Women's Oncology, Springfield, Missouri, United States|Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center, Springfield, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|Summit Medical Group, Berkeley Heights, New Jersey, United States|Summit Medical Group PA, Florham Park, New Jersey, United States|University Hospital, Investigational Drug Pharmacy, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|University Hospital, Ambulatory Care Center, Newark, New Jersey, United States|University Hospital, The Cancer Center, Newark, New Jersey, United States|Montefiore - Einstein Center for Cancer Care, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Montefiore Medical Center, Centennial Women's Center, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Medical Arts Radiology, Huntington, New York, United States|ProHealth Radiology, Huntington, New York, United States|NYU Winthrop Hospital, Clinical Trials Center, Mineola, New York, United States|NYU Winthrop Hospital, Gynecologic Oncology, Mineola, New York, United States|NYU Winthrop Hospital, Infusion Center, Mineola, New York, United States|NYU Winthrop Hospital, Research Pharmacy, Mineola, New York, United States|NYU Winthrop Radiology, Mineola, New York, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|OSU Wexner Medical Center, Arthur G. James Cancer Hospital & Solove Research Institute, Columbus, Ohio, United States|OSU Wexner Medical Center, Investigational Drug Services, Columbus, Ohio, United States|OSU Wexner Medical Center, Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio, United States|Oncology Hematology Care, Inc., Fairfield, Ohio, United States|OSU Wexner Medical Center, Gynecologic Oncology at Mill Run, Hilliard, Ohio, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Asante Three Rivers Medical Center, Grants Pass, Oregon, United States|Hematology Oncology Associates, Grants Pass, Oregon, United States|Asante Pharmacy, Medford, Oregon, United States|Asante Rogue Regional Medical Center, Medford, Oregon, United States|Hematology Oncology Associates, Medford, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Magee-Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute Investigational Drug Service, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Shelbyville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|Texas Oncology-Austin Central, Austin, Texas, United States|Texas Oncology - South Austin, Austin, Texas, United States|Texas Oncology Bedford, Bedford, Texas, United States|Parkland Health and Hospital System, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center-Clements University Hospital, Dallas, Texas, United States|UT Southwestern Medical Center-Zale Lipshy University Hospital, Dallas, Texas, United States|Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, United States|US Oncology Investigational Products Center (IPC), Irving, Texas, United States|US Oncology Investigational Products Center, Irving, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|Utah Cancer Specialists, Layton, Utah, United States|Utah Cancer Specialists, Murray, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Utah Cancer Specialists, West Jordan, Utah, United States|Emily Couric Cancer Center, Charlottesville, Virginia, United States|MHAT for Female Health-Nadezhda OOD, Sofia, Bulgaria|Shato Ead, Sofia, Bulgaria|Cross Cancer Institute, Edmonton, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University Health Centre-Glen Site, Montreal, Quebec, Canada|Oncology Pharmacy McGill University Health Centre, Montreal, Quebec, Canada|CHU de Quebec-Universite Laval, Quebec, Canada|Klinicki bolnicki centar Split, Split, Croatia|Klinicki bolnicki centar Sestre milosrdnice, Zagreb, Croatia|East Tallinn Central Hospital, Tallinn, Estonia|East-Tallinn Central Hospital, Center of Oncology, Tallinn, Estonia|North Estonia Medical Centre Foundation, Pharmacy, Tallinn, Estonia|North Estonia Medical Centre Foundation, Tallinn, Estonia|Tartu University Hospital, Hematology and Oncology Clinic, Tartu, Estonia|Zentralapotheke Zytostatika, Chemnitz, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Johannes Apotheke Klinikversorgung, Groebenzell, Germany|Radiologie Uniklinik Koeln, Koeln, Germany|Uniklinik Koeln Apotheke, Koeln, Germany|Uniklinik Koeln Klinik fuer Frauenheilkunde und Geburtshilfe, Koeln, Germany|Radiologie Muenchen, Muenchen, Germany|Frauenklinik am Rotkreuzklinikum Muenchen, Muenchen, Germany|Diagnostische und Interventionelle Radiologie, Potsdam, Germany|Klinikum Ernst von Bergmann gGmbH, Potsdam, Germany|Universitaetsklinikum Wuerzburg Frauenklinik und Poliklinik, Wuerzburg, Germany|Queen Elizabeth Hospital, Hong Kong, Hong Kong|The University of Hong Kong, Hong Kong, Hong Kong|Semmelweis Egyetem Onkologiai Kozpont, Budapest, Hungary|Debreceni Egyetem Klinikai Gyogyszertar, Debrecen, Hungary|Debreceni Egyetem Klinikai Kozpont, Szuleszeti es Nogyogyaszati Klinika, Debrecen, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Onkologiai Kozpont, Szolnok, Hungary|Mater Misericordiae University Hospital, Dublin 7, Dublin, Ireland|Mater Private Hospital, Dublin 7, Dublin, Ireland|Bon Secours Hospital Ireland, Cork, Ireland|Bon Secours Hospital, Cork, Ireland|Pharmacy Department, St James's Hospital, Dublin 8, Ireland|St James's Hospital, Dublin 8, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|Azienda Ospedaliero -Universitaria di Bologna Policlinico S. Orsola - Malpighi, Bologna, BO, Italy|Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola - Malpighi, Bologna, BO, Italy|E.O. Ospedali Galliera, Genova, GE, Italy|Farmacia Galliera, Genova, GE, Italy|Istituto Europeo di Oncologia, Milano, MI, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, MI, Italy|Azienda Socio Sanitaria Territoriale ASST della Valtellina e dell Alto Lario, Sondrio, SO, Italy|Istituto Nazionale Tumori Napoli IRCCS Fondazione Pascale, Napoli, Italy|Dip.to per la Tutela della Salute della Donna, della Vita Nascente, del Bambino e dell'Adolescente, Roma, Italy|The Jikei University Kashiwa Hospital, Kashiwa-shi, Chiba, Japan|Shikoku Cancer Center, Matsuyama, Ehime, Japan|Ehime University Hospital, Toon, Ehime, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|Kyoto University Hospital, Sakyo-ku, Kyoto, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|National Defense Medical College Hospital, Tokorozawa, Saitama, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Center for Uterine Cancer, National Cancer Center, Goyang-Si, Gyeonggi-do, Korea, Republic of|Clinical Trial Pharmacy, National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|CHA Bundang Medical Center, CHA University, Clinical Trial Pharmacy, Seongnam, Gyeonggi-do, Korea, Republic of|CHA Bundang Medical Center, CHA University, Seongnam, Gyeonggi-do, Korea, Republic of|Korea University Anam Hospital, Clinical Trial Pharmacy, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|CTC Cancer Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Clinical Research Pharmacy, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Clinical Trial Pharmacy, Samsung Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Clinical Trial Pharmacy, Korea University Guro Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Daugavpils Regional Hospital, Oncology Department (11 floor), Daugavpils, Latvia|Daugavpils Regional Hospital, Daugavpils, Latvia|Natalja Goncarova -Radiology Services, Daugavpils, Latvia|Inga Vigule-Radiology services, Liepaja, Latvia|Liepaja Regional hospital, Liepaja, Latvia|Pauls Stradins Clinical University Hospital, Riga, Latvia|Medical Society ""ARS"" Ltd, Riga, Latvia|Instituto Nacional de Cancerologia, Mexico, Distrito Federal, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Academisch Medisch Centrum, Amsterdam, Netherlands|Pharmacy Universitair Medisch Centrum Groningen, Groningen, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|LUMC, Leiden, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|Pharmacy Zuyderland Medisch Centrum, Sittard-Geleen, Netherlands|Zuyderland Medisch Centrum, Sittard-Geleen, Netherlands|Szpitale Pomorskie Sp. z.o.o., Apteka Szpitalna, Gdynia, Poland|Szpitale Pomorskie, Sp. z o. o., Oddzial Onkologii i Radioterapii, Gdynia, Poland|Centrum Onkologii, Instytut im. M. Sklodowskiej-Curie, Oddzial w Krakowie, Apteka Szpitalna, Krakow, Poland|Centrum Onkologii, Instytut im.M.Sklodowskiej-Curie, Oddzial w Krakowie, Krakow, Poland|Wojewodzki Szpital Specjalistyczny w Olsztynie. Apteka Szpitalna, Olsztyn, Poland|Wojewodzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Poland|Opolskie Centrum Onkologii im. prof. Tadeusza Koszarowskiego w Opolu, Opole, Poland|Ginekologiczno - Polozniczy Szpital Kliniczny Uniwersytetu Medycznego im. Karola Marcinkowskiego w, Poznan, Poland|SC Medisprof SRL, Cluj Napoca, Cluj, Romania|SC Oncolab SRL, Craiova, Dolj, Romania|SC Centrul de Oncologie Euroclinic SRL, Iasi, Romania|Limited liability company (LLC) EVIMED, Chelyabinsk, Chelyabinsk Region, Russian Federation|State Budgetary Healthcare Institution, Chelyabinsk, Chelyabinsk Region, Russian Federation|Regional Budgetary Healthcare Institution (RBHI) Ivanovo Regional Oncology Dispensary, Ivanovo, Ivanovo Region, Russian Federation|FSBI - NMRRC Minzdrav Russia at the branch A.F.Tsyb Medical Radiological Research Centre, Obninsk, Kaluga Region, Russian Federation|SBHI Orenburg Regional Clinical Oncology Dispensary (SBHI ORCOD), Orenburg, Orenburg Region, Russian Federation|SAHI ""Republican Clinical Oncology Dispensary of the MoH of TR"", Kazan, Tatarstan Republic, Russian Federation|SBHI Moscow Clinical Scientific and Practical Centre of Moscow City Healthcare Department, Moscow, Russian Federation|FSBI National Research Medical Center of Oncology N.A., Moscow, Russian Federation|Clinic, Moscow, Russian Federation|Limited liability company VitaMed-LLC VitaMed, Moscow, Russian Federation|SBHI Saint-Petersburg Clinical Scientific - Practice Center of Specialized Types of Medical Care, Saint Petersburg, Russian Federation|National University Hospital, Singapore, Singapore|National University Hospital, Pharmacy @ NCIS, Singapore, Singapore|Raffles Hospital, Singapore, Singapore|NsP sv. Jakuba, n.o. , Bardejov, Bardejov, Slovakia|Onkologicky ustav sv. Alzbety a.s., Bratislava, Slovakia|Narodny onkologicky ustav, Bratislava, Slovakia|Vychodoslovensky onkologicky ustav, a.s., Kosice, Slovakia|POKO Poprad s.r.o., Poprad, Slovakia|Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Ticino, Switzerland|Ospedale San Giovanni, Bellinzona, Ticino, Switzerland|Radiologia ORBV, Bellinzona, Ticino, Switzerland|Kantonsspital Winterthur, Winterthur, Zuerich, Switzerland|Kantonsspital Winterthur, Winterthur, Zurich, Switzerland|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Clinical Trial Pharmacy, MacKay Memorial Hospital, Taipei city, Taiwan|Mackay Memorial Hospital, Taipei City, Taiwan|Cathay General Hospital, Taipei City, Taiwan|Clinical Trial Pharmacy, Koo Foundation Sun Yat-Sen Cancer Center, Taipei City, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei City, Taiwan|Clinical Trial Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou Branch, Taoyuan City, Taiwan|Chemotherapy Pharmacy, Chang Gung Memorial Hospital - Linkou Branch, Taoyuan City, Taiwan|Baskent University Adana Training and Research Hospital, Adana, Turkey|Baskent University Ankara Hospital, Department of Oncology, Ankara, Turkey|Bezmialem Vakif University Medical Faculty Hospital, Istanbul, Turkey|Istanbul University Oncology Institute, Istanbul, Turkey|Istanbul University Cerrahpasa-Cerrahpasa Medical Faculty, Istanbul, Turkey|Ege University Faculty of Medicine Hospital, Izmir, Turkey|Communal Institution Chernivtsi Regional Clinical Oncology Dispensary, Chernivtsi, Ukraine|Cl Dnipropetrovsk City Multifield Clinical Hospital, Dnipropetrovsk, Ukraine|Municipal Institution Kryviy Rih Oncology Center of Dnipropetrovsk regional Council, Kryviy Rig, Ukraine|Clinic of National Cancer Institute, Kyiv, Ukraine|CNE of Lviv Regional Council ""Lviv Oncological Regional Therapeutical and Diagnostic Centre"", Lviv, Ukraine|Central Municipal Clinical Hospital, Municipal oncology center, therapeutics department, Uzhhorod, Ukraine|Torbay and South Devon NHS Foundation Trust, Torquay, Devon, United Kingdom|East Kent Hospitals University NHS Foundation Trust, Margate, Kent, United Kingdom|University College London Hospital NHS Foundation Trust, Islington, London, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, Merseyside, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Merseyside, United Kingdom|East and North Hertfordshire NHS Trust, Northwood, Middlesex, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Headington, Oxford, United Kingdom|Royal Surrey County Hospital NHS Foundation Trust, Guildford, Surrey, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|University Hospitals Bristol NHS Foundation trust, Bristol, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|University College London Hospital NHS Foundation Trust, London, United Kingdom|University College London Hospital NHS Foundation Trust, London, United Kingdom|Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom|Royal Marsden NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|University College London Hospital, London, United Kingdom|The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Baxter Healthcare, Stockport, United Kingdom",56.54782196,50.89303977,Female,"18 Years and older ¬† (Adult, Older Adult)",650,636,583,423,76,84,2/4/2015,8/4/2015,6/7/2015,7/9/2015,6/10/2015,6/28/2015,7/7/2015,7/12/2015,8/4/2015,11/25/2017,12/18/2017,5/4/2018,9/7/2018,10/21/2018,12/1/2018,1/14/2019,2/24/2019,4/9/2019,6/5/2019,12/25/2015,6/22/2016,12/19/2016,6/17/2017,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02718417,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02718417/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02718417/SAP_001.pdf"
Pfizer,Pfizer,ST00415,SP00015,HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes,,,,,Oncology,,,,,,Industry,"Active, not recruiting",,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Suzie K,Mary H,Jene M,Mac L,Mara A,Anthony P,Suzie K,Frank T,Patria R,Perter K,Lavina S,Lucie P,Kandace p,Otis Thode †,Rima Y ,Tamesha T,Quentin N,Louann C,Ngan D,,,"Pfizer United States, New York, New York, United States",90.5564255,81.50078295,All,"50 Years to 74 Years ¬† (Adult, Older Adult)",641,614,584,210,340,34,12/16/2016,6/6/2017,4/29/2017,5/24/2017,4/15/2017,5/7/2017,5/16/2017,5/18/2017,6/15/2017,3/21/2020,1/31/2020,5/23/2020,9/30/2020,11/27/2020,1/2/2021,2/24/2021,4/3/2021,5/27/2021,7/16/2021,11/3/2017,5/2/2018,10/29/2018,4/27/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04396626,,,,,,
Pfizer,Pfizer,ST00433,SP00015,Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients,,,,,Oncology,,,,,,Industry,Terminated,,Observational,,Observational Model: Case-Control|Time Perspective: Prospective,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Quentin N,Suzie K,Marcelina X,Liberty A,Ngan D,Terrell p,Terisa Sikora †,Jerold Goo †,Terrell p,Louann C,Stephan T,Jene M,Quentin N,Suzie K,Dinah R,Jaquelyn H,Geralyn K,Jeanene Y,Chetan K,,,,48.47712556,43.62941301,Female,"18 Years to 99 Years ¬† (Adult, Older Adult)",658,639,585,452,57,76,11/25/2006,5/19/2007,3/16/2007,4/16/2007,3/27/2007,3/29/2007,4/5/2007,4/9/2007,4/26/2007,5/26/2011,1/3/2011,4/17/2011,9/1/2011,10/6/2011,11/14/2011,12/21/2011,2/4/2012,3/14/2012,4/24/2012,9/25/2007,3/23/2008,9/19/2008,3/18/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01155063,,,,,,
Pfizer,Pfizer,ST00437,SP00015,Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer,,,,,Oncology,,,,,,Industry,Terminated,Phase 2,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug I,,,,,,,,,,,,,,,,,,,Donovan H,Chetan K,Suk T,Ngan D,Xochitl D,Jene M,Geralyn K,John G,Marceline R,Aleta H,Tiffiny K,Donovan H,Anthony P,Naren G,Jene M,Dinah R,Anthony P,Mary H,Liberty A,,,"Pfizer Investigational Site, Lake Worth, Florida, United States|Pfizer Investigational Site, Joliet, Illinois, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, New Brunswick, New Jersey, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Bethlehem, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, South Brisbane, Queensland, Australia|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Liege, Belgium|Pfizer Investigational Site, Wilrijk, Belgium|Pfizer Investigational Site, Kelowna, British Columbia, Canada|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Mumbai, Maharashtra, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Olsztyn, Poland|Pfizer Investigational Site, Lynnwood, Gauteng, South Africa|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site",61.70512471,55.53461224,Female,"Child, Adult, Older Adult",648,638,586,270,287,29,6/4/2008,12/16/2008,10/13/2008,11/18/2008,10/23/2008,10/30/2008,11/9/2008,11/10/2008,12/3/2008,11/11/2009,9/14/2009,4/30/2010,6/1/2010,7/26/2010,9/23/2010,11/9/2010,12/12/2010,1/25/2011,3/25/2011,4/28/2009,10/25/2009,4/23/2010,10/20/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00793546,,,,,,
Pfizer,Pfizer,ST00439,SP00015,"Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy",,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Perter K,Xochitl D,Lavina S,Chetan K,Harry A,Terisa Sikora †,Mara A,Selizabeth F,Mee M,John G,Terrell p,Anthony P,Lilla Stilson †,Terisa Sikora †,Patria R,Christian G,Mara A,Tammara F,Mara A,,,"Syapse, San Francisco, California, United States",35.2457453,31.72117077,All,"18 Years to 120 Years ¬† (Adult, Older Adult)",599,593,587,294,246,47,12/11/2016,6/5/2017,3/26/2017,5/6/2017,4/5/2017,4/23/2017,4/27/2017,4/28/2017,5/21/2017,3/21/2020,4/22/2020,10/8/2020,12/31/2020,2/10/2021,3/25/2021,5/9/2021,6/15/2021,7/17/2021,9/1/2021,10/20/2017,4/18/2018,10/15/2018,4/13/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04394247,,,,,,
Pfizer,Pfizer,ST00443,SP00015,Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Randomized|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Hee Y,James y,Dalton E,James y,Gertrudis T,Corrine U,Corrine U,Lilla Stilson †,Suzie K,In Bellini †,Frank T,Mara A,Mara A,Jerold Goo †,Kandace p,Beulah N,Livia Pacheo †,Selizabeth F,Chetan K,,,"Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Raleigh Hematology/Oncology Associates - Wake Practice, Raleigh, North Carolina, United States|Jewish Hospital of Cincinnati, Inc., Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|West Clinic, P.C., Memphis, Tennessee, United States|Sarah Cannon-Minnie Pearl Cancer Center, Nashville, Tennessee, United States|Tyler Cancer Center, Tyler, Texas, United States|Northern Virginia Oncology Group, Fairfax, Virginia, United States|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada|Ottawa Regional Cancer Center - General Division, Ottawa, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada",77.11405235,69.40264712,All,"40 Years and older ¬† (Adult, Older Adult)",643,634,588,252,296,40,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,2/23/1900,4/5/1900,5/16/1900,7/6/1900,8/20/1900,10/13/1900,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,###############################################################################################################################################################################################################################################################,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00004861,,,,,,
Pfizer,Pfizer,ST00480,SP00015,Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Garnet T,Federico L,Chetan K,Frank T,Xochitl D,Suzie K,Jeanene Y,Suzie K,Donovan H,Mee M,Lavina S,Xochitl D,Harry A,Marceline R,In Bellini †,Naren G,Terisa Sikora †,Mary H,Suzie K,,,"Pfizer Investigational Site, Bakersfield, California, United States|Pfizer Investigational Site, Burbank, California, United States|Pfizer Investigational Site, Fountain Valley, California, United States|Pfizer Investigational Site, Hawthorne, California, United States|Pfizer Investigational Site, Long Beach, California, United States|Pfizer Investigational Site, Boynton Beach, Florida, United States|Pfizer Investigational Site, Zion, Illinois, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, Maple Grove, Minnesota, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, Columbia, Missouri, United States|Pfizer Investigational Site, Asheville, North Carolina, United States|Pfizer Investigational Site, Chapel Hill, North Carolina, United States|Pfizer Investigational Site, Kernersville, North Carolina, United States|Pfizer Investigational Site, Lexington, North Carolina, United States|Pfizer Investigational Site, North Wilkesboro, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Bismarck, North Dakota, United States|Pfizer Investigational Site, Franklin, Tennessee, United States|Pfizer Investigational Site, Gallatin, Tennessee, United States|Pfizer Investigational Site, Hermitage, Tennessee, United States|Pfizer Investigational Site, Lebanon, Tennessee, United States|Pfizer Investigational Site, Murfreesboro, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Smyrna, Tennessee, United States|Pfizer Investigational Site, Everett, Washington, United States",51.08640419,45.97776377,Female,"18 Years and older ¬† (Adult, Older Adult)",651,624,589,262,287,40,11/17/2006,4/25/2007,2/16/2007,3/6/2007,2/13/2007,3/1/2007,3/3/2007,3/4/2007,3/16/2007,10/8/2009,9/23/2009,1/22/2010,6/1/2010,7/16/2010,8/31/2010,10/11/2010,12/9/2010,2/1/2011,3/15/2011,8/28/2007,2/24/2008,8/22/2008,2/18/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00471276,,,,,,
Pfizer,Pfizer,ST00483,SP00015,Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Tammara F,James y,Mara A,Jene M,John G,Tiffiny K,Xochitl D,Liberty A,Otis Thode †,Clarice N,Kala R,Jaquelyn H,Stephan T,Anthony P,Ngan D,James y,Mee M,Frank T,Marceline R,,,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China|PLA 307 Hospital, Beijing, China|Ba Yi Hospital, Cancer Center of CPLA, Nanjing, China|Jiangsu Cancer Hospital, Nanjing, China|Cancer Hospital, Shanghai, China|The 2nd Central Hospital of Tianjin, Tianjin, China|The 1st Affiliated Hospital, Xi'an Jiao Tong University, Xi'an, China",97.60725661,87.84653095,Female,"18 Years and older ¬† (Adult, Older Adult)",607,596,590,440,79,71,11/30/2004,7/21/2005,4/30/2005,6/11/2005,5/11/2005,5/22/2005,6/6/2005,6/10/2005,6/21/2005,7/10/2007,2/19/2007,8/29/2007,12/1/2007,1/10/2008,2/22/2008,4/12/2008,5/21/2008,6/25/2008,8/6/2008,11/18/2005,5/17/2006,11/13/2006,5/12/2007,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01237327,,,,,,
Pfizer,Pfizer,ST00497,SP00015,A Study Of PF-05280014 Or Trastuzumab Plus Taxotere¬Æ And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug D,,,,,,,,,,,,,,,,,,,Suzie K,Chetan K,James y,Jaquelyn H,Anthony P,Harry A,Livia Pacheo †,Doreen T,Kala R,Marcelina X,Suzie K,Suk T,Xochitl D,Rima Y ,Kala R,Mac L,Suk T,Clarice N,Hee Y,,,"Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|Millennium Oncology (Imaging Facility), Kingwood, Texas, United States|Millennium Oncology (Imaging Facility), Shenandoah, Texas, United States|Millennium Oncology, Shenandoah, Texas, United States|SI 'Republican Research and Practice Centre of Oncology and Medical Radiology n.a. N.N. Alexandrov', Lesnoy, Minsk Region, Belarus|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Bacs-Kiskun Megyei Korhaz, Kecskemet, Bacs-kiskun, Hungary|Semmelweis Egyetem Altalanos Orvostudomanyi Kar-I. sz. Belgyogyaszati Klinika Onkologiai Reszleg, Budapest, Hungary|Szent Imre Egyetemi Oktato Korhaz, Budapest, Hungary|Uzsoki Utcai Korhaz, Onkoradiologia, Sugarterapia Fovarosi Onkoradiologiai Kozpont, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktatokorhaz,, Miskolc, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendelointezet, Szolnok, Hungary|Division of Medical Senology, Milano, MI, Italy|Divisione di Oncologia Medica B, Roma, RM, Italy|IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Roma, RM, Italy|Dept. of Surgery, Roma, RM, Italy|Szpitale Wojewodzkie w Gdyni Sp. z o.o., Oddzial Onkoligii i Radioterapii, Gdynia, Poland|Oddzial Chorob Rozrostowych, Lodz, Poland|SPZOZ MSW z Warminsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn, Poland|State Budgetary Healthcare Institution ""Leningrad Regional Oncological Dispensary"", Kuzmolovo, Leningrad Region, Russian Federation|""State Budgetary Healthcare Institution """"Republican Clinical Oncological Dispensary of the Ministry, Ufa, Republic Bashkortost, Russian Federation|Regional Budgetary Healthcare Institution ""Kursk regional clinical oncological Dispensary"", Kislino Settlement, Ryshkovskiy Village Council, Russian Federation|""State Budgetary Healthcare Institution of Stavropol Region """"Pyatigorsk Oncological Dispensary"""""", Pyatigorsk, Stavropol Region, Russian Federation|State Budgetary Healthcare Institution ""Volgograd Regional Oncological Dispensary #3"", Volzhskiy, Volgograd Region, Russian Federation|SBHI ""Regional Oncology Dispensary"", Irkutsk, Russian Federation|Regional Budgetary Healthcare Institution, Kursk, Russian Federation|FSBI ""Russian Oncology Scientific center n.a. N. N. Blokhin"" RAMS, Moscow, Russian Federation|State Budgetary Institution Of Healthcare, Moscow, Russian Federation|SBHI of NNR ""Clinical diagnostic center"", Nizhniy Novgorod, Russian Federation|State Budgetary Healthcare Institution of NNR ""Nizhniy Novgorod Regional Oncological Dispensary"", Nizhniy Novgorod, Russian Federation|Budgetary Institution of healthcare of Omsk region ""Clinical oncological dispensary"", Omsk, Russian Federation|State Budgetary Educational Institution of Higher Professional Education ""North-Western State, Saint-Petersburg, Russian Federation|Saint-Peterbsurg Clinical Oncological dispensary of Moscow district, Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Healthcare Institution ""Oncological Dispensary of Moscow District"", Saint-Petersburg, Russian Federation|LLC RAMSAY Diagnostic RUS, Saint-Petersburg, Russian Federation|""Federal State Institution """"Scientific Research Institute of Oncology n.a. N.N.Petrov"""", Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Institution of healthcare ""City Clinical Oncological Dispensary"", Saint-Petersburg, Russian Federation|SRBHI ""Regional Clinical Oncology Dispensary"", Velikiy Novgorod, Russian Federation|Institute For Oncology And Radiology Of Serbia, Belgrade, Serbia|Onkologicky ustav sv. Alzbety, s.r.o., Bratislava, Slovakia|Narodny Onkologicky ustav, Bratislava, Slovakia|Vychodoslovensky onkologicky ustav, a.s., Kosice, Slovakia|Municipal Healthcare Institution 'Chernihiv Regional Oncology Dispensary', Mamology Department, Chernihiv, Ukraine|MI 'City Dnipropetrovsk Multi-field Clin. Hospital #4 of DRC', Dep.-nt of Chemotherapy;, Dnipropetrovsk, Ukraine|SI ""Institute of Medical Radiology n.a.S.P. Hrygoriev of National Academy, Kharkiv, Ukraine|Munincipal Healthcare Institution""Kharkiv Regional Clinical Oncologic Center, Kharkiv, Ukraine|Khmelnytskyi Regional Oncologic Dispensary, Khmelnytskyi, Ukraine|MI 'Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council', Kryvyi Rih, Ukraine|Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine|Municipal Institution 'Odesa Regional Clinical Hospital', Mamology Center, Odesa, Ukraine|Regional Municipal Institution ""Sumy Regional Clinical Oncology Dispensary"", Thoracic Department, Sumy, Ukraine|Vinnytsia Regional Oncology Clinical Dispensary, Chemotherapy Department, Vinnytsia, Ukraine",68.48436665,61.63592998,Female,"18 Years and older ¬† (Adult, Older Adult)",611,598,591,260,304,27,4/18/2012,10/22/2012,8/30/2012,10/3/2012,8/31/2012,9/15/2012,9/20/2012,9/22/2012,10/4/2012,7/14/2015,7/1/2015,12/31/2015,3/9/2016,4/11/2016,6/8/2016,7/10/2016,8/19/2016,10/8/2016,11/24/2016,3/14/2013,9/10/2013,3/9/2014,9/5/2014,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02187744,,,,,,
Pfizer,Pfizer,ST00500,SP00015,Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone,,,,,Oncology,,,,,,Industry,"Active, not recruiting",,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Ngan D,Perter K,Rima Y ,Suzie K,Jerold Goo †,Kala R,Liberty A,Remedios Z,Naren G,In Bellini †,John G,James y,Tiffiny K,Beulah N,Mac L,Remedios Z,Marceline R,Mac L,Tiffiny K,,,"Pfizer New York, New York, New York, United States",89.44960966,80.50464869,Female,"18 Years and older ¬† (Adult, Older Adult)",634,615,592,579,98,85,9/23/2016,4/7/2017,2/23/2017,3/15/2017,2/13/2017,3/1/2017,3/12/2017,3/13/2017,4/8/2017,2/8/2021,4/21/2021,8/8/2021,12/13/2021,2/9/2022,3/22/2022,5/17/2022,7/11/2022,8/30/2022,10/29/2022,8/28/2017,2/24/2018,8/23/2018,2/19/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05012644,,,,,,
Pfizer,Pfizer,ST00501,SP00015,Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Jerold Goo †,Livia Pacheo †,Quentin N,Lucie P,John G,Frank T,Lucie P,Liberty A,Garnet T,Chetan K,Ross S,Frank T,Corrine U,Selizabeth F,Rima Y ,Terrell p,Kala R,Lavina S,Mee M,,,"Allgemeines Krankenhaus der Stadt Wien, Vienna (Wien), Austria|U.Z. Gasthuisberg, Leuven, Belgium|National Cancer Institute of Egypt, Cairo, Egypt|CHU Pitie-Salpetriere, Paris, France|Hopital Tenon, Paris, France|Universitats-Krankenhaus Eppendorf, Hamburg, Germany|Ospedali Riuniti di Bergamo, Bergamo, Italy|Universita Degli Studi di Firenze - Policlin. di Careggi, Firenze (Florence), Italy|Ospedale San Carlo Borromeo, Milano (Milan), Italy|Azienda Ospedaliera S. Maria, Terni, Italy|Universita Degli Studi di Udine, Udine, Italy|Instituto Portugues de Oncologia do Porto, Porto, Portugal|Hospital Universarito ""Reina Sofia"", Cordoba, Spain|Hopital Cantonal Universitaire de Geneva, Geneva, Switzerland|Royal Marsden Hospital, Sutton, England, United Kingdom",76.92800161,69.23520145,All,"18 Years and older ¬† (Adult, Older Adult)",644,627,593,253,310,30,4/17/2003,9/26/2003,7/31/2003,8/24/2003,8/13/2003,8/16/2003,8/22/2003,8/26/2003,9/25/2003,11/15/2003,1/26/2004,5/14/2004,9/1/2004,10/22/2004,11/23/2004,12/30/2004,2/22/2005,4/7/2005,5/23/2005,2/12/2004,8/10/2004,2/6/2005,8/5/2005,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00026273,,,,,,
Pfizer,Pfizer,ST00504,SP00015,A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF),,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Patria R,Lavina S,Lucie P,Aleta H,Lucie P,Jeanene Y,Jaquelyn H,Chetan K,Marceline R,Aleta H,Gertrudis T,Dinah R,Kala R,Christian G,Stephan T,Perter K,Mary H,Lilla Stilson †,Federico L,,,"Arizona Oncology Associates- Saguaro Cancer Center, Glendale, Arizona, United States|Arizona Oncology Associates- Biltmore Cancer Center, Phoenix, Arizona, United States|Arizona Oncology Associates- Deer Valley Cancer Center, Phoenix, Arizona, United States|Arizona Oncology Associates- East Valley Cancer Center, Tempe, Arizona, United States|The Oncology Institute of Hope and Innovation, Glendale, California, United States|The Oncology Institute of Hope and Innovation, Long Beach, California, United States|The Oncology Institute of Hope and Innovation, Santa Ana, California, United States|The Oncology Institute of Hope and Innovation, Whittier, California, United States|Oncology Hematology Associates, Springfield, Missouri, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Saint Francis Hospital Cancer Center, Greenville, South Carolina, United States|Bacs-Kiskun Megyei Korhaz Onkoradiologiai Kozpont, Kecskemet, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, Hungary|Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Italy|Cardiologia - Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Italy|Farmacia Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Italy|UOC di Radiologia - Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Italy|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Regionalny Szpital Specjalistyczny Im. Dr. Wladyslawa Bieganskiego w Grudziadzu, Grudziadz, Poland|Centrum Medyczne Dom Lekarski S.A., Szczecin, Poland|Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie w Warszawie, Warszawa, Poland|GBUZ of Stavropol Territory ""Pyatigorsk Inter-regional Oncology Dispanser"", Pyatigorsk, Stavropol Territory, Russian Federation|LLC ""University clinic of headache"", Moscow, Russian Federation|Limited Liability Company ""VitaMed"" (LLC ""VitaMed""), Moscow, Russian Federation|LLC ""University Clinic of Headache"", Moscow, Russian Federation|Limited Liability Company ""VitaMed"" (LLC ""VitaMed""), Moscow, Russian Federation|Instituto Catalan de Oncologia, Hospitalet de Llobregat, Barcelona, Spain|Consorcio Hospitalario Provincial de Castellon, Castellon, Spain|Chi Mei Hospital, Liouying, Tainan City, Liouying District, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan",26.5217891,23.86961019,All,"Child, Adult, Older Adult",663,640,594,495,14,85,12/26/2017,8/18/2018,6/7/2018,7/10/2018,6/4/2018,6/21/2018,6/30/2018,7/5/2018,8/3/2018,9/13/2021,11/1/2021,2/19/2022,6/28/2022,8/17/2022,9/29/2022,11/13/2022,1/9/2023,3/3/2023,4/7/2023,12/18/2018,6/16/2019,12/13/2019,6/10/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03472560,,,,,,
Pfizer,Pfizer,ST00511,SP00015,Hepatic Impairment Study for Lorlatinib in Cancer Patients,,,,,Oncology,,,,,,Industry,Recruiting,Phase 1,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Suzie K,Suk T,Lavina S,Anthony P,Mac L,John G,Otis Thode †,Perter K,Clarice N,Stephan T,John G,Ross S,Mara A,Terrell p,Naren G,Terrell p,Stephan T,Chetan K,Chetan K,,,"Keck Hospital of USC - Norris Healthcare Center (HC3), Los Angeles, California, United States|Keck Hospital of USC, Los Angeles, California, United States|LAC+USC Medical Center, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|University of Colorado Denver CTO (CTRC), Aurora, Colorado, United States|University of Colorado Hospital, Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States|University of Colorado Hospital, Anschutz Inpatient Pavilion (AIP), Aurora, Colorado, United States|University of Colorado Hospital, Anschutz Outpatient Pavilion (AOP), Aurora, Colorado, United States|Emory University Hospital, Atlanta, Georgia, United States|Investigational Drug Service, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Mays Cancer Center, San Antonio, Texas, United States|University Health System, San Antonio, Texas, United States",84.15904516,75.74314065,All,"18 Years to 125 Years ¬† (Adult, Older Adult)",650,623,595,578,68,51,6/15/2017,2/1/2018,11/17/2017,12/16/2017,11/10/2017,12/4/2017,12/7/2017,12/9/2017,1/3/2018,8/22/2022,2/13/2022,7/21/2022,11/15/2022,12/23/2022,1/23/2023,3/23/2023,5/5/2023,6/18/2023,8/7/2023,6/2/2018,11/29/2018,5/28/2019,11/24/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03726333,,,,,,
Pfizer,Pfizer,ST00517,SP00015,Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review,,,,,Oncology,,,,,,Industry,"Active, not recruiting",,Observational,,Observational Model: Cohort|Time Perspective: Other,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Suk T,Suzie K,Livia Pacheo †,Ngan D,Otis Thode †,John G,Anthony P,Ross S,John G,Mary H,Marceline R,Jeanene Y,Garnet T,Remedios Z,Anthony P,John G,Mac L,Mee M,Anthony P,,,"Beacon Hospital, Petaling Jaya, Malaysia",90.95973166,81.8637585,All,70 Years and older ¬† (Older Adult),648,635,596,586,57,47,6/11/2021,12/6/2021,9/17/2021,10/30/2021,9/27/2021,10/10/2021,10/22/2021,10/23/2021,10/28/2021,7/9/2023,5/27/2023,12/13/2023,2/29/2024,4/22/2024,6/16/2024,8/8/2024,9/29/2024,11/9/2024,1/3/2025,4/8/2022,10/5/2022,4/3/2023,9/30/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04609319,,,,,,
Pfizer,Pfizer,ST00529,SP00015,Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 3,Interventional,,Allocation: Randomized|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Patria R,Lyman W,Naren G,Frank T,Christian G,Suk T,Jene M,Corrine U,Jerold Goo †,Kala R,Xochitl D,Terrell p,Corrine U,Remedios Z,Louann C,Mary H,Perter K,Marceline R,Lavina S,,,"Alabama Oncology, LLC, Montgomery, Alabama, United States|Office of Richard Shapiro, Benjamin Stafford, and Sharon J. Yee, Arcadia, California, United States|Scripps Clinic, La Jolla, California, United States|Tower Hematology Oncology Medical Group, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|St. Francis Hospital, San Francisco, California, United States|Comprehensive Cancer Care Specialists of Boca Raton, Boca Raton, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Cancer Center of Boston, Boston, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|APN-IMPATH Research Corporation, Fort Lee, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New York Medical College, Valhalla, New York, United States|Presbyterian Healthcare, Charlotte, North Carolina, United States|Raleigh Hematology/Oncology Associates - Wake Practice, Raleigh, North Carolina, United States|Hematology/Oncology Associates of NE Pennsylvania, P.C., Scranton, Pennsylvania, United States|Associates in Oncology & Hematology, Chattanooga, Tennessee, United States|Dial Research Associates, Inc., Nashville, Tennessee, United States|Presbyterian Hospital of Dallas, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States",62.89664257,56.60697832,All,"18 Years and older ¬† (Adult, Older Adult)",636,611,597,197,380,20,10/5/2002,2/18/2003,12/18/2002,1/15/2003,12/18/2002,1/6/2003,1/10/2003,1/14/2003,1/19/2003,1/22/2007,12/14/2006,5/16/2007,9/1/2007,10/11/2007,12/2/2007,1/7/2008,2/22/2008,3/29/2008,5/12/2008,7/5/2003,1/1/2004,6/29/2004,12/26/2004,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00004252,,,,,,
Pfizer,Pfizer,ST00538,SP00015,Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 2,Interventional,,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Quentin N,Chetan K,Chetan K,Tien C,Jerold Goo †,Suzie K,Perter K,Mary H,Mary H,Perter K,Jene M,Hee Y,Ross S,Liberty A,Marcelina X,Donovan H,Mara A,Frank T,Gertrudis T,,,"Pfizer Investigational Site, Montgomery, Alabama, United States|Pfizer Investigational Site, Newark, Delaware, United States|Pfizer Investigational Site, Newark, Delaware, United States|Pfizer Investigational Site, Wilmington, Delaware, United States|Pfizer Investigational Site, Fort Lauderdale, Florida, United States|Pfizer Investigational Site, Harvey, Illinois, United States|Pfizer Investigational Site, Tinley Park, Illinois, United States|Pfizer Investigational Site, Munster, Indiana, United States|Pfizer Investigational Site, Lafayette, Louisiana, United States|Pfizer Investigational Site, New Iberia, Louisiana, United States|Pfizer Investigational Site, Corinth, Mississippi, United States|Pfizer Investigational Site, Southaven, Mississippi, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Ottignies, Belgium|Pfizer Investigational Site, Wilrijk, Belgium|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Greenfield Park, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Besancon, France|Pfizer Investigational Site, Lyon, France|Pfizer Investigational Site, Saint Cloud, France|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Valencia, Spain",12.94061788,11.64655609,All,"18 Years and older ¬† (Adult, Older Adult)",659,635,598,419,129,50,3/23/2007,10/19/2007,8/21/2007,9/16/2007,9/6/2007,9/8/2007,9/23/2007,9/24/2007,10/7/2007,9/3/2008,7/20/2008,1/15/2009,4/1/2009,5/23/2009,6/26/2009,8/13/2009,9/20/2009,10/25/2009,12/18/2009,3/6/2008,9/2/2008,3/1/2009,8/28/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT00243503,,,,,,
Pfizer,Pfizer,ST00542,SP00015,A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley),,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 2,Interventional,,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug H,,,,,,,,,,,,,,,,,,,John G,Rima Y ,Harry A,Anthony P,In Bellini †,Chetan K,John G,Lavina S,Aleta H,Mary H,Mary H,Mary H,Anthony P,Kala R,Kandace p,Mary H,Kandace p,Rima Y ,Kala R,,,"UCSD Medical Center - Encinitas, Encinitas, California, United States|Koman Family Outpatient Pavilion, La Jolla, California, United States|UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion), La Jolla, California, United States|UC San Diego Perlman Medical Offices, La Jolla, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA Clinical Research Unit (Adminstration Office), Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCLA Hematology-Oncology Clinic, Los Angeles, California, United States|UCLA Hematology-Oncology Infusion Center, Los Angeles, California, United States|UC San Diego Medical Center - Hillcrest, San Diego, California, United States|UCSD Medical Center - Vista, Vista, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Mount Sinai Comprehensive Cancer Center - Aventura, Aventura, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Michigan Hospitals, Ann Arbor, Michigan, United States|University of Michigan, Ann Arbor, Michigan, United States|Investigational Pharmacy, Karmanos Cancer Center, Detroit, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|VA NY Harbor Healthcare System, New York, New York, United States|NYU Investigational Pharmacy, New York, New York, United States|NYU Langone Medical Center, New York, New York, United States|NYU Laura and Isaac Perlmutter Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Research Pharmacy #PH#, New York, New York, United States|Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York, United States|Sampson Regional Medical Center, Clinton, North Carolina, United States|Southeastern Medical Oncology Center, Clinton, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center, Jacksonville, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|UPCI Investigational Drug Service, Pittsburgh, Pennsylvania, United States|UPMC Shadyside Hospital, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Miriam Hospital, Providence, Rhode Island, United States|Sanford Cancer Center Oncology Clinic & Pharmacy, Sioux Falls, South Dakota, United States|Sanford Gynecologic Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford Interventional Radiology, Sioux Falls, South Dakota, United States|Sanford ENT Clinic, Sioux Falls, South Dakota, United States|Sanford Research, Sioux Falls, South Dakota, United States|Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|Vanderbilt University Oncology Pharmacy, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|UT Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Macquarie University, Macquarie University, New South Wales, Australia|Melanoma Institute Australia, North Sydney, New South Wales, Australia|The Mater Hospital, North Sydney, New South Wales, Australia|Baxter Healthcare, Old Toongabie, New South Wales, Australia|Brighton Medical Imaging, Brighton, Victoria, Australia|Cabrini Hospital Brighton, Brighton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Cabrini Hospital Malvern, Malvern, Victoria, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Malvern Medical Imaging, Malvern, Victoria, Australia|Macquarie Heart, New South Wales, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|PH 145294, Centre Hospitalier de l'Universite de Montreal (CHUM), Oncology Research Pharmacy, Montreal, Quebec, Canada|Centre Hospitalier de l'Universit√© de Montr√©al (CHUM), Montreal, Quebec, Canada|Institut Gustave Roussy, Villejuif, Cedex, France|Institut Gustave Roussy, Villejuif, France|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warszawa, Mazowieckie, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warszawa, Poland|Investigational Drug Services, National Taiwan University Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|The Royal Marsden Hospital, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|Sarah Cannon Research Institute UK, London, United Kingdom|The Harley Street Clinic, London, United Kingdom|The Harley Street Clinic, London, United Kingdom",63.17758617,56.85982756,All,"18 Years to 75 Years ¬† (Adult, Older Adult)",660,646,599,285,267,47,10/18/2018,3/3/2019,1/9/2019,2/13/2019,1/3/2019,1/28/2019,2/4/2019,2/8/2019,3/9/2019,8/10/2021,9/28/2021,1/11/2022,4/29/2022,6/18/2022,8/5/2022,10/3/2022,12/2/2022,1/19/2023,3/16/2023,7/27/2019,1/23/2020,7/21/2020,1/17/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02554812,,,,,,
Pfizer,Pfizer,ST00560,SP00015,"Aromasin¬Æ As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer",,,,,Oncology,,,,,,Industry,Terminated,,Observational,,Observational Model: Case-Control|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Selizabeth F,Mee M,Suzie K,Marceline R,Tiffiny K,Kandace p,John G,Tammara F,Mac L,Lyman W,Gertrudis T,Louann C,Mara A,Garnet T,Livia Pacheo †,Anthony P,Hee Y,Kandace p,Chetan K,,,"General Hospital Karlovac, Karlovac, Croatia|University Hospital Center Osijek, Osijek, Croatia|General Hospital Pula, Pula, Croatia|University Hospital Center Rijeka, Rijeka, Croatia|University Hospital Center Split, Split, Croatia|General Hospital Varazdin, Varazdin, Croatia|Clinic for Tumors, Zagreb, Croatia|University Hospital Center ""Sestre milosrdnice"", Zagreb, Croatia|North Estonia Medical Centre Foundation, Tallinn, Estonia|Institute for Oncology and Radiology of Serbia, Belgrade, Serbia|Oncology Clinic, Medical center, Bezanijska Kosa, Beograd, Serbia",82.41738249,74.17564424,Female,,652,624,600,257,296,47,12/27/2007,7/18/2008,5/23/2008,6/18/2008,5/23/2008,6/2/2008,6/4/2008,6/7/2008,7/2/2008,2/14/2011,2/21/2011,6/21/2011,10/1/2011,11/15/2011,1/1/2012,2/13/2012,3/17/2012,5/15/2012,7/8/2012,11/29/2008,5/28/2009,11/24/2009,5/23/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01239745,,,,,,
Pfizer,Pfizer,ST00571,SP00015,A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin¬Æ) In Postmenopausal Hr+ Patients,,,,,Oncology,,,,,,Industry,Terminated,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Otis Thode †,Mee M,Selizabeth F,Tiffiny K,Anthony P,Lavina S,Gertrudis T,Frank T,Corrine U,Harry A,Frank T,In Bellini †,Dalton E,Chetan K,Mara A,Gertrudis T,Ngan D,Clarice N,Remedios Z,,,,21.80219547,19.62197592,Female,,675,649,601,190,388,23,12/16/2007,7/14/2008,5/25/2008,6/24/2008,5/20/2008,6/7/2008,6/17/2008,6/20/2008,6/26/2008,2/4/2011,9/2/2010,1/2/2011,5/1/2011,6/20/2011,8/8/2011,9/14/2011,10/15/2011,12/10/2011,2/3/2012,12/4/2008,6/2/2009,11/29/2009,5/28/2010,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT01305239,,,,,,
Takeda,Takeda,ST00105,SP00017,A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults,,,Healthy Volunteers,,,,,,,,Industry,Not yet recruiting,,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Marceline R,Terrell p,Donovan H,Selizabeth F,Naren G,Aleta H,Tien C,Mac L,Stephan T,Jeanene Y,Anthony P,Mac L,Remedios Z,Livia Pacheo †,Mary H,Marceline R,Naren G,James y,Anthony P,,,,2.152149001,1.936934101,All,"18 Years and older ¬† (Adult, Older Adult)",668,655,602,283,270,49,4/15/2018,11/10/2018,9/13/2018,10/16/2018,9/20/2018,10/3/2018,10/13/2018,10/16/2018,11/12/2018,1/23/2021,4/16/2021,8/17/2021,11/21/2021,1/3/2022,2/8/2022,4/2/2022,5/13/2022,6/14/2022,8/6/2022,4/1/2019,9/28/2019,3/26/2020,9/22/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05064449,,,,,,
Takeda,Takeda,ST00120,SP00017,A Study of Real-World Outcomes of People With Crohn's Disease (CD),,EVOLVE,Crohn Disease,,I&I,,,,,,Industry,Not yet recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Mary H,Clarice N,John G,Jaquelyn H,Frank T,Terrell p,Mee M,Frank T,Jene M,Jerold Goo †,Tien C,Kala R,Mara A,Christian G,Garnet T,Stephan T,Geralyn K,Mary H,Patria R,,,,83.59403846,75.23463462,All,"18 Years and older ¬† (Adult, Older Adult)",625,615,603,268,301,34,6/2/2017,10/28/2017,8/25/2017,9/26/2017,8/29/2017,9/12/2017,9/23/2017,9/25/2017,10/25/2017,3/30/2022,9/20/2021,2/16/2022,4/30/2022,6/29/2022,8/28/2022,9/29/2022,11/2/2022,12/8/2022,1/8/2023,3/11/2018,9/7/2018,3/6/2019,9/2/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05056441,,,,,,
Takeda,Takeda,ST00150,SP00017,An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer,,,Colorectal Cancer,,Oncology,,,,,,Industry,Not yet recruiting,Phase 1,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Geralyn K,Tien C,Geralyn K,Louann C,Liberty A,John G,Mac L,Ngan D,Lavina S,Naren G,Ross S,Remedios Z,Marceline R,Mee M,Louann C,Lilla Stilson †,Doreen T,Jerold Goo †,Jerold Goo †,,,,43.77614418,39.39852977,All,"18 Years and older ¬† (Adult, Older Adult)",625,615,604,494,17,93,1/11/2023,5/18/2023,3/23/2023,4/21/2023,4/1/2023,4/13/2023,4/27/2023,5/2/2023,5/24/2023,10/13/2023,10/30/2023,4/25/2024,7/31/2024,9/25/2024,11/15/2024,1/11/2025,3/4/2025,4/6/2025,6/5/2025,10/10/2023,4/7/2024,10/4/2024,4/2/2025,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05030493,,,,,,
Takeda,Takeda,ST00154,SP00017,A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Who Are 4 Months or Older,,,Short Bowel Syndrome,,,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Liberty A,Chetan K,Suk T,Liberty A,Harry A,Quentin N,Jene M,Anthony P,Selizabeth F,Suzie K,Garnet T,Mary H,Terrell p,Tiffiny K,Suzie K,Ngan D,Xochitl D,Tien C,Xochitl D,,,,23.09543358,20.78589023,All,"18 Years and older ¬† (Adult, Older Adult)",654,623,605,310,263,32,1/6/2021,6/14/2021,4/7/2021,5/14/2021,3/31/2021,4/24/2021,4/28/2021,5/2/2021,5/16/2021,8/1/2022,4/13/2022,10/21/2022,11/23/2022,12/28/2022,2/19/2023,4/15/2023,5/25/2023,7/17/2023,9/15/2023,10/21/2021,4/19/2022,10/16/2022,4/14/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05027308,,,,,,
Takeda,Takeda,ST00158,SP00017,A Study of Danavorexton in Anesthetized Adults,,,Healthy Volunteers,,,,,,,,Industry,Not yet recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Gertrudis T,Terrell p,Liberty A,Garnet T,Tien C,Kala R,Mee M,Jerold Goo †,Anthony P,John G,Suk T,Suzie K,Naren G,Naren G,Frank T,John G,Mara A,Marceline R,Jerold Goo †,,,,22.84163524,20.55747171,All,30 Years to 45 Years ¬† (Adult),646,636,606,504,36,66,10/11/2018,4/30/2019,3/7/2019,4/1/2019,3/2/2019,3/27/2019,4/10/2019,4/12/2019,5/9/2019,6/6/2021,5/11/2021,12/17/2021,2/8/2022,3/23/2022,5/11/2022,6/20/2022,7/30/2022,9/10/2022,10/24/2022,9/23/2019,3/21/2020,9/17/2020,3/16/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05025397,,,,,,
Takeda,Takeda,ST00160,SP00017,A Study of Teduglutide in Japanese People With Short Bowel Syndrome,,,Short Bowel Syndrome,,,,,,,,Industry,Not yet recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Clarice N,Mary H,Mary H,Chetan K,Liberty A,Ngan D,Ross S,Jeanene Y,Clarice N,Aleta H,Hee Y,Mee M,Garnet T,Naren G,Tamesha T,Mary H,Tamesha T,Lucie P,Aleta H,,,"Takeda Selected Site, Tokyo, Japan",92.0455803,82.84102227,All,"22 Years and older ¬† (Adult, Older Adult)",634,618,607,199,381,27,9/29/2027,4/17/2028,2/22/2028,3/17/2028,3/3/2028,3/10/2028,3/21/2028,3/25/2028,4/8/2028,10/15/2029,12/5/2029,3/15/2030,7/31/2030,8/31/2030,10/30/2030,12/2/2030,1/17/2031,3/13/2031,5/1/2031,9/6/2028,3/5/2029,9/1/2029,2/28/2030,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05023382,,,,,,
Takeda,Takeda,ST00163,SP00017,A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice,,,Ovarian Cancer,,Oncology,,,,,,Industry,Not yet recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Selizabeth F,Dalton E,Mara A,Selizabeth F,Garnet T,Jerold Goo †,Selizabeth F,Ngan D,Lilla Stilson †,Tamesha T,Marcelina X,Mara A,John G,Marceline R,Lilla Stilson †,Remedios Z,Christian G,Lavina S,Tien C,,,"Takeda Selected Site, Tokyo, Japan",44.30476261,39.87428635,Female,"18 Years to 74 Years ¬† (Adult, Older Adult)",627,620,608,443,104,61,5/25/2021,10/8/2021,7/29/2021,9/12/2021,8/7/2021,8/25/2021,8/28/2021,8/31/2021,9/6/2021,10/6/2025,6/25/2025,12/6/2025,3/31/2026,5/2/2026,6/4/2026,7/24/2026,8/31/2026,10/18/2026,12/17/2026,2/21/2022,8/20/2022,2/16/2023,8/15/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05021562,,,,,,
Takeda,Takeda,ST00166,SP00017,A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL),,,Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL),,Oncology,,,,,,Industry,Not yet recruiting,Phase 2|Phase 3,Interventional,,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,John G,Mee M,Selizabeth F,Gertrudis T,Hee Y,Remedios Z,Terisa Sikora †,Ngan D,Patria R,Naren G,Mac L,Gertrudis T,Ross S,Terrell p,Gertrudis T,Stephan T,Mara A,Tamesha T,Mary H,,,,60.74922002,54.67429801,All,"Child, Adult, Older Adult",660,633,609,434,107,68,7/1/2025,11/4/2025,9/13/2025,10/9/2025,9/17/2025,10/2/2025,10/6/2025,10/9/2025,10/27/2025,8/19/2029,4/7/2029,9/1/2029,10/26/2029,12/8/2029,1/11/2030,3/9/2030,4/28/2030,6/24/2030,8/8/2030,3/31/2026,9/27/2026,3/26/2027,9/22/2027,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05020015,,,,,,
Takeda,Takeda,ST00170,SP00017,A Study of NINLARO¬Æ in Chinese Adults With Multiple Myeloma,,,Multiple Myeloma,,Oncology,,,,,,Industry,Not yet recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Selizabeth F,Suzie K,Lilla Stilson †,Kala R,Harry A,Tien C,Anthony P,Anthony P,John G,Mary H,Stephan T,Suzie K,John G,Ngan D,Ngan D,John G,Geralyn K,Jene M,Hee Y,,,"Hematology Department, Beijing, Beijing, China",66.03696035,59.43326431,All,"50 Years to 80 Years ¬† (Adult, Older Adult)",667,639,610,377,174,59,3/20/2024,9/3/2024,7/16/2024,8/20/2024,7/19/2024,8/3/2024,8/17/2024,8/19/2024,9/4/2024,2/28/2025,4/10/2025,7/18/2025,10/31/2025,12/12/2025,1/26/2026,3/16/2026,4/20/2026,5/25/2026,7/20/2026,1/30/2025,7/29/2025,1/25/2026,7/24/2026,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05013190,,,,,,
Takeda,Takeda,ST00189,SP00017,A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin,,BELIEVE,"Hodgkin Disease|Lymphoma, T-Cell, Cutaneous",,Oncology,,,,,,Industry,Not yet recruiting,Phase 4,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Perter K,Mac L,Marceline R,Naren G,Jene M,Ross S,Kandace p,Harry A,Louann C,Suk T,Garnet T,Livia Pacheo †,Mary H,Mac L,Doreen T,Kandace p,Remedios Z,Anthony P,Livia Pacheo †,,,,99.19736076,89.27762469,All,"18 Years to 85 Years ¬† (Adult, Older Adult)",670,650,611,497,63,51,7/28/2020,3/3/2021,1/3/2021,2/9/2021,12/29/2020,1/22/2021,2/2/2021,2/4/2021,2/19/2021,7/5/2021,10/16/2021,1/29/2022,5/31/2022,7/18/2022,8/25/2022,10/8/2022,11/12/2022,1/2/2023,2/7/2023,7/21/2021,1/17/2022,7/16/2022,1/12/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04998331,,,,,,
Takeda,Takeda,ST00197,SP00017,"Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants",,,Healthy Volunteers,,,,,,,,Industry,Completed,,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Dalton E,Selizabeth F,Kala R,Geralyn K,Tien C,Mara A,Ross S,Beulah N,Gertrudis T,Clarice N,John G,Mac L,Tiffiny K,James y,Tammara F,Suk T,Suk T,Otis Thode †,Mac L,,,"Celerion, Lincoln, Nebraska, United States",12.56719134,11.31047221,Male,"18 Years and older ¬† (Adult, Older Adult)",645,635,612,312,256,44,6/10/2015,1/18/2016,11/18/2015,12/7/2015,11/7/2015,11/28/2015,12/13/2015,12/14/2015,1/13/2016,10/16/2019,1/19/2020,5/4/2020,8/18/2020,10/7/2020,11/17/2020,12/22/2020,2/14/2021,3/23/2021,5/16/2021,5/26/2016,11/22/2016,5/21/2017,11/17/2017,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04992442,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04992442/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04992442/SAP_001.pdf"
Takeda,Takeda,ST00202,SP00017,A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland,,,"Inflammatory Bowel Diseases|Crohns Disease|Colitis, Ulcerative",,,,,,,,Industry,Recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Ngan D,Mara A,Dalton E,Anthony P,Chetan K,Federico L,Xochitl D,Doreen T,Frank T,Chetan K,Selizabeth F,In Bellini †,Mara A,Mac L,Mary H,Mary H,Garnet T,Hee Y,Livia Pacheo †,,,"Kantonsspital St. Gallen, St. Gallen, Saint Gallen, Switzerland|Clarunis AG, Basel, Switzerland|Bauchzentrum INSELSPITAL, Universitatsspital Bern, Bern, Switzerland|Gastroenterologische Praxis Balsiger, Seibold & Partner Crohn-Colitis-Zentrum, Bern, Switzerland|Zentrum fur Gastroenterologie und Hepatologie AG, Zurich, Switzerland|Universitatsspital Zurich, Zurich, Switzerland",71.05338469,63.94804622,All,20 Years to 50 Years ¬† (Adult),640,630,613,531,5,77,8/7/2021,2/17/2022,11/27/2021,12/31/2021,12/20/2021,12/22/2021,12/30/2021,1/3/2022,1/14/2022,2/27/2023,9/11/2022,1/11/2023,4/1/2023,5/15/2023,6/17/2023,8/13/2023,10/3/2023,11/6/2023,12/7/2023,6/20/2022,12/17/2022,6/15/2023,12/12/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04989907,,,,,,
Takeda,Takeda,ST00208,SP00017,A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes,,PEVOBINE,Myelodysplastic Syndromes (MDS),,Oncology,,,,,,Industry,Withdrawn,Phase 4,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Suk T,Garnet T,Jaquelyn H,Livia Pacheo †,Jeanene Y,Perter K,Donovan H,Ross S,Marcelina X,Remedios Z,Mary H,Christian G,Lyman W,Frank T,Dinah R,Ngan D,Tamesha T,Mary H,Corrine U,,,,80.9316942,72.83852478,All,"18 Years and older ¬† (Adult, Older Adult)",654,643,614,384,161,69,9/22/2020,3/28/2021,1/12/2021,2/16/2021,1/13/2021,1/31/2021,2/13/2021,2/16/2021,3/2/2021,4/5/2023,5/9/2023,11/11/2023,1/8/2024,3/6/2024,4/23/2024,6/4/2024,7/7/2024,8/27/2024,10/4/2024,7/30/2021,1/26/2022,7/25/2022,1/21/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04985656,,,,,,
Takeda,Takeda,ST00209,SP00017,A Study of Real Life Treatment for Multiple Myeloma (MM),,LEADER,Multiple Myeloma,,Oncology,,,,,,Industry,Not yet recruiting,Phase 2,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Louann C,Beulah N,Marcelina X,John G,Doreen T,Lucie P,Perter K,Mee M,Liberty A,Anthony P,Patria R,Dalton E,Jeanene Y,John G,Xochitl D,Remedios Z,Frank T,Geralyn K,Donovan H,,,"Alexandro-Mariinsky Regional Clinical Hospital, Astrakhan, Russian Federation|Altai Regional Clinical Hospital, Barnaul, Russian Federation|Bryansk Regional Hospital No. 1, Bryansk, Russian Federation|Kaluga Regional Clinical Hospital, Kaluga, Russian Federation|National Research Center of Hematology of the Ministry of Health, Moscow, Russian Federation|Herzen Moscow Scientific Research Oncological Institute, Moscow, Russian Federation|Novosibirsk State Medical University, Department of Therapy, Hematology and Transfusiology based on City Clinical Hospital No. 2, Novosibirsk, Russian Federation|Rostov Regional Clinical Hospital, Rostov-on-Don, Russian Federation|Clinics of Samara State Medical University, Samara, Russian Federation|Smolensk Clinical Hospital of Russian Railways-Medicine, Smolensk, Russian Federation|Russian Research Institute of Hematology and Transfusiology, St. Peterburg, Russian Federation|Leningrad Regional Clinical Hospital, St. Peterburg, Russian Federation|City Clinical Hospital No. 31, St. Peterburg, Russian Federation|Republican Hospital No. 1 - National Center of Medicine, Yakutsk, Russian Federation",8.675301231,7.807771108,All,"18 Years to 85 Years ¬† (Adult, Older Adult)",673,661,615,472,53,90,11/20/2021,4/19/2022,2/7/2022,3/19/2022,3/2/2022,3/6/2022,3/16/2022,3/20/2022,3/27/2022,6/16/2025,1/25/2025,4/3/2025,8/30/2025,10/6/2025,11/21/2025,1/1/2026,2/23/2026,3/26/2026,5/9/2026,9/2/2022,3/1/2023,8/28/2023,2/24/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04985643,,,,,,
Takeda,Takeda,ST00210,SP00017,A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency,,,Congenital Protein C Deficiency,,,,,,,,Industry,Recruiting,Not Applicable,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Patria R,Donovan H,Marcelina X,Naren G,Lyman W,Beulah N,Selizabeth F,Jaquelyn H,Lavina S,Liberty A,Jaquelyn H,Mara A,Selizabeth F,Marceline R,Anthony P,Lyman W,Quentin N,Dalton E,Gertrudis T,,,"Nara Medical University Hospital, Kashihara, Nara, Japan|Chiba Children's Hospital, Chiba, Japan|Chiba University Hospital, Chiba, Japan|Saitama Prefectural Children's Medical Center, Saitama, Japan",22.01584351,19.81425916,All,"Child, Adult, Older Adult",651,641,616,564,60,8,6/30/2018,12/18/2018,9/29/2018,11/6/2018,10/19/2018,10/25/2018,11/7/2018,11/10/2018,12/3/2018,11/19/2021,3/22/2021,11/2/2021,12/22/2021,1/24/2022,3/3/2022,4/19/2022,5/27/2022,7/10/2022,8/29/2022,4/23/2019,10/20/2019,4/17/2020,10/14/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04984889,,,,,,
Takeda,Takeda,ST00216,SP00017,A Study for Post-Marketing Surveillance of Nesina¬Æ Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea,,,Type 2 Diabetes Mellitus,,Metabolic,,,,,,Industry,Completed,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Stephan T,Mary H,Perter K,Lucie P,Chetan K,Anthony P,Donovan H,Xochitl D,Naren G,Ross S,Otis Thode †,Donovan H,Mee M,Garnet T,Terisa Sikora †,Kala R,Livia Pacheo †,Geralyn K,Terisa Sikora †,,,"Andong, Korea, Republic of|Anyang-si, Korea, Republic of|Bucheon-si, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Gimhae, Korea, Republic of|Gongju, Korea, Republic of|Goyang-si, Korea, Republic of|Gwangju, Korea, Republic of|Gyeongju, Korea, Republic of|Incheon, Korea, Republic of|Jeonju, Korea, Republic of|Namyangju-si, Korea, Republic of|Osan, Korea, Republic of|Seongnam-si, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Suncheon, Korea, Republic of|Suwon- si, Korea, Republic of|Suwon-si, Korea, Republic of|Ulsan, Korea, Republic of|Wonju, Korea, Republic of",22.4765369,20.22888321,All,"Child, Adult, Older Adult",673,647,617,299,260,58,7/17/2017,3/4/2018,1/3/2018,1/21/2018,12/25/2017,1/9/2018,1/20/2018,1/24/2018,2/21/2018,3/25/2019,11/19/2018,7/19/2019,8/30/2019,10/2/2019,12/1/2019,1/19/2020,3/11/2020,4/29/2020,6/2/2020,7/8/2018,1/4/2019,7/3/2019,12/30/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04980040,,,,,,
Takeda,Takeda,ST00217,SP00017,A Post-Marketing Surveillance Study on NesinaAct¬Æ Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea,,,Type 2 Diabetes Mellitus,,Metabolic,,,,,,Industry,Completed,Phase 4,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Jeanene Y,Patria R,John G,Terisa Sikora †,Lilla Stilson †,Christian G,Rima Y ,John G,Federico L,Tamesha T,Federico L,Jene M,Jene M,Hee Y,Xochitl D,Hee Y,Stephan T,Kala R,Tamesha T,,,"Busan, Korea, Republic of|Chuncheon, Korea, Republic of|Daejeon, Korea, Republic of|Gangneung-si, Korea, Republic of|Goyang-si, Korea, Republic of|Jeonju, Korea, Republic of|Seongam, Korea, Republic of|Seoul, Korea, Republic of",48.69232433,43.82309189,All,"40 Years and older ¬† (Adult, Older Adult)",692,675,618,576,19,23,1/15/2015,6/8/2015,3/23/2015,4/28/2015,3/28/2015,4/17/2015,4/26/2015,4/27/2015,5/24/2015,6/14/2019,11/10/2018,7/29/2019,8/30/2019,10/28/2019,12/17/2019,2/7/2020,3/8/2020,4/18/2020,6/17/2020,10/14/2015,4/11/2016,10/8/2016,4/6/2017,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04980014,,,,,,
Takeda,Takeda,ST00224,SP00017,A Study of REPLAGAL¬Æ in Treatment-naive Chinese Participants With Fabry Disease,,,Fabry Disease,,Metabolic,,,,,,Industry,Not yet recruiting,Not Applicable,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Livia Pacheo †,Garnet T,Kala R,Tamesha T,Anthony P,Jerold Goo †,Liberty A,Suk T,Ngan D,In Bellini †,Lavina S,Hee Y,Kandace p,Hee Y,Selizabeth F,John G,John G,Terrell p,Chetan K,,,,75.70500377,68.13450339,All,18 Years to 55 Years ¬† (Adult),646,638,619,247,329,43,1/24/2019,8/29/2019,7/1/2019,7/23/2019,6/17/2019,7/7/2019,7/13/2019,7/18/2019,8/17/2019,2/23/2024,7/24/2023,11/11/2023,3/29/2024,5/3/2024,6/12/2024,8/5/2024,9/12/2024,11/9/2024,12/23/2024,1/3/2020,7/1/2020,12/28/2020,6/26/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04974749,,,,,,
Takeda,Takeda,ST00232,SP00017,A Study to Check How Often People Treated With Darvadstrocel for Crohn's Disease Are Diagnosed With Cancer,,,Crohn Disease|Complex Perianal Fistula,,,,,,,,Industry,Not yet recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Kandace p,Stephan T,Mary H,Quentin N,Kandace p,Marceline R,Perter K,Xochitl D,Tammara F,Selizabeth F,Mac L,Jene M,Anthony P,Mac L,Louann C,Jerold Goo †,Liberty A,Garnet T,Lavina S,,,,81.77916643,73.60124979,All,18 Years to 34 Years ¬† (Adult),703,671,620,546,0,74,12/22/2021,5/29/2022,4/1/2022,5/3/2022,3/30/2022,4/24/2022,5/8/2022,5/11/2022,6/9/2022,8/7/2025,6/4/2025,10/1/2025,12/31/2025,2/1/2026,3/9/2026,4/23/2026,6/19/2026,8/2/2026,9/19/2026,10/21/2022,4/19/2023,10/16/2023,4/13/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04971525,,,,,,
Takeda,Takeda,ST00240,SP00017,A Study of TAK-105 in Healthy Adults,,,Healthy Volunteers,,,,,,,,Industry,Recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",,,,,,Drug C,,,,,,,,,,,,,,,,,,,Gertrudis T,Mary H,Lyman W,Lilla Stilson †,Anthony P,Jene M,Perter K,Christian G,Selizabeth F,Chetan K,Aleta H,Dinah R,Selizabeth F,Federico L,Anthony P,Suzie K,Federico L,Clarice N,Beulah N,,,"PPD Development, LP, Las Vegas, Nevada, United States|PPD Development, LP, Austin, Texas, United States",74.2807477,66.85267293,All,"40 Years to 80 Years ¬† (Adult, Older Adult)",654,632,621,538,4,79,1/7/2019,7/6/2019,5/6/2019,6/5/2019,5/8/2019,5/22/2019,6/3/2019,6/8/2019,6/29/2019,7/14/2022,6/16/2022,9/1/2022,1/11/2023,2/24/2023,4/10/2023,5/24/2023,7/3/2023,8/12/2023,9/20/2023,11/18/2019,5/16/2020,11/12/2020,5/11/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04964258,,,,,,
Takeda,Takeda,ST00249,SP00017,A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy,,,Constipation|Pregnancy,,,,,,,,Industry,Not yet recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Gertrudis T,Doreen T,Suk T,Mara A,Hee Y,Frank T,Selizabeth F,Anthony P,Kala R,Doreen T,Suzie K,Mac L,Marceline R,Gertrudis T,Tien C,Beulah N,Chetan K,Perter K,Dalton E,,,,21.33417915,19.20076123,Female,"50 Years to 85 Years ¬† (Adult, Older Adult)",658,639,622,351,223,48,9/13/2020,4/1/2021,2/1/2021,3/10/2021,2/14/2021,2/21/2021,3/6/2021,3/9/2021,4/4/2021,11/20/2025,7/21/2025,1/25/2026,3/1/2026,4/20/2026,5/27/2026,7/17/2026,9/13/2026,11/8/2026,12/10/2026,8/20/2021,2/16/2022,8/15/2022,2/11/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04961840,,,,,,
Takeda,Takeda,ST00253,SP00017,A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgium),,,"Inflammatory Bowel Diseases|Colitis, Ulcerative|Crohns Disease",,,,,,,,Industry,Not yet recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Suk T,Stephan T,Chetan K,Tammara F,Marcelina X,Perter K,Jaquelyn H,Perter K,Lilla Stilson †,Suzie K,Remedios Z,Tien C,Ross S,Doreen T,Selizabeth F,Kandace p,Jerold Goo †,Mary H,Harry A,,,"GZA St. Vincentius, Antwerpen, Belgium|UZA, Antwerpen, Belgium|Erasme, Bruxelles, Belgium|ZOL, Genk, Belgium|AZ St. Lucas, Gent, Belgium|CHR Citadelle, Li√®ge, Belgium|CHU Li√®ge, Li√®ge, Belgium|CHC MontL√©gia, Li√®ge, Belgium|AZ Delta, Roeselaere, Belgium|CHWAPI, Tournai, Belgium",28.28194237,25.45374813,All,18 Years to 55 Years ¬† (Adult),696,681,623,438,128,57,4/7/2019,11/23/2019,9/9/2019,10/17/2019,9/18/2019,9/27/2019,10/3/2019,10/4/2019,10/21/2019,11/20/2023,5/31/2023,1/6/2024,3/1/2024,4/8/2024,5/14/2024,6/13/2024,7/23/2024,8/27/2024,10/23/2024,3/25/2020,9/21/2020,3/20/2021,9/16/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04959851,,,,,,
Takeda,Takeda,ST00257,SP00017,A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults With Hereditary Angioedema,,BOISTERN,Hereditary Angioedema,,Cardiovascular,,,,,,Industry,Not yet recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Mary H,Jaquelyn H,Chetan K,Jeanene Y,James y,Anthony P,John G,Tamesha T,Dinah R,John G,Naren G,Garnet T,Tamesha T,Geralyn K,John G,Mary H,Mee M,Federico L,Livia Pacheo †,,,,73.84556285,66.46100657,All,"18 Years and older ¬† (Adult, Older Adult)",663,652,624,441,105,78,2/19/2020,6/29/2020,5/12/2020,6/8/2020,5/13/2020,5/26/2020,5/29/2020,6/2/2020,6/7/2020,12/10/2021,1/22/2022,4/19/2022,8/31/2022,10/13/2022,12/6/2022,1/18/2023,3/10/2023,5/7/2023,6/26/2023,11/22/2020,5/21/2021,11/17/2021,5/16/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04957641,,,,,,
Takeda,Takeda,ST00260,SP00017,A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina,,,"Angioedemas, Hereditary",,Cardiovascular,,,,,,Industry,Recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Mee M,Mara A,Kala R,Federico L,Kala R,Geralyn K,Lilla Stilson †,Anthony P,Terisa Sikora †,Terrell p,Ross S,John G,John G,Tien C,Quentin N,Jene M,Marceline R,Kandace p,Mara A,,,"Ic Projects Srl, Ciudad Aut√≥noma de Buenos Aires, Buenos Aires, Argentina",89.2399746,80.31597714,All,"18 Years to 80 Years ¬† (Adult, Older Adult)",675,653,625,587,70,32,6/1/2018,11/16/2018,9/15/2018,11/1/2018,9/25/2018,10/13/2018,10/15/2018,10/19/2018,11/7/2018,8/22/2022,8/22/2022,4/26/2023,6/15/2023,7/17/2023,8/23/2023,10/8/2023,11/30/2023,1/14/2024,2/13/2024,4/11/2019,10/8/2019,4/5/2020,10/2/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04955964,,,,,,
Takeda,Takeda,ST00262,SP00017,A Study of Standard and Individualized Prophylactic Treatment With Advate in Men and Boys With Severe Hemophilia A,,HAPKIDO,Hemophilia A,,,,,,,,Industry,Recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Other,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Suzie K,Perter K,Otis Thode †,Naren G,Selizabeth F,Frank T,Frank T,Mary H,Selizabeth F,Anthony P,Corrine U,Suk T,Naren G,Xochitl D,Geralyn K,Xochitl D,Beulah N,Christian G,Clarice N,,,"City Children's Hospital No. 1, Kazan, Tatarstan, Russian Federation|Chelyabinsk Regional Children's Clinical Hospital, Chelyabinsk, Russian Federation|Children's Regional Clinical Hospital, Khabarovsk, Russian Federation|Krasnoyarsk Regional Clinical Center for Maternal and Child Health, Krasnoyarsk, Russian Federation|Morozovskaya Children's City Clinical Hospital of the Department of Healthcare of the city of Moscow, Moscow, Russian Federation|State Novosibirsk Regional Clinical Hospital, Novosibirsk, Russian Federation|Regional Children's Clinical Hospital, Rostov-on-Don, Russian Federation|City Polyclinic No. 37, St. Petersburg, Russian Federation|Regional Children's Clinical Hospital No. 1, Vladivostok, Russian Federation|Volgograd Regional Clinical Oncological Dispensary, Volgograd, Russian Federation|Voronezh Regional Children's Clinical Hospital No. 1, Voronezh, Russian Federation|LLC ""European Medical Center "" UGMK-Zdorovye"", Yekaterinburg, Russian Federation",17.33974464,15.60577018,Male,6 Weeks to 14 Years ¬† (Child),664,640,626,488,71,67,5/14/2019,12/19/2019,10/5/2019,11/6/2019,10/13/2019,10/26/2019,11/1/2019,11/4/2019,11/30/2019,9/13/2022,7/3/2022,9/20/2022,2/10/2023,4/8/2023,5/13/2023,6/18/2023,7/31/2023,9/22/2023,11/18/2023,4/23/2020,10/20/2020,4/18/2021,10/15/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04953000,,,,,,
Takeda,Takeda,ST00273,SP00017,A Study on How Often Adults With Psychiatric Conditions Who Did Not Respond To Treatment Are Underdiagnosed as Having ADHD,,LANDSCAPE,Attention Deficit Hyperactivity Disorder (ADHD),,,,,,,,Industry,Not yet recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Naren G,Tiffiny K,Mara A,Aleta H,Anthony P,Corrine U,Dinah R,Terrell p,Stephan T,Suk T,Beulah N,Naren G,Jaquelyn H,Dalton E,Livia Pacheo †,Christian G,Tiffiny K,Lilla Stilson †,Geralyn K,,,,35.77234748,32.19511273,All,"18 Years and older ¬† (Adult, Older Adult)",681,658,627,346,239,42,3/26/2019,10/10/2019,8/8/2019,9/12/2019,8/28/2019,9/3/2019,9/13/2019,9/16/2019,10/12/2019,12/1/2021,1/8/2022,6/16/2022,9/1/2022,10/26/2022,12/21/2022,2/7/2023,4/6/2023,5/11/2023,6/23/2023,3/1/2020,8/28/2020,2/24/2021,8/23/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04943796,,,,,,
Takeda,Takeda,ST00274,SP00017,A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.,,,Hemophilia A,,,,,,,,Industry,Not yet recruiting,Phase 2,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Jene M,Donovan H,Anthony P,Ngan D,Ross S,Chetan K,Naren G,Mary H,Otis Thode †,Harry A,Garnet T,Suk T,Mara A,Marceline R,Tamesha T,Corrine U,Gertrudis T,Tammara F,Mary H,,,"Takeda Selected Site, Tokyo, Japan",99.42785939,89.48507345,All,"18 Years and older ¬† (Adult, Older Adult)",667,636,628,417,149,62,1/13/2019,6/14/2019,4/21/2019,5/9/2019,4/14/2019,4/28/2019,5/4/2019,5/6/2019,5/14/2019,5/6/2023,3/12/2023,9/9/2023,12/31/2023,2/7/2024,3/16/2024,4/28/2024,6/16/2024,8/1/2024,9/5/2024,10/25/2019,4/22/2020,10/19/2020,4/17/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04941898,,,,,,
Takeda,Takeda,ST00276,SP00017,Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination,,,Prevention of Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2),,,,,,,,Industry,Recruiting,Not Applicable,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug D,,,,,,,,,,,,,,,,,,,Ross S,Federico L,Dalton E,Anthony P,Liberty A,Ngan D,Suk T,Remedios Z,Anthony P,Rima Y ,Patria R,Marceline R,Selizabeth F,Corrine U,Donovan H,Stephan T,Mara A,Doreen T,Corrine U,,,"Takeda selected site, Tokyo, Japan",74.14745327,66.73270794,All,"18 Years and older ¬† (Adult, Older Adult)",655,640,629,565,39,25,5/12/2020,11/25/2020,9/25/2020,10/14/2020,9/14/2020,10/2/2020,10/15/2020,10/17/2020,11/8/2020,5/8/2022,5/10/2022,9/5/2022,12/31/2022,2/10/2023,3/27/2023,5/10/2023,6/17/2023,8/4/2023,10/1/2023,3/31/2021,9/27/2021,3/26/2022,9/22/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04941144,,,,,,
Takeda,Takeda,ST00277,SP00017,A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome,,,Dravet Syndrome (DS),,,,,,,,Industry,Not yet recruiting,Phase 2,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug E,,,,,,,,,,,,,,,,,,,James y,Mara A,Xochitl D,Naren G,Mary H,Federico L,Jaquelyn H,John G,Mara A,John G,Doreen T,Suk T,Marceline R,Otis Thode †,Anthony P,Terisa Sikora †,Clarice N,Kala R,Tiffiny K,,,,54.37979876,48.94181889,All,"18 Years and older ¬† (Adult, Older Adult)",656,637,630,301,281,48,6/6/2019,12/20/2019,10/13/2019,11/26/2019,10/31/2019,11/8/2019,11/22/2019,11/25/2019,12/17/2019,8/26/2022,6/30/2022,12/29/2022,3/5/2023,4/21/2023,5/27/2023,7/14/2023,8/26/2023,9/26/2023,11/5/2023,5/6/2020,11/2/2020,5/1/2021,10/28/2021,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04940624,,,,,,
Takeda,Takeda,ST00278,SP00017,A Study of Surgical Interventions in Fistulizing Conditions,,,Crohns Disease|Fistula|Rectovaginal Fistula|Complex Perianal Fistula|Complex Cryptoglandular Fistula,,,,,,,,Industry,Recruiting,Phase 3,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug F,,,,,,,,,,,,,,,,,,,Perter K,Dalton E,Stephan T,Suzie K,Tammara F,Lilla Stilson †,Lyman W,Perter K,Frank T,Patria R,Aleta H,Jeanene Y,Suk T,Mara A,Garnet T,Mac L,Livia Pacheo †,Marcelina X,Louann C,,,"Cedars-Sinai Medical Center,, Los Angeles, California, United States",35.00388836,31.50349952,All,"19 Years to 90 Years ¬† (Adult, Older Adult)",678,650,631,558,0,73,1/14/2022,6/28/2022,4/13/2022,5/27/2022,4/23/2022,5/12/2022,5/19/2022,5/22/2022,6/7/2022,3/18/2026,10/3/2025,1/26/2026,5/2/2026,6/13/2026,7/15/2026,9/5/2026,10/20/2026,11/30/2026,1/5/2027,11/8/2022,5/7/2023,11/3/2023,5/1/2024,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04940611,,,,,,
Takeda,Takeda,ST00282,SP00017,Assessment of Updated Educational Materials for Instanyl¬Æ,,,Pain|Cancer Pain,,Oncology,,,,,,Industry,Not yet recruiting,Phase 1,Observational,,Observational Model: Cohort|Time Perspective: Cross-Sectional,,,,,,Drug H,,,,,,,,,,,,,,,,,,,Geralyn K,Ross S,Naren G,Anthony P,Terisa Sikora †,Patria R,Otis Thode †,Donovan H,Tien C,Jeanene Y,Perter K,Naren G,Corrine U,Liberty A,Anthony P,Doreen T,Dinah R,Christian G,Xochitl D,,,"Central Contact, Cambridge, Massachusetts, United States",43.95800972,39.56220875,All,"18 Years and older ¬† (Adult, Older Adult)",677,667,632,335,230,67,2/15/2018,8/14/2018,7/3/2018,7/17/2018,6/19/2018,7/10/2018,7/14/2018,7/17/2018,7/22/2018,10/15/2022,5/14/2022,10/30/2022,12/31/2022,2/9/2023,3/30/2023,5/22/2023,7/7/2023,8/27/2023,10/8/2023,1/6/2019,7/5/2019,1/1/2020,6/29/2020,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04938440,,,,,,
Takeda,Takeda,ST00283,SP00017,"A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome",,,Lennox Gastaut Syndrome (LGS),,,,,,,,Industry,Not yet recruiting,,Interventional,,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,,,,Drug B,,,,,,,,,,,,,,,,,,,Doreen T,Marcelina X,Dalton E,Gertrudis T,Corrine U,Chetan K,Rima Y ,Jerold Goo †,Marceline R,Suzie K,Selizabeth F,Terisa Sikora †,Patria R,John G,Kandace p,Selizabeth F,Liberty A,Dalton E,Dalton E,,,,69.40822463,62.46740217,All,"18 Years to 70 Years ¬† (Adult, Older Adult)",707,675,633,506,58,69,10/17/2020,4/11/2021,2/8/2021,3/15/2021,2/8/2021,3/2/2021,3/13/2021,3/17/2021,4/4/2021,11/10/2022,6/22/2022,12/21/2022,3/5/2023,4/17/2023,6/2/2023,7/6/2023,8/16/2023,9/26/2023,11/3/2023,8/29/2021,2/25/2022,8/24/2022,2/20/2023,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT04938427,,,,,,
Takeda,Takeda,ST00299,SP00017,A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer,,,,,Oncology,,,,,,Industry,Completed,Phase 1|Phase 2,Interventional,,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,,,,Drug A,,,,,,,,,,,,,,,,,,,Terrell p,Mee M,Terrell p,Liberty A,Ross S,Harry A,Quentin N,Lavina S,Selizabeth F,Dinah R,Lavina S,Tammara F,Christian G,Perter K,James y,Geralyn K,Christian G,Louann C,Louann C,,,"Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Matsuyama, Ehime, Japan|Kitakyushu, Fukuoka, Japan|Kurume, Fukuoka, Japan|Hakodate, Hokkaido, Japan|Kushiro, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Amagasaki, Hyogo, Japan|Kobe, Hyogo, Japan|Tsukuba, Ibaragi, Japan|Kasama, Ibaraki, Japan|Miki, Kagawa, Japan|Sagamihara, Kanagawa, Japan|Osaki, Miyagi, Japan|Matsumoto, Nagano, Japan|Sasebo, Nagasaki, Japan|Yamatotakada, Nara, Japan|Takatsuki, Osaka, Japan|Ina, Saitama, Japan|Shizuoka, Shizioka, Japan|Nagaizumi, Shizuoka, Japan|Koto-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Chiba, Japan|Fukui, Japan|Fukuoka, Japan|Kumamoto, Japan|Okayama, Japan|Okinawa, Japan|Osaka, Japan|Toyama, Japan",71.10492181,63.99442963,All,"18 Years and older ¬† (Adult, Older Adult)",690,661,634,610,91,67,2/25/2016,7/18/2016,4/30/2016,6/16/2016,5/8/2016,5/27/2016,5/29/2016,6/3/2016,6/24/2016,3/2/2017,2/28/2017,7/19/2017,10/6/2017,11/17/2017,1/3/2018,3/2/2018,4/24/2018,5/28/2018,7/9/2018,11/23/2016,5/22/2017,11/18/2017,5/17/2018,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02613221,,,,,,"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02613221/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02613221/Prot_001.pdf"
Takeda,Takeda,ST00327,SP00017,An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-na√Øve Unresectable Advanced or Recurrent Colorectal Cancer,,,,,Oncology,,,,,,Industry,"Active, not recruiting",Phase 3,Interventional,,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Quentin N,Patria R,Donovan H,Mara A,Chetan K,John G,Jerold Goo †,Lucie P,Terisa Sikora †,Doreen T,Naren G,James y,Corrine U,Lyman W,Perter K,John G,Mary H,Ngan D,Anthony P,,,"Ichinomiya, Aichi, Japan|Komaki, Aichi, Japan|Kounan, Aichi, Japan|Nagakute, Aichi, Japan|Nagoya, Aichi, Japan|Okazaki, Aichi, Japan|Toyohashi, Aichi, Japan|Toyokawa, Aichi, Japan|Toyota, Aichi, Japan|Yatomi, Aichi, Japan|Daisen, Akita, Japan|Hirosaki, Aomori, Japan|Misawa, Aomori, Japan|Kashiwa, Chiba, Japan|Yachiyo, Chiba, Japan|Matsuyama, Ehime, Japan|Toon, Ehime, Japan|Tsuruga, Fukui, Japan|Yoshida, Fukui, Japan|Kitakyushu, Fukuoka, Japan|Koga, Fukuoka, Japan|Kurume, Fukuoka, Japan|Omuta, Fukuoka, Japan|Onga, Fukuoka, Japan|Aizuwakamatsu, Fukushima, Japan|Iwaki, Fukushima, Japan|Koriyama, Fukushima, Japan|Shirakawa, Fukushima, Japan|Hashima, Gifu, Japan|Kakamigahara, Gifu, Japan|Minokamo, Gifu, Japan|Ogaki, Gifu, Japan|Okazai, Gifu, Japan|Maebashi, Gunma, Japan|Ota, Gunma, Japan|Fukuyama, Hiroshima, Japan|Hakodate, Hokkaido, Japan|Kitami, Hokkaido, Japan|Kushiro, Hokkaido, Japan|Obihiro, Hokkaido, Japan|Otaru, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Akashi, Hyogo, Japan|Amagasaki, Hyogo, Japan|Himeji, Hyogo, Japan|Kobe, Hyogo, Japan|Nishinomiya, Hyogo, Japan|Hitachi, Ibaraki, Japan|Kasama, Ibaraki, Japan|Ryugasaki, Ibaraki, Japan|Tsuchiura, Ibaraki, Japan|Tsukuba, Ibaraki, Japan|Hakusan, Ishikawa, Japan|Kaga, Ishikawa, Japan|Kahoku, Ishikawa, Japan|Kanazawa, Ishikawa, Japan|Nanao, Ishikawa, Japan|Morioka, Iwate, Japan|Kida, Kagawa, Japan|Marugame, Kagawa, Japan|Takamatsu, Kagawa, Japan|Fujisawa, Kanagawa, Japan|Hiratsuka, Kanagawa, Japan|Isehara, Kanagawa, Japan|Kamakura, Kanagawa, Japan|Kanazawa, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Nankoku, Kochi, Japan|Matsuzaka, Mie, Japan|Tsu, Mie, Japan|Yokkaichi, Mie, Japan|Ishinomaki, Miyagi, Japan|Natori, Miyagi, Japan|Osaki, Miyagi, Japan|Sendai, Miyagi, Japan|Shibata, Miyagi, Japan|Matsumoto, Nagano, Japan|Saku, Nagano, Japan|Omura, Nagasaki, Japan|Sasebo, Nagasaki, Japan|Ikoma, Nara, Japan|Tenri, Nara, Japan|Yamatotakada, Nara, Japan|Yufu, Oita, Japan|Kurashiki, Okayama, Japan|Naha, Okinawa, Japan|Tomigusuku, Okinawa, Japan|Urasoe, Okinawa, Japan|Hirakata, Osaka, Japan|Kawachinagano, Osaka, Japan|Moriguchi, Osaka, Japan|Neyagawa, Osaka, Japan|Osakasayama, Osaka, Japan|Suita, Osaka, Japan|Takatsuki, Osaka, Japan|Kawagoe, Saitama, Japan|Kitaadachi, Saitama, Japan|Koshigaya, Saitama, Japan|Moriyama, Shiga, Japan|Otsu, Shiga, Japan|Izumi, Shimane, Japan|Izumo, Shimane, Japan|Hamamatsu, Shizuoka, Japan|Izunokuni, Shizuoka, Japan|Sunto, Shizuoka, Japan|Shimotsuga, Tochigi, Japan|Shimotsuke, Tochigi, Japan|Utsunomiya, Tochigi, Japan|Komatsushima, Tokushima, Japan|Bunkyo-ku, Tokyo, Japan|Chiyoda-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Machida, Tokyo, Japan|Minato-ku, Tokyo, Japan|Musashino, Tokyo, Japan|Shinagawa-ku, Tokyo, Japan|Shinjyuku-ku, Tokyo, Japan|Yonago, Tottori, Japan|Kurobe, Toyama, Japan|Takaoka, Toyama, Japan|Sakata, Yamagata, Japan|Tsuruoka, Yamagata, Japan|Iwakuni, Yamaguchi, Japan|Kofu, Yamanashi, Japan|Akita, Japan|Aomori, Japan|Chiba, Japan|Fukui, Japan|Fukuoka, Japan|Gifu, Japan|Kagoshima, Japan|Kochi, Japan|Kumamoto, Japan|Kyoto, Japan|Miyazaki, Japan|Nagano, Japan|Nagasaki, Japan|Niigata, Japan|Okayama, Japan|Okinawa, Japan|Osaka, Japan|Saga, Japan|Saitama, Japan|Shizuoka, Japan|Tokushima, Japan|Toyama, Japan|Yamagata, Japan",63.46323385,57.11691047,All,"21 Years and older ¬† (Adult, Older Adult)",696,666,635,487,76,72,9/13/2016,4/30/2017,2/14/2017,3/10/2017,2/23/2017,3/5/2017,3/12/2017,3/15/2017,3/28/2017,2/25/2021,2/11/2021,4/21/2021,8/30/2021,10/6/2021,11/15/2021,12/31/2021,2/9/2022,3/26/2022,5/4/2022,9/1/2017,2/28/2018,8/27/2018,2/23/2019,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02394834,,,,,,
Takeda,Takeda,ST00461,SP00017,Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain,,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug G,,,,,,,,,,,,,,,,,,,Remedios Z,Dalton E,Lucie P,Geralyn K,Perter K,Aleta H,Geralyn K,Kala R,Patria R,Stephan T,Liberty A,Patria R,Mac L,Jaquelyn H,Suzie K,Lyman W,Kala R,Terisa Sikora †,Dalton E,,,"Hospital General Universitario de Elda-Virgen de La Salud, Elda, Alicante, Spain|Hospital Universitario San Juan de Alicante, San Juan, Alicante, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Baleares, Spain|Hospital Son Llatzer, Palma de Mallorca, Baleares, Spain|Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital de Especialidades de Puerto Real, Puerto Real, Cadiz, Spain|Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas De Gran Canarias, Canarias, Spain|Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Canarias, Spain|Hospital Universitario Nuestra Senora de Candelaria, Santa Cruz de Tenerife, Canarias, Spain|Hospital de Alta Resolucion de Guadix, Guadix, Granada, Spain|Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Majadahonda, Madrid, Spain|Hospital Quiron Madrid, Pozuelo de Alarcon, Madrid, Spain|Complejo Hospital Costa Del Sol, Marbella,, Malaga, Spain|Hospital General Universitario Santa Lucia, Cartagena, Murcia, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Los Montalvos, Carrascal de Barregas,, Salamanca, Spain|Complexo Hospitalario Universitario A Coruna, A Coruna, Spain|Centro Oncoloxico de Galicia, A Coruna, Spain|Hospital Torrecardenas, Almeria, Spain|Hospital Puerta Del Mar, Cadiz, Spain|Hospital Reina Sofia, Cordoba, Spain|Hospital Universitario Virgen de Las Nieves, Granada, Spain|Complejo Hospitalario de Jaen, Jaen, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Complejo Hospitalario Regional de Malaga, Malaga, Spain|Hospital Virgen de La Victoria, Malaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Nuestra Senora de Valme, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain",59.40661515,53.46595364,All,"50 Years and older ¬† (Adult, Older Adult)",720,686,636,337,240,59,3/2/2013,8/15/2013,6/30/2013,7/26/2013,6/25/2013,7/6/2013,7/16/2013,7/18/2013,8/7/2013,8/24/2017,8/29/2017,11/14/2017,4/4/2018,5/17/2018,6/19/2018,7/21/2018,9/1/2018,10/21/2018,12/15/2018,1/2/2014,7/1/2014,12/28/2014,6/26/2015,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02899884,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02899884/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02899884/SAP_001.pdf"
Takeda,Takeda,ST00472,SP00017,"Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for ""Prostate Cancer""",,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug E,,,,,,,,,,,,,,,,,,,Otis Thode †,Xochitl D,John G,Patria R,Xochitl D,Christian G,Anthony P,Frank T,Perter K,Mary H,Mary H,Beulah N,Livia Pacheo †,Hee Y,John G,Frank T,Suk T,Selizabeth F,Christian G,,,"Takeda Selected Site, Tokyo, Japan",4.364506754,3.928056079,Male,"18 Years and older ¬† (Adult, Older Adult)",661,645,637,486,67,84,4/9/2013,11/12/2013,8/26/2013,9/22/2013,9/10/2013,9/15/2013,9/30/2013,10/3/2013,10/24/2013,8/13/2017,4/27/2017,9/10/2017,12/1/2017,1/11/2018,2/24/2018,4/12/2018,5/12/2018,6/16/2018,7/16/2018,3/14/2014,9/10/2014,3/9/2015,9/5/2015,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03209492,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT03209492/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT03209492/SAP_001.pdf"
Takeda,Takeda,ST00482,SP00017,"Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: ""QOL Survey in Premenopausal Breast Cancer Patients""",,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Perter K,Terrell p,James y,Selizabeth F,Gertrudis T,Xochitl D,Lyman W,Beulah N,Harry A,Chetan K,Doreen T,Tamesha T,Remedios Z,Jaquelyn H,Louann C,Mac L,Chetan K,Tiffiny K,Patria R,,,,23.70791471,21.33712324,Female,"18 Years and older ¬† (Adult, Older Adult)",678,650,638,530,49,59,3/3/2011,9/15/2011,8/5/2011,8/26/2011,8/2/2011,8/13/2011,8/25/2011,8/30/2011,9/25/2011,9/25/2014,8/12/2014,1/23/2015,3/1/2015,4/5/2015,5/29/2015,7/15/2015,9/8/2015,10/18/2015,11/24/2015,2/9/2012,8/7/2012,2/3/2013,8/2/2013,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02134977,,,,,,
Takeda,Takeda,ST00502,SP00017,"Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey ""Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)""",,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Selizabeth F,Louann C,Hee Y,In Bellini †,Geralyn K,Federico L,Suzie K,Patria R,Ross S,Anthony P,Xochitl D,Otis Thode †,Mary H,Lavina S,John G,Corrine U,Rima Y ,Liberty A,John G,,,,9.029547646,8.126592881,Female,"18 Years to 75 Years ¬† (Adult, Older Adult)",703,673,639,532,52,55,11/5/2006,5/7/2007,3/2/2007,4/2/2007,3/7/2007,3/16/2007,3/25/2007,3/28/2007,4/25/2007,10/29/2009,6/20/2009,10/23/2009,3/1/2010,4/14/2010,6/8/2010,7/14/2010,9/7/2010,10/7/2010,11/25/2010,9/12/2007,3/10/2008,9/6/2008,3/5/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02154139,,,,,,
Takeda,Takeda,ST00534,SP00017,An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer,,,,,Oncology,,,,,,Industry,Not yet recruiting,,Observational,,Observational Model: Cohort|Time Perspective: Retrospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Naren G,Kala R,Hee Y,Ross S,John G,Lucie P,Otis Thode †,Chetan K,Federico L,Remedios Z,Frank T,Aleta H,Livia Pacheo †,Aleta H,Donovan H,Suk T,Ngan D,Kala R,Liberty A,,,,17.06045764,15.35441187,All,"18 Years and older ¬† (Adult, Older Adult)",682,666,640,317,261,62,1/28/2020,8/20/2020,6/8/2020,7/19/2020,6/10/2020,7/5/2020,7/11/2020,7/15/2020,8/13/2020,11/27/2023,12/15/2023,5/30/2024,7/31/2024,9/8/2024,10/22/2024,12/3/2024,1/30/2025,3/6/2025,4/17/2025,1/1/2021,6/30/2021,12/27/2021,6/25/2022,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT05030493,,,,,,
Takeda,Takeda,ST00541,SP00017,"Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in ""Premenopausal Breast Cancer""",,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug C,,,,,,,,,,,,,,,,,,,Jaquelyn H,Rima Y ,Selizabeth F,Terisa Sikora †,Kala R,Perter K,Garnet T,Naren G,Jerold Goo †,Corrine U,John G,Doreen T,Mary H,Chetan K,Donovan H,Corrine U,Marceline R,Mary H,Jaquelyn H,,,"Takeda selected site, Tokyo, Japan",51.38155124,46.24339612,Female,"18 Years and older ¬† (Adult, Older Adult)",690,673,641,588,37,16,1/22/2015,8/23/2015,6/20/2015,7/20/2015,6/12/2015,7/4/2015,7/13/2015,7/18/2015,8/6/2015,11/10/2017,3/21/2018,7/1/2018,10/10/2018,11/30/2018,1/2/2019,2/1/2019,3/9/2019,4/12/2019,5/28/2019,12/31/2015,6/28/2016,12/25/2016,6/23/2017,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT03209518,,,,,,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03209518/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03209518/SAP_001.pdf"
Takeda,Takeda,ST00573,SP00017,"Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey ""Long-term Use Survey in Prostate Cancer Patients (96 Weeks)""",,,,,Oncology,,,,,,Industry,Completed,,Observational,,Observational Model: Cohort|Time Perspective: Prospective,,,,,,Drug B,,,,,,,,,,,,,,,,,,,Tiffiny K,Suk T,Chetan K,Lavina S,Aleta H,Ngan D,Gertrudis T,Marceline R,Clarice N,Ross S,Jaquelyn H,Gertrudis T,Hee Y,Suzie K,Tammara F,Chetan K,Lavina S,Jerold Goo †,Naren G,,,,39.05000398,35.14500358,Male,,700,670,642,415,163,64,3/27/2007,9/29/2007,7/16/2007,8/17/2007,7/26/2007,8/2/2007,8/17/2007,8/22/2007,9/17/2007,5/10/2010,4/10/2010,10/25/2010,12/1/2010,1/7/2011,2/24/2011,4/14/2011,5/23/2011,6/28/2011,8/16/2011,1/29/2008,7/27/2008,1/23/2009,7/22/2009,,,,,,,,,,,,,,,,https://ClinicalTrials.gov/show/NCT02167893,,,,,,
